Page last updated: 2024-10-22

albuterol and Asthma

albuterol has been researched along with Asthma in 3866 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"A prospective, single center, open-label, two-arm, parallel-group, nonrandomized trial among children ages 5-17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively."9.69Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. ( Darville, KK; Goldenberg, NA; Martin, M; McKinley, SD; Nakagawa, TA; Roddy, MR; Sellers, AR; Sochet, AA; Teppa-Sanchez, B, 2023)
"We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol-budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial."9.51Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. ( Albers, FC; Beasley, R; Cappelletti, C; Chipps, BE; Cooper, M; Dunsire, L; Israel, E; Jeynes-Ellis, A; Johnsson, E; Panettieri, RA; Papi, A; Rees, R, 2022)
"To evaluate bronchodilator responses (BDR) to albuterol nebulized with 3%-HSS in asthmatic children, compared to albuterol nebulized with NSS."9.41Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children. ( Alchundia Moreira, J; García Bournissen, F; Kofman, C; Köhler, T; Teper, A, 2021)
"The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma."9.41Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. ( Albers, FC; Cappelletti, C; Chipps, BE; Johnsson, E; Papi, A; Reilly, L, 2021)
" The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments."9.34Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. ( Atenafu, EG; Beer, D; Black, K; Coates, AL; Curtis, S; Ducharme, FM; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Klassen, TP; Nicksy, D; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Willan, AR; Zemek, R, 2020)
"Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan."9.30Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. ( Adachi, Y; Akashi, K; Fujisawa, T; Hashimoto, K; Imai, T; Katsunuma, T; Maekawa, T; Mizuno, M; Nakamura, H; Oba, MS; Ohashi, Y; Ohya, Y; Sako, M, 2019)
"The objective of this study was to determine if a rapid albuterol delivery pathway with a breath-enhanced nebulizer can reduce emergency department (ED) length of stay (LOS), while maintaining admission rates and side effects, when compared to a traditional asthma pathway with a standard jet nebulizer."9.27Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. ( Allen, C; Higginbotham, E; Hovinga, C; Iyer, S; King, B; Wallace, A; Wilkinson, M, 2018)
"BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma."9.27Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018)
"To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma."9.24Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. ( Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)
"Evaluate the safety of albuterol multidose dry powder inhaler (MDPI), a novel, inhalation-driven device that does not require coordination of actuation with inhalation, in patients with persistent asthma."9.22Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. ( Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016)
"To compare the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of albuterol MDPI and albuterol HFA after a single inhaled dose in children with asthma."9.22Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. ( Iverson, H; Ratnayake, A; Shore, P; Taveras, H, 2016)
"To demonstrate the comparability of albuterol MDPI and albuterol HFA in children with asthma."9.22Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. ( Iverson, H; Qaqundah, PY; Shore, P; Taveras, H, 2016)
"We have previously shown that in patients with asthma a single dose of an inhaled glucocorticosteroid (ICS) acutely potentiates inhaled albuterol-induced airway vascular smooth muscle relaxation through a nongenomic action."9.20Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma. ( Arana, J; Cadet, L; Mendes, ES; Wanner, A, 2015)
"Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented."9.20Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. ( Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015)
"Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity."9.19Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014)
"This study compares the effect of heliox-driven to that of air-driven bronchodilator therapy on the pulmonary function test (PFT) in patients with different levels of asthma severity."9.19Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma. ( Alawieh, M; Bou-Akl, I; Bou-Khalil, P; Chami, H; El-Khatib, MF; Husari, A; Jamaleddine, G; Kanj, N; Zeineddine, S, 2014)
"In subjects with either asthma or COPD, FEV(1) decline and bronchospasm can occur following inhaled loxapine, but more frequently in asthmatic subjects."9.19Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. ( Cassella, JV; Fishman, RS; Greos, LS; Gross, N; Meltzer, EO; Spangenthal, S; Spyker, DA, 2014)
"To compare tulobuterol patch and oral salbutamol sulfate in terms of efficacy and safety in children with mild or moderate acute attack of bronchial asthma."9.17[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013)
"The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD."9.17Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. ( Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013)
"Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma."9.17Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma. ( Aizawa, H; Fukuyama, S; Inoue, H; Komori, M; Koto, H; Matsumoto, K; Takata, S; Yoshida, M, 2013)
"To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients."9.17Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma. ( Ding, X; Hu, S; Huang, Y; Liu, M; Nie, H; Zhang, G, 2013)
"Fourteen subjects with moderate asthma inhaled single doses of salmeterol (50 μg), fluticasone propionate (250 μg), salmeterol/fluticasone propionate (50/250 μg), or placebo; Qaw was measured before and serially for 240 min after drug administration."9.16Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma. ( Mendes, ES; Rebolledo, P; Wanner, A, 2012)
"Combination therapy with an inhaled corticosteroid (ICS) and a long-acting β(2)-agonist (LABA) in a single inhaler is the mainstay of asthma management and salmeterol/fluticasone combination (SFC) and fixed-dose formoterol/budesonide combination (FBC) are currently available in Japan; however, there is nothing to choose between the two."9.16Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma. ( Akamatsu, T; Chida, K; Hashimoto, D; Hayakawa, H; Ide, K; Inui, N; Kato, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yasui, H; Yokomura, K, 2012)
"Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control group."9.16Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. ( Bozek, A; Filipowska-Gronska, A; Jarzab, J; Warkocka-Szoltysek, B, 2012)
"The pentosidine levels did not significantly differ between the two asthmatic subgroups with and without airway obstruction."9.16Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients. ( Hirata, K; Kanazawa, H; Tamagaki, G, 2012)
"In a randomized, two-period, two-sequence crossover clinical trial, we analyzed 31 stable asthmatic children (6-18 yrs of age) on two consecutive days, who were randomly assigned to receive 100 μg of albuterol MDI through either a locally produced valved spacer or a non-valved spacer."9.16Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2012)
"To compare racemic albuterol (RAC) with levalbuterol (LEV) in continuous form for the treatment of acute pediatric asthma exacerbations in the emergency department."9.15Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. ( Bulloch, B; Garcia-Filion, P; Keahey, L; Wilkinson, M, 2011)
"In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention."9.15Active albuterol or placebo, sham acupuncture, or no intervention in asthma. ( Boyd, IO; Dutile, S; Israel, E; Kaptchuk, TJ; Kelley, JM; Kirsch, I; Marigowda, G; Wechsler, ME, 2011)
"In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score."9.15The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011)
"All patients between 6 and 17 years of age who presented to a pediatric emergency department in the winter months with acute exacerbation of bronchial asthma were given a combination of nebulized albuterol and ipratropium with warmed or room temperature humidified oxygen."9.14Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. ( Hassen, GW; Nibhanipudi, K; Smith, A, 2009)
"We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP) administered, in addition to CIC 160 microg x day(-1) and salmeterol 50 microg twice daily, in 32 patients with persistent asthma using a randomised double-blind, placebo-controlled, double-dummy, five-period crossover design."9.14Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. ( Derom, E; Engelstätter, R; Joos, GF; Kaufman, JM; Louis, R; Tiesler, C, 2009)
"To evaluate the efficacy of add-on montelukast on asthma control and allergic rhinitis symptoms in asthmatic patients still symptomatic with chronic treatment with inhaled corticosteroid and long-acting beta(2) agonist (ICS/LABA), irrespective of the dose."9.14Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. ( Dramaix, M; Herbots, E; Korn, D; Peché, R; Potvin, E; Van den Brande, P, 2009)
" This double-blind, parallel group, non-inferiority study compared lung function and asthma control, based on Global Initiative for Asthma guidelines, in children receiving either salmeterol/fluticasone propionate (SFC) 50/100 microg bd (n = 160) or fluticasone propionate (FP) 200 microg bd (n = 161) for 12 wks."9.14Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. ( Anderton, S; Attali, V; Bennedbaek, O; de Blic, J; Desfougeres, JL; Hofman, J; Klink, R; Ogorodova, L; Poterre, M; Sidorenko, I; Valiulis, A, 2009)
"The modified adenosine infusion protocol with salbutamol premedication can be used in patients with asthma."9.14Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. ( Notghi, A; Smith, NB; Sundram, F, 2009)
"To assess asthma-related quality of life after treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane 134a metered-dose inhaler compared with the individual components alone."9.14Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. ( Andersen, LB; Edin, HM; Ho, SY; Ortega, HG; Schoaf, L; Scott-Wilson, CA, 2009)
"Salmeterol and fluticasone propionate combination (SFC) provides better asthma control than fluticasone propionate (FP) alone, however, little is known on the effects of differential treatments on airway function and inflammation in patients with mild asthma."9.14Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. ( Handa, H; Hoshino, M; Miyazawa, T, 2009)
"To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus."9.14High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. ( Andrews, T; Chew, A; McGintee, E; Mittal, MK; Pawlowski, N; Tyler, L; Zhang, X; Zorc, JJ, 2009)
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid."9.14Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009)
"To reduce symptoms and emergency department (ED) visits, the National Asthma Education and Prevention Program (NAEPP) guidelines recommend early treatment of acute asthma symptoms with albuterol and oral corticosteroids."9.14Home use of albuterol for asthma exacerbations. ( Freiner, D; Garbutt, JM; Highstein, GR; Nelson, KA; Smith, SR; Strunk, RC, 2009)
"Inhaled corticosteroids, such as fluticasone propionate (FP) and ciclesonide (CIC), are commonly used for the treatment of asthma."9.14Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ( Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010)
"We investigated if a higher proportion of adults with previously uncontrolled asthma can achieve total control when given salmeterol/fluticasone propionate (50/250 microg) bid and compliance enhancement training (CET) compared to those given medication alone."9.14Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. ( Backer, V; Claudius, BK; Dahl, R; Harving, H; Hellquist, B; Høgholm, A; Jøhnk, IK; Siersted, HC; Tamm, M; Ulrik, CS, 2009)
"Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treatment."9.1424-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. ( Adachi, M; Emery, C; Haida, M; Higgins, M; Hosoe, M; Ichinose, M; Kanada, S; Kramer, B; Sugihara, N, 2010)
"To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice a day Diskus in children with symptomatic asthma."9.14Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. ( Brackel, HJ; Duiverman, EJ; Gerrits, GP; Hop, WC; Vaessen-Verberne, AA; van den Berg, NJ; van Nierop, JC, 2010)
"We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV₁ or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation."9.14Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. ( Cydulka, RK; Emerman, CL; Muni, A, 2010)
"In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison)."9.14Tiotropium bromide step-up therapy for adults with uncontrolled asthma. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, L; DiMango, EA; Engle, LL; Fahy, JV; Icitovic, N; Israel, E; Jarjour, N; Kazani, SD; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2010)
"The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital."9.13Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. ( Andrews, WT; Ciubotaru, RL; Claus, R; Donohue, JF; Hanania, NA; Noe, L; Pasta, DJ; Roach, J; Schaefer, K, 2008)
"This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects."9.13A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. ( Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008)
"Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma."9.13Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. ( Bacharier, LB; Chinchilli, VM; Covar, R; Guilbert, T; Krawiec, M; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Paul, IM; Phillips, BR; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2008)
"We analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily."9.13Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. ( Patel, AC; Strunk, RC; Tonascia, J; Van Natta, ML; Wise, RA, 2008)
"The efficacy and safety of twice-daily inhaled salmeterol/fluticasone propionate combination (SFC) therapy have been well established in the treatment of adults and adolescents with asthma."9.13Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. ( Chuchalin, A; Frith, L; Jacques, L, 2008)
"Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of albuterol on esophageal function in asthmatic patients are not known."9.13The effects of nebulized albuterol on esophageal function in asthmatic patients. ( DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008)
"Although albuterol remains the standard treatment for asthma in the emergency department, formoterol fumarate may be more advantageous, with its rapid and long-lasting bronchodilation."9.13Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. ( Chou, V; Lee-Wong, M; Ogawa, Y, 2008)
"To compare the efficacy and safety of the salmeterol/fluticasone propionate combination product with concurrent sustained release theophylline plus fluticasone propionate in adult Japanese patients with persistent asthma."9.13Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. ( Adachi, M; Aizawa, H; Ishihara, K; Nakashima, M; Ohta, K; Sano, Y; Taniguchi, H, 2008)
"An outpatient, randomized, double-blind, single-dose, crossover study in adult asthmatics with moderate-to-severe obstruction despite treatment with inhaled corticosteroids (ICS) was conducted comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB)."9.13Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ( Cassino, C; Conoscenti, CS; Gelb, AF; Johnson, P; Karpel, J; Wise, RA, 2008)
" Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use."9.13Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008)
"In this randomized controlled, double blind study, 30 asthmatics were challenged with histamine until forced expiratory volume in 1s (FEV(1)) fell with > or =20%."9.12Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction. ( De Peuter, S; Lemaigre, V; Smets, A; Van den Bergh, O; Verleden, GM, 2006)
"The aim of this study was to assess asthma control using salmeterol plus fluticasone propionate (FP) in combination (SFC) versus salmeterol or FP as monotherapy in patients with mild to moderate asthma."9.12Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. ( James, M; Jonsson, AC; Larsson, LG; Lindberg, A; Lundbäck, B; Pétavy, F; Rönmark, E, 2006)
"Therefore, we compared the effects of beclomethasone dipropionate (BDP) on the degree of BHR to inhaled histamine and NKA in a double-blind, controlled, cross-over study of asthmatic patients."9.12Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma. ( Arcidiacono, G; Ciamarra, I; Crimi, N; Polosa, R; Prosperini, G, 2006)
" Therefore, a 12-week randomized double-blind placebo-controlled clinical study was conducted to investigate the efficacy of a plant-based formulation (DCBT4567-Astha-15) in comparison with oral salbutamol, salbutamol + theophylline and a matching placebo in patients with reversible asthma."9.12Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline. ( Deivanayagam, CN; Krishnarajasekar, OR; Lakshmisubramanian, S; Murali, PM; Nalini, K; Perumal, T; Rajasekaran, S, 2006)
"A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED."9.12Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. ( Brown, L; Kim, TY; Minasyan, L; Rivera, ML; Stewart, GM, 2006)
"This study compared the efficacy and tolerability of the combination of fluticasone propionate (FP) and salmeterol (SAL) delivered via a single hydrofluoroalkane (HFA) 134a metered-dose inhaler (MDI) with those of its 2 components alone delivered via a chlorofluorocarbon (CFC) MDI and placebo (PLA) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses (equivalent to FP 440-660 microg/d) of inhaled corticosteroids (ICSs)."9.12Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. ( Dorinsky, P; Ellsworth, A; House, K; Nathan, RA; Rooklin, A; Schoaf, L; Scott, C, 2006)
"Although frequently used to treat status asthmaticus in children, intravenous (IV) terbutaline has not been shown to decrease hospital length of stay (LOS)."9.12Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. ( Carroll, CL; Schramm, CM, 2006)
"Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases--migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma."9.12Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. ( Lomia, M; Pruidze, M; Tchelidze, T, 2006)
" Additional endpoints included asthma symptom scores, daily albuterol use, and safety, including hypothalamic-pituitary-adrenal (HPA) axis function."9.12Once-daily ciclesonide in children: efficacy and safety in asthma. ( Gelfand, EW; Georgitis, JW; Noonan, M; Ruff, ME, 2006)
"This multicenter, randomized, double-blind trial compared nebulized levalbuterol (Lev) and racemic albuterol (Rac) in the treatment of acute asthma."9.12A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. ( Baumgartner, RA; Claus, R; Emerman, C; Hanania, NA; Hanrahan, JP; Nowak, R; Parsey, MV; Schaefer, K, 2006)
"To investigate the safety and effectiveness of a 4-mg tablet of oral montelukast in addition to short-acting beta2-agonist bronchodilator as the initial treatment in mild to moderate asthma exacerbations in children between 2 and 5 years old."9.12Oral montelukast treatment of preschool-aged children with acute asthma. ( Bakirtas, A; Degim, T; Harmanci, K; Turktas, I, 2006)
"Compared with placebo use, fluticasone propionate, 88 microg administered twice daily, significantly reduced asthma exacerbations, asthma symptoms, and rescue albuterol use and was well tolerated, with no clinically relevant systemic effects, as measured by growth velocity or 12-hour urinary cortisol excretion levels."9.12Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. ( Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006)
"In this study, levalbuterol administered via MDI significantly improved airway function in comparison with placebo in asthmatic children aged 4-11 years with a safety profile that was similar to placebo."9.12Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. ( Baumgartner, RA; Berger, WE; Milgrom, H; Parsey, MV; Skoner, DP; Tripp, K, 2006)
"To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy."9.12Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. ( Baumgartner, RA; Grasela, T; Hsu, R; Maier, G; Rubino, C, 2007)
"To investigate the duration of bronchodilator action of a salmeterol/fluticasone combination (SFC) inhaler when administered in the evening to children with asthma."9.12Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. ( Aldington, S; Beasley, R; Weatherall, M; Williams, M, 2006)
"Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy."9.12Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006)
"The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma."9.12Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. ( Aizawa, H; Fukuyama, S; Inoue, H; Kanaya, A; Komori, M; Matsumoto, K; Matsumoto, T; Matsumura, M; Moriwaki, A; Nakanishi, Y; Nakano, T; Tsuda, M; Yoshida, M, 2007)
"Multiple studies have examined adding nebulized ipratropium bromide to intermittent albuterol for the treatment of acute asthma."9.12A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. ( Lavery, RF; Lebowitz, J; Moore, T; Reischel, U; Salo, D; Tuel, M, 2006)
"To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma."9.12Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. ( Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006)
" Thirty-six patients with persistent mild bronchial asthma were treated with the leukotriene receptor antagonist montelukast, administered once a day for 4 weeks."9.12Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. ( Hajduch, M; Janostáková, A; Jarmila, S; Kopriva, F; Zápalka, M, 2006)
"To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i."9.12Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. ( Albers, JM; Costongs, RJ; Schermer, TR; Verblackt, HW; Westers, P, 2007)
"Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study."9.12Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007)
" After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 microg of albuterol as needed (as-needed albuterol therapy); 250 microg of beclomethasone twice daily and 100 microg of albuterol as needed (regular beclomethasone therapy); or 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler twice daily plus 100 microg of albuterol as needed (regular combination therapy)."9.12Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. ( Canonica, GW; Crimi, N; Fabbri, LM; Maestrelli, P; Morelli, P; Nicolini, G; Olivieri, D; Paggiaro, P; Papi, A; Pozzi, E; Vignola, AM, 2007)
"This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma."9.12Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. ( Borrill, ZL; Houghton, CM; Langley, SJ; Lawson, N; Singh, D; Wixon, CL; Woodcock, A; Yoxall, S, 2007)
"To identify the asthma patients, on short-acting beta2-agonists alone, who would benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC) propionate 50/100 microg bd compared with fluticasone propionate (FP) 100 microg bd alone."9.12Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. ( Barnes, NC; Bateman, ED; Goldfrad, C; Jacques, L, 2007)
" After a 2-week run-in period, 228 patients with moderate to severe asthma were randomized to a 12-week treatment with either beclomethasone 100 microg plus formoterol 6 microg or fluticasone 125 microg plus salmeterol 25 microg, both delivered two inhalations b."9.12Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. ( Fabbri, LM; Nicolini, G; Paggiaro, P; Papi, A; Vignola, AM, 2007)
"The effect of ethnicity on the efficacy of salmeterol (S)+fluticasone propionate (FP) has not been examined in Japanese and Caucasian asthmatics."9.12Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. ( Hashimoto, K; Kawai, M; Kempsford, R; Lötvall, J; Pullerits, T; Takaori, S; Takemoto, Y, 2007)
"During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for 1 year."9.12Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Pedersen, SE; Yoxall, S, 2007)
"This study compared the bronchodilator efficacy and safety of indacaterol with placebo, salbutamol and salmeterol, in patients with persistent asthma, at single therapeutic and supratherapeutic doses."9.12Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. ( Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007)
"To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma."9.12Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. ( Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)
" 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1000 microg beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 microg) and fluticasone propionate (250 microg) in a single dry powder inhaler (Diskus) or 500 microg FP twice daily."9.11Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. ( Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004)
"Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone."9.11Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. ( Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)
"To determine whether a higher dose of albuterol is required to normalize lung function during nocturnal asthma."9.11Response to inhaled albuterol during nocturnal asthma. ( Ahrens, R; Beaty, R; Harman, EM; Hendeles, L; Stevens, G, 2004)
"A prospective, randomized, double blinded study was conducted to determine whether a combination of nebulized magnesium sulfate and albuterol as a single dose adds any benefit in management of children with mild to moderate asthma when compared to nebulized albuterol with saline."9.11Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. ( Haritos, D; Mahajan, P; Rosenberg, N; Thomas, R, 2004)
" Montelukast significantly reduced blood eosinophil counts compared with salmeterol, whereas salmeterol significantly increased prealbuterol forced expiratory volume in 1 second, asthma-specific quality of life, morning peak expiratory flow rate, and decreased nocturnal awakenings compared with montelukast."9.11Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. ( Bird, SR; Edelman, JM; Friedman, B; Hustad, CM; Ilowite, J; Kerwin, E; Webb, R, 2004)
"The effects of high-dose fluticasone propionate therapy on dynamic cortisol stimulation in severe asthma are unknown."9.11Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. ( Bates, CE; Cowan, LM; Currie, GP; Lee, DK; Lipworth, BJ; McFarlane, LC, 2004)
"To determine whether initiation of maintenance treatment with the salmeterol (S)/fluticasone propionate (FP) combination (Seretide/Viani/Advair) is more effective than inhaled steroid alone in patients with asthma symptomatic on short-acting bronchodilator alone."9.11Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. ( Luckow, A; Strand, AM, 2004)
"We report a 4 yr follow up study of seven asthmatic children with chronic persistent asthma, high-residual volume and low-density areas at high-resolution computerized tomography after treatment with salmeterol and fluticasone."9.11Montelukast and airway remodeling in children with chronic persistent asthma: an open study. ( Boner, AL; Caramella, D; De Marco, E; Pietrobelli, A; Pifferi, M; Ragazzo, V, 2004)
"To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children."9.11Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004)
"The goal of this study was to evaluate the efficacy, tolerability, and effect on asthma-related quality of life (QOL) of a long-acting beta(2)-adrenoreceptor agonist, formoterol, delivered via multidose DPI, compared with albuterol delivered via pMDI or placebo in adolescents and adults with persistent asthma."9.11Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p ( Andriano, K; Busse, W; Lavecchia, C; Levine, B; Yegen, U, 2004)
"The present study aimed to investigate whether a fixed combination of salmeterol and fluticasone (SFC) from a single inhaler provides sufficient asthma control comparable to that achieved with standard treatment (inhaled steroid in a dose of 1,000 mcg BDP- (beclomethasone dipropionate) equivalent plus a LABA and/or theophylline and/or montelukast)."9.11[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. ( Liefring, E; Molitor, S; Trautmann, M, 2005)
"To evaluate the efficacy and the safety of low dose salmeterol/fluticasone (SM/FP) combination therapy as compared to morate dose of budesonide (BUD) in the management of adult asthma."9.11[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. ( Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)
"Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted."9.11Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. ( Cline, SM; Coakley, TA; Euwema, MS; Knecht, KR; Ralston, ME; Ziolkowski, TJ, 2005)
"A randomised, open-label, multicentre study compared the efficacy and tolerability of salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) delivered via a hydrofluoroalkane metered-dose inhaler (HFA-MDI) and salmeterol 50microg/fluticasone propionate 250 microg (one puff, twice daily) delivered via a Diskus inhaler in Chinese patients with moderate asthma uncontrolled with inhaled corticosteroids (ICSs)."9.11Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. ( Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005)
"An efficacy treatment study is conducted comparing levalbuterol to racemic albuterol for acute pediatric asthma in the emergency department (ED)."9.11Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. ( Burke, BL; Meadows, T; Qureshi, F; Welch, C; Zaritsky, A, 2005)
"To compare levalbuterol and racemic albuterol for the treatment of acute exacerbation of asthma in pediatric population."9.11Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. ( Bithoney, WG; DeBari, V; Gold, N; Hardasmalani, MD, 2005)
"To compare the safety of twice-daily treatment with inhaled fluticasone propionate plus the inhaled long-acting beta2-agonist salmeterol with that of fluticasone propionate used alone in children aged 4 to 11 years with persistent asthma."9.11The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. ( Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005)
"To determine the relative cost-effectiveness of twice-daily treatment with inhaled fluticasone propionate-salmeterol via Diskus, 100/50 microg, with that of once-daily treatment with oral montelukast as initial maintenance therapy in patients with persistent asthma uncontrolled with a short-acting beta2-agonist alone."9.11Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Rickard, K, 2005)
"To determine and define the beneficial effects of heliox-driven albuterol therapy on severe asthma exacerbation and clinical factors that affect greater response."9.11Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. ( Chang, HW; Hsu, CW; Huang, YC; Lee, DL; Lee, H, 2005)
"In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically as effective as regular, scheduled administration."9.11Regular vs ad-lib albuterol for patients hospitalized with acute asthma. ( Chandra, A; Chung, V; Cohen, HW; Dhuper, S; Maggiore, D; Mani, K; Shim, C, 2005)
"Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo."9.11Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005)
"Continuously nebulized albuterol delivered by heliox was associated with a greater degree of clinical improvement compared with that delivered by oxygen among children with moderate to severe asthma exacerbations."9.11Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. ( Corcoran, T; Funt, N; Gracely, E; Kim, IK; Phrampus, E; Pitetti, R; Saville, A; Thompson, A; Venkataraman, S, 2005)
"To evaluate the efficacy and safety of mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids."9.11Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. ( Busse, WW; Karpel, JP; Lutsky, B; Monahan, ME; Noonan, MJ; Staudinger, H, 2005)
"Forty-two asthmatic patients sensitized to pollen allergens were randomly allocated to treatment with fluticasone propionate-salmeterol (n=21) or fluticasone propionate alone (n=21)."9.11Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. ( Badiola, C; Bruno, L; Ferrer, A; Gutiérrez, V; Lanuza, A; Pérez-Francés, C; Prieto, L, 2005)
"To investigate whether, after 48 h of IV treatment with corticosteroids, the use of high-dose inhaled flunisolide is as effective as systemic corticosteroids in adults hospitalized for a severe asthma exacerbation."9.10Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. ( Acquah, S; Dayrit, FM; Kohli, AR; Lee-Wong, M; Mayo, PH, 2002)
"To compare the relative cost effectiveness of salmeterol (50 microg)/ fluticasone propionate (100 microg) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone."9.10Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Rickard, K; Sheth, K, 2002)
"We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone."9.10Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. ( Bates, CE; Currie, GP; Haggart, K; Lee, DK; Lipworth, BJ, 2003)
"The aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propionate combination product (SFC) with fluticasone propionate (FP) plus oral montelukast (M) over 12 weeks in symptomatic asthma patients."9.10The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. ( Akveld, M; Bateman, ED; Eliraz, A; Mulder, PG; Pruzinec, R; Ringdal, N; Weber, HH, 2003)
"A prospective, randomized, double-blind study was conducted to determine whether there was any benefit to the addition of ipratropium to a single nebulized albuterol treatment in infants and children with mild to moderate acute asthma presenting to a pediatric office."9.10Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office. ( Gunawardane, G; Kumaratne, M, 2003)
"The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear."9.10Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. ( Begent, J; Buchdahl, R; Gomez, K; Habel, A; Lachman, P; Newsom, D; Raffles, A; Roberts, G; Saglani, S; Sloper, K, 2003)
"Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks."9.10Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003)
"Fifteen mild-to-moderate asthmatics (mean FEV(1) 80% predicted) uncontrolled on inhaled corticosteroids (mean dose 470 microg) were randomised in a single-blind crossover fashion to receive 2 weeks each of fluticasone 250 microg plus salmeterol 50 microg in combination (FP+SM), 1 puff b."9.10Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. ( Bates, CE; Currie, GP; Jackson, CM; Lee, DK; Lipworth, BJ, 2003)
"The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid."9.10Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003)
"The objective of this study was to evaluate parental preference for the treatment of asthmatic children with oral montelukast sodium or inhaled cromolyn sodium."9.10Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. ( Bird, SR; Bratton, DL; Bukstein, DA; Edelman, JM; Estojak, J; Firriolo, KM; Hustad, CM, 2003)
"To compare the efficacy and safety of twice-daily fluticasone propionate (FP) 88 microg and salmeterol 42 microg combined in a chlorofluorocarbon (CFC)-free (hydrofluoroalkane 134a) metered-dose inhaler (MDI) with the individual agents alone, each delivered through an MDI containing CFC propellants, in patient with persistent asthma previously uncontrolled with as-needed short-acting beta2-agonists alone."9.10Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. ( Baitinger, L; Dorinsky, P; Greos, LS; Gross, G; Nelson, HS; Scott, C; Wolfe, JD, 2003)
"To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide."9.10Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. ( Bisgaard, H; Buchvald, F, 2003)
"To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone."9.10Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. ( Bisgaard, H; Bjermer, L; Bousquet, J; Dass, SB; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Leff, JA; Menten, J; Picado, C; Polos, PG, 2003)
"To determine whether levalbuterol resulted in fewer hospital admissions than racemic albuterol when used for treatment of acute asthma."9.10Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. ( Carl, JC; Kercsmar, CM; Kirchner, HL; Myers, TR, 2003)
"Treatment of moderate-to-severe asthma with salmeterol/fluticasone propionate resulted in superior gains in HR-QOL relative to increasing the dose of inhaled corticosteroids."9.10Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. ( James, MH; Jenkins, C; Juniper, EF; Price, MJ, 2002)
"The goal of the present study was to evaluate the efficacy and safety of salmeterol/ fluticasone (50/250 microg twice daily) as initial treatment for symptomatic patients with mild to moderate bronchial asthma who had not previously received appropriate anti-asthma medication."9.10Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). ( Baumgarten, C; Behre, U; Geldszus, R; Peslis, N; Trautmann, M, 2002)
"Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast."9.10Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. ( Bowers, B; Dorinsky, P; Emmett, A; Kalberg, C; Lieberman, AK; Pearlman, DS; Pepsin, PJ; Rickard, KA; White, MV, 2002)
" Patients kept records of peak flow meter (PFM) measurements, asthma attack rate and beta-2-agonist use (albuterol)."9.10Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial. ( Chervinsky, P; Goldstein, MF, 2002)
" We studied the spirometric effects of albuterol nebulized with heliox during emergency room visits for asthma exacerbations."9.10The utility of albuterol nebulized with heliox during acute asthma exacerbations. ( Barman, N; Gehlbach, BK; Hall, JB; Kress, JP; Miller, A; Morgan, S; Noth, I; Pohlman, AS, 2002)
"We sought to compare the efficacy and safety of nebulized magnesium sulfate (MgSO(4)) plus albuterol with that of albuterol alone in adult patients with mild-to-moderate acute asthma exacerbations."9.10A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. ( Becker, E; Bessmertny, O; Cohen, H; DiGregorio, RV; Golden, J; Johnson, T; Kohl, L; Looney, D, 2002)
" Sixty-three adolescent and adult asthmatic patients were randomized to receive at separate treatment visits single doses via a pressurized metered-dose inhaler of either placebo/hydrofluoroalkane (HFA) 134a; 100 microg, 200 microg, or 400 microg albuterol/HFA 134a; 100 microg or 200 microg albuterol/chlorofluorocarbon (CFC)."9.10A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. ( Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002)
"We examined the partitioning of total lung resistance (RL) into airway resistance (Raw) and tissue resistance (Rti) in patients with mild to moderate asthma (baseline FEV1, 54 to 91% of predicted) before and after albuterol inhalation."9.09Airway and lung tissue mechanics in asthma. Effects of albuterol. ( Ingenito, EP; Israel, E; Kaczka, DW; Lutchen, KR, 1999)
"Thus in stable asthmatic subjects receiving regular salmeterol or formoterol, bronchoprotective subsensitivity was not overcome by administering a high dose of albuterol."9.09A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. ( Aziz, I; Lipworth, BJ, 1999)
"To compare the effectiveness of a helium-oxygen mixture with that of oxygen alone as an aerosolizing gas for beta-agonist therapy in patients with mild to moderate exacerbation of asthma."9.09Use of heliox-driven nebulizer therapy in the treatment of acute asthma. ( Acharya, P; Chan, LS; Henderson, SO; Kilaghbian, T; Korn, CS; Perez, J, 1999)
"The optimal dose of albuterol to use in the treatment of acute asthma has yet to be established."9.09Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. ( Cydulka, RK; Emerman, CL; McFadden, ER, 1999)
"To compare the long-term efficacy and safety of albuterol administration using a Spiros Inhalation System (Dura Pharmaceuticals; San Diego, CA) dry powder inhaler (DPI) and albuterol (Ventolin; Glaxo Wellcome; Research Triangle Park, NC) administration using a metered-dose inhaler (MDI) in patients with asthma."9.09Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. ( Bieler, S; Hill, MR; Kemp, JP; Nelson, H; Vaughan, LM, 1999)
"To evaluate the 12-hour efficacy and safety of single doses of 25 micrograms and 50 micrograms of salmeterol powder administered via Diskus inhaler versus albuterol aerosol via pressurized metered-dose inhaler and placebo in preventing EIB in asthmatic children."9.09Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. ( Arledge, T; Blake, K; Pearlman, DS; Scott, C; Stahl, E; Wang, Y, 1999)
"To determine whether initiation of salmeterol and fluticasone propionate treatment together improves asthma control greater than initiation of monotherapy with the individual agents alone with no additional safety risk in patients with asthma who had not previously been treated with inhaled corticosteroids."9.09Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. ( Chervinsky, P; Gross, G; Pearlman, DS; Prillaman, B; Shah, T; Stricker, W; Weinstein, S; Woodring, A, 1999)
"Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma."9.09Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. ( Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999)
"The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients."9.09The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. ( DeGraw, SS; Gawchik, SM; Noonan, M; Reasner, DS; Saccar, CL, 1999)
"In a randomized, double-blind, placebo-controlled trial, 56 adult asthmatic patients with peak expiratory flow rates (PEFRs) less than 50% predicted after an initial albuterol aerosol treatment were studied."9.09Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. ( Bakalchuk, L; Curry, A; Dow, AM; Heyl, GT; Lin, RY; Pesola, GR; Tenenbaum, C; Westfal, RE, 1999)
"In patients with mild-to-moderate asthma in this study, the albuterol DPI was determined to be therapeutically comparable to albuterol MDI in the delivery of one and two actuations of albuterol."9.09Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. ( Ahrens, R; Clarke, W; Geoffroy, P; Grossman, J; Hill, MR; Lalonde, RL; Vaughan, LM, 1999)
"Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma."9.09The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. ( Condemi, JJ; Emmett, A; Goldstein, S; Kalberg, C; Rickard, K; Yancey, S, 1999)
"The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids."9.09Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. ( Mol, SJ; Mulder, PG; Schreurs, AJ; van Noord, JA, 1999)
"We sought to compare the efficacy and safety of 2 doses of fluticasone propionate (88 micrograms twice daily and 220 micrograms twice daily) with 2 doses of beclomethasone dipropionate (168 micrograms twice daily and 336 micrograms twice daily) in subjects with persistent asthma."9.09A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. ( Baker, J; Edwards, L; Lanier, RQ; Lincourt, WR; Raphael, GD; Rickard, K, 1999)
" We undertook a double-blind, randomized, placebo-controlled, cross-over study to investigate the effects of a single dose of formoterol inhaled via Turbuhaler (12 micrograms) and of albuterol inhaled via Turbuhaler (200 micrograms) on airway responsiveness to AMP and histamine in 16 subjects with mild atopic asthma."9.09Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. ( Barnes, PJ; Nightingale, JA; Rogers, DF, 1999)
"To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma."9.09Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. ( Mende, CN; Petrocella, VJ; Rickard, KA; Wiegand, L; Yancey, SW; Zaidel, G; Zwillich, CW, 1999)
"In children with mild acute asthma, to compare treatment with a single dose of albuterol delivered by a metered dose inhaler (MDI) with a spacer in either a weight-adjusted high dose or a standard low-dose regimen with delivery by a nebulizer."9.09Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. ( Callahan, S; Canny, GJ; Johnson, DW; Schuh, S; Stephens, D; Winders, P, 1999)
" In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients."9.09Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. ( Fujimura, M; Hashimoto, T; Hirose, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S; Tachibana, H, 1999)
"To compare efficacy of an extended release oral beta-2 agonist, albuterol sulfate (Volmax), to a long-acting inhaled agent, salmeterol (Serevent) in the treatment of nocturnal asthma."9.09Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma. ( Beaucher, WN; Kiechel, F; Kraft, M; LaVallee, N; Martin, RJ; Shilstone, J; Sublett, JL, 1999)
"Outcome measures included FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment."9.09Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. ( Baraniuk, J; Berger, WE; Edwards, LD; Johnson, M; Murray, JJ; Nathan, RA; Rickard, KA; Srebro, S, 1999)
"We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic."9.09Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. ( Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999)
"To evaluate the efficacy of nebulized budesonide compared to oral prednisolone early in the emergency room management of acute asthma, we conducted a double-blind, placebo-controlled trial."9.09Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. ( Jayshree, M; Kumar, L; Singhi, S, 1999)
"Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma."9.09The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. ( Bradding, P; Britten, KM; Gratziou, C; Holgate, ST; Howarth, PH; Roberts, JA; Walls, AF; Wilson, S, 1999)
"Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial."9.09Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. ( Everts, B; Hedner, J; Möller, CS, 1999)
"Fluticasone propionate 880 microg/day improved lung function and quality of life in adolescents with moderate-to-severe asthma when compared with flunisolide 1500 microg/day."9.09Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma. ( Eid, N; Goldsmith, LJ; Howell, L; Sheikh, S, 1999)
"All active treatment groups showed statistically significant improvement compared with placebo in pulmonary function (FEV1, FEF25-75%, morning and evening PEF), use of rescue albuterol, and asthma symptom scores."9.09Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. ( Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999)
" Efficacy was assessed by spirometry, and by daily recordings of albuterol use, peak expiratory flow (PEF), asthma symptom ratings, and nighttime awakenings throughout the study."9.09A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. ( Banerji, D; Bernstein, D; Gross, G; Kane, RE; Welch, M, 1999)
"Three hundred forty-nine patients with asthma previously treated with medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 microg, FP 250 microg, or placebo, each given twice daily through a Diskus device for 12 wk."9.09Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. ( Baitinger, L; Given, J; House, K; Lumry, W; Prillaman, B; Shah, T; Shapiro, G; White, MV; Wolfe, J; Woodring, A, 2000)
"Magnesium sulfate is thought to be an effective bronchodilator when administered intravenously to patients with acute severe asthma, and it can be safely administered via inhalation to patients with stable asthma."9.09Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. ( Corna, RA; Mannarino, S; Nannini, LJ; Pendino, JC; Quispe, R, 2000)
"Twelve asthmatic patients were enrolled into a single-blind, placebo-controlled, crossover study, receiving additive therapy as either of the following: (1) montelukast alone, 10 mg (ML(10)); (2) inhaled salmeterol alone, 50 microg (SM(50)); (3) ML(10) and SM(50); (4) ML(10) and inhaled salmeterol, 100 microg (SM(100)); or (5) placebo inhaler and tablet."9.09Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Mistry, C; Sims, EJ; Wilson, AM, 2000)
"Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma."9.09Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. ( Arshad, H; Harrison, JE; Holgate, ST; Stryszak, P, 2000)
"Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)."9.09Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. ( Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000)
"Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide 800-1200 microg day(-1) (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 microg and fluticasone propionate 250 microg (Seretide, Advair, Viani 50/250 microg) twice daily or budesonide 800 microg twice daily for 24 weeks."9.09Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. ( James, MH; Jenkins, C; Lundback, B; Saarelainen, P; Woolcock, AJ, 2000)
"Once-daily treatment with fluticasone propionate resulted in an improvement in efficacy variables, such as FEV(1), morning and evening peak expiratory flow (PEF), asthma symptom scores, nighttime awakenings, albuterol use, and duration of study participation."9.09A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. ( Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000)
"To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma."9.09Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. ( Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)
"Eighteen patients with mild-to-moderate persistent asthma receiving inhaled corticosteroid who expressed the homozygous glycine-16 genotype were randomized to completion (mean [SEM] age, 35."9.09Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. ( Aziz, I; Dempsey, OJ; Lipworth, BJ, 2000)
"This study was undertaken to compare the outcome of adults with acute severe asthma treated with 4 puffs of salbutamol (100 microg/actuation) every 20 minutes for 3 doses plus 4 puffs of oxitropium bromide (100 microg/actuation) with each of the 3 salbutamol doses versus salbutamol alone administered by means of a metered-dose inhaler with a spacer device."9.09Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ( Chida, K; Enomoto, N; Hirai, R; Kawamoto, A; Nakano, Y, 2000)
"The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists."9.09Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. ( Berkowitz, RB; Harrison, JE; Kemp, JP; Miller, SD; Murray, JJ; Nolop, K, 2000)
"Intravenous magnesium sulfate (MgSO4), as an adjunctive medication to the standard treatment of acute asthma, improves admission rate or severity score in acute severe asthma patients."9.09Intravenous magnesium sulfate in acute severe asthma. ( Boonyavorakul, C; Charoenpan, P; Thakkinstian, A, 2000)
" The authors performed a prospective, randomized, double-blind, placebo-controlled trial to test the ability of intravenous lidocaine and inhaled albuterol to attenuate airway reactivity after tracheal intubation in asthmatic patients undergoing general anesthesia."9.09Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. ( Boughton, R; Darvish, A; Israel, E; Loring, SH; Maslow, AD; Mehrez, M; Regan, MM, 2000)
"FP/Salm Combo treatment provided better overall asthma control than FP + montelukast with significantly greater improvements in morning peak expiratory flow (+24."9.09Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. ( Busse, WW; Church, N; Emmett, A; Kerwin, E; Knobil, K; Nelson, HS; Rickard, K, 2000)
"This was an open-label, parallel group, randomized, age-stratified, multicenter study designed to compare the safety and efficacy of regular use of albuterol formulated in hydrofluoroalkane-134a (HFA albuterol) and albuterol formulated in chlorofluorocarbons-11/12 (CFC albuterol) in children with asthma."9.09Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Shapiro, GS, 2000)
"This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 microg administered twice daily to patients with mild-to-moderate asthma for 12 weeks."9.09Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. ( Bateman, ED; Bogolubov, M; Silins, V, 2001)
"Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy."9.09Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Sims, EJ; Wilson, AM, 2001)
"Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids."9.09Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. ( Boone, R; Emmett, A; Fish, JE; Israel, E; Murray, JJ; Rickard, KA; Yancey, SW, 2001)
"Asthmatic children having their tracheas intubated with sevoflurane often have an increase in respiratory system resistance (Rrs)."9.09Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. ( Habre, W; Scalfaro, P; Sims, C; Sly, PD, 2001)
"To determine whether the addition of inhaled ipratropium bromide to inhaled albuterol and systemic corticosteroid therapy was more efficacious than inhaled albuterol and systemic corticosteroids alone in the inpatient treatment of acute asthma exacerbations in children."9.09Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. ( Goggin, N; Macarthur, C; Parkin, PC, 2001)
" In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective."9.09Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. ( Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001)
"The aim of this study was to evaluate if continuous treatment with budesonide or salmeterol influences the bronchodilator response to terbutaline in children with asthma; 23 children, aged 7 to 16 years (mean = 11 years), with mild asthma were treated with inhaled budesonide 100 micrograms b."9.08Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995)
"High-dose continuous nebulization of albuterol is as safe and as efficacious as intermittent nebulization of albuterol in the early treatment of asthma in an emergency department."9.08Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. ( Dworkin, G; Kotch, A; Reisner, C, 1995)
"The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec) against controlled release (CR) salbutamol (Volmax) in the treatment of nocturnal asthma."9.08Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. ( Ayres, JG; Gunn, SD; McConchie, SM, 1995)
"We have recently demonstrated that a 2-week course of inhaled albuterol 200 micrograms four times daily caused a near doubling of the allergen-induced early asthmatic response."9.08Regular use of inhaled albuterol and the allergen-induced late asthmatic response. ( Bhagat, R; Cockcroft, DW; O'Byrne, PM; Swystun, VA, 1995)
"Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol."9.08Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995)
"Salmeterol (42 micrograms twice daily) was compared with the short-acting beta 2-agonist albuterol (180 micrograms four times daily) in two double-blind, randomized studies involving 556 patients with mild-to-moderate asthma."9.08Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. ( Pearlman, DS, 1995)
"The objective of this trial was to determine the efficacy of frequent nebulized ipratropium added to high-dose albuterol therapy in children with severe asthma."9.08Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. ( Callahan, S; Canny, G; Johnson, DW; Levison, H; Schuh, S, 1995)
"This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma."9.08Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995)
"Adult, nonsmoking patients with mild to moderate asthma were randomized to receive 4 mg nedocromil sodium (n = 13), 200 micrograms albuterol (n = 13), or placebo (n = 12) four times daily for 16 wk in a double-blind, double-dummy protocol."9.08Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. ( Davies, RJ; Devalia, JL; Manolitsas, ND; McAulay, AE; Trigg, CJ; Wang, J, 1995)
"Asthmatics aged 18 to 65 years during acute exacerbation with FEV1 less than 75% predicted both before and after a single albuterol treatment."9.08Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. ( Bloch, H; Grant, S; Jagminas, L; Mancherje, N; Scharf, SM; Silverman, R, 1995)
"In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks."9.08Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol. ( Findlay, SR; Furukawa, CT; Gross, GN; Henochowicz, SI; Hudson, LD; Marcoux, JP; Myers, DJ; Prenner, BM; Steinberg, P; Wasserman, SI, 1995)
"We performed a double-blind, two-phase study on protective and bronchodilator effects of prostaglandins E2 and E1 (PGE2, PGE1) and salbutamol in patients with aspirin-induced asthma (AIA)."9.08Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. ( Cmiel, A; Mastalerz, L; Nizankowska, E; Szczeklik, A, 1996)
"This was a 4-week, open-label, parallel-group study designed to compare the efficacy and safety of the long-acting inhaled bronchodilator, salmeterol, with the established inhaled bronchodilator, terbutaline, in the treatment of patients with mild to moderate asthma."9.08A 4-week comparison of salmeterol and terbutaline in adult asthma. ( Hermansson, BA; Jenkins, RJ, 1995)
"The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year."9.08Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995)
"To compare the magnitudes of the immediate effects of the nebulized beta-agonists isoetharine and albuterol in the treatment of acute severe asthma."9.08Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. ( Bidadi, K; Gourlay, S; Hayes, J; Robertson, S; Shrestha, M; Wainscott, M, 1996)
"Albuterol sulfate, in the syrup and tablet form for oral administration, has been an effective treatment for adults and children with bronchial asthma."9.08Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. ( Boltansky, H; Harrison, JE; Kobayashi, RH; Lorber, RR; Pearlman, DS; Shapiro, G; Skoner, DP; Trochelmann, LM, 1996)
"Azelastine, an oral nonsteroidal, antiinflammatory drug with a good safety profile, has demonstrated relief of symptoms in patients with asthma."9.08An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996)
"Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid effective in the treatment of asthma."9.08A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. ( Gross, GN; Kellerman, DJ; Kral, KM; Munk, ZM; Schaberg, A; Schoenwetter, WF; Wasserman, SI, 1996)
"The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma."9.08The effect of inhaled albuterol in moderate to severe asthma. ( Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996)
"The inhaled corticosteroid, fluticasone propionate, was compared with the oral bronchodilator theophylline in the maintenance treatment of asthma."9.08Fluticasone propionate compared with theophylline for mild-to-moderate asthma. ( Baker, KA; Galant, SP; Kellerman, DJ; Lawrence, M; Meltzer, EO; Tomasko, M, 1996)
"In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients)."9.08Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. ( Boushey, HA; Chinchilli, VM; Drazen, JM; Fahy, JV; Fish, JE; Israel, E; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ, 1996)
"To evaluate the role of inhaled ipratropium bromide in acute asthma, a double-blind study of 384 emergency department patients compared the effect of the combination of ipratropium and albuterol with that of albuterol alone."9.08A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. ( Aldrich, T; Fanta, C; Karpel, JP; Levey, D; Menjoge, SS; Schacter, EN; Spiro, P; Witek, TJ, 1996)
"The purpose of the study was to compare bronchodilator responses to albuterol between an ultrasonic and a jet nebulizer in moderate to severe asthma."9.08A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. ( Leickly, FE; Pallares, DE; Pilarski, BR; Rodriguez, JL, 1996)
"To compare the efficacy and safety of continuous nebulized (CN) albuterol therapy with those of intermittent nebulized (IN) albuterol therapy in the ED treatment of children with moderate to severe asthma exacerbations."9.08Continuous vs intermittent nebulized albuterol for emergency management of asthma. ( Fuchs, SM; Khine, H; Saville, AL, 1996)
"Nedocromil sodium is recommended for daily treatment of mild persistent asthma but its effect on cellular changes in asthmatic airways is poorly understood."9.08Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1996)
" The bronchodilator, cardiovascular, and tremorigenic responses following administration of salbutamol (SAL), terbutaline (TER) and fenoterol (FEN) by closed-port intermittent nebulization were compared for a period of 8 hr."9.08Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. ( Naspitz, CK; Scalabrin, DM; Solé, D, 1996)
"These results confirm that there is activation of the RAS in asthmatic subjects by single doses of nebulized beta 2-agonists and that repeated dosing with nebulized albuterol has further, additive effects on plasma Ang II levels."9.08The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. ( Connell, JM; Millar, EA; Thomson, NC, 1997)
"Nocturnal cough and wheeze are common in asthma and often treated with beta2 agonists or theophyllines."9.08Inhaled salmeterol or oral theophylline in nocturnal asthma? ( Douglas, NJ; Engleman, HM; Fitzpatrick, MF; Mackay, TW; Selby, C; Sime, PM, 1997)
" The present study was undertaken to compare the therapeutic effects of sustained release theophylline and a conventional low dose oral fenoterol in patients with asthma."9.08Oral fenoterol versus sustained release theophylline in adult asthmatics. ( Almagro, J; Andrade, RJ; Hidalgo Sanchez, R; Lucena, MI; Sanchez de la Cuesta, F, 1997)
"Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial."9.08Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. ( Botto, A; Busse, WW; Kundu, S; Reiss, TF; Sorkness, CA; Stricker, W; Zhang, J, 1997)
"To determine the efficacy of combination therapy using atropine sulfate and albuterol in the treatment for an acute exacerbation of asthma."9.08Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. ( Bradley, K; Díaz, JE; Dubin, R; Gaeta, TJ; Pelczar, P, 1997)
"The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid."9.08The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. ( Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997)
"Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler."9.08Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. ( Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)
"Although theophylline is recommended by current guidelines for the management of asthma in patients with persistent symptoms, theophylline has a narrow therapeutic index, requiring individual dose titration and regular monitoring of serum theophylline concentrations to avoid adverse effects."9.08Salmeterol versus theophylline in the treatment of asthma. ( Cox, FM; Emmett, A; Pollard, SJ; Spector, SL; Yancey, SW, 1997)
"The aim of the present study was to compare the efficacy and the tolerability of salmeterol and theophylline in patients with nocturnal asthma."9.08[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance]. ( Braun, H; Koper, I; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D, 1997)
" In a recent study in 17 adults with stable asthma, albuterol given using an ultrasonic nebulizer (UN) appeared to produce greater bronchodilatation than the same dose of albuterol given by a jet nebulizer (JN)."9.08Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. ( Foster, C; Lamb, BM; Nakanishi, AK; Rubin, BK, 1997)
"To determine the optimal treatment interval for administering albuterol metered-dose inhaler (MDI) with a holding chamber to patients presenting to the emergency department (ED) with acute asthma."9.08Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? ( Aldrich, TK; Gaitan-Salas, A; Guguchev, K; Karpel, JP; Pathiparti, R; Prezant, DJ, 1997)
" Efficacy was assessed by changes in FEV1, asthma symptom scores, albuterol use, and peak flow rates."9.08Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. ( Farrar, JR; Feiss, G; Levy, S; Smith, JA; Welch, MJ, 1997)
" A total of 291 male and female patients at least 12 years of age with asthma (FEV1 between 50% and 80% of predicted value), who had previously received maintenance therapy with beclomethasone dipropionate or triamcinolone acetonide, were switched to treatment with fluticasone propionate powder (250 microg twice daily), triamcinolone acetonide aerosol (200 microg four times daily), or placebo for 24 weeks."9.08Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. ( Ayars, GH; Berger, WE; Chervinsky, P; Condemi, JJ; Edwards, L; Ford, LB; Goldstein, MF; Pepsin, PJ; Rogenes, PR, 1997)
" We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma."9.08Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. ( Aikman, SL; Barnes, PJ; Harris, JG; Jensen, MW; O'Connor, BJ; Taylor, DA, 1997)
"We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma."9.08Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997)
"To assess the effect of a long-acting inhaled beta 2-agonist, salmeterol (SM), compared to a short-acting inhaled beta 2-agonist, salbutamol (or albuterol, SB) on the occurrence of morning dip (MD) in patients recovering from an acute severe asthma attack (ASA)."9.08Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack. ( Arnold-Ketterer, M; Chevrolet, JC; Ritz, M; Thorens, JB, 1997)
"In a randomized, double-blind, placebo-controlled trial, 55 adult asthmatic patients with peak expiratory flow rate (PEFR) less than 200 L/min were randomly assigned to nebulization treatment with albuterol alone (2."9.08Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. ( Bakalchuk, L; Cataquet, D; Freyberg, CW; Heyl, GT; Lin, RY; Morgan, JP; Pesola, GR; Westfal, RE, 1998)
"We assessed the acute bronchodilator effect of nebulized furosemide when added to conventional therapy of acute emergency department (ED) asthma."9.08Effect of inhaled furosemide in acute asthma. ( Chapman, KR; Molfino, NA; Nannini, LJ; Pendino, JC; Slutsky, A, 1998)
"This randomized, double-blind trial was designed to determine the benefit of high and cumulative doses of flunisolide added to salbutamol in patients with acute asthma in the emergency room (ER)."9.08Inhaled flunisolide for acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998)
" We compared the safety and efficacy of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) in 306 patients with moderate to severe asthma in a double-blind, multicenter, cross-over study of 12 mo duration."9.08Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. ( Demedts, MG; Geusens, P; Pauwels, RA; Yernault, JC, 1998)
"Although these preliminary results suggest that nebulized budesonide may be an effective adjunct to oral prednisone in the management of moderate to severe asthma exacerbations, a larger trial will be required before the widespread use of inhaled budesonide in acute asthma can be advocated."9.08Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. ( Klassen, TP; Osmond, MH; Sung, L, 1998)
" Efficacy was measured by weekly spirometry and daily diary recordings of peak flow rates, asthma symptom scores, and albuterol use."9.08A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. ( Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998)
"The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma."9.08Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998)
"To evaluate the impact on asthma-specific quality of life, efficacy, and safety of salmeterol versus albuterol in adult patients with mild-to-moderate persistent asthma."9.08Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. ( Cox, F; Emmett, A; Kalberg, C; Lumry, W; Manning, M; Rickard, K; Wenzel, SE, 1998)
"The aim of the present multicentre, open, randomized, parallel group study was to evaluate the efficacy and safety of salmeterol versus theophylline in asthmatic patients."9.08Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline. ( Martini, T; Nutini, S; Righi, R, 1998)
"In an emergency department, 160 patients who presented with acute exacerbations of asthma received either standard (n = 80) or high-dose (n = 80) albuterol treatment."9.08Comparison of two dosage regimens of albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1998)
" Overall reductions in supplemental albuterol use and mean asthma symptom scores were also significantly greater in children administered salmeterol compared with placebo (P=."9.08Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. ( Arledge, T; Bronsky, EA; Byrne, A; Liddle, R; Pearlman, DS; Stahl, E; Weinstein, SF, 1998)
"We determined the effect of a long acting beta2-agonist, salmeterol, on aspirin-induced asthma (AIA) attacks and urinary release of eicosanoids in a double-blind, placebo-controlled, crossover study in 10 asthmatics sensitive to aspirin."9.08Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. ( Cmiel, A; Dworski, R; Mastalerz, L; Nizankowska, E; Oates, JA; Prokop, A; Sheller, JR; Szczeklik, A, 1998)
"To determine whether children with severe acute asthma treated with large doses of inhaled salbutamol, inhaled ipratropium, and intravenous steroids are conferred any further benefits by the addition of aminophylline given intravenously."9.08Randomised controlled trial of aminophylline for severe acute asthma. ( South, M; Yung, M, 1998)
"To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma."9.07Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. ( D'Alonzo, GE; Henochowicz, S; Morris, RJ; Nathan, RA; Ratner, P; Rennard, SI, 1994)
"The aim of the multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial with a 2-week treatment period was to compare the efficacy and safety of salmeterol (50 micrograms twice daily) with slow-release (SR) terbutaline (5 mg orally, twice daily) in nocturnal asthma."9.07Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group. ( Bertin, L; Brambilla, C; Chastang, C; Georges, D, 1994)
"This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)."9.07Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994)
"We investigated whether the beta 2-agonists fenoterol and salbutamol decreased plasma selenium and glutathione peroxidase activity in patients with asthma as this may partially explain the findings of reduced selenium status in asthmatic patients."9.07Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma. ( Beasley, R; Bremner, P; Burgess, CD; Crane, J; Siebers, RW; Thomson, CD, 1994)
"We conducted a randomized, double-blind, placebo-controlled study to determine if intravenous aminophylline adds any benefit to high doses of inhaled salbutamol in patients who presented for treatment of acute asthma."9.07Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. ( Rodrigo, C; Rodrigo, G, 1994)
"A double-blind, randomized, crossover study was done to determine the efficacy of colchicine in 30 atopic children with moderately severe asthma."9.07A clinical study of colchicine in childhood asthma. ( Adalioglu, G; Saraçlar, Y; Tuncer, A; Türktas, I, 1994)
"Clinical studies of inhaled salmeterol xinafoate have been conducted mainly in moderately to severely affected asthmatic subjects in hospital settings."9.07Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. ( Jones, KP, 1994)
"5 mg) albuterol (salbutamol) over 1 h in 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (PEF) below 150 L/min and hypercapnia (Pa(CO2) > or = 40 mm Hg)."9.07Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. ( Brochard, L; Duroux, P; Henry-Amar, M; Mal, H; Renon, D; Salmeron, S; Simonneau, G; Tenaillon, A, 1994)
"In a double-blind, double-placebo, randomized crossover study, we compared the effects of 6 wk of treatment with the anti-inflammatory drug nedocromil sodium (16 mg/day) with 6 wk of treatment with the bronchodilator drug albuterol (800 micrograms/day) in 29 adults with allergic asthma."9.07Nedocromil sodium versus albuterol in the management of allergic asthma. ( de Jong, JW; de Monchy, JG; Koëter, GH; Postma, DS; Teengs, JP; van der Mark, TW, 1994)
"To evaluate the effects of aminophylline (Am) in children hospitalized with asthma."9.07Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. ( Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)
"The use of oral prednisolone (2 mg/kg) to treat children admitted to hospital with acute asthma was assessed in a placebo controlled study."9.07Prednisolone and salbutamol in the hospital treatment of acute asthma. ( Connett, GJ; Lenney, W; Warde, C; Wooler, E, 1994)
"In an open randomised study 25 patients with severe acute asthma who presented to the emergency department were treated with either a combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0."9.07Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. ( Ismail, O; Yusoff, K; Zainudin, BM, 1994)
"Patients who presented to the ED with moderate to severe asthma and did not improve after one treatment with nebulized albuterol."9.07Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. ( Eberlein, RS; Mazur, JE; Rudnitsky, GS; Schoffstall, JM; Spivey, WH, 1993)
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma."9.07The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993)
"To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma."9.07Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? ( Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993)
"The role of intravenous aminophylline in acute asthma is unclear despite meta-analysis of many studies comparing aminophylline with other bronchodilator therapies."9.07Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. ( Cameron, P; Coleridge, J; Epstein, J; Teichtahl, H, 1993)
" The purpose of this study was to investigate whether the addition of a single aerosolized dose of glycopyrrolate to an albuterol regimen results in a greater improvement in pulmonary function than treatment with an albuterol regimen alone in patients with acute asthma."9.07Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. ( Cydulka, RK; Emerman, CL, 1994)
"The aim of this study was to compare the response to inhaled albuterol after administration by nebulizer with the response after administration by a metered-dose inhaler and spacer device (MDI-spacer) to children with acute asthma."9.07Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. ( Bentur, L; Canny, GJ; Kerem, E; Levison, H; O'Brodovich, H; Reisman, J; Schuh, S, 1993)
" Patients with acute asthma received either albuterol, 0."9.07A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993)
"These data demonstrate that oral prednisone, within 4 hours of its administration, reduced the need for hospitalization among a subset of children treated in the emergency department for acute asthma."9.07Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. ( Fuchs, SM; Nager, AL; Scarfone, RJ; Shane, SA, 1993)
"To determine the efficacy of theophylline when given in addition to nebulized albuterol and intravenously administered corticosteroid to children hospitalized with mild to moderate asthma."9.07Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. ( Alpert, SE; DiGiulio, GA; Kercsmar, CM; Krug, SE; Marx, CM, 1993)
"To determine whether intravenously administered theophylline, when added to frequently nebulized albuterol and intravenously administered methylprednisolone, benefits children hospitalized with severe asthma."9.07Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. ( Carter, E; Chesrown, S; Cruz, M; Hendeles, L; Reilly, K; Shieh, G, 1993)
"The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days."9.07Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992)
"Ninety-six patients with nocturnal asthma (FEV1 = 60-90% pred, reversibility greater than or equal to 15%, at least 2 awakenings in the week preceding the trial) were included in a double-blind, randomized, crossover, multicenter study which compared the efficacy and side effects of inhaled salmeterol (50 micrograms morning and evening) to the association theophylline-ketotifen (300 mg and 1 mg morning and evening, respectively)."9.07[Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group]. ( Georges, D; Muir, JF, 1992)
"At four medical centers, 98 patients with stable asthma, histories of nighttime awakening at least three times weekly and nighttime declines of pulmonary function of at least 15%, who were not taking oral adrenergic agonists, were randomly treated with either oral repeat-action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4-16 mg at bedtime, or a placebo for 2 weeks."9.07The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. ( Bodman, SF; Greenstein, SM; Morris, RJ; Nathan, RA; Selner, JC; Storms, WW; Zwillich, CW, 1992)
"The aim of this investigation was to study whether certain patients benefit from adding theophylline to the beta 2-agonist treatment of acute asthma."9.07Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma? ( Boe, J; Boman, G; Janson, C, 1992)
"For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed."9.07A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. ( Chervinsky, P; Dockhorn, RJ; Grossman, J; Kemp, JP; LaForce, C; Liddle, RF; Pearlman, DS; Seltzer, JM; Southern, DL; Yancey, SW, 1992)
"The hypoxic effects of salbutamol 200 micrograms (CAS 18559-94-9) and bitolterol mesilate 740 micrograms (Biterol, CAS 30392-41-7), both administered by pressurized aerosol, were assessed by transcutaneous pO2 monitoring in 18 asthmatic subjects and in 12 normal volunteers."9.07Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers. ( Allegra, L; Cogo, AL; Dal Negro, R; Pomari, C; Turati, C; Turco, P, 1992)
"In a placebo-controlled, double-blind, crossover study with a washout phase of 2 months between each treatment period, single daily doses of 10 and 30 mg of astemizole were given to 12 patients with extrinsic asthma during 28 consecutive days."9.07Effect of astemizole on allergic asthma. ( Abadías, M; Cisteró, A; Jané, F; Lafuente, V; Lleonart, R; Pintó, E; Torrent, J, 1992)
"The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor antagonist, were studied in 12 asthmatic subjects with more than 15% increase in FEV1 after salbutamol inhalation."9.07Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. ( Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992)
"Three combination regimens, (1) inhaled albuterol (ALB) with oral theophylline (THEO), (2) inhaled ALB with inhaled beclomethasone dipropionate (BDP), or (3) inhaled ALB, inhaled BDP, and oral THEO, were evaluated and compared as optimal pharmacotherapy for chronic asthma in 111 children."9.07Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. ( Eigen, HN; Ellis, EF; Hemstreet, MP; Meltzer, EO; Orgel, HA, 1992)
" We compared the effect of 50 micrograms salmeterol administered by metered dose inhaler (MDI) and dry powder inhaler (DPI), with 200 micrograms albuterol (by MDI) on FEV1 and histamine-induced bronchoconstriction in 12 asthmatic subjects in a double-blind, placebo-controlled crossover study."9.07A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. ( Gongora, HC; Tattersfield, AE; Wisniewski, AF, 1991)
"In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma."9.07Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. ( Kroll, VM; Schneider, B; Völkl, KP; Wiesemann, HG, 1991)
"This study compared the acute and chronic effects of albuterol syrup (2 mg) and metaproterenol syrup (10 mg) three times a day over 28 days in 65 children, aged 6 to 9 years, with mild to moderate asthma."9.07Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. ( Ratner, PH; Shapiro, GG; Wolfe, JD, 1991)
"We compared the efficacy of inhaled formoterol, a long-acting beta 2-agonist, with inhaled albuterol in 145 stable adult asthmatics in a 12-wk multicenter trial."9.07A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. ( Broder, I; Cartier, A; Chapman, KR; Hyland, RH; Kesten, S; Knight, A; Malo, JL; Mazza, JA; Moote, DW; Small, P, 1991)
"To determine whether treatment of acute asthma with repeated doses of nebulized albuterol leads to greater bronchodilation and lower hospital admission rate than treatment with nebulized isoetharine."9.07A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma. ( Boehm, SP; Cydulka, RK; Effron, D; Emerman, CL; Gershman, H; Lukens, TW, 1991)
"In a multicentre, randomized, cross-over double-blind, double placebo trial the effectiveness and tolerability of slow-release oral salbutamol (SRS) were compared with those of long-acting (LA) theophylline (T) in the treatment of nocturnal asthma of adults."9.07[Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. ( Arnaud, A; Desfougères, JL; Michel, FB; Pappo, M, 1991)
"The additional effect, if any, of subcutaneous, long-acting epinephrine (Sus-Phrine) to aerosolized albuterol for acute pediatric asthma was studied."9.07Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children. ( Aquino, N; Kornberg, AE; Mezzadri, F; Welliver, JR; Zuckerman, S, 1991)
"The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma."9.06Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990)
"The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days."9.06Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990)
"The airway response and cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline given in multiples of standard doses from metered-dose inhalers were studied in ten patients with mild asthma."9.06Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. ( Britton, JR; Pavord, ID; Tattersfield, AE; Williams, J; Wong, CS, 1990)
"A double-blind, randomized, crossover chronic study was done to determine the efficacy of colchicine in 10 atopic patients with asthma."9.06A clinical and immunologic study of colchicine in asthma. ( Garty, MS; Greif, J; Ilfeld, DN; Kivity, S; Schlesinger, M; Schwarz, YA; Topilsky, M, 1990)
"We have investigated the ability of salbutamol to protect against bronchoconstriction induced by methacholine, histamine, and adenosine 5'-monophosphate (AMP) in nine subjects with asthma."9.06Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. ( Finnerty, JP; Holgate, ST; Phillips, GD, 1990)
"The bronchodilator effect of nebulized AMN, albuterol and their combination was evaluated in 16 steroid-dependent asthmatic children."9.06Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. ( Hill, MR; Nelson, HS; Sladek, WA; Sur, S; Szefler, SJ; Vichyanond, P, 1990)
"Thirty-three children and adolescents from 5 to 17 years of age with moderate to severe acute asthma were given nebulized albuterol therapy in either a high (0."9.06Nebulized albuterol in acute childhood asthma: comparison of two doses. ( Bailey, D; Canny, G; Forbes, T; Levison, H; Pender, E; Reider, MJ; Schuh, S; Tan, YK, 1990)
"To determine the efficacy of intravenous aminophylline in the treatment of adult patients hospitalized for exacerbation of asthma."9.06Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit? ( Abou-Shala, N; Burns, R; Ellis, RF; Kellermann, AL; Self, TH; Stewart, CF; Tsiu, SJ, 1990)
"We studied the safety and efficacy of albuterol (salbutamol) delivered by continuous nebulization (CN) in the initial emergency department treatment of asthma."9.06Continuous nebulization of albuterol (salbutamol) in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Rosenthal, TM; Stern, E; Wolkove, N, 1990)
"A double-blind, crossover trial was conducted to examine the effect of albuterol aerosol on the fine-motor performance of children with chronic asthma."9.06The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. ( Bender, B; Figueroa-Rosario, W; Mazer, B, 1990)
"Twenty asthmatic patients clinically free of heart disease were studied for the possible arrhythmogenic action of albuterol (salbutamol)."9.06Asthma, cardiac arrhythmias, and albuterol aerosol. ( Lazzari, JO; Martelli, NA; Raimondi, AC, 1986)
"The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients."9.06The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986)
"Bronchodilator responses to both nebulized albuterol (salbutamol) and ipratropium bromide and aerosol delivery to the tracheobronchial tree have been assessed in eight patients with chronic stable asthma (mean baseline FEV1, 50 percent; reversibility greater than 20 percent)."9.06Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. ( Bloom, R; Clarke, SW; Johnson, MA; Newman, SP; Talaee, N, 1989)
"We studied the effects of salbutamol, ipratropium bromide and cromolyn sodium on PGF2 alpha-induced bronchospasm in ten patients with asthma."9.06Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm. ( Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989)
"Two double-blind, double-dummy, randomized, crossover studies were performed in 8 asthmatic patients to evaluate beta 2-adrenoceptor selectivity and potency of broxaterol compared to salbutamol."9.06Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. ( Löfdahl, CG; Sigvaldasson, A; Skoogh, BE; Svedmyr, N, 1989)
"A study was carried out in 8 patients with chronic stable bronchial asthma to compare the bronchodilator response with terbutaline, administered by a recently developed powder inhalation system ('Turbuhaler') and equipotent doses of salbutamol administered by a widely used powder inhaler ('Rotahaler')."9.06Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics. ( Bogaard, JM; Slingerland, R; Verbraak, AF, 1989)
"A dose-ranging study and a 12-week treatment study were conducted in children with asthma, aged 4 to 12 years, to assess the efficacy and safety of albuterol inhaled as either an aerosol or as dry powder."9.06Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. ( Bronsky, EA; Furukawa, CT; Grossman, J; Kemp, JP; Lemanske, RF; Mansfield, LE; Murphy, S; Ratner, PH; Reese, ME; Rogenes, PR, 1989)
"In order to examine a possible mechanism of action of ketotifen in asthma, a double-blind study was undertaken to determine whether ketotifen showed any effects on the beta-adrenergic system in asthmatic patients."9.06The effects of ketotifen on beta-adrenergic activity in asthmatics. ( Burge, PS; Gove, RI; Skinner, C; Stableforth, DE, 1988)
"Forty patients suffering from asthmatic conditions, often accompanied by emphysema, were treated either with an extempore combination of salbutamol syrup plus 30-mg oxatomide tablets or with 30-mg oxatomide tablets alone for purposes of comparison."9.06Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide. ( Caprioglio, L; Scremin, S, 1986)
"The effect of long-term treatment with theophylline was studied in 20 chronic asthmatic patients receiving oral and inhaled beta 2-agonists."9.06Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. ( Billing, B; Dahlqvist, R; Hörnblad, Y; Leideman, T; Ripe, E; Skareke, L, 1987)
"140 children of 184 with acute asthma entered a randomised double-blind trial of oral prednisolone (n = 67) compared with placebo (n = 73) administered soon after admission."9.06Effect of a single oral dose of prednisolone in acute childhood asthma. ( Barrell, E; Barry, W; Hatcher, G; Lenney, W; Storr, J, 1987)
"4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma."9.06A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988)
"The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)."9.06A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986)
" The inadvertent administration of timolol to asthmatic patients continues to cause occasional severe and even fatal attacks of asthma."9.06Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. ( Richards, R; Tattersfield, AE, 1987)
"The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients."9.06Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988)
"Single-dose salbutamol (200 micrograms), beclomethasone dipropionate (200 micrograms), and sodium cromoglycate (SCG) (10 mg) administered by inhalation 10 minutes before allergen challenge were examined with regard to inhibition of allergen-induced early (EAR) and late (LAR) asthmatic responses and allergen-induced increase in bronchial responsiveness to inhaled histamine."9.06Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. ( Cockcroft, DW; Murdock, KY, 1987)
" Terfenadine, a histamine H1-receptor antagonist, was studied in 52 patients with stable mild perennial asthma with an allergic basis."9.06Treatment of bronchial asthma with terfenadine; a randomized controlled trial. ( Beaumont, D; Lewis, PJ; Pujet, JC; Sapene, M; Taytard, A, 1987)
"The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients."9.06Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988)
" Since inhalation of these drugs results in less systemic side effects, the present double-blind study was designed to investigate the influence of inhalation of the beta 2-adrenergic agonist albuterol (salbutamol) on esophageal motor function and gastroesophageal reflux in ten healthy volunteers."9.06Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers. ( Heinrich, C; Huber, RM; Müller-Lissner, SA; Schindlbeck, NE, 1988)
"Nifedipine, 30 mg/day for 4 weeks, was compared to placebo in a double-blind, randomized, crossover study, as an additional drug added to the usual treatment of 14 patients with bronchial asthma."9.06Nifedipine treatment of patients with bronchial asthma. ( Dascalopoulou, E; Maniki, E; Patakas, D; Tsara, V, 1987)
"Twelve patients with chronic severe asthma, having previously shown an FEV1 increase of less than 20% of the predicted value with prednisolone treatment (20-60 mg daily for 10 days), took part in a double blind crossover comparison of equipotent anti-inflammatory doses of betamethasone and prednisolone."9.06Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. ( Belmatoug, N; De Lauture, D; Grandordy, B; Marsac, J; Morelle, A, 1987)
"Clenbuterol (C), a long-acting beta 2-selective bronchodilator was compared with salbutamol (S) in exercise-induced asthma (EIA) at two premedication time levels."9.06Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children. ( Boner, AL; Brighenti, C; Miglioranzi, P; Richelli, C; Schiassi, M; Vallone, G, 1988)
"In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC."9.06Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986)
"The extrapulmonary effects of slow-release theophylline and an inhaled beta 2-agonist (albuterol) were examined separately and in combination among 18 adults and adolescents with asthma during a 3-month randomized, double-blind, crossover trial."9.06Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1986)
"In order to study the dose-related effect of nifedipine on expiratory flow rates, 15 asthmatic patients were given sublingually 10 mg and 20 mg of the drug on two different days and the FVC and FEV1 were measured during 90 minutes."9.06Nifedipine in asthma. Dose-related effect on resting bronchial tone. ( Chaniac, A; Gruzman, C; Katz, I; Lidgi, M; Molho, M, 1987)
"The bronchodilator effect of a combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide, given as pressurized aerosols, was compared to that of 200 and 400 micrograms of salbutamol in a controlled experiment on adult patients with asthma."9.06Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. ( Laitinen, LA; Poppius, H, 1986)
"Sustained-release, 24-hour theophylline preparations have been formulated and may provide for convenient once-a-day dosing, although the use of such products in clinical asthma has yet to be fully established."9.06The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment. ( Bush, RK; Busse, WW; Smith, A, 1986)
"The relative benefit of maintenance therapy with theophylline, inhaled albuterol, and the combination was examined in 18 adolescents and adults with chronic asthma during a 3-month, randomized, double-blind, crossover trial."9.06Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1987)
"Three parenteral routes of albuterol sulfate were compared with placebo in their effects on serum potassium and glucose levels, heart rate, and pulmonary function in adult asthmatic subjects."9.06Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine. ( Katz, RM; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1986)
"The benefits of metered-dose inhalers with a spacer (MDI+S) have increasingly been recognized as an alternative method of albuterol administration for treating pediatric asthma exacerbations."9.05Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. ( Barrios-Sanjuanelo, A; Contreras-Arrieta, S; Florez-García, V; Payares-Salamanca, L; Rodriguez-Martinez, CE; Stand-Niño, I, 2020)
"The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study."9.05Ketotifen in adult asthma. ( Dyson, AJ; Mackay, AD, 1980)
"A double-blind crossover comparative study between carbuterol 3 mg thrice daily, carbuterol 2 mg thrice daily and salbutamol 4 mg thrice daily by the oral route was conducted in thirty patients suffering from bronchial asthma, selected at random, with more than 20% reduction in airway obstruction following isoprenaline inhalation."9.05Double-blind crossover study of carbuterol and salbutamol in bronchial asthma. ( Khemchandani, GT; Misra, NP; Tiwari, UC, 1981)
"Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests)."9.05Inhaled prazosin in asthma. ( Barnes, PJ; Dollery, CT; Ind, PW, 1981)
"A study to compare the bronchodilator effect of salbutamol powder (Ventolin, 200 micrograms) administered via a Rotahaler (SR), with that of terbutaline sulphate (Bricanyl, 500 micrograms) administered via a Misthaler (TM) was carried out in 25 children with stable moderate to severe asthma."9.05Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma. ( Mellis, CM; Sharota, E; Simpson, SJ; Towns, SJ, 1983)
" We evaluated 140 patients with bronchial asthma in a prospective double-blind controlled study of possible tachyphylaxis to albuterol aerosol as compared to isoproterenol aerosol."9.05Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. ( Anderson, JA; Bush, RK; Falliers, CJ; Kass, I; Kemp, JP; Reed, C; Repsher, LH; Siegel, S; Webb, DR, 1984)
"The bronchodilator activity in nebulised salbutamol, ipratropium bromide, clemastine, and a placebo was studied in 14 asthmatic children aged between 3 and 5 years."9.05Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma. ( Groggins, RC; Milner, AD; Stokes, GM, 1981)
"The bronchodilator effect of 400 micrograms of salbutamol powder (2 capsules) administered by a rota-haler was compared with that of 500 micrograms of terbutaline (2 metered doses) administered as an aerosol via a tube-spacer in a group of ten stable asthmatic children (mean age 12 years)."9.05Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children. ( Francis, PW; Kelly, CA; Zimmerman, PV, 1983)
"A double-blind randomised controlled trial was conducted to study the effects of oral theophylline alone compared with oral theophylline and salbutamol in a sample of asthmatic children."9.05Effects of oral theophylline and oral salbutamol in the treatment of asthma. ( Dawson, KP; Fergusson, DM, 1982)
"The effect of adding theophylline to treatment with a beta2-adrenoceptor stimulant was studied in 18 asthmatic children in a double-blind cross-over trial."9.05Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma. ( Foucard, T; Lindström, B; Lönnerholm, G, 1981)
"Sixty-four patients with mild of moderate extrinsic asthma were treated with placebo for 1 month and thereafter with ketotifen (1 mg twice daily, orally), disodium cromoglycate (inhalation of 20 mg, four times daily), or placebo for 2 subsequent months."9.05Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma. ( Ahonen, A; Haahtela, T; Hurme, R; Maasilta, P; Mattson, K; Muittari, A; Poppius, H; Venho, K, 1981)
"Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma."9.05A double blind crossover trial of lithium carbonate in asthma. ( Bearman, J; Saltz, H; Spitz, E, 1982)
"The efficacy of nebulised sodium cromoglycate and an oral theophylline solution at currently recommended doses were compared in one to six-year-old children with chronic asthma."9.05Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. ( Newth, CJ; Newth, CV; Turner, JA, 1982)
"In a double-blind trial we compared the efficacy and safety of inhaled salbutamol (albuterol), nebulized with oxygen by face mask, and subcutaneous epinephrine in 40 children with acute asthma."9.05Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. ( Becker, AB; Nelson, NA; Simons, FE, 1983)
"Although albuterol aerosol is an effective bronchodilator in adult asthmatics its efficacy and safety are not fully established in asthmatic children."9.05Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children. ( Katz, R; Littner, MR; Siegel, SC; Tashkin, DP, 1983)
"Inhalation histamine challenges were performed in groups of normal and asthmatic subjects."9.05Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. ( Walters, EH, 1983)
"Oral administration of salbutamol and theophylline has been shown to be effective in relieving bronchoconstriction in asthmatic children aged between 3 and 5 years."9.05Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma. ( Groggins, RC; Lenney, W; Milner, AD; Stokes, GM, 1980)
"In a double-blind controlled trial 14 chronic asthmatic patients with regular nocturnal exacerbations took 16 mg slow-release oral salbutamol (two Ventolin spandets), 450 mg slow-release aminophylline (two Phyllocontin Continus tablets), or placebo at midnight."9.05Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. ( Davies, HJ; Fairfax, AJ; McNabb, WR; Spiro, SG, 1980)
"Twenty-one patients admitted to hospital with acute severe asthma were allocated in a random, single-blind manner to receive intravenous infusions for 24 hours or either aminophylline or salbutamol or a combination of the two drugs."9.05Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma. ( Crimmins, J; Evans, WV; Monie, RD; Seaton, A, 1980)
"The efficacy, safety, tolerance, and bio-equivalence of albuterol (a relatively selective beta 2-adrenergic drug) was evaluated in 20 asthmatic children (6 to 14 years of age)."9.05Oral albuterol in the treatment of childhood asthma. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1982)
"Albuterol (salbutamol) syrup was studied in 14 asthmatic children (three to six years of age) in a four-week, double-blind, crossover (with placebo) trial to determine efficacy, safety and tolerance."9.05Albuterol syrup in the treatment of the young asthmatic child. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1981)
"The bronchodilation produced by increasing intravenous doses of aminophylline, salbutamol, and a combination of aminophylline and salbutamol given in random order was determined in 10 stable asthmatics on three consecutive days."9.05Intravenous salbutamol and aminophylline in asthma: a search for synergy. ( Dart, AM; Davies, BH; Handslip, PD, 1981)
"The effect of slow-release aminophylline, salbutamol and a half dose combination of both was compared in children with chronic asthma."9.05A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma. ( Blumenthal, I, 1980)
" In this randomized, double-blind, crossover study, each of 20 male patients with moderate to severe asthma, ages 12 to 23 yr, received a single treatment with 100, 200, or 400 mcg of albuterol powder or placebo by Rotahaler on 4 study days separated by 2 to 10 days."9.05Inhaled albuterol powder for the treatment of asthma--a dose-response study. ( Kemp, JP; Meltzer, EO; Orgel, HA; Welch, MJ, 1985)
"1 mg/kg/6 hr) or placebo to 2- to 6-year old children whose extrinsic asthma was treated with maintenance theophylline in a prerandomized, double-blind crossover study design."9.05Albuterol syrup in the treatment of asthma. ( Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985)
"Our investigation supports the use of intravenous salbutamol as an alternative to aminophylline in the early stages of acute severe asthma."9.05Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks. ( Greif, J; Markovitz, L; Topilsky, M, 1985)
"Calcium-channel blockers such as verapamil and nifedipine have been shown to inhibit exercise-induced asthma as well as acutely induced bronchoconstriction, but little is known of their chronic effects, if any, on bronchial asthma."9.05Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo. ( Boismare, F; Lemercier, JP; Leprevost, A; Moore, ND; Ozenne, G; Pasquis, P; Tardif, C, 1985)
"11 mg) and albuterol aerosol (two sprays, 180 mcg) were compared for efficacy of bronchodilation in 120 adolescent and young adult patients with moderate to severe asthma."9.05Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. ( Kemp, JP; Orgel, HA; Tinkelman, DG; Webb, DR, 1985)
"The acute cardiopulmonary effects of oral albuterol, 4 mg, metaproterenol sulfate, 20 mg, and terbutaline sulfate, 5 mg, were compared over eight hours in 20 moderate to severe asthmatics."9.05Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. ( Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985)
"In 24 adult asthmatics the effects of clinically recommended doses of fenoterol (320 micrograms) and albuterol (180 micrograms) were compared to placebo in a double-blind, crossover trial."9.05A comparison of inhaled fenoterol and albuterol in asthma. ( Hordvik, NL; König, P; Sunderrajan, EV, 1985)
"The bronchodilator effects of 375 mg theophylline orally and 200 microg salbutamol by pressurized aerosol were compared in a randomized, cross-over, double-blind trial in fourteen asthmatic patients."9.04Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. ( Hartnett, BJ; Marlin, GE, 1976)
"Eleven patients with bronchial asthma and 10 with chronic bronchitis were treated over four consecutive 3-day periods, firstly with aerosols either of ipratropium bromide (40 microgram four times a day) or of salbutamol (200 microgram four times daily) by random allocation, then the alternate drug, next by both drugs together, and finally with prednisolone (10 mg three times daily) in addition to both drugs."9.04Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. ( Ingram, CG; Johnston, RN; Legge, JS; Lightbody, IM, 1978)
"The bronchodilating efficacy and the degree of beta2-selectivity of rimiterol, salbutamol and isoprenaline were determined in seven asthmatic patients."9.04The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients. ( Marlin, GE; Turner, P, 1975)
"Albuterol, a new bronchodilator drug known to cause beta2-adrenergic receptor stimulation, was compared with isoproterenol sulphate for their pulmonary and cardiovascular effects in patients suffering from bronchial asthma."9.04Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. ( Huber, GL; Mahajan, VK; Tomashefski, JF, 1977)
"Albuterol and isoproterenol aerosols were compared with placebo in a double-blind manner in 18 patients with bronchial asthma."9.04Comparison of albuterol and isoproterenol aerosols in bronchial asthma. ( George, RB; Jenkinson, SG; Light, RW, 1977)
"The bronchodilator effects of aerosols of hexoprenaline (200 microgram and 400 microgram), and salbutamol (200 microgram) were compared in 15 patients with asthma, and nine patients with chronic bronchitis."9.04Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis. ( Evers, R; Harris, M; Jenne, H; McMiken, D; Schonell, M, 1977)
"Dose-response curves to intravenous salbutamol were constructed after injection of saline or aminophylline in a group of ten asthmatic patients."9.04Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves. ( Handslip, P; Leopold, D, 1979)
"A double-blind comparison between orally administered NAB 365 (clenbuterol) and salbutamol was conducted in 30 impatients with either asthma or chronic bronchitis with asthma who had at least 15% reversibility in airway obstruction following inhalation of 1,500 microgram of orciprenaline."9.04NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial. ( Capra, A; Pasotti, C; Vibelli, C, 1979)
"In a single blind crossover study 12 asthmatics received in randomised order single doses of pirbuterol (200 and 400 microgram), salbutamol (200 microgram) and placebo-aerosols, in order to determine the extent and duration of bronchodilator activity, the optimum dosage, the incidence, type and degree of side effects and the cardiovascular as well as hematologic, renal and hepatic functions after inhalative administration."9.04Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma. ( Beumer, HM, 1979)
"A double-blind test to compare IV aminophylline with salbutamol in the treatment of acute, uncontrolled asthma showed that both drugs were equally effective during the first 24 hours."9.04Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood. ( Hambleton, G; Stone, MJ, 1979)
"The effect of clenbuterol (NAB 365) in inhibiting exercise-induced asthma was compared with that of salbutamol in a single-blind, placebo-controlled, crossover study."9.04Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma. ( Del Bono, N; Quartieri, F; Vibelli, C, 1979)
"In a single blind cross-over study 12 patients with asthma received in randomised order aerosols of pirbuterol 400 micrograms, salbutamol 200 micrograms or placebo."9.04[Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients]. ( Verstraeten, JM, 1978)
"A double-blind crossover trial was conducted in 10 asthmatic patients for comparison of fenoterol with salbutamol, in 12 other asthmatic patients for comparison of reproterol with salbutamol, and in 15 other asthmatic patients for comparison of terbutaline with salbutamol."9.04[The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer]. ( Budmiger, H; Kyd, K; Scherrer, M, 1978)
"In a randomized double-blind trial an intravenous injection of salbutamol (100mug) was compared with an intravenous injection of aminophylline (250mg) in 23 patients with acute exacerbations of asthma."9.04A controlled trial of intravenous salbutamol and aminophylline in acute asthma. ( Robinson, JS; Tribe, AE; Wong, RM, 1976)
"To evaluate the cost-utility of the treatment with a long acting beta-agonist (LABA) and inhaled corticosteroid (ICS) combination inhaler [salmeterol xinafoate (SAL)/fluticasone propionate (FP) combination inhaler (SFC) (Advair(®))] to continuing on current ICS dose (no ICS dose change) or increased ICS dose [fluticasone propionate (FP)] in patients with uncontrolled asthma in Canada."8.90COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. ( Corriveau, D; FitzGerald, JM; Hawkins, N; Ismaila, AS; Li, C; Risebrough, N; Su, Z, 2014)
"To evaluate efficacy and safety of levalbuterol versus albuterol in acute asthma."8.89Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. ( Jat, KR; Khairwa, A, 2013)
"To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma."8.87Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Ferrara, G; Lasserson, TJ, 2011)
"To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function."8.84Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Cates, CJ; Ferrara, G; Lasserson, TJ, 2008)
"Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."8.84Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. ( Gibson, PG; Irving, LB; Koh, MS; Lasserson, TJ; Tee, AK; Wilson, AJ, 2007)
"To systematically review the evidence for the medium to long term benefits and risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with placebo and active controls in mild to moderate asthma."8.84Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. ( Grouven, U; Joos, S; Kaiser, T; Miksch, A; Schneider, A; Szecsenyi, J; Wieseler, B, 2008)
"Our understanding of albuterol nebulization driven by helium-oxygen mixture (heliox) has matured with recent advances in clinical therapy, delivery systems, and understanding of dosing; this has led to substantial improvements in delivery as well as refinements of research protocols for asthma exacerbations."8.83Heliox-driven albuterol nebulization for asthma exacerbations: an overview. ( Corcoran, TE; Kim, IK; Saville, AL; Sikes, KL, 2006)
"To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma."8.82Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. ( Berger, WE, 2003)
"Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."8.82Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Shah, L; Wilson, AJ, 2003)
"Pharmacoeconomic analyses indicate that salmeterol/fluticasone propionate administered via a single inhaler represents a cost-effective treatment option (relative to fluticasone propionate at the same nominal dosage, budesonide, formoterol plus budesonide and montelukast plus fluticasone propionate) in patients with asthma not controlled with inhaled corticosteroid therapy."8.82Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. ( Lyseng-Williamson, KA; Plosker, GL, 2003)
"A short cut review was carried out to establish whether intravenous salbutamol or intravenous aminophylline offers the quickest and least complicated treatment for patients with moderate to severe asthma not responding to inhaled therapy."8.82Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma? ( Jacobs, M; Munro, A, 2004)
"To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control."8.81Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. ( Arnold, AD; Crafts, R; Heyneman, CA; Holland, J, 2002)
"Theophylline and long acting beta2-agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."8.80Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Wilson, AJ, 2000)
"The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma."8.80Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. ( Jarvis, B; Markham, A, 2000)
"Aminophylline is routinely recommended as a basic part of the emergency treatment of asthma."8.77Aminophylline treatment in severe, acute asthma. A meta-analysis. ( Littenberg, B, 1988)
"The effectiveness of a fix-dose salmeterol/fluticasone combination therapy in asthma was previously shown for the original product."8.31The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. ( Almgren-Rachtan, A; Chudek, J; Doniec, Z; Hantulik, P; Olszanecka-Glinianowicz, M, 2023)
"Standardized acute asthma management with score-based, respiratory therapist (RT)-driven pathways and protocols improves outcomes including decreased length of stay (LOS) and time on continuous albuterol therapy."8.12Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022)
"Inability to access an albuterol inhaler at school increases risk to students of severe asthma attack."8.02Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol. ( Fu, L; Gessner, L; Thompson, D; Torres, R, 2021)
"A decision-analysis model was developed to estimate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations."7.96Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2020)
"This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD)."7.85Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. ( Cai, S; Dong, H; Li, R; Lv, Y; Wu, Y; Xiao, G; Yao, L; Zhao, H, 2017)
"The goal of this study was to examine the impact of a multidisciplinary intervention designed to improve appropriate albuterol inhaler utilization among patients with asthma."7.85Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. ( Delate, T; Jenkins, DW; Lowe, R; Rader, N, 2017)
"Racemic albuterol and levalbuterol are used to treat acute episodes of asthma."7.85Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population. ( Love, BL; Lu, ZK; Schulz, RM; Wu, J; Yuan, J; Zhang, Y, 2017)
"This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response."7.83Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016)
"Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma."7.83The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. ( Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016)
" We present a case of a patient who was admitted with acute asthma exacerbation and was treated with β-2 agonist nebulisation and intravenous aminophylline."7.83Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. ( Khwaja, YH; Tai, JM, 2016)
"Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management."7.81Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015)
"Using private insurance data from January 1, 2004, to December 31, 2010, we investigated the effect of the CFC ban on out-of-pocket costs and utilization of albuterol inhalers among individuals with asthma (109,428 adults; 37,281 children), as well as asthma-related hospitalizations, emergency department visits, and outpatient visits."7.81The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. ( Goldman, DP; Ho, O; Jena, AB; Karaca-Mandic, P, 2015)
"To determine if nitrites (nitric oxide metabolites) measured in induced sputum decrease and correlate with improvement of clinical asthma symptoms after treatment, we performed a prospective longitudinal study in a tertiary care hospital in Arequipa, Peru."7.80Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren. ( Cáceres, M; Castro-Rodriguez, JA; Molina, RO; Recabarren, A, 2014)
"To estimate the relative perinatal safety with the use of salmeterol and formoterol (LABAs) and that of fluticasone and budesonide (ICSs) during pregnancy."7.80Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. ( Beauchesne, MF; Blais, L; Cossette, B; Forget, A; Larivée, P; Lemière, C; Rey, E, 2014)
"This study aimed to assess the safety and efficacy of a high-dose continuous nebulized albuterol (CNA) protocol for treatment of asthma in the pediatric emergency department (ED)."7.79Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. ( Flood, RG; Gerard, JM; Krebs, SE; Peter, JR, 2013)
"The concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known."7.78Exhaled carbon monoxide levels in preschool-age children with episodic asthma. ( Arai, H; Asamura, T; Morikawa, T; Ohara, T; Ohara, Y; Ohrui, T; Sasaki, H, 2012)
"The purpose of this study was to evaluate the use of xenon-enhanced dual-energy CT of the chest to assess ventilation changes after methacholine and salbutamol inhalation in subjects with asthma and healthy subjects."7.78Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation. ( Cho, SH; Goo, JM; Kim, JH; Kim, WW; Lee, CH; Park, EA; Park, SJ, 2012)
" Laboratory findings showed hypokalemia, hypophosphatemia, and lactic acidosis."7.78Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone. ( Hantson, P; Manara, A; Thys, F; Vanpee, D, 2012)
"To examine the proportion of children presenting to the emergency department (ED) with an acute asthma exacerbation with incorrect home use of their albuterol inhaler and to identify factors associated with improper treatment."7.78Inappropriate home albuterol use during an acute asthma exacerbation. ( Clayton, K; Harrington, K; King, W; Magruder, T; Monroe, K, 2012)
" We isolated caffeic acid and phenylpropanoid glycosides, 1-O-caffeoyl glycoside and acteoside [β-(3',4'-dihydroxyphenyl) ethyl-O-α-l-rhamnopyranosyl(1→3)-β-d-(4-O-caffeoyl)-glucopyranoside] from their ethylacetate fractions, respectively, and evaluated their anti-asthmatic effects on the aerosolized ovalbumin (OA) challenge in the OA-sensitized guinea-pigs measuring the specific airway resistance (sRaw) during the immediate-phase response (IAR) and late-phase response (LAR), and also measured recruitment of leukocytes and chemical mediators on the bronchoalveolar lavage fluids (BALF) in LAR, as well as histopathological survey."7.77Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin. ( Kim, CJ; Lee, JG; Lee, JY; Sim, SS; Whang, WK, 2011)
" albuterol, are used for quick reversal of bronchoconstriction in asthmatics."7.77Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011)
"A retrospective observational cohort study compared the risk of asthma-related exacerbations [hospitalization, emergency department visit, and/or treatment with systemic corticosteroid] in patients receiving treatment with fluticasone propionate/salmeterol in a single inhaler (FSC) within 90 days following an initial asthma-related exacerbation (early treatment) versus patients receiving the treatment subsequently (late treatment)."7.77Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation. ( Delea, TE; Hagiwara, M; Stanford, RH, 2011)
"We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients."7.76[Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients]. ( Arakawa, I; Miyamoto, T; Nishima, S; Shiragami, M; Tohda, Y, 2010)
"The aim of this work was to compare rates of asthma-related health service utilization for Medicaid-eligible pediatric and adult patients with asthma treated with fixed-dose fluticasone propionate/salmeterol (FSC) or fluticasone propionate (FP) monotherapy."7.76Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. ( Astry, CL; Johnson, JC; Riedel, AA; Stanford, RH, 2010)
" Asthma patients 16-65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol."7.75Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol. ( Beauchesne, MF; Blais, L; Forget, A, 2009)
"Six healthy and 5 experimentally asthmatic cats were randomized to receive inhaled R,S-albuterol, S-albuterol, R-albuterol, or placebo (saline) twice daily for 2 weeks, followed by a 6-week washout before crossover to the next treatment."7.75Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. ( DeClue, AE; Delgado, C; Dhand, R; Reinero, CR; Spinka, C, 2009)
"The goal of this study was to examine whether the claims history for children in a US insured population indicate proper fluticasone propionate/ salmeterol (FPS) fixed-dose combination use in accordance with recommended asthma guidelines and a US Food and Drug Administration (FDA) advisory and black box warning regarding LABA use."7.75Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. ( Crespi, S; Eid, NS; Friedman, HS; Reardon, G; Wilcox, TK, 2009)
"To investigate the effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of adult patients with asthma."7.75Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma. ( de Melo, PL; Jansen, JM; Lopes, AJ; Veiga, J, 2009)
"We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol."7.75Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. ( Basu, K; Lipworth, BJ; Mukhopadhyay, S; Palmer, CN; Tavendale, R, 2009)
"To compare the rates of asthma-related emergency department (ED) visits and hospitalizations in the fall (September, October, November) between users and nonusers of fluticasone propionate plus salmeterol in a single inhaler (FSC) in the preceding summer."7.75Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. ( Sheth, K; Spahn, J; Stanford, RH; Stempel, DA; Yeh, WS, 2009)
"Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA."7.74Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008)
"Eighty-one patients with asthma (24% African American [AA]; 8 to 65 years old; baseline FEV1, 40 to 80% of predicted) received 180 microg of albuterol from a metered-dose inhaler (MDI), and then 90 microg every 15 min until maximum improvement or 540 microg was administered; all then received 2."7.74Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. ( Blake, K; Derendorf, H; Lima, J; Madabushi, R, 2008)
"To identify the relationship between resource utilization and treatment of asthma in subjects who were first time users of controller therapies, either fluticasone propionate (FP) and salmeterol delivered in a single Diskus device (FSC) or FP monotherapy."7.74An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes . ( Fuhlbrigge, A; Rey, GG; Riedel, A; Stanford, RH; Stempel, DA, 2008)
"Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol."7.74Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007)
"This study evaluated the use and drug costs of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs), and fluticasone propionate and salmeterol in a fixed-dose combination (FSC) and their relationship to asthma exacerbations before and after the market introduction of FSC in April 2001."7.74The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. ( Brixner, DI; Lenhart, G; Samuelson, WM; Young, DC, 2007)
"To assess the frequency of beta2-AR polymorphisms in asthmatic children from Argentina, and to evaluate their influence on bronchodilator desensitization to albuterol over a 4-week treatment."7.74Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. ( Castaños, C; Chertkoff, L; Giubergia, V; Gravina, LP; Grenoville, M, 2008)
"This study was designed to expand on these earlier findings by comparing asthma-related health care resource utilization and costs, as well as adherence to ICSs, in children and adults with asthma receiving ICS monotherapy who either were switched to fluticasone propionate plus SAL from a single inhaler (FSC) or initiated add-on therapy with SAL from a separate inhaler or MON."7.74Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. ( Delea, TE; Hagiwara, M; Stanford, RH; Stempel, DA, 2008)
"Salmeterol/fluticasone propionate is a more cost-effective treatment option than fluticasone propionate plus montelukast for patients with symptomatic asthma uncontrolled by ICS."7.73Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. ( Pieters, WR; Smith, HC; Sondhi, S; Tamminga, JJ; Wilson, KK, 2005)
"To demonstrate that basic emergency medical technicians (EMT-Bs) are able to effectively administer nebulized albuterol to asthma patients in the out-of-hospital environment."7.73Out-of-hospital administration of albuterol for asthma by basic life support providers. ( Kusick, M; Matallana, L; Richmond, NJ; Silverman, R; Winokur, J, 2005)
"We conducted a prospective and descriptive study to assess levels of lactate and effects on bronchodilator response in adult patients with acute severe asthma treated with high doses of albuterol in the ED."7.73Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2005)
"A disease-related, corticosteroid-insensitive increase in the expression of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase in asthmatic bronchial epithelium has been shown previously by the current authors."7.73Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. ( Davies, DE; Dearman, RJ; Hamilton, LM; Holgate, ST; Howarth, PH; Kimber, I; Puddicombe, SM; Sandström, T; Wallin, A; Wilson, SJ, 2005)
"A post hoc resource use analysis of a 52-week, double-blind multicentre clinical trial (Investigation of Montelukast as a Partner Agent for Complementary Therapy) [corrected] including 1490 adults with chronic asthma, aged 15-72 years, with FEV(1) 50-90% of predicted and > or =12% increase in FEV(1) after salbutamol administration, treated with either montelukast 10 mg daily or salmeterol 50 microg twice daily in addition to fluticasone 200 microg, was undertaken."7.73Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. ( Bjermer, L; Bousquet, J; Gaugris, S; Kocevar, VS; Polos, PG; Yin, DD; Zhang, Q, 2005)
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma."7.73Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005)
"Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol."7.73Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. ( Babin, S; Schreck, DM, 2005)
"British Thoracic Society guidelines recommend intravenous salbutamol or aminophylline for acute severe asthma in children."7.73A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia. ( Parr, JR; Salama, A; Sebire, P, 2006)
"Carbon monoxide (CO) can be detected in exhaled air and is increased in adult and childhood persistent asthmatic patients."7.73Exhaled carbon monoxide levels in school-age children with episodic asthma. ( He, M; Morikawa, T; Ohara, Y; Ohrui, T; Sasaki, H; Yamaya, M; Yasuda, H, 2006)
"To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON."7.73Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. ( Carranza Rosenzweig, JR; Riedel, AA; Stempel, DA, 2006)
"We present 2 cases of Cushing syndrome with secondary adrenal insufficiency from concomitant use of ritonavir and inhaled corticosteroids in children with human immunodeficiency virus infection."7.73Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. ( Emmanuel, PJ; Johnson, SR; Lujan-Zilbermann, J; Marion, AA; Vrchoticky, T, 2006)
"The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype."7.73Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. ( Ismail, T; Lee, S; Lipworth, BJ; Macgregor, DF; Mukhopadhyay, S; Palmer, CN, 2006)
"To compare asthma-related health care resource utilization among a matched cohort of asthma patients using inhaled corticosteroids (ICSs) plus either montelukast (MON) or salmeterol (SAL) as combination therapy for asthma, during a time prior to the availability of fixed-dose combinations of ICS/SAL."7.73Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. ( Allen-Ramey, FC; Bukstein, D; Luskin, A; Markson, LE; Sajjan, SG, 2006)
"Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE(4), monitoring of FEV(1), and albuterol use."7.73Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. ( Gelfand, EW; Rabinovitch, N; Zhang, L, 2006)
" Theophylline possesses anti-inflammatory activities in asthma."7.72Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003)
"This was a prospective, open-label, nonrandomized pilot study to evaluate efficacy and tolerability of levalbuterol (LEV) in acute asthma."7.72Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. ( Disantostefano, RL; Emerman, CL; Nowak, RM; Roach, JM; Schaefer, K; Vaickus, L, 2004)
"To determine the relative cost effectiveness when persistent asthma is treated with FP/salmeterol 100/50 microg twice daily administered via a single Diskus inhaler device versus treatment with FP 100 microg twice daily via a Diskus inhaler plus oral montelukast 10mg once daily."7.72Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Nelson, H; O'Connor, RD; Rickard, K, 2004)
"Because the clinical efficacy of inhaled corticosteroids combined with long-acting beta 2 -agonists has been widely demonstrated in asthma, we studied, in vitro, the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor kappaB inhibitor (IkappaBalpha), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects."7.72Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. ( Bonsignore, G; Bousquet, J; Ferraro, M; Gagliardo, R; Gjomarkaj, M; La Grutta, S; Melis, M; Pace, E; Siena, L; Vignola, AM, 2004)
"To compare the effectiveness of (1) fluticasone propionate, 100 microg, and salmeterol, 50 microg; (2) fluticasone propionate, 100 microg; and (3) montelukast, 10 mg, as first-line maintenance treatment for persistent asthma."7.72Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. ( Crim, C; Dorinsky, P; Edwards, L; O'Connor, RD; Rickard, KA; Stanford, R; Yancey, SW, 2004)
"Inhaled acetaldehyde and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in asthmatics by a mechanism believed to involve histamine release from airway mast cells."7.71Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness. ( Cervera, A; Gutiérrez, V; Liñana, J; Prieto, L, 2002)
"To determine whether NOs influence the bronchodilator activity of albuterol in asthmatic patients."7.71Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma. ( Hirata, K; Kanazawa, H; Yoshikawa, J, 2002)
"The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U."7.71Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. ( Ben-Joseph, RH; Price, DB; Zhang, Q, 2001)
"The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy."7.71Lidocaine inhalation for cough suppression. ( Udezue, E, 2001)
"To compare a combination of salmeterol and fluticasone with common asthma pharmacologic regimens used in real-world clinical practice, and to evaluate the associated costs and outcomes of care."7.71Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments. ( Bowers, BW; Legorreta, AP; Liu, X; Sennett, C; Wang, SW; Wiener, DJ, 2001)
"To investigate the mechanism of anti-inflammatory action of theophylline on asthma."7.71Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects. ( Hu, SP; Nie, HX; Wu, XJ; Yang, J, 2002)
"Albuterol administered by MDI/spacer is an efficacious and cost-effective alternative to nebulization in adults with acute asthma who present at a large urban ED."7.71A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. ( Hall, K; Hamilton, C; Milne, S; Newman, KB, 2002)
"A case of albuterol abuse by a pediatric patient with the development of hypokalemia with electrocardiographic changes is presented."7.70Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler. ( Farrar, HC; Kearns, GL; Rakhmanina, NY, 1998)
"Acutely ill asthmatic patients chronically taking salmeterol, and similar patients who were not taking salmeterol, were treated with albuterol, either as three aerosols of 2."7.70Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. ( Korosec, M; McFadden, ER; Myers, E; Novak, RD; Skowronski, M, 1999)
"This study was undertaken to assess drug-use patterns associated with albuterol delivery via a new propellant device compared with conventional chlorofluorocarbon (CFC) metered-dose inhalers (MDIs) in patients taking asthma medications in a population with pharmacy benefits."7.70Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. ( Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000)
"To determine whether race and gender affect beta(2)receptor-stimulated bronchodilation, we quantified FEV(1)and plasma concentrations of albuterol at various times following the oral administration of a single 8-mg dose of albuterol in 15 black and 15 white male and female asthmatics."7.70Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH, 2000)
"The respiratory effects of nebivolol, a new selective ss(1)-adrenergic blocking agent, and celiprolol, a ss-blocker possessing strong ss(1)-adrenoceptor antagonist and mild ss(2)-agonist properties, were investigated in 12 patients with mild asthma."7.70Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. ( Cazzola, M; D'Amato, G; D'Amato, M; Noschese, P, 2000)
" Incubation of bronchial epithelial cells from patients with asymptomatic asthma with interleukin-1 or histamine, for 8 to 24 hours, resulted in increased expression of endothelin-1 messenger RNA and release of appreciable amounts of the peptide to the culture medium."7.69Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. ( Ackerman, V; Bellini, A; Carpi, S; Marini, M; Mattoli, S; Vassalli, G, 1995)
"Forty-four adult patients with acute asthma were treated with albuterol at a rate of 15 mg/h over 2 h."7.69Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting. ( Fox, S; Lin, RY; Newman, TG; Sauter, D; Sirleaf, J; Tavakol, M; Walters, J, 1994)
"The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented."7.69Hypokalemia after normal doses of neubulized albuterol (salbutamol). ( D'Souza, L; Mahajan, M; Udezue, E, 1995)
"Hypomagnesaemia in a woman treated with theophylline and albuterol because of recurrent asthmatic attacks prompted us to explore the effects of these drugs on the metabolism of magnesium, calcium, sodium and phosphate in such patients."7.69Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks. ( Bøhmer, T; Falch, J; Knutsen, R, 1994)
"Air-flow standardized breath sounds were recorded at the chest and at the trachea during histamine challenge test and after subsequent bronchodilation in 12 asthmatics and 6 healthy controls for spectral analysis, to be compared with simultaneous changes in spirometric variables."7.69Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects. ( Haahtela, T; Katila, T; Malmberg, LP; Paajanen, E; Piirilä, P; Sovijärvi, AR, 1994)
"To determine the dose of albuterol required to terminate acute episodes of asthma, 92 acutely ill subjects received three doses of 2."7.69Observations on the effects of aerosolized albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1997)
"We investigated platelet-activating factor (PAF)-induced migration in eosinophils obtained from asthmatic patients who were treated with or without intravenous prednisolone."7.69PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro. ( Fukumura, M; Koide, K; Shindo, K, 1997)
"A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported."7.69Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997)
"The cases of two asthmatic adolescents who overdosed on albuterol are presented."7.68Propranolol treatment of albuterol poisoning in two asthmatic patients. ( Henretig, F; Joffe, M; Ramoska, EA; Spiller, HA, 1993)
" Throughout the study, the children received the standardized course of therapy for hospitalized asthmatics with corticosteroids and albuterol nebulizations."7.68Chronopharmacology of albuterol in hospitalized asthmatic children. ( Cloutier, M; Labrecque, G; Rivard, GB, 1993)
"To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm."7.68Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993)
"To study the feasibility of using high-dose continuously aerosolized albuterol aerosol in adults, seven adult asthmatic patients were treated eight times with 0."7.68High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. ( Hergenroeder, P; Lin, RY; Smith, AJ, 1993)
"We performed a prospective study over a 6-month period to test the efficacy and safety of a continuous nebulized albuterol protocol for the treatment of acute adult asthma attacks."7.68The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. ( Barish, RA; Brandt, G; Hooper, F; Jerrard, D; Olshaker, J, 1993)
"Leukotriene B4 levels were measured after stimulation by calcium ionophore A23187: (i) in peripheral, neutrophils (PMN) from allergic asthmatics, rhinitis and healthy subjects; (ii) in macrophages collected by bronchoalveolar lavage."7.68Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. ( Chabannes, B; Gormand, F; Grosclaude, M; Hosni, R; Lagarde, M; Moliere, P; Pacheco, Y; Perrin-Fayolle, M; Piperno, D, 1992)
"Seven children from 3 to 14 years old with chronic steroid-dependent asthma were treated with methotrexate (MTX)."7.68Methotrexate treatment of severe asthma in children. ( Guss, S; Portnoy, J, 1992)
"The effect of a prior histamine challenge on the bronchodilator response to salbutamol after spontaneous recovery of FEV1 to 95% of the prechallenge level was studied in two groups of asthmatic children."7.68Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children. ( Duiverman, EJ; Kerrebijn, KF; Merkus, PJ; Quanjer, PH; Rooda, HM; van Essen-Zandvliet, EE, 1992)
"The effects of prednisolone, salbutamol or theophylline treatment were studied in guinea pigs on bronchial hyperreactivity induced by chronic administration of PAF, (subsequently measuring respiratory flow after an intravenous injection of histamine) and the chemokinesis of leucocytes in vitro."7.68Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs. ( Berga, P; Fernández, AG; Gristwood, RW; Llupiá, J, 1991)
"Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction."7.68[Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. ( Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990)
"To examine the effects of serum theophylline concentration on the bronchodilating effect of beta 2-stimulant inhalated by patients with bronchial asthma, 200 micrograms-Salbutamol inhalation test was performed on 30 patients with bronchial asthma (from 17 to 71 years old, averaging 49."7.68[The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma]. ( Hashimoto, T; Kondo, A; Nakamata, M; Tsukioka, K, 1990)
"The purpose of this study is to evaluate the effect of disodium cromoglycate and albuterol on energy cost of running, gas exchange, and ventilation during maximal exercise in children with exercise-induced asthma (EIA)."7.68Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children. ( Baraldi, E; Magagnin, G; Santuz, P; Zacchello, F; Zanconato, S, 1990)
"Albuterol used with a spacer device which induced atrial fibrillation is described."7.68Albuterol and spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990)
"Our study was designed to assess potential cardiovascular adverse effects in clinically stable asthmatic children due either to oral sustained-release theophylline or theophylline in combination with an inhaled beta-2 adrenergic agonist."7.68Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children. ( Bastianon, V; Bernardini, L; Businco, L; Coletta, F; Colloridi, V; Di Fazio, A; Ferrucci, A; Marzano, MC; Pucci, S; Sorbara, N, 1990)
"Out of a group of 55 asthmatics, 16 fitted the strict definition of atropine resistance (less than 20% FEV1 response to inhaled anticholinergic drugs, with a 20% or more FEV1 response to subsequent inhalation of beta 2-adrenergic stimulants)."7.67Atropine resistance in asthma: definition and provisional hypothesis. ( Jolobe, OM, 1984)
"Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months."7.67Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984)
"Twenty-seven asymptomatic asthmatic children with airway obstruction received a single oral dose of one out of three solutions, in a double-blind, randomized fashion, containing: etamiphylline, 6."7.67[Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma]. ( Labayru, MT; Vázquez, C, 1984)
"We report a case of respiratory arrest in a ten-year-old asthmatic girl under beta-2-agonists and theophylline."7.67[Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients]. ( Benhamou, PH; Devoldere, C; Epelbaum, S; Kremp, O; Pautard, JC; Piussan, C, 1989)
"4 mg salbutamol on the impedance of the respiratory system was studied in 25 asthmatic subjects after histamine-induced bronchoconstriction."7.67Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects. ( Polko, AH; Visser, BF; Wouters, EF, 1989)
"In 13 patients with bronchial asthma, who were on beta 2-adrenergic bronchodilator therapy, the effects of prednisolone and ketotifen on lymphocyte beta 2-adrenoceptor density and -responsiveness were investigated."7.67Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. ( Brodde, OE; Egerszegi, S; Howe, U; Konietzko, N; Michel, MC, 1988)
"The effect of a fish oil enriched diet containing about 3 g of eicosapentaenoic acid was studied in 10 patients with aspirin intolerant asthma."7.67Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study. ( Agusti-Vidal, A; Castillo, JA; Coronas, A; Ordinas, A; Picado, C; Pujades, M; Schinca, N, 1988)
"An albuterol (salbutamol) sulphate solution was successfully administered endotracheally to a 67-year-old woman suffering severe bronchospasm and impending ventilatory arrest secondary to asthma."7.67Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol). ( Gareau, AB; Rubes, CJ; Verbeek, PR, 1988)
"To explore the possibility that theophylline may act through adrenomedullary secretion of catecholamines, we examined the time courses of plasma norepinephrine (NE), epinephrine (E), and theophylline concentrations and peak expiratory flow (PEF) in nine children with an acute exacerbation of asthma receiving a 72-hour constant infusion of aminophylline."7.67Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma. ( Ishizaki, T; Kanagawa, S; Minegishi, A; Morishita, M; Nagai, T; Odajima, Y; Yamaguchi, M, 1988)
"Single photon emission computed tomography, a rotating gamma camera, and continuous inhalation or infusion of krypton 81m (half life 13 seconds) were used to measure regional ventilation (V), perfusion (Q), and ventilation-perfusion (V/Q) ratios in five normal subjects in supine, prone, and lateral decubitus postures and in three asthmatic patients (supine posture only) before and after inhalation of 2."7.67Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients. ( Al-Suhali, AR; Henderson, B; Hughes, JM; Myers, MJ; Orphanidou, D, 1986)
"The concentrations of theophylline, terbutaline and salbutamol in post-mortem blood samples from 68 patients (17-85 years old) with asthma or chronic obstructive lung disease, 54 of whom had died of asthma, were analysed."7.67Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients. ( Boman, G; Lindsjö, M; Lindström, B; Strandberg, K; Wiholm, BE, 1987)
" On oral challenges, she developed an urticarial reaction after tartrazine; urticarial and bronchospastic reactions after salicylsalicylic acid; and urticarial and bronchospastic reactions after choline magnesium trisalicylate."7.67Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. ( Chudwin, DS; Frey, C; Golden, HE; Luskin, AT; Richmond, GW; Strub, M, 1986)
"Asthma was provoked by histamine inhalation in five children in order to study the hypoxaemia that might ensue and the underlying ventilation-perfusion (VA/Q) mismatching."7.67Histamine-induced asthma in children: effects on the ventilation-perfusion relationship. ( Freyschuss, U; Hedenstierna, G; Hedlin, G, 1985)
"Studies using the guinea pig ileum bioassay technique have previously shown that patients with either asthma or chronic bronchitis have increased amounts of histamine in their sputum."7.66Histamine content of sputum from patients with asthma and chronic bronchitis. ( Bryant, DH; Pui, A, 1982)
"We have prospectively examined in 51 patients the relationship between the level of airway responsiveness to histamine and methacholine and the minimum medications required to control asthma."7.66Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. ( Frith, PA; Hargreave, FE; Juniper, EF, 1981)
"The efficacy and side effects of intravenous and intramuscular albuterol were determined in 13 adult asthmatic patients whose airway responsiveness had previously been evaluated with inhaled albuterol."7.66Intramuscular and intravenous albuterol in the treatment of asthma. ( Contreras, M; Rebuck, AS, 1982)
"We examined the effects of pharmacologic antagonists on the bronchial response to inhaled histamine in 11 normal and 11 asthmatic subjects."7.66Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. ( Chung, KF; Keyes, SJ; Morgan, B; Snashall, PD, 1982)
"Plasma cholesterol, plasma and white blood cell ascorbic acid concentrations were estimated in 30 untreated, 32 salbutamol-treated patients with bronchial asthma and in 57 normal controls."7.66Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma. ( Iboko, MI; Jessop, WJ; Ojutiku, OO; Olusi, SO, 1979)
"In a double-blind trial the effects on ventilatory function (FEV1), heart rate and blood pressure of oral pirbuterol and oral salbutamol in various single doses were studied in ten patients with chronic asthma."7.65Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. ( Grant, IW; Pocock, SJ; Willey, RF, 1976)
"Controlled standardised histamine inhalation tests were carried out in 21 asthmatics to determine the degree of non-specific bronchial hyperreactivity with and without prior treatment with several anti-asthmatic drugs."7.65Protective effect of drugs on histamine-induced asthma. ( Cockcroft, DW; Hargreave, FE; Killian, DN; Mellon, JJ, 1977)
"Ten patients with exercise-induced asthma were premedicated with oral salbutamol and oral theophylline on separate occasions before performing a standardised exercise test."7.65A comparison of oral theophylline and oral salbutamol in exercise-induced asthma. ( Anderson, SD; Lindsay, DA; Seale, JP, 1977)
"Albuterol mDPI was comparable to ProAir HFA at 90 and 180 µg."6.82Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. ( Iverson, H; Kerwin, EM; Lepore, MS; Miller, DS; Shah, T; Taveras, H; Wayne, D, 2016)
" Adverse events were comparable across groups."6.82Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. ( Bleecker, ER; Busse, WW; Donohue, JF; Garfinkel, S; Ghafouri, M; Manuel, RC; Schlenker-Herceg, R; Wise, R; Zubek, VB, 2016)
"Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS)."6.79Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. ( Bateman, ED; Bleecker, ER; Busse, WW; Goldfrad, C; Jacques, L; Lötvall, J; O'Byrne, PM; Toler, WT; Woodcock, A, 2014)
"Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12."6.76Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. ( Bodzenta-Lukaszyk, A; Dymek, A; Mansikka, H; McAulay, K, 2011)
" Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A."6.76Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. ( Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)
" The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population."6.73Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. ( Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008)
"We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium."6.73A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. ( Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007)
" Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)."6.72Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. ( Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)
" Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250."6.71Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. ( Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003)
" This randomized, placebo-controlled, multicenter, crossover study investigated the efficacy, dose-response and safety of HFA-albuterol delivered via a breath-actuated Autohaler inhalation device in comparison with the same medication delivered using a conventional P&B device."6.71Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. ( Cohen, RM; Gross, G; Guy, H, 2003)
" A bivariate dose-response model based on these principles was fitted simultaneously to all data."6.70Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, P; Poczi, M; Rosenborg, J; Rott, Z, 2002)
"Histamine challenges were carried out by tidal breathing method at entry, and at Days 4, 8, 22, 36, and 40."6.69Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. ( Cheung, D; de GOEIJ, JA; de GRAAFF, CS; Steen, H; Sterk, PJ; Wever, AM, 1998)
" Pulmonary function and safety measures were assessed after each dosing interval."6.69Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998)
" Safety was assessed by measuring changes in pulse rate, blood pressure, and electrocardiogram (ECG) intervals after dosing with study drug, monitoring adverse events, and performing prestudy and poststudy laboratory testing and physical examinations."6.69Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. ( Bronsky, E; Colice, GL; Ekholm, BP; Klinger, NM, 1999)
" On both assessment days for salmeterol, and during placebo administration periods, significant increases from predose FEV1 values were observed beginning with the lowest dose of albuterol and continuing throughout the dose-response assessment (p 6.69Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. ( Berkowitz, RB; Emmett, AH; Nelson, HS; Rickard, KA; Tinkelman, DA; Yancey, SW, 1999)
"Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9."6.69Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1999)
"Levalbuterol was found to provide significant bronchodilatory activity and was well tolerated."6.69Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. ( Caron, J; Handley, DA; Noonan, M; Rollins, TE; Snider, ME; Tinkelman, D, 2000)
" Safety assessments included monitoring of adverse events and morning serum cortisol concentrations."6.69Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. ( Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000)
"Albuterol OR was added to their usual treatment."6.68Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. ( Ariaansz, M; Nauta, JJ; Postmus, PE; Raaijmakers, JA; Van Keimpema, AR, 1996)
"Theophylline may produce a paradoxical increase in awareness of asthma in some individuals."6.68Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. ( Higgs, CM; Laszlo, G, 1996)
" This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia."6.68Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. ( Abboud, RT; Bowie, DM; Chapman, KR; Hodder, RV; McCallum, AL; Mesic-Fuchs, H; Molfino, NA; Newhouse, MT; Paré, PD, 1996)
"Albuterol treatment significantly increased the LAR compared to placebo treatment (p = 0."6.68Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. ( Cockroft, DW; Gauvreau, GM; Jordana, M; O'Byrne, PM; Watson, RM, 1997)
" 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day)."6.67[Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil]. ( Krasnowska, M; Liebhart, E; Małolepszy, J, 1994)
" A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])."6.67The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. ( Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994)
"Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated."6.67Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992)
"Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator."6.67Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991)
"treatment."6.67High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine. ( , 1990)
"Theophylline was titrated for patients to receive, unblinded, theophylline serum concentrations of 10 to 20 micrograms/ml."6.67Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. ( Bell, TD; LaForce, CF; MacCosbe, PE; Pierson, WE; Sykes, RS; Tinkelman, D, 1990)
" The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated."6.66Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy. ( Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986)
"Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7."6.66Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. ( Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985)
"Pindolol was administered gradually by mouth (2."6.66Influence of pindolol on asthmatics and effect of bronchodilators. ( Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986)
"Histamine PD20 FEV1 was assessed 4 h after the administration of salbutamol 200 micrograms, a combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms, and placebo."6.66Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients. ( Cresci, F; Fontana, G; Mugnai, M; Panuccio, P, 1986)
" Airway responsiveness thus appears to be a useful tool for evaluating inhaled beta 2-agonists and designing beta 2-agonist dosing regimens."6.66Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. ( Ahrens, RC; Annis, L; Harris, JB; Milavetz, G; Ries, R, 1987)
"Tiaramide hydrochloride is a new non-steroidal anti-inflammatory agent previously shown to inhibit allergic responses both in vitro and in vivo."6.66A trial of tiaramide in asthma. ( Harvey, JE; Jones, P; Tanser, AR, 1985)
"Twenty-five patients with chronic bronchial asthma completed the trial."6.65A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma. ( Beskow, R; Ericsson, CH; Grönneberg, R; Sjögren, I; Skedinger, M, 1984)
"Clenbuterol is a beta 2-sympathomimetic bronchodilator."6.64A trial of clenbuterol in bronchial asthma. ( Anderson, G; Wilkins, E, 1977)
"The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction."6.53Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. ( Welch, MJ, 2016)
"For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath."6.42Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease. ( Dalonzo, GE, 2004)
" Two recently completed trials have demonstrated that with respect to asthma control the combination of inhaled steroid (400 - 800 microg/d) plus theophylline is at least as effective as doubling the dose of inhaled steroid in patients who remain symptomatic on a dosage of 400 - 800 microg daily."6.40[Asthma therapy: combination of topical glucocorticosteroids and theophylline]. ( Ukena, D, 1997)
"Pulmonary function, asthma symptoms, supplemental albuterol use, asthma quality of life scores, and adverse events."6.19Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. ( Kalberg, C; Nathan, RA; Nelson, HS; Rickard, KA; Yancey, SW, 2001)
"We examined the effects of two year's treatment of three inhaled beta 2-agonists (beta 2), such as salbutamol (S), procaterol (P) and fenoterol (F) on acetylcholine induced bronchial hyperresponsiveness (BHR) in mild approximately moderate asthmatics."6.18[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics]. ( Ogawa, C; Sano, Y, 1996)
"A prospective, single center, open-label, two-arm, parallel-group, nonrandomized trial among children ages 5-17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively."5.69Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. ( Darville, KK; Goldenberg, NA; Martin, M; McKinley, SD; Nakagawa, TA; Roddy, MR; Sellers, AR; Sochet, AA; Teppa-Sanchez, B, 2023)
"In Colombia, compared with the use of albuterol alone, the use of beclomethasone dipropionate added to albuterol as needed for symptom relief is cost-effective in children 5 to 11 years old with mild intermittent (step 1) asthma, because it involves a higher probability of a lack of a requirement for prednisone for AE at lower total treatment costs."5.51As-Needed Use of Short-Acting β ( Buendia, JA; Rodríguez-Martínez, CE; Sossa-Briceño, MP, 2022)
"We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol-budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial."5.51Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. ( Albers, FC; Beasley, R; Cappelletti, C; Chipps, BE; Cooper, M; Dunsire, L; Israel, E; Jeynes-Ellis, A; Johnsson, E; Panettieri, RA; Papi, A; Rees, R, 2022)
"In this 12-week study, participants aged 13 years or older with suboptimal asthma control (Asthma Control Test [ACT] score < 19) were randomized to use either RDS or standard of care albuterol reliever inhalers."5.51Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1). ( Brown, R; DePietro, M; Hill, TD; Hoyte, FCL; Li, T; Mosnaim, GS; Reich, M; Rogers, L; Safioti, G; Wechsler, ME, 2022)
"To evaluate bronchodilator responses (BDR) to albuterol nebulized with 3%-HSS in asthmatic children, compared to albuterol nebulized with NSS."5.41Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children. ( Alchundia Moreira, J; García Bournissen, F; Kofman, C; Köhler, T; Teper, A, 2021)
"The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma."5.41Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. ( Albers, FC; Cappelletti, C; Chipps, BE; Johnsson, E; Papi, A; Reilly, L, 2021)
"The study suggests that LMWH in mild-moderate asthma attacks may be beneficial in the short term and could be prescribed in addition to standard albuterol therapy."5.41Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study. ( Hesam, S; Motamed, H; Nematollahi, AV; Verki, MM, 2021)
"Despite guidelines recommending administration of intravenous (IV) magnesium sulfate for refractory pediatric asthma, the number of asthma-related hospitalizations has remained stable, and IV magnesium therapy is independently associated with hospitalization."5.41Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma: Secondary Analysis of a Randomized Clinical Trial. ( Beer, D; Black, KJ; Coates, AL; Curtis, S; Ducharme, F; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Zemek, R, 2021)
"006), while asthma symptoms and albuterol use was higher (p < 0."5.34Impact of sleep opportunity on asthma outcomes in adolescents. ( Beebe, DW; Flewelling, K; Jump, S; Meltzer, LJ; Strand, MJ; Sundström, D; White, M; Zeitlin, PL, 2020)
"Pilot, placebo-controlled, double-blinded, and randomized-controlled trial PATIENTS: Thirty children (15 per group) with critical asthma receiving high-intensity albuterol per a standardized pathway utilizing objective assessments to wean patients to less frequent albuterol administration."5.34Randomized pilot trial of ipratropium versus placebo in children with critical asthma. ( Craven, D; Gallagher, J; Mahmood, N; Murphy, K; Ross, K; Rotta, AT; Shein, SL; Speicher, R, 2020)
" The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments."5.34Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. ( Atenafu, EG; Beer, D; Black, K; Coates, AL; Curtis, S; Ducharme, FM; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Klassen, TP; Nicksy, D; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Willan, AR; Zemek, R, 2020)
" Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared."5.33Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. ( Angus, R; Cheesbrough, A; Reagon, R, 2005)
"Levalbuterol-treated patients required significantly fewer treatments with beta-agonists (mean [+/- SD] number of treatments, 19."5.32Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. ( Halpern, M; Truitt, T; Witko, J, 2003)
" The area under the plasma albuterol concentration versus time curve (AUC) was 72% greater for the HFA formulation, indicating a greater lung bioavailability (p = 0."5.32Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. ( Anderson, P; Breen, P; Compadre, C; Gann, L; Hiller, FC; Joguparthi, V; Zhou, X, 2003)
"Malondialdehyde levels of BAL were compared before and after treatment."5.31Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist. ( Aydin, S; Besirli, K; Cetinkaya, A; Ozaras, R; Tahan, V; Talay, F; Turkmen, S; Uzun, H, 2000)
" Lung function, quality of life and adverse events were evaluated as primary outcome variables."5.31[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. ( Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)
"Baseline survey data, salivary cotinine levels, and allergen specific IgE serologic test results were obtained from children with uncontrolled asthma enrolled in a randomized clinical trial of a behavioral education environmental control intervention."5.30Characteristics of inner-city children with life-threatening asthma. ( Bollinger, ME; Butz, A; Lewis-Land, C; Morphew, T; Mudd, S; Tsoukleris, M, 2019)
"Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan."5.30Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. ( Adachi, Y; Akashi, K; Fujisawa, T; Hashimoto, K; Imai, T; Katsunuma, T; Maekawa, T; Mizuno, M; Nakamura, H; Oba, MS; Ohashi, Y; Ohya, Y; Sako, M, 2019)
"In an open-label trial involving adults with mild asthma, budesonide-formoterol used as needed was superior to albuterol used as needed for the prevention of asthma exacerbations."5.30Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. ( Beasley, R; Braithwaite, I; Ebmeier, S; Hancox, RJ; Harrison, T; Holliday, M; Houghton, C; Oldfield, K; Papi, A; Pavord, ID; Reddel, HK; Weatherall, M; Williams, M, 2019)
" Beta 2 adrenoceptor function was evaluated by measuring lymphocyte beta 2 adrenoceptor parameters and constructing dose-response curves to salbutamol (100-1600 micrograms)."5.30Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)
"Procaterol was administered per os (tabl."5.28[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992)
"Patients with bronchial asthma often develop acute attack in kitchen while burning honeycomb briquet which is widely used for cooking in southern China."5.28[Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol]. ( Luo, DF; Luo, ZY; Zheng, JP, 1990)
"The objective of this study was to determine if a rapid albuterol delivery pathway with a breath-enhanced nebulizer can reduce emergency department (ED) length of stay (LOS), while maintaining admission rates and side effects, when compared to a traditional asthma pathway with a standard jet nebulizer."5.27Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. ( Allen, C; Higginbotham, E; Hovinga, C; Iyer, S; King, B; Wallace, A; Wilkinson, M, 2018)
"Magnesium sulfate has been shown to be an effective treatment in older children with asthma exacerbations, but it has not been investigated in acute severe virus-induced wheezing in young children."5.27Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial. ( Dunder, T; Kallio, M; Pokka, T; Pruikkonen, H; Renko, M; Tapiainen, T; Uhari, M, 2018)
"BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma."5.27Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018)
" Subjects presenting with a Pediatric Asthma Score ranging from 5 to 11 received albuterol by BAN or MDI via standard weight-based and symptom severity dosing protocols."5.27A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers. ( Arnold, SR; Gilmore, B; Jacobs, J; Kink, R; Snider, MA; Wan, JY, 2018)
"To compare the efficacy of a long-term treatment with Fluticasone Propionate administered by an MDI through both type of spacers, with and without valves, in young children with recurrent wheezing and risk factors for asthma."5.27Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma. ( Kofman, C; Teper, A, 2018)
" We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0."5.27A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985)
"The long-acting muscarinic antagonist, umeclidinium (UMEC), combined with the inhaled corticosteroid, fluticasone furoate (FF), improves lung function in symptomatic patients with asthma."5.24The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. ( Collison, K; Kerwin, E; Lee, L; Nelsen, L; Pascoe, S; Wu, W; Yang, S, 2017)
"To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma."5.24Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. ( Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)
"Evaluate the safety of albuterol multidose dry powder inhaler (MDPI), a novel, inhalation-driven device that does not require coordination of actuation with inhalation, in patients with persistent asthma."5.22Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. ( Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016)
"To compare the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of albuterol MDPI and albuterol HFA after a single inhaled dose in children with asthma."5.22Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. ( Iverson, H; Ratnayake, A; Shore, P; Taveras, H, 2016)
"To demonstrate the comparability of albuterol MDPI and albuterol HFA in children with asthma."5.22Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. ( Iverson, H; Qaqundah, PY; Shore, P; Taveras, H, 2016)
"To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol."5.22Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β ( Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)
"To determine if the addition of ipratropium bromide (IB) by metered-dose inhaler in moderate acute asthma in children affects hospital admission rates when compared with inhaled salbutamol and oral prednisolone alone."5.20Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial. ( Borland, ML; Doyle, SK; Geelhoed, GC; Wyatt, EL, 2015)
"We have previously shown that in patients with asthma a single dose of an inhaled glucocorticosteroid (ICS) acutely potentiates inhaled albuterol-induced airway vascular smooth muscle relaxation through a nongenomic action."5.20Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma. ( Arana, J; Cadet, L; Mendes, ES; Wanner, A, 2015)
"Patients aged 2 to 14 y with moderate and severe asthma (PRAM severity score ≥ 4) admitted to infirmary/observation unit care were randomized double-blind on admission to receive 800 mg nebulized magnesium or normal saline placebo after all received intensive therapy with combined nebulized albuterol-ipratropium and intravenous methylprednisolone."5.20Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. ( Ahmed, W; Alamri, M; Alansari, K; Alrifaai, M; Davidson, BL; Zakaria, I, 2015)
"Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented."5.20Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. ( Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015)
" Patients with mild to moderate asthma will be randomly allocated to either a verum acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets group or a sham acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets group."5.20Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial. ( Fan, L; Feng, JT; Hu, CP; Liu, YY; Shao, SJ; Wang, PY; Wang, WQ; Wang, Y; Xu, YD; Yang, YQ; Yin, LM; Zhang, TF, 2015)
"Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity."5.19Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014)
"Three hundred and thirty children of asthma with positive bronchial provocation test were randomly divided into three groups: magnesium sulfate, albuterol, and a combination of magnesium sulfate and albuterol."5.19Effect of inhaled MgSO4 on FEV1 and PEF in children with asthma induced by acetylcholine: a randomized controlled clinical trail of 330 cases. ( Dai, JH; Gong, CH; Liu, S; Shi, TT; Sun, YX; Yan, L; Yin, LJ; Yuan, XP, 2014)
"Post hoc descriptive analysis of data stratified by FAO category (screening post-albuterol FEV1/FVC asthma patients."5.19Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. ( Chipps, BE; Tashkin, DP; Trudo, F; Zangrilli, JG, 2014)
"This study compares the effect of heliox-driven to that of air-driven bronchodilator therapy on the pulmonary function test (PFT) in patients with different levels of asthma severity."5.19Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma. ( Alawieh, M; Bou-Akl, I; Bou-Khalil, P; Chami, H; El-Khatib, MF; Husari, A; Jamaleddine, G; Kanj, N; Zeineddine, S, 2014)
"In subjects with either asthma or COPD, FEV(1) decline and bronchospasm can occur following inhaled loxapine, but more frequently in asthmatic subjects."5.19Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. ( Cassella, JV; Fishman, RS; Greos, LS; Gross, N; Meltzer, EO; Spangenthal, S; Spyker, DA, 2014)
"Subjects with acute exacerbation of asthma (FEV1 <50% predicted following 30 min of standardized treatment: 5 mg nebulized albuterol; 0."5.19Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation. ( Ferguson, I; House, SL; Johnson, K; Lewis, LM; Liu, J; Matsuda, K; Schneider, JE, 2014)
"To compare hyperpolarized helium-3 ((3) He) and xenon-129 ((129) Xe) MRI in asthmatics before and after salbutamol inhalation."5.17Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. ( Kirby, M; Leary, D; Maksym, GN; McCormack, DG; Parraga, G; Starr, D; Svenningsen, S; Wheatley, A, 2013)
"To compare tulobuterol patch and oral salbutamol sulfate in terms of efficacy and safety in children with mild or moderate acute attack of bronchial asthma."5.17[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013)
"The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD."5.17Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. ( Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013)
"Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma."5.17Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma. ( Aizawa, H; Fukuyama, S; Inoue, H; Komori, M; Koto, H; Matsumoto, K; Takata, S; Yoshida, M, 2013)
"To investigate the clinical benefits of 'add-on' therapy with GSK2190915 in combination with the inhaled corticosteroid (ICS) fluticasone propionate (FP) and the ICS/long-acting beta 2 agonist (LABA) combination FP/salmeterol in asthmatic subjects."5.17Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. ( Clements, D; Follows, RM; Ho, SY; Snowise, NG, 2013)
"In a randomized, open-label, placebo-controlled, parallel group study, 66 patients with mild to moderate asthma received one of the following four treatments bid through an MDI for 42 days: mometasone furoate/formoterol (MF/F) 200 μg/10 μg, MF/F 400 μg/10 μg, fluticasone propionate/salmeterol (FP/S) 460 μg/42 μg, or placebo."5.17Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. ( Cutler, DL; Hubbell, J; Johnson-Levonas, AO; Kantesaria, BS; Kim, K; Kosoglou, T; Miller, SD; Xu, D, 2013)
"Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials."5.17Predictors of response to tiotropium versus salmeterol in asthmatic adults. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, LC; Dimango, EA; Engle, LL; Icitovic, N; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2013)
"Patients with asthma aged 18 to 65 years requiring high-dose inhaled corticosteroids (ICSs) (>750 μg/d of fluticasone propionate or equivalent) and long-acting β2-agonists (LABAs) (at least 100 μg/d of salmeterol or equivalent), with or without oral prednisone (≤30 mg/d), leukotriene modifiers, theophylline, or other asthma controller medications were enrolled in the Research in Severe Asthma (RISA) Trial."5.17Safety of bronchial thermoplasty in patients with severe refractory asthma. ( Armstrong, B; Chung, KF; Corris, PA; Cox, G; Laviolette, M; Niven, RM; Pavord, ID; Shargill, NS; Thomson, NC, 2013)
"To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients."5.17Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma. ( Ding, X; Hu, S; Huang, Y; Liu, M; Nie, H; Zhang, G, 2013)
"To determine whether adding salmeterol or montelukast to low-dose inhaled corticosteroids (ICSs) can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma."5.17Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. ( James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013)
"The objective of this study was to investigate whether high-dose inhaled fluticasone propionate (FP), alone or in combination with salmeterol (SAL), is as effective as oral prednisolone in reducing airway inflammation and obstruction in cats with experimentally-induced acute asthma."5.16Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model. ( Clercx, C; Gustin, P; Kirschvink, N; Leemans, J; Snaps, F, 2012)
"Fourteen subjects with moderate asthma inhaled single doses of salmeterol (50 μg), fluticasone propionate (250 μg), salmeterol/fluticasone propionate (50/250 μg), or placebo; Qaw was measured before and serially for 240 min after drug administration."5.16Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma. ( Mendes, ES; Rebolledo, P; Wanner, A, 2012)
"Combination therapy with an inhaled corticosteroid (ICS) and a long-acting β(2)-agonist (LABA) in a single inhaler is the mainstay of asthma management and salmeterol/fluticasone combination (SFC) and fixed-dose formoterol/budesonide combination (FBC) are currently available in Japan; however, there is nothing to choose between the two."5.16Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma. ( Akamatsu, T; Chida, K; Hashimoto, D; Hayakawa, H; Ide, K; Inui, N; Kato, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yasui, H; Yokomura, K, 2012)
"Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control group."5.16Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. ( Bozek, A; Filipowska-Gronska, A; Jarzab, J; Warkocka-Szoltysek, B, 2012)
"Forty steroid-naïve, symptomatic asthmatic patients, with sputum eosinophils <3%, were randomized to receive open-label salmeterol (50 µg twice a day, n = 30) or fluticasone (125 µg twice a day, n = 10) and were then assessed at 1, 3 and 6 months."5.16Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol. ( Bacci, E; Bartoli, M; Cianchetti, S; Costa, F; Dente, FL; Di Franco, A; Latorre, M; Malagrinò, L; Novelli, F; Paggiaro, P; Vagaggini, B, 2012)
"The pentosidine levels did not significantly differ between the two asthmatic subgroups with and without airway obstruction."5.16Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients. ( Hirata, K; Kanazawa, H; Tamagaki, G, 2012)
"In a randomized, two-period, two-sequence crossover clinical trial, we analyzed 31 stable asthmatic children (6-18 yrs of age) on two consecutive days, who were randomly assigned to receive 100 μg of albuterol MDI through either a locally produced valved spacer or a non-valved spacer."5.16Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2012)
"Adults with mild-to-moderate-severe persistent asthma were randomized to fluticasone/formoterol (100/10 or 250/10 μg twice daily [b."5.16Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. ( Aalbers, R; Bodzenta-Lukaszyk, A; Brusselle, G; Grothe, B; McIver, T, 2012)
" Patients with mild-to-moderate persistent stable asthma taking 1,000 μg/day or less beclomethasone dipropionate equivalent received 10 or 20 mg of oral propranolol followed by histamine challenge, with recovery to nebulized salbutamol (5 mg)."5.16Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma. ( Lipworth, BJ; Short, PM; Williamson, PA, 2012)
"Provision of a written action plan significantly increased patient adherence to inhaled and oral corticosteroids and asthma control and physicians' recommendation for maintenance fluticasone and medical follow-up, supporting its independent value in the acute-care setting."5.15Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control. ( Chalut, D; Ducharme, FM; Khomenko, L; McGillivray, D; Noya, FJ; Resendes, S; Rouleau, R; Zemek, RL; Zhang, X, 2011)
"To compare racemic albuterol (RAC) with levalbuterol (LEV) in continuous form for the treatment of acute pediatric asthma exacerbations in the emergency department."5.15Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. ( Bulloch, B; Garcia-Filion, P; Keahey, L; Wilkinson, M, 2011)
"Children with mild persistent asthma should not be treated with rescue albuterol alone and the most effective treatment to prevent exacerbations is daily inhaled corticosteroids."5.15Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. ( Bacharier, LB; Bade, E; Boehmer, SJ; Chinchilli, VM; Covar, RA; Friedman, NJ; Guilbert, TW; Heidarian-Raissy, H; Kelly, HW; Lemanske, RF; Malka-Rais, J; Martinez, FD; Mauger, DT; Mellon, MH; Morgan, WJ; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, L; Zeiger, RS, 2011)
"We conducted a randomized study of one-time albuterol treatment with the AeroEclipse breath-actuated nebulizer versus standard therapy (single treatment via small-volume nebulizer or 1-hour of continuous nebulized albuterol) in pediatric asthma patients in the emergency department."5.15Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. ( Asselin, JM; Gildengorin, V; Hawk, W; Sabato, K; Ward, P, 2011)
"To determine whether adiposity worsens the clinical and physiological manifestations of acute asthma and limits therapeutic effectiveness of standard treatment, we contrasted signs, symptoms, medication use, arterial oxygen saturation, peak expiratory flow rate, and the bronchodilator response to standard doses of albuterol in 90 non-obese and 90 obese asthmatics as they presented for urgent care."5.15Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma. ( Coreno, AJ; Dickey-White, H; McFadden, ER; Seitz, RE; Skowronski, ME; Villalba, KD; Yeh, KH, 2011)
"In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention."5.15Active albuterol or placebo, sham acupuncture, or no intervention in asthma. ( Boyd, IO; Dutile, S; Israel, E; Kaptchuk, TJ; Kelley, JM; Kirsch, I; Marigowda, G; Wechsler, ME, 2011)
" Patients 2 to 18 years of age with moderate to severe acute asthma were randomized to receive either a single 2-mg dose of budesonide inhalation suspension (BUD) or normal sterile saline (NSS) placebo, added to albuterol, ipratropium bromide (IB), and systemic corticosteroids (SCS)."5.15Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial. ( Chew, A; Mollen, CJ; Scarfone, RJ; Seiden, J; Upham, BD; Zorc, JJ, 2011)
"We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oral corticosteroids were used for worsening asthma symptoms."5.15Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity. ( Bacharier, LB; Graber, NJ; Horner, CC; Lemanske, RF; Mauger, D; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2011)
"We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10 ACRN trials (1993-2003)."5.15Impact of race on asthma treatment failures in the asthma clinical research network. ( Castro, M; Chinchilli, VM; Denlinger, L; Israel, E; Lazarus, SC; Lehman, E; Peters, SP; Sutherland, ER; Wechsler, ME, 2011)
"In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score."5.15The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011)
"Adults admitted to hospital with acute exacerbation of asthma were randomized to receive oral prednisolone 100 mg once daily or hydrocortisone 100 mg i."5.15Oral versus intravenous steroids in acute exacerbation of asthma--randomized controlled study. ( Dembla, G; Doifoide, DV; Mundle, RP; Salkar, HR, 2011)
"All patients between 6 and 17 years of age who presented to a pediatric emergency department in the winter months with acute exacerbation of bronchial asthma were given a combination of nebulized albuterol and ipratropium with warmed or room temperature humidified oxygen."5.14Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. ( Hassen, GW; Nibhanipudi, K; Smith, A, 2009)
"We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP) administered, in addition to CIC 160 microg x day(-1) and salmeterol 50 microg twice daily, in 32 patients with persistent asthma using a randomised double-blind, placebo-controlled, double-dummy, five-period crossover design."5.14Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. ( Derom, E; Engelstätter, R; Joos, GF; Kaufman, JM; Louis, R; Tiesler, C, 2009)
"To evaluate the efficacy of add-on montelukast on asthma control and allergic rhinitis symptoms in asthmatic patients still symptomatic with chronic treatment with inhaled corticosteroid and long-acting beta(2) agonist (ICS/LABA), irrespective of the dose."5.14Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. ( Dramaix, M; Herbots, E; Korn, D; Peché, R; Potvin, E; Van den Brande, P, 2009)
"Eighteen patients with mild allergic asthma who did not use any regular antiasthmatic therapy inhaled the long-acting beta(2)-agonist salmeterol for 2 weeks followed by 2 weeks of combination therapy with salmeterol and the corticosteroid fluticasone."5.14Adverse effects of salmeterol in asthma: a neuronal perspective. ( Bratke, K; Edner, A; Kuepper, M; Lindner, Y; Lommatzsch, M; Virchow, JC, 2009)
" This double-blind, parallel group, non-inferiority study compared lung function and asthma control, based on Global Initiative for Asthma guidelines, in children receiving either salmeterol/fluticasone propionate (SFC) 50/100 microg bd (n = 160) or fluticasone propionate (FP) 200 microg bd (n = 161) for 12 wks."5.14Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. ( Anderton, S; Attali, V; Bennedbaek, O; de Blic, J; Desfougeres, JL; Hofman, J; Klink, R; Ogorodova, L; Poterre, M; Sidorenko, I; Valiulis, A, 2009)
"The modified adenosine infusion protocol with salbutamol premedication can be used in patients with asthma."5.14Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. ( Notghi, A; Smith, NB; Sundram, F, 2009)
"To assess asthma-related quality of life after treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane 134a metered-dose inhaler compared with the individual components alone."5.14Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. ( Andersen, LB; Edin, HM; Ho, SY; Ortega, HG; Schoaf, L; Scott-Wilson, CA, 2009)
"Salmeterol and fluticasone propionate combination (SFC) provides better asthma control than fluticasone propionate (FP) alone, however, little is known on the effects of differential treatments on airway function and inflammation in patients with mild asthma."5.14Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. ( Handa, H; Hoshino, M; Miyazawa, T, 2009)
"To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus."5.14High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. ( Andrews, T; Chew, A; McGintee, E; Mittal, MK; Pawlowski, N; Tyler, L; Zhang, X; Zorc, JJ, 2009)
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid."5.14Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009)
"To reduce symptoms and emergency department (ED) visits, the National Asthma Education and Prevention Program (NAEPP) guidelines recommend early treatment of acute asthma symptoms with albuterol and oral corticosteroids."5.14Home use of albuterol for asthma exacerbations. ( Freiner, D; Garbutt, JM; Highstein, GR; Nelson, KA; Smith, SR; Strunk, RC, 2009)
" Future exacerbations were somewhat predicted by asthma symptoms, albuterol use, previous exacerbations, and lung function, whereas maximum symptom days were predicted, also to a modest extent, by symptoms, albuterol use, and previous exacerbations, but not lung function."5.14Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. ( Bloomberg, GR; Brown, M; Busse, WW; Calatroni, A; Chmiel, JF; David, G; Gergen, PJ; Gruchalla, RS; Kumar, R; Lamm, C; Liu, AH; Matsui, E; Sampson, HA; Smartt, E; Sorkness, CA; Steinbach, SF; Stone, KD; Szefler, SJ, 2009)
"Retrospective pharmacogenetic studies have questioned whether patients with asthma who are arginine homozygous at the beta(2-)adrenergic receptor (position 16) should use long-acting beta-agonists."5.14Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. ( Anderson, WH; Bleecker, ER; Corren, J; Emmett, AH; Kraft, M; Meyers, DA; Nelson, HS; Ortega, HG; Yancey, SW, 2010)
"Inhaled corticosteroids, such as fluticasone propionate (FP) and ciclesonide (CIC), are commonly used for the treatment of asthma."5.14Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ( Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010)
"We randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up)."5.14Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. ( Bacharier, LB; Boehmer, SJ; Covar, RA; Guilbert, TW; Jackson, DJ; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Moss, MH; Sorkness, CA; Spahn, JD; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2010)
"We investigated if a higher proportion of adults with previously uncontrolled asthma can achieve total control when given salmeterol/fluticasone propionate (50/250 microg) bid and compliance enhancement training (CET) compared to those given medication alone."5.14Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. ( Backer, V; Claudius, BK; Dahl, R; Harving, H; Hellquist, B; Høgholm, A; Jøhnk, IK; Siersted, HC; Tamm, M; Ulrik, CS, 2009)
"To evaluate the effect of montelukast, 5 mg, or inhaled salmeterol, 50 microg, added to inhaled fluticasone in reducing the maximum percentage decrease in forced expiratory volume in 1 second (FEV1) after a standardized exercise challenge and response to rescue bronchodilation with albuterol in children aged 6 to 14 years with persistent asthma and exercise-induced bronchoconstriction (EIB)."5.14Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. ( Aristizabal, G; Fogel, RB; Gaile, S; Loeys, T; Noonan, G; Polos, PG; Rosario, N; Smugar, SS, 2010)
"Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treatment."5.1424-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. ( Adachi, M; Emery, C; Haida, M; Higgins, M; Hosoe, M; Ichinose, M; Kanada, S; Kramer, B; Sugihara, N, 2010)
"To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice a day Diskus in children with symptomatic asthma."5.14Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. ( Brackel, HJ; Duiverman, EJ; Gerrits, GP; Hop, WC; Vaessen-Verberne, AA; van den Berg, NJ; van Nierop, JC, 2010)
"We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV₁ or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation."5.14Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. ( Cydulka, RK; Emerman, CL; Muni, A, 2010)
"In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison)."5.14Tiotropium bromide step-up therapy for adults with uncontrolled asthma. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, L; DiMango, EA; Engle, LL; Fahy, JV; Icitovic, N; Israel, E; Jarjour, N; Kazani, SD; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2010)
"To compare the cost-effectiveness of budesonide/formoterol in a single inhaler used as Maintenance and Reliever Therapy (SMART) versus fixed higher-dose budesonide/formoterol plus as-needed terbutaline reliever (FHDBF) or fixed dose fluticasone/salmeterol plus as-needed terbutaline reliever (FDFS) in controlling asthma in adults and adolescents."5.13Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. ( FitzGerald, JM; Miller, E, 2008)
"GOAL was a 1-year, randomized, stratified, double-blind study of 3421 patients with uncontrolled asthma, which compared salmeterol/fluticasone propionate combination with fluticasone propionate in achieving two composite, guideline-based measures of control: totally controlled and well-controlled asthma."5.13Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Gibbs, M; Gul, N; Pedersen, S, 2008)
"The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital."5.13Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. ( Andrews, WT; Ciubotaru, RL; Claus, R; Donohue, JF; Hanania, NA; Noe, L; Pasta, DJ; Roach, J; Schaefer, K, 2008)
"This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects."5.13A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. ( Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008)
"Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma."5.13Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. ( Bacharier, LB; Chinchilli, VM; Covar, R; Guilbert, T; Krawiec, M; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Paul, IM; Phillips, BR; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2008)
"We analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily."5.13Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. ( Patel, AC; Strunk, RC; Tonascia, J; Van Natta, ML; Wise, RA, 2008)
"Asthmatics treated adequately with ICS (750-1000 mcg ICS daily) were randomised to receive ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd) or ICS alone (500 mcg bd)."5.13Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. ( Dahl, R; Harving, H; Heinig, JH; Hoffmann, HJ; Nielsen, LP, 2008)
"In 10 asthmatic and 10 healthy subjects, airway blood flow and FEV(1) were measured before and 30 minutes after fluticasone or placebo inhalation and 15 minutes after the subsequent inhalation of racemic albuterol (0."5.13Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma. ( Campos, M; Horvath, G; Mendes, ES; Wanner, A, 2008)
"The efficacy and safety of twice-daily inhaled salmeterol/fluticasone propionate combination (SFC) therapy have been well established in the treatment of adults and adolescents with asthma."5.13Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. ( Chuchalin, A; Frith, L; Jacques, L, 2008)
"Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of albuterol on esophageal function in asthmatic patients are not known."5.13The effects of nebulized albuterol on esophageal function in asthmatic patients. ( DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008)
"Although albuterol remains the standard treatment for asthma in the emergency department, formoterol fumarate may be more advantageous, with its rapid and long-lasting bronchodilation."5.13Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. ( Chou, V; Lee-Wong, M; Ogawa, Y, 2008)
" Two groups followed a BHR treatment strategy (based on clinical parameters [lung function, asthma symptoms, and bronchodilator use] and BHR) and were treated with either fluticasone propionate/salmeterol (FSC(BHR) group) or fluticasone propionate (FP(BHR) group) (n=156 each)."5.13Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? ( Andersen, L; Dorinsky, P; Koenig, SM; Murray, JJ; Prillaman, B; Stauffer, J; Wolfe, J; Yancey, S, 2008)
"To compare the efficacy and safety of the salmeterol/fluticasone propionate combination product with concurrent sustained release theophylline plus fluticasone propionate in adult Japanese patients with persistent asthma."5.13Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. ( Adachi, M; Aizawa, H; Ishihara, K; Nakashima, M; Ohta, K; Sano, Y; Taniguchi, H, 2008)
"An outpatient, randomized, double-blind, single-dose, crossover study in adult asthmatics with moderate-to-severe obstruction despite treatment with inhaled corticosteroids (ICS) was conducted comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB)."5.13Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ( Cassino, C; Conoscenti, CS; Gelb, AF; Johnson, P; Karpel, J; Wise, RA, 2008)
"We investigated 28 single nucleotide polymorphisms in CRHR2 for associations with acute bronchodilator response to albuterol in 607 Caucasian asthmatic patients recruited as part of the Childhood Asthma Management Program."5.13Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. ( Hanrahan, JP; Irvin, CG; Lange, C; Lasky-Su, J; Lazarus, R; Lima, JJ; Litonjua, AA; Poon, AH; Tantisira, KG; Weiss, ST; Xu, J, 2008)
" Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use."5.13Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008)
"In this randomized controlled, double blind study, 30 asthmatics were challenged with histamine until forced expiratory volume in 1s (FEV(1)) fell with > or =20%."5.12Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction. ( De Peuter, S; Lemaigre, V; Smets, A; Van den Bergh, O; Verleden, GM, 2006)
"The aim of this study was to assess asthma control using salmeterol plus fluticasone propionate (FP) in combination (SFC) versus salmeterol or FP as monotherapy in patients with mild to moderate asthma."5.12Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. ( James, M; Jonsson, AC; Larsson, LG; Lindberg, A; Lundbäck, B; Pétavy, F; Rönmark, E, 2006)
"Therefore, we compared the effects of beclomethasone dipropionate (BDP) on the degree of BHR to inhaled histamine and NKA in a double-blind, controlled, cross-over study of asthmatic patients."5.12Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma. ( Arcidiacono, G; Ciamarra, I; Crimi, N; Polosa, R; Prosperini, G, 2006)
" Therefore, a 12-week randomized double-blind placebo-controlled clinical study was conducted to investigate the efficacy of a plant-based formulation (DCBT4567-Astha-15) in comparison with oral salbutamol, salbutamol + theophylline and a matching placebo in patients with reversible asthma."5.12Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline. ( Deivanayagam, CN; Krishnarajasekar, OR; Lakshmisubramanian, S; Murali, PM; Nalini, K; Perumal, T; Rajasekaran, S, 2006)
"Suppressing the release of pro-inflammatory mediators may play a role, at least in part, in the beneficial effects of aminophylline in the treatment of acute exacerbations in asthma."5.12Aminophilline suppress the release of chemical mediators in treatment of acute asthma. ( Nakano, J; Ohbayashi, O; Ohta, K; Yamamura, K; Yamashita, N; Yano, T; Yoshihara, H, 2006)
"A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED."5.12Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. ( Brown, L; Kim, TY; Minasyan, L; Rivera, ML; Stewart, GM, 2006)
"To compare the safety of salmeterol xinafoate or placebo added to usual asthma care."5.12The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. ( Bleecker, ER; Dorinsky, PM; Nelson, HS; Weiss, ST; Yancey, SW, 2006)
"After a 4 week fluticasone run-in period, 54 patients with allergic asthma were randomised to receive twice daily treatment with fluticasone 250 microg with or without salmeterol 50 microg for 1 year in a double blind, parallel group design (total daily dose of fluticasone 500 microg in both treatment groups)."5.12Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2006)
"Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols."5.12Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use. ( Batra, V; Cirelli, R; Foster, GC; Hastie, AT; Hawkins, GA; Peters, SP; Rybinski, KA; Wu, M; Zangrilli, JG, 2006)
"This study compared the efficacy and tolerability of the combination of fluticasone propionate (FP) and salmeterol (SAL) delivered via a single hydrofluoroalkane (HFA) 134a metered-dose inhaler (MDI) with those of its 2 components alone delivered via a chlorofluorocarbon (CFC) MDI and placebo (PLA) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses (equivalent to FP 440-660 microg/d) of inhaled corticosteroids (ICSs)."5.12Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. ( Dorinsky, P; Ellsworth, A; House, K; Nathan, RA; Rooklin, A; Schoaf, L; Scott, C, 2006)
"Although frequently used to treat status asthmaticus in children, intravenous (IV) terbutaline has not been shown to decrease hospital length of stay (LOS)."5.12Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. ( Carroll, CL; Schramm, CM, 2006)
"To assess the effectiveness of distinct salbutamol and terbutaline doses delivered via an MDI with spacer for the treatment of acute asthma in the pediatric emergency department."5.12[Bronchodilators via metered-dose inhaler with spacer in the pediatric emergency department: what is the dosage?]. ( Benito Fernández, J; González Díaz, C; Landa Garriz, M; Mintegi Raso, S; Trebolazabala Quirante, N, 2006)
"2 mg of salbutamol on histamine-induced bronchoconstriction was assessed in 101 steroid-naïve asthmatic subjects."5.12Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction. ( Kiviniemi, V; Koskela, HO; Purokivi, MK; Taivainen, AH; Tukiainen, HO, 2006)
"Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases--migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma."5.12Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. ( Lomia, M; Pruidze, M; Tchelidze, T, 2006)
" Additional endpoints included asthma symptom scores, daily albuterol use, and safety, including hypothalamic-pituitary-adrenal (HPA) axis function."5.12Once-daily ciclesonide in children: efficacy and safety in asthma. ( Gelfand, EW; Georgitis, JW; Noonan, M; Ruff, ME, 2006)
"The Gaining Optimal Asthma ControL (GOAL) study has shown the superiority of a combination of salmeterol/fluticasone propionate (SFC) compared with fluticasone propionate alone (FP) in terms of improving guideline defined asthma control."5.12Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. ( Bateman, ED; Bousquet, J; Briggs, AH; Busse, WW; Clark, TJ; Pedersen, SE; Wallace, MV, 2006)
"This multicenter, randomized, double-blind trial compared nebulized levalbuterol (Lev) and racemic albuterol (Rac) in the treatment of acute asthma."5.12A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. ( Baumgartner, RA; Claus, R; Emerman, C; Hanania, NA; Hanrahan, JP; Nowak, R; Parsey, MV; Schaefer, K, 2006)
"To investigate the safety and effectiveness of a 4-mg tablet of oral montelukast in addition to short-acting beta2-agonist bronchodilator as the initial treatment in mild to moderate asthma exacerbations in children between 2 and 5 years old."5.12Oral montelukast treatment of preschool-aged children with acute asthma. ( Bakirtas, A; Degim, T; Harmanci, K; Turktas, I, 2006)
"Oral magnesium supplementation helped to reduce bronchial reactivity to methacholine, to diminish their allergen-induced skin responses and to provide better symptom control in pediatric patients with moderate persistent asthma treated with inhaled fluticasone."5.12Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial. ( Condino-Neto, A; Gontijo, LS; Gontijo-Amaral, C; Ribeiro, JD; Ribeiro, MA, 2007)
"Compared with placebo use, fluticasone propionate, 88 microg administered twice daily, significantly reduced asthma exacerbations, asthma symptoms, and rescue albuterol use and was well tolerated, with no clinically relevant systemic effects, as measured by growth velocity or 12-hour urinary cortisol excretion levels."5.12Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. ( Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006)
"This study investigated whether clinical asthma control and airway inflammation could be maintained after switching therapy from medium-dose fluticasone propionate (FP) to low-dose FP administered with the long-acting beta2-agonist (LABA) salmeterol."5.12Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. ( Davis, WB; Djukanovic, R; Doherty, DE; Dorinsky, PM; Edwards, LD; Hamid, Q; Israel, E; Jarjour, NN; Kavuru, MS; Koenig, SM; Laviolette, M; Moore, WC; Ramsdell, JW; Reilly, DS; Stauffer, JL; Tashkin, DP; Wilson, SJ; Yancey, SW, 2006)
"In this study, levalbuterol administered via MDI significantly improved airway function in comparison with placebo in asthmatic children aged 4-11 years with a safety profile that was similar to placebo."5.12Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. ( Baumgartner, RA; Berger, WE; Milgrom, H; Parsey, MV; Skoner, DP; Tripp, K, 2006)
"To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy."5.12Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. ( Baumgartner, RA; Grasela, T; Hsu, R; Maier, G; Rubino, C, 2007)
"To investigate the duration of bronchodilator action of a salmeterol/fluticasone combination (SFC) inhaler when administered in the evening to children with asthma."5.12Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. ( Aldington, S; Beasley, R; Weatherall, M; Williams, M, 2006)
"Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy."5.12Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006)
"The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma."5.12Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. ( Aizawa, H; Fukuyama, S; Inoue, H; Kanaya, A; Komori, M; Matsumoto, K; Matsumoto, T; Matsumura, M; Moriwaki, A; Nakanishi, Y; Nakano, T; Tsuda, M; Yoshida, M, 2007)
"We sought to determine whether the combination of the LTRA montelukast and the LABA salmeterol could provide an effective therapeutic strategy for asthma."5.12Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. ( Boushey, HA; Chinchilli, VM; Craig, TJ; Deykin, A; DiMango, E; Fahy, JV; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Leone, F; Martin, RJ; Pesola, GR; Peters, SP; Sorkness, CA; Szefler, SJ; Wechsler, ME, 2007)
" In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed."5.12Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction. ( Carranza-Rosenzweig, J; Crim, C; Lincourt, WR; Locantore, NW; Sheth, K; Wasserman, RL, 2006)
"Recent studies suggest that there might be an association between albuterol use and worsening asthma in patients homozygous for arginine (Arg/Arg) at codon 16 of the beta-receptor."5.12Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. ( Anderson, WH; Baitinger, LA; Bleecker, ER; Dorinsky, PM; Edwards, LD; Klotsman, M; Yancey, SW, 2006)
"Multiple studies have examined adding nebulized ipratropium bromide to intermittent albuterol for the treatment of acute asthma."5.12A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. ( Lavery, RF; Lebowitz, J; Moore, T; Reischel, U; Salo, D; Tuel, M, 2006)
"Current guidelines recommend repeated doses of albuterol for the emergency treatment of acute asthma."5.12The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. ( Bag, R; Dickey, BF; Hanania, NA; Miller, CT; Moore, RH; Sharafkhaneh, A; Zimmerman, JL, 2007)
"To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma."5.12Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. ( Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006)
"Both fluticasone monotherapy and PACT combination achieved greater improvements in asthma control days than montelukast."5.12Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. ( Bacharier, LB; Bloomberg, GR; Boehmer, SJ; Chinchilli, VM; Covar, RA; Guilbert, TW; Heldt, G; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Mellon, MH; Morgan, WJ; Moss, MH; Sorkness, CA; Spahn, JD; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2007)
" Thirty-six patients with persistent mild bronchial asthma were treated with the leukotriene receptor antagonist montelukast, administered once a day for 4 weeks."5.12Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. ( Hajduch, M; Janostáková, A; Jarmila, S; Kopriva, F; Zápalka, M, 2006)
"To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i."5.12Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. ( Albers, JM; Costongs, RJ; Schermer, TR; Verblackt, HW; Westers, P, 2007)
"Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study."5.12Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007)
"We randomly assigned 500 patients with asthma that was well controlled by inhaled fluticasone (100 microg twice daily) to receive continued fluticasone (100 microg twice daily) (169 patients), montelukast (5 or 10 mg each night) (166 patients), or fluticasone (100 microg) plus salmeterol (50 microg) each night (165 patients)."5.12Randomized comparison of strategies for reducing treatment in mild persistent asthma. ( Anthonisen, N; Castro, M; Holbrook, JT; Irvin, CG; Peters, SP; Smith, LJ; Wise, RA, 2007)
" After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 microg of albuterol as needed (as-needed albuterol therapy); 250 microg of beclomethasone twice daily and 100 microg of albuterol as needed (regular beclomethasone therapy); or 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler twice daily plus 100 microg of albuterol as needed (regular combination therapy)."5.12Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. ( Canonica, GW; Crimi, N; Fabbri, LM; Maestrelli, P; Morelli, P; Nicolini, G; Olivieri, D; Paggiaro, P; Papi, A; Pozzi, E; Vignola, AM, 2007)
"This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma."5.12Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. ( Borrill, ZL; Houghton, CM; Langley, SJ; Lawson, N; Singh, D; Wixon, CL; Woodcock, A; Yoxall, S, 2007)
"To identify the asthma patients, on short-acting beta2-agonists alone, who would benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC) propionate 50/100 microg bd compared with fluticasone propionate (FP) 100 microg bd alone."5.12Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. ( Barnes, NC; Bateman, ED; Goldfrad, C; Jacques, L, 2007)
" After a 2-week run-in period, 228 patients with moderate to severe asthma were randomized to a 12-week treatment with either beclomethasone 100 microg plus formoterol 6 microg or fluticasone 125 microg plus salmeterol 25 microg, both delivered two inhalations b."5.12Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. ( Fabbri, LM; Nicolini, G; Paggiaro, P; Papi, A; Vignola, AM, 2007)
"The effect of ethnicity on the efficacy of salmeterol (S)+fluticasone propionate (FP) has not been examined in Japanese and Caucasian asthmatics."5.12Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. ( Hashimoto, K; Kawai, M; Kempsford, R; Lötvall, J; Pullerits, T; Takaori, S; Takemoto, Y, 2007)
"During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for 1 year."5.12Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Pedersen, SE; Yoxall, S, 2007)
"This study compared the bronchodilator efficacy and safety of indacaterol with placebo, salbutamol and salmeterol, in patients with persistent asthma, at single therapeutic and supratherapeutic doses."5.12Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. ( Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007)
"To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma."5.12Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. ( Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)
"Our objective was to evaluate the efficacy and safety of two doses of fluticasone propionate (FP) in young children with recurrent wheezing and risk factors for asthma."5.11Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. ( Bergadá, I; Colom, AJ; Kofman, CD; Maffey, AF; Teper, AM; Vidaurreta, SM, 2004)
" 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1000 microg beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 microg) and fluticasone propionate (250 microg) in a single dry powder inhaler (Diskus) or 500 microg FP twice daily."5.11Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. ( Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004)
"Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone."5.11Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. ( Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)
"To determine whether a higher dose of albuterol is required to normalize lung function during nocturnal asthma."5.11Response to inhaled albuterol during nocturnal asthma. ( Ahrens, R; Beaty, R; Harman, EM; Hendeles, L; Stevens, G, 2004)
"A prospective, randomized, double blinded study was conducted to determine whether a combination of nebulized magnesium sulfate and albuterol as a single dose adds any benefit in management of children with mild to moderate asthma when compared to nebulized albuterol with saline."5.11Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. ( Haritos, D; Mahajan, P; Rosenberg, N; Thomas, R, 2004)
" Montelukast significantly reduced blood eosinophil counts compared with salmeterol, whereas salmeterol significantly increased prealbuterol forced expiratory volume in 1 second, asthma-specific quality of life, morning peak expiratory flow rate, and decreased nocturnal awakenings compared with montelukast."5.11Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. ( Bird, SR; Edelman, JM; Friedman, B; Hustad, CM; Ilowite, J; Kerwin, E; Webb, R, 2004)
"The variability of asthma rescue-free days, asthma symptoms, albuterol use, medical resource use, and exercise Limitations among patients with documented mild persistent asthma was compared between the month before study enrollment and the last 2 weeks of the run-in period."5.11Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. ( Baker, JW; Bird, S; Edelman, J; Hustad, C; Kaplan, MS; Pearlman, DS; Schatz, M; Zeiger, RS, 2004)
"The effects of high-dose fluticasone propionate therapy on dynamic cortisol stimulation in severe asthma are unknown."5.11Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. ( Bates, CE; Cowan, LM; Currie, GP; Lee, DK; Lipworth, BJ; McFarlane, LC, 2004)
"To determine whether initiation of maintenance treatment with the salmeterol (S)/fluticasone propionate (FP) combination (Seretide/Viani/Advair) is more effective than inhaled steroid alone in patients with asthma symptomatic on short-acting bronchodilator alone."5.11Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. ( Luckow, A; Strand, AM, 2004)
"We report a 4 yr follow up study of seven asthmatic children with chronic persistent asthma, high-residual volume and low-density areas at high-resolution computerized tomography after treatment with salmeterol and fluticasone."5.11Montelukast and airway remodeling in children with chronic persistent asthma: an open study. ( Boner, AL; Caramella, D; De Marco, E; Pietrobelli, A; Pifferi, M; Ragazzo, V, 2004)
"In patients symptomatic while taking short-acting beta2-agonists alone, initial maintenance treatment of the 2 main components of asthma, inflammation and smooth muscle dysfunction, with fluticasone propionate and salmeterol, 100 and 50 microg, administered via the Diskus results in greater improvements in overall asthma control compared with treatment of either component alone."5.11Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. ( Baitinger, L; Blake, K; Dorinsky, P; House, K; Murray, J; Rosenthal, R; Somerville, L; VanderMeer, A, 2004)
"To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children."5.11Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004)
"The goal of this study was to evaluate the efficacy, tolerability, and effect on asthma-related quality of life (QOL) of a long-acting beta(2)-adrenoreceptor agonist, formoterol, delivered via multidose DPI, compared with albuterol delivered via pMDI or placebo in adolescents and adults with persistent asthma."5.11Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p ( Andriano, K; Busse, W; Lavecchia, C; Levine, B; Yegen, U, 2004)
"The present study aimed to investigate whether a fixed combination of salmeterol and fluticasone (SFC) from a single inhaler provides sufficient asthma control comparable to that achieved with standard treatment (inhaled steroid in a dose of 1,000 mcg BDP- (beclomethasone dipropionate) equivalent plus a LABA and/or theophylline and/or montelukast)."5.11[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. ( Liefring, E; Molitor, S; Trautmann, M, 2005)
"The pharmacokinetics and pharmacodynamics of albuterol were studied following inhalation of three different in-house dry powder formulations in healthy volunteers and in asthmatics."5.11The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ( Muanpanarai, D; Srichana, T; Suedee, R; Tanmanee, N, 2005)
"To evaluate the efficacy and the safety of low dose salmeterol/fluticasone (SM/FP) combination therapy as compared to morate dose of budesonide (BUD) in the management of adult asthma."5.11[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. ( Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)
"Our objective was to compare the efficacy and safety of formoterol (Foradil) delivered via a novel multidose dry powder inhaler (Certihaler) with placebo and albuterol [pressurized metered-dose inhaler (pMDI)], in patients with persistent asthma."5.11Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. ( Andriano, K; LaForce, C; Lavecchia, C; Prenner, BM; Yegen, U, 2005)
"Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted."5.11Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. ( Cline, SM; Coakley, TA; Euwema, MS; Knecht, KR; Ralston, ME; Ziolkowski, TJ, 2005)
"A randomised, open-label, multicentre study compared the efficacy and tolerability of salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) delivered via a hydrofluoroalkane metered-dose inhaler (HFA-MDI) and salmeterol 50microg/fluticasone propionate 250 microg (one puff, twice daily) delivered via a Diskus inhaler in Chinese patients with moderate asthma uncontrolled with inhaled corticosteroids (ICSs)."5.11Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. ( Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005)
"An efficacy treatment study is conducted comparing levalbuterol to racemic albuterol for acute pediatric asthma in the emergency department (ED)."5.11Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. ( Burke, BL; Meadows, T; Qureshi, F; Welch, C; Zaritsky, A, 2005)
"To compare levalbuterol and racemic albuterol for the treatment of acute exacerbation of asthma in pediatric population."5.11Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. ( Bithoney, WG; DeBari, V; Gold, N; Hardasmalani, MD, 2005)
"To compare the safety of twice-daily treatment with inhaled fluticasone propionate plus the inhaled long-acting beta2-agonist salmeterol with that of fluticasone propionate used alone in children aged 4 to 11 years with persistent asthma."5.11The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. ( Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005)
"To determine the relative cost-effectiveness of twice-daily treatment with inhaled fluticasone propionate-salmeterol via Diskus, 100/50 microg, with that of once-daily treatment with oral montelukast as initial maintenance therapy in patients with persistent asthma uncontrolled with a short-acting beta2-agonist alone."5.11Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Rickard, K, 2005)
"To determine and define the beneficial effects of heliox-driven albuterol therapy on severe asthma exacerbation and clinical factors that affect greater response."5.11Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. ( Chang, HW; Hsu, CW; Huang, YC; Lee, DL; Lee, H, 2005)
"In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically as effective as regular, scheduled administration."5.11Regular vs ad-lib albuterol for patients hospitalized with acute asthma. ( Chandra, A; Chung, V; Cohen, HW; Dhuper, S; Maggiore, D; Mani, K; Shim, C, 2005)
"Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo."5.11Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005)
"Continuously nebulized albuterol delivered by heliox was associated with a greater degree of clinical improvement compared with that delivered by oxygen among children with moderate to severe asthma exacerbations."5.11Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. ( Corcoran, T; Funt, N; Gracely, E; Kim, IK; Phrampus, E; Pitetti, R; Saville, A; Thompson, A; Venkataraman, S, 2005)
"To evaluate the efficacy and safety of mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids."5.11Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. ( Busse, WW; Karpel, JP; Lutsky, B; Monahan, ME; Noonan, MJ; Staudinger, H, 2005)
"Investigating whether adding the long-acting beta(2)-agonist salmeterol to the inhaled corticosteroid fluticasone propionate has an effect on allergen-induced allergic inflammation in asthma."5.11Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2005)
"Forty-two asthmatic patients sensitized to pollen allergens were randomly allocated to treatment with fluticasone propionate-salmeterol (n=21) or fluticasone propionate alone (n=21)."5.11Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. ( Badiola, C; Bruno, L; Ferrer, A; Gutiérrez, V; Lanuza, A; Pérez-Francés, C; Prieto, L, 2005)
"To investigate whether, after 48 h of IV treatment with corticosteroids, the use of high-dose inhaled flunisolide is as effective as systemic corticosteroids in adults hospitalized for a severe asthma exacerbation."5.10Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. ( Acquah, S; Dayrit, FM; Kohli, AR; Lee-Wong, M; Mayo, PH, 2002)
"To compare the relative cost effectiveness of salmeterol (50 microg)/ fluticasone propionate (100 microg) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone."5.10Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Rickard, K; Sheth, K, 2002)
"On separate study days, 15 nonsmokers with mild asthma received randomized nominal albuterol doses of 0 to 576 microg by using specially manufactured MDI canisters."5.10A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. ( Adams, WP; Creticos, PS; Khattignavong, AP; Lewis, LD; Lietman, PS; Martinez, MN; Molzon, JA; Petty, BG; Singh, GJ; Williams, RL, 2002)
"In a prospective, pragmatic, randomised, parallel group study, 170 patients of mean (SD) age 37 (12) years with acute asthma (peak expiratory flow (PEF) 212 (80) l/min) presenting to hospital received treatment with either high dose prednisolone and continuous nebulised salbutamol as recommended in the US or lower dose prednisolone and bolus nebulised salbutamol as recommended in the UK by the BTS."5.10Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital. ( Daynes, TJ; Harrison, BD; Innes, NJ; Stocking, JA, 2002)
"We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone."5.10Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. ( Bates, CE; Currie, GP; Haggart, K; Lee, DK; Lipworth, BJ, 2003)
"In asthmatics, awake fiberoptic intubation evokes a more than 50% decrease in FEV1 following dyclonine inhalation."5.10Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation. ( Groeben, H; Pavlakovic, G; Peters, J; Schlicht, M; Stieglitz, S, 2002)
"The aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propionate combination product (SFC) with fluticasone propionate (FP) plus oral montelukast (M) over 12 weeks in symptomatic asthma patients."5.10The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. ( Akveld, M; Bateman, ED; Eliraz, A; Mulder, PG; Pruzinec, R; Ringdal, N; Weber, HH, 2003)
"A prospective, randomized, double-blind study was conducted to determine whether there was any benefit to the addition of ipratropium to a single nebulized albuterol treatment in infants and children with mild to moderate acute asthma presenting to a pediatric office."5.10Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office. ( Gunawardane, G; Kumaratne, M, 2003)
"The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear."5.10Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. ( Begent, J; Buchdahl, R; Gomez, K; Habel, A; Lachman, P; Newsom, D; Raffles, A; Roberts, G; Saglani, S; Sloper, K, 2003)
"We examined whether a combination of glucocorticoids and beta-agonists inhaled by asthmatics had an influence on the metabolism of L-arginine, an amino acid involved in the production of urea, creatinine, and NO that is known to play a significant role in asthma."5.10Creatininuria in asthmatic children treated with a combination of glucocorticoid and beta-agonist. ( Ferrières, J; Giroux, M, 2003)
"1) Mean weekly inhaled steroid adherence [(number of actuations/prescribed number of actuations) x 100]; 2) number of days with overuse of inhaled steroids; 3) 24-hour and nighttime albuterol use; 4) included forced expiratory volume in 1 second; and 5) Asthma Quality of Life Questionnaire total score."5.10Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. ( Apter, A; Connors, M; Litt, M; McCusker, C; Onyirimba, F; Reisine, S; ZuWallack, R, 2003)
"Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks."5.10Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003)
"Fifteen mild-to-moderate asthmatics (mean FEV(1) 80% predicted) uncontrolled on inhaled corticosteroids (mean dose 470 microg) were randomised in a single-blind crossover fashion to receive 2 weeks each of fluticasone 250 microg plus salmeterol 50 microg in combination (FP+SM), 1 puff b."5.10Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. ( Bates, CE; Currie, GP; Jackson, CM; Lee, DK; Lipworth, BJ, 2003)
"This study tests the hypothesis that the administration of multiple doses of inhaled albuterol (A), ipratropium bromide (IB), and flunisolide (F) provides an additional benefit to adults with acute severe asthma compared with the administration of A plus IB (A/IB) or A plus F (A/F)."5.10Triple inhaled drug protocol for the treatment of acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2003)
"The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid."5.10Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003)
"The goal of this study was to examine the efficacy of formoterol in patients with moderate to severe persistent asthma that was suboptimally controlled with an inhaled corticosteroid (ICS) combined with on-demand salbutamol (albuterol in the United States) with or without salmeterol."5.10Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study. ( Bourdeix, I; Brambilla, C; Le Gros, V, 2003)
"The objective of this study was to evaluate parental preference for the treatment of asthmatic children with oral montelukast sodium or inhaled cromolyn sodium."5.10Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. ( Bird, SR; Bratton, DL; Bukstein, DA; Edelman, JM; Estojak, J; Firriolo, KM; Hustad, CM, 2003)
"To compare the efficacy and safety of twice-daily fluticasone propionate (FP) 88 microg and salmeterol 42 microg combined in a chlorofluorocarbon (CFC)-free (hydrofluoroalkane 134a) metered-dose inhaler (MDI) with the individual agents alone, each delivered through an MDI containing CFC propellants, in patient with persistent asthma previously uncontrolled with as-needed short-acting beta2-agonists alone."5.10Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. ( Baitinger, L; Dorinsky, P; Greos, LS; Gross, G; Nelson, HS; Scott, C; Wolfe, JD, 2003)
"To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide."5.10Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. ( Bisgaard, H; Buchvald, F, 2003)
"To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone."5.10Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. ( Bisgaard, H; Bjermer, L; Bousquet, J; Dass, SB; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Leff, JA; Menten, J; Picado, C; Polos, PG, 2003)
"To determine whether levalbuterol resulted in fewer hospital admissions than racemic albuterol when used for treatment of acute asthma."5.10Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. ( Carl, JC; Kercsmar, CM; Kirchner, HL; Myers, TR, 2003)
"Treatment of moderate-to-severe asthma with salmeterol/fluticasone propionate resulted in superior gains in HR-QOL relative to increasing the dose of inhaled corticosteroids."5.10Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. ( James, MH; Jenkins, C; Juniper, EF; Price, MJ, 2002)
"The goal of the present study was to evaluate the efficacy and safety of salmeterol/ fluticasone (50/250 microg twice daily) as initial treatment for symptomatic patients with mild to moderate bronchial asthma who had not previously received appropriate anti-asthma medication."5.10Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). ( Baumgarten, C; Behre, U; Geldszus, R; Peslis, N; Trautmann, M, 2002)
"Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast."5.10Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. ( Bowers, B; Dorinsky, P; Emmett, A; Kalberg, C; Lieberman, AK; Pearlman, DS; Pepsin, PJ; Rickard, KA; White, MV, 2002)
" Patients kept records of peak flow meter (PFM) measurements, asthma attack rate and beta-2-agonist use (albuterol)."5.10Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial. ( Chervinsky, P; Goldstein, MF, 2002)
" We studied the spirometric effects of albuterol nebulized with heliox during emergency room visits for asthma exacerbations."5.10The utility of albuterol nebulized with heliox during acute asthma exacerbations. ( Barman, N; Gehlbach, BK; Hall, JB; Kress, JP; Miller, A; Morgan, S; Noth, I; Pohlman, AS, 2002)
"We sought to compare the efficacy and safety of nebulized magnesium sulfate (MgSO(4)) plus albuterol with that of albuterol alone in adult patients with mild-to-moderate acute asthma exacerbations."5.10A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. ( Becker, E; Bessmertny, O; Cohen, H; DiGregorio, RV; Golden, J; Johnson, T; Kohl, L; Looney, D, 2002)
" Sixty-three adolescent and adult asthmatic patients were randomized to receive at separate treatment visits single doses via a pressurized metered-dose inhaler of either placebo/hydrofluoroalkane (HFA) 134a; 100 microg, 200 microg, or 400 microg albuterol/HFA 134a; 100 microg or 200 microg albuterol/chlorofluorocarbon (CFC)."5.10A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. ( Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002)
"We compared the bronchodilator response to salbutamol (albuterol) delivered by a compressed air nebulizer through a mouthpiece and via a facemask in 18 asthmatic children, to determine the most appropriate delivery method."5.10Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma. ( Aoki, T; Izawa, M; Kabayama, H; Kishida, M; Koshibu, T; Kurita, F; Okada, M; Shinomiya, N; Suzuki, I; Takeshita, Y, 2002)
"To compare albuterol with isoproterenol as a bronchodilator in pulmonary function test and their value in the diagnosis and differential diagnosis of asthma."5.09[A comparison between the effects of albuterol and isoproterenol in bronchodilation test]. ( He, T; Luo, Y; Wang, L; Yuan, Y; Zeng, J, 2001)
"We examined the partitioning of total lung resistance (RL) into airway resistance (Raw) and tissue resistance (Rti) in patients with mild to moderate asthma (baseline FEV1, 54 to 91% of predicted) before and after albuterol inhalation."5.09Airway and lung tissue mechanics in asthma. Effects of albuterol. ( Ingenito, EP; Israel, E; Kaczka, DW; Lutchen, KR, 1999)
"Thus in stable asthmatic subjects receiving regular salmeterol or formoterol, bronchoprotective subsensitivity was not overcome by administering a high dose of albuterol."5.09A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. ( Aziz, I; Lipworth, BJ, 1999)
"To compare the effectiveness of a helium-oxygen mixture with that of oxygen alone as an aerosolizing gas for beta-agonist therapy in patients with mild to moderate exacerbation of asthma."5.09Use of heliox-driven nebulizer therapy in the treatment of acute asthma. ( Acharya, P; Chan, LS; Henderson, SO; Kilaghbian, T; Korn, CS; Perez, J, 1999)
"The optimal dose of albuterol to use in the treatment of acute asthma has yet to be established."5.09Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. ( Cydulka, RK; Emerman, CL; McFadden, ER, 1999)
"Patients with mild-to-moderate asthma (12 to 76 years old) who were treated with albuterol alone were randomized (nZ = 879; nP = 605) and included in subset analyses."5.09An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. ( Bonuccelli, CM; Howland, WC; Minkwitz, MC; Nathan, RA; Simonson, SG; Tashkin, DP, 1999)
"To compare the long-term efficacy and safety of albuterol administration using a Spiros Inhalation System (Dura Pharmaceuticals; San Diego, CA) dry powder inhaler (DPI) and albuterol (Ventolin; Glaxo Wellcome; Research Triangle Park, NC) administration using a metered-dose inhaler (MDI) in patients with asthma."5.09Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. ( Bieler, S; Hill, MR; Kemp, JP; Nelson, H; Vaughan, LM, 1999)
"The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting beta-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol."5.09The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. ( , 1999)
"These data demonstrate that asthma duration is associated with lower lung function, greater methacholine responsiveness, more asthma symptomatology, and greater use of as-needed albuterol, which are all measures of asthma severity."5.09Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP) ( Dawson, C; Weiss, S; Zeiger, RS, 1999)
"The objective of this study was to compare the effect of twice daily formoterol (Foradil), 4 times daily albuterol, and on-demand albuterol on bronchial hyperresponsiveness (BHR), lung function measurements, symptoms, and other indicators of disease control over 6 months inpatients with asthma of moderate or greater severity receiving concomitant inhaled corticosteroids."5.09Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. ( Brambilla, R; Chapman, KR; Della Cioppa, G; Fairbarn, MS; FitzGerald, JM; Stubbing, D; Till, MD, 1999)
"To evaluate the 12-hour efficacy and safety of single doses of 25 micrograms and 50 micrograms of salmeterol powder administered via Diskus inhaler versus albuterol aerosol via pressurized metered-dose inhaler and placebo in preventing EIB in asthmatic children."5.09Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. ( Arledge, T; Blake, K; Pearlman, DS; Scott, C; Stahl, E; Wang, Y, 1999)
" Backup albuterol was available to control asthma symptoms."5.09Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. ( Arledge, T; Chervinsky, P; Galant, S; Goldberg, P; Stahl, E; Wang, Y; Welch, MB, 1999)
"Outcome measures included Asthma Quality of Life Questionnaire (AQLQ) global and individual domain scores, FEV1, PEF, nighttime awakenings, asthma symptoms, and supplemental albuterol use."5.09Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. ( Cox, F; DuBuske, LM; Friedman, B; Lockey, RF; Petrocella, V; Rickard, K, 1999)
"To determine whether initiation of salmeterol and fluticasone propionate treatment together improves asthma control greater than initiation of monotherapy with the individual agents alone with no additional safety risk in patients with asthma who had not previously been treated with inhaled corticosteroids."5.09Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. ( Chervinsky, P; Gross, G; Pearlman, DS; Prillaman, B; Shah, T; Stricker, W; Weinstein, S; Woodring, A, 1999)
"Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma."5.09Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. ( Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999)
"Patients >12 months of age were eligible if they were to be treated according to a standardized ED protocol for acute asthma with nebulized albuterol (2."5.09Ipratropium bromide added to asthma treatment in the pediatric emergency department. ( Duggan, AK; Lebet, R; Ogborn, CJ; Pusic, MV; Zorc, JJ, 1999)
"The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients."5.09The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. ( DeGraw, SS; Gawchik, SM; Noonan, M; Reasner, DS; Saccar, CL, 1999)
"The primary objective was to compare the safety of HFA albuterol to an albuterol product formulated in chlorofluorocarbon propellants (CFC albuterol) during 1 year of treatment in asthmatics."5.09Safety of long-term treatment with HFA albuterol. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)
"Randomized, double-blind, placebo-controlled comparison of the bronchodilator response to albuterol DPI (200 microg) at inspiratory flow rates of approximately 15, 30, and 60 L/min in patients with stable asthma with demonstrated reversibility to albuterol."5.09Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. ( Chambers, CB; Nantel, NP; Newhouse, MT; Parry-Billings, M; Pratt, B, 1999)
"In a randomized, double-blind, placebo-controlled trial, 56 adult asthmatic patients with peak expiratory flow rates (PEFRs) less than 50% predicted after an initial albuterol aerosol treatment were studied."5.09Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. ( Bakalchuk, L; Curry, A; Dow, AM; Heyl, GT; Lin, RY; Pesola, GR; Tenenbaum, C; Westfal, RE, 1999)
"In patients with mild-to-moderate asthma in this study, the albuterol DPI was determined to be therapeutically comparable to albuterol MDI in the delivery of one and two actuations of albuterol."5.09Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. ( Ahrens, R; Clarke, W; Geoffroy, P; Grossman, J; Hill, MR; Lalonde, RL; Vaughan, LM, 1999)
"Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma."5.09The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. ( Condemi, JJ; Emmett, A; Goldstein, S; Kalberg, C; Rickard, K; Yancey, S, 1999)
"The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids."5.09Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. ( Mol, SJ; Mulder, PG; Schreurs, AJ; van Noord, JA, 1999)
"We sought to compare the efficacy and safety of 2 doses of fluticasone propionate (88 micrograms twice daily and 220 micrograms twice daily) with 2 doses of beclomethasone dipropionate (168 micrograms twice daily and 336 micrograms twice daily) in subjects with persistent asthma."5.09A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. ( Baker, J; Edwards, L; Lanier, RQ; Lincourt, WR; Raphael, GD; Rickard, K, 1999)
" We undertook a double-blind, randomized, placebo-controlled, cross-over study to investigate the effects of a single dose of formoterol inhaled via Turbuhaler (12 micrograms) and of albuterol inhaled via Turbuhaler (200 micrograms) on airway responsiveness to AMP and histamine in 16 subjects with mild atopic asthma."5.09Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. ( Barnes, PJ; Nightingale, JA; Rogers, DF, 1999)
" The primary efficacy measure was morning peak expiratory flow (PEF); secondary efficacy measures included evening PEF, asthma symptom scores, supplemental albuterol use, nighttime awakenings, sleep symptoms, asthma exacerbations, and FEV1."5.09Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. ( Busse, W; Kalberg, C; Nelson, H; Rickard, KA; Wolfe, J; Yancey, SW, 1999)
"To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma."5.09Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. ( Mende, CN; Petrocella, VJ; Rickard, KA; Wiegand, L; Yancey, SW; Zaidel, G; Zwillich, CW, 1999)
"In children with mild acute asthma, to compare treatment with a single dose of albuterol delivered by a metered dose inhaler (MDI) with a spacer in either a weight-adjusted high dose or a standard low-dose regimen with delivery by a nebulizer."5.09Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. ( Callahan, S; Canny, GJ; Johnson, DW; Schuh, S; Stephens, D; Winders, P, 1999)
"To compare the safety and efficacy of salmeterol xinafoate, beclomethasone dipropionate (BDP), and placebo over a 6-month treatment period in patients with persistent asthma."5.09A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. ( Emmett, AH; Grossman, J; Nathan, RA; Pinnas, JL; Rickard, KA; Schwartz, HJ; Yancey, SW, 1999)
" In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients."5.09Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. ( Fujimura, M; Hashimoto, T; Hirose, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S; Tachibana, H, 1999)
"To compare efficacy of an extended release oral beta-2 agonist, albuterol sulfate (Volmax), to a long-acting inhaled agent, salmeterol (Serevent) in the treatment of nocturnal asthma."5.09Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma. ( Beaucher, WN; Kiechel, F; Kraft, M; LaVallee, N; Martin, RJ; Shilstone, J; Sublett, JL, 1999)
" Subjects recorded asthma-related symptoms, morning and evening peak expiratory flow (PEF) levels, and use of supplemental albuterol daily on diary cards."5.09Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. ( Baker, JW; Busse, WW; Emmett, A; Kalberg, C; Kemp, JP; Rickard, KA; Rosenthal, RR, 1999)
"Outcome measures included FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment."5.09Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. ( Baraniuk, J; Berger, WE; Edwards, LD; Johnson, M; Murray, JJ; Nathan, RA; Rickard, KA; Srebro, S, 1999)
"We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic."5.09Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. ( Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999)
"To evaluate the efficacy of nebulized budesonide compared to oral prednisolone early in the emergency room management of acute asthma, we conducted a double-blind, placebo-controlled trial."5.09Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. ( Jayshree, M; Kumar, L; Singhi, S, 1999)
"Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma."5.09The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. ( Bradding, P; Britten, KM; Gratziou, C; Holgate, ST; Howarth, PH; Roberts, JA; Walls, AF; Wilson, S, 1999)
"Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial."5.09Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. ( Everts, B; Hedner, J; Möller, CS, 1999)
"Fluticasone propionate 880 microg/day improved lung function and quality of life in adolescents with moderate-to-severe asthma when compared with flunisolide 1500 microg/day."5.09Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma. ( Eid, N; Goldsmith, LJ; Howell, L; Sheikh, S, 1999)
"All active treatment groups showed statistically significant improvement compared with placebo in pulmonary function (FEV1, FEF25-75%, morning and evening PEF), use of rescue albuterol, and asthma symptom scores."5.09Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. ( Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999)
" Efficacy was assessed by spirometry, and by daily recordings of albuterol use, peak expiratory flow (PEF), asthma symptom ratings, and nighttime awakenings throughout the study."5.09A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. ( Banerji, D; Bernstein, D; Gross, G; Kane, RE; Welch, M, 1999)
"05) to doubling the dose of beclomethasone in improving peak expiratory flow (PEF) and forced expiratory volume in 1 sec (FEV1), and in reducing symptoms of asthma, sleep loss, nighttime awakenings, and use of albuterol."5.09Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. ( Anderson, WH; Church, NL; Emmett, AH; Gillman, SA; Kelsen, SG; Lanier, BQ; Rickard, KA, 1999)
"Three hundred forty-nine patients with asthma previously treated with medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 microg, FP 250 microg, or placebo, each given twice daily through a Diskus device for 12 wk."5.09Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. ( Baitinger, L; Given, J; House, K; Lumry, W; Prillaman, B; Shah, T; Shapiro, G; White, MV; Wolfe, J; Woodring, A, 2000)
"Magnesium sulfate is thought to be an effective bronchodilator when administered intravenously to patients with acute severe asthma, and it can be safely administered via inhalation to patients with stable asthma."5.09Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. ( Corna, RA; Mannarino, S; Nannini, LJ; Pendino, JC; Quispe, R, 2000)
"In order to compare the efficacy of different asthma treatment in subjects with mild-to-moderate asthma, three groups of 11 patients were treated with nedocromil sodium (NS), beclomethasone dipropionate (BDP) and beclomethasone dipropionate plus salmeterol (BDP + S) in an open, randomized study."5.09Comparison of different long-term asthma treatments in subjects with mild-to-moderate asthma. ( Bacci, E; Dente, FL; Di Franco, A; Giannini, D; Paggiaro, PL; Vagaggini, B, 1999)
" Efficacy was assessed by serial measurements of forced expiratory volume in one second (FEV1) over 12 hours, daily peak expiratory flow (PEF), self-rated asthma symptom scores, nighttime awakenings, and supplemental albuterol use."5.09Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. ( Chervinsky, P; Davis, S; Kreitzer, S; Lawrence, M; Reilly, D; Stahl, E; Wang, Y; Wolfe, J, 2000)
"To compare the costs and effectiveness of albuterol by metered dose inhaler (MDI) and spacer versus nebulizer in young children with moderate and severe acute asthma."5.09Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. ( Aickin, RP; Asher, MI; Campanella, SG; Leversha, AM, 2000)
"Twelve asthmatic patients were enrolled into a single-blind, placebo-controlled, crossover study, receiving additive therapy as either of the following: (1) montelukast alone, 10 mg (ML(10)); (2) inhaled salmeterol alone, 50 microg (SM(50)); (3) ML(10) and SM(50); (4) ML(10) and inhaled salmeterol, 100 microg (SM(100)); or (5) placebo inhaler and tablet."5.09Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Mistry, C; Sims, EJ; Wilson, AM, 2000)
"Undiluted albuterol short treatments seem to be as effective as standard diluted albuterol in severe asthmatics, while offering the ease and efficiency of shorter treatment administration time."5.09Undiluted albuterol aerosols in the pediatric emergency department. ( Gutglass, DJ; Hampers, L; Krug, SE; Nimmagadda, SR; Roosevelt, G; Teoh, D, 2000)
"Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma."5.09Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. ( Arshad, H; Harrison, JE; Holgate, ST; Stryszak, P, 2000)
"Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)."5.09Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. ( Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000)
"Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide 800-1200 microg day(-1) (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 microg and fluticasone propionate 250 microg (Seretide, Advair, Viani 50/250 microg) twice daily or budesonide 800 microg twice daily for 24 weeks."5.09Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. ( James, MH; Jenkins, C; Lundback, B; Saarelainen, P; Woolcock, AJ, 2000)
"Once-daily treatment with fluticasone propionate resulted in an improvement in efficacy variables, such as FEV(1), morning and evening peak expiratory flow (PEF), asthma symptom scores, nighttime awakenings, albuterol use, and duration of study participation."5.09A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. ( Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000)
"To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma."5.09Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. ( Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)
"To assess the safety and efficacy of salmeterol xinafoate as an adjunct to conventional therapy for the in-hospital management of acute asthma."5.09A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. ( Davis, CP; Jones, AP; Lawson, RW; LeGrand, TS; Peters, JI; Shelledy, DC, 2000)
"Eighteen patients with mild-to-moderate persistent asthma receiving inhaled corticosteroid who expressed the homozygous glycine-16 genotype were randomized to completion (mean [SEM] age, 35."5.09Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. ( Aziz, I; Dempsey, OJ; Lipworth, BJ, 2000)
"This study was undertaken to compare the outcome of adults with acute severe asthma treated with 4 puffs of salbutamol (100 microg/actuation) every 20 minutes for 3 doses plus 4 puffs of oxitropium bromide (100 microg/actuation) with each of the 3 salbutamol doses versus salbutamol alone administered by means of a metered-dose inhaler with a spacer device."5.09Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ( Chida, K; Enomoto, N; Hirai, R; Kawamoto, A; Nakano, Y, 2000)
"The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists."5.09Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. ( Berkowitz, RB; Harrison, JE; Kemp, JP; Miller, SD; Murray, JJ; Nolop, K, 2000)
"Intravenous magnesium sulfate (MgSO4), as an adjunctive medication to the standard treatment of acute asthma, improves admission rate or severity score in acute severe asthma patients."5.09Intravenous magnesium sulfate in acute severe asthma. ( Boonyavorakul, C; Charoenpan, P; Thakkinstian, A, 2000)
" The authors performed a prospective, randomized, double-blind, placebo-controlled trial to test the ability of intravenous lidocaine and inhaled albuterol to attenuate airway reactivity after tracheal intubation in asthmatic patients undergoing general anesthesia."5.09Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. ( Boughton, R; Darvish, A; Israel, E; Loring, SH; Maslow, AD; Mehrez, M; Regan, MM, 2000)
"FP/Salm Combo treatment provided better overall asthma control than FP + montelukast with significantly greater improvements in morning peak expiratory flow (+24."5.09Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. ( Busse, WW; Church, N; Emmett, A; Kerwin, E; Knobil, K; Nelson, HS; Rickard, K, 2000)
"To evaluate the clinical comparability of albuterol sulfate formulated in a new hydrofluoroalkane-134a (HFA) propellant (Ventolin HFA Inhalation Aerosol), and conventional CFC-containing albuterol (Ventolin Inhalation Aerosol) in children with asthma."5.09Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. ( Barnhart, F; Bronsky, E; Murray, A; Reisner, C; Shapiro, G; VanderMeer, A, 2000)
"Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma."5.09Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. ( Barraza, CH; Boulet, LP; Bousquet, J; D'Urzo, A; Harnest, U; Hebert, J; Lundbäck, B; Lutsky, BN; Martinez Morales, G; Nieminen, MM; Nolop, KB; Suárez-Chacón, R; Visser, S, 2000)
"This was an open-label, parallel group, randomized, age-stratified, multicenter study designed to compare the safety and efficacy of regular use of albuterol formulated in hydrofluoroalkane-134a (HFA albuterol) and albuterol formulated in chlorofluorocarbons-11/12 (CFC albuterol) in children with asthma."5.09Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Shapiro, GS, 2000)
"The aim of this study was to compare the efficacy, safety, and tolerability of formoterol powder for inhalation delivered via the Aerolizer device with placebo and with albuterol delivered via metered-dose inhaler in patients with mild to moderate persistent asthma."5.09A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. ( Bensch, G; Della Cioppa, G; Kiselev, P; Lapidus, RJ; Levine, BE; Lumry, W; Yegen, U, 2001)
"This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 microg administered twice daily to patients with mild-to-moderate asthma for 12 weeks."5.09Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. ( Bateman, ED; Bogolubov, M; Silins, V, 2001)
" We therefore studied the effects of therapeutic doses of inhaled albuterol in five asthmatic subjects (mean age 23."5.09Effects of therapeutic doses of albuterol on beta2-adrenergic receptor density and metabolic changes. ( Anstead, MI; Burki, NK; Hunt, TA; McConnell, JW, 2001)
"Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy."5.09Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Sims, EJ; Wilson, AM, 2001)
" The efficacy, safety and tolerability of the Novolizer has been compared with those of established inhalational devices for the delivery of salbutamol (Sultanol) in patients with chronic obstructive pulmonary disease and for the administration of budesonide (Pulmicort Turbuhaler) to patients with asthma."5.09Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma. ( Chuchalin, AG; Kunkel, G, 2001)
"Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids."5.09Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. ( Boone, R; Emmett, A; Fish, JE; Israel, E; Murray, JJ; Rickard, KA; Yancey, SW, 2001)
"The objective of this study was to determine whether initial maintenance therapy for the treatment of inflammation and bronchoconstriction associated with persistent asthma is more effective with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]) administered twice daily through the Diskus device (GlaxoWellcome, Research Triangle Park, NC) or with montelukast at 10 mg once daily."5.09Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. ( Calhoun, WJ; Dorinsky, P; Emmett, A; Kalberg, C; Nathan, RA; Nelson, HS; Pepsin, PJ; Rickard, KA, 2001)
"Asthmatic children having their tracheas intubated with sevoflurane often have an increase in respiratory system resistance (Rrs)."5.09Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. ( Habre, W; Scalfaro, P; Sims, C; Sly, PD, 2001)
"To determine whether the addition of inhaled ipratropium bromide to inhaled albuterol and systemic corticosteroid therapy was more efficacious than inhaled albuterol and systemic corticosteroids alone in the inpatient treatment of acute asthma exacerbations in children."5.09Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. ( Goggin, N; Macarthur, C; Parkin, PC, 2001)
" In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective."5.09Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. ( Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001)
"Two identically designed, prospective, randomized, double-blind, parallel studies were conducted comparing salmeterol 42 micrograms twice daily, albuterol 180 micrograms four times daily, and placebo over 12 weeks in 556 patients (12 to 73 years old) with mild-to-moderate chronic asthma."5.08Safety of salmeterol in the maintenance treatment of asthma. ( Alexander, WJ; Chervinsky, P; Kemp, JP; Liddle, R; Mills, R; Nathan, RA; Seltzer, JM, 1995)
"The aim of this study was to evaluate if continuous treatment with budesonide or salmeterol influences the bronchodilator response to terbutaline in children with asthma; 23 children, aged 7 to 16 years (mean = 11 years), with mild asthma were treated with inhaled budesonide 100 micrograms b."5.08Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995)
"The purpose of this study was to assess the efficacy and safety of inhaled salmeterol xinafoate 50 micrograms bid via the Diskhaler when added to the existing treatment of children with moderate to severe asthma."5.08Salmeterol xinafoate in children on high dose inhaled steroids. ( Price, JF; Russell, G; Weller, P; Williams, DA, 1995)
"High-dose continuous nebulization of albuterol is as safe and as efficacious as intermittent nebulization of albuterol in the early treatment of asthma in an emergency department."5.08Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. ( Dworkin, G; Kotch, A; Reisner, C, 1995)
"The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec) against controlled release (CR) salbutamol (Volmax) in the treatment of nocturnal asthma."5.08Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. ( Ayres, JG; Gunn, SD; McConchie, SM, 1995)
"We have recently demonstrated that a 2-week course of inhaled albuterol 200 micrograms four times daily caused a near doubling of the allergen-induced early asthmatic response."5.08Regular use of inhaled albuterol and the allergen-induced late asthmatic response. ( Bhagat, R; Cockcroft, DW; O'Byrne, PM; Swystun, VA, 1995)
"Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol."5.08Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995)
"Salmeterol (42 micrograms twice daily) was compared with the short-acting beta 2-agonist albuterol (180 micrograms four times daily) in two double-blind, randomized studies involving 556 patients with mild-to-moderate asthma."5.08Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. ( Pearlman, DS, 1995)
"The objective of this trial was to determine the efficacy of frequent nebulized ipratropium added to high-dose albuterol therapy in children with severe asthma."5.08Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. ( Callahan, S; Canny, G; Johnson, DW; Levison, H; Schuh, S, 1995)
"This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma."5.08Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995)
"Adult, nonsmoking patients with mild to moderate asthma were randomized to receive 4 mg nedocromil sodium (n = 13), 200 micrograms albuterol (n = 13), or placebo (n = 12) four times daily for 16 wk in a double-blind, double-dummy protocol."5.08Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. ( Davies, RJ; Devalia, JL; Manolitsas, ND; McAulay, AE; Trigg, CJ; Wang, J, 1995)
"Asthmatics aged 18 to 65 years during acute exacerbation with FEV1 less than 75% predicted both before and after a single albuterol treatment."5.08Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. ( Bloch, H; Grant, S; Jagminas, L; Mancherje, N; Scharf, SM; Silverman, R, 1995)
"These data suggest that the addition of theophylline to albuterol and corticosteroids does not enhance improvement of children admitted to the hospital with asthma."5.08Theophylline does not shorten hospital stay for children admitted for asthma. ( Gladstein, J; Kaifer, MC; Needleman, JP; Nold, JT; Redding, MM; Shuster, PE, 1995)
"In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks."5.08Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol. ( Findlay, SR; Furukawa, CT; Gross, GN; Henochowicz, SI; Hudson, LD; Marcoux, JP; Myers, DJ; Prenner, BM; Steinberg, P; Wasserman, SI, 1995)
"We performed a double-blind, two-phase study on protective and bronchodilator effects of prostaglandins E2 and E1 (PGE2, PGE1) and salbutamol in patients with aspirin-induced asthma (AIA)."5.08Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. ( Cmiel, A; Mastalerz, L; Nizankowska, E; Szczeklik, A, 1996)
"This was a 4-week, open-label, parallel-group study designed to compare the efficacy and safety of the long-acting inhaled bronchodilator, salmeterol, with the established inhaled bronchodilator, terbutaline, in the treatment of patients with mild to moderate asthma."5.08A 4-week comparison of salmeterol and terbutaline in adult asthma. ( Hermansson, BA; Jenkins, RJ, 1995)
"The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year."5.08Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995)
"To compare the magnitudes of the immediate effects of the nebulized beta-agonists isoetharine and albuterol in the treatment of acute severe asthma."5.08Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. ( Bidadi, K; Gourlay, S; Hayes, J; Robertson, S; Shrestha, M; Wainscott, M, 1996)
"Albuterol sulfate, in the syrup and tablet form for oral administration, has been an effective treatment for adults and children with bronchial asthma."5.08Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. ( Boltansky, H; Harrison, JE; Kobayashi, RH; Lorber, RR; Pearlman, DS; Shapiro, G; Skoner, DP; Trochelmann, LM, 1996)
"These findings suggest that albuterol behaves as a partial agonist at beta-receptors when compared with fenoterol, and that when inhaled in doses currently recommended for severe asthma, albuterol will result in lesser maximum cardiac and metabolic effects than fenoterol."5.08Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. ( Beasley, R; Bremner, P; Burgess, C; Crane, J; Siebers, R, 1996)
"Azelastine, an oral nonsteroidal, antiinflammatory drug with a good safety profile, has demonstrated relief of symptoms in patients with asthma."5.08An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996)
"Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid effective in the treatment of asthma."5.08A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. ( Gross, GN; Kellerman, DJ; Kral, KM; Munk, ZM; Schaberg, A; Schoenwetter, WF; Wasserman, SI, 1996)
"The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma."5.08The effect of inhaled albuterol in moderate to severe asthma. ( Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996)
"The inhaled corticosteroid, fluticasone propionate, was compared with the oral bronchodilator theophylline in the maintenance treatment of asthma."5.08Fluticasone propionate compared with theophylline for mild-to-moderate asthma. ( Baker, KA; Galant, SP; Kellerman, DJ; Lawrence, M; Meltzer, EO; Tomasko, M, 1996)
"In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients)."5.08Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. ( Boushey, HA; Chinchilli, VM; Drazen, JM; Fahy, JV; Fish, JE; Israel, E; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ, 1996)
"To evaluate the role of inhaled ipratropium bromide in acute asthma, a double-blind study of 384 emergency department patients compared the effect of the combination of ipratropium and albuterol with that of albuterol alone."5.08A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. ( Aldrich, T; Fanta, C; Karpel, JP; Levey, D; Menjoge, SS; Schacter, EN; Spiro, P; Witek, TJ, 1996)
"In a pediatric emergency department setting, aerosolized albuterol delivered by MDI-spacer was equal in effectiveness to nebulization in the acute asthma management of children > or = six years of age."5.08Delivery of albuterol in a pediatric emergency department. ( Bothner, JP; Swanton, RD; Williams, JR, 1996)
"The aim of this study was to compare the clinical efficacy of salmeterol versus theophylline in the treatment of moderate-to-severe asthma."5.08Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. ( Di Franco, A; Giannini, D; Paggiaro, PL; Testi, R, 1996)
"The purpose of the study was to compare bronchodilator responses to albuterol between an ultrasonic and a jet nebulizer in moderate to severe asthma."5.08A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. ( Leickly, FE; Pallares, DE; Pilarski, BR; Rodriguez, JL, 1996)
"To compare the efficacy and safety of continuous nebulized (CN) albuterol therapy with those of intermittent nebulized (IN) albuterol therapy in the ED treatment of children with moderate to severe asthma exacerbations."5.08Continuous vs intermittent nebulized albuterol for emergency management of asthma. ( Fuchs, SM; Khine, H; Saville, AL, 1996)
"Bronchodilator effect and toxicity of theophylline 300 mg twice a day (E1), Salbutamol 4 mg tid (E2), their combination in higher (200/4 mg, E3), and lower doses (100/2 mg E4), and placebo calcium lactate (300 mg) tid (E5) were compared in 30 patients with bronchial asthma in a randomized cross over trial."5.08[Sympathomimetics and theophylline: combined use?]. ( Alvarez Castro, MR; Alvarez Sintes, R, 1995)
"Nedocromil sodium is recommended for daily treatment of mild persistent asthma but its effect on cellular changes in asthmatic airways is poorly understood."5.08Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1996)
" The bronchodilator, cardiovascular, and tremorigenic responses following administration of salbutamol (SAL), terbutaline (TER) and fenoterol (FEN) by closed-port intermittent nebulization were compared for a period of 8 hr."5.08Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. ( Naspitz, CK; Scalabrin, DM; Solé, D, 1996)
" In a double-blind placebo-controlled crossover study in 12 patients with mild asthma, we investigated the effect of inhaled budesonide or identical placebo on the protection conferred by albuterol (200 micrograms) against methacholine-induced bronchoconstriction before and after treatment with the long-acting beta 2-agonist salmeterol."5.08An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. ( Barnes, PJ; Kharitonov, SA; Yates, DH, 1996)
"These results confirm that there is activation of the RAS in asthmatic subjects by single doses of nebulized beta 2-agonists and that repeated dosing with nebulized albuterol has further, additive effects on plasma Ang II levels."5.08The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. ( Connell, JM; Millar, EA; Thomson, NC, 1997)
"Nocturnal cough and wheeze are common in asthma and often treated with beta2 agonists or theophyllines."5.08Inhaled salmeterol or oral theophylline in nocturnal asthma? ( Douglas, NJ; Engleman, HM; Fitzpatrick, MF; Mackay, TW; Selby, C; Sime, PM, 1997)
"We detected significant improvement in pulmonary function studies over 120 minutes in children with severe asthma who were given nebulized ipratropium combined with albuterol and oral steroids, compared with children who received the standard therapy."5.08Efficacy of nebulized ipratropium in severely asthmatic children. ( Lakkis, H; Qureshi, F; Zaritsky, A, 1997)
"These data suggest that for children with moderate to severe asthma exacerbation, hospital admission rates are similar in children given oral methylprednisolone and those given i."5.08Intravenous versus oral corticosteroids in the management of acute asthma in children. ( Barnett, PL; Baskin, M; Caputo, GL; Kuppermann, N, 1997)
" The present study was undertaken to compare the therapeutic effects of sustained release theophylline and a conventional low dose oral fenoterol in patients with asthma."5.08Oral fenoterol versus sustained release theophylline in adult asthmatics. ( Almagro, J; Andrade, RJ; Hidalgo Sanchez, R; Lucena, MI; Sanchez de la Cuesta, F, 1997)
"Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial."5.08Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. ( Botto, A; Busse, WW; Kundu, S; Reiss, TF; Sorkness, CA; Stricker, W; Zhang, J, 1997)
"To determine the efficacy of combination therapy using atropine sulfate and albuterol in the treatment for an acute exacerbation of asthma."5.08Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. ( Bradley, K; Díaz, JE; Dubin, R; Gaeta, TJ; Pelczar, P, 1997)
"The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid."5.08The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. ( Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997)
"Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler."5.08Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. ( Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)
"Although theophylline is recommended by current guidelines for the management of asthma in patients with persistent symptoms, theophylline has a narrow therapeutic index, requiring individual dose titration and regular monitoring of serum theophylline concentrations to avoid adverse effects."5.08Salmeterol versus theophylline in the treatment of asthma. ( Cox, FM; Emmett, A; Pollard, SJ; Spector, SL; Yancey, SW, 1997)
"The aim of the present study was to compare the efficacy and the tolerability of salmeterol and theophylline in patients with nocturnal asthma."5.08[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance]. ( Braun, H; Koper, I; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D, 1997)
" In a recent study in 17 adults with stable asthma, albuterol given using an ultrasonic nebulizer (UN) appeared to produce greater bronchodilatation than the same dose of albuterol given by a jet nebulizer (JN)."5.08Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. ( Foster, C; Lamb, BM; Nakanishi, AK; Rubin, BK, 1997)
"To determine the optimal treatment interval for administering albuterol metered-dose inhaler (MDI) with a holding chamber to patients presenting to the emergency department (ED) with acute asthma."5.08Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? ( Aldrich, TK; Gaitan-Salas, A; Guguchev, K; Karpel, JP; Pathiparti, R; Prezant, DJ, 1997)
"To determine what proportion of asthmatic patients attending a tertiary University-based respiratory clinic meet typical drug study spirometric criteria of a baseline FEV1 of 50% to 80% predicted and > or = 15% delta FEV1 improvement following 200 micrograms inhaled albuterol."5.08The current dilemma with spirometric inclusion criteria for asthma drug trials. ( Cockcroft, DW; Fitzpatrick, MF; Jokic, R; Marciniuk, DD, 1997)
" Efficacy was assessed by changes in FEV1, asthma symptom scores, albuterol use, and peak flow rates."5.08Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. ( Farrar, JR; Feiss, G; Levy, S; Smith, JA; Welch, MJ, 1997)
" A total of 291 male and female patients at least 12 years of age with asthma (FEV1 between 50% and 80% of predicted value), who had previously received maintenance therapy with beclomethasone dipropionate or triamcinolone acetonide, were switched to treatment with fluticasone propionate powder (250 microg twice daily), triamcinolone acetonide aerosol (200 microg four times daily), or placebo for 24 weeks."5.08Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. ( Ayars, GH; Berger, WE; Chervinsky, P; Condemi, JJ; Edwards, L; Ford, LB; Goldstein, MF; Pepsin, PJ; Rogenes, PR, 1997)
" We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma."5.08Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. ( Aikman, SL; Barnes, PJ; Harris, JG; Jensen, MW; O'Connor, BJ; Taylor, DA, 1997)
"We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma."5.08Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997)
"To assess the effect of a long-acting inhaled beta 2-agonist, salmeterol (SM), compared to a short-acting inhaled beta 2-agonist, salbutamol (or albuterol, SB) on the occurrence of morning dip (MD) in patients recovering from an acute severe asthma attack (ASA)."5.08Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack. ( Arnold-Ketterer, M; Chevrolet, JC; Ritz, M; Thorens, JB, 1997)
"In a randomized, double-blind, placebo-controlled trial, 55 adult asthmatic patients with peak expiratory flow rate (PEFR) less than 200 L/min were randomly assigned to nebulization treatment with albuterol alone (2."5.08Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. ( Bakalchuk, L; Cataquet, D; Freyberg, CW; Heyl, GT; Lin, RY; Morgan, JP; Pesola, GR; Westfal, RE, 1998)
"We assessed the acute bronchodilator effect of nebulized furosemide when added to conventional therapy of acute emergency department (ED) asthma."5.08Effect of inhaled furosemide in acute asthma. ( Chapman, KR; Molfino, NA; Nannini, LJ; Pendino, JC; Slutsky, A, 1998)
"This randomized, double-blind trial was designed to determine the benefit of high and cumulative doses of flunisolide added to salbutamol in patients with acute asthma in the emergency room (ER)."5.08Inhaled flunisolide for acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998)
" We compared the safety and efficacy of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) in 306 patients with moderate to severe asthma in a double-blind, multicenter, cross-over study of 12 mo duration."5.08Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. ( Demedts, MG; Geusens, P; Pauwels, RA; Yernault, JC, 1998)
"Although these preliminary results suggest that nebulized budesonide may be an effective adjunct to oral prednisone in the management of moderate to severe asthma exacerbations, a larger trial will be required before the widespread use of inhaled budesonide in acute asthma can be advocated."5.08Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. ( Klassen, TP; Osmond, MH; Sung, L, 1998)
" Efficacy was measured by weekly spirometry and daily diary recordings of peak flow rates, asthma symptom scores, and albuterol use."5.08A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. ( Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998)
"The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma."5.08Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998)
"To evaluate the impact on asthma-specific quality of life, efficacy, and safety of salmeterol versus albuterol in adult patients with mild-to-moderate persistent asthma."5.08Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. ( Cox, F; Emmett, A; Kalberg, C; Lumry, W; Manning, M; Rickard, K; Wenzel, SE, 1998)
"The aim of the present multicentre, open, randomized, parallel group study was to evaluate the efficacy and safety of salmeterol versus theophylline in asthmatic patients."5.08Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline. ( Martini, T; Nutini, S; Righi, R, 1998)
" The aim of the study was to determine the carbachol and albuterol responsiveness in treated and untreated asthmatic and allergic children exposed to environmental tobacco smoke assessed by urinary cotinine measurements."5.08Possible interaction between exposure to environmental tobacco smoke and therapy in children with asthma. ( Badier, M; Bruguerolle, B; Dubus, JC; Guillot, C; Oddoze, C, 1998)
"In an emergency department, 160 patients who presented with acute exacerbations of asthma received either standard (n = 80) or high-dose (n = 80) albuterol treatment."5.08Comparison of two dosage regimens of albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1998)
" Overall reductions in supplemental albuterol use and mean asthma symptom scores were also significantly greater in children administered salmeterol compared with placebo (P=."5.08Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. ( Arledge, T; Bronsky, EA; Byrne, A; Liddle, R; Pearlman, DS; Stahl, E; Weinstein, SF, 1998)
"Among children with a severe exacerbation of asthma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospitalization rate."5.08Effect of nebulized ipratropium on the hospitalization rates of children with asthma. ( Davis, P; Pestian, J; Qureshi, F; Zaritsky, A, 1998)
"We determined the effect of a long acting beta2-agonist, salmeterol, on aspirin-induced asthma (AIA) attacks and urinary release of eicosanoids in a double-blind, placebo-controlled, crossover study in 10 asthmatics sensitive to aspirin."5.08Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. ( Cmiel, A; Dworski, R; Mastalerz, L; Nizankowska, E; Oates, JA; Prokop, A; Sheller, JR; Szczeklik, A, 1998)
" Four asthma medications, salbutamol, salmeterol, fluticasone propionate (FP) and beclomethasone dipropionate (BDP), currently containing standard CFC propellants, were formulated with HFA134a for investigation."5.08Clinical evaluation of CFC-free metered dose inhalers. ( Jenkins, M, 1995)
"To determine whether children with severe acute asthma treated with large doses of inhaled salbutamol, inhaled ipratropium, and intravenous steroids are conferred any further benefits by the addition of aminophylline given intravenously."5.08Randomised controlled trial of aminophylline for severe acute asthma. ( South, M; Yung, M, 1998)
" Patients treated with salmeterol also had significant improvements in mean PEF rates, supplemental albuterol use, asthma symptom scores, and forced expiratory volume in 1 second compared with those given placebo."5.08Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. ( Busse, WW; Casale, TB; Cox, F; Murray, JJ; Petrocella, V; Rickard, K, 1998)
" When tested for the spirometric response to albuterol, patients with a history of asthma had a slightly greater increase in FEV1 and FEF25-75% than those who had never had asthma."5.07The effect of transfusion on pulmonary function in patients with thalassemia major. ( Barreto, M; Cutrera, R; Ronchetti, R; Santamaria, F; Villa, MP; Werner, B, 1994)
" Their airway smooth muscle relaxant potencies and effect on histamine contraction in human bronchi in vitro were compared with their effects on airway calibre and histamine reactivity in asthmatic subjects in vivo."5.07Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo. ( Baldwin, DR; Knox, AJ; Pavord, ID; Sivardeen, Z, 1994)
"To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma."5.07Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. ( D'Alonzo, GE; Henochowicz, S; Morris, RJ; Nathan, RA; Ratner, P; Rennard, SI, 1994)
"The aim of the multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial with a 2-week treatment period was to compare the efficacy and safety of salmeterol (50 micrograms twice daily) with slow-release (SR) terbutaline (5 mg orally, twice daily) in nocturnal asthma."5.07Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group. ( Bertin, L; Brambilla, C; Chastang, C; Georges, D, 1994)
"This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)."5.07Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994)
"We investigated whether the beta 2-agonists fenoterol and salbutamol decreased plasma selenium and glutathione peroxidase activity in patients with asthma as this may partially explain the findings of reduced selenium status in asthmatic patients."5.07Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma. ( Beasley, R; Bremner, P; Burgess, CD; Crane, J; Siebers, RW; Thomson, CD, 1994)
"We conducted a randomized, double-blind, placebo-controlled study to determine if intravenous aminophylline adds any benefit to high doses of inhaled salbutamol in patients who presented for treatment of acute asthma."5.07Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. ( Rodrigo, C; Rodrigo, G, 1994)
"A double-blind, randomized, crossover study was done to determine the efficacy of colchicine in 30 atopic children with moderately severe asthma."5.07A clinical study of colchicine in childhood asthma. ( Adalioglu, G; Saraçlar, Y; Tuncer, A; Türktas, I, 1994)
"In atopic asthmatics we have found, that 2 weeks of regular inhalative salbutamol monotherapy (200 mcg/qid) enhances BHR to histamine."5.07[Inhalation corticosteroid therapy and nonspecific bronchial responsiveness enhanced with salbutamol]. ( Brzostek, D; Droszcz, W; Piotrowska, B, 1994)
"Clinical studies of inhaled salmeterol xinafoate have been conducted mainly in moderately to severely affected asthmatic subjects in hospital settings."5.07Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. ( Jones, KP, 1994)
"To determine the effect of the institution of out-of-hospital albuterol treatments for acute asthma on out-of-hospital time intervals emergency department (ED) morbidity."5.07Effect of out-of-hospital albuterol inhalation treatments on patient comfort and morbidity. ( Anand, P; Ernst, AA; May, WL; Orgeron, D; Weiss, SJ, 1994)
"5 mg) albuterol (salbutamol) over 1 h in 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (PEF) below 150 L/min and hypercapnia (Pa(CO2) > or = 40 mm Hg)."5.07Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. ( Brochard, L; Duroux, P; Henry-Amar, M; Mal, H; Renon, D; Salmeron, S; Simonneau, G; Tenaillon, A, 1994)
"Nine young asthmatic children aged 2-5 years underwent methacholine challenge after placebo or albuterol administered by metered dose inhaler through a spacer device (Babyhaler) with a face mask in a double-blind, cross-over, randomized study."5.07Protective effect of albuterol delivered via a spacer device (Babyhaler) against methacholine induced bronchoconstriction in young wheezy children. ( Avital, A; Godfrey, S; Schachter, J; Springer, C, 1994)
"In a double-blind, double-placebo, randomized crossover study, we compared the effects of 6 wk of treatment with the anti-inflammatory drug nedocromil sodium (16 mg/day) with 6 wk of treatment with the bronchodilator drug albuterol (800 micrograms/day) in 29 adults with allergic asthma."5.07Nedocromil sodium versus albuterol in the management of allergic asthma. ( de Jong, JW; de Monchy, JG; Koëter, GH; Postma, DS; Teengs, JP; van der Mark, TW, 1994)
"To evaluate the effects of aminophylline (Am) in children hospitalized with asthma."5.07Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. ( Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)
"The use of oral prednisolone (2 mg/kg) to treat children admitted to hospital with acute asthma was assessed in a placebo controlled study."5.07Prednisolone and salbutamol in the hospital treatment of acute asthma. ( Connett, GJ; Lenney, W; Warde, C; Wooler, E, 1994)
"Twenty seven adults and 20 children with previously diagnosed stable asthma, using a salbutamol pressurized metered dose inhaler (P-MDI) and living in Cairns, Townsville and Southport, Queensland, Australia participated in a randomized, open-label cross-over comparison of terbutaline administered via Turbuhaler and salbutamol administered via P-MDI."5.07A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions. ( Buchanan, PR; Lindsay, DA; Russell, NL; Shellshear, ID; Thompson, JE; Warnock, TH, 1994)
"In an open randomised study 25 patients with severe acute asthma who presented to the emergency department were treated with either a combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0."5.07Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. ( Ismail, O; Yusoff, K; Zainudin, BM, 1994)
"Patients who presented to the ED with moderate to severe asthma and did not improve after one treatment with nebulized albuterol."5.07Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. ( Eberlein, RS; Mazur, JE; Rudnitsky, GS; Schoffstall, JM; Spivey, WH, 1993)
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma."5.07The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993)
"To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma."5.07Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? ( Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993)
"The role of intravenous aminophylline in acute asthma is unclear despite meta-analysis of many studies comparing aminophylline with other bronchodilator therapies."5.07Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. ( Cameron, P; Coleridge, J; Epstein, J; Teichtahl, H, 1993)
" The purpose of this study was to investigate whether the addition of a single aerosolized dose of glycopyrrolate to an albuterol regimen results in a greater improvement in pulmonary function than treatment with an albuterol regimen alone in patients with acute asthma."5.07Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. ( Cydulka, RK; Emerman, CL, 1994)
"The aim of this study was to compare the response to inhaled albuterol after administration by nebulizer with the response after administration by a metered-dose inhaler and spacer device (MDI-spacer) to children with acute asthma."5.07Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. ( Bentur, L; Canny, GJ; Kerem, E; Levison, H; O'Brodovich, H; Reisman, J; Schuh, S, 1993)
" Patients with acute asthma received either albuterol, 0."5.07A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993)
"We investigated the effects of inhaled nedocromil sodium and albuterol administered prior to allergen challenge in the late asthmatic response (LAR) and circulating cells in a double-blind placebo-controlled study."5.07Albuterol and nedocromil sodium affect airway and leukocyte responses to allergen. ( Holgate, ST; Sams, VR; Twentyman, OP, 1993)
"These data demonstrate that oral prednisone, within 4 hours of its administration, reduced the need for hospitalization among a subset of children treated in the emergency department for acute asthma."5.07Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. ( Fuchs, SM; Nager, AL; Scarfone, RJ; Shane, SA, 1993)
"Bronchodilator effect and toxicity of theophylline 300 mg twice a day (R1), salbutamol 4 mg tid (R2), their combination in higher (200/4mg, R3), and lower doses (100/2mg R4), and placebo (calcium lactate 300 mg) tid (R5) were compared in 25 patients with bronchial asthma in a randomized crossover trial."5.07Is combined therapy of sympathomimetics and theophylline indicated? ( Devpura, K; Garg, VK; Jain, NK; Sharma, SD; Sharma, TN, 1993)
"To determine the efficacy of theophylline when given in addition to nebulized albuterol and intravenously administered corticosteroid to children hospitalized with mild to moderate asthma."5.07Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. ( Alpert, SE; DiGiulio, GA; Kercsmar, CM; Krug, SE; Marx, CM, 1993)
"To determine whether intravenously administered theophylline, when added to frequently nebulized albuterol and intravenously administered methylprednisolone, benefits children hospitalized with severe asthma."5.07Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. ( Carter, E; Chesrown, S; Cruz, M; Hendeles, L; Reilly, K; Shieh, G, 1993)
"5, 25, 50, 100 micrograms) were compared with albuterol aerosol 200 micrograms and placebo in 24 patients with moderate asthma with 24-hour pulmonary function testing and Holter monitoring."5.07Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. ( Bierman, CW; Cocchetto, DM; Kemp, JP, 1993)
"Nine patients with asthma with a mean(SE) age of 65(5) years and percentage predicted forced expiratory volume in one second (FEV1 of 61(9)% participated in a double blind, placebo controlled, within subject crossover study to assess the effect of two weeks of treatment with salbutamol (Volmax; 8 mg twice daily) or theophylline (Phyllocontin; 350 mg twice daily) on lung mucociliary clearance during sleep."5.07Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma. ( Agnew, JE; Clarke, SW; Hasani, A; Pavia, D; Vora, H, 1993)
"We treated 30 asthmatic patients in 2 sessions with the beta-agonist albuterol using the above-mentioned devices."5.07Clinical comparison of Gentle-Haler Actuator and Aerochamber Spacer for Metered Dose Inhaler (MDI) use by asthmatics. ( Chipps, BE; Naumann, PF; Raabe, OG; Wong, GA, 1992)
"The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days."5.07Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992)
"The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms) and placebo was compared in a double-blind study carried out in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air on 4 study days."5.07[Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air]. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992)
"Ninety-six patients with nocturnal asthma (FEV1 = 60-90% pred, reversibility greater than or equal to 15%, at least 2 awakenings in the week preceding the trial) were included in a double-blind, randomized, crossover, multicenter study which compared the efficacy and side effects of inhaled salmeterol (50 micrograms morning and evening) to the association theophylline-ketotifen (300 mg and 1 mg morning and evening, respectively)."5.07[Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group]. ( Georges, D; Muir, JF, 1992)
"At four medical centers, 98 patients with stable asthma, histories of nighttime awakening at least three times weekly and nighttime declines of pulmonary function of at least 15%, who were not taking oral adrenergic agonists, were randomly treated with either oral repeat-action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4-16 mg at bedtime, or a placebo for 2 weeks."5.07The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. ( Bodman, SF; Greenstein, SM; Morris, RJ; Nathan, RA; Selner, JC; Storms, WW; Zwillich, CW, 1992)
"The aim of this investigation was to study whether certain patients benefit from adding theophylline to the beta 2-agonist treatment of acute asthma."5.07Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma? ( Boe, J; Boman, G; Janson, C, 1992)
"For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed."5.07A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. ( Chervinsky, P; Dockhorn, RJ; Grossman, J; Kemp, JP; LaForce, C; Liddle, RF; Pearlman, DS; Seltzer, JM; Southern, DL; Yancey, SW, 1992)
" Thirty six adults with chronic asthma requiring beta-agonists four times daily were treated with terbutaline 500 micrograms via T and salbutamol 400 micrograms via D four times daily, each period lasting four weeks."5.07Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. ( Armstrong, S; Brown, PH; Crompton, GK; Lenney, J; Ning, AC, 1992)
"The hypoxic effects of salbutamol 200 micrograms (CAS 18559-94-9) and bitolterol mesilate 740 micrograms (Biterol, CAS 30392-41-7), both administered by pressurized aerosol, were assessed by transcutaneous pO2 monitoring in 18 asthmatic subjects and in 12 normal volunteers."5.07Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers. ( Allegra, L; Cogo, AL; Dal Negro, R; Pomari, C; Turati, C; Turco, P, 1992)
"Twenty-five patients with acute severe asthma were treated with oxygen, corticosteroids and either salbutamol or aminophylline by intravenous infusion."5.07Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma. ( Banks, J; Buchanan, K; Cheong, B; Gunawardena, KA; Smith, AP, 1992)
"In a placebo-controlled, double-blind, crossover study with a washout phase of 2 months between each treatment period, single daily doses of 10 and 30 mg of astemizole were given to 12 patients with extrinsic asthma during 28 consecutive days."5.07Effect of astemizole on allergic asthma. ( Abadías, M; Cisteró, A; Jané, F; Lafuente, V; Lleonart, R; Pintó, E; Torrent, J, 1992)
"Both drugs are effective bronchodilators in young and old asthmatic subjects, but albuterol results in a greater magnitude of response in both age groups."5.07Effect of age on bronchodilator response. ( Abuan, TH; Driesner, NK; Emmick, G; Kradjan, WA; Schoene, RB, 1992)
"One hundred twenty consecutive patients aged 18 to 65 years with acute asthma unresponsive to a single albuterol treatment."5.07Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. ( Green, SM; Rothrock, SG, 1992)
"We have measured the plasma levels of salbutamol, terbutaline and theophylline in 140 patients (70 men, mean age 57 yrs) arriving for emergency treatment with severe acute asthma."5.07Bronchodilator intake and plasma levels on admission for severe acute asthma. ( Boe, J; Boman, G; Janson, C; Mossberg, B; Svedmyr, N, 1992)
"The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor antagonist, were studied in 12 asthmatic subjects with more than 15% increase in FEV1 after salbutamol inhalation."5.07Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. ( Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992)
"Three combination regimens, (1) inhaled albuterol (ALB) with oral theophylline (THEO), (2) inhaled ALB with inhaled beclomethasone dipropionate (BDP), or (3) inhaled ALB, inhaled BDP, and oral THEO, were evaluated and compared as optimal pharmacotherapy for chronic asthma in 111 children."5.07Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. ( Eigen, HN; Ellis, EF; Hemstreet, MP; Meltzer, EO; Orgel, HA, 1992)
"In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart."5.07Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. ( Barnes, NC; Hui, KP, 1991)
" We compared the effect of 50 micrograms salmeterol administered by metered dose inhaler (MDI) and dry powder inhaler (DPI), with 200 micrograms albuterol (by MDI) on FEV1 and histamine-induced bronchoconstriction in 12 asthmatic subjects in a double-blind, placebo-controlled crossover study."5.07A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. ( Gongora, HC; Tattersfield, AE; Wisniewski, AF, 1991)
"In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma."5.07Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. ( Kroll, VM; Schneider, B; Völkl, KP; Wiesemann, HG, 1991)
"Salbutamol controlled-release (CR), a new salbutamol formulation, was compared in asthmatic patients to another long-acting bronchodilator, theophylline L."5.07[Delayed-release salbutamol, a new beta-mimetic with prolonged action. Results of a comparative study against theophylline L.A]. ( Brune, J; Desfougères, JL, 1991)
"This study compared the acute and chronic effects of albuterol syrup (2 mg) and metaproterenol syrup (10 mg) three times a day over 28 days in 65 children, aged 6 to 9 years, with mild to moderate asthma."5.07Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. ( Ratner, PH; Shapiro, GG; Wolfe, JD, 1991)
"We compared the efficacy of inhaled formoterol, a long-acting beta 2-agonist, with inhaled albuterol in 145 stable adult asthmatics in a 12-wk multicenter trial."5.07A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. ( Broder, I; Cartier, A; Chapman, KR; Hyland, RH; Kesten, S; Knight, A; Malo, JL; Mazza, JA; Moote, DW; Small, P, 1991)
"To determine whether treatment of acute asthma with repeated doses of nebulized albuterol leads to greater bronchodilation and lower hospital admission rate than treatment with nebulized isoetharine."5.07A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma. ( Boehm, SP; Cydulka, RK; Effron, D; Emerman, CL; Gershman, H; Lukens, TW, 1991)
"In a multicentre, randomized, cross-over double-blind, double placebo trial the effectiveness and tolerability of slow-release oral salbutamol (SRS) were compared with those of long-acting (LA) theophylline (T) in the treatment of nocturnal asthma of adults."5.07[Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. ( Arnaud, A; Desfougères, JL; Michel, FB; Pappo, M, 1991)
"The additional effect, if any, of subcutaneous, long-acting epinephrine (Sus-Phrine) to aerosolized albuterol for acute pediatric asthma was studied."5.07Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children. ( Aquino, N; Kornberg, AE; Mezzadri, F; Welliver, JR; Zuckerman, S, 1991)
"The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma."5.06Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990)
"The cardiovascular, respiratory, and hypokalemic effects of repeated inhalation of fenoterol, albuterol, and isoproterenol were compared in 12 subjects with stable asthma according to a double-blind, crossover design."5.06The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma. ( Beasley, R; Burgess, CD; Crane, J; Pearce, N; Purdie, G; Siebers, RW; Windom, HH, 1990)
"The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days."5.06Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990)
"The airway response and cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline given in multiples of standard doses from metered-dose inhalers were studied in ten patients with mild asthma."5.06Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. ( Britton, JR; Pavord, ID; Tattersfield, AE; Williams, J; Wong, CS, 1990)
"To determine the effect of pharmacologic modulation of alterations of peripheral blood T-cell subsets caused by antigen-induced bronchoconstriction, we administered albuterol immediately after antigen-induced bronchoconstriction in a double-blind to protocol to 12 atopic asthmatic subjects."5.06Antigen-induced T-cell changes: modulation by pharmacologic agents. ( Gerblich, A; Salik, H; Schuyler, M; Varghese, J, 1990)
"A double-blind, randomized, crossover chronic study was done to determine the efficacy of colchicine in 10 atopic patients with asthma."5.06A clinical and immunologic study of colchicine in asthma. ( Garty, MS; Greif, J; Ilfeld, DN; Kivity, S; Schlesinger, M; Schwarz, YA; Topilsky, M, 1990)
"We have investigated the ability of salbutamol to protect against bronchoconstriction induced by methacholine, histamine, and adenosine 5'-monophosphate (AMP) in nine subjects with asthma."5.06Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. ( Finnerty, JP; Holgate, ST; Phillips, GD, 1990)
"The bronchodilator effect of nebulized AMN, albuterol and their combination was evaluated in 16 steroid-dependent asthmatic children."5.06Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. ( Hill, MR; Nelson, HS; Sladek, WA; Sur, S; Szefler, SJ; Vichyanond, P, 1990)
"Thirty-three children and adolescents from 5 to 17 years of age with moderate to severe acute asthma were given nebulized albuterol therapy in either a high (0."5.06Nebulized albuterol in acute childhood asthma: comparison of two doses. ( Bailey, D; Canny, G; Forbes, T; Levison, H; Pender, E; Reider, MJ; Schuh, S; Tan, YK, 1990)
"To determine the efficacy of intravenous aminophylline in the treatment of adult patients hospitalized for exacerbation of asthma."5.06Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit? ( Abou-Shala, N; Burns, R; Ellis, RF; Kellermann, AL; Self, TH; Stewart, CF; Tsiu, SJ, 1990)
"In a randomised controlled trial 38 asthmatic children aged 2-11 yr who had not received regular oral or inhaled steroids during the previous year, were treated with a standard regime of nebulised salbutamol and intravenous aminophylline plus either hydrocortisone and oral prednisolone for 5 days, or placebo."5.06Placebo controlled trial of systemic corticosteroids in acute childhood asthma. ( Gleeson, JG; Loftus, BG; Price, JF, 1990)
"We studied the safety and efficacy of albuterol (salbutamol) delivered by continuous nebulization (CN) in the initial emergency department treatment of asthma."5.06Continuous nebulization of albuterol (salbutamol) in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Rosenthal, TM; Stern, E; Wolkove, N, 1990)
"A double-blind, crossover trial was conducted to examine the effect of albuterol aerosol on the fine-motor performance of children with chronic asthma."5.06The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. ( Bender, B; Figueroa-Rosario, W; Mazer, B, 1990)
"Twenty asthmatic patients clinically free of heart disease were studied for the possible arrhythmogenic action of albuterol (salbutamol)."5.06Asthma, cardiac arrhythmias, and albuterol aerosol. ( Lazzari, JO; Martelli, NA; Raimondi, AC, 1986)
"The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients."5.06The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986)
"Bronchodilator responses to both nebulized albuterol (salbutamol) and ipratropium bromide and aerosol delivery to the tracheobronchial tree have been assessed in eight patients with chronic stable asthma (mean baseline FEV1, 50 percent; reversibility greater than 20 percent)."5.06Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. ( Bloom, R; Clarke, SW; Johnson, MA; Newman, SP; Talaee, N, 1989)
"We studied the effects of salbutamol, ipratropium bromide and cromolyn sodium on PGF2 alpha-induced bronchospasm in ten patients with asthma."5.06Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm. ( Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989)
"Two double-blind, double-dummy, randomized, crossover studies were performed in 8 asthmatic patients to evaluate beta 2-adrenoceptor selectivity and potency of broxaterol compared to salbutamol."5.06Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. ( Löfdahl, CG; Sigvaldasson, A; Skoogh, BE; Svedmyr, N, 1989)
"A study was carried out in 8 patients with chronic stable bronchial asthma to compare the bronchodilator response with terbutaline, administered by a recently developed powder inhalation system ('Turbuhaler') and equipotent doses of salbutamol administered by a widely used powder inhaler ('Rotahaler')."5.06Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics. ( Bogaard, JM; Slingerland, R; Verbraak, AF, 1989)
"A dose-ranging study and a 12-week treatment study were conducted in children with asthma, aged 4 to 12 years, to assess the efficacy and safety of albuterol inhaled as either an aerosol or as dry powder."5.06Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. ( Bronsky, EA; Furukawa, CT; Grossman, J; Kemp, JP; Lemanske, RF; Mansfield, LE; Murphy, S; Ratner, PH; Reese, ME; Rogenes, PR, 1989)
"Fifteen otherwise healthy asthmatics with reversible airway obstruction were treated with salbutamol (8 mg slow release twice daily) and theophylline (300 mg twice daily)."5.06Effect of theophylline and salbutamol on hepatic drug metabolism. ( Christensen, HR; Døssing, M; Evald, T; Lange, P, 1989)
"In order to examine a possible mechanism of action of ketotifen in asthma, a double-blind study was undertaken to determine whether ketotifen showed any effects on the beta-adrenergic system in asthmatic patients."5.06The effects of ketotifen on beta-adrenergic activity in asthmatics. ( Burge, PS; Gove, RI; Skinner, C; Stableforth, DE, 1988)
"Forty patients suffering from asthmatic conditions, often accompanied by emphysema, were treated either with an extempore combination of salbutamol syrup plus 30-mg oxatomide tablets or with 30-mg oxatomide tablets alone for purposes of comparison."5.06Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide. ( Caprioglio, L; Scremin, S, 1986)
"The effect of long-term treatment with theophylline was studied in 20 chronic asthmatic patients receiving oral and inhaled beta 2-agonists."5.06Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. ( Billing, B; Dahlqvist, R; Hörnblad, Y; Leideman, T; Ripe, E; Skareke, L, 1987)
"140 children of 184 with acute asthma entered a randomised double-blind trial of oral prednisolone (n = 67) compared with placebo (n = 73) administered soon after admission."5.06Effect of a single oral dose of prednisolone in acute childhood asthma. ( Barrell, E; Barry, W; Hatcher, G; Lenney, W; Storr, J, 1987)
"In 12 adult patients with reversible bronchospasm (7 bronchial asthma and 5 chronic obstructive bronchitis) the bronchodilator activity and tolerability of 200 and 400 mcg of broxaterol hydrochloride (Z 1170) were compared to those of 200 mcg of salbutamol administered by metered-dose inhaler."5.06A comparison of the bronchodilator effects of broxaterol and salbutamol. ( Casali, L; Colombo, ML; Manazza, P; Rossi, A; Zoia, MC, 1988)
"4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma."5.06A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988)
"The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)."5.06A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986)
" The inadvertent administration of timolol to asthmatic patients continues to cause occasional severe and even fatal attacks of asthma."5.06Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. ( Richards, R; Tattersfield, AE, 1987)
"The efficacy and safety of orally administered procaterol hydrochloride, a potent beta 2-adrenergic bronchodilator, was compared with that of albuterol in an eight-center, double-blind study conducted in 223 patients with mild to moderate, reversible bronchial airway obstruction."5.06A comparison of oral procaterol and albuterol in reversible airflow obstruction. ( Beaupre, A; Boulet, LP; Brandon, ML; Busse, WW; Chervinsky, P; Mazza, J; Petty, TL; Schoenweter, W, 1988)
"The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients."5.06Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988)
"Single-dose salbutamol (200 micrograms), beclomethasone dipropionate (200 micrograms), and sodium cromoglycate (SCG) (10 mg) administered by inhalation 10 minutes before allergen challenge were examined with regard to inhibition of allergen-induced early (EAR) and late (LAR) asthmatic responses and allergen-induced increase in bronchial responsiveness to inhaled histamine."5.06Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. ( Cockcroft, DW; Murdock, KY, 1987)
" Terfenadine, a histamine H1-receptor antagonist, was studied in 52 patients with stable mild perennial asthma with an allergic basis."5.06Treatment of bronchial asthma with terfenadine; a randomized controlled trial. ( Beaumont, D; Lewis, PJ; Pujet, JC; Sapene, M; Taytard, A, 1987)
"The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients."5.06Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988)
" Since inhalation of these drugs results in less systemic side effects, the present double-blind study was designed to investigate the influence of inhalation of the beta 2-adrenergic agonist albuterol (salbutamol) on esophageal motor function and gastroesophageal reflux in ten healthy volunteers."5.06Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers. ( Heinrich, C; Huber, RM; Müller-Lissner, SA; Schindlbeck, NE, 1988)
"Twelve subjects with stable asthma each inhaled two puffs (200 micrograms) of salbutamol on 2 separate days 3 h after double-blind oral administration of ketotifen (two 1-mg capsules) or identical placebo."5.06Effect of ketotifen on the bronchodilation induced by salbutamol. ( Baldanza, C; Bonanno, CT; Carpentiere, G; Castello, F; Marino, S, 1988)
"Nifedipine, 30 mg/day for 4 weeks, was compared to placebo in a double-blind, randomized, crossover study, as an additional drug added to the usual treatment of 14 patients with bronchial asthma."5.06Nifedipine treatment of patients with bronchial asthma. ( Dascalopoulou, E; Maniki, E; Patakas, D; Tsara, V, 1987)
"Twelve patients with chronic severe asthma, having previously shown an FEV1 increase of less than 20% of the predicted value with prednisolone treatment (20-60 mg daily for 10 days), took part in a double blind crossover comparison of equipotent anti-inflammatory doses of betamethasone and prednisolone."5.06Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. ( Belmatoug, N; De Lauture, D; Grandordy, B; Marsac, J; Morelle, A, 1987)
"Inhalation of albuterol aerosol, 200 micrograms, delivered from metered dose inhalers via Aerochamber, elicited a highly significant improvement in peak expiratory flow rate from 70% to 84% and 91% predicted normal 5 and 20 minutes after treatment, respectively, in 30 asthmatic children 3 to 6 years of age."5.06Delivery of albuterol aerosol by aerochamber to young children. ( Barbera, JM; Eby, DM; Middleton, HB; Sly, RM, 1988)
"Clenbuterol (C), a long-acting beta 2-selective bronchodilator was compared with salbutamol (S) in exercise-induced asthma (EIA) at two premedication time levels."5.06Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children. ( Boner, AL; Brighenti, C; Miglioranzi, P; Richelli, C; Schiassi, M; Vallone, G, 1988)
"The bronchodilator efficacy of two brands of salbutamol (USAN albuterol) metered-dose inhalers (MDIs) was compared in a double-blind protocol involving 31 asthmatics."5.06Differing bioavailability of salbutamol metered-dose inhalers. ( Chhabra, SK, 1987)
"In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC."5.06Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986)
"The extrapulmonary effects of slow-release theophylline and an inhaled beta 2-agonist (albuterol) were examined separately and in combination among 18 adults and adolescents with asthma during a 3-month randomized, double-blind, crossover trial."5.06Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1986)
"Four regimens of bronchodilatation therapy administered on 2 consecutive days were tested in 4 randomly selected groups of 6 asthmatic patients: 1) intravenous atropine + inhaled oxitropium bromide; 2) intravenous atropine alone; 3) intravenous salbutamol + inhaled salbutamol; 4) intravenous salbutamol alone."5.06[Comparative study of anticholinergic and betamimetic agents in the treatment of asthma attacks]. ( Arnaud, A; Herkert, A; Philip-Joet, F; Vervloet, D, 1986)
"In order to study the dose-related effect of nifedipine on expiratory flow rates, 15 asthmatic patients were given sublingually 10 mg and 20 mg of the drug on two different days and the FVC and FEV1 were measured during 90 minutes."5.06Nifedipine in asthma. Dose-related effect on resting bronchial tone. ( Chaniac, A; Gruzman, C; Katz, I; Lidgi, M; Molho, M, 1987)
"The bronchodilator effect of a combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide, given as pressurized aerosols, was compared to that of 200 and 400 micrograms of salbutamol in a controlled experiment on adult patients with asthma."5.06Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. ( Laitinen, LA; Poppius, H, 1986)
"Sustained-release, 24-hour theophylline preparations have been formulated and may provide for convenient once-a-day dosing, although the use of such products in clinical asthma has yet to be fully established."5.06The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment. ( Bush, RK; Busse, WW; Smith, A, 1986)
"The relative benefit of maintenance therapy with theophylline, inhaled albuterol, and the combination was examined in 18 adolescents and adults with chronic asthma during a 3-month, randomized, double-blind, crossover trial."5.06Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1987)
"Three parenteral routes of albuterol sulfate were compared with placebo in their effects on serum potassium and glucose levels, heart rate, and pulmonary function in adult asthmatic subjects."5.06Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine. ( Katz, RM; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1986)
"The benefits of metered-dose inhalers with a spacer (MDI+S) have increasingly been recognized as an alternative method of albuterol administration for treating pediatric asthma exacerbations."5.05Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. ( Barrios-Sanjuanelo, A; Contreras-Arrieta, S; Florez-García, V; Payares-Salamanca, L; Rodriguez-Martinez, CE; Stand-Niño, I, 2020)
"The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study."5.05Ketotifen in adult asthma. ( Dyson, AJ; Mackay, AD, 1980)
"A double-blind crossover comparative study between carbuterol 3 mg thrice daily, carbuterol 2 mg thrice daily and salbutamol 4 mg thrice daily by the oral route was conducted in thirty patients suffering from bronchial asthma, selected at random, with more than 20% reduction in airway obstruction following isoprenaline inhalation."5.05Double-blind crossover study of carbuterol and salbutamol in bronchial asthma. ( Khemchandani, GT; Misra, NP; Tiwari, UC, 1981)
"Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests)."5.05Inhaled prazosin in asthma. ( Barnes, PJ; Dollery, CT; Ind, PW, 1981)
"A study to compare the bronchodilator effect of salbutamol powder (Ventolin, 200 micrograms) administered via a Rotahaler (SR), with that of terbutaline sulphate (Bricanyl, 500 micrograms) administered via a Misthaler (TM) was carried out in 25 children with stable moderate to severe asthma."5.05Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma. ( Mellis, CM; Sharota, E; Simpson, SJ; Towns, SJ, 1983)
"Chlorpheniramine, clemastine and a placebo have been compared for their ability to relieve bronchoconstriction in 14 childhood asthmatics between the ages of 6 and 14 years."5.05Bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children. ( Hodges, IG; Milner, AD; Stokes, GM, 1983)
"Forty-four asthmatic patients were treated on separate days with increasing doses of albuterol in four double-blind studies that included placebo controls."5.05The bronchodilator response to inhalation of increasing doses of aerosolized albuterol. ( Dwek, JH; George, RB; Nelson, HS; Spector, SL; Whitsett, TL, 1983)
" We evaluated 140 patients with bronchial asthma in a prospective double-blind controlled study of possible tachyphylaxis to albuterol aerosol as compared to isoproterenol aerosol."5.05Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. ( Anderson, JA; Bush, RK; Falliers, CJ; Kass, I; Kemp, JP; Reed, C; Repsher, LH; Siegel, S; Webb, DR, 1984)
"Dose-response curves for atropine and ipratropium bromide were made in nine asthmatics unresponsive to salbutamol."5.05Comparison of atropine with ipratropium bromide in patients with reversible airways obstruction unresponsive to salbutamol. ( Burge, PS; Harries, MG; l'Anson, E, 1980)
"The bronchodilator activity in nebulised salbutamol, ipratropium bromide, clemastine, and a placebo was studied in 14 asthmatic children aged between 3 and 5 years."5.05Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma. ( Groggins, RC; Milner, AD; Stokes, GM, 1981)
"The bronchodilator effect of 400 micrograms of salbutamol powder (2 capsules) administered by a rota-haler was compared with that of 500 micrograms of terbutaline (2 metered doses) administered as an aerosol via a tube-spacer in a group of ten stable asthmatic children (mean age 12 years)."5.05Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children. ( Francis, PW; Kelly, CA; Zimmerman, PV, 1983)
"A double-blind randomised controlled trial was conducted to study the effects of oral theophylline alone compared with oral theophylline and salbutamol in a sample of asthmatic children."5.05Effects of oral theophylline and oral salbutamol in the treatment of asthma. ( Dawson, KP; Fergusson, DM, 1982)
"Double-blind cross-over studies of oral and inhaled terbutaline and salbutamol have been performed in two groups of asthmatic patients."5.05A comparison of the effects of different methods of administration of beta-2-sympathomimetics in patients with asthma. ( Clark, TJ; Rees, J; Webb, J, 1982)
"The effect of adding theophylline to treatment with a beta2-adrenoceptor stimulant was studied in 18 asthmatic children in a double-blind cross-over trial."5.05Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma. ( Foucard, T; Lindström, B; Lönnerholm, G, 1981)
"Sixty-four patients with mild of moderate extrinsic asthma were treated with placebo for 1 month and thereafter with ketotifen (1 mg twice daily, orally), disodium cromoglycate (inhalation of 20 mg, four times daily), or placebo for 2 subsequent months."5.05Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma. ( Ahonen, A; Haahtela, T; Hurme, R; Maasilta, P; Mattson, K; Muittari, A; Poppius, H; Venho, K, 1981)
"Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma."5.05A double blind crossover trial of lithium carbonate in asthma. ( Bearman, J; Saltz, H; Spitz, E, 1982)
"The efficacy of nebulised sodium cromoglycate and an oral theophylline solution at currently recommended doses were compared in one to six-year-old children with chronic asthma."5.05Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. ( Newth, CJ; Newth, CV; Turner, JA, 1982)
"In a double-blind trial we compared the efficacy and safety of inhaled salbutamol (albuterol), nebulized with oxygen by face mask, and subcutaneous epinephrine in 40 children with acute asthma."5.05Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. ( Becker, AB; Nelson, NA; Simons, FE, 1983)
"Fifteen patients suffering from asthma received inhalations of phentolamine, albuterol (salbutamol), a combination of phentolamine and albuterol, and placebo, in a single-blind fashion; the changes in the pulmonary function tests were recorded over a three-hour period."5.05Comparison between an alpha-adrenergic antagonist and a beta 2-adrenergic agonist in bronchial asthma. ( Molho, MI; Shiner, RJ, 1983)
"Although albuterol aerosol is an effective bronchodilator in adult asthmatics its efficacy and safety are not fully established in asthmatic children."5.05Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children. ( Katz, R; Littner, MR; Siegel, SC; Tashkin, DP, 1983)
"Inhalation histamine challenges were performed in groups of normal and asthmatic subjects."5.05Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. ( Walters, EH, 1983)
"Oral administration of salbutamol and theophylline has been shown to be effective in relieving bronchoconstriction in asthmatic children aged between 3 and 5 years."5.05Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma. ( Groggins, RC; Lenney, W; Milner, AD; Stokes, GM, 1980)
"In a double-blind controlled trial 14 chronic asthmatic patients with regular nocturnal exacerbations took 16 mg slow-release oral salbutamol (two Ventolin spandets), 450 mg slow-release aminophylline (two Phyllocontin Continus tablets), or placebo at midnight."5.05Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. ( Davies, HJ; Fairfax, AJ; McNabb, WR; Spiro, SG, 1980)
"Twenty-one patients admitted to hospital with acute severe asthma were allocated in a random, single-blind manner to receive intravenous infusions for 24 hours or either aminophylline or salbutamol or a combination of the two drugs."5.05Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma. ( Crimmins, J; Evans, WV; Monie, RD; Seaton, A, 1980)
"Salbutamol increased significantly the bronchodilating effect of proxyphylline both in experimental animals and in asthmatic patients."5.05Interaction between proxyphylline and salbutamol. ( Allonen, H; Kanto, J; Kulmala, T; Mäntylä, R; Tala, E, 1981)
"The efficacy, safety, tolerance, and bio-equivalence of albuterol (a relatively selective beta 2-adrenergic drug) was evaluated in 20 asthmatic children (6 to 14 years of age)."5.05Oral albuterol in the treatment of childhood asthma. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1982)
"Albuterol (salbutamol) syrup was studied in 14 asthmatic children (three to six years of age) in a four-week, double-blind, crossover (with placebo) trial to determine efficacy, safety and tolerance."5.05Albuterol syrup in the treatment of the young asthmatic child. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1981)
"The bronchodilation produced by increasing intravenous doses of aminophylline, salbutamol, and a combination of aminophylline and salbutamol given in random order was determined in 10 stable asthmatics on three consecutive days."5.05Intravenous salbutamol and aminophylline in asthma: a search for synergy. ( Dart, AM; Davies, BH; Handslip, PD, 1981)
"The effect of slow-release aminophylline, salbutamol and a half dose combination of both was compared in children with chronic asthma."5.05A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma. ( Blumenthal, I, 1980)
"Forty asthmatic children were treated either with a combination of salbutamol plus oxatomide (20 cases) or with salbutamol alone (20 cases) for purposes of comparison."5.05Treatment of asthma syndromes in pediatric patients using a combination of a beta 2-stimulant drug and a histamine antagonist. ( Bianchi, G, 1985)
" In this randomized, double-blind, crossover study, each of 20 male patients with moderate to severe asthma, ages 12 to 23 yr, received a single treatment with 100, 200, or 400 mcg of albuterol powder or placebo by Rotahaler on 4 study days separated by 2 to 10 days."5.05Inhaled albuterol powder for the treatment of asthma--a dose-response study. ( Kemp, JP; Meltzer, EO; Orgel, HA; Welch, MJ, 1985)
"1 mg/kg/6 hr) or placebo to 2- to 6-year old children whose extrinsic asthma was treated with maintenance theophylline in a prerandomized, double-blind crossover study design."5.05Albuterol syrup in the treatment of asthma. ( Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985)
"Our investigation supports the use of intravenous salbutamol as an alternative to aminophylline in the early stages of acute severe asthma."5.05Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks. ( Greif, J; Markovitz, L; Topilsky, M, 1985)
"Calcium-channel blockers such as verapamil and nifedipine have been shown to inhibit exercise-induced asthma as well as acutely induced bronchoconstriction, but little is known of their chronic effects, if any, on bronchial asthma."5.05Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo. ( Boismare, F; Lemercier, JP; Leprevost, A; Moore, ND; Ozenne, G; Pasquis, P; Tardif, C, 1985)
"11 mg) and albuterol aerosol (two sprays, 180 mcg) were compared for efficacy of bronchodilation in 120 adolescent and young adult patients with moderate to severe asthma."5.05Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. ( Kemp, JP; Orgel, HA; Tinkelman, DG; Webb, DR, 1985)
"The acute cardiopulmonary effects of oral albuterol, 4 mg, metaproterenol sulfate, 20 mg, and terbutaline sulfate, 5 mg, were compared over eight hours in 20 moderate to severe asthmatics."5.05Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. ( Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985)
"In 24 adult asthmatics the effects of clinically recommended doses of fenoterol (320 micrograms) and albuterol (180 micrograms) were compared to placebo in a double-blind, crossover trial."5.05A comparison of inhaled fenoterol and albuterol in asthma. ( Hordvik, NL; König, P; Sunderrajan, EV, 1985)
"The bronchodilator effects of 375 mg theophylline orally and 200 microg salbutamol by pressurized aerosol were compared in a randomized, cross-over, double-blind trial in fourteen asthmatic patients."5.04Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. ( Hartnett, BJ; Marlin, GE, 1976)
"Eleven patients with bronchial asthma and 10 with chronic bronchitis were treated over four consecutive 3-day periods, firstly with aerosols either of ipratropium bromide (40 microgram four times a day) or of salbutamol (200 microgram four times daily) by random allocation, then the alternate drug, next by both drugs together, and finally with prednisolone (10 mg three times daily) in addition to both drugs."5.04Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. ( Ingram, CG; Johnston, RN; Legge, JS; Lightbody, IM, 1978)
"The bronchodilating efficacy and the degree of beta2-selectivity of rimiterol, salbutamol and isoprenaline were determined in seven asthmatic patients."5.04The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients. ( Marlin, GE; Turner, P, 1975)
"Ninety-nine patients with severe bronchial asthma were tested with two inhalations of Terbutaline."5.04Terbutaline: an effective bronchodilator by inhalation. ( Goldgraber, MB, 1977)
"The bronchodilator effects of terbutaline, 500 microng, and salbutamol, 200 microng, by pressurised aerosol were compared in 16 patients (eight asthma, eight chronic bronchitis with asthma)."5.04Comparison of terbutaline and salbutamol aerosols. ( Hartnett, BJ; Marlin, GE, 1977)
"Albuterol, a new bronchodilator drug known to cause beta2-adrenergic receptor stimulation, was compared with isoproterenol sulphate for their pulmonary and cardiovascular effects in patients suffering from bronchial asthma."5.04Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. ( Huber, GL; Mahajan, VK; Tomashefski, JF, 1977)
"Albuterol and isoproterenol aerosols were compared with placebo in a double-blind manner in 18 patients with bronchial asthma."5.04Comparison of albuterol and isoproterenol aerosols in bronchial asthma. ( George, RB; Jenkinson, SG; Light, RW, 1977)
"2 mg of albuterol (salbutamol), or placebo were compared in a double-blind three-way crossover study in a group of 12 asthmatic patients."5.04Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. ( Huhti, E; Poukkula, A, 1978)
"The bronchodilator effects of aerosols of hexoprenaline (200 microgram and 400 microgram), and salbutamol (200 microgram) were compared in 15 patients with asthma, and nine patients with chronic bronchitis."5.04Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis. ( Evers, R; Harris, M; Jenne, H; McMiken, D; Schonell, M, 1977)
"Dose-response curves to intravenous salbutamol were constructed after injection of saline or aminophylline in a group of ten asthmatic patients."5.04Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves. ( Handslip, P; Leopold, D, 1979)
"A double-blind comparison between orally administered NAB 365 (clenbuterol) and salbutamol was conducted in 30 impatients with either asthma or chronic bronchitis with asthma who had at least 15% reversibility in airway obstruction following inhalation of 1,500 microgram of orciprenaline."5.04NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial. ( Capra, A; Pasotti, C; Vibelli, C, 1979)
"In a single blind crossover study 12 asthmatics received in randomised order single doses of pirbuterol (200 and 400 microgram), salbutamol (200 microgram) and placebo-aerosols, in order to determine the extent and duration of bronchodilator activity, the optimum dosage, the incidence, type and degree of side effects and the cardiovascular as well as hematologic, renal and hepatic functions after inhalative administration."5.04Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma. ( Beumer, HM, 1979)
"A double-blind test to compare IV aminophylline with salbutamol in the treatment of acute, uncontrolled asthma showed that both drugs were equally effective during the first 24 hours."5.04Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood. ( Hambleton, G; Stone, MJ, 1979)
"The effect of clenbuterol (NAB 365) in inhibiting exercise-induced asthma was compared with that of salbutamol in a single-blind, placebo-controlled, crossover study."5.04Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma. ( Del Bono, N; Quartieri, F; Vibelli, C, 1979)
"In a single blind cross-over study 12 patients with asthma received in randomised order aerosols of pirbuterol 400 micrograms, salbutamol 200 micrograms or placebo."5.04[Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients]. ( Verstraeten, JM, 1978)
"Out of 62 asthmatic patients admitted to hospital with an acute exacerbation of their disease, those whose symptoms had not sufficiently improved 15 minutes after an initial intensive regimen were randomly allocated to receive an intravenous infusion of either salbutamol 10 microgram/min (20 patients) or aminophylline 1 mg/min (19 patients)."5.04Intravenous infusion of salbutamol in severe acute asthma. ( Bateman, S; Clarke, SW; Johnson, AJ; Pidgeon, J; Spiro, SG, 1978)
"A double-blind crossover trial was conducted in 10 asthmatic patients for comparison of fenoterol with salbutamol, in 12 other asthmatic patients for comparison of reproterol with salbutamol, and in 15 other asthmatic patients for comparison of terbutaline with salbutamol."5.04[The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer]. ( Budmiger, H; Kyd, K; Scherrer, M, 1978)
"In a randomized double-blind trial an intravenous injection of salbutamol (100mug) was compared with an intravenous injection of aminophylline (250mg) in 23 patients with acute exacerbations of asthma."5.04A controlled trial of intravenous salbutamol and aminophylline in acute asthma. ( Robinson, JS; Tribe, AE; Wong, RM, 1976)
" Other findings indicate that there is no robust evidence to support the use of intravenous or nebulized magnesium sulphate in adults with severe acute asthma, and that levalbuterol was not superior to albuterol regarding efficacy and safety in individuals with acute asthma."4.91Advances in acute asthma. ( Rodrigo, GJ, 2015)
"To evaluate the cost-utility of the treatment with a long acting beta-agonist (LABA) and inhaled corticosteroid (ICS) combination inhaler [salmeterol xinafoate (SAL)/fluticasone propionate (FP) combination inhaler (SFC) (Advair(®))] to continuing on current ICS dose (no ICS dose change) or increased ICS dose [fluticasone propionate (FP)] in patients with uncontrolled asthma in Canada."4.90COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. ( Corriveau, D; FitzGerald, JM; Hawkins, N; Ismaila, AS; Li, C; Risebrough, N; Su, Z, 2014)
"To evaluate efficacy and safety of levalbuterol versus albuterol in acute asthma."4.89Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. ( Jat, KR; Khairwa, A, 2013)
" Bogie 2007 investigated the addition of intravenous terbutaline to high dose nebulised albuterol in children with acute severe asthma, requiring intensive care unit (ICU) admission."4.88Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. ( Camargo, CA; Jones, AP; Milan, SJ; Rowe, BH; Travers, AH, 2012)
"To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma."4.87Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Ferrara, G; Lasserson, TJ, 2011)
"To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function."4.84Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Cates, CJ; Ferrara, G; Lasserson, TJ, 2008)
"Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."4.84Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. ( Gibson, PG; Irving, LB; Koh, MS; Lasserson, TJ; Tee, AK; Wilson, AJ, 2007)
"To systematically review the evidence for the medium to long term benefits and risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with placebo and active controls in mild to moderate asthma."4.84Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. ( Grouven, U; Joos, S; Kaiser, T; Miksch, A; Schneider, A; Szecsenyi, J; Wieseler, B, 2008)
"Levalbuterol is an alternative to racemic albuterol with the potential to improve patient outcomes and reduce costs in the treatment of acute asthma exacerbations."4.83Asthma pathophysiology and evidence-based treatment of severe exacerbations. ( Schreck, DM, 2006)
"Our understanding of albuterol nebulization driven by helium-oxygen mixture (heliox) has matured with recent advances in clinical therapy, delivery systems, and understanding of dosing; this has led to substantial improvements in delivery as well as refinements of research protocols for asthma exacerbations."4.83Heliox-driven albuterol nebulization for asthma exacerbations: an overview. ( Corcoran, TE; Kim, IK; Saville, AL; Sikes, KL, 2006)
"Compared with saline,the use of isotonic magnesium sulfate as an adjuvant to nebulize salbutamol is a beneficial therapy with improving spirometric airway function in the severe asthma exacerbation."4.83[Comparison of different vehicles for nebulized salbutamol in treatment of bronchial asthma exacerbations: a Meta-analysis]. ( Lu, XY; Zhou, JY, 2006)
"Levalbuterol, the pure (R)-isomer of racemic albuterol, is a new therapeutic option for patients with asthma."4.82Single-isomer levalbuterol: a review of the acute data. ( Nowak, R, 2003)
"To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma."4.82Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. ( Berger, WE, 2003)
"Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."4.82Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Shah, L; Wilson, AJ, 2003)
"Pharmacoeconomic analyses indicate that salmeterol/fluticasone propionate administered via a single inhaler represents a cost-effective treatment option (relative to fluticasone propionate at the same nominal dosage, budesonide, formoterol plus budesonide and montelukast plus fluticasone propionate) in patients with asthma not controlled with inhaled corticosteroid therapy."4.82Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. ( Lyseng-Williamson, KA; Plosker, GL, 2003)
"A short cut review was carried out to establish whether intravenous salbutamol or intravenous aminophylline offers the quickest and least complicated treatment for patients with moderate to severe asthma not responding to inhaled therapy."4.82Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma? ( Jacobs, M; Munro, A, 2004)
"The studies fell into 3 primary categories with some overlap: those assessing toxicity of the S-enantiomer of albuterol, those evaluating the risk of specific genotypes regarding worsening asthma, and those assessing asthma outcomes with LABA therapy."4.82What is new with the beta2-agonists: issues in the management of asthma. ( Kelly, HW, 2005)
"A meta-analysis was carried out of randomised, double blind clinical trials that compared the efficacy of adding salmeterol to moderate doses of ICS (fluticasone propionate 200 mug/day or equivalent) with increasing the ICS dose by at least twofold in symptomatic adult patients with asthma."4.82Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. ( Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2005)
"Overall, this review supports the equivalence of continuous and intermittent albuterol nebulization in the treatment of acute adult asthma."4.81Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. ( Rodrigo, C; Rodrigo, GJ, 2002)
"To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control."4.81Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. ( Arnold, AD; Crafts, R; Heyneman, CA; Holland, J, 2002)
"Salbutamol (albuterol) is a beta2-adrenoceptor agonist used as a bronchodilator for the treatment of asthma and as a uterine relaxant for the suspension of premature labour."4.81The pharmacokinetics of levosalbutamol: what are the clinical implications? ( Boulton, DW; Fawcett, JP, 2001)
"The aim of this study was to compare the efficacy and safety of salmeterol vs theophylline in asthma management using meta-analysis of clinical trials."4.80The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. ( Brooks, G; Davies, B; Devoy, M, 1998)
"Salmeterol xinafoate is a highly selective beta2-adrenoceptor for the maintenance treatment of asthma in adults and children."4.80Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy. ( Buchwald, A; Hochhaus, G, 1998)
"Theophylline and long acting beta2-agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma."4.80Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Wilson, AJ, 2000)
"The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma."4.80Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. ( Jarvis, B; Markham, A, 2000)
"Albuterol has been proven to be a vital component in the management of severe, acute asthma in children and adults."4.79Administration of albuterol by continuous nebulization. ( Buck, ML, 1995)
"This report describes a precocious eight-year-old child who presented with hallucinations from excessive use of albuterol inhalers."4.79Beta-agonist inhaler causing hallucinations. ( Santeiro, ML; Schnapf, BM, 1994)
"Salmeterol xinafoate is a selective beta 2-adrenoceptor agonist indicated for the maintenance treatment of adults and children with asthma."4.79Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. ( Adkins, JC; McTavish, D, 1997)
" It is, further, necessary to apply these agents systemically together with theophylline, the best approach to pre-status and status asthmaticus being continuous i."4.77[Treatment of the severe asthma attack and status asthmaticus]. ( Baur, X, 1989)
"Aminophylline is routinely recommended as a basic part of the emergency treatment of asthma."4.77Aminophylline treatment in severe, acute asthma. A meta-analysis. ( Littenberg, B, 1988)
"The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma)."4.76[Pulmonary function tests with the bronchodilator Terbutaline]. ( Bonelli, J; Hitzenberger, G; Kaik, G; Laggner, A; Magometschnigg, D, 1979)
"To compare hospital costs and resource utilization for pediatric asthma admissions based on the hospitals' availability of continuous albuterol aerosolization administration (CAA) in non-intensive care unit (ICU) settings."4.31Cost analysis of hospitals performing continuous albuterol in non-intensive care settings. ( Andoh, AA; Bode, RS; Gee, SW; Leonard, JC; Lo, CB; Shi, J, 2023)
"The effectiveness of a fix-dose salmeterol/fluticasone combination therapy in asthma was previously shown for the original product."4.31The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. ( Almgren-Rachtan, A; Chudek, J; Doniec, Z; Hantulik, P; Olszanecka-Glinianowicz, M, 2023)
"A new asthma drug, Airsupra, combines the short-acting β2-adrenergic agonist albuterol with the corticosteroid budesonide to treat acute asthma attacks."4.31New Combination Asthma Drug. ( Aschenbrenner, DS, 2023)
"We examined the baseline change in FEV1 and FVC in response to albuterol among 931 participants with poorly controlled asthma pooled from three clinical trials conducted by the American Lung Association - Airways Clinical Research Centers."4.31Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma. ( Dixon, AE; He, J; Henderson, R; Holbrook, JT; Irvin, CG; Kaminsky, DA; Mastronarde, J; Smith, LJ; Sugar, EA; Wise, RA, 2023)
"Outcomes of interest were utilization of asthma medications on the PDL (controllers and albuterol), asthma exacerbations (oral steroid bursts and asthma-related emergency department use), and out-of-pocket spending (all and asthma-specific)."4.31Utilization and Spending With Preventive Drug Lists for Asthma Medications in High-Deductible Health Plans. ( Galbraith, AA; LeCates, RF; Ross-Degnan, D; Sinaiko, AD; Wharam, JF; Wu, AC; Zhang, F, 2023)
" There was high agreement in albuterol use for bronchospasm and epinephrine use in anaphylaxis."4.12Variation in Prehospital Protocols for Pediatric Respiratory Distress Management in the United States. ( Martin-Gill, C; McCans, K; Owusu-Ansah, S; Ramgopal, S; Varma, S, 2022)
"Ensuring students with asthma residing in disadvantaged communities have access to rescue medication (albuterol) is important."4.12School-based Stock Inhaler Programs and Neighborhood Disadvantage. ( Clemens, C; Gerald, JK; Gerald, LB; Lowe, AA, 2022)
"Standardized acute asthma management with score-based, respiratory therapist (RT)-driven pathways and protocols improves outcomes including decreased length of stay (LOS) and time on continuous albuterol therapy."4.12Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022)
"Albuterol has been a cornerstone of asthma treatment for several decades, but evidence suggests that it may be overused at the expense of more efficacious treatment."4.12Albuterol: Still first-line in rescue therapy? ( Pitonzo, DG, 2022)
"Between January and December, 2015, asthmatic children aged between 5 and 17 years old performed impulse oscillometry (IOS) and spirometry during the same visit before and after albuterol administration."4.02A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude. ( Alvarez, I; Aristizabal-Duque, R; Ramirez, O; Rodriguez-Martinez, CE; Sossa-Briceño, MP; Villamil, M, 2021)
" Using the continuous albuterol metric, predictability of the asthma scale had an area under the curve of 0."4.02Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma. ( Kolaitis, IN; Nevin, MA; Palac, H; Samady, W; Schroeder, SK; Shreffler, L; Smith, CM, 2021)
"Implementation of an asthma protocol in the pediatric ICU did not result in significant improvements in time on continuous albuterol or hospital and pediatric ICU LOS, likely due to low adherence to the protocol."4.02Implementation of a Critical Asthma Protocol in a Pediatric ICU. ( Davey, CS; Fischer, GA; Gupta, S; Kucher, NM; S Dhaliwal, D, 2021)
"A total of 15 states allow schools to manage respiratory emergencies among multiple students by using a single albuterol inhaler (stock inhaler) paired with a disposable holding chamber."4.02Managing respiratory emergencies at school: A county-wide stock inhaler program. ( Clemens, CJ; Gerald, JK; Gerald, LB; Lowe, AA; Stern, DA, 2021)
"Inability to access an albuterol inhaler at school increases risk to students of severe asthma attack."4.02Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol. ( Fu, L; Gessner, L; Thompson, D; Torres, R, 2021)
"Higher neighbourhood-level social deprivation was associated with more albuterol and inhaled steroid prescriptions among children with asthma, while problem list documentation of asthma and asthma severity varied little across neighbourhoods with differing deprivation scores."4.02Role of social deprivation on asthma care quality among a cohort of children in US community health centres. ( Bazemore, A; Cowburn, S; Ezekiel-Herrera, D; Fankhauser, K; Giebultowicz, S; Heintzman, J; Kaufmann, J; Lucas, JA; Marino, M, 2021)
"Children (6-11 years, N = 299) and adolescents (12-21 years, N = 331) with confirmed asthma underwent clinical phenotyping procedures and a test of maximal bronchodilation with escalating doses of albuterol sulfate up to 720 mcg."3.96Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations. ( Bruce, AC; Fitzpatrick, AM; Grunwell, JR; Nguyen, KM, 2020)
"A decision-analysis model was developed to estimate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations."3.96Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2020)
" Stock asthma rescue medication policies authorize school districts to maintain unassigned albuterol and enable trained staff members to administer the medication in response to asthma symptoms, exercise premedication, and asthma emergencies."3.96Preventing Asthma Emergencies in Schools. ( O'Rourke, A; Pappalardo, AA; Platt, H; Zimmerman, A, 2020)
" Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma-related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch."3.91Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. ( Ban, GY; Carter, V; Hardjojo, A; Jie, JLZ; Lee, HY; Park, HS; Price, DB; Van Boven, JFM; Wan Yau Ming, S; Yoon, D, 2019)
"The implementation of an asthma pathway was associated with decreased hospital LOS, PICU LOS, and time on continuous albuterol."3.91A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit. ( Bartlett, KW; Gates, RM; Haynes, KE; Heath, TS; McLean, HS; Miller, AG; Rehder, KJ; Zimmerman, KO, 2019)
"Phenylephrine and salbutamol are drugs that are used widely to treat diseases/disorders, such as nasal congestion, hypotension, and asthma, in individuals of different age groups."3.91Impact of SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of phenylephrine and salbutamol by human SULT1A3 allozymes. ( Abunnaja, MS; Alatwi, ES; Alherz, FA; Bairam, AF; El Daibani, AA; Gohal, SA; Kurogi, K; Liu, MC; Rasool, MI, 2019)
" For asthma, albuterol was reported most frequently (77."3.88Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma. ( Ansari, S; Bandoli, G; Chambers, CD; Hulugalle, A; Kuo, GM; Palmsten, K; Xu, R, 2018)
"Albuterol, a bronchodilator medication, is the first-line therapy for asthma worldwide."3.88Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma. ( Ahituv, N; Avila, PC; Brigino-Buenaventura, E; Bunting, KL; Burchard, EG; Celedón, JC; Dahlin, A; Darnell, RB; Eckalbar, WL; Eng, C; Farber, HJ; Forno, E; Galanter, J; Germer, S; Goddard, P; Hakonarson, H; Hernandez, RD; Himes, BE; Hu, D; Huntsman, S; Keys, KL; Kumar, R; Kwok, PY; Lenoir, MA; Levin, AM; Liberto, J; Mak, ACY; Meade, K; Moreno-Estrada, A; Nguyen, TA; Nuckton, TJ; Oh, SS; Pino-Yanes, M; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Salazar, S; Sandoval, K; Seibold, MA; Sen, S; Serebrisky, D; Sleiman, PM; Szpiech, ZA; Tantisira, KG; Thyne, SM; Torgerson, DG; Vogel, JM; Weiss, ST; White, MJ; Williams, LK; Winkler, CA; Wu, AC; Zaitlen, N; Ziv, E, 2018)
" We analyze microparticles (1-5 μm diameter) composed of polystyrene latex and from three real-world pressurized metered dose inhalers (pMDIs) used in the treatment of asthma: salmeterol xinafoate (Serevent), salbutamol sulfate (Salamol), and ciclesonide (Alvesco)."3.881064 nm Dispersive Raman Microspectroscopy and Optical Trapping of Pharmaceutical Aerosols. ( Davidson, NM; Gallimore, PJ; Kalberer, M; Pope, FD; Ward, AD, 2018)
"The objective of this study was to evaluate ordering of albuterol via metered-dose inhaler with spacer (MDI-spacer), length of stay (LOS), and 72-hour return rates before and after publication of an internally developed pediatric asthma clinical practice guideline (CPG)."3.88Effect of an Asthma Guideline in 2 Pediatric Emergency Departments and an Urgent Care Center. ( Allen, NH; Dilts, JJ; Humiston, SG; Lee, BR; Michael, JG, 2018)
"This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD)."3.85Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. ( Cai, S; Dong, H; Li, R; Lv, Y; Wu, Y; Xiao, G; Yao, L; Zhao, H, 2017)
"The goal of this study was to examine the impact of a multidisciplinary intervention designed to improve appropriate albuterol inhaler utilization among patients with asthma."3.85Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. ( Delate, T; Jenkins, DW; Lowe, R; Rader, N, 2017)
"Racemic albuterol and levalbuterol are used to treat acute episodes of asthma."3.85Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population. ( Love, BL; Lu, ZK; Schulz, RM; Wu, J; Yuan, J; Zhang, Y, 2017)
"This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response."3.83Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016)
"The objective was to determine the occurrence of, and the factors associated with, diastolic hypotension and troponin elevation or electrocardiogram (ECG) ST-segment changes in a convenience sample of children with moderate to severe asthma receiving continuous albuterol nebulization."3.83Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. ( Fagbuyi, DB; Jeong, K; Lin, Y; Manole, MD; Pitetti, RD; Ralphe, JC; Saladino, RA; Venkataraman, S; Zuckerbraun, NS, 2016)
"The ideal dosing of albuterol via metered-dose inhalers for acute childhood asthma is not well established."3.83Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. ( da Silva Filho, LV; De Lalibera, IB; de Souza, AV; Muchão, FP; Rodrigues, JC; Schvartsman, C; Souza, JM; Torres, HC, 2016)
"Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma."3.83The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. ( Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016)
" We present a case of a patient who was admitted with acute asthma exacerbation and was treated with β-2 agonist nebulisation and intravenous aminophylline."3.83Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. ( Khwaja, YH; Tai, JM, 2016)
"Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management."3.81Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015)
"Using private insurance data from January 1, 2004, to December 31, 2010, we investigated the effect of the CFC ban on out-of-pocket costs and utilization of albuterol inhalers among individuals with asthma (109,428 adults; 37,281 children), as well as asthma-related hospitalizations, emergency department visits, and outpatient visits."3.81The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. ( Goldman, DP; Ho, O; Jena, AB; Karaca-Mandic, P, 2015)
"To determine if nitrites (nitric oxide metabolites) measured in induced sputum decrease and correlate with improvement of clinical asthma symptoms after treatment, we performed a prospective longitudinal study in a tertiary care hospital in Arequipa, Peru."3.80Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren. ( Cáceres, M; Castro-Rodriguez, JA; Molina, RO; Recabarren, A, 2014)
"To estimate the relative perinatal safety with the use of salmeterol and formoterol (LABAs) and that of fluticasone and budesonide (ICSs) during pregnancy."3.80Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. ( Beauchesne, MF; Blais, L; Cossette, B; Forget, A; Larivée, P; Lemière, C; Rey, E, 2014)
" The majority of asthmatics were admitted to PICUs based on clinical asthma examination/score or because the patient was receiving continuous albuterol."3.79Corticosteroid therapy in critically ill pediatric asthmatic patients. ( Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)
" Among different strategies conducted to identify this 'missing heritability', here we illustrate the importance of complex gene-environment interactions using findings regarding the role of leukotrienes on the bronchodilator response to albuterol in Latino asthmatics."3.79Role of interactions in pharmacogenetic studies: leukotrienes in asthma. ( González Burchard, E; Tcheurekdjian, H; Via, M, 2013)
"This study aimed to assess the safety and efficacy of a high-dose continuous nebulized albuterol (CNA) protocol for treatment of asthma in the pediatric emergency department (ED)."3.79Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. ( Flood, RG; Gerard, JM; Krebs, SE; Peter, JR, 2013)
"The concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known."3.78Exhaled carbon monoxide levels in preschool-age children with episodic asthma. ( Arai, H; Asamura, T; Morikawa, T; Ohara, T; Ohara, Y; Ohrui, T; Sasaki, H, 2012)
"Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-α-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma."3.78Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. ( Barnes, PJ; Ito, K; Ito, M; Osoata, G; Rossios, C; To, Y, 2012)
"In mild asthma exacerbations, administering albuterol via MDI+S decreases ED treatment time when compared to administering nebulized albuterol."3.78Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems. ( Baxendale, S; Cross, KP; Gracely, E; Kim, IK; Peek, M; Southard, G; Staggs, L, 2012)
"To examine the use of intravenous magnesium in Canadian pediatric emergency departments (EDs) in children requiring hospitalization for acute asthma and association of administration of frequent albuterol/ipratropium and timely corticosteroids with hospitalization."3.78Magnesium use in asthma pharmacotherapy: a Pediatric Emergency Research Canada study. ( Black, KJ; Freedman, S; Gouin, S; Hernandez, A; Johnson, DW; Plint, A; Porter, R; Schuh, S; Zemek, R, 2012)
"To investigate the dynamic changes in airways in response to methacholine and salbutamol inhalation and to correlate the xenon ventilation index on xenon-enhanced chest CTs in asthmatics."3.78Quantitative analysis of dynamic airway changes after methacholine and salbutamol inhalation on xenon-enhanced chest CT. ( Cho, SH; Goo, JM; Jung, JW; Kim, JH; Lee, CH; Park, EA; Park, HW; Park, SJ, 2012)
"The overwhelming majority of children discharged from Canadian pediatric EDs with acute asthma are prescribed inhaled albuterol via MDIs."3.78Practice patterns in asthma discharge pharmacotherapy in pediatric emergency departments: a pediatric emergency research Canada study. ( Black, KJ; Freedman, S; Gouin, S; Johnson, DW; Plint, A; Porter, R; Schuh, S; Zemek, R, 2012)
"The purpose of this study was to evaluate the use of xenon-enhanced dual-energy CT of the chest to assess ventilation changes after methacholine and salbutamol inhalation in subjects with asthma and healthy subjects."3.78Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation. ( Cho, SH; Goo, JM; Kim, JH; Kim, WW; Lee, CH; Park, EA; Park, SJ, 2012)
" Laboratory findings showed hypokalemia, hypophosphatemia, and lactic acidosis."3.78Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone. ( Hantson, P; Manara, A; Thys, F; Vanpee, D, 2012)
"To examine the proportion of children presenting to the emergency department (ED) with an acute asthma exacerbation with incorrect home use of their albuterol inhaler and to identify factors associated with improper treatment."3.78Inappropriate home albuterol use during an acute asthma exacerbation. ( Clayton, K; Harrington, K; King, W; Magruder, T; Monroe, K, 2012)
" Both studies were continued for a further 9 months during which time exacerbation rates, lung function at the clinic and adverse events were monitored."3.78Efficacy and safety of salmeterol in childhood asthma. ( Boner, AL; Ebbutt, A; Jenkins, MM; Lenney, W; Pedersen, S, 1995)
" We isolated caffeic acid and phenylpropanoid glycosides, 1-O-caffeoyl glycoside and acteoside [β-(3',4'-dihydroxyphenyl) ethyl-O-α-l-rhamnopyranosyl(1→3)-β-d-(4-O-caffeoyl)-glucopyranoside] from their ethylacetate fractions, respectively, and evaluated their anti-asthmatic effects on the aerosolized ovalbumin (OA) challenge in the OA-sensitized guinea-pigs measuring the specific airway resistance (sRaw) during the immediate-phase response (IAR) and late-phase response (LAR), and also measured recruitment of leukocytes and chemical mediators on the bronchoalveolar lavage fluids (BALF) in LAR, as well as histopathological survey."3.77Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin. ( Kim, CJ; Lee, JG; Lee, JY; Sim, SS; Whang, WK, 2011)
" albuterol, are used for quick reversal of bronchoconstriction in asthmatics."3.77Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011)
"We measured the incremental cost-effectiveness from the perspective of the hospital, by creating a model using outcome characteristics from a Cochrane systematic review comparing the efficacy of using MDIs versus nebulizers for the delivery of albuterol to children presenting to the ED with asthma."3.77Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department. ( Doan, Q; Johnson, D; Shefrin, A, 2011)
" We describe asthma prescription patterns in a cohort of patients (n =17,745) in the General Practice Research Database who initiated treatment with salmeterol-containing prescriptions between 2003 and 2006, including salmeterol and salmeterol/fluticasone propionate in a single device."3.77Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). ( Davis, KJ; DiSantostefano, RL, 2011)
"A retrospective observational cohort study compared the risk of asthma-related exacerbations [hospitalization, emergency department visit, and/or treatment with systemic corticosteroid] in patients receiving treatment with fluticasone propionate/salmeterol in a single inhaler (FSC) within 90 days following an initial asthma-related exacerbation (early treatment) versus patients receiving the treatment subsequently (late treatment)."3.77Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation. ( Delea, TE; Hagiwara, M; Stanford, RH, 2011)
" Asthmatic patients with the Arg19/Arg19 genotype showed decreased responsiveness to albuterol."3.77Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China. ( Dai, LM; Fang, LZ; Fu, WP; Liu, L; Shu, JK; Sun, C; Wang, L; Wang, XM; Zhang, JQ; Zhao, ZH; Zhong, L, 2011)
"Ambient particulate matter concentrations have been positively associated with urinary leukotriene E(4) (LTE(4)) levels and albuterol usage in children with asthma but interactions with environmental tobacco smoke (ETS) exposure have not been demonstrated despite obvious exposure to both pollutants in an urban setting."3.77The response of children with asthma to ambient particulate is modified by tobacco smoke exposure. ( Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011)
"04), but not to asthma symptoms or albuterol use."3.76Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis. ( Drotar, D; Kercsmar, C; McNally, K; Redline, S; Riekert, K; Rohan, J; Schluchter, M; Schmidt, A; Vavrek, P, 2010)
"We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol."3.76A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010)
"Two large datasets comparing treatment with fluticasone propionate and fluticasone propionate plus salmeterol were analyzed, including the number of clinically reported upper respiratory tract infections, asthma-related exacerbations, and the presence of an exacerbation and concurrent report of an upper respiratory tract infection."3.76Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. ( Gul, N; Kral, KM; Prazma, CM; Stempel, DA; Yancey, SW, 2010)
"Short-acting inhaled beta2-agonists such as albuterol are used for bronchodilation and are the mainstay of asthma treatment worldwide."3.76GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. ( Avila, PC; Burchard, EG; Chapela, R; Choudhry, S; Eng, C; Kim, SO; Kumar, G; Liu, L; Que, LG; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Stamler, JS; Thyne, S; Yang, Z, 2010)
"We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients."3.76[Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients]. ( Arakawa, I; Miyamoto, T; Nishima, S; Shiragami, M; Tohda, Y, 2010)
"Epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and COPD (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (CSE) and/or Th2 cytokine IL-13, followed by Mp infection and treatment with beta2-agonists albuterol and formoterol for up to seven days."3.76beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells. ( Bowler, RP; Chu, HW; Green, RM; Gross, CA; Schnell, C; Weinberger, AR, 2010)
" Fifteen (8 males), non-smoking, patients with moderate-to-severe treated (inhaled corticosteroid (ICS) and inhaled long-acting beta(2)-agonist (LABA)) asthma, age 57+/-13 years (mean+/-SD), were studied at baseline, during exacerbation prior to oral corticosteroid, and during recovery after an 8 day tapering prednisone course."3.76Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma. ( Fraser, C; Gelb, AF; George, SC; Krishnan, A; Maginot, T; Shinar, CM; Silkoff, PE; Taylor, CF, 2010)
"In a cross-sectional study of 293 Mexicans and 356 Puerto Ricans with asthma, ALOX5AP and LTA4H genes were sequenced, and interactions between gene polymorphisms and bronchodilator responsiveness to albuterol were compared between leukotriene modifier users and nonusers."3.76ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. ( Avila, PC; Burchard, EG; Chapela, R; Corvol, H; De Giacomo, A; Eng, C; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, S; Via, M, 2010)
"We present the case of an 83-year-old woman who was diagnosed with bronchial asthma in 1929 and had been treated in her childhood with "Dr Nathan Tucker Asthma Specific", a cocaine-based aerosolised asthma treatment."3.76Dr Nathan Tucker's Asthma Specific--a treatment for asthma preceding inhaled steroids and beta-agonists. ( Beckert, L; Hamilton, N, 2010)
"The aim of this work was to compare rates of asthma-related health service utilization for Medicaid-eligible pediatric and adult patients with asthma treated with fixed-dose fluticasone propionate/salmeterol (FSC) or fluticasone propionate (FP) monotherapy."3.76Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. ( Astry, CL; Johnson, JC; Riedel, AA; Stanford, RH, 2010)
" With currently used dosing regimens, theophylline appears to produce relatively constant levels of effect on airway responsiveness and clinical efficacy around the clock, while inhaled beta 2 agonists appear to have insufficient effects at the end of longer dosing intervals."3.76The effect of theophylline and beta 2 agonists on airway reactivity. ( Ahrens, RC; Joad, J; Milavetz, G, 1987)
" The suggestion is made that failure to recognize the nonlinearity of the dose-response curves for bronchodilators has resulted in underestimating their combined action."3.76Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs. ( Jenne, JW, 1987)
" Asthma patients 16-65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol."3.75Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol. ( Beauchesne, MF; Blais, L; Forget, A, 2009)
" Despite similar clinical asthma scores on hospital admission, the children with the Gly/Gly genotype had significantly shorter hospital ICU length of stay and duration of continuously nebulized albuterol therapy and were significantly less likely to require IV beta(2)-AR therapy than those with Arg/Arg or Arg/Gly genotypes."3.75Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. ( Carroll, CL; Schramm, CM; Stoltz, P; Zucker, AR, 2009)
"Six healthy and 5 experimentally asthmatic cats were randomized to receive inhaled R,S-albuterol, S-albuterol, R-albuterol, or placebo (saline) twice daily for 2 weeks, followed by a 6-week washout before crossover to the next treatment."3.75Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. ( DeClue, AE; Delgado, C; Dhand, R; Reinero, CR; Spinka, C, 2009)
"Quantitative and qualitative methods were used to collect data from a convenience sample of adolescents with asthma previously prescribed fluticasone/salmeterol (F/S)."3.75Adolescents and asthma: why bother with our meds? ( Apter, AJ; Bogen, D; Freedman, TG; Ginsburg, KR; Naimi, DR; Rand, CS, 2009)
"The goal of this study was to examine whether the claims history for children in a US insured population indicate proper fluticasone propionate/ salmeterol (FPS) fixed-dose combination use in accordance with recommended asthma guidelines and a US Food and Drug Administration (FDA) advisory and black box warning regarding LABA use."3.75Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. ( Crespi, S; Eid, NS; Friedman, HS; Reardon, G; Wilcox, TK, 2009)
"Among children with persistent asthma, use of leukotriene modifiers is associated with augmented bronchodilator responsiveness to albuterol in Puerto Ricans, but not Mexican Americans."3.75Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children. ( Avila, PC; Burchard, EG; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, SM; Via, M; Williams, LK, 2009)
"To investigate the effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of adult patients with asthma."3.75Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma. ( de Melo, PL; Jansen, JM; Lopes, AJ; Veiga, J, 2009)
"Albuterol has been used for more than 40 years to treat acute asthma exacerbations as a racemic mixture of isomers: the active form, (R)-albuterol, or levalbuterol, and (S)-albuterol, classically considered inert."3.75Levalbuterol versus albuterol. ( Ameredes, BT; Calhoun, WJ, 2009)
" During the visit, the simulated patient enacted a standardized scenario of someone with moderately controlled asthma who wished to purchase a salbutamol (albuterol) inhaler without prescription."3.75Measuring the assessment and counseling provided with the supply of nonprescription asthma reliever medication: a simulated patient study. ( Clifford, RM; Everett, AW; Geelhoed, E; Kendall, PA; Schneider, CR, 2009)
"We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol."3.75Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. ( Basu, K; Lipworth, BJ; Mukhopadhyay, S; Palmer, CN; Tavendale, R, 2009)
"To compare the rates of asthma-related emergency department (ED) visits and hospitalizations in the fall (September, October, November) between users and nonusers of fluticasone propionate plus salmeterol in a single inhaler (FSC) in the preceding summer."3.75Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. ( Sheth, K; Spahn, J; Stanford, RH; Stempel, DA; Yeh, WS, 2009)
"Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA."3.74Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008)
"Eighty-one patients with asthma (24% African American [AA]; 8 to 65 years old; baseline FEV1, 40 to 80% of predicted) received 180 microg of albuterol from a metered-dose inhaler (MDI), and then 90 microg every 15 min until maximum improvement or 540 microg was administered; all then received 2."3.74Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. ( Blake, K; Derendorf, H; Lima, J; Madabushi, R, 2008)
"National asthma guidelines recommend that patients with persistent asthma regularly use an inhaled corticosteroid (ICS) in addition to as-needed albuterol, yet recent debates question whether this combination is equally efficacious in all ethnicities."3.74Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. ( Avila, PC; Burchard, EG; Castro, RA; Chapela, R; Choudhry, S; DeBoard, JA; LeNoir, M; Meade, K; Naqvi, M; Navarro, D; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, SM; Watson, HG; Williams, LK, 2008)
" We describe an unusual case of a 47-year-old woman whose increased use of inhaled albuterol led to a non-ST-segment elevation myocardial infarction and unmasking of hemodynamically significant myocardial bridging."3.74Increased use of beta-agonists leading to non-ST-segment elevation myocardial infarction in a patient with hemodynamically significant myocardial bridging. ( Gold, DR; Makaryus, AN; Zolli, JR, 2008)
"The aim of the present study was to assess the response of high-dose salmeterol/fluticasone combination (SFC) and low-dose SFC compared with regimens without inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) in a large cohort with severe or difficult-to-treat asthma."3.74The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. ( Borish, L; Campbell, JD; Haselkorn, T; Lee, JH; Rasouliyan, L; Sullivan, SD; Wenzel, SE, 2008)
"Data on German asthma patients initiating treatment with budesonide/formoterol or salmeterol/fluticasone between June 2001 and June 2005 were obtained from the IMS Disease Analyzer database."3.74A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany. ( Aballéa, S; Cure, S; Vogelmeier, C; Wirén, A, 2008)
"To identify the relationship between resource utilization and treatment of asthma in subjects who were first time users of controller therapies, either fluticasone propionate (FP) and salmeterol delivered in a single Diskus device (FSC) or FP monotherapy."3.74An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes . ( Fuhlbrigge, A; Rey, GG; Riedel, A; Stanford, RH; Stempel, DA, 2008)
"We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects with asthma, and 15 subjects with chronic obstructive pulmonary disease (COPD) with mean (SD) age in years of 38 (SD, 11), 45 (SD, 11), and 64 (SD, 8), respectively."3.74The confounding effects of thoracic gas compression on measurement of acute bronchodilator response. ( Babb, TG; Boriek, AM; Hanania, NA; Officer, TM; Sharafkhaneh, A; Sharafkhaneh, H, 2007)
"Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol."3.74Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007)
"This study evaluated the use and drug costs of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs), and fluticasone propionate and salmeterol in a fixed-dose combination (FSC) and their relationship to asthma exacerbations before and after the market introduction of FSC in April 2001."3.74The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. ( Brixner, DI; Lenhart, G; Samuelson, WM; Young, DC, 2007)
"Peripheral blood lymphocytes from asthmatic subjects were cultured 6 days ex vivo with IL-2 and various concentrations of albuterol, formoterol, and budesonide."3.74Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. ( Foster, S; Loza, MJ; Penn, RB; Peters, SP, 2008)
"There are theoretical benefits of delivering drug aerosols to patients with asthma and chronic obstructive pulmonary disease (COPD) using Heliox as a carrier gas."3.74The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers. ( Bland, H; Crosby, D; Dougill, B; Jackson, J; O'Callaghan, C; White, J, 2007)
"MDI-VHC utilization increased from 25% to 77% among all non-intensive-care patients receiving albuterol, and from 10% to 79% among patients with asthma (p < 0."3.74The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. ( Carter, ER; Cowan, CA; Crotwell, DN; DiBlasi, RM; Salyer, JW, 2008)
"CPGs for mild to moderate asthma were similar across sites and based on salbutamol delivery by metered dose inhaler with spacer and oral prednisolone."3.74Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. ( Acworth, J; Babl, FE; Borland, M; Cotterell, E; Francis, P; Jamison, S; Krieser, D; Neutze, J; Ngo, P; Schutz, J; Sheriff, N; Thomson, F, 2008)
"Our data show that S-albuterol stimulates cell proliferation by activating expression and phosphorylation of several intracellular mitogenic proteins and may exacerbate asthma by stimulating the release of IL-6."3.74Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. ( Abdallah, MF; Ibe, BO; Raj, JU, 2008)
"To assess the frequency of beta2-AR polymorphisms in asthmatic children from Argentina, and to evaluate their influence on bronchodilator desensitization to albuterol over a 4-week treatment."3.74Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. ( Castaños, C; Chertkoff, L; Giubergia, V; Gravina, LP; Grenoville, M, 2008)
"This study was designed to expand on these earlier findings by comparing asthma-related health care resource utilization and costs, as well as adherence to ICSs, in children and adults with asthma receiving ICS monotherapy who either were switched to fluticasone propionate plus SAL from a single inhaler (FSC) or initiated add-on therapy with SAL from a separate inhaler or MON."3.74Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. ( Delea, TE; Hagiwara, M; Stanford, RH; Stempel, DA, 2008)
"To determine whether there are differences in health care use and costs of asthma treatment in asthma patients treated with montelukast compared with fluticasone proponiate 44 microg."3.73Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. ( Balkrishnan, R; Kulkarni, AS; Nelsen, LM; Pleasants, RA; Schechter, MS; Whitmire, JT, 2005)
"Salmeterol/fluticasone propionate is a more cost-effective treatment option than fluticasone propionate plus montelukast for patients with symptomatic asthma uncontrolled by ICS."3.73Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. ( Pieters, WR; Smith, HC; Sondhi, S; Tamminga, JJ; Wilson, KK, 2005)
"To demonstrate that basic emergency medical technicians (EMT-Bs) are able to effectively administer nebulized albuterol to asthma patients in the out-of-hospital environment."3.73Out-of-hospital administration of albuterol for asthma by basic life support providers. ( Kusick, M; Matallana, L; Richmond, NJ; Silverman, R; Winokur, J, 2005)
"We conducted a prospective and descriptive study to assess levels of lactate and effects on bronchodilator response in adult patients with acute severe asthma treated with high doses of albuterol in the ED."3.73Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2005)
"A disease-related, corticosteroid-insensitive increase in the expression of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase in asthmatic bronchial epithelium has been shown previously by the current authors."3.73Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. ( Davies, DE; Dearman, RJ; Hamilton, LM; Holgate, ST; Howarth, PH; Kimber, I; Puddicombe, SM; Sandström, T; Wallin, A; Wilson, SJ, 2005)
"A post hoc resource use analysis of a 52-week, double-blind multicentre clinical trial (Investigation of Montelukast as a Partner Agent for Complementary Therapy) [corrected] including 1490 adults with chronic asthma, aged 15-72 years, with FEV(1) 50-90% of predicted and > or =12% increase in FEV(1) after salbutamol administration, treated with either montelukast 10 mg daily or salmeterol 50 microg twice daily in addition to fluticasone 200 microg, was undertaken."3.73Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. ( Bjermer, L; Bousquet, J; Gaugris, S; Kocevar, VS; Polos, PG; Yin, DD; Zhang, Q, 2005)
"(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma."3.73Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005)
"Airway responsiveness to histamine, diurnal peak-flow variability, and bronchodilator reversibility cannot be used interchangeably as objective markers of asthma in epidemiologic studies."3.73Recognition of asthma in adolescents and young adults: which objective measure is best? ( Backer, V; Postma, DS; Ulrik, CS, 2005)
"Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol."3.73Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. ( Babin, S; Schreck, DM, 2005)
"After a 4-week steroid-run-in period (fluticasone 250 microg twice daily) 48 allergic patients with persistent asthma underwent a bronchial challenge with a single dose of allergen, after inhalation of salbutamol (400 microg, nebulized dose)."3.73Clinically masked increases in bronchial inflammation in guideline-treated persistent asthma. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2006)
"To compare asthma exacerbations, medication switch, and use of SABAs among 3 treatment cohorts: fluticasone propionate and salmeterol as a single inhaler (FSC), fluticasone and salmeterol as separate inhalers (FP + SAL), and fluticasone propionate alone (FP)."3.73Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. ( Gilmore, AS; Legorreta, AP; O'Connor, RD; Rosenzweig, JR; Ryskina, KL; Stanford, RH; Stempel, DA, 2005)
"British Thoracic Society guidelines recommend intravenous salbutamol or aminophylline for acute severe asthma in children."3.73A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia. ( Parr, JR; Salama, A; Sebire, P, 2006)
"Carbon monoxide (CO) can be detected in exhaled air and is increased in adult and childhood persistent asthmatic patients."3.73Exhaled carbon monoxide levels in school-age children with episodic asthma. ( He, M; Morikawa, T; Ohara, Y; Ohrui, T; Sasaki, H; Yamaya, M; Yasuda, H, 2006)
"To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON."3.73Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. ( Carranza Rosenzweig, JR; Riedel, AA; Stempel, DA, 2006)
"We present 2 cases of Cushing syndrome with secondary adrenal insufficiency from concomitant use of ritonavir and inhaled corticosteroids in children with human immunodeficiency virus infection."3.73Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. ( Emmanuel, PJ; Johnson, SR; Lujan-Zilbermann, J; Marion, AA; Vrchoticky, T, 2006)
"Asthma severity was categorized individually for symptoms, albuterol use, and morning peak expiratory flow and then overall taking into account all three parameters."3.73Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists. ( Baitinger, L; Chipps, BE; Dorinsky, PM; Emmett, AH; Sorkness, CA; Spahn, JD; Sutton, LB, 2006)
"We contrasted clinical features, airflow limitation, and albuterol responsiveness in adults acutely ill with asthma, 155 of whom where African American and 140 white, as they presented to eight emergency departments."3.73Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness. ( Brianas, L; Coreno, AJ; Dickey-White, H; El-Ekiaby, A; Galan, G; Kaeberlein, FJ; McFadden, ER; Seitz, RE; Skowronski, ME; Villaba, KD, 2006)
"The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype."3.73Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. ( Ismail, T; Lee, S; Lipworth, BJ; Macgregor, DF; Mukhopadhyay, S; Palmer, CN, 2006)
"To compare asthma-related health care resource utilization among a matched cohort of asthma patients using inhaled corticosteroids (ICSs) plus either montelukast (MON) or salmeterol (SAL) as combination therapy for asthma, during a time prior to the availability of fixed-dose combinations of ICS/SAL."3.73Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. ( Allen-Ramey, FC; Bukstein, D; Luskin, A; Markson, LE; Sajjan, SG, 2006)
" In multivariable regression analyses, hospitalists were significantly more likely to report often or almost always using the following evidence-based therapies for asthma: albuterol and ipratropium in the first 24 hours of hospitalization."3.73Variations in management of common inpatient pediatric illnesses: hospitalists and community pediatricians. ( Chiang, VW; Conway, PH; Edwards, S; Landrigan, CP; Ottolini, MC; Stucky, ER, 2006)
"Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE(4), monitoring of FEV(1), and albuterol use."3.73Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. ( Gelfand, EW; Rabinovitch, N; Zhang, L, 2006)
"Studies of the efficacy of heliox in patients with severe asthma have shown mixed results."3.73Room air entrainment during beta-agonist delivery with heliox. ( Ahmed, A; Babbar, H; Chandra, A; Choksi, S; Chung, V; Dhuper, S; Jha, G; Selvaraj, S; Shim, C; Walia, B, 2006)
"A retrospective, observational study using an integrated managed care database of children aged 4-17 years with an initial medical claim for asthma and an initial pharmacy claim for fluticasone propionate (FP) and salmeterol in a single inhaler (FSC), FP alone, montelukast (MON), or combination FP + MON."3.73The use of rhinitis medications in children receiving initial controller therapy for asthma. ( Carranza Rosenzweig, JR; McLaughlin, TP; Stanford, RH; Stempel, DA, 2006)
"To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma."3.72Clinical and biological heterogeneity in children with moderate asthma. ( Bellia, V; Bonsignore, G; Bousquet, J; Gagliardo, R; La Grutta, S; Mirabella, F; Pajno, GB; Vignola, AM, 2003)
" Theophylline possesses anti-inflammatory activities in asthma."3.72Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003)
" The most dangerous potential herbal and prescription medication combination reported was ephedra and albuterol in an adolescent with asthma."3.72Herbal therapy use in a pediatric emergency department population: expect the unexpected. ( Greenwald, M; Lanski, SL; Perkins, A; Simon, HK, 2003)
"At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV(1) of 64% of predicted value or albuterol use and symptoms on 4."3.72Asthma variability in patients previously treated with beta2-agonists alone. ( Calhoun, WJ; Dorinsky, PM; Emmett, A; Sutton, LB, 2003)
"This was a prospective, open-label, nonrandomized pilot study to evaluate efficacy and tolerability of levalbuterol (LEV) in acute asthma."3.72Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. ( Disantostefano, RL; Emerman, CL; Nowak, RM; Roach, JM; Schaefer, K; Vaickus, L, 2004)
"PBMCs from control subjects and allergic asthmatic patients were stimulated with PHA in the presence of low doses of fluticasone propionate (FP) with or without salmeterol for 72 hours."3.72Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. ( Dunlap, A; Goleva, E; Leung, DY, 2004)
"To determine the relative cost effectiveness when persistent asthma is treated with FP/salmeterol 100/50 microg twice daily administered via a single Diskus inhaler device versus treatment with FP 100 microg twice daily via a Diskus inhaler plus oral montelukast 10mg once daily."3.72Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Nelson, H; O'Connor, RD; Rickard, K, 2004)
"Because the clinical efficacy of inhaled corticosteroids combined with long-acting beta 2 -agonists has been widely demonstrated in asthma, we studied, in vitro, the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor kappaB inhibitor (IkappaBalpha), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects."3.72Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. ( Bonsignore, G; Bousquet, J; Ferraro, M; Gagliardo, R; Gjomarkaj, M; La Grutta, S; Melis, M; Pace, E; Siena, L; Vignola, AM, 2004)
"To compare the effectiveness of (1) fluticasone propionate, 100 microg, and salmeterol, 50 microg; (2) fluticasone propionate, 100 microg; and (3) montelukast, 10 mg, as first-line maintenance treatment for persistent asthma."3.72Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. ( Crim, C; Dorinsky, P; Edwards, L; O'Connor, RD; Rickard, KA; Stanford, R; Yancey, SW, 2004)
"While 127 (77%) of subjects used albuterol as the first treatment for their last asthma attack, 18 (11%) used rubbing ointments."3.72Rubbing ointments and asthma morbidity in adolescents. ( Ozuah, PO; Reznik, M; Sharif, I, 2004)
"2 years; range, 12-18 years; healthy controls (n = 6); asthmatics on inhaled steroids (n = 5); and asthmatics on no steroids (n = 5)] had exhaled nitric oxide (FE(NO)) measurements on 4 consecutive days as follows: pre- and postspirometry (day 1); pre- and postalbuterol metered dose inhaler (MDI) therapy (day 2); pre- and postspirometry and albuterol MDI therapy (day 3); and pre- and postspirometry and placebo MDI (day 4)."3.71Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma. ( Blake, KV; Duckworth, LJ; Kissoon, N; Lima, JJ; Murphy, SP, 2002)
"Inhaled acetaldehyde and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in asthmatics by a mechanism believed to involve histamine release from airway mast cells."3.71Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness. ( Cervera, A; Gutiérrez, V; Liñana, J; Prieto, L, 2002)
"To determine whether NOs influence the bronchodilator activity of albuterol in asthmatic patients."3.71Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma. ( Hirata, K; Kanazawa, H; Yoshikawa, J, 2002)
"Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma."3.71Beta2-agonist eutomers: a rational option for the treatment of asthma? ( Boulton, DW; Fawcett, JP, 2002)
"The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U."3.71Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. ( Ben-Joseph, RH; Price, DB; Zhang, Q, 2001)
"The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy."3.71Lidocaine inhalation for cough suppression. ( Udezue, E, 2001)
" This paper presents age- and gender-specific asthma death rates in patients prescribed the long-acting beta2-agonists salmeterol and bambuterol."3.71Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies. ( Martin, RM; Shakir, S, 2001)
"In 9 healthy and 14 asthmatic subjects before and after a standard bronchial challenge and a modified [deep inspiration (DI), inhibited] bronchial challenge and after albuterol, we tracked airway caliber by synthesizing a method to measure airway resistance (Raw; i."3.71Selected contribution: airway caliber in healthy and asthmatic subjects: effects of bronchial challenge and deep inspirations. ( Atileh, H; Ingenito, EP; Jensen, A; Lutchen, KR; Suki, B, 2001)
"To compare a combination of salmeterol and fluticasone with common asthma pharmacologic regimens used in real-world clinical practice, and to evaluate the associated costs and outcomes of care."3.71Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments. ( Bowers, BW; Legorreta, AP; Liu, X; Sennett, C; Wang, SW; Wiener, DJ, 2001)
"In comparison with the use of montelukast and ICS, the use of salmeterol and ICS was associated with a significant reduction in SABA use, decreased hospital event rates, and significantly lower total asthma care costs."3.71Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. ( Meyer, JW; O'Donnell, JC; Stempel, DA, 2002)
"To investigate the mechanism of anti-inflammatory action of theophylline on asthma."3.71Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects. ( Hu, SP; Nie, HX; Wu, XJ; Yang, J, 2002)
"To compare asthma-related health-care utilization and expenditures for patients prescribed one of three dual-controller therapies: fluticasone plus salmeterol, inhaled corticosteroids (ICS) [excluding fluticasone] plus salmeterol, and ICS plus a leukotriene modifier (LTM)."3.71Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. ( Legorreta, AP; O'Connor, RD; O'Donnell, JC; Pinto, LA; Wiener, DJ, 2002)
"Albuterol administered by MDI/spacer is an efficacious and cost-effective alternative to nebulization in adults with acute asthma who present at a large urban ED."3.71A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. ( Hall, K; Hamilton, C; Milne, S; Newman, KB, 2002)
"The state of inducible NO-synthase (iNOs) in the rat lung with experimental model of bronchial asthma (BA) was studied after administrating short-acting beta 2-agonist fenoterol, long-acting beta 2-agonist salmeterol, and adrenoblocker propranolol."3.71[Inducible nitric oxide synthase in rat lungs in experimental bronchial asthma and its status in administering drugs with adrenergic action]. ( Eliseeva, EV, 2002)
"High levels of histamine can be found in the airways of asthma patients."3.70Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood. ( Bast, A; Bruinier, B; Hol, BE; Jansen, HM; Krouwels, FH; Lutter, R; Out, TA, 1998)
"A case of albuterol abuse by a pediatric patient with the development of hypokalemia with electrocardiographic changes is presented."3.70Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler. ( Farrar, HC; Kearns, GL; Rakhmanina, NY, 1998)
"This paper reviews the impact of the use of technologically dissimilar beta-agonist aerosols--the Maxair Autohaler (pirbuterol acetate) breath-actuated aerosol and the traditional albuterol press-and-breathe inhaler-on the treatment costs of asthma."3.70The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. ( Langley, PC, 1999)
"To determine whether genetic polymorphisms of the beta2-adrenergic receptor gene affect the relationship between albuterol (INN, salbutamol) plasma concentrations and the forced expiratory volume in 1 second (FEV1) in subjects with moderate asthma."3.70Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH; Thomason, DB, 1999)
"Acutely ill asthmatic patients chronically taking salmeterol, and similar patients who were not taking salmeterol, were treated with albuterol, either as three aerosols of 2."3.70Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. ( Korosec, M; McFadden, ER; Myers, E; Novak, RD; Skowronski, M, 1999)
"We determined airway mucosal blood flow (Qaw) and FEV (1) before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients with mild intermittent asthma, and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these parameters."3.70Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. ( Brieva, JL; Danta, I; Wanner, A, 2000)
"A 22-year-old woman with mild intermittent asthma, who had no previous history of an adverse reaction to an albuterol metered-dose inhaler, developed paradoxical bronchoconstriction after inhalation of the fourth dose of an albuterol nebulizer solution."3.70Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium. ( Chan, L; Moonjelly, E; Mutlu, GM; Olopade, CO, 2000)
"This study was undertaken to assess drug-use patterns associated with albuterol delivery via a new propellant device compared with conventional chlorofluorocarbon (CFC) metered-dose inhalers (MDIs) in patients taking asthma medications in a population with pharmacy benefits."3.70Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. ( Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000)
"To determine whether race and gender affect beta(2)receptor-stimulated bronchodilation, we quantified FEV(1)and plasma concentrations of albuterol at various times following the oral administration of a single 8-mg dose of albuterol in 15 black and 15 white male and female asthmatics."3.70Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH, 2000)
"In a 75-year-old woman with asthma, acute angle-closure glaucoma in the right eye was probably caused by local absorption of albuterol after nebulizer administration."3.70Acute angle-closure glaucoma after albuterol nebulizer treatment. ( Rho, DS, 2000)
"The respiratory effects of nebivolol, a new selective ss(1)-adrenergic blocking agent, and celiprolol, a ss-blocker possessing strong ss(1)-adrenoceptor antagonist and mild ss(2)-agonist properties, were investigated in 12 patients with mild asthma."3.70Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. ( Cazzola, M; D'Amato, G; D'Amato, M; Noschese, P, 2000)
" Incubation of bronchial epithelial cells from patients with asymptomatic asthma with interleukin-1 or histamine, for 8 to 24 hours, resulted in increased expression of endothelin-1 messenger RNA and release of appreciable amounts of the peptide to the culture medium."3.69Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. ( Ackerman, V; Bellini, A; Carpi, S; Marini, M; Mattoli, S; Vassalli, G, 1995)
"To determine the relationship between changes in room air oxygen saturation (SaO2) and changes in the clinical signs of pediatric asthma patients after treatment with nebulized albuterol, a 9-month prospective observational study was conducted."3.69Pediatric asthma--a correlation of clinical treatment and oxygen saturation. ( Cook, T; Stone, G, 1995)
"Forty-four adult patients with acute asthma were treated with albuterol at a rate of 15 mg/h over 2 h."3.69Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting. ( Fox, S; Lin, RY; Newman, TG; Sauter, D; Sirleaf, J; Tavakol, M; Walters, J, 1994)
" A case of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction is described in a patient with steroid-dependent asthma."3.69Scintigraphic appearance of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction. ( Alavi, A; Kim, E; Palevsky, HI; Worsley, DF, 1994)
"The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented."3.69Hypokalemia after normal doses of neubulized albuterol (salbutamol). ( D'Souza, L; Mahajan, M; Udezue, E, 1995)
" We measured EPBF with the argon freon-22 rebreathing technique in children with acute severe asthma to assess their response to nebulized salbutamol and to determine whether induced changes in the EPBF could be predicted from baseline measurements."3.69Effective pulmonary blood flow in children with acute asthma attack requiring hospitalization. ( Milner, AD; Yiallouros, PK, 1994)
"Short-term circulatory effects with the maximum recommended dose of inhaled albuterol (Proventil) were studied on 12 asthmatic patients between 33 and 39 weeks' gestation."3.69Short-term effects of inhaled albuterol on maternal and fetal circulations. ( Atkinson, BD; Gilbert, K; Rayburn, WF; Turnbull, GL, 1994)
"Hypomagnesaemia in a woman treated with theophylline and albuterol because of recurrent asthmatic attacks prompted us to explore the effects of these drugs on the metabolism of magnesium, calcium, sodium and phosphate in such patients."3.69Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks. ( Bøhmer, T; Falch, J; Knutsen, R, 1994)
"Air-flow standardized breath sounds were recorded at the chest and at the trachea during histamine challenge test and after subsequent bronchodilation in 12 asthmatics and 6 healthy controls for spectral analysis, to be compared with simultaneous changes in spirometric variables."3.69Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects. ( Haahtela, T; Katila, T; Malmberg, LP; Paajanen, E; Piirilä, P; Sovijärvi, AR, 1994)
"The following study was performed to further characterize a primate model of asthma using classes of drugs that target allergy (pyrilamine, cetirizine), are bronchodilators for the treatment of asthma (salbutamol, salmeterol) or are anti-inflammatory (dexamethasone)."3.69Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. ( Andresen, CJ; Smith, WB; Turner, CR; Watson, JW, 1996)
"There was no relationship between the bronchial responsiveness to histamine and acetic acid cough threshold in these patients."3.69Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma. ( Mochizuki, H; Morikawa, A; Shimizu, T; Tokuyama, K, 1996)
"We performed pulmonary function tests and HRCT on eight asthmatic adults and two nonasthmatic control adults under three conditions: baseline, after methacholine inhalation, and after albuterol inhalation."3.69High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers. ( Chen, DR; Fahy, JV; Gamsu, G; Kee, ST, 1996)
" A careful review of his medical history and the mechanisms of drug-induced asthma revealed that the etiology of his death was more likely due to heroin abuse and noncardiogenic pulmonary edema."3.69The role of pharmacology and forensics in the death of an asthmatic. ( Blaho, K; Merigian, K, 1995)
"To determine the dose of albuterol required to terminate acute episodes of asthma, 92 acutely ill subjects received three doses of 2."3.69Observations on the effects of aerosolized albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1997)
" Bronchial challenge tests were carried out with cumulative doses of inhaled carbachol in 10 healthy children (aged 7-14 yrs) and 50 asthmatic children (aged 5-15 yrs)."3.69Oscillatory pressure transients after flow interruption during bronchial challenge test in children. ( Frey, U; Kraemer, R, 1997)
"We compared mood variables, symptom severity, albuterol use, and peak expiratory flow rate (PEFR) measured three times daily over a 21-day period in 21 adults with moderate to severe asthma."3.69Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. ( Affleck, G; Apter, AJ; Barrows, E; Reisine, ST; Tennen, HA; Wells, M; Willard, A; ZuWallack, RL, 1997)
"In the UK population studied, salmeterol, ipratropium bromide and theophylline are regularly used to treat patients with asthma of increasing severity."3.69Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. ( Jick, H; Meier, CR, 1997)
"We investigated platelet-activating factor (PAF)-induced migration in eosinophils obtained from asthmatic patients who were treated with or without intravenous prednisolone."3.69PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro. ( Fukumura, M; Koide, K; Shindo, K, 1997)
"A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported."3.69Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997)
"The bronchodilating effects of 5 different beta-adrenergic stimulants, isoproterenol, salbutamol, trimetoquinol, orciprenaline and procaterol were examined in 28 same patients who were in a free period from asthmatic attack."3.68[Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma]. ( Kokubu, H, 1993)
" Allergic bronchial eosinophilia in guinea pigs was inhibited by orally administered dexamethasone and methylprednisolone."3.68Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs. ( Chand, N; De Vine, CL; Diamantis, W; Harrison, JE; Jakubicki, RG; Nolan, KW; Pillar, J; Rooney, SM; Sofia, RD, 1993)
"A 40-yr-old woman with severe chronic asthma complained that her regular nebulized albuterol was exacerbating her symptoms."3.68Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline. ( Finnerty, JP; Howarth, PH, 1993)
"The cases of two asthmatic adolescents who overdosed on albuterol are presented."3.68Propranolol treatment of albuterol poisoning in two asthmatic patients. ( Henretig, F; Joffe, M; Ramoska, EA; Spiller, HA, 1993)
" Throughout the study, the children received the standardized course of therapy for hospitalized asthmatics with corticosteroids and albuterol nebulizations."3.68Chronopharmacology of albuterol in hospitalized asthmatic children. ( Cloutier, M; Labrecque, G; Rivard, GB, 1993)
"To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm."3.68Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993)
"To study the feasibility of using high-dose continuously aerosolized albuterol aerosol in adults, seven adult asthmatic patients were treated eight times with 0."3.68High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. ( Hergenroeder, P; Lin, RY; Smith, AJ, 1993)
"We performed a prospective study over a 6-month period to test the efficacy and safety of a continuous nebulized albuterol protocol for the treatment of acute adult asthma attacks."3.68The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. ( Barish, RA; Brandt, G; Hooper, F; Jerrard, D; Olshaker, J, 1993)
"We have compared radioaerosol deposition pattern and bronchodilator response following inhalation of 100 micrograms of albuterol from a correctly used conventional metered dose inhaler (MDI) to those from Gentlehaler, a new compact low-velocity pressurized aerosol device (Schering Corporation), in a group of ten asthmatic patients (mean baseline FEV1 52 percent; reversibility > 15 percent)."3.68Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. ( Clarke, SW; Newman, SP, 1993)
"Leukotriene B4 levels were measured after stimulation by calcium ionophore A23187: (i) in peripheral, neutrophils (PMN) from allergic asthmatics, rhinitis and healthy subjects; (ii) in macrophages collected by bronchoalveolar lavage."3.68Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. ( Chabannes, B; Gormand, F; Grosclaude, M; Hosni, R; Lagarde, M; Moliere, P; Pacheco, Y; Perrin-Fayolle, M; Piperno, D, 1992)
"The effect of inhaled corticosteroid therapy on airway mucosal inflammation was investigated in 10 symptomatic atopic asthmatic patients treated with inhaled albuterol and whose disease severity required preventative antiinflammatory treatment."3.68Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. ( Britten, KM; Djukanović, R; Holgate, ST; Howarth, PH; Roche, WR; Walls, AF; Wilson, JW; Wilson, SJ, 1992)
"Seven children from 3 to 14 years old with chronic steroid-dependent asthma were treated with methotrexate (MTX)."3.68Methotrexate treatment of severe asthma in children. ( Guss, S; Portnoy, J, 1992)
"The effect of a prior histamine challenge on the bronchodilator response to salbutamol after spontaneous recovery of FEV1 to 95% of the prechallenge level was studied in two groups of asthmatic children."3.68Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children. ( Duiverman, EJ; Kerrebijn, KF; Merkus, PJ; Quanjer, PH; Rooda, HM; van Essen-Zandvliet, EE, 1992)
"The effects of prednisolone, salbutamol or theophylline treatment were studied in guinea pigs on bronchial hyperreactivity induced by chronic administration of PAF, (subsequently measuring respiratory flow after an intravenous injection of histamine) and the chemokinesis of leucocytes in vitro."3.68Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs. ( Berga, P; Fernández, AG; Gristwood, RW; Llupiá, J, 1991)
"Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction."3.68[Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. ( Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990)
"To examine the effects of serum theophylline concentration on the bronchodilating effect of beta 2-stimulant inhalated by patients with bronchial asthma, 200 micrograms-Salbutamol inhalation test was performed on 30 patients with bronchial asthma (from 17 to 71 years old, averaging 49."3.68[The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma]. ( Hashimoto, T; Kondo, A; Nakamata, M; Tsukioka, K, 1990)
" Inhaled beta-agonists were the most commonly prescribed antiasthmatic agents in 1986, followed by sustained-release theophylline and inhaled corticosteroids."3.68Use of antiasthmatic drugs in Australia. ( Bowes, G; Hurley, SF; Jenkins, MA; McNeil, JJ, 1990)
"The purpose of this study is to evaluate the effect of disodium cromoglycate and albuterol on energy cost of running, gas exchange, and ventilation during maximal exercise in children with exercise-induced asthma (EIA)."3.68Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children. ( Baraldi, E; Magagnin, G; Santuz, P; Zacchello, F; Zanconato, S, 1990)
" We discuss a case report of albuterol used with a spacer device that induced atrial fibrillation."3.68Spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990)
"Albuterol used with a spacer device which induced atrial fibrillation is described."3.68Albuterol and spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990)
"Our study was designed to assess potential cardiovascular adverse effects in clinically stable asthmatic children due either to oral sustained-release theophylline or theophylline in combination with an inhaled beta-2 adrenergic agonist."3.68Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children. ( Bastianon, V; Bernardini, L; Businco, L; Coletta, F; Colloridi, V; Di Fazio, A; Ferrucci, A; Marzano, MC; Pucci, S; Sorbara, N, 1990)
"Concomitant intradermal injection of salbutamol inhibits histamine-induced weal volume in the skin of atopic asthmatic subjects and the degree of this inhibition (index of beta-adrenergic effect in the skin) correlates with the bronchodilator effect of inhaled salbutamol in the same subjects (index of beta-adrenergic effect in the lung)."3.67Beta-adrenoceptor agonist responses in the skin and lungs of asthmatic subjects. ( Basran, GS; Morley, J; Paul, W, 1984)
"Drug intake and plasma concentrations of theophylline and beta-agonists were recorded in 19 patients with acute asthma (peak expiratory flow rate less than 50% of predicted normal value and heart rate greater than 100 beats/min)."3.67Drug intake and plasma concentrations in acute asthma. ( Boe, J; Ljungholm, K, 1984)
"Ten male asthmatic volunteers each inhaled two puffs (200 micrograms) of salbutamol on two separate days 30 minutes after double blind oral administration of either 20 mg nifedipine or identical placebo."3.67Nifedipine enhances the bronchodilator effect of salbutamol. ( Corris, PA; Gibson, GJ; Lever, AM, 1984)
"Out of a group of 55 asthmatics, 16 fitted the strict definition of atropine resistance (less than 20% FEV1 response to inhaled anticholinergic drugs, with a 20% or more FEV1 response to subsequent inhalation of beta 2-adrenergic stimulants)."3.67Atropine resistance in asthma: definition and provisional hypothesis. ( Jolobe, OM, 1984)
"Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months."3.67Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984)
"Twenty-seven asymptomatic asthmatic children with airway obstruction received a single oral dose of one out of three solutions, in a double-blind, randomized fashion, containing: etamiphylline, 6."3.67[Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma]. ( Labayru, MT; Vázquez, C, 1984)
"To determine whether asthma alone can cause irreversible airflow obstruction 42 men and 47 women with chronic asthma (mean duration 22 (SD 13) years) without evidence of other disease likely to cause irreversible airflow obstruction were treated with theophylline orally and a beta agonist both orally and by inhalation for four weeks."3.67Asthma and irreversible airflow obstruction. ( Brown, PJ; Finucane, KE; Greville, HW, 1984)
"We report a case of respiratory arrest in a ten-year-old asthmatic girl under beta-2-agonists and theophylline."3.67[Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients]. ( Benhamou, PH; Devoldere, C; Epelbaum, S; Kremp, O; Pautard, JC; Piussan, C, 1989)
"The plasma potassium level was studied in 15 patients with acute severe asthma before and six to 14 hours (mean = seven) after treatment with a nebulised beta 2-agonist, salbutamol, intravenous aminophylline and hydrocortisone in recommended doses."3.67Plasma potassium in acute severe asthma before and after treatment. ( Khan, MA, 1989)
"4 mg salbutamol on the impedance of the respiratory system was studied in 25 asthmatic subjects after histamine-induced bronchoconstriction."3.67Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects. ( Polko, AH; Visser, BF; Wouters, EF, 1989)
"Beta-adrenoceptor binding in lymphocytes of asthmatic and non-asthmatic children and healthy adult volunteers was investigated with the radioligand 125-iodocyanopindolol (ICYP)."3.67Beta-adrenoceptor density and resolution of high and low affinity state on B- and T-cells in asthmatic and non-asthmatic children. ( Griese, M; Körholz, D; Reifenhäuser, A; Reinhardt, D; Seeger, K; Wahn, V, 1988)
"In 13 patients with bronchial asthma, who were on beta 2-adrenergic bronchodilator therapy, the effects of prednisolone and ketotifen on lymphocyte beta 2-adrenoceptor density and -responsiveness were investigated."3.67Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. ( Brodde, OE; Egerszegi, S; Howe, U; Konietzko, N; Michel, MC, 1988)
" Inhalation of ovalbumin by sensitized guinea pigs induced three phases of airways obstruction: an early asthmatic response (EAR) peaking at 2 h, a late response (LAR) peaking at 17 h, and a further late response (LLAR) being observed at 72 h."3.67The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs. ( Church, MK; Holgate, ST; Hutson, PA, 1988)
"The effect of a fish oil enriched diet containing about 3 g of eicosapentaenoic acid was studied in 10 patients with aspirin intolerant asthma."3.67Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study. ( Agusti-Vidal, A; Castillo, JA; Coronas, A; Ordinas, A; Picado, C; Pujades, M; Schinca, N, 1988)
"An albuterol (salbutamol) sulphate solution was successfully administered endotracheally to a 67-year-old woman suffering severe bronchospasm and impending ventilatory arrest secondary to asthma."3.67Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol). ( Gareau, AB; Rubes, CJ; Verbeek, PR, 1988)
"A study of patients with a stable course of bronchial asthma (BA) has confirmed the absence of a significant bronchodilating effect of nifedipine during an acute drug test (a single sublingual administration of the drug at a dose of 20 mg)."3.67[The possibilities and prospects in using the calcium antagonist korinfar in patients with bronchial asthma]. ( Alekseev, VG; Efimov, AV; Sinopal'nikov, AI, 1988)
"Co-administration of intravenous albuterol and theophylline resulted in increased theophylline clearance in a child with severe asthma."3.67Enhancement of theophylline clearance by intravenous albuterol. ( Amirav, I; Amitai, Y; Avital, A; Godfrey, S, 1988)
"To explore the possibility that theophylline may act through adrenomedullary secretion of catecholamines, we examined the time courses of plasma norepinephrine (NE), epinephrine (E), and theophylline concentrations and peak expiratory flow (PEF) in nine children with an acute exacerbation of asthma receiving a 72-hour constant infusion of aminophylline."3.67Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma. ( Ishizaki, T; Kanagawa, S; Minegishi, A; Morishita, M; Nagai, T; Odajima, Y; Yamaguchi, M, 1988)
"Single photon emission computed tomography, a rotating gamma camera, and continuous inhalation or infusion of krypton 81m (half life 13 seconds) were used to measure regional ventilation (V), perfusion (Q), and ventilation-perfusion (V/Q) ratios in five normal subjects in supine, prone, and lateral decubitus postures and in three asthmatic patients (supine posture only) before and after inhalation of 2."3.67Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients. ( Al-Suhali, AR; Henderson, B; Hughes, JM; Myers, MJ; Orphanidou, D, 1986)
"The concentrations of theophylline, terbutaline and salbutamol in post-mortem blood samples from 68 patients (17-85 years old) with asthma or chronic obstructive lung disease, 54 of whom had died of asthma, were analysed."3.67Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients. ( Boman, G; Lindsjö, M; Lindström, B; Strandberg, K; Wiholm, BE, 1987)
" On oral challenges, she developed an urticarial reaction after tartrazine; urticarial and bronchospastic reactions after salicylsalicylic acid; and urticarial and bronchospastic reactions after choline magnesium trisalicylate."3.67Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. ( Chudwin, DS; Frey, C; Golden, HE; Luskin, AT; Richmond, GW; Strub, M, 1986)
"Asthma was provoked by histamine inhalation in five children in order to study the hypoxaemia that might ensue and the underlying ventilation-perfusion (VA/Q) mismatching."3.67Histamine-induced asthma in children: effects on the ventilation-perfusion relationship. ( Freyschuss, U; Hedenstierna, G; Hedlin, G, 1985)
"Studies using the guinea pig ileum bioassay technique have previously shown that patients with either asthma or chronic bronchitis have increased amounts of histamine in their sputum."3.66Histamine content of sputum from patients with asthma and chronic bronchitis. ( Bryant, DH; Pui, A, 1982)
"The anti-asthmatic activity, pulmonary mechanics and cardiovascular effects of BB-1502 (9-cyclohexyl-2-n-propoxy-9H-adenine) administered by aerosol were evaluated in guinea pigs and dogs and compared with the effects of salbutamol."3.66Anti-asthmatic activity of BB-1502 by inhalation. ( Hirano, M; Imanishi, H; Kamei, H; Kawaguchi, H; Kawano, K, 1982)
"In five subjects with mild asthma and in five normal subjects, we determined the effect of a 4 wk course of inhaled salbutamol (albuterol), 200 micrograms q."3.66Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol. ( Conolly, ME; Hui, KK; Littner, MR; Tashkin, DP; Wolfe, RN, 1982)
"We have prospectively examined in 51 patients the relationship between the level of airway responsiveness to histamine and methacholine and the minimum medications required to control asthma."3.66Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. ( Frith, PA; Hargreave, FE; Juniper, EF, 1981)
" The added observation that theophylline and salbutamol were effective suggests that the condition is a manifestation of asthma."3.66Persistent cough a forme-fruste of asthma. ( Benzaray, S; Katznelson, D; Yahav, Y, 1982)
"Bronchial responsiveness to histamine was measured in 35 adult asthmatics whose symptoms were controlled on a minimum of medication."3.66Long-term stability of bronchial responsiveness to histamine. ( Frith, PA; Hargreave, FE; Juniper, EF, 1982)
"The efficacy and side effects of intravenous and intramuscular albuterol were determined in 13 adult asthmatic patients whose airway responsiveness had previously been evaluated with inhaled albuterol."3.66Intramuscular and intravenous albuterol in the treatment of asthma. ( Contreras, M; Rebuck, AS, 1982)
"We examined the effects of pharmacologic antagonists on the bronchial response to inhaled histamine in 11 normal and 11 asthmatic subjects."3.66Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. ( Chung, KF; Keyes, SJ; Morgan, B; Snashall, PD, 1982)
"In the management of severe chronic asthma, extensive avoidance of known precipitating factors and optimum betastimulation supported by theophylline have pride of place."3.66[Problems of indication and execution of long-term steroid therapy in advanced disabling bronchial asthma]. ( Imhof, K; Scherrer, M, 1980)
"Plasma cholesterol, plasma and white blood cell ascorbic acid concentrations were estimated in 30 untreated, 32 salbutamol-treated patients with bronchial asthma and in 57 normal controls."3.66Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma. ( Iboko, MI; Jessop, WJ; Ojutiku, OO; Olusi, SO, 1979)
"There are many sympathomimetic products available in treatment of asthma, such as ephedrin, isoproterenol, orciprenalin, salbutamol, terbutalin."3.66[Use of sympathomimetics in the treatment of asthma]. ( Hugues, FC; Julien, D, 1978)
"In a double-blind trial the effects on ventilatory function (FEV1), heart rate and blood pressure of oral pirbuterol and oral salbutamol in various single doses were studied in ten patients with chronic asthma."3.65Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. ( Grant, IW; Pocock, SJ; Willey, RF, 1976)
"Controlled standardised histamine inhalation tests were carried out in 21 asthmatics to determine the degree of non-specific bronchial hyperreactivity with and without prior treatment with several anti-asthmatic drugs."3.65Protective effect of drugs on histamine-induced asthma. ( Cockcroft, DW; Hargreave, FE; Killian, DN; Mellon, JJ, 1977)
"Twenty asthmatics and 14 non-atopic controls were given long-acting theophylline tablets, 400 mg twice daily, and were then challenged, after a control period, with 0."3.65Effect of salbutamol inhalations of plasma and urinary cyclic adenosine monophosphate levels in asthmatics and non-atopic controls. ( Härkönen, M; Muittari, A; Raij K-Alanko, K, 1976)
"Ten patients with exercise-induced asthma were premedicated with oral salbutamol and oral theophylline on separate occasions before performing a standardised exercise test."3.65A comparison of oral theophylline and oral salbutamol in exercise-induced asthma. ( Anderson, SD; Lindsay, DA; Seale, JP, 1977)
"The therapeutic efficacy of atropine and salbutamol sprays alone or in association was experimented in patients with atopic bronchial asthma as part of an investigation of the bronchodilatatory drugs and the pathogenesis of bronchospasm."3.65[The neurovegetative system in the pathogenesis of bronchial spasm]. ( Giammarruto, R; Mannino, F; Mariotta, S; Pasqua, F, 1977)
"Six asthmatic patients whose airway obstruction improved significantly during a trial of prednisone have been studied in detail."3.65Patterns of response to isoprenaline in asthmatic patients. ( Clarke, SW; Hodson, ME; Paterson, JW; Shenfield, GM, 1975)
" Pharmacokinetic-pharmacodynamic (PKPD) models to guide paediatric dosing are lacking."3.30Optimising intravenous salbutamol in children: a phase 2 study. ( Anderson, BJ; Kloprogge, F; Pan, S; Ramnarayan, P; Sheng, Y; Standing, JF; Walsh, S, 2023)
"This study aimed to investigate the dose-response and pharmacology of a range of single doses of nebulised ensifentrine (RPL554), an inhaled dual phosphodiesterase (PDE) 3/4 inhibitor in patients with asthma."2.90Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. ( Abbott-Banner, K; Bjermer, L; Newman, K, 2019)
"A total of 180 patients with pediatric bronchial asthma were randomized into the oxygen-driven aerosol group (Group A, n=90) and the air compressor-driven aerosol group (Group B, n=90)."2.87Analysis of the advantages and disadvantages in application of oxygen-driven aerosol and aerosol inhalation by air compressor for the pediatric asthma. ( Wang, J; Wang, X, 2018)
"Salbutamol sulphate (SS) is a model short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm having poor bioavailability (50%) due to its extensive first-pass effect."2.84Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ( Kharshoom, RM; Sallam, NM; Sanad, RA; Zeneldin, MA, 2017)
" Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions."2.82Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. ( Biollaz, J; Buclin, T; Courlet, P; Guidi, M; Mazzoni, I; Rabin, O, 2022)
"Albuterol mDPI was comparable to ProAir HFA at 90 and 180 µg."2.82Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. ( Iverson, H; Kerwin, EM; Lepore, MS; Miller, DS; Shah, T; Taveras, H; Wayne, D, 2016)
"The albuterol MDPI was generally well tolerated."2.82Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. ( Given, J; Iverson, H; Taveras, H, 2016)
"To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children."2.82Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. ( Ahmed Khan, KM; Bai, C; Gowa, MA; Memon, BN; Parkash, A, 2016)
" Adverse events were comparable across groups."2.82Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. ( Bleecker, ER; Busse, WW; Donohue, JF; Garfinkel, S; Ghafouri, M; Manuel, RC; Schlenker-Herceg, R; Wise, R; Zubek, VB, 2016)
"After discontinuation of the treatment, cough scores increased, pulmonary function and eosinophilic airway inflammation were aggravated and returned to the baseline levels."2.80Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. ( Kawagoe, M; Kirishi, S; Kondo, M; Kubota, N; Tagaya, E; Tamaoki, J, 2015)
"Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment."2.80Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. ( Beasley, R; Bowles, D; Charles, T; Fingleton, J; Shirtcliffe, P; Strik, R; Travers, J; Weatherall, M; Williams, M, 2015)
" For the combined asthma and COPD subjects, the plasma AUC and Cmax for FP and salmeterol were higher for Rotahaler:Rotahaler/Diskus geometric mean ratios (90% confidence intervals) for FP AUC0-τ of 1."2.79Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. ( Chan, RH; Daley-Yates, PT; Despa, SX; Louey, MD; Mehta, R, 2014)
"Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS)."2.79Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. ( Bateman, ED; Bleecker, ER; Busse, WW; Goldfrad, C; Jacques, L; Lötvall, J; O'Byrne, PM; Toler, WT; Woodcock, A, 2014)
" The profile of treatment-emergent adverse events judged as related to abediterol was consistent with that seen after adrenergic stimulation and occurred exclusively in patients who received abediterol 10 μg or 25 μg."2.79Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma. ( Beier, J; de Miquel, G; Fuhr, R; Jiménez, E; Massana, E; Ruiz, S; Seoane, B, 2014)
"Patients with asthma or chronic obstructive pulmonary disease (COPD) (n = 1016)."2.78Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD. ( Gálffy, G; Mezei, G; Müller, V; Németh, G; Orosz, M; Selroos, O; Tamási, L, 2013)
"We found no significant difference in pharmacokinetic profile of inhaled and oral salbutamol between elite athletes with asthma and nonasthmatic subjects."2.77The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ( Backer, V; Dalhoff, K; Elers, J; Hemmersbach, P; Henninge, J; Pedersen, L, 2012)
" Other endpoints included adverse events and pulmonary function."2.76A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. ( Curry, L; Goodwin, E; Hanrahan, JP; Hinkle, J; Hinson, J; Kerwin, E; Sciarappa, K, 2011)
"Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12."2.76Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. ( Bodzenta-Lukaszyk, A; Dymek, A; Mansikka, H; McAulay, K, 2011)
" Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A."2.76Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. ( Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)
"We hypothesised that airway remodelling contributes to airway hyper-responsiveness in asthma, independent of steroid-responsive airway inflammation."2.76The effect of airway remodelling on airway hyper-responsiveness in asthma. ( Berend, N; Brown, NJ; Farah, CS; Hardaker, KM; Kermode, JA; King, GG; Salome, CM, 2011)
"To compare the clinical diagnosis of chronic obstructive pulmonary disease (COPD) with results of post-bronchodilator spirometry in general practice, and examine practitioner, practice and patient characteristics associated with agreement between clinical and spirometric diagnoses."2.76Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. ( Comino, EJ; Hasan, I; Hermiz, O; Marks, GB; Middleton, S; Vagholkar, S; Wilson, SF; Zwar, NA, 2011)
"For chronic persistent bronchial asthma, heat-sensitive moxibustion can improve the clinical symptoms and the pulmonary ventilation function, and it is better than Seretide inhalant."2.75[Comparative observation on therapeutic effect of chronic persistent bronchial asthma treated with heat-sensitive moxibustion and medication]. ( Liang, C; Yang, K; Zhang, TF, 2010)
" During the 40-day period, subjects performed resistance exercise (REX) with their unloaded leg on an inertial resistance ergometer and, as part of a double-blind design, consumed the maximal oral therapeutic dosage of albuterol (i."2.73Temporal strength changes from resistance exercise and albuterol on unloaded muscle. ( Caruso, JF; Cook, TD; Hamill, JL; Mercado, DR; Saito, K; Yamauchi, M, 2008)
" The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population."2.73Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. ( Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008)
"We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium."2.73A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. ( Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007)
"For similar systemic exposure, dosing should be adjusted to age or size but not on a fixed microg kg(-1) basis, which may lead to unnecessary suboptimal dosing."2.73Age dependent systemic exposure to inhaled salbutamol. ( Bisgaard, H; Bønnelykke, K; Jespersen, JJ, 2007)
"The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler, Innovata Biomed)."2.73Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. ( Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007)
" The aims of this study were to evaluate the long-term efficacy (including symptom-free days and exacerbations) and impact on HRQoL of a stable-dose regimen of salmeterol/fluticasone propionate (SAL/FP) and an adjustable maintenance dosing (AMD) regimen of formoterol/budesonide (FOR/BUD) where treatment is adjusted based on symptoms [SAM40056]."2.73Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. ( Price, DB; Williams, AE; Yoxall, S, 2007)
" At the baseline visit 2-6 days later, the provocative concentration of methacholine to induce a 30% decrease in forced expiratory volume in 1 second (FEV(1) PC(30)) was determined, followed by a nebulized racemic albuterol dose-response study with three doses of albuterol, to familiarize patients with the procedures."2.73Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ( Esparham, A; Harkins, M; Kelly, HW; Raissy, HH, 2007)
" For patients in group A, a fixed dosage was maintained for 18 months, while those in group B received tailored dosage or withdrawal of therapy according to the clinical control level (well or total control)."2.73[A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients]. ( Liu, CT; Pang, YM; Tan, CW; Wang, G; Wang, YM, 2007)
"The aim of these experiments was to investigate the use of artificial neural networks (ANNs) for generating models able to predict the relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs)."2.73Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks. ( Chrystyn, H; de Matas, M; Richardson, CH; Shao, Q, 2008)
"This study evaluated pharmacokinetic and glucodynamic responses to AIR inhaled insulin relative to subcutaneous insulin lispro, safety, pulmonary function, and effects of salbutamol coadministration."2.73AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ( Berclaz, PY; de la Peña, A; Gates, JR; Muchmore, DB; Tibaldi, FS; Wolzt, M, 2008)
" The two FSC treatments were similar except that QD dosing did not maintain improvements in lung function for 24h compared with twice daily dosing."2.73Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. ( Dorinsky, PM; Kerwin, EM; Meltzer, EO; Nathan, RA; Ortega, HG; Schoaf, L; Yancey, SW, 2008)
" Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)."2.72Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. ( Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)
" FEV(1) 90 min after dosing (primary variable) increased compared with pre-dose FEV(1) by an average of 30% and 32% for budesonide/formoterol and salbutamol, respectively (P = 0."2.72Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. ( Balanag, VM; Jorup, C; Yang, PC; Yunus, F, 2006)
" The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort Turbuhaler compared with the Seretide Diskus."2.72Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. ( Assi, KH; Chrystyn, H; Pearson, SB; Tarsin, WY, 2006)
"Bronchial asthma is defined as "a chronic inflammatory disease of the airways involving many cells" and inhaled corticosteroids have therefore become the fundamental drugs for the long-term management of the disease."2.72The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma. ( Dal Negro, RW; Guerriero, M; Micheletto, C; Tognella, S; Trevisan, F, 2006)
"The effect of treatment on FEV1 and breathlessness (using the Borg scale) was measured at 1, 3, 5, 10, 15, 20, 25 and 30 minutes after test treatment."2.72Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. ( Aalbers, R; Bantje, TA; Jonkers, RE, 2006)
"Non-cortisone-treated asthmatic patients displayed higher levels of both R- and S-salbutamol in plasma than did healthy volunteers after one single ingestion of racemic salbutamol (CMAX both comparisons P<0."2.71Metabolism of salbutamol differs between asthmatic patients and healthy volunteers. ( Ahlner, J; Andersson, RG; Josefsson, M; Naidu Sjöswärd, K; Schmekel, B, 2003)
" Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250."2.71Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. ( Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003)
"Chronic obstructive pulmonary disease (COPD) is characterised by limited bronchial reversibility and chronic neutrophilic inflammation."2.71Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation. ( Lötvall, J; Malakauskas, K; Sakalauskas, R; Sitkauskiene, B, 2003)
"However, in the severe COPD group, 7-19% of the patients were not able to generate the optimum flows through the DPIs."2.71Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. ( Broeders, ME; Folgering, HT; Hop, WC; Molema, J, 2003)
"The cumulative dose-response study compared the biological effects (pulmonary function, respiratory muscle function, systemic effects) of an equal dose of salbutamol delivered via four different devices in 23 patients with asthma and 21 patients with moderate or severe chronic obstructive pulmonary disease (COPD)."2.71Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients? ( Broeders, ME; Folgering, HT; Hop, WC; Molema, J; Vermue, NA, 2003)
" This randomized, placebo-controlled, multicenter, crossover study investigated the efficacy, dose-response and safety of HFA-albuterol delivered via a breath-actuated Autohaler inhalation device in comparison with the same medication delivered using a conventional P&B device."2.71Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. ( Cohen, RM; Gross, G; Guy, H, 2003)
"Patients with bronchial asthma were chosen on clinical grounds."2.71Effect of inhalation of salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in some patients with chronic stable bronchial asthma. ( Guleria, R; Gupta, K; Padhy, AK; Pande, JN; Singh, TR; Sinha, S, 2003)
" Primary safety variables were asthma-related and nonasthma-related serious adverse events (SAE)s and adverse events (AE)s resulting in discontinuation (DAE)s."2.71Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. ( Aubier, M; Bengtsson, T; Campbell, M; Huang, S; Lindh, A; Pauwels, RA; Petermann, W; Schwabe, G; Sears, MR; Villasante, C, 2003)
" Forced expiratory volume in 1 s (FEV1), pulse, blood pressure, electrocardiogram, adverse events and urine formoterol were assessed."2.71Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. ( Honomichlová, H; Kopriva, F; Matulka, M; Pohunek, P; Rybnícek, O; Svobodová, T, 2004)
" Our aim was to establish whether adverse effects of SABAs are greater at higher than normal doses and after withdrawing inhaled corticosteroid (ICS) therapy."2.71Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. ( Cowan, JO; Flannery, EM; Herbison, GP; Smith, AD; Taylor, DR; Wraight, JM, 2004)
"The earlier described faster onset-of-action of formoterol as compared to a equipotent dosage of salmeterol was confirmed in this study."2.71Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. ( Creemers, JP; Greefhorst, AP; Hoff, WJ; Schermer, TR; Sips, AP; van Herwaarden, CL; Westbroek, J, 2004)
" The lack of differences in FEV(1) increases observed after 200 and 400 microg salbutamol may reflect attainment of the flat portion of the dose-response curve using either device."2.71Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. ( Fontana, GA; Geri, P; Lavorini, F; Luperini, M; Maluccio, NM; Mariani, L; Marmai, C; Pistolesi, M, 2004)
" This study compared the dose-response of salbutamol delivered by the Aerodose Inhaler (Aerogen Inc."2.71Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. ( Cockburn, W; Fishman, R; Lipworth, BJ; Sims, EJ; Taylor, K, 2005)
" No patients discontinued due to treatment-related adverse events."2.71Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. ( Ayre, G; Dobson, C; Horowitz, A; Kruse, M; Rosenkranz, B, 2005)
"This was a randomised, double-blind, placebo-controlled, cross-over study comparing the systemic pharmacodynamic effects (heart rate and serum potassium) and pharmacokinetics of salmeterol delivered by the non-CFC hydrofluoralkane (HFA) propellant 134a and the CFC propellant (propellant 11/12) metered dose inhalers (MDI) in healthy subjects."2.71Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. ( Daley-Yates, P; De Silva, M; Handel, M; Kempsford, R; Mehta, R, 2005)
"A patient-driven, adjustable maintenance dosing (AMD) approach to asthma therapy, in which the dose is adjusted by patients according to the severity of their symptoms, has recently been compared with fixed-dose therapy in open-label studies."2.71The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast ( Boulet, LP; FitzGerald, JM; Follows, RM, 2005)
"Optimum treatment of bronchial asthma requires accurate diagnosis and severity classification."2.71Evaluation of severity of bronchial asthma through an exercise bronchial challenge. ( Cruz, HM; Lazo-Velásquez, JC; Lozada, AR, 2005)
" A bivariate dose-response model based on these principles was fitted simultaneously to all data."2.70Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, R; Poczi, M; Rosenborg, J; Rott, Z, 2002)
" A bivariate dose-response model based on these principles was fitted simultaneously to all data."2.70Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, P; Poczi, M; Rosenborg, J; Rott, Z, 2002)
" Cumulative dose-response curves (200, 400, 800 and 1600 microg) were constructed."2.70Metal versus plastic spacers: an in vitro and in vivo comparison. ( Ekkelenkamp, MB; Janssen, R; Lammers, JW; Weda, M; Zanen, P, 2002)
" Blood samples were taken for plasma salbutamol at 5, 10, 15 and 20 min after inhalation to measure lung bioavailability as a surrogate for relative lung dose."2.70Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. ( Anhøj, J; Bisgaard, H; Lee, DK; Lipworth, BJ, 2002)
"Airway inflammation was assessed 24 h after the AC by bronchoalveolar lavage (BAL) (n = 16) and bronchial biopsies (n = 13)."2.70Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. ( Boulet, LP; Boutet, M; Chakir, J; Laviolette, M; Milot, J, 2001)
" Dose-response curves for change in FEV1 with salbutamol were compared using analysis of covariance to take account of methacholine-induced changes in spirometry."2.70Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. ( Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; Jones, SL; Taylor, DR, 2001)
" This study investigated the influence of the chronic use of short-acting and long-acting beta(2)-agonists, compared with the additional use of inhaled corticosteroids on the perception of histamine-induced bronchoconstriction."2.70Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma. ( Bijl-Hofland, ID; Cloosterman, SG; Folgering, HT; van den Elshout, FJ; van Schayck, CP; van Weel, C, 2001)
"In both asthmatic and COPD patients, the overall effect of salmeterol and zafirlukast on the forced expiratory volume in 1 s (FEV1) was considered extremely significant (p < 0."2.70Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. ( Allegra, L; Boveri, B; Cazzola, M; Centanni, S; Di Marco, F; Matera, MG; Santus, P, 2001)
" The difference in percent change in FEV1 between the Taifun and the other devices was statistically significant at the two first dose levels, but diminished towards the higher doses when the plateau of the dose-response curve was reached."2.70The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices. ( Aalto, E; Hakonen, T; Jouhikainen, T; Liipp, K; Lukkari-Lax, E; Nieminen, MM; Seppälä, OR, 2001)
" This study showed that chronic use of short- or long-acting beta2-agonists in asthmatics for a period of 12 weeks, did not significantly change the perception of histamine-induced bronchoconstriction compared with placebo."2.70Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma. ( Bijl-Hofland, ID; Cloosterman, SG; Folgering, HT; van der Elshout, FJ; van Schayck, CP; Van Weel, C, 2002)
"Fifteen patients of bronchial asthma were included in the study."2.70Comparative evaluation of market spacer and home made spacer in the management of bronchial asthma. ( Gaur, SN; Vatsa, HK, 2002)
" Vital signs were recorded over 6 h after dosing with study drug at weeks 0, 4, 8, and 12."2.69Proventil HFA and ventolin have similar safety profiles during regular use. ( Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)
"At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug."2.69Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. ( Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)
" Lymphocyte beta2-adrenoceptor parameters and a dose-response curve to inhaled albuterol (200 to 1600 microg) were evaluated at 36 hours after the last dose of each treatment period."2.69Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. ( Aziz, I; Hall, IP; Lipworth, BJ; McFarlane, LC, 1998)
" Peak inspiratory flow (PIF) through Turbuhaler was measured on each dosing occasion."2.69Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. ( Boe, J; Löfdahl, CG; Maranetra, N; Nana, A; Selroos, O; Ståhl, E; Youngchaiyud, P, 1998)
" No adverse events of clinical relevance were reported."2.69Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. ( Bondesson, E; Friberg, K; Löfdahl, CG; Soliman, S, 1998)
"Albuterol was administered at the maximum recommended dosages of two puffs for MDI."2.69Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer, and Rotahaler device--a comparison of efficacy and safety. ( Beck, G; Curtis-McCarthy, P; Eng, P; Golish, J; Kavuru, M; McCarthy, K; Wagner, W, 1998)
"Histamine challenges were carried out by tidal breathing method at entry, and at Days 4, 8, 22, 36, and 40."2.69Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. ( Cheung, D; de GOEIJ, JA; de GRAAFF, CS; Steen, H; Sterk, PJ; Wever, AM, 1998)
"Although beta2-adrenoceptor agonists are widely used in the treatment of asthma, a number of studies have suggested that their long-term use may exacerbate the condition."2.69Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo. ( Beasely, R; Church, M; Corne, JM; Howarth, PH; Lau, LC; Linaker, CH; Merrett, T, 1998)
" Pulmonary function and safety measures were assessed after each dosing interval."2.69Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998)
"Hypokalemia is a common side effect in adult asthmatic patients on beta 2 adrenergic therapy."2.69Hypokalemia and salbutamol therapy in asthma. ( Chu, DM; Hung, CH; Wang, CL; Yang, KD, 1999)
" Safety was assessed by measuring changes in pulse rate, blood pressure, and electrocardiogram (ECG) intervals after dosing with study drug, monitoring adverse events, and performing prestudy and poststudy laboratory testing and physical examinations."2.69Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. ( Bronsky, E; Colice, GL; Ekholm, BP; Klinger, NM, 1999)
"As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment."2.69Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. ( Demirsoy, S; Olguntürk, R; Tunaoğlu, FS; Türktaş, I, 1999)
" On both assessment days for salmeterol, and during placebo administration periods, significant increases from predose FEV1 values were observed beginning with the lowest dose of albuterol and continuing throughout the dose-response assessment (p 2.69Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. ( Berkowitz, RB; Emmett, AH; Nelson, HS; Rickard, KA; Tinkelman, DA; Yancey, SW, 1999)
" Salmeterol, however, showed a flatter dose-response curve, and a significantly weaker maximal protective effect (2."2.69Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. ( Ibsen, T; Lötvall, J; Mellén, A; Palmqvist, M, 1999)
"Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9."2.69Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1999)
", a significant dose-response relationship was present (p = 0."2.69Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. ( Ahrens, RC; Clarke, WR; Dockhorn, RJ; Han, SH; Hendeles, L; Hill, MR; Lux, C; Vaughan, LM, 1999)
" Dose-response curves were compared using an analysis of covariance."2.69Tolerance to beta-agonists during acute bronchoconstriction. ( Aldridge, RE; Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; McLachlan, CR; Taylor, DR; Town, GI, 1999)
"Different mixed-effects models were compared to evaluate the population dose-response and relative potency of two albuterol inhalers."2.69Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. ( Hill, MR; Kimanani, EK; Lalonde, RL; Ouellet, D; Potvin, D; Vaughan, LM, 1999)
" The pharmacokinetic parameters were determined by noncompartmental analysis and model-fitting."2.69Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ( DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1999)
" Patients received treatments each for 2 weeks followed by a bolus (IV/inhaled) of corticosteroid or placebo: (1) placebo inhaler bid + bolus placebo; (2) formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo; (3) formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg; or (4) formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg."2.69Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. ( Aziz, I; Lipworth, BJ, 2000)
" Deviation from parallelism of the generic and Ventolin dose-response curves (p = 0."2.69Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. ( Ahrens, RC; Carrier, S; Frosolono, M; Han, SH; Lux, C; Milavetz, G; Stewart, BA, 2000)
" As opposed to data from an adult population, no plateau was reached in the dose-response curve using the above doses over time."2.69Is nebulized aerosol treatment necessary in the pediatric emergency department? ( Gilad, E; Houri, S; Mandelberg, A; Morag, B; Priel, IE; Tsehori, S, 2000)
"Levalbuterol was found to provide significant bronchodilatory activity and was well tolerated."2.69Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. ( Caron, J; Handley, DA; Noonan, M; Rollins, TE; Snider, ME; Tinkelman, D, 2000)
" Safety assessments included monitoring of adverse events and morning serum cortisol concentrations."2.69Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. ( Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000)
"Homozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting beta(2) agonist salbutamol."2.69Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. ( Drazen, JM; Hancox, RJ; Herbison, GP; Taylor, DR; Town, GI; Yandava, CN, 2000)
" Urine was also obtained from subjects who had received the maximum dosage of inhaled salbutamol advisable for competing athletes to provide protection from exercise-induced asthma and treatment of asthma (1600 microgram in 24 h, 800 microgram being in the last 4 h)."2.69Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. ( Bergés, R; de La Torre, X; Farré, M; Fitch, KD; Mas, M; Morton, AR; Segura, J; Ventura, R, 2000)
" A histamine challenge test was done 12 h after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 micrograms) were constructed 36 h after the last dose."2.68Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. ( Grove, A; Lipworth, BJ, 1995)
" Bronchodilator dose-response studies were performed by administering increasing doses of isuprel intravenously before and after treatment with salbutamol."2.68[Bronchial reactivity after regular inhalation of salbutamol]. ( Krasnowska, M; Małlolepszy, J; Passowicz-Muszyńska, E, 1995)
" Part 3, the effect of cessation of long-term administration of inhaled corticosteroid on FEV1 PD20 histamine and symptoms was investigated for 6 months in 28 steroid group children."2.68Long-term intervention in childhood asthma: the Dutch study results. Dutch Chronic Nonspecific Lung Disease Study Group. ( van Essen-Zandvliet, EE, 1995)
" Dosing intervals and the use of other medications were determined by the treating physician."2.68Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. ( Chou, KJ; Crain, EF; Cunningham, SJ, 1995)
" Dose-response curves were constructed using cumulative doses of 100 micrograms, 200 micrograms, 400 micrograms, 1000 micrograms, 2000 micrograms, and 4000 micrograms, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments."2.68Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. ( Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Newnham, DM; Winter, JH, 1995)
"We studied three doses of inhaled salbutamol, 200, 400, and 800 micrograms/day, to determine dose-response curves for these two adverse effects."2.68Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. ( Bhagat, R; Cockcroft, DW; Swystun, VA, 1996)
"Albuterol OR was added to their usual treatment."2.68Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. ( Ariaansz, M; Nauta, JJ; Postmus, PE; Raaijmakers, JA; Van Keimpema, AR, 1996)
"This study compares the safety and efficacy of HFA 134a salbutamol sulfate (Airomir in the 3M CFC-free system [3M Pharmaceuticals]) and CFC 11/12 salbutamol (Ventolin [Allen & Hanburys]) in a cumulative dose-response (1, 1, 2, 4, 8 inhalations at 30-min intervals) study in asthmatic patients."2.68Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. ( Cline, AC; Ekholm, BP; Kleerup, EC; Tashkin, DP, 1996)
" Hypothetically, twice daily dosing of salmeterol may result in continuous protection."2.68Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. ( Creyghton, FB; de Jongste, JC; Hop, WC; Kerrebijn, KF; van den Berg, M; van Rooij, RW; Verberne, AA, 1996)
" One hour after inhaling single doses of placebo, salmeterol 25 micrograms, or formoterol 12 micrograms, dose-response curves to repeated doses of inhaled fenoterol were constructed (cumulative doses of 100-3200 micrograms)."2.68Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. ( Grove, A; Lipworth, BJ, 1996)
"Theophylline may produce a paradoxical increase in awareness of asthma in some individuals."2.68Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. ( Higgs, CM; Laszlo, G, 1996)
" We wanted to assess whether the combination of a beta 2-bronchodilator with an anti-inflammatory treatment in the same metered-dose inhaler (MDI) with a regular dosing schedule might improve compliance."2.68Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. ( Braunstein, GL; Harper, AE; Trinquet, G, 1996)
" This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia."2.68Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. ( Abboud, RT; Bowie, DM; Chapman, KR; Hodder, RV; McCallum, AL; Mesic-Fuchs, H; Molfino, NA; Newhouse, MT; Paré, PD, 1996)
" Additionally, during dosing with TBH, fewer patients experienced adverse events than during dosing with RH or DH."2.68Relative efficacy of three different inhalers containing salbutamol in patients with asthma. ( Hamersma, WB; Mahadewsingh, JV; Schreurs, AJ, 1996)
"This was a 1-week study evaluating the safety and efficacy of two dosage regimens of salmeterol in children with asthma."2.68A one-week dose-ranging study of inhaled salmeterol in children with asthma. ( Bronsky, EA; Chervinsky, P; Howland, WC; Liddle, R; Nathan, RA; Pollard, SJ; Prenner, B; Stahl, E; Weinstein, S, 1997)
" The aim of this study was to determine the effects of regular treatment with the long-acting beta-agonist, salmeterol, on the methacholine dose-response curve (DRC) in mild-to-moderate asthmatics."2.68Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. ( O'Shaughnessy, AD; Sears, MR; Walker, CM; Wong, AG, 1997)
" The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions."2.68Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask. ( Bersten, AD; Parkes, SN, 1997)
" For secondary end points salmeterol treatment was associated with higher morning and evening peak expiratory flow and forced expiratory volume in one second; a reduction in symptoms, bronchodilator use and airway responsiveness to methacholine; and no effect on serum potassium concentration, 24 hour heart rate, or the final forced expiratory volume in one second achieved during a salbutamol dose-response study."2.68Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. ( Bennett, J; Clark, M; Cooper, S; Lewis, S; Oborne, J; Rushton, L; Tattersfield, AE; Thompson Coon, J; Wilding, P, 1997)
"Patients treated for severe bronchial asthma often suffer from attacks of bronchoconstriction despite appropriate anti-inflammatory treatment."2.68[Better control of asthma symptoms with salmeterol]. ( Barliński, J; Kurzawa, R, 1997)
"Albuterol treatment significantly increased the LAR compared to placebo treatment (p = 0."2.68Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. ( Cockroft, DW; Gauvreau, GM; Jordana, M; O'Byrne, PM; Watson, RM, 1997)
"01), but significant differences between salmeterol doses were no longer evident, despite an apparent dose-response effect."2.67A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. ( Bierman, CW; Bronsky, EA; Kemp, JP; Liddle, RF; Orgel, HA; Tinkelman, DG; van As, A, 1994)
" Cough, headache and itchy throat were adverse events possibly related to the use of Salmeterol."2.67Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi. ( Gikonyo, BM; Nganga, LW; Odhiambo, JA, 1994)
" 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day)."2.67[Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil]. ( Krasnowska, M; Liebhart, E; Małolepszy, J, 1994)
"As a result, it was concluded that in bronchial asthmatic patients, the bronchodilator effects of the combination of a beta-2 agonist with anticholinergic drugs was as effective and lasted as long as salbutamol."2.67Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients. ( Bulgur, D; Dikensoy, O; Ekinci, E; Filiz, A; Oz, M, 1994)
" We studied the effect of a mild increase in serum magnesium level on the bronchial dose-response curve to salbutamol in six patients with asthma (age 54 +/- 3."2.67Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma. ( Brussino, L; Bucca, C; Colagrande, P; Rolla, G, 1994)
" The PD20 (dose of histamine causing a 20% fall in FEV1) was measured before and 11, 35, and 59 h after cessation of treatment and a bronchodilator dose-response study before and 83 h after cessation of treatment."2.67Asthma control during and after cessation of regular beta 2-agonist treatment. ( Pavord, ID; Tattersfield, AE; Wahedna, I; Wisniewski, AF; Wong, CS, 1993)
" The lung function parameters after cumulative dosing of salbutamol were equal during each study day."2.67A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses. ( Haahtela, T; Korhonen, P; Laurikainen, K; Nyberg, A; Silvasti, M; Vidgren, M, 1994)
" A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])."2.67The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. ( Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994)
"The relative bronchodilator (delta FEV1, V25, V50) potency and side effect profile (delta tremor, heart rate, breathlessness, BP) of nebulized salbutamol and fenoterol were evaluated by means of a randomized, double-blind, crossover, cumulative (50 to 2,500 micrograms) dose-response study."2.67Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. ( Dolovich, MB; Kazim, F; Newhouse, MT, 1994)
" The slopes of the dose-response curves of FEV1 and plasma cAMP to intravenous S were unaffected by the two treatment courses."2.67Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients. ( Adami, S; Ferrari, M; Lo Cascio, V; Olivieri, M; Prior, M; Romito, D; Squassante, L; Testi, R, 1993)
"Tremor was objectively measured, as well as heart rate (HR), respiratory rate (RR), and blood pressure (BP)."2.67Efficacy and side effects of salbutamol in acute asthma in children: comparison of oral route and two different nebulizer systems. ( Naspitz, CK; Scalabrin, DM, 1993)
"Twelve patients with mild bronchial asthma participated in a double-blind, randomized, placebo-controlled clinical trial."2.67Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. ( Behr, N; Jörres, R; Magnussen, H; Nowak, D; Rabe, KF, 1993)
" The dose-response curves for change in PC20 indicated that the higher doses of the nebulizer solution delivered more drug to beta 2 receptors in the lung than the lower doses from the MDI."2.67Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. ( Blake, KV; Harman, E; Hendeles, L; Hoppe, M, 1992)
" Of 25 subjects whose control differed significantly between treatments with baseline vs increased corticosteroid, 22 (88 percent) favored the increased dosage (p < 0."2.67Increased inhaled bronchodilator vs increased inhaled corticosteroid in the control of moderate asthma. ( Flannery, EM; Herbison, GP; Lake, DC; Print, CG; Sears, MR; Taylor, DR, 1992)
" Thirty-two patients requested home nebulizer treatment for long-term use (nine salbutamol, five IB, 18 mixture)."2.67A long-term prospective assessment of home nebulizer treatment. ( Bernstein, A; Chetty, MC; Kay, EA; O'Driscoll, BR; Taylor, RJ; Weatherby, H, 1992)
"Finally, baseline airway obstruction correlated with the degree of bronchodilation achieved with MK-571 (r = -0."2.67Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. ( Bush, RK; Busse, WW; Gaddy, JN; Margolskee, DJ; Williams, VC, 1992)
"To study the dose-response relationship of salmeterol for protection against a naturally occurring stimulus, isocapnic hyperventilation tests of cold air were done in 16 asthmatic patients."2.67Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. ( Jörres, R; Lüthke, M; Magnussen, H; Nowak, D; Rabe, KF; Wiessmann, J, 1992)
" After each period, dose-response curves were measured on 4 study days with doubling doses of salbutamol, ipratropium, a combination of salbutamol and ipratropium, and placebo until a plateau in FEV1 was reached."2.67Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. ( Alting-Hebing, D; Breederveld, N; Koëter, GH; Postma, DS; van der Mark, TW; Wempe, JB, 1992)
"Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated."2.67Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992)
" Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found."2.67Inhaled formoterol during one year in asthma: a comparison with salbutamol. ( Arvidsson, P; Larsson, S; Löfdahl, CG; Melander, B; Svedmyr, N; Wåhlander, L, 1991)
"For most patients with mild to moderate bronchial asthma higher doses will not add much to the bronchodilating effect."2.67A study with cumulative doses of formoterol and salbutamol in children with asthma. ( Foucard, T; Lönnerholm, G, 1991)
"tremor) were more frequent after treatment with 100 micrograms b."2.67Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. ( Dahl, R; Earnshaw, JS; Palmer, JB, 1991)
"Pretreatment with albuterol, cromolyn, and a combination of albuterol and cromolyn 30 minutes before ETS exposure significantly diminished airway reactivity to ETS."2.67Asthmatic responses to passive cigarette smoke: persistence of reactivity and effect of medications. ( Lehrer, SB; Menon, PK; Rando, RJ; Salvaggio, JE; Stankus, RP, 1991)
" In 8 patients the single dose mean Cmax was 4."2.67Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. ( Lee, HS; Tan, WC, 1991)
"Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator."2.67Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991)
" To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the dose-response curves for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease."2.67The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. ( Bel, EH; Dijkman, JH; Sterk, PJ; Timmers, MC; Zwinderman, AH, 1991)
"Tulobuterol is a synthetic beta-adrenergic agonist which, when administered orally, is a potent, long-acting bronchodilator."2.67Can a new beta 2-agonist reduce the mortality of asthma? ( Aldons, PM, 1990)
" Dose-response curves to inhaled SB were obtained the day before and the day after each treatment period."2.67Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. ( Hedner, J; Svedmyr, N; Ullman, A, 1990)
" The study which is the first report in Africa to assess this novel formulation of salbutamol in a group of African patients, demonstrates that controlled release salbutamol 8 mg administered twice daily is safe and effective, offering benefits over current therapies in the treatment of asthma."2.67The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya. ( Aluoch, JA; Gathua, SN, 1990)
"treatment."2.67High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine. ( , 1990)
"Theophylline was titrated for patients to receive, unblinded, theophylline serum concentrations of 10 to 20 micrograms/ml."2.67Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. ( Bell, TD; LaForce, CF; MacCosbe, PE; Pierson, WE; Sykes, RS; Tinkelman, D, 1990)
" The drug dosage was controlled by limiting the inspired volumes of gas (single and cumulative) to the pretested inspiratory capacity."2.67Single breath versus panting technique in salbutamol delivery through a 750 mL spacing device. ( James, RW; Masters, IB, 1990)
"The purpose of the present study was to compare the efficacy and systemic effects of 4 mg and 8 mg doses of salbutamol controlled release (SCR) after single dosing and at steady state in patients with asthma."2.67Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. ( Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1990)
"In a randomized, double-blind, double-dummy, crossover study consisting of two 1-month periods with a 2-week 'run-in' we compared the effects of a combination of fenoterol with ipratropium bromide (Duovent, Boehringer Ingelheim) and salbutamol administered by standard metered dose inhalers in conventional dosage in young adults with nocturnal asthma."2.66Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. ( Shettar, SP; Wolstenholme, RJ, 1989)
" It is concluded that IPB alone is less effective than beta-adrenoceptor agonist, but its combination with SAS would be an effective and safe treatment in acute asthmatic attack."2.66[Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack]. ( Chen, L; Deng, K; Ye, YQ, 1989)
" At steady-state the geometric mean values for Cmax were 8."2.66Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ( Charter, MK; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1989)
" The purpose of the present study was to assess the pharmacokinetics, efficacy and adverse effects of standard salbutamol tablets given by this route to patients with asthma."2.66Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. ( Clark, GA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Moreland, TA; Struthers, AD, 1989)
" At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)."2.66Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. ( Lipworth, BJ; McDevitt, DG; Struthers, AD, 1989)
"Sixteen patients suffering from bronchial asthma, with or without chronic bronchitis, sufficiently severe to be treated with inhaled corticosteroids, were studied in a single-blind trial (blind observer) of beclomethasone dipropionate (BDP) given in three randomized dosage regimens: 500, 1000 and 2000 micrograms per day, each for 4 weeks."2.66Effects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma. ( Folgering, HT; Lammers, JW; Molema, J; van Herwaarden, CL, 1988)
" The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated."2.66Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy. ( Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986)
"Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7."2.66Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. ( Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985)
" Dose-response effects were clearly seen with salbutamol but not with ipratropium bromide."2.66Nebulized salbutamol and ipratropium bromide in asthmatic children. ( Evans, NA; Lenney, W, 1986)
"Pindolol was administered gradually by mouth (2."2.66Influence of pindolol on asthmatics and effect of bronchodilators. ( Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986)
"Histamine PD20 FEV1 was assessed 4 h after the administration of salbutamol 200 micrograms, a combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms, and placebo."2.66Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients. ( Cresci, F; Fontana, G; Mugnai, M; Panuccio, P, 1986)
"Nine patients with clinically stable bronchial asthma who had received no drug treatment in the preceding 48 hours were examined."2.66[Ultrasonic spray protection against bronchospasm. Comparison of fenoterol and a combination of salbutamol and ipratropium bromide]. ( Ardizzi, A; Galietti, F; Giorgis, GE; Gribaldo, E; Miravalle, C; Oliaro, A, 1987)
" In fifteen selected chronic asthmatics, individual cumulative dose-response curves to S and IB were performed on two separate days (linear regression of bronchodilator response (delta FEV1) between 20 and 80% of maximal response, versus log dose), and the dose of S equipotent to the IB dose giving the maximal bronchodilator effect (IBopt) was calculated by interpolation of each S curve."2.66Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma. ( de Lauture, D; Grandordy, BM; Marsac, J; Thomas, V, 1988)
"The albuterol group was also studied at 2 and 4 weeks, but they only used their inhaler as needed between study visits."2.66A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. ( Katz, RM; Lanier, R; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987)
" Airway responsiveness thus appears to be a useful tool for evaluating inhaled beta 2-agonists and designing beta 2-agonist dosing regimens."2.66Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. ( Ahrens, RC; Annis, L; Harris, JB; Milavetz, G; Ries, R, 1987)
"It is likely that arrhythmias may be precipitated in patients with hypoxaemia, acidosis or those with preexisting cardiovascular disease."2.66Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease. ( Burgess, CD; Crane, J; Graham, AN; Maling, TJ, 1987)
"Pretreatment with albuterol attenuated both the cough and the drop in FEV1."2.66Cough and wheezing from beclomethasone aerosol. ( Shim, C; Williams, MH, 1987)
"Tiaramide hydrochloride is a new non-steroidal anti-inflammatory agent previously shown to inhibit allergic responses both in vitro and in vivo."2.66A trial of tiaramide in asthma. ( Harvey, JE; Jones, P; Tanser, AR, 1985)
" No significant differences were observed between the three dosage groups."2.66Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe? ( Crompton, GK; Douglas, JG; Fergusson, RJ; Grant, IW; Prescott, RJ; Rafferty, P, 1985)
" Ipratropium bromide in adequate dosage appears to be effective in reducing morning dipping in asthma."2.65Ipratropium bromide in patients with nocturnal asthma. ( Cox, ID; Hughes, DT; McDonnell, KA, 1984)
" This provides a simple, rapid and reproducible way of obtaining linear dose-response curves by plotting times of exposures against absolute or percent increases in sRaw."2.65Drug effect on bronchial response to PGF2 alpha and water inhalation. ( Bianco, S; Damonte, C; Robuschi, M, 1983)
" Cumulative log dose-response curves were constructed."2.65Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism. ( Chung, KF; Snashall, PD, 1984)
"Twenty-five patients with chronic bronchial asthma completed the trial."2.65A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma. ( Beskow, R; Ericsson, CH; Grönneberg, R; Sjögren, I; Skedinger, M, 1984)
" The FEV1 dose-response curves were almost identical indicating bronchodilating equipotency between the two modes of administration."2.65The effect of powder aerosol compared to pressurized aerosol. ( Löfdahl, CG; Svedmyr, K; Svedmyr, N, 1982)
"Histamine challenge is a satisfactory method of assessing the proective effect of a drug in asthmatic children."2.65Protective effect of inhaled salbutamol powder in children assessed by histamine challenge. ( Martin, AJ; Pullan, CR, 1980)
" The highest dose used in the dose-response trials (=0."2.65Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol. ( Kjellman, B; Tollig, H; Wettrell, G, 1980)
" Increase of dosage did not lead to improved effectiveness."2.65[Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)]. ( Gonsior, E; Meier-Sydow, J; Schultze-Werninghaus, G, 1979)
" Salbutamol powder in a dose of 200 micrograms per capsule was able to control asthma as well as the aerosol, but some patients needed to increase the frequency of dosage when using the powder."2.65Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. ( Hartley, JP; Nogrady, SG; Seaton, A, 1979)
"Albuterol aerosol was an effective bronchodilator as reflected by indices of pulmonary function obtained from spirometry and flow volume curves; Compared with isoproterenol, there were minimal side effects even at the highest doses, and bronchodilation lasted significantly longer."2.64Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols. ( Garza Gomez, M; Spector, SL, 1977)
"Clenbuterol is a beta 2-sympathomimetic bronchodilator."2.64A trial of clenbuterol in bronchial asthma. ( Anderson, G; Wilkins, E, 1977)
"Salbutamol in a powder aerosol from the Rotahaler insufflator was compared, with equal doses of the conventional pressurized aerosol by dose-response curves and in a 1 month open trial, in the treatment of asthma patients with good inhalation technique."2.64Comparison of salbutamol Rotahaler with conventional pressurized aerosol. ( Clark, TJ; Hetzel, MR, 1977)
" Drug dosage was one 4-mg tablet, of two inhalations of 100 mug of salbutamol aerosol or a combination of both, four times daily."2.64The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes. ( Alanko, K; Lahdensuo, A, 1976)
"Rimiterol is an acceptable alternative to the short-acting isoprenaline but lacks the cardiovascular effects of isoprenaline and is an alternative to salbutamol where very prolonged action is unnecessary."2.64Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol. ( Bianco, S; Kamburoff, PL; Prime, FJ, 1975)
"1 In a double-blind placebo controlled dose-response experiment in six asthmatic patients with reversible airways obstruction the effect of i."2.64The effect of intramuscular salbutamol in asthmatics. ( Gaddie, J; Ingram, J; Palmer, KN; Skinner, C, 1975)
" There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection."2.58Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed. ( Calzetta, L; Farber, MO; Hostrup, M; Jacobson, GA; Page, CP; Raidal, S; Walters, EH; Wood-Baker, R, 2018)
"  OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS."2.58Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. ( Cates, CJ; Ferrer, M; Sayer, B; Schmidt, S; Waterson, S, 2018)
"The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction."2.53Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. ( Welch, MJ, 2016)
" Clinical trials record these safety outcomes as non-fatal and fatal serious adverse events (SAEs), respectively."2.50Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. ( Cates, CJ; Kew, KM; Oleszczuk, M; Wieland, LS, 2014)
" Although their usefulness in reversing acute bronchospasm remains undiminished, there is increasing evidence that chronic use may lead to development of tolerance and thus, potentially increasing morbidity and even mortality."2.49Tolerance & resistance to β₂-agonist bronchodilators. ( Koumbourlis, AC; Yim, RP, 2013)
"To assess the risk of mortality and non-fatal serious adverse events in trials which randomised patients with chronic asthma to regular salmeterol and inhaled corticosteroids in comparison to the same dose of inhaled corticosteroids."2.49Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. ( Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013)
"Pregnancy is also associated with a physiological suppression of the immune system."2.49Management of asthma during pregnancy. ( Adams, SG; Levine, SM; Maselli, DJ; Peters, JI, 2013)
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews."2.48Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2012)
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists."2.48Regular treatment with formoterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ, 2012)
" As a result, asthma exacerbation can be treated with pMDIs used through holding chambers in emergency room successfully when applied with dosing scheme appropriate for the patient's age, weight and severity of exacerbation (usually 1/4th of nebule dosing) on the contrary to ordinary method of nebulizers."2.48[Salbutamol in asthma treatment: with nebulizer or inhaler?]. ( Cavkaytar, O; Sekerel, BE, 2012)
"Adrenal insufficiency was diagnosed in a 7-year-old boy on 460 µg ICS for 16 months, with a diagnosis of chronic persistent asthma."2.48Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. ( Alpan, O; Ascher, DP; Neacsu, O; Schwartz, RH, 2012)
" We extracted the data relating to children from each review and from new trials found in the updated searches (including risks of bias, study characteristics, serious adverse event outcomes, and control arm event rates)."2.48Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. ( Cates, CJ; Oleszczuk, M; Stovold, E; Wieland, LS, 2012)
"Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory disorders that have an increasing prevalence and associated morbidity and mortality."2.47(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease. ( Patel, M; Thomson, NC, 2011)
" However, several studies have indicated an increased risk of asthma mortality and asthma-related serious adverse events and the FDA recently mandated restrictions to the use of LABAs in asthma."2.47Safe use of long-acting β-agonists: what have we learnt? ( Sears, MR, 2011)
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews."2.46Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2010)
"an increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews."2.46Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2010)
" Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of ICS."2.45Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. ( Castro-Rodriguez, JA; Marcos, LG; Moral, VP; Rodrigo, GJ, 2009)
"For the acute COPD studies, one was double-blind and randomised, one was single-blind and randomised, and one was open-label."2.45Use of dry powder inhalers in acute exacerbations of asthma and COPD. ( Borgström, L; Ingelf, J; Selroos, O, 2009)
" Using the same stratified data to calculate the sample size required to prove or disprove an association between the use of LABA with mandatory ICS therapy and adverse outcomes, assuming the RD is exactly 0."2.45Safety of long-acting beta-agonists: are new data really required? ( Sears, MR, 2009)
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol with inhaled corticosteroids versus the same dose of inhaled corticosteroids alone."2.45Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. ( Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009)
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews."2.45Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2009)
"For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment."2.45Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. ( Gordon, E; Lazarus, SC, 2009)
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol versus placebo or regular short-acting beta(2)-agonists."2.44Regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ, 2008)
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists."2.44Regular treatment with formoterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ; Lasserson, TJ, 2008)
" Whether this association represents adverse effects of beta -agonist use or is entirely due to disease severity is a matter of ongoing debate."2.44Safety of long-acting beta2-agonists in the treatment of asthma. ( Cazzola, M; Matera, MG, 2007)
"The costs of asthma and chronic obstructive pulmonary disease (COPD), the two most common chronic respiratory illnesses, are substantial and rising."2.44Seretide: a pharmacoeconomic analysis. ( Chapman, KR; Fritscher, L, 2008)
" There has been concern that chronic use of racemic salbutamol may lead to loss of effectiveness and clinical deterioration."2.44Evidence based review on levosalbutamol. ( Gupta, MK; Singh, M, 2007)
" Traditional press-and-breathe Metered Dose Inhalers (pMDIs) have recently improved their ecological appeal, can be used in every clinical and environmental situation, their dosing is convenient and highly reproducible, but their efficient delivery remains highly technique dependent."2.44Inhalatory therapy training: a priority challenge for the physician. ( Melani, AS, 2007)
"Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality."2.43Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. ( Cazzola, M; Donner, CF; Matera, MG, 2005)
"Levalbuterol was evaluated in several recent trials for treatment of asthma in the emergency department, for its effect in improving pulmonary function and on hospitalization rate."2.43Review of guidelines and the literature in the treatment of acute bronchospasm in asthma. ( Blake, K, 2006)
" There is much to suggest that the adverse outcomes associated with LABA monotherapy have been due to "masking of inflammation" rather than a toxic effect of the drugs."2.43Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe. ( Nelson, HS, 2006)
"Airway inflammation is a key factor in the mechanisms of asthma."2.42Mechanisms of asthma. ( Busse, WW; Rosenwasser, LJ, 2003)
"To determine the magnitude of residual bronchoprotection after chronic dosing with long-acting beta(2)-agonists."2.42Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. ( Currie, GP; Jackson, CM; Lipworth, BJ; Ogston, SA, 2003)
"Despite concerns in the 1970s and 1980s about the safety of short-acting beta2-agonists, it is now generally accepted that these agents, used at appropriate doses, provide safe and effective treatment for asthma symptoms."2.42State of the art in beta2-agonist therapy: a safety review of long-acting agents. ( Rabe, KF, 2003)
"Chronic-obstructive pulmonary disease (COPD) is a global public health problem and its impact is increasing."2.42Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. ( Bailey, WC; Dransfield, MT, 2004)
"For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath."2.42Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease. ( Dalonzo, GE, 2004)
"Albuterol is a selective beta2-agonist that is widely used in the prevention and treatment of reactive airway disease."2.42The cost effectiveness of levalbuterol versus racemic albuterol. ( Quinn, C, 2004)
" Fixed dosing with budesonide/formoterol or salmeterol/fluticasone provides effective asthma control in line with guideline goals."2.42Combination therapy in asthma--fixed or variable dosing in different patients? ( Lötvall, J, 2004)
"Indeed, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy emphasises the role of bronchodilators in symptomatic management of all stages of COPD."2.41Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. ( Barnes, PJ; Hansel, TT, 2002)
" Long-term use of long-acting beta(2)-agonists can induce tolerance, which can be partially reversed with corticosteroids."2.41Long-acting beta2-agonists: comparative pharmacology and clinical outcomes. ( Aalbers, R; van der Woude, HJ, 2002)
"The goal of management of patients with respiratory failure is to restore them to a state of quiet breathing, without complication."2.41Management of respiratory failure in patients with asthma. ( Corbridge, T; Gluckman, TJ, 2000)
"Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-albuterol, which appears to be inactive in humans."2.41Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? ( Asmus, MJ; Hendeles, L, 2000)
" This dosage is also as effective when added to low-dosage inhaled corticosteroid therapy as doubling of corticosteroid dosages."2.41Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. ( Dunn, CJ; Goa, KL, 2001)
"R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties."2.41Levalbuterol hydrochloride. ( Colin, AA; Slattery, D; Wong, SW, 2002)
" Two recently completed trials have demonstrated that with respect to asthma control the combination of inhaled steroid (400 - 800 microg/d) plus theophylline is at least as effective as doubling the dose of inhaled steroid in patients who remain symptomatic on a dosage of 400 - 800 microg daily."2.40[Asthma therapy: combination of topical glucocorticosteroids and theophylline]. ( Ukena, D, 1997)
"These drugs are particularly useful in bronchial asthma and meet the requirements of several treatment guidelines to combine long-acting bronchodilator therapy with inhaled corticosteroids in patients with persistent asthma."2.40[Long-acting beta(2)-adrenoceptor agonists for asthma and COPD]. ( Magnussen, H; Rabe, KF; Ukena, D, 1997)
"Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid."2.40Salmeterol/fluticasone propionate combination. ( Jarvis, B; Spencer, CM, 1999)
"(S)-albuterol does not activate beta(2 )-adrenoceptors and does not modify activation of beta(2 )-adrenoceptors by (R)-albuterol so that for many years it was presumed to be biologically inert."2.40Contrasting properties of albuterol stereoisomers. ( Morley, J; Page, CP, 1999)
" We sought to determine how many children required escalation of care once placed on every 4-h dosing of albuterol."1.91Inpatient albuterol spacing as an indicator of discharge readiness. ( Aoyama, B; Lee, B; Shen, BH, 2023)
"Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods."1.91Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era. ( Alsuwaigh, R; Binte Mohd Noor, N; Cao, Y; Chen, H; Li, XL; Liew, J; Mohamed Noor, SB; Puan, Y; Tay, TR; Ye, H; Yii, A, 2023)
"Bronchial asthma is one of the much known long-term respiratory conditions."1.91Use of Drugs Considering Route of Administration on Drug Prescription Pattern for Bronchial Asthma in a Tertiary Level Hospital. ( Akter, S; Khatun, S; Nishi, MK; Shams, N; Tania, IJ, 2023)
" The primary safety outcome was a composite of serious adverse events (SAEs) and/or adverse events leading to discontinuation (DAEs); the primary effectiveness outcome was time-to-first exacerbation."1.91Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy. ( Anderson, GP; Brusselle, G; Gustafson, P; Jorup, C; Lamarca, R; Reddel, HK, 2023)
"Amitriptyline is a drug of high potential, which inhibits acute bronchoconstriction and induces bronchodilatation in pre-contracted airways."1.91Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways. ( Böll, S; Braunschweig, T; Hempel, P; Klein, V; Martin, C; Michely, A; Rieg, AD; Spillner, J; Tenbrock, K; Verjans, E; von Stillfried, S; Wagner, N, 2023)
"Although studies on epileptic seizures occurring during acute asthma attacks are limited, there is widespread belief among families and physicians that salbutamol causes seizures."1.72Is Seizure an Adverse Effect of Salbutamol in the Pediatric Population? ( Özünal, ZG; Uysalol, M; Yıldız, R, 2022)
"Asthma airway remodeling is closely related to the abnormal migration of human airway smooth muscle cells (ASMCs), and vascular endothelial growth factor (VEGF) is involved in the pathophysiological process of asthma."1.72Effects of Different Intervention Factors on Vascular Endothelial Growth Factor-Induced Human Airway Smooth Muscle Cell Migration. ( Gao, Y; Li, J; Liao, G; Lv, C; Wu, L, 2022)
"Obesity was defined as BMI ≥95%."1.72Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations. ( Arca, M; Delgado, Y; Isbell, T; Parlar-Chun, R; Truong, G, 2022)
"The aim of this study was to investigate and discuss the salbutamol combined with budesonide in treatment of pediatric bronchial asthma (BA) and its effect on eosinophils (EOS)."1.62Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils. ( Fan, C; Huang, X; Li, S; Mei, Q; Qian, D; Quan, J, 2021)
"Lactic acidosis is a common complication of status asthmaticus in adults."1.62Prevalence and risk factors of lactic acidosis in children with acute moderate and severe asthma, a prospective observational study. ( Di Paolo, ER; Gehri, M; Pauchard, JY; Rochat Guignard, I; Ruman-Colombier, M, 2021)
"Our aim was to survey treatment practices used for preschool children with wheezing in emergency rooms (ER) focussing on inhalation device choice and handling, face mask use, salbutamol dosing and written instructions."1.62Heterogeneity of emergency treatment practices in wheezing preschool children. ( Csonka, P; Lehtimäki, L; Mäkelä, MJ; Tapiainen, T, 2021)
"Albuterol was prescribed for 19 (86%) of the patients with two patients who had both albuterol and QVAR® prescribed."1.56Prevalence of asthma at a school-based health clinic in Nicaragua. ( Banasiak, NC; Meadows-Oliver, M, 2020)
" This study evaluated the relative lung and systemic bioavailability and oropharyngeal deposition of salbutamol post-inhalation from Ventolin® Evohaler® (GlaxoSmithKline) either alone following verbal inhaler technique counselling (VC) or connected to a newly improved Able Spacer® (AS)."1.56Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ( Ammari, WG; Oriquat, GA; Sanders, M, 2020)
"The risk of dental caries was evaluated with the dietary record, oral hygiene index and number of carious lesions."1.51]Risk of dental caries in pediatric asthmatic patients undergoing treatment with salbutamol and budesonide inhalation therapy, Peru.] ( Bustos de la Cruz, J; Carhuamaca-Salvador, M; Chávez-Rimache, L; Chumpitaz-Cerrate, V, 2019)
" Conventional dosage schemes used in public health to cure various diseases generally lead to undesirable side effects and renders the overall treatment ineffective."1.51An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles. ( Al-Dhubiab, BE; Attimarad, M; Handral, M; Haroun, M; Hiremath, JG; Nair, AB; Ramnarayanan, C; Roopashree, TS; Shinu, P; SreeHarsha, N; Tratrat, C; Venugopala, KN, 2019)
"The motive behind present work was to discover a solution for overcoming the problems allied with a deprived oral bioavailability of salbutamol sulfate (SS) due to its first pass hepatic metabolism, shorter half-life, and systemic toxicity at high doses."1.51Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. ( Hajare, A; Honmane, S; More, H; Osmani, RAM; Salunkhe, S, 2019)
" The assay was successfully applied to the quantification of blood salbutamol concentrations in three healthy volunteers dosed with 1 mg salbutamol by inhalation."1.48Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma. ( Cordell, RL; Hawcutt, DB; Monks, PS; Pandya, HC; Semple, MG; Valkenburg, TSE, 2018)
"Dyspnea has been reported to be a main contributor to exercise avoidance in asthma."1.48Exertional dyspnea and operating lung volumes in asthma. ( Bhutani, M; Brotto, AR; Moore, LE; Phillips, DB; Stickland, MK, 2018)
"Oxymetazoline or Salbutamol were prescribed according to best clinical practice guidelines."1.46Efficacy and usability of a novel nebulizer targeting both upper and lower airways. ( Hofmaier, S; Lau, S; Matricardi, PM; Perna, S; Pizzulli, A; Posa, D; Wagner, P, 2017)
"Airway obstruction was more severe in COPD patients as compared with controls (mean FEV1 and FEV1% predicted both P<0."1.43Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data. ( Gálffy, G; Kováts, Z; Müller, V; Odler, B; Orosz, M; Selroos, O; Tamási, L, 2016)
" For salbutamol and formoterol, urine thresholds have been adopted to limit supratherapeutic dosing and to discriminate between inhaled (permitted) and oral (prohibited) use."1.43Beta2-Agonist Doping Control and Optical Isomer Challenges. ( Fawcett, JP; Jacobson, GA, 2016)
"The sensitivity of detecting airway obstruction in these children by FEV1 was 15."1.43Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma. ( Bar-Yoseph, R; Bentur, L; Hakim, F; Livnat, G; Ofek, M; Vilozni, D, 2016)
"Although lactic acidosis is a rare side effect to β ² agonist treatment, it is important to recog-nize it when present."1.43[Lactic acidosis in a 24-year-old woman with status asthmaticus]. ( Albertsen, S; Bergmann, TK; Madsen, PH; Ramazan-Yousif, L; Steen, NP, 2016)
" Twenty-five subjects with asthma were recruited and underwent SULT1A3 genotyping, from which four SNP homozygote (GG) subjects and nine wild-type (AA) subjects were selected to participated in the pharmacokinetic investigation."1.42SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ( Jacobson, GA; Walters, EH; Wood-Baker, R; Yee, KC, 2015)
"The effectiveness of inhaled salbutamol in routine care depends particularly on prescribed dosage and applied inhalation technique."1.42How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up. ( Bertsche, A; Bertsche, T; Frontini, R; Kaune, A; Kiess, W; Musiol, J; Neininger, MP; Prenzel, F; Rink, J, 2015)
"Obesity is associated with poor asthma control, increased asthma morbidity, and decreased response to inhaled corticosteroids."1.42Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. ( Avila, PC; Bibbins-Domingo, K; Borrell, LN; Brigino-Buenaventura, E; Burchard, EG; Castellanos, E; Davis, A; Eng, C; Farber, HJ; Kumar, R; LeNoir, MA; McGarry, ME; Meade, K; Oh, SS; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Sen, S; Serebrisky, D; Thakur, N; Thyne, SM, 2015)
" Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone."1.42HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma? ( Madlon-Kay, DJ; Townsend, L, 2015)
"Asthma and chronic obstructive pulmonary disease (COPD) are common lung diseases characterized by chronic airway inflammation and airway obstruction."1.42[Asthma-COPD overlap syndrome]. ( Bavbek, S; Çelik, G; Demir, T; Gemicioğlu, B; Günen, H; Kıyan, E; Mungan, D; Oğuzülgen, K; Polatlı, M; Saryal, S; Sayıner, A; Şen, E; Türktaş, H; Yıldırım, N; Yıldız, F; Yorgancıoğlu, A, 2015)
"We report the case of a severe acute pulmonary edema secondary to the administration of salbutamol to a patient admitted for severe asthma."1.42[Cardiogenic pulmonary edema following β2 agonist infusion for acute, severe asthma]. ( Abid, L; Bahloul, M; Bouaziz, M; Chaari, A; Chelly, H; Chtourou, K; Dammak, H; Kallel, H; Medhioub, F; Rekik, N, 2015)
"Hypokalemic periodic paralysis is the most common form of periodic paralysis and is characterized by attacks of muscle paralysis associated with a low serum potassium (K+) level due to an acute intracellular shifting."1.40Thyrotoxic periodic paralysis triggered by β2-adrenergic bronchodilators. ( Chiang, WF; Lin, SH; Wang, CC; Yeh, FC, 2014)
" Using SBS as the model drug in this study, we developed SBS-loaded liposomes for oral administration and explored the relationship between their bioavailability and anti-asthmatic efficacy."1.39Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration. ( Bian, Z; Chen, H; Chen, X; Huang, W; Lu, A; Wong, BC; Xu, M; Yang, Z; Zhang, G; Zhao, Z, 2013)
" Patients remaining on FP-SAL (n=1,146) were compared with those switched to efBDP-FOR at an equivalent or lower inhaled corticosteroid (ICS) dosage (n=382)."1.39Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. ( Brockman, J; Burden, A; Gruffydd-Jones, K; Harris, T; Haughney, J; King, C; Lavorini, F; Papi, A; Price, D; Ryan, D; Small, I, 2013)
"Although lactic acidosis is a rare complication to inhalation of beta-agonists, it is important for the clinicians to recognize this."1.39[Lactic acidosis in a patient with exercabation of asthma receiving inhalation therapy]. ( Ekelund, K; Følsgaard, S, 2013)
"The main objective of this study was to develop a novel aerosolized liposome formulation for pulmonary delivery of anti-asthmatic medication and to explore the relationship between the bioavailability and anti-asthmatic efficacy of such a formulation."1.38Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. ( Chen, X; Huang, W; Wong, BC; Wong, YF; Xu, M; Yang, Z; Yin, L, 2012)
" In conclusion, our results suggest that abediterol has a preclinical profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile."1.38Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. ( Aparici, M; Beleta, J; Carcasona, C; Cortijo, J; De Alba, J; Gavaldà, A; Gómez-Angelats, M; Gras, J; Miralpeix, M; Morcillo, E; Otal, R; Puig, C; Ramos, I; Ryder, H; Vilella, D; Viñals, M, 2012)
"Chronic obstructive pulmonary disease (COPD) management was investigated in two sub-studies of the BEACH (Bettering the Evaluation and Care of Health) program at 5711 general practitioner-patient encounters in February to March 2010 and April to May 2011."1.38Management of COPD in general practice. ( Harrison, C; Henderson, J; Miller, G, 2012)
"Treatment with rosiglitazone preserved salbutamol relaxant activity, mitigated carbachol hyperresponsiveness and partially restored β₂-adrenoceptor binding sites in tracheal tissues from homologously desensitized animals."1.37Rosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle. ( Adinolfi, B; Bardelli, C; Betti, L; Breschi, MC; Brunelleschi, S; Fabbrini, L; Fogli, S; Giannaccini, G; Lucacchini, A; Mariotti, V; Melissari, E; Pellegrini, S; Stefanelli, F, 2011)
"One of them, obesity, has been reported to exert a harmful influence on asthma control."1.37Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity. ( Arakawa, M; Gejyo, F; Hasegawa, T; Koya, T; Narita, I; Sakagami, T; Suzuki, E; Suzuki, K; Toyabe, S; Youkou, A, 2011)
" The films were designed to release the drug for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms of SS."1.36In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate. ( Deshpande, SB; Jain, A; Muthu, MS; Rawat, MK; Singh, S; Singh, SK; Soni, R, 2010)
"Wheezing is common in preschool children, but objective evidence for airway obstruction and its reversibility are rarely available in clinical practice."1.36Lung function in preschool children with a history of wheezing measured by forced oscillation and plethysmographic specific airway resistance. ( Gibson, AM; Harrison, J; Johnson, K; Ranganathan, S; Singh, G; Skoric, B, 2010)
"5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg."1.36Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks. ( Biddiscombe, MF; Chrystyn, H; de Matas, M; Meah, S; Shao, Q; Usmani, OS, 2010)
"COPD was likely the predominant diagnosis but patients with asthma may have been included."1.36Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. ( Deesomchok, A; Forkert, L; Jensen, D; Lam, YM; O'Donnell, DE; Ofir, D; Webb, KA, 2010)
"Wheezing was the most common mentioned symptoms in taking asthma into consideration."1.35A survey of pediatricians' knowledge on asthma management in children. ( Abdollahpour, H; Bemanian, MH; Gharagozlou, M; Moinfar, Z; Sedaghat, M, 2008)
"Subjects with bronchial asthmatic symptoms, forced expiratory volume in 1 second (FEV(1)) and FEV(1)/forced vital capacity [FVC] > 80% could show a positive reversibility test with salbutamol in about 25% of the cases."1.35When should a reversibility test be performed on patients with early stages of asthma and normal spirometry? ( Mariotta, S; Ricci, A; Sposato, B, 2008)
"We report a case of dilated cardiomyopathy that we believe is secondary to excessive use of inhaled beta agonists."1.35Can beta agonists cause dilated cardiomyopathy? ( Choudhary, AS; Robinson, GM, 2009)
"Prevalence of wheezing is increasing, bronchodilators are sub-optimally utilized and antibiotics are over-prescribed."1.35Are we adequately managing children with wheeze using the standard case management guidelines? ( Bunnag, T; Jatanachai, P; Lochindarat, S; Nisar, YB; Qazi, SA, 2008)
"In subjects with persistent asthma, the ADRB2 Arg16Gly polymorphism does not alter lung function responses to SAL or FSC over the 12 hour dosing interval following acute and chronic dosing."1.35Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. ( Anderson, WH; Edwards, LD; Klotsman, M; Ortega, HG; Yancey, SW, 2009)
" Adverse events, clinical laboratory test results, and vital signs were recorded throughout the 2 clinical studies."1.35Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona ( Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009)
"COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable."1.35An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma. ( Barry, M; Bennett, K; McGowan, B; O'Connor, M; Owens, M, 2009)
" Studies have shown that a large volume spacer attached to a metered dose inhaler provides similar bronchodilator effects to nebulized dosing during the management of patients following an acute exacerbation."1.35Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation. ( Chrystyn, H; Ismail, NE; Mazhar, SH; Newton, DA, 2008)
"Cough is one of the most common symptoms of asthma."1.35Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. ( Kontra, KM; Koskela, HO; Purokivi, MK; Taivainen, AH; Tukiainen, HO, 2008)
" Lactic acidosis improved within 24 h after discontinuation or decrease in the dosage of beta2-agonists."1.34Lactic acidosis in children with acute exacerbation of severe asthma. ( Koul, PB; Minarik, M; Totapally, BR, 2007)
" An increased frequency of dosing with these drugs seems preferable for cases of severe or uncontrolled asthma."1.34Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model. ( Hayasaka, N; Honma, K; Honma, S; Kudo, T; Kuwaki, T; Shibata, S; Yaita, T, 2007)
"Albuterol (180 microg) was given, by spacer, at 15 min intervals until the FEV1 increased < 5%."1.34Adrenergic responsiveness: FEV1 and symptom differences in Whites and African Americans with mild asthma. ( Brown, JK; Gold, WM; Hardie, GE, 2007)
"Thirty subjects with bronchial asthma and 10 normal controls inhaled up to three 600 microg nebulized doses of BAC using a jet nebulizer."1.34Benzalkonium chloride induced bronchoconstriction in patients with stable bronchial asthma. ( Kim, SH; Lee, BH, 2007)
"Both asthma and chronic obstructive pulmonary disease (COPD) are often underdiagnosed and undertreated among the elderly."1.33Treatment of acute bronchospasm in elderly patients. ( Berger, WE, 2005)
"Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after 1 dose of formoterol (28% reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and 2 weeks (58% reduction, 95% CI 38, 78%)."1.33Rapid onset of tolerance to beta-agonist bronchodilation. ( Hancox, RJ; Haney, S, 2005)
" Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared."1.33Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. ( Angus, R; Cheesbrough, A; Reagon, R, 2005)
" Seventy-two hours after the last OVA challenge, guinea pigs were anesthetized and tracheostomized, respiratory system resistance and elastance were measured and a dose-response curve to inhaled methacholine chloride was obtained."1.33Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs. ( Arantes-Costa, FM; Kasahara, DI; Lopes, FD; Martins, MA; Nunes, MP; Perini, A, 2005)
"Six patients with bronchial asthma and 12 patients with mild COPD."1.33Acute electrophysiologic effects of inhaled salbutamol in humans. ( Kallergis, EM; Kanoupakis, EM; Klapsinos, NK; Manios, EG; Mavrakis, HE; Schiza, SE; Vardas, PE, 2005)
"Based on time from onset of symptoms to death, cases fell into two distinct groups: short course <3 (1."1.33Time to death, airway wall inflammation and remodelling in fatal asthma. ( Abramson, MJ; Elliot, JG; James, AL; Walters, EH, 2005)
"The prevalence of bronchial asthma is 4-8% among pregnant women."1.33[The management of bronchial asthma during pregnancy--Hungarian experiences]. ( Bohács, A; Losonczy, G; Magyar, P; Pállinger, E; Rigó, J; Tamási, L, 2005)
" Effective maintenance therapywith the correct dosage ofinhalational corticosteroids administered correctly can probably stop the potentially fatal asthma type II from developing."1.33[Fatal asthma in childhod preventable by recognizing risk factors and presenting features]. ( Corel, LJ; de Hoog, M; Joosten, KF; Tiddens, HA; Verbruggen, SC, 2006)
"He also had subcutaneous emphysema on the left side of the chest anteriorly."1.33Spontaneous pneumopericardium, pneumomediastinum and subcutaneous emphysema: unusual complications of asthma in a 2-year-old boy. ( Ameh, V; Bradbury, A; Jenner, R; Jilani, N, 2006)
" According to the dose-response curve to methacholine, they were categorized as having either unlimited airway narrowing (UAN group) (n = 20) or response plateau (RP group) (n = 18)."1.33Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics. ( Malakauskas, K; Sakalauskas, R; Sitkauskiene, B; Stravinskaite, K, 2006)
" The strategy of adjustable maintenance dosing (AMD) involves adjustment of the maintenance dose, (using a single combination [budesonide/formoterol] inhaler, Symbicort((R))) in response to variability of asthma control over time."1.33Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management. ( D'Urzo, AD, 2006)
"Sixty-five patients with bronchial asthma were treated for pre- and post-bronchodilation of 400 microg salbutamol."1.33[Expiratory flow limitation detected by negative expiratory pressure in patients with bronchial asthma]. ( Chen, AH; Chen, RC; Li, JM; Liu, Q; Zhang, NF; Zhong, NS, 2006)
"Levalbuterol-treated patients required significantly fewer treatments with beta-agonists (mean [+/- SD] number of treatments, 19."1.32Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. ( Halpern, M; Truitt, T; Witko, J, 2003)
" The main outcome measures were: indication for use of Ventolin MDI, assessment of disease severity, event rates during each period of observation; deaths, pregnancies, reported adverse drug reactions and reasons for discontinuation of MDI."1.32Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. ( Craig-McFeely, PM; Maier, WC; Shakir, SA; Soriano, JB; Wilton, LV, 2003)
" The area under the plasma albuterol concentration versus time curve (AUC) was 72% greater for the HFA formulation, indicating a greater lung bioavailability (p = 0."1.32Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. ( Anderson, P; Breen, P; Compadre, C; Gann, L; Hiller, FC; Joguparthi, V; Zhou, X, 2003)
" These findings suggest that ways need to be found: (i) to increase the use of current asthma management guidelines by practitioners; (ii) to improve documentation of prescribed medications and their dosage and; (iii) to improve education of parents in home management measures."1.32Prescribing for asthmatic children in primary care. Are we following guidelines? ( Dashash, NA; Mukhtar, SH, 2003)
"Recently, dry powder inhaler (DPI) was more available than pressure metered dosed inhaler (pMDI) for the inhalation therapy of the respiratory disease."1.32[Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma]. ( Fujimura, M; Kasahara, K; Nakao, S; Yasui, M; Yoshimi, Y, 2004)
"Pulmonary function methods which are able to detect small pharmacological effects may be useful for assessing the full dose-response curve of bronchodilatators."1.32A comparison of lung function methods for assessing dose-response effects of salbutamol. ( Houghton, CM; Singh, D; Woodcock, AA, 2004)
"Tremor was measured using a laser pointer technique."1.32Tremor side effects of salbutamol, quantified by a laser pointer technique. ( Broeders, ME; Folgering, HT; Nizet, TA, 2004)
" Combination therapy is highly efficacious and safe for asthmatics under the age of 5."1.32Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5. ( Alam, M; Parekh, M; Sait, T; Sekhsaria, S; Starr, B, 2004)
" However, in view of the steep bronchodilator dose-response curve for salbutamol, further studies are needed to determine whether such device care is clinically necessary."1.32Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin. ( Bosnic-Anticevich, SZ; Chan, HK; Chew, NY; Reddel, HK, 2004)
"Albuterol delivery was estimated by measuring the amount of the albuterol collected on a filter placed at the inlet of the lung model."1.31In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. ( Chatmongkolchart, S; Dillman, C; Hess, DR; Kacmarek, RM; Schettino, GP, 2002)
" Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used."1.31[Two out-of-the-ordinary (?) case reports an asthmatic disease]. ( Hausen, T, 2000)
"Lung sounds were measured in nine patients with asthma and five control subjects, alongside air flow measurements of forced expiratory volume (FEV1) and forced vital capacity (FVC)."1.31Limitations in the use of median frequency for lung sound analysis. ( Anderson, K; Carter, R; Lucas, M; Whittaker, AR, 2000)
"Malondialdehyde levels of BAL were compared before and after treatment."1.31Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist. ( Aydin, S; Besirli, K; Cetinkaya, A; Ozaras, R; Tahan, V; Talay, F; Turkmen, S; Uzun, H, 2000)
"0), and hourly albuterol dosing interval (OR 4."1.31Predictors of hospitalization in children with acute asthma. ( Arseneault, R; Bacal, L; Keogh, KA; Macarthur, C; Parkin, PC; Schuh, S; Stephens, D; Tennis, O, 2001)
" Outcomes assessed were completion of the test protocol, adequacy of sputum samples, decrease in FEV1, and adverse effects during the procedure."1.31The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children. ( Gibson, PG; Hankin, R; Henry, RL; Jones, PD; Simpson, J, 2001)
"Sputum induction is a safe and effective technique to study airway inflammation in stable asthma."1.31Safety of sputum induction with isotonic saline in adults with acute severe asthma. ( Gibson, PG; Hensley, MJ; Simpson, JL; Wark, PA, 2001)
" These results indicate that the difference in FPM does not warrant a change in the recommended dosage of salmeterol administered when using the VHCs tested."1.31Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers. ( Ahrens, RC; Garris, T; Holmes, M; Kelly, HW; Reisner, C; Stevens, AL; Vandermeer, AK, 2001)
" Lung function, quality of life and adverse events were evaluated as primary outcome variables."1.31[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. ( Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)
"Latent forms of long QT syndrome have been already reported."1.30[Latent long QT syndrome: discription of a clinical case]. ( Bianconi, L; Castro, A; Pandozi, C; Santini, M; Toscano, S, 1997)
" Beta 2 adrenoceptor function was evaluated by measuring lymphocyte beta 2 adrenoceptor parameters and constructing dose-response curves to salbutamol (100-1600 micrograms)."1.30Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)
" Even when controlling for dosage in the preceding 24 h, there was a 262-fold and 810-fold variation in the urinary concentrations for unchanged and total salbutamol, respectively, among the community patients."1.30Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. ( Jacobson, GA; McLean, S; Peterson, GM, 1997)
"albuterol, Airomir, 3M) has been approved for marketing in over 35 countries."1.30The change to non-CFC metered dose inhalers. ( Rubinfeld, A, 1997)
"Childhood pneumonia is associated with reduced ventilatory function in adults."1.30Effect of pneumonia and whooping cough in childhood on adult lung function. ( Anderson, HR; Johnston, ID; Strachan, DP, 1998)
"Serum sex hormones, lymphocyte beta2-adrenoceptor parameters, and bronchodilator and systemic dose-response curves (DRCs) to albuterol (Salbutamol) (100 to 1,600 microg) were measured at both on and off periods."1.30Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1998)
"A dose-response increase in pulmonary function was found, but only 70% improved sufficiently to be discharged."1.30Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998)
"A study was undertaken to test the hypothesis that airway calibre may alter lung deposition and therefore lung bioavailability of inhaled drugs as a result of narrowed airways reducing peripheral drug delivery."1.30Effects of airway calibre on lung delivery of nebulised salbutamol. ( Clark, DJ; Lipworth, BJ, 1997)
" One theory for this paradox is that chronic use of beta2-adrenoceptor agonists compromises the anti-inflammatory action of glucocorticosteroids."1.30Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release. ( Adcock, IM; Barnes, PJ; Giembycz, MA; O'Connor, BJ; Seldon, PM; Stevens, DA, 1998)
" The accuracy of dosing and the technically perfect use of devices are extremely important, especially when drugs with potential systemic side effects are administered."1.30Inhalation devices in childhood asthma. ( Gács, E; Göndöcs, R; Jákly, A; Uhereczky, G, 1998)
"We suggest that children with bronchial asthma treated with inhaler drugs should receive special preventive attention."1.30Inhaler medicament effects on saliva and plaque pH in asthmatic children. ( Dagli, E; Ergeneli, S; Karakoc, F; Kargul, B; Tanboga, I, 1998)
" Intratracheal administration of IL-1beta or chronic administration of albuterol significantly decreased (p < 0."1.30An in vivo model of beta-adrenoceptor desensitization. ( Agrawal, DK; Chong, BT; Romero, FA; Townley, RG, 1998)
" Metered dosing (metered-dosing inhaler or premixed solution) were chosen by 22 caregivers (54%), calibrated measuring tools (droppers, syringes) by 15 (37%), and noncalibrated delivery devices (teaspoon) by 4 (10%)."1.30Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children. ( Simon, HK, 1999)
"Salbutamol is widely used in the treatment of bronchial asthma, and is usually administered either by inhalation, orally, or parenterally."1.30Intranasal salbutamol instillation in asthma attack. ( Brill, S; Gurman, GM; Tarnapolski, A; Weksler, N, 1999)
" A dose-response curve for nebulized ipratropium was determined."1.29[Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience]. ( Beck, R, 1995)
" The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position)."1.29Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. ( Huang, TJ; Kuo, HP; Lin, HC; Shieh, WB; Wang, CH; Yang, CT; Yu, CT, 1995)
"04), a relative oral bioavailability of 104%, indicating equivalent total salbutamol output, was also obtained in the human subjects."1.29Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ( Chang, C; Simon, OR, 1994)
" In the 11 patients with complete dose-response curves, the geometric mean of diurnal PFV variation (% mean range) was 5."1.29[Relations between nonspecific bronchial hyperreactivity, diurnal variation of peak expiratory flow and medication requirements in patients with mild asthma]. ( Bertó, JM; Camps, B; Gutiérrez, V; Pérez, MJ; Prieto, L, 1994)
" The main finding was that older children had higher concentrations than younger children, despite similar dosage regimens."1.29Systemic absorption of salbutamol following nebulizer delivery in acute asthma. ( Dawson, KP; Manglick, P; Penna, AC; Tam, J, 1993)
" Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1."1.29A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. ( Blais, L; Boivin, JF; Buist, AS; Cockroft, D; Ernst, P; Habbick, B; Horwitz, RI; McNutt, M; Spitzer, WO; Suissa, S, 1994)
"The authors compared the effectiveness and advantages of the powdered inhalation variety of the preparation Ventodisc (Glaxo) with the "classical" dosed inhalation form of Salbutamol (Polfa) in 21 patients with bronchial asthma."1.29[The bronchodilator agent, Ventodisk, in the powdered inhalation form without freon is better]. ( Malý, M; Reisová, M; Vondra, V, 1993)
" These aerosolized medications are not without the potential for adverse effects."1.29Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. ( Oenbrink, RJ, 1993)
"Fourteen patients with moderate bronchial asthma were selected for the study."1.29[Effect of corticosteroids on tachyphylaxis induced by beta-2- receptor agonists in patients with bronchial asthma]. ( Małolepszy, J; Passowicz-Muszyńska, E, 1993)
" The aim of this study was to seek such a relationship in young asthmatic children using dose-response curves (DRC)."1.29The effect of age on bronchodilator responsiveness. ( Landau, LI; LeSouëf, PN; Turner, DJ, 1993)
"Taking into account that in bronchial asthma an alteration in the beta-adrenergic neural control of airways has been hypothesized, we aimed to verify whether, in asthmatic children, beta-adrenergic activation inhibits or not GH secretion."1.29Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children. ( Bellone, J; Camanni, F; Castello, D; Gaggero, L; Ghigo, E; Valente, F; Valetto, MR; Visca, A, 1993)
"Albuterol delivery was significantly (p < or = ."1.29Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model. ( Bradley, JW; Garner, SS; Habib, DM; Lesher, BA; Wiest, DB, 1996)
"Nimesulide is a nonsteroidal anti-inflammatory drug, supposed to act by inhibition of phosphodiesterase type IV."1.29The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. ( Knol, EF; Mul, FP; Roos, D; Tool, AT; Verhoeven, AJ, 1996)
" Given orally, RP 58802B (5 mg/kg, 60 min before challenge) produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine by 39 +/- 11%."1.28RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ( Lewis, SA; Raeburn, D; Underwood, SL, 1992)
"Procaterol was administered per os (tabl."1.28[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992)
" Bronchial lability was characterized by (1) variability in mean daily peak expiratory flow rate and (2) bronchial responsiveness to either carbachol (as assessed by the threshold dose and the slope of the dose-response curve) or salbutamol (as assessed by the threshold dose and maximal response)."1.28Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma. ( Lockhart, A; Marsac, J; Peiffer, C; Razzouk, H; Toumi, M, 1992)
" Before salmeterol treatment was initiated and after 3, 6, 9 and 12 months of salmeterol treatment, a cumulative dose-response curve to inhaled salbutamol (100, 300 and 900 micrograms) was performed, and FEV1 measured."1.28Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. ( Lötvall, J; Lunde, H; Svedmyr, N; Törnqvist, H; Ullman, A, 1992)
"Albuterol was effective in increasing the PEFR in patients with asthma, COPD and NANC."1.28The prehospital use of nebulized albuterol on patients with wheezing whose chief complaint is shortness of breath. ( Dickinson, ET; Megargel, R; O'Connor, RE, 1992)
" During the high dosing the secretion rate of parotid saliva decreased and the concentrations of its total protein, amylase, hexosamine and the ratio of hexosamine/total protein were lowered."1.28Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist. ( Ericson, T; Möller, C; Ryberg, M, 1990)
"Albuterol was administered from each of the delivery systems in the following manner: MDI, two actuations (180 micrograms); JN, 0."1.28Assessment of bronchodilator response to a beta-adrenergic delivered from an ultrasonic nebulizer. ( Ballard, RD; Bogin, RM; Pak, J, 1991)
"Recently, it was suggested that long-term administration of an inhaled beta 2-agonist might increase bronchial hyperresponsiveness (BHR) to histamine, possibly as a consequence of subsensitization to the inhaled beta 2-agonist."1.28Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. ( Dompeling, E; Graafsma, SJ; van Herwaarden, CL; van Schayck, CP; van Weel, C; Visch, MB, 1990)
"Patients with bronchial asthma often develop acute attack in kitchen while burning honeycomb briquet which is widely used for cooking in southern China."1.28[Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol]. ( Luo, DF; Luo, ZY; Zheng, JP, 1990)
"Aminophylline is a potent antagonist at purinoceptor level."1.28Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects. ( Carapella, N; Filippelli, A; Loffreda, A; Marmo, E; Matera, MG; Montanaro, C; Santagata, A; Servodio, R; Susanna, V, 1990)
" Plasma glucose, potassium, and magnesium were measured at each step of the dose-response curve."1.28The biochemical effects of high-dose inhaled salbutamol in patients with asthma. ( Clark, RA; Fraser, CG; Lipworth, BJ; McDevitt, DG, 1989)
"We have compared bronchodilator dose-response curves to inhaled salbutamol in seven normal and eight asthmatic subjects."1.27Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. ( Barnes, PJ; Pride, NB, 1983)
" Although it is safe to use oxygen as the driving gas for nebulisers in patients with obstructive airways disease with normal Pco2, caution should be exercised in those who already have carbon dioxide retention."1.27Oxygen as a driving gas for nebulisers: safe or dangerous? ( Campbell, IA; Gunawardena, KA; MacDonald, JB; Patel, B; Smith, AP, 1984)
" There was a linear log dose-response relationship for each airways parameter (FEV1, VC, sGaw, FEF 50%)."1.27Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. ( Brown, RA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG, 1988)
" We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0."1.27A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985)
" Dose-response curves were plotted upon the inhalation of salbutamol in two-week intervals in patients treated with betamimetics."1.27Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs. ( Böszörményi-Nagy, G; Debreczeni, LA; Herjavecz, I; Szeitz, A, 1987)
"Twenty patients with mild chronic bronchial asthma (females and males between 45-69 years old) treated with single dose of 0."1.27Pharmacodynamics of salbutamol in humans. ( Chazan, R; Droszcz, W; Maruchin, JE, 1988)
" This reduction in severity appears to require the long-term use of medications, including aerosol corticosteroids, with daily home monitoring to allow adjustment of the amount of treatment required."1.27Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma. ( Salome, CM; Woolcock, AJ; Yan, K, 1988)
" The bronchodilator effect of the two aerosols was determined from cumulative dose-response studies."1.27Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. ( Mitchell, DM; Short, M; Solomon, MA; Spiro, SG; Tolfree, SE, 1987)
" This study was undertaken to compare the clinical effectiveness and toxicity of these two drugs and to try to establish dosage schedules of inhaled salbutamol with spacer in the treatment of acute asthma."1.27[Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis]. ( Bonal de Falgas, J; Farré Riba, R; Ferrés Mataró, J; Juliá Brugues, A; Mangues Bafalluy, MA, 1987)
"Thirteen patients with bronchial asthma were treated with 2 mg salbutamol three times daily (one patient with 4 mg three times daily)."1.26Effect of beta 2-adrenergic stimulation on serum lipids. ( Elo, J; Lehtonen, A; Sallinen, VP; Viikari, J, 1982)
" The development of resistance was assessed from salbutamol dose-response studies in which the airway response was measured as specific airway conductance (sGaw)."1.26Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. ( Harvey, JE; Tattersfield, AE, 1982)
"A review of childhood bronchial asthma in Zaria, northern Nigeria is presented."1.26Childhood bronchial asthma in northern Nigeria. ( Abdurrahman, MB; Taqi, AM, 1982)
"Cumulative inhalation dose-response curves for the response to prostaglandin E2 (PGE2) have been constructed in normal subjects and patients with mild, stable asthma."1.26Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment. ( Bevan, M; Davies, BH; Walters, EH, 1982)
" The dose-response curve for non-esterified fatty acids and insulin, though displaced downwards, did not indicate an impaired response to salbutamol since the shape was unchanged."1.26Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. ( Alberti, KG; Baldwin, CJ; Harvey, JE; Tattersfield, AE; Wood, PJ, 1981)
"1 Cumulative dose-response curves (FEV1) to pressurized aerosol salbutamol were established in 17 patients admitted to hospital with acute severe asthma."1.26Comparative efficacy of salbutamol by pressurized aerosol and wet nebulizer in acute asthma. ( Madsen, BW; Paterson, JW; Tarala, RA, 1980)
" Adequate theophylline dosage is an effective bronchodilator."1.26Treatment of asthma in children. ( Hobday, JD, 1978)
" Tremor was found to be the dose-limiting side effect with both modes of administration."1.26Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. ( Larsson, S; Svedmyr, N, 1977)

Research

Studies (3,866)

TimeframeStudies, this research(%)All Research%
pre-1990843 (21.81)18.7374
1990's1107 (28.63)18.2507
2000's1167 (30.19)29.6817
2010's606 (15.68)24.3611
2020's143 (3.70)2.80

Authors

AuthorsStudies
Sohda, S1
Fujimoto, M1
Tamegai, T1
Hirose, N1
Jacobsen, JR1
Choi, SK1
Combs, J1
Fournier, EJ1
Klein, U1
Pfeiffer, JW1
Thomas, GR1
Yu, C1
Moran, EJ1
Xing, G1
Woo, AY1
Pan, L1
Lin, B1
Cheng, MS1
Teper, A2
Kofman, C2
Alchundia Moreira, J1
Köhler, T1
García Bournissen, F1
Wilkinson, A1
Woodcock, A11
Zhou, XJ1
Qin, Z1
Lu, J1
Hong, JG1
Chipps, BE6
Albers, FC2
Reilly, L1
Johnsson, E2
Cappelletti, C3
Papi, A14
Arnold, DH3
Gong, W1
Antoon, JW1
Bacharier, LB13
Stewart, TG1
Johnson, DP1
Akers, WS1
Hartert, TV2
Shen, BH1
Aoyama, B1
Lee, B3
Busse, WW28
Panettieri, RA6
Corren, J8
Morgenstern-Kaplan, D1
Gonzalez-Estrada, A1
Amir Najim Abood, HA1
Al-Musawi, ZM1
Hussein, AM1
Hameed, RM1
Ramey, OL1
Silva Almodóvar, A1
Nahata, MC1
Andoh, AA1
Lo, CB1
Shi, J1
Bode, RS1
Gee, SW1
Leonard, JC1
Lucas, JA3
Kaufmann, J2
Jones, M1
Garg, A2
Ezekiel-Herrera, D2
Puro, J1
Marino, M3
Heintzman, J3
Rodríguez-Martínez, CE6
Sossa-Briceño, MP5
Buendia, JA2
McCans, K1
Varma, S1
Ramgopal, S2
Martin-Gill, C2
Owusu-Ansah, S2
Courlet, P1
Buclin, T1
Biollaz, J1
Mazzoni, I1
Rabin, O1
Guidi, M1
Vega-Briceño, L1
Muchão, FP2
Souza, AV1
Souza, JME1
Silva Filho, LVRFD1
Zhang, H1
Cui, Y1
Zhang, X8
Yuan, X2
Xu, D2
Zhang, L4
Colombo, M1
Plebani, A1
Bosco, A1
Agosti, M1
Lajunen, K1
Kataja, J1
Jartti, T1
Peltoniemi, O1
Tervonen, M1
Elenius, V1
Nash, JL1
Southcott, AM1
Jayaram, L1
Beasley, R30
Israel, E32
Cooper, M1
Dunsire, L1
Jeynes-Ellis, A1
Rees, R1
Lowe, AA2
Gerald, JK4
Clemens, C1
Gerald, LB6
Koldeweij, C1
Appelbaum, N1
Rodriguez Gonzalvez, C1
Nijman, J1
Nijman, R1
Sinha, R1
Maconochie, I2
Clarke, J1
Alsuwaigh, R1
Cao, Y1
Puan, Y1
Yii, A1
Mohamed Noor, SB1
Ye, H1
Chen, H3
Li, XL1
Binte Mohd Noor, N1
Liew, J1
Tay, TR1
Hsiao, YH1
Lin, YJ1
Jeng, TH1
Su, KC1
Ko, HK1
Yang, SN1
Perng, DW1
Kou, YR1
Ball, J2
Doniec, Z1
Olszanecka-Glinianowicz, M1
Hantulik, P1
Almgren-Rachtan, A1
Chudek, J1
Uysalol, M1
Yıldız, R1
Özünal, ZG1
Boeschoten, SA2
Buysse, CMP2
de Winter, BCM2
van Rosmalen, J2
de Jongste, JC8
de Jonge, RC1
Heisterkamp, SGJ2
van Woensel, JB1
Kneyber, MCJ1
van Zwol, A1
Boehmer, ALM2
de Hoog, M5
Willis, LD1
Danner, NP1
Lloyd, TL1
Carper, NL1
Berlinski, A1
Siddiqui, H1
Siddiqui, SA1
Yadav, RK1
Singh, MV1
Kumar, D2
Singh, DK1
Hoyte, FCL1
Mosnaim, GS1
Rogers, L1
Safioti, G1
Brown, R1
Li, T1
DePietro, M1
Reich, M1
Hill, TD1
Wechsler, ME13
Confalonieri, M1
Lipworth, BJ72
Chan, R4
Stewart, KE1
Pitonzo, DG1
Lv, C1
Liao, G1
Wu, L1
Li, J1
Gao, Y1
Zyryanov, SK1
Dyakov, IN1
Aisanov, ZR1
Kosoko, AA1
Khoei, AA1
Khose, S1
Genisca, AE1
Mackey, JM1
Marques, L4
Vale, N3
Crossingham, I3
AlKhalidi, L3
Zhao, W2
Hogan, MB2
Alizadeh Bahmani, AH2
Slob, EMA2
Bloemsma, LD2
Brandstetter, S2
Corcuera-Elosegui, P2
Gorenjak, M2
Harner, S2
Hashimoto, S2
Hedman, AM2
Kabesch, M3
Koppelman, GH2
Korta-Murua, J2
Kraneveld, AD2
Neerincx, AH2
Pijnenburg, MW2
Pino-Yanes, M4
Potočnik, U2
Sardón-Prado, O2
Vijverberg, SJH2
Wolff, C2
Abdel-Aziz, MI2
Maitland-van der Zee, AH2
Walsh, S1
Pan, S2
Sheng, Y1
Kloprogge, F1
Standing, JF1
Anderson, BJ2
Ramnarayan, P2
Rabbany, MA1
Saha, BK1
Subha, N1
Sultana, I1
Islam, MS1
Hossain, AJ1
Seraj, S1
Farzana, S1
Sharmin, M1
Ali, MM1
Nahar, A1
Siddiqui, KA1
Nishi, MK1
Akter, S1
Tania, IJ1
Shams, N1
Khatun, S1
Douros, K1
Moriki, D1
Sardeli, O1
Boutopoulou, B1
Galani, A1
Papaevangelou, V1
Priftis, KN1
Roddy, MR1
Sellers, AR1
Darville, KK1
Teppa-Sanchez, B1
McKinley, SD1
Martin, M1
Goldenberg, NA1
Nakagawa, TA1
Sochet, AA1
Rajashekar, C1
Shankar, NCG1
S, A1
Sharada, RC1
Nedunchelian, K1
Reddel, HK8
Brusselle, G2
Lamarca, R1
Gustafson, P1
Anderson, GP2
Jorup, C3
Bilak, VM1
Ignatko, LV1
Sochka, NV1
Debretseni, OV1
Kossey, GB1
Mashika, VY1
Griadil, TI1
Steward, M1
Sheth, S1
Ouédraogo, AR1
Boncoungou, K1
Ouédraogo, JCRP1
Ouédraogo, GA1
Kiendrebeogo, JA1
Sourabie, A1
Maiga, S1
Kafando, S1
Ouédraogo, G1
Badoum, G1
Ouédraogo, M1
Aschenbrenner, DS1
Diao, J1
Lam, M1
Gregory, KJ1
Leach, K1
Bourke, JE2
Anderson, K2
Hall-Lipsy, E1
McCulley, K1
Vuong, E1
Phan, H1
Bailey, SR1
Hsu, A2
Datta, R1
Cottrell, E1
Kim, YJ1
Suglia, SF1
Bazemore, A2
Meredith, E1
Thomas, J1
Kaminsky, DA3
He, J1
Henderson, R1
Dixon, AE2
Irvin, CG9
Mastronarde, J1
Smith, LJ3
Sugar, EA1
Wise, RA6
Holbrook, JT2
Jayasooriya, S1
Stolbrink, M1
Khoo, EM1
Sunte, IT1
Awuru, JI1
Cohen, M1
Lam, DC1
Spanevello, A1
Visca, D1
Centis, R1
Migliori, GB1
Ayuk, AC1
Awokola, BI1
Del-Rio-Navarro, BE2
Muteti-Fana, S1
Lao-Araya, M1
Chiarella, P1
Badellino, H1
Somwe, SW1
Anand, MP1
Garcí-Corzo, JR1
Bekele, A1
Soto-Martinez, ME1
Ngahane, BHM1
Florin, M1
Voyi, K1
Tabbah, K1
Bakki, B1
Alexander, A1
Garba, BL1
Salvador, EM1
Fischer, GB1
Falade, AG1
ŽivkoviĆ, Z1
Romero-Tapia, SJ1
Erhabor, GE1
Zar, H1
Gemicioglu, B2
Brandão, HV1
Kurhasani, X1
El-Sharif, N1
Singh, V1
Ranasinghe, JC1
Kudagammana, ST1
Masjedi, MR1
Velásquez, JN1
Jain, A2
Cherrez-Ojeda, I1
Valdeavellano, LFM1
Gómez, RM1
Mesonjesi, E1
Morfin-Maciel, BM1
Ndikum, AE1
Mukiibi, GB1
Reddy, BK1
Yusuf, O1
Taright-Mahi, S1
Mérida-Palacio, JV1
Kabra, SK10
Nkhama, E1
Filho, NR1
Zhjegi, VB1
Mortimer, K1
Rylance, S1
Masekela, RR1
Sinaiko, AD1
Ross-Degnan, D1
Wharam, JF1
LeCates, RF1
Wu, AC3
Zhang, F1
Galbraith, AA2
Barchilon, M1
Reinero, CR2
Emel, E1
Ayhan, O1
Recep, B1
Ulku, S1
Hempel, P1
Klein, V1
Michely, A1
Böll, S1
Rieg, AD1
Spillner, J1
Braunschweig, T1
von Stillfried, S1
Wagner, N1
Martin, C1
Tenbrock, K1
Verjans, E1
Knox, SK1
Mahr, TA1
Wongwaree, S1
Daengsuwan, T1
Coverstone, AM1
Wilson, BS1
Fitzpatrick, AM6
Teague, WG3
Phipatanakul, W5
Wenzel, SE8
Gaston, BM2
Bleecker, ER17
Moore, WC7
Ramratnam, S2
Jarjour, NN5
Ly, NP1
Fahy, JV16
Mauger, DT13
Schechtman, KB1
Yin-DeClue, H1
Boomer, JS1
Castro, M11
Saeed, H2
Abdelrahim, ME2
Rabea, H1
Salem, HF1
Louis, R3
Bougard, N1
Guissard, F1
Paulus, V1
Henket, M2
Schleich, F1
Graden, A1
Gandhi, S1
Joshi, AY1
Lipworth, B8
Kuo, CR2
Grunwell, JR1
Nguyen, KM1
Bruce, AC1
Mazzarini, A1
Winter, BK1
Carlton, E1
Meltzer, LJ1
Beebe, DW1
Jump, S1
Flewelling, K1
Sundström, D1
White, M3
Zeitlin, PL1
Strand, MJ1
Carhuamaca-Salvador, M1
Bustos de la Cruz, J1
Chávez-Rimache, L1
Chumpitaz-Cerrate, V1
Calzetta, L3
Matera, MG7
Goldstein, MF5
Fairweather, WR2
Howard, WW2
Cazzola, M9
Rogliani, P1
Woodward, S1
Mundorff, M1
Weng, C1
Gamboa, DG1
Johnson, MD1
Lin, NY1
Ramsey, RR1
Miller, JL1
McDowell, KM2
Zhang, N1
Hommel, K1
Guilbert, TW6
Dickman, CTD1
Russo, V1
Thain, K1
Beyer, ST1
Walus, K1
Getsios, S1
Mohamed, T1
Wadsworth, SJ1
SreeHarsha, N1
Venugopala, KN1
Nair, AB1
Roopashree, TS1
Attimarad, M1
Hiremath, JG1
Al-Dhubiab, BE1
Ramnarayanan, C1
Shinu, P1
Handral, M1
Haroun, M1
Tratrat, C1
Pearmain, L1
Gupta, R2
Bright-Thomas, RJ1
Castro-Rodriguez, JA6
Elgendy, MO1
Hassan, AH1
Eldin, RS1
Vempilly, JJ1
Abejie, BA1
Rashidian, A1
Jain, VV1
Bhakta, N1
Banasiak, NC1
Meadows-Oliver, M1
Vet, NJ1
Dunk-Craaijo, JH1
Koch, BCP1
de Wildt, SN1
Zhao, T1
Liu, Z2
Niu, J1
Lv, B1
Xiao, Y1
Li, Y2
Andrews, AL1
Williams, DC1
Hogan, AH1
Smith, NMJ1
Couper, J1
Fullerton, CJ1
Richmond, G1
Talbot, NP1
Hancock, G1
Pavord, I2
Ritchie, GAD1
Robbins, PA1
Petousi, N1
Ammari, WG1
Oriquat, GA1
Sanders, M1
Woolf, AD1
Manzi, SF1
Pertzborn, MC1
Prabhakaran, S1
Abu-Hasan, M2
Baker, D1
Wu, S2
Wu, Y2
Hendeles, L14
O'Rourke, A1
Zimmerman, A1
Platt, H1
Pappalardo, AA2
Moody, GB1
Luckett, PM1
Shockley, CM1
Huang, R1
Ari, A2
Cockcroft, DW24
Davis, BE6
Tollefson, G1
Yurach Pikaluk, M1
Suárez-Medina, R1
Venero-Fernández, S1
Alvarez-Valdés, V1
Sardiñas-Baez, N1
Cristina, C1
Loinaz-Gonzalez, M1
Verdecia-Pérez, Z1
Corona-Tamayo, B1
Betancourt-López, M1
Britton, J2
Fogarty, AW1
Guezguez, F1
Ben Saad, H1
Taytard, J1
Aupiais, C1
Jovien, S1
Assouline Kabla, J1
Haziot, N1
Fuger, M1
Alberti, C1
Beydon, N3
Codispoti, CD1
Bandi, S1
Patel, P1
Mahdavinia, M1
Amirav, I5
Newhouse, MT7
Harding, AM1
Taylor, SE1
O'Keefe, C1
Stone, RG1
McDonald, M1
Elnazir, B1
Tommola, M1
Won, HK1
Ilmarinen, P1
Jung, H1
Tuomisto, LE1
Lehtimäki, L2
Niemelä, O1
Kim, TB1
Kankaanranta, H2
Traynor, K1
Gillette, C1
Cooney, JW1
Sisson, CB1
Rockich-Winston, N1
Perry, CJ1
Ramirez, O1
Alvarez, I1
Aristizabal-Duque, R1
Villamil, M1
Hodroge, SS1
Glenn, M1
Breyre, A1
Aldridge, NR1
Sporer, KA1
Koenig, KL1
Gausche-Hill, M1
Salvucci, AA1
Rudnick, EM1
Brown, JF1
Gilbert, GH1
Higaki, N1
Iwamoto, H1
Yamaguchi, K2
Sakamoto, S1
Horimasu, Y1
Masuda, T1
Miyamoto, S1
Nakashima, T1
Ohshimo, S1
Fujitaka, K1
Hamada, H1
Hattori, N1
Alhammad, AM1
Alajmi, G1
Alenizi, A1
Alrashidi, E1
Alghannam, G1
Alaki, E1
Alsaadi, MM1
Mayet, AY1
Payares-Salamanca, L1
Contreras-Arrieta, S1
Florez-García, V1
Barrios-Sanjuanelo, A1
Stand-Niño, I1
Li, S2
Mei, Q1
Qian, D1
Huang, X1
Fan, C1
Quan, J1
Parlar-Chun, R1
Truong, G1
Isbell, T1
Delgado, Y1
Arca, M1
Schroeder, SK1
Samady, W1
Kolaitis, IN1
Smith, CM2
Palac, H1
Shreffler, L1
Nevin, MA1
Hikino, K1
Kobayashi, S1
Ota, E1
Mushiroda, T1
Urayama, KY1
Kobayashi, T1
Bennett, MR1
Chang, CL2
Tuffery, C1
Hopping, S1
Hancox, RJ11
Murphy, K1
Mahmood, N1
Craven, D1
Gallagher, J1
Ross, K4
Speicher, R1
Rotta, AT3
Shein, SL1
Ruman-Colombier, M1
Rochat Guignard, I1
Di Paolo, ER1
Gehri, M1
Pauchard, JY1
Chen, KYH1
Lawrence, J1
Berry, A1
Hiscock, H1
Robertson, C4
Boddy, CE1
Naveed, S1
Craner, M1
Murphy, AC1
Siddiqui, S2
Bradding, P7
Kan, K1
Shaunfield, S1
Kanaley, M1
Chadha, A1
Boon, K1
Morales, L1
Davis, MM1
Vojta, D1
Gupta, RS1
Schuh, S15
Sweeney, J2
Rumantir, M2
Coates, AL3
Willan, AR2
Stephens, D5
Atenafu, EG1
Finkelstein, Y2
Thompson, G2
Zemek, R5
Plint, AC3
Gravel, J2
Ducharme, FM7
Johnson, DW6
Black, K1
Curtis, S2
Beer, D2
Klassen, TP3
Nicksy, D1
Freedman, SB2
Cloutier, MM2
Krishnan, JA2
Lemanske, RF27
Pace, W1
Schatz, M3
Monteverde-Fernandez, N1
Diaz-Rubio, F1
Vásquez-Hoyos, P1
González-Dambrauskas, S1
Moore, A1
Preece, A1
Sharma, R4
Heaney, LG1
Costello, RW1
Ludwig-Sengpiel, A1
Mosnaim, G1
Rees, J3
Tomlinson, R1
Tal-Singer, R1
Stempel, DA17
Barnes, N3
Motamed, H2
Forouzan, A2
Heybar, H1
Khorasani, MJ1
Hesam, S2
Kucher, NM1
S Dhaliwal, D1
Fischer, GA1
Davey, CS1
Gupta, S3
Clemens, CJ1
Stern, DA1
Xu, H1
Tong, L1
Gao, P1
Hu, Y1
Wang, H2
Chen, Z1
Fang, L1
Saad, HB1
Chenuel, B1
Guijon, OL2
Morphew, T4
Ehwerhemuepha, L1
Galant, SP6
Gates, RM2
Haynes, KE2
Rehder, KJ2
Zimmerman, KO2
Miller, AG2
Csonka, P2
Tapiainen, T2
Mäkelä, MJ3
Verki, MM1
Nematollahi, AV1
Nino, G2
Hopp, RJ2
Wilson, M1
Pasha, MA2
Gessner, L1
Thompson, D1
Torres, R1
Fu, L2
Fankhauser, K1
Giebultowicz, S1
Cowburn, S1
Ducharme, F1
Black, KJ3
Napolitano, N1
Nanda, A1
Russell, AF1
Bingemann, TA1
Pound, CM1
Gelt, V1
Akiki, S1
Eady, K1
Moreau, K1
Momoli, F1
Murchison, B1
Mulholland, B1
Kovesi, T2
Koh, MS2
Yii, AC1
Ong, YY1
Sofianopoulou, E2
Pless-Mulloli, T2
Rushton, S1
Diggle, PJ2
Horn, FC1
Marshall, H1
Collier, GJ1
Kay, R1
Brightling, CE2
Parra-Robles, J1
Wild, JM1
Steinbacher, M1
Pfleger, A1
Schwantzer, G1
Jauk, S1
Weinhandl, E1
Eber, E2
Pilcher, J4
Patel, M6
Pritchard, A4
Thayabaran, D1
Ebmeier, S2
Shaw, D4
Black, P4
Braithwaite, I2
Weatherall, M14
Wilkinson, M2
King, B1
Iyer, S1
Higginbotham, E1
Wallace, A1
Hovinga, C1
Allen, C1
Mukherjee, M1
Cingolani, E1
Pritchard, DI2
Bosquillon, C1
Capaldi, DPI1
Sheikh, K1
Eddy, RL1
Guo, F1
Svenningsen, S3
Nair, P2
McCormack, DG4
Parraga, G4
Helm, ME1
Carlson, S1
Borrell, LN3
Eng, C6
Nguyen, M1
Thyne, S5
LeNoir, MA4
Burke-Harris, N1
Burchard, EG13
Thakur, N2
Fischer, J1
Ohmer, M1
Petersen, M1
Liu, Q2
Li, Q3
Han, T1
Hu, T1
Hu, J1
Hu, H1
Tan, W2
Cogen, JD1
DiBlasi, RM2
Gibson, RL1
Debley, JS1
Zhao, C1
Liu, J3
Yang, H1
Xiang, L1
Zhao, S1
Knihtilä, H1
Kotaniemi-Syrjänen, A2
Pelkonen, AS2
Kalliola, S1
Malmberg, LP3
Zook, HG1
Payne, NR1
Puumala, SE1
Ziegler, KM1
Kharbanda, AB1
Lee, L1
Kerwin, E4
Collison, K1
Nelsen, L1
Wu, W3
Yang, S1
Pascoe, S3
Shariff, A1
Hillerson, D1
Ross, J1
Ayala-Pena, E1
Posa, D1
Pizzulli, A1
Wagner, P1
Perna, S1
Hofmaier, S1
Matricardi, PM1
Lau, S1
Palmsten, K1
Hulugalle, A1
Bandoli, G1
Kuo, GM1
Ansari, S1
Xu, R1
Chambers, CD1
Ko, FW1
Hui, DS1
Tehrany, R1
DeVos, R1
Bruton, A1
Masoumi, K1
Delirrooyfard, A1
Asgari Darian, A1
Mokhtar Gandomani, L1
Koskela, HO3
Lätti, AM1
Purokivi, MK3
Gelb, AF5
Yamamoto, A1
Verbeken, EK1
Schein, MJ2
Moridzadeh, R1
Tran, D1
Fraser, C2
Barbers, R1
Elatre, W1
Koss, MN1
Glassy, EF1
Nadel, JA1
Cordell, RL1
Valkenburg, TSE1
Pandya, HC2
Hawcutt, DB1
Semple, MG1
Monks, PS1
Kibirige, D1
Kampiire, L1
Atuhe, D1
Mwebaze, R1
Katagira, W1
Muttamba, W1
Nantanda, R1
Worodria, W1
Kirenga, B1
Morjaria, JB1
Rigby, AS1
Morice, AH2
Strother, J1
Burkholder, B1
Ozer, M1
Buyuktiryaki, B2
Sahiner, UM3
Teksam, O1
Karaatmaca, B2
Soyer, O2
Sekerel, BE3
Jacobson, GA5
Raidal, S1
Hostrup, M1
Wood-Baker, R3
Farber, MO1
Page, CP3
Walters, EH23
Suissa, S5
Donohue, J1
Evans, S1
Kemp, J2
Pruikkonen, H1
Kallio, M1
Dunder, T1
Pokka, T1
Uhari, M1
Renko, M1
Huang, G1
Jin, L1
Han, S1
Keeley, D1
Jackson, DJ4
Boehmer, S1
Beigelman, A2
Chmiel, JF4
Gaffin, JM2
Morgan, WJ8
Peters, SP25
Sheehan, WJ2
Cabana, MD2
Holguin, F4
Martinez, FD10
Pongracic, JA3
Baxi, SN2
Benson, M2
Blake, K6
Covar, R5
Gentile, DA2
Kumar, HV2
Lang, JE2
Lazarus, SC18
Lima, JJ9
Long, D1
Ly, N3
Marbin, J2
Moy, JN3
Myers, RE2
Olin, JT2
Raissy, HH3
Robison, RG2
Sorkness, CA23
Mak, ACY1
White, MJ1
Eckalbar, WL1
Szpiech, ZA1
Oh, SS3
Hu, D2
Goddard, P1
Huntsman, S2
Galanter, J1
Himes, BE3
Germer, S1
Vogel, JM1
Bunting, KL1
Salazar, S1
Keys, KL1
Liberto, J1
Nuckton, TJ1
Nguyen, TA1
Torgerson, DG2
Kwok, PY1
Levin, AM2
Celedón, JC2
Forno, E2
Hakonarson, H1
Sleiman, PM1
Dahlin, A1
Tantisira, KG6
Weiss, ST14
Serebrisky, D3
Brigino-Buenaventura, E3
Farber, HJ4
Meade, K5
Avila, PC9
Sen, S3
Thyne, SM5
Rodriguez-Cintron, W9
Winkler, CA1
Moreno-Estrada, A2
Sandoval, K2
Rodriguez-Santana, JR9
Kumar, R4
Williams, LK4
Ahituv, N1
Ziv, E2
Seibold, MA2
Darnell, RB1
Zaitlen, N1
Hernandez, RD2
Langton, D2
Wang, W1
Thien, F5
Plummer, V2
Merkus, PJFM1
van Wijngaarden, JMC1
Cochius-den Otter, SCM1
Barakat, D1
Rockers, PC1
Vian, T1
Onyango, MA1
Laing, RO1
Wirtz, VJ1
Lui, KJ2
Snider, MA1
Wan, JY1
Jacobs, J1
Kink, R1
Gilmore, B1
Arnold, SR1
Murayama, N2
Murayama, K1
Dufetelle, E1
Bokov, P1
Delclaux, C1
Moore, LE2
Brotto, AR2
Phillips, DB1
Bhutani, M1
Stickland, MK2
Sharif, Z1
Al-Alawi, M1
Leelathipkul, L1
Tanticharoenwiwat, P1
Ithiawatchakul, J1
Prommin, D1
Sirisalee, P1
Junhunee, P1
Poachanukoon, O1
Gallimore, PJ1
Davidson, NM1
Kalberer, M1
Pope, FD1
Ward, AD1
Zhang, HP1
Wang, L5
Wang, Z1
Xu, XR1
Zhou, XM1
Liu, G1
He, LY1
Wang, J6
Li, WM1
Wang, G2
Schissler, AJ1
Celli, BR1
Nilsen, K1
Gove, K1
Wilkinson, T1
Thompson, BR1
Chachi, L3
Alzahrani, A1
Koziol-White, C1
Biddle, M1
Bagadood, R1
Amrani, Y3
Kane, JM1
Phillips, M1
Sanchez, J2
Sánchez, A1
Cardona, R1
Starczewska-Dymek, L1
Bozek, A3
Jakalski, M1
Szefler, SJ29
Hoch, HE1
Tuffli, M1
Gondalia, R1
Barrett, MA1
Van Sickle, D1
Hanania, NA7
Dini, FL1
Honmane, S1
Hajare, A1
More, H1
Osmani, RAM1
Salunkhe, S1
Magee, JS1
Pittman, LM1
Jette-Kelly, LA1
Valenzuela, PL1
Santos-Lozano, A1
Morales, JS1
Drobnic, F1
Lucia, A1
Ing, A1
Sha, J1
Bennetts, K1
Hersch, N1
Kwok, M1
Farah, C1
Cates, CJ15
Schmidt, S2
Ferrer, M2
Sayer, B1
Waterson, S1
Kozian, A1
Schilling, T1
Wang, X1
Gonem, S1
Cumella, A1
Richardson, M1
Ibrahim, WH1
Rasul, F1
Ahmad, M1
Bajwa, AS1
Alamlih, LI1
El Arabi, AM1
Al-Mohannadi, D1
Siddiqui, MY1
Al-Sheikh, IS1
Ibrahim, AA1
Iramain, R2
Jara, A1
Cardozo, L1
Bogado, N2
Morinigo, R1
De Jesús, R1
Fu, M1
Zou, B1
An, K1
Yu, Y1
Tang, D1
Wu, J2
Xu, Y1
Ti, H1
Varegg, MS1
Kløverød, KM1
Austnes, MK1
Siwinska, N1
Slowikowska, M1
Zak, A1
Niedzwiedz, A1
D'Vaz, N1
Okitika, TA1
Shackleton, C2
Devadason, SG8
Hall, GL3
Bollinger, ME4
Butz, A2
Tsoukleris, M1
Lewis-Land, C2
Mudd, S1
Fishe, JN1
Palmer, E1
Finlay, E1
Smotherman, C1
Gautam, S1
Hendry, P1
Rowe, BH5
Villa-Roel, C1
Krebs, L1
Charlier, P1
Deo, S2
Kluger, N1
Katsunuma, T1
Fujisawa, T2
Maekawa, T1
Akashi, K1
Ohya, Y1
Adachi, Y1
Hashimoto, K2
Mizuno, M1
Imai, T1
Oba, MS1
Sako, M1
Ohashi, Y1
Nakamura, H5
Giubergia, V4
Ramírez Farías, MJ1
Pérez, V1
Crespi, N1
Castaños, C3
Allen, H1
Backhouse, SH1
Hull, JH1
Price, OJ1
Park, HS1
Yoon, D1
Lee, HY1
Ban, GY1
Wan Yau Ming, S1
Jie, JLZ1
Carter, V1
Hardjojo, A1
Van Boven, JFM1
Price, DB4
Heath, TS1
Bartlett, KW1
McLean, HS1
Ravi, A1
Chowdhury, S1
Dijkhuis, A1
Bonta, PI1
Sterk, PJ12
Lutter, R5
Holliday, M1
Harrison, T1
Houghton, C1
Oldfield, K1
Pavord, ID9
Williams, M5
Geier, ET1
Theilmann, RJ1
Prisk, GK1
Sá, RC1
Bairam, AF1
Rasool, MI1
Alherz, FA1
Abunnaja, MS1
El Daibani, AA1
Gohal, SA1
Alatwi, ES1
Kurogi, K1
Liu, MC3
Bjermer, L7
Abbott-Banner, K1
Newman, K1
Janson, C5
Malinovschi, A1
Amaral, AFS1
Accordini, S1
Bousquet, J27
Buist, AS3
Canonica, GW4
Dahlén, B2
Garcia-Aymerich, J1
Gnatiuc, L1
Kowalski, ML1
Patel, J1
Torén, K1
Zuberbier, T1
Burney, P1
Jarvis, D1
Kahveci, M1
Arık Yılmaz, E1
Esenboğa, S1
Gür Çetinkaya, P1
Jabbal, S3
Kapoor, K1
Byers, BW1
Ghods-Esfahani, D1
Henry, SL1
St James, RB1
Ming, M1
Li, C2
Luo, Z1
Lv, S1
Domingo, C1
Ahmed, S1
Sutradhar, SR2
Miah, AH1
Bari, MA1
Hasan, MJ1
Alam, MK1
Tariquzzaman, M1
Sarker, CN1
Liu, D1
Yi, HL1
Guo, C1
Chen, M2
Li, WK1
Char, DS1
Ibsen, LM1
Ramamoorthy, C1
Bratton, SL1
Hill-Taylor, BJ1
Hurley, KF2
Sketris, I2
O'Connell, C1
Sinclair, D1
Wing, A1
Yim, RP1
Koumbourlis, AC1
van Noord, JA5
Brindicci, C2
Lindemann, L3
Varoli, G1
Perpiña, M1
Guastalla, D1
Casula, D1
Patel, S2
Chanez, P10
Jaeschke, R2
Eeftinck Schattenkerk, JK1
Lager, PS1
Gravina, L1
Chertkoff, L2
Serra, HA1
Klapouszko, FP1
De Salvo, MC1
Bavasso, EC1
Rey, L1
Downey, D1
Lopez, D1
Roganovich, JM1
Rizzo, LF1
Akamatsu, T2
Shirai, T2
Kato, M2
Yasui, H2
Hashimoto, D2
Tsuchiya, T1
Inui, N2
Suda, T3
Chida, K4
Kirby, M2
Starr, D1
Leary, D1
Wheatley, A1
Maksym, GN2
Yang, Z3
Lu, A1
Wong, BC2
Chen, X2
Bian, Z1
Zhao, Z1
Huang, W2
Zhang, G4
Xu, M3
Giuliano, JS1
Faustino, EV1
Pinto, MG1
Canarie, MF1
Carroll, CL4
Coleman, M1
DiSantostefano, RL4
Yeakey, AM2
Raphiou, I1
Nuijsink, M2
Hop, WC9
Jongste, JC1
Duiverman, AE1
Barker, D1
Chin, H1
Hossain, AS1
Barua, UK1
Roy, GC1
Rahman, I1
Rahman, G1
Via, M3
Tcheurekdjian, H4
González Burchard, E1
Popov, TA2
Petrova, D1
Kralimarkova, TZ1
Ivanov, Y1
Popova, T1
Peneva, M1
Odzhakova, T1
Ilieva, Y1
Yakovliev, P1
Lazarova, T1
Georgiev, O1
Hodzhev, V1
Hodzheva, E1
Staevska, MT1
Dimitrov, VD1
Lin, Q1
Liu, QH1
Bao, YX1
Anderson, WJ2
Short, PM3
Williamson, PA5
Morrison, AE1
Palmer, C2
Tavendale, R3
Molina, RO1
Cáceres, M1
Recabarren, A1
Lötvall, J19
O'Byrne, PM15
Bateman, ED18
Medley, H1
Ellsworth, A3
Jacques, L7
Gedeit, RG1
Paggiaro, P11
Nicolini, G8
Pradelli, L1
Zaniolo, O1
Currie, GP16
Small, I2
Douglas, G1
Bel, EH3
Pencharz, D1
Quigley, AM1
Hall, M1
Wagner, TL1
García-Falcón, D1
Lawrence, KK1
Prendes-Columbié, MC1
Lewis, LM3
Ferguson, I3
House, SL3
Aubuchon, K2
Schneider, J2
Johnson, K4
Matsuda, K3
Matsumoto, K3
Aizawa, H3
Fukuyama, S2
Yoshida, M2
Komori, M2
Takata, S1
Koto, H1
Inoue, H2
Drake, KA1
Gignoux, CR1
Galanter, JM1
Roth, LA1
Yee, SW1
Lin, L1
Bustamante, CD1
Davis, A2
Chapela, R6
Ford, JG4
Lurmann, F1
Giacomini, KM1
Snowise, NG1
Clements, D1
Ho, SY3
Follows, RM2
Schauer, SG1
Cuenca, PJ1
Johnson, JJ1
Ramirez, S1
Levy, ML1
Hardwell, A1
McKnight, E1
Holmes, J1
Gálffy, G2
Mezei, G1
Németh, G1
Tamási, L3
Müller, V2
Selroos, O8
Orosz, M2
Vichyanond, P4
Veskitkul, J1
Rienmanee, N1
Pacharn, P1
Jirapongsananuruk, O1
Visitsunthorn, N1
Daley-Yates, PT2
Mehta, R3
Chan, RH1
Despa, SX1
Louey, MD1
Corin, A1
Helm, C1
Tofield, C1
Kosoglou, T1
Hubbell, J1
Cutler, DL1
Johnson-Levonas, AO1
Kantesaria, BS1
Kim, K1
Miller, SD2
Wu, XH1
Cai, C1
Xu, JP1
Ru, CH1
He, F1
Rabinovitch, N6
Reisdorph, N1
Malka, J2
Zeiger, RS12
Kunselman, SJ6
Icitovic, N3
Pascual, R2
Ameredes, BT6
Boushey, HA14
Calhoun, WJ10
Cherniack, RM4
Craig, T2
Denlinger, LC4
Engle, LL2
Dimango, EA2
Kraft, M14
Lugogo, N2
Martin, RJ14
Meyers, DA8
Ramsdell, J5
Sutherland, ER6
Wasserman, SI5
Walter, MJ3
Chinchilli, VM18
Koch, S2
MacInnis, MJ1
Sporer, BC1
Rupert, JL1
Koehle, MS2
Thomson, NC13
Niven, RM1
Corris, PA3
Chung, KF9
Cox, G2
Armstrong, B1
Shargill, NS1
Laviolette, M6
Babar, ZU1
Lessing, C1
Mace, C1
Bissell, K1
Chang, TS1
Gangnon, RE1
Page, CD1
Price, D5
Haughney, J1
Ryan, D1
Gruffydd-Jones, K1
Lavorini, F4
Harris, T2
Burden, A2
Brockman, J1
King, C1
FitzPatrick, M1
Donovan, C1
Rushton, SP1
Corradi, M2
Pigeon-Francisco, C1
Baronio, R2
Siergiejko, Z4
Petruzzelli, S2
Fabbri, LM9
Rabe, KF8
Sun, YX1
Gong, CH1
Liu, S1
Yuan, XP1
Yin, LJ1
Yan, L1
Shi, TT1
Dai, JH1
Morales, DR2
Petreschi, F1
Ullmann, N1
Bottero, S1
Tomà, P1
Inserra, A1
Francalanci, P1
Zicari, AM1
Cutrera, R4
Moustafa, F1
Garrouste, C1
Bertrand, PM1
Kauffmann, S1
Schmidt, J1
Grzelewski, T2
Majak, P1
Jerzyńska, J2
Stelmach, W2
Stelmach, R2
Janas, A1
Grzelewska, A1
Witkowski, K1
Makandjou-Ola, E1
Stelmach, I2
Hozawa, S2
Terada, M2
Hozawa, M2
Rodrigo, GJ10
Senthilkumaran, S1
Shah, S1
Menezes, RG1
Thirumalaikolundusubramanian, P1
Powell, C1
Kolamunnage-Dona, R1
Lowe, J1
Boland, A1
Petrou, S1
Doull, I2
Hood, K1
Williamson, P1
Chang, KC1
Wieland, LS2
Oleszczuk, M2
Kew, KM1
Tashkin, DP9
Trudo, F1
Zangrilli, JG2
Hojo, M1
Iikura, M1
Hirashima, J1
Suzuki, M1
Sugiyama, H2
Coro, M1
Cowl, A1
Sala, KA1
Schramm, CM3
Ioan, I2
Coutier, L2
Bonabel, C2
Demoulin, B4
Marchal, F5
Schweitzer, C4
Varechova, S2
El-Khatib, MF1
Jamaleddine, G1
Kanj, N1
Zeineddine, S1
Chami, H1
Bou-Akl, I1
Husari, A1
Alawieh, M1
Bou-Khalil, P1
Yatera, K1
Yamasaki, K1
Nishida, C1
Noguchi, S1
Oda, K1
Akata, K1
Nagata, S1
Kawanami, Y1
Kawanami, T1
Ishimoto, H1
Mukae, H1
Cossette, B1
Beauchesne, MF2
Forget, A2
Lemière, C2
Larivée, P1
Rey, E1
Blais, L4
Ismaila, A1
Corriveau, D2
Vaillancourt, J1
Parsons, D1
Stanford, R3
Su, Z2
Sampalis, JS1
Itoga, NK1
Kinoshita, CK1
Masutani, SM1
Yamamoto, LG3
Konno, S1
Hizawa, N3
Makita, H1
Shimizu, K1
Sakamoto, T2
Kokubu, F3
Saito, T1
Endo, T1
Ninomiya, H1
Iijima, H1
Kaneko, N1
Ito, YM1
Nishimura, M3
Yee, KC1
Tsuchida, T1
Matsuse, H3
Gross, N1
Greos, LS3
Meltzer, EO8
Spangenthal, S1
Fishman, RS1
Spyker, DA1
Cassella, JV1
Maneechotesuwan, K2
Assawabhumi, J1
Rattanasaengloet, K1
Suthamsmai, T1
Pipopsuthipaiboon, S1
Udompunturak, S1
Sliwiński, P1
Chazan, R9
Dąbrowiecki, P1
Jahnz-Różyk, K1
Mróz, R1
Pirożyński, M1
Spahn, JD5
Strunk, RC11
Yeh, FC1
Chiang, WF1
Wang, CC1
Lin, SH1
Pelham, A1
Claret, PG1
Bobbia, X1
de La Coussaye, JE1
Smith, A4
Davies, C1
Travers, J2
Harwood, M3
Toler, WT1
Goldfrad, C3
Wang, Y8
Wells, KE1
Padhukasahasram, B1
Yang, JJ1
Starkey, ES1
Mulla, H1
Sammons, HM1
Hallberg, CJ1
Lysaught, MT1
Najarro, RA1
Cea Gil, F1
Villatoro, C1
Diaz de Uriarte, AC1
Olson, LE1
Radhakrishna, N1
Hew, M1
Wyatt, EL1
Borland, ML1
Doyle, SK1
Geelhoed, GC4
Pellegrino, R4
Antonelli, A1
Crimi, E4
Gulotta, C1
Torchio, R1
Dutto, L1
Pedersen, OF5
Brusasco, V8
Ditcham, W1
Murdzoska, J1
Roller, C1
von Hollen, D1
Nikander, K1
Foster, JM2
Usherwood, T2
Smith, L2
Sawyer, SM2
Xuan, W1
Rand, CS3
Mehra, R1
Schneider, JE1
Zwitserloot, A1
Fuchs, SI1
Müller, C1
Bisdorf, K1
Gappa, M2
Kamps, AW2
Veeger, NJ1
Heijsman, SM1
Ismaila, AS1
Risebrough, N1
Hawkins, N2
FitzGerald, JM6
Rodriguez, E1
Barthold, JS1
Kreiger, PA1
Armani, MH1
Michelini, KA1
Wolfson, MR1
Boyce, R1
Barone, CA1
Zhu, Y1
Waldman, SA1
Shaffer, TH1
Beier, J3
Fuhr, R2
Massana, E1
Jiménez, E1
Seoane, B1
de Miquel, G1
Ruiz, S1
Morris, I1
Lyttle, MD1
O'Sullivan, R1
Sargant, N1
Doull, IJ2
Powell, CV2
Tagaya, E1
Kondo, M1
Kirishi, S1
Kawagoe, M1
Kubota, N1
Tamaoki, J1
Albrecht, J1
Devillier, P2
Salvator, H1
Grassin-Delyle, S1
Naline, E1
Advenier, C1
Roche, N2
Mehta, N1
Aggarwal, B1
Gogtay, J2
Abdool-Gaffar, S1
Desai, AG1
Togias, A5
Schechter, C1
Fisher, B1
Parow, A1
Skloot, G1
Shahane, G1
Parsania, C1
Sengupta, D1
Joshi, M1
Erokhina, IL1
Voronchikhin, PA1
Okovityĭ, SV1
Emel'ianova, OI1
Golden, C1
Estrada, CM1
Bandaru, S3
Tiwari, G1
Akka, J3
Marri, VK3
Alvala, M2
Gutlapalli, VR1
Nayarisseri, A2
Mundluru, HP3
Neame, M1
Aragon, O1
Fernandes, RM1
Sinha, I1
Mendes, ES3
Cadet, L1
Arana, J1
Wanner, A7
Neininger, MP1
Kaune, A1
Bertsche, A1
Rink, J1
Musiol, J1
Frontini, R1
Prenzel, F1
Kiess, W1
Bertsche, T1
Alansari, K1
Ahmed, W1
Davidson, BL1
Alamri, M1
Zakaria, I1
Alrifaai, M1
Dissanayake, SB1
Visser, R2
van der Palen, J2
de Jongh, FH2
Thio, BJ2
Wisecup, S1
Eades, S1
Hashmi, SS1
Samuels, C1
Mosquera, RA1
McGarry, ME1
Castellanos, E1
Bibbins-Domingo, K1
Fingleton, J1
Charles, T1
Bowles, D1
Strik, R1
Shirtcliffe, P1
Ahn, JR1
Blake, LK1
Silverstone, E1
Yates, DH5
Redberg, RF2
Ross, JS1
Jena, AB1
Ho, O1
Goldman, DP1
Karaca-Mandic, P1
Maggini, V1
Lombardi, N1
Lenti, MC1
Masi, S1
Trapani, S1
Pugi, A1
Mugelli, A1
Vannacci, A1
Cochius-den Otter, SC1
Joosten, KF2
Buysse, CM1
Shah, NJ1
Vinod Kumar, S1
Gurusamy, U1
Annan Sudarsan, AK1
Shewade, DG1
Quirce, S1
Domínguez-Ortega, J1
Barranco, P1
Brunetti, L2
Poiani, G1
Dhanaliwala, F1
Poppiti, K1
Kang, H1
Suh, DC1
Hartman, S1
Merkus, P1
Maseland, M1
Roovers, L1
van Setten, P1
Anwar, MM1
El-Haggar, RS1
Zaghary, WA1
Ponnala, D1
Zhao, H1
Li, R1
Lv, Y1
Dong, H1
Yao, L1
Xiao, G1
Cai, S1
Stephen, D1
Vatsa, M1
Lodha, R9
Townsend, L1
Madlon-Kay, DJ1
O'Reilly, DA1
Awale, A1
Cartledge, P1
de Boer, AH2
Gjaltema, D1
Hagedoorn, P2
Frijlink, HW2
Brehm, JM1
Man Tse, S1
Croteau-Chonka, DC1
Litonjua, AA4
Raby, BA2
Chen, W1
Yan, Q1
Boutaoui, N1
Acosta-Pérez, E1
Avila, L1
Soto-Quiros, M1
Spear, ML1
Kolls, JK1
Canino, G1
Kelderman, S1
Füeßl, HS1
Breuer, O1
Shoseyov, D1
Kerem, E4
Brooks, R2
Eke Gungor, H1
Altuner Torun, Y1
Batmaz, SB1
Kuyucu, S1
Arıkoglu, T1
Tezol, O1
Aydogdu, A1
Raphael, G1
Taveras, H6
Iverson, H6
O'Brien, C1
Miller, D1
Ledochowski, S1
Mohkam, K1
Rague, P1
Glehen, O1
Friggeri, A1
Yin, LM1
Fan, L1
Xu, YD1
Wang, WQ1
Liu, YY1
Feng, JT1
Hu, CP1
Wang, PY1
Zhang, TF2
Shao, SJ1
Yang, YQ1
Perez, T1
Dusser, D1
Yawn, BP3
Fuhlbrigge, AL3
Pace, WD1
Pencina, MJ1
Doros, G1
Kazani, S2
Lanzillotti, J1
Madison, S1
Swenson, ER2
Kerwin, EM2
Wayne, D1
Shah, T5
Lepore, MS1
Miller, DS1
Chauhan, BF1
Chartrand, C1
Ni Chroinin, M3
Milan, SJ2
Zha, N1
Pike, D1
Capaldi, DP1
Knight, JM1
Mak, G1
Shaw, J1
Porter, P1
McDermott, C1
Roberts, L1
You, R1
Millien, VO1
Qian, Y1
Song, LZ1
Frazier, V1
Kim, C1
Kim, JJ1
Bond, RA2
Milner, JD1
Zhang, Y4
Mandal, PK1
Luong, A1
Kheradmand, F1
McMurray, JS1
Corry, DB1
Lewis, RJ1
Newby, C1
Pillard, F1
Lavit, M1
Cances, VL1
Rami, J1
Houin, G1
Didier, A2
Rivière, D1
Cheng, QJ1
Huang, SG1
Chen, YZ1
Lin, JT1
Zhou, X3
Chen, BY2
Feng, YL2
Ling, X1
Sears, MR18
Heffler, E2
Crimi, C1
Campisi, R1
Sichili, S1
Nicolosi, G1
Porto, M1
Intravaia, R1
Sberna, ME1
Liuzzo, MT1
Crimi, N6
Given, J2
Kováts, Z1
Odler, B1
Snyder, A1
Disney, J1
Thomas, A1
Wilcox, G1
Brown, MA1
Manoharan, A2
Lipworth, J2
Anderson, W1
Short, P1
Holt, S4
Şen, E1
Oğuzülgen, K1
Bavbek, S1
Günen, H2
Kıyan, E1
Türktaş, H2
Yorgancıoğlu, A1
Polatlı, M1
Yıldız, F1
Çelik, G1
Demir, T1
Mungan, D2
Saryal, S1
Sayıner, A1
Yıldırım, N1
Memon, BN1
Parkash, A1
Ahmed Khan, KM1
Gowa, MA1
Bai, C2
Yu, H1
Tan, X1
Zhang, P1
Fang, Z2
Wang, C1
He, X1
Ricciardolo, FL1
Rindone, E1
Schiavetti, I1
Ciprandi, G3
Sahi, PK1
Shastri, S1
Gupta, N1
Pandey, RM3
Kabra, M1
Craig, S1
Tuszynski, M1
Armstrong, D1
Andrzejowski, P1
Carroll, W1
Brown, RH2
Eisenstein, EM1
Phillips, JE1
Renteria, L1
Burns, L1
Harris, P1
Peng, R1
Bauer, CM1
Laine, D1
Stevenson, CS1
Virchow, JC4
Backer, V7
Kuna, P3
Prieto, L5
Nolte, H1
Villesen, HH1
Ljørring, C1
Riis, B1
de Blay, F1
Singanayagam, A1
Johnston, SL3
Fagbuyi, DB1
Venkataraman, S2
Ralphe, JC1
Zuckerbraun, NS1
Pitetti, RD1
Lin, Y1
Jeong, K1
Saladino, RA1
Manole, MD1
Donohue, JF4
Wise, R1
Garfinkel, S1
Zubek, VB1
Ghafouri, M1
Manuel, RC1
Schlenker-Herceg, R1
Fawcett, JP4
Isaac, BT1
McLellan, T1
Samuel, J1
Yung, B1
Souza, JM1
Torres, HC1
De Lalibera, IB1
de Souza, AV1
Rodrigues, JC2
Schvartsman, C1
da Silva Filho, LV1
Czövek, D1
Hantos, Z1
Taylor, K2
Kumar, A1
Chacko, A1
Ware, RS1
Makan, G1
Radics, B1
Gingl, Z1
Sly, PD6
Rajaure, Y1
Kumar, B1
Sahoo, K1
T, V1
Shaw, N1
Le Souëf, P1
Turkovic, L1
McCahon, L1
Kicic, A1
Devadason, S1
Schultz, A2
Fattore, E1
Davoli, E1
Castiglioni, S1
Bosetti, C1
Re Depaolini, A1
Marzona, I1
Zuccato, E1
Fanelli, R1
Sarhan, HA1
El-Garhy, OH1
Ali, MA1
Youssef, NA1
Du, H1
Shi, Y1
Yu, J1
Sun, W1
Delate, T1
Rader, N1
Jenkins, DW1
Lowe, R1
Welch, MJ5
Vilozni, D1
Hakim, F1
Livnat, G1
Ofek, M1
Bar-Yoseph, R1
Bentur, L4
Tarigopula, P1
Kattamuri, RK1
Mangalarapu, M1
Vinukonda, S1
Sagurthi, SR1
Spin, P1
Hill-Taylor, B1
Ward, C7
Ratnayake, A1
Shore, P3
Phillips, BR2
Bhakta, NR1
Cardet, JC1
Aujla, S1
Comhair, SA1
Coverstone, A1
DeBoer, M1
Erzurum, SC2
Fain, SB1
Fajt, M1
Gaffin, J1
Gaston, B1
Hastie, AT3
Hawkins, GA4
Irani, AM1
Levy, BD1
Myers, R1
Opina, MT1
Peters, MC1
Schiebler, ML1
Sorkness, RL3
Woodruff, PG1
Bush, A3
Frey, U4
He, M2
Driehuys, B1
Que, LG2
Huang, YT1
Pascoe, SJ2
Wilsdon, T1
Kichenadasse, G1
Rowland, A1
Hasegawa, T2
Uno, H1
Wei, LJ1
Weinberger, M8
Qaqundah, PY2
Yuan, J1
Lu, ZK1
Love, BL1
Schulz, RM1
Hall, AB1
Novotny, A1
Bhisitkul, DM2
Melton, J1
Regan, T1
Leckie, M1
Adams, CD1
Strand, M3
Koehler, K1
Volckens, J1
Quan-Jun, Y1
Jian-Ping, Z1
Jian-Hua, Z1
Yong-Long, H1
Bo, X1
Jing-Xian, Z1
Bona, D1
Yuan, Z1
Cheng, G1
Parsa, SA1
Khaheshi, I1
Memaryan, M1
Naderian, M1
Boehmer, SJ6
Paul, IM2
Daines, CL1
Daines, MO1
Gower, WA1
Morgan, W2
Sallam, NM1
Sanad, RA1
Kharshoom, RM1
Zeneldin, MA1
Mudd, SS1
Ogborn, CJ2
Kub, J1
Bellin, MH1
Khwaja, YH1
Tai, JM1
Fung, V1
Li, L1
Butler, MG1
Nordin, JD1
Hsu, J1
Smith, D1
Vollmer, WM2
Lieu, TA2
Soumerai, SB1
Comaru, T1
Pitrez, PM1
Friedrich, FO1
Silveira, VD1
Pinto, LA2
Chen, P1
Dai, A1
Shang, S1
Kong, L2
Nieto, A1
Mazón, Á1
Nieto, M1
Ramazan-Yousif, L1
Albertsen, S1
Bergmann, TK1
Madsen, PH1
Steen, NP1
Chauhan, B1
LaForce, C5
Delstanche, S1
Servais, L1
Gidaro, T1
Kirkland, SW1
Vandenberghe, C1
Voaklander, B1
Nikel, T1
Campbell, S1
Biswas, R1
Sabharwal, A1
Kola, M1
Hacıoğlu, D1
Erdöl, H1
Türk, A1
Dilts, JJ1
Humiston, SG1
Lee, BR1
Allen, NH1
Michael, JG1
Navanandan, N1
Federico, M1
Mistry, RD1
Mathew, JL2
Walia, M1
O' Kane, R1
Green, RH1
Miller, E1
Weiss, KB1
Bateman, E1
Nelson, H4
Kral, K2
Sutton, L1
Ortega, H2
Yancey, S6
Dachs, R1
Darby-Stewart, A1
Graber, MA1
Caruso, JF1
Hamill, JL1
Yamauchi, M1
Saito, K1
Cook, TD1
Mercado, DR1
Gharagozlou, M1
Abdollahpour, H1
Moinfar, Z1
Bemanian, MH1
Sedaghat, M1
Fujimura, M4
Moon, H1
Choi, HH1
Lee, JY3
Moon, HJ1
Sim, SS2
Kim, CJ3
Al Obaidi, AH1
Al Samarai, AM1
Madabushi, R1
Derendorf, H2
Lima, J1
Clark, TJ18
Gul, N3
Gibbs, M1
Pedersen, S9
Naqvi, M2
DeBoard, JA1
Navarro, D2
Castro, RA3
Watson, HG2
LeNoir, M2
Choudhry, S4
Davis, KJ2
Crim, C6
Godard, P7
Greillier, P1
Pigearias, B1
Nachbaur, G2
Desfougeres, JL9
Attali, V3
Sposato, B1
Mariotta, S2
Ricci, A1
Ciubotaru, RL1
Noe, L1
Pasta, DJ1
Schaefer, K3
Claus, R3
Andrews, WT1
Roach, J1
Lasserson, TJ12
Ferrara, G2
Casali, L6
Cates, MJ3
Gold, DR1
Zolli, JR1
Makaryus, AN1
Macleod, KA1
Horsley, AR1
Bell, NJ1
Greening, AP3
Innes, JA1
Cunningham, S1
Campbell, JD1
Borish, L1
Haselkorn, T1
Rasouliyan, L2
Lee, JH2
Sullivan, SD1
Tripp, K3
McVicar, WK2
Pleskow, WW2
Goodwin, E2
Baumgartner, RA7
Hanrahan, JP5
Duplessis, CA1
Gumpert, B1
Cooper, PR1
Chang, C2
Wang, XH1
Yao, WZ1
Liu, XF1
Hang, YJ1
Boonsarngsuk, V2
Pipopchaiyasit, N1
Kiatboonsri, S2
Aballéa, S1
Cure, S1
Vogelmeier, C7
Wirén, A1
Maspero, J2
Guerra, F1
Cuevas, F1
Gutierrez, JP1
Soto-Ramos, M1
Anderton, S2
Mechali, D1
Stanford, RH13
Fuhlbrigge, A1
Riedel, A1
Rey, GG1
Lowe, DO1
Lummis, H1
Sketris, IS1
Wijesinghe, M3
Perrin, K4
Koenig, SM3
Ostrom, N1
Pearlman, D2
Waitkus-Edwards, K1
Prillaman, BA1
Dorinsky, P16
Taussig, LM6
Guilbert, T1
Krawiec, M1
Larsen, G3
Huchon, G1
Magnussen, H13
Chuchalin, A4
Dymek, L1
Gonod, FB1
Qian, Z2
Lin, HM2
Lehman, EB2
Stewart, WF1
Shah, N1
Duan, Y2
Craig, TJ7
Wilson, WE2
Liao, D2
Bascom, R2
Covar, RA4
Moss, M1
Patel, AC1
Van Natta, ML1
Tonascia, J1
Friedman, H1
Wilcox, T1
Reardon, G2
Crespi, S2
Butt, AT1
Kamat, D1
Pansare, M1
Moral, VP1
Marcos, LG1
Stoltz, P1
Zucker, AR1
Jung, KS1
Uh, ST1
Lee, YC1
Shim, JJ1
Park, SK1
Williams, AE2
Uspal, NG1
Agrawal, D1
Lundbäck, B10
Rönmark, E3
Lindberg, A3
Jonsson, AC2
Larsson, LG2
James, M3
Miyagawa, T3
Nibhanipudi, K1
Hassen, GW1
Dell'Aniello, S1
Ernst, P7
Larsen, GL2
Heldt, GP1
Martinez, F1
Radford, S1
Pillmann, F1
Choudhary, AS1
Robinson, GM1
Dhuper, S3
Chandra, A3
Ahmed, A2
Bista, S1
Moghekar, A1
Verma, R1
Chong, C1
Shim, C4
Cohen, H2
Choksi, S2
Foliaki, S1
Fakakovikaetau, T1
D'Souza, W1
Latu, S1
Tutone, V1
Cheng, S1
Pearce, N9
Hackshaw, A1
Djukanovic, R8
Lindmark, B1
Clearie, K1
Chhabra, R1
Maheshwari, P1
Kardos, P4
Awab, A1
Alilou, M1
El Moussaoui, R1
El Hijri, A1
Azzouzi, A1
Derom, E2
Tiesler, C1
Engelstätter, R1
Kaufman, JM1
Joos, GF1
Watanabe, N1
Makino, S4
Kihara, N1
Fukuda, T4
Stavreska, V1
Verheggen, M1
Oostryck, J1
Stick, SM1
Korn, D1
Van den Brande, P1
Potvin, E1
Dramaix, M1
Herbots, E1
Peché, R1
Shi, L2
Guadarrama, A1
Schell, K1
Green, D1
Morrin, A1
Hogan, K1
Gern, JE1
Peters, M1
Lommatzsch, M1
Lindner, Y1
Edner, A1
Bratke, K1
Kuepper, M1
de Blic, J5
Ogorodova, L1
Klink, R1
Sidorenko, I1
Valiulis, A1
Hofman, J2
Bennedbaek, O1
Poterre, M1
Miller, DP1
Tom, G1
Chipps, B3
Yilmaz, O1
Sogut, A1
Kose, U1
Sakinci, O1
Yuksel, H3
Lochindarat, S1
Qazi, SA1
Bunnag, T1
Nisar, YB1
Jatanachai, P1
Vangveeravong, M2
Bloomberg, GR4
Banister, C1
Sterkel, R1
Epstein, J2
Bruns, J1
Swerczek, L1
Wells, S1
Yan, Y1
Garbutt, JM2
Sundram, F1
Notghi, A1
Smith, NB1
Yancey, SW21
Klotsman, M2
Ortega, HG7
Edwards, LD5
Anderson, WH5
Richter, DC1
Joubert, JR4
Nell, H1
Schuurmans, MM1
Irusen, EM1
Parkins, DA1
Thomas, MJ1
Gillett, B1
House, KW2
Hernández-Cadena, L1
Barraza-Villarreal, A1
Del Río-Navarro, BE2
Sienra-Monge, JJ2
Romieu, I1
Ferrua, S1
Varbella, F1
Conte, MR1
Delgado, C1
Spinka, C1
DeClue, AE1
Dhand, R2
Naimi, DR1
Freedman, TG1
Ginsburg, KR1
Bogen, D1
Apter, AJ5
Munnik, P1
Wissink, J1
Heskamp, I1
de Kruijf, W1
van Rijn, CJ1
Zanen, P4
Edin, HM1
Andersen, LB1
Schoaf, L4
Scott-Wilson, CA2
Borgström, L2
Ingelf, J1
Fritscher, L1
Chapman, KR16
Hoshino, M1
Handa, H1
Miyazawa, T1
Andrews, T1
McGintee, E1
Mittal, MK1
Tyler, L1
Chew, A2
Pawlowski, N1
Zorc, JJ3
Taylor, CF3
Simmons, M1
Shinar, C1
Ukena, D4
González Jiménez, D1
Concha Torre, A1
Menéndez Cuervo, S1
García Hernández, I1
McGowan, B1
Bennett, K1
Barry, M1
Owens, M1
O'Connor, M1
Moore, PE3
Ryckman, KK1
Williams, SM1
Patel, N2
Summar, ML1
Sheller, JR2
Cayley, WE1
El-Gendy, NA1
Sabry, NA1
El-Attar, M1
Omar, E1
Mahmoud, M1
Friedman, HS3
Eid, NS1
Wilcox, TK1
Milanese, M3
Saporiti, R1
Bartolini, S1
Baroffio, M2
Freiner, D1
Highstein, GR1
Nelson, KA2
Smith, SR2
Greenstone, I2
Gruchalla, RS1
Sampson, HA2
Matsui, E1
David, G1
Gergen, PJ2
Calatroni, A2
Brown, M1
Liu, AH3
Lamm, C1
Smartt, E1
Steinbach, SF1
Stone, KD2
Kercsmar, CM3
Di Corcia, D1
Morra, V1
Pazzi, M1
Vincenti, M1
Berger, WE9
Veiga, J1
Lopes, AJ1
Jansen, JM1
de Melo, PL1
Holley, AD1
Boots, RJ1
Schneider, CR1
Everett, AW1
Geelhoed, E1
Kendall, PA1
Clifford, RM1
Erickson, E1
Sivasankar, M1
Kurosaka, F1
Nishio, H1
Rohan, J2
Drotar, D2
McNally, K1
Schluchter, M2
Riekert, K1
Vavrek, P2
Schmidt, A3
Redline, S2
Kercsmar, C2
Page, C1
McKeage, K1
Keam, SJ1
Carroll, WD1
Jones, PW1
Boit, P1
Clayton, S1
Cliff, I1
Lenney, W16
Aumiller, J1
Baraldi, E3
Boner, AL9
Rossi, GA3
Basu, K2
Palmer, CN3
Mukhopadhyay, S4
Tilemann, L1
Gindner, L1
Meyer, FJ1
Laux, G1
Szecsenyi, J2
Schneider, A2
Navaratnam, P1
Urdaneta, E1
Zachgo, W1
von Berg, A5
Kamin, W2
Stern-Sträter, C1
Steinkamp, G3
Ridley-Smith, RM1
Hussain-Rizvi, A1
Kunkov, S1
Crain, EF2
Cruse, G1
Yang, W1
Duffy, SM1
Leyland, M1
Vandeleur, M1
Chróinín, MN1
Gordon, E1
Fernández, A2
Guardia, S2
González, A2
Serrano, R1
Rodenstein, D3
Sala, H2
McNally, KA1
Riekert, KA1
Spahn, J1
Sheth, K3
Yeh, WS1
Nelson, HS20
Emmett, AH8
Papiris, SA1
Manali, ED1
Kolilekas, L1
Triantafillidou, C1
Tsangaris, I1
Elers, J3
Pedersen, L3
Henninge, J3
Lund, TK1
Hemmersbach, P3
Dalhoff, K3
Bleecker, E2
Denlinger, L3
Jarjour, N2
Kim, S1
Markezich, A1
Permaul, P1
Spier, S4
Bérubé, D2
Carr, S1
Watson, W1
McIvor, RA3
Virchow, C1
Renzi, PM1
Howard, LA1
Ahmad, FF1
Pérez-de-Llano, LA1
Carballada, F1
Castro Añón, O1
Pizarro, M1
Golpe, R1
Baloira, A1
Vázquez Caruncho, M1
Boquete, M1
Punj, A1
Prakash, A1
Bhasin, A1
Pinto Pereira, LM3
Boodoo, S1
Dindial, KA1
Hosein, A1
Seemungal, TA1
Bekele, I1
Park, HY1
Lim, SY1
Park, HK1
Park, SY1
Kim, TS1
Suh, GY1
Puckett, JL1
Taylor, RW2
Leu, SY1
Aledia, AS1
George, SC2
Camargo, CA5
Boulet, LP19
Ferro, TJ1
Menzella, F1
Facciolongo, N1
Castagnetti, C1
Simonazzi, A1
Zucchi, L1
Frois, C1
Wu, EQ1
Ray, S1
Colice, GL9
Scichilone, N2
Battaglia, S1
Sorino, C1
Paglino, G1
Martino, L1
Paternò, A1
Santagata, R1
Spatafora, M1
Bellia, V3
Di Berardino, F1
Forti, S1
Piatti, G1
Fasano, V1
Cross, KP2
Randell, KA1
Herr, SM1
VanHaitsma, TA1
Mickleborough, T1
Stager, JM1
Koceja, DM1
Lindley, MR2
Chapman, R1
Xu, J2
Nave, R1
Lahu, G1
Burgess, SW1
O'Connor, RD6
Patrick, DL1
Parasuraman, B2
Martin, P3
Goldman, M4
Wiwanitkit, V1
Riesenfeld, EP3
Sullivan, MJ2
Thompson-Figueroa, JA1
Haverkamp, HC1
Lundblad, LK3
Bates, JH3
Singh, S1
Soni, R1
Rawat, MK1
Deshpande, SB2
Singh, SK2
Muthu, MS1
Rotta, ET1
Amantéa, SL1
Froehlich, PE1
Becker, A2
von Mutius, E1
Drazen, JM14
Moss, MH2
Prazma, CM1
Kral, KM2
Yang, Y2
Shi, Q1
Li, RJ1
Pan, PW1
Hou, YY1
Lu, WG1
Bai, G1
Hoffmann, HJ1
Nielsen, LP2
Harving, H2
Heinig, JH1
Dahl, R10
Ulrik, CS3
Claudius, BK1
Tamm, M2
Siersted, HC1
Hellquist, B1
Høgholm, A1
Jøhnk, IK1
Vu, LT1
Nguyen, MT1
Nguyen, YT2
Ortega, HA1
Liu, L2
Kim, SO1
Kumar, G1
Stamler, JS1
Tohda, Y1
Nishima, S2
Arakawa, I2
Shiragami, M2
Miyamoto, T1
Hu, A1
Grunstein, JS1
Grunstein, MM1
Ahmad, Z1
Kumar, P1
Parashette, KR1
Noronha, P1
Holden, NS1
Rider, CF1
Bell, MJ1
Velayudhan, J1
King, EM1
Kaur, M1
Salmon, M1
Giembycz, MA3
Newton, R1
Gibson, PG8
Peters, MJ3
Wark, PA2
Sand, IB1
Hoyos, CM1
Jenkins, CR2
Kovacevic, A1
Schwahn, B1
Schuster, A2
Stallaert, R1
Reznikova, E1
Bloemen, P1
Adamek, L1
Joos, G1
Gross, CA1
Bowler, RP1
Green, RM1
Weinberger, AR1
Schnell, C1
Chu, HW1
Aalbers, R14
Boorsma, M3
van der Woude, HJ7
Jonkers, RE3
Yamaguchi, T1
Soma, T1
Takaku, Y1
Nakagome, K1
Hagiwara, K1
Kanazawa, M2
Nagata, M2
Hirst, C1
Calingaert, B1
Castellsague, J3
Bianchi, M1
Clavenna, A1
Bonati, M1
Berdel, D4
Buhl, R6
Criée, CP1
Freihorst, J1
Gillissen, A3
Karg, O1
Pfeifer, M1
Teschler, H1
Welte, T3
Wettengel, R4
Worth, H2
Andrade, WC1
Camargos, P3
Lasmar, L1
Liao, MM1
Ginde, AA1
Clark, S2
Fogel, RB1
Rosario, N1
Aristizabal, G1
Loeys, T1
Noonan, G1
Gaile, S1
Smugar, SS1
Polos, PG3
Mele, L1
Calogero, C1
Bernardini, R1
Novembre, E1
Azzari, C1
de Martino, M1
Lombardi, E1
Sugihara, N1
Kanada, S1
Haida, M1
Ichinose, M2
Adachi, M7
Hosoe, M1
Emery, C1
Higgins, M1
Kramer, B1
Vaessen-Verberne, AA1
van den Berg, NJ2
van Nierop, JC1
Brackel, HJ2
Gerrits, GP1
Duiverman, EJ12
Silkoff, PE2
Krishnan, A1
Shinar, CM2
Maginot, T1
Turner, DL1
Ferrari, N1
Ford, WR1
Kidd, EJ1
Paquet, L1
Renzi, P1
Broadley, KJ2
Harada, M1
Hirota, T1
Jodo, AI1
Hitomi, Y1
Sakashita, M1
Tsunoda, T1
Doi, S2
Kameda, M2
Fujita, K1
Miyatake, A2
Enomoto, T1
Noguchi, E2
Masuko, H1
Suzuki, Y2
Yoshihara, S1
Ebisawa, M1
Saito, H2
Nakajima, T1
Mathias, RA1
Rafaels, N1
Barnes, KC1
Duan, QL2
Nakamura, Y1
Ziegler, SF1
Tamari, M1
Krakowiak, J1
Crompton, GK22
Pisarik, P1
Kim, TD1
Lee, JG1
Whang, WK1
Zemek, RL1
Chalut, D2
McGillivray, D2
Noya, FJ1
Resendes, S1
Khomenko, L1
Rouleau, R2
De Giacomo, A1
Corvol, H2
Welsh, EJ1
Qazi, K1
Altamimi, SA1
Tamim, H1
Serrano, K1
Fogli, S1
Pellegrini, S1
Adinolfi, B1
Mariotti, V1
Melissari, E1
Betti, L1
Fabbrini, L1
Giannaccini, G1
Lucacchini, A1
Bardelli, C1
Stefanelli, F2
Brunelleschi, S1
Breschi, MC1
Harrison, J1
Gibson, AM1
Singh, G1
Skoric, B1
Ranganathan, S1
Jayakrishnan, B1
Al-Rawas, OA1
Gaume, BR1
Klanderman, B1
Liggett, SB3
Mannava, B1
Franklin, AE1
Garner, WJ1
Dickey, BF3
Knobil, K2
Cydulka, RK8
Emerman, CL8
Muni, A1
Hamilton, N1
Beckert, L3
de Matas, M3
Shao, Q2
Biddiscombe, MF6
Meah, S1
Chrystyn, H6
Usmani, OS6
Reszka, KJ1
Sallans, L1
Macha, S1
Brown, K1
McGraw, DW1
Kovacic, MB1
Britigan, BE1
Kazani, SD1
Curfman, GD1
Morrissey, S1
Krajewska, J1
Jarzab, J2
Mishra, RK1
Radhi, S1
Nugent, KM1
Brillet, PY1
Capderou, A1
Becquemin, MH1
Beigelman-Aubry, C1
Fetita, CI1
Similowski, T1
Zelter, M1
Grenier, PA1
Le Souëf, TJ1
Venter, A1
Le Souëf, PN2
Sellers, WF3
Ahmad, I1
Bathke, PS1
Brown, CJ1
Fernandez, T1
Barker, A1
Postma, DS12
Asamoto, H1
Boucher, A1
Payen, C1
Garayt, C1
Ibanez, H1
Dieny, A1
Doche, C1
Chuniaud, C1
Descotes, J1
Chen, R3
Xiong, J1
Yi, F1
Chi, Z1
Zhang, B1
Vora, C1
Renvall, MJ1
Chao, P1
Ferguson, P1
Ramsdell, JW4
Deesomchok, A1
Webb, KA1
Forkert, L2
Lam, YM1
Ofir, D1
Jensen, D1
O'Donnell, DE2
Riedel, AA2
Johnson, JC1
Astry, CL1
Zedan, M1
Settin, A1
El-Chennawi, F1
El-Desouky, T1
Nasef, N1
Fouda, A1
Liang, C1
Yang, K1
Bulloch, B1
Garcia-Filion, P1
Keahey, L1
Abramo, TJ1
Ozier, A1
Girodet, PO1
Bara, I1
Tunon de Lara, JM1
Marthan, R2
Berger, P1
Miller, DR1
Chetty, M1
Matsuda, S1
Shikada, M1
Sakai, T1
Nakano, T2
Oh, Y1
Lam, KP1
Chu, YT1
Lee, MS1
Chen, HN1
Wang, WL1
Tok, TS1
Chin, YY1
Chen, SC1
Kuo, CH1
Hung, CH2
Checkley, W1
Bade, E1
Friedman, NJ1
Heidarian-Raissy, H1
Kelly, HW7
Malka-Rais, J1
Mellon, MH2
Taussig, L1
López-Herce, J1
Coronel, J1
Spitters, C1
Guggiari, J1
Sabato, K1
Ward, P1
Hawk, W1
Gildengorin, V1
Asselin, JM1
Guo, JJ1
Tsai, K1
Kelton, CM1
Bian, B1
Wigle, PR1
Leemans, J2
Kirschvink, N2
Clercx, C2
Snaps, F2
Gustin, P2
Casarosa, P1
Kollak, I1
Kiechle, T1
Ostermann, A1
Schnapp, A1
Kiesling, R1
Pieper, M1
Sieger, P1
Gantner, F1
Kurashima, K1
Kagiyama, N1
Takayanagi, N1
Sugita, Y1
Halterman, JS1
Szilagyi, PG1
Fisher, SG1
Fagnano, M1
Tremblay, P1
Conn, KM1
Borrelli, B1
Rinaldi, LM1
Poynter, ME1
Wu, M2
Aimi, S1
Barone, LM1
Bar-Yishay, E1
Avital, A3
Springer, C2
Meah, SN1
Underwood, SR3
Doan, Q1
Shefrin, A1
Johnson, D3
Polat, TB1
Saz, EU1
Nursoy, MA1
Araújo, L1
Moreira, A1
Palmares, C1
Beltrão, M1
Fonseca, J1
Delgado, L2
Direkwatanachai, C1
Teeratakulpisarn, J1
Suntornlohanakul, S1
Trakultivakorn, M1
Ngamphaiboon, J1
Wongpitoon, N1
Hinkle, J1
Hinson, J1
Sciarappa, K1
Curry, L1
Panontin, E2
Longo, G3
Thamrin, C1
Nydegger, R1
Stern, G1
Watt, RA1
FitzPatrick, S1
Taylor, DR21
Yeh, KH1
Skowronski, ME2
Coreno, AJ2
Seitz, RE2
Villalba, KD1
Dickey-White, H2
McFadden, ER11
Bodzenta-Lukaszyk, A2
Dymek, A1
McAulay, K1
Mansikka, H1
Grainge, CL1
Lau, LC2
Ward, JA1
Dulay, V1
Lahiff, G1
Wilson, S3
Holgate, S3
Davies, DE2
Howarth, PH11
Christian Virchow, J1
Ali, M1
Chisholm, A1
Lee, AJ1
Hillyer, EV1
von Ziegenweidt, J1
Signori, A1
Cirillo, I1
Clearie, KL1
McKinlay, L1
Radice, S2
Milanesi, A1
Antoniazzi, S2
Perrone, V2
Carnovale, C2
Clementi, E2
Khianey, R1
Oppenheimer, J2
Harrison, LI1
Novak, CC1
Needham, MJ1
Ratner, P2
Fink, JB1
Armstrong, L1
Wan, Y1
Alagappan, VK1
Ohlssen, D1
Kelley, JM1
Boyd, IO1
Dutile, S1
Marigowda, G1
Kirsch, I1
Kaptchuk, TJ1
Moerman, DE1
Upham, BD1
Mollen, CJ1
Scarfone, RJ3
Seiden, J1
Mendonça, NT1
Kenyon, J1
LaPrad, AS1
Syeda, SN1
O'Connor, GT3
Lutchen, KR4
Hagiwara, M3
Delea, TE3
Fu, WP1
Zhao, ZH1
Zhong, L1
Sun, C1
Fang, LZ1
Zhang, JQ1
Shu, JK1
Wang, XM1
Dai, LM1
Kornmann, O3
Schmidt, P1
Pivovarova, A1
Engel, M1
Kermode, JA1
Brown, NJ1
Hardaker, KM1
Farah, CS1
Berend, N1
King, GG2
Salome, CM3
Garriga, T1
Labrador-Horrillo, M1
Guillén, M1
Luengo, O1
Eseverri, JL1
Guilarte, M1
Marin, AM1
Cardona, V1
Tovey, D1
Zwar, NA1
Marks, GB1
Hermiz, O1
Middleton, S1
Comino, EJ1
Hasan, I1
Vagholkar, S1
Wilson, SF1
Matos, AC1
Srirangalingam, U1
Barry, T1
Grossman, AB1
Horner, CC1
Mauger, D1
Graber, NJ1
Kupczyk, M2
Dahlén, SE2
Silveira, L1
Gelfand, EW4
Lehman, E3
Korn, S2
Flor-Escriche, X1
Rodríguez-Mas, M1
Espiau, M1
Castán-Enseñat, X1
Vigatà-Reig, JM1
Poblet-Cortés, R1
Miravitlles, M1
Youkou, A1
Suzuki, K2
Koya, T1
Sakagami, T1
Toyabe, S1
Arakawa, M1
Gejyo, F1
Narita, I1
Suzuki, E1
Ogorodova, LM2
Kulikov, ES1
Deev, IA2
Cherniak, BA1
Fassakhov, RS1
Mangunnegoro, H1
Novariska, F1
Wiyono, WH1
Setiawati, A1
Louisa, M1
Nair, A1
Ward, J3
Rebolledo, P1
Kroegel, C2
Rolla, G4
Bucca, C4
Bibalo, C1
Straumann, A1
Safroneeva, E1
Schoepfer, AM1
Debley, J1
Stanojevic, S2
Filbrun, AG1
Subbarao, P1
Mysore, S1
Ruffin, RE4
Ohara, Y2
Ohara, T1
Ohrui, T2
Morikawa, T2
Asamura, T1
Sasaki, H2
Arai, H1
Bernaerts, F1
Billen, F1
McCabe, JC1
Koppenhagen, F1
Blair, J1
Zeng, XM1
Hartnett, BJ2
Marlin, GE5
Willey, RF4
Grant, IW11
Pocock, SJ2
Sanchez, AM1
Collomp, K1
Carra, J1
Borrani, F1
Coste, O1
Préfaut, C3
Candau, R1
Hu, Z1
Cai, Z1
Yu, L1
Fei, Y1
Weng, L1
Ge, X1
Zhu, T1
Wildfire, JJ1
Mitchell, HE1
Kattan, M4
Teach, SJ1
Wood, RA1
Conroy, K1
Rivera-Sanchez, Y1
Lin, S1
Munsie, JP1
Herdt-Losavio, ML1
Druschel, CM1
Campbell, K1
Browne, ML1
Romitti, PA1
Olney, RS1
Bell, EM1
Rossios, C1
To, Y1
Osoata, G1
Ito, M2
Barnes, PJ24
Ito, K3
Bledsoe, B1
Buchannan, K1
Hodnick, R1
Yasmin, S1
Mollah, AH1
Basak, R1
Islam, KT1
Chowdhury, YS1
Spears, M1
Janssens, T1
Verleden, G1
De Peuter, S2
Petersen, S1
Van den Bergh, O2
Gerzeli, S1
Rognoni, C1
Quaglini, S1
Cavallo, MC1
Cremonesi, G1
Mougey, EB1
Chen, C2
Blake, KV5
Leach, CL1
Kuehl, PJ1
Chand, R1
Ketai, L1
Norenberg, JP1
McDonald, JD1
Doan, ML1
Roy, D1
Pinsker, JE1
Arun, JJ1
Staggs, L1
Peek, M1
Southard, G1
Gracely, E2
Baxendale, S1
Kim, IK3
Melosini, L1
Dente, FL16
Bacci, E15
Bartoli, ML6
Cianchetti, S6
Costa, F2
Di Franco, A15
Malagrinò, L2
Novelli, F2
Vagaggini, B15
Yin, L1
Wong, YF1
Vasudevan, VP1
Suryanarayanan, M1
Shahzad, S1
Megjhani, M1
Bahloul, M1
Chaari, A1
Dammak, H1
Medhioub, F1
Abid, L1
Chtourou, K1
Rekik, N1
Chelly, H1
Kallel, H1
Bouaziz, M1
Yokomura, K1
Hayakawa, H1
Ide, K1
Toyoshima, M1
Kuroishi, S1
Yasuda, K1
Suganuma, H1
Yamada, T2
Masuda, M1
Gómez, FP2
Casas, A1
Rodriguez-Roisin, R8
Dembla, G1
Mundle, RP1
Salkar, HR1
Doifoide, DV1
Plint, A2
Freedman, S2
Porter, R2
Gouin, S2
Hernandez, A1
Teoh, L1
Hurwitz, M1
Acworth, JP1
van Asperen, P2
Chang, AB1
Machado, D1
Pereira, C1
Tavares, B1
Loureiro, G1
Segorbe-Luís, A1
Jenkins, C4
Seccombe, L1
Tomlins, R1
Jacobs, TS1
Jones, BL1
MacGinnitie, AJ1
Warkocka-Szoltysek, B1
Filipowska-Gronska, A1
Trifilieff, A1
Fozard, JR1
Sturney, S1
Suntharalingam, J1
Aparici, M1
Gómez-Angelats, M1
Vilella, D1
Otal, R1
Carcasona, C1
Viñals, M1
Ramos, I1
Gavaldà, A1
De Alba, J1
Gras, J1
Cortijo, J1
Morcillo, E1
Puig, C1
Ryder, H1
Beleta, J1
Miralpeix, M1
Naya, I2
Ekelund, J1
Chiang, WC1
Chen, YM1
Tan, HK1
Balakrishnan, A1
Liew, WK1
Lim, HH1
Goh, SH1
Loh, WY1
Wong, P1
Teoh, OH1
Goh, A1
Chay, OM1
Nicholls, DJ1
Jordan, S1
Cadogan, E1
Lawson, M1
Austin, RP1
Paine, SW1
Gardiner, P1
Bonnert, R1
Connolly, S1
Young, A1
Klemola, T1
Kajosaari, M1
Fabbri, L2
Olivieri, D3
Rossi, A5
Park, SJ2
Lee, CH2
Goo, JM2
Kim, JH2
Park, EA2
Jung, JW1
Park, HW1
Cho, SH3
Zuccotti, G1
Piazza, A1
Cavkaytar, O1
Kalo, Z1
Abonyi-Toth, Z1
Bartfai, Z1
Voko, Z1
Singh, D3
Bindi, E1
Haran, M1
Schattner, A1
Mate, A1
Starobin, D1
Haran, G1
Shtalrid, M1
Molise, MC1
Maffey, AF2
Ramos, P1
Rubinstein, F1
Latorre, M1
Bartoli, M1
Matsunaga, K1
Akamatsu, K1
Hirano, T2
Costella, S1
Paterson, NA1
Mecklin, M1
Paassilta, M1
Korppi, M2
Zajda, E1
Durmišević, S1
Durmišević-Serdarević, J1
Ahmetović, N1
Sivic, S1
Lelić, M1
Titus, MO1
Eady, M1
King, L1
Bowman, CM1
Jackson, C4
Fielding, S1
Guthrie, B1
Tamagaki, G1
Kanazawa, H5
Hirata, K3
Song, NC1
He, JB1
Xu, HB1
Wu, JF1
Schwartz, RH1
Neacsu, O1
Ascher, DP1
Alpan, O1
Golden, LR1
DeSimone, HA1
Yeroshalmi, F1
Pranevicius, M1
Saraghi, M1
Stovold, E1
McIver, T1
Grothe, B1
Blanchette, CM1
Roberts, MH1
Petersen, H1
Kanemitsu, Y1
Kita, H2
Niimi, A1
Fuseya, Y1
Tanimura, K1
Katayama, Y1
Takahashi, T2
Hatachi, Y1
Nishihara, Y1
Sado, T1
Kim, WW1
Smith, TC1
Feustel, PJ1
Jourd'heuil, D1
Donald, HP1
Macgregor, DF2
Ogston, SA2
Maselli, DJ1
Adams, SG1
Peters, JI2
Levine, SM1
Manara, A1
Hantson, P1
Vanpee, D1
Thys, F1
McMillan, SS1
Hattingh, HL1
King, MA1
Manthei, DM1
Ahn, K1
Chinchili, VM1
King, T1
Sheerar, D1
Henderson, J1
Harrison, C1
Miller, G1
Tosca, MA1
Capasso, M1
Liu, ZW1
Yue, F1
Gao, FY1
Qian, YB1
Wang, RL1
Clayton, K1
Monroe, K1
Magruder, T1
King, W1
Harrington, K1
Stewart, SL1
Martin, AL1
Labuda, M1
Laberge, S1
Brière, J1
Krajinovic, M1
Jat, KR1
Khairwa, A1
Travers, AH1
Jones, AP2
Richards, DH2
Beghé, B1
Nie, H1
Liu, M1
Ding, X1
Huang, Y1
Hu, S1
Borrego, LM1
Stocks, J1
Almeida, I1
Antunes, J1
Leiria-Pinto, P1
Rosado-Pinto, JE1
Hoo, AF1
Lauritsen, L1
Sahl, C1
Thorsen, S1
Ekelund, K1
Følsgaard, S1
Krebs, SE1
Flood, RG1
Peter, JR1
Gerard, JM1
McKay, AJ1
Tudur Smith, C1
Williamson, PR1
Werfel, PA1
Moreau-Colson, C1
Rodrigo, C15
Stratakos, G1
Kalomenidis, J1
Routsi, C1
Papiris, S1
Roussos, C1
Rosenborg, J4
Larsson, R1
Rott, Z2
Böcskei, C2
Poczi, M2
Juhász, G2
Furusho, K1
Nishikawa, K2
Sasaki, S1
Akasaka, T1
Arita, M1
Edwards, A2
Carnevali, S3
Giannini, D14
Ruocco, L2
Paggiaro, PL10
Chowdhury, BA2
Asmus, MJ2
Ahrens, RC8
Bisgaard, H7
Chhabra, SK5
Vijayan, VK1
De, S1
Bensch, G4
Blokhin, BM1
Socolovsky, AL1
Thomson, MH1
Till, MD3
Della Cioppa, G6
Kissoon, N1
Duckworth, LJ1
Murphy, SP1
Sternberg, AL1
Larsson, P3
Pandey, KK1
Gutiérrez, V4
Torres, V1
Uixera, S1
Marín, J1
Janssen, R1
Weda, M1
Ekkelenkamp, MB1
Lammers, JW5
Frith, LF1
Braunstein, GL3
Asano, K1
Shiomi, T1
Hasegawa, N1
Kudo, H1
Matsuzaki, T1
Hakuno, H1
Fukunaga, K1
Pizzichini, E3
Pizzichini, MM3
Leigh, R1
Cervera, A1
Liñana, J1
Ortiz, G1
Menendez, R2
Lee-Wong, M2
Dayrit, FM1
Kohli, AR1
Acquah, S1
Mayo, PH1
Borker, R3
Emmett, A14
Rickard, K11
Wolf, BL1
Bowie, D1
Cartier, A19
Cockroft, D2
Cowie, R2
Fitzgerald, M2
Sears, M1
Terzano, C2
Allegra, L4
Grembiale, RD2
Pelaia, G3
Naty, S2
Vatrella, A3
Tranfa, CM2
Marsico, SA3
Fraser, J1
Duarte, M1
Abbott, MB3
Levin, RH3
Miller, JA2
Creticos, PS1
Adams, WP1
Petty, BG1
Lewis, LD3
Singh, GJ1
Khattignavong, AP1
Molzon, JA1
Martinez, MN1
Lietman, PS1
Williams, RL1
Ringdal, N3
Chovan, L1
Tudoric, N1
Maggi, E1
Whitehead, PJ2
Gustafsson, P1
Källman, S1
Goedhart, DM1
Chatmongkolchart, S1
Schettino, GP1
Dillman, C1
Kacmarek, RM1
Hess, DR1
Lee, DK14
Anhøj, J1
Kanniess, F1
Richter, K3
Janicki, S1
Schleiss, MB1
Jörres, RA3
Robert, J1
Heyneman, CA1
Crafts, R1
Holland, J1
Arnold, AD1
Innes, NJ1
Stocking, JA1
Daynes, TJ1
Harrison, BD1
Smithline, HA1
Malice, MP1
Green, SA1
Reiss, TF2
Haggart, K2
Bates, CE5
Yoshikawa, J4
Braunstein, G2
Groeben, H1
Schlicht, M1
Stieglitz, S1
Pavlakovic, G1
Peters, J1
Brito, FF1
Mur, P1
Barber, D1
Lombardero, M1
Galindo, PA1
Gómez, E1
Borja, J1
Verbanck, S2
Schuermans, D2
Paiva, M2
Vincken, W3
Sarver, JH1
Friedlaender, EY1
Zeggwagh, AA1
Abouqal, R1
Madani, N1
Abidi, K1
Moussaoui, R1
Zekraoui, A1
Kerkeb, O1
Jeffery, PK1
Venge, P3
Gizycki, MJ1
Egerod, I1
Faurschou, P5
Arets, HG1
Mulder, PG7
Vermue, NA3
van der Ent, CK1
Habib, GS1
Saliba, WR1
Cohen, L2
Campbell, LM3
Walters, JA3
Gibson, PW1
Truitt, T1
Witko, J1
Halpern, M1
Yuan, Y1
He, T1
Zeng, J1
Luo, Y1
Bowes, D1
Sjöswärd, KN1
Josefsson, M2
Ahlner, J2
Schmekel, B2
Nowak, R2
La Grutta, S2
Gagliardo, R4
Mirabella, F1
Pajno, GB2
Bonsignore, G2
Vignola, AM7
Mamoto, T1
Molimard, M3
Moore, N1
Nagel, MW1
Wiersema, KJ1
Bates, SL1
Mitchell, JP1
Hansel, TT1
Schultze-Werninghaus, G2
Craig-McFeely, PM1
Wilton, LV2
Soriano, JB1
Maier, WC1
Shakir, SA2
Rosenwasser, LJ2
Rickard, KA15
Stiegler, KA1
Yunker, NS1
Crouch, MA1
Wooltorton, E2
Eliraz, A1
Pruzinec, R1
Weber, HH2
Akveld, M1
Shann, F1
Kumaratne, M1
Gunawardane, G1
Sharma, S1
Godatwar, P1
Kulkarni, LR1
South, M2
Roberts, G1
Newsom, D1
Gomez, K1
Raffles, A1
Saglani, S1
Begent, J1
Lachman, P1
Sloper, K1
Buchdahl, R1
Habel, A1
Nakano, Y2
Morita, S1
Kawamoto, A2
Naito, T1
Enomoto, N2
Wang, CH2
Lin, HC2
Lin, CH1
Yu, CT2
Liu, SL1
Huang, KH1
Kuo, HP2
Soroksky, A1
Stav, D1
Shpirer, I1
Silvestri, M1
Sabatini, F1
Sale, R1
Defilippi, AC1
Fregonese, L1
Battistini, E1
Biraghi, MG1
Pershad, J1
Chin, T2
Giroux, M1
Ferrières, J1
Naidu Sjöswärd, K1
Andersson, RG1
Onyirimba, F1
Apter, A1
Reisine, S1
Litt, M1
McCusker, C1
Connors, M1
ZuWallack, R2
Lanski, SL1
Greenwald, M1
Perkins, A1
Simon, HK2
Ind, PW7
Dal Negro, R2
Colman, NC1
Fletcher, CP1
Browning, D1
James, MH3
Joguparthi, V1
Breen, P1
Compadre, C1
Gann, L1
Hiller, FC1
Anderson, P1
Baena-Cagnani, CE1
DuBuske, LM2
Gurné, SE1
Stryszak, P2
Lorber, R1
Danzig, M1
Jackson, CM9
van Veen, A1
Weller, FR3
Wierenga, EA1
Jansen, HM7
Wraight, JM2
Herbison, GP10
Cowan, JO6
Flannery, EM8
Messahel, B1
Chong, FV1
Reid, DW3
Wang, N1
Zheng, L1
Bish, R4
Orsida, B1
Weiner, P2
Magadle, R2
Beckerman, M1
Berar-Yanay, N2
Kizkin, O1
Turker, G1
Hacievliyagil, SS1
Sitkauskiene, B2
Sakalauskas, R2
Malakauskas, K2
Hasani, A2
Toms, N1
O'Connor, J2
Dilworth, JP1
Agnew, JE2
Coleman, CI1
Reddy, P1
Laster-Bradley, NM1
Dorval, S1
Munagala, B1
White, CM1
Watt, PM1
Clements, B1
Chaney, GM1
Syme-Grant, NJ1
McFarlane, LC5
Carey, FA1
Broeders, ME5
Molema, J6
Folgering, HT11
Hughes, R1
Goldkorn, A1
Masoli, M5
Burgess, C9
Clement, YN1
Pinto Pereira, SM1
Lindqvist, A2
Karjalainen, EM1
Laitinen, LA5
Kava, T1
Altraja, A3
Pulkkinen, M1
Halme, M1
Laitinen, A3
Pyke, SD1
Johnson, M7
Pritchard, JN1
Wallin, A4
Sue-Chu, M1
Sandström, T7
Dashash, NA1
Mukhtar, SH1
Stenback, S1
Khan, SR1
Henry, RL4
Hurst, T1
Li, SL1
Browne, GJ4
Wilkins, BH1
Balanov, I1
Gorenberg, M1
Groshar, D1
Luder, AS2
Dubus, JC3
Guillot, C2
Badier, M2
Gordon, JR2
Swystun, VA11
Li, F1
Hull, P1
Nightingale, JA3
Marotta, A1
Klinnert, MD1
Price, MR1
Shah, L1
Wilson, AJ3
Coughlan, J2
Miesen, WM1
van der Heide, S1
Kerstjens, HA5
Dubois, AE1
de Monchy, JG3
Oguri, K1
Brambilla, C3
Le Gros, V3
Bourdeix, I2
Meyts, I1
Proesmans, M1
De Boeck, K2
Lyseng-Williamson, KA2
Plosker, GL2
Meyer, MF1
Hopkins, WE1
Crater, GD1
Hartzema, A1
Habashy, D1
Lam, LT1
Martinat, Y2
SJOGREN, I2
Boonsawat, W3
Charoenratanakul, S1
Pothirat, C1
Sawanyawisuth, K1
Seearamroongruang, T1
Bengtsson, T4
Brander, R1
Paul, N1
John, G1
Kurtaran, H1
Karadag, A1
Catal, F1
Isik, B1
Uras, N1
Bukstein, DA2
Bratton, DL1
Firriolo, KM1
Estojak, J1
Bird, SR2
Hustad, CM2
Edelman, JM2
Gross, G6
Cohen, RM1
Guy, H1
Pleskow, W2
LaForce, CF2
Yegen, U4
Matos, D1
Wolfe, JD3
Baitinger, L6
Scott, C4
Buchvald, F1
Haahtela, T8
Holgate, ST21
Picado, C7
Menten, J1
Dass, SB1
Leff, JA2
Ellis, C1
Taccola, M3
Tonelli, M2
Zingoni, M2
Slaughter, JC1
Lumley, T1
Sheppard, L1
Koenig, JQ1
Shapiro, GG4
Gibson, MD1
Guleria, R2
Singh, TR1
Sinha, S1
Padhy, AK1
Gupta, K1
Pande, JN4
Fenton, C1
Keating, GM1
MaCartney, NJ1
Hadjikoumi, I2
Hassan, A1
Milner, AD13
Pauwels, RA6
Campbell, M3
Villasante, C2
Huang, S2
Lindh, A2
Petermann, W3
Aubier, M2
Schwabe, G1
Nathan, RA15
Rosenzweig, JR2
Edin, H1
Prillaman, B6
Barbato, A2
Panizzolo, C1
Landi, L1
Semenzato, R1
Rugge, M1
Al-Mobeireek, A1
Cockburn, WJ1
Carl, JC1
Myers, TR1
Kirchner, HL1
Sutton, LB2
Dorinsky, PM9
Marabini, A2
Siracusa, A2
Stopponi, R1
Tacconi, C1
Abbritti, G1
Sims, EJ4
Hall, IP2
Pereira, A1
Mendes, E1
Ferreira, T1
Magnan, A1
Fardon, TC3
Grosclaude, M3
Cerruti, JL1
Delannay, B1
Hérent, M1
Spilthooren, F1
Kapoor, U1
Tayal, G1
Mittal, SK1
Sharma, VK1
Tekur, U1
Juniper, EF8
Price, MJ3
Boulton, DW2
Nowak, RM1
Vaickus, L1
Roach, JM2
Girgis, M1
Milner, Q1
Teper, AM1
Colom, AJ1
Kofman, CD1
Vidaurreta, SM1
Bergadá, I1
Munro, A2
Jacobs, M1
Mutschler, E1
Perera, BJ4
Boskabady, MH1
Saadatinejad, M1
Bergmann, KC1
Braun, R1
Botting, C1
Sutherland, M1
Wells, E2
Town, I1
Sainsbury, R1
Toop, L1
Delvaux, M1
Lau, L1
Kange, P1
Bartsch, P1
Wilkinson, TS1
Potter-Perigo, S1
Tsoi, C1
Altman, LC1
Wight, TN1
Gupta, G1
Baruah, BP1
Nagpal, R1
Martinez-Moragón, E1
Plaza, V2
Serrano, J1
Galdiz, JB1
López-Viña, A1
Sanchis, J1
Stoloff, SW2
Meyer, J1
Carranza Rosenzweig, JR5
Rissmiller, RW2
Larj, MJ2
Wisniewski, ME1
Cox, FM3
Nielsen, KE1
Pohunek, P1
Matulka, M1
Rybnícek, O1
Kopriva, F2
Honomichlová, H1
Svobodová, T1
Everden, P2
Harnden, C1
McGoldrick, H1
Bodalia, B1
Manion, V1
Reynia, S1
Kava, TT1
Omenaas, ER1
Nowak-Wegrzyn, A1
Beyer, K1
Bardina, L1
Metcalfe, S2
Moodie, P2
Clement, Y1
Rouse, J1
Matthew, J1
Asgarali, Z1
Ramoutar, D1
Teelucksingh, S1
Koninck, JC1
Magro, P1
Khanjari, F1
Lemarié, E2
Diot, P2
Tomari, S2
Machida, I2
Kondo, Y2
Kawano, T2
Obase, Y2
Fukushima, C2
Shimoda, T2
Kohno, S3
Fukkuda, T1
Sharma, A2
Madaan, A1
Wolf, B1
Schwindt, C1
Hamilton, RG1
Lee, E2
McNally, DL1
Zuckerman, IH1
Bergqvist, PB1
Winter, TH3
Makolkin, VI1
Ovcharenko, SI1
Peredel'skaia, OA1
Axel'rod, AS1
Du-Thanh, A1
Groleron, S1
Le Quellec, A1
Smith, AD2
Weir, RE1
Whitehead, DE1
Zaidi, FH1
Greaves, BB1
Sobolev, I1
Mazzeo, AT1
Spada, A1
Praticò, C1
Lucanto, T1
Santamaria, LB1
van Helden, HP1
Kuijpers, WC1
Diemel, RV1
Beaty, R1
Ahrens, R3
Stevens, G1
Harman, EM1
Merkus, PJ5
van Pelt, W1
van Houwelingen, JC1
van Essen-Zandvliet, LE1
Kerrebijn, KF14
Quanjer, PH5
Schermer, TR2
Hoff, WJ1
Greefhorst, AP1
Creemers, JP1
Sips, AP1
Westbroek, J1
van Herwaarden, CL10
Mahajan, P1
Haritos, D1
Rosenberg, N1
Thomas, R1
Nussbaum, E2
Gutierrez, C2
Schein, A1
Epstein, JD1
Zamel, N4
Ilowite, J1
Webb, R1
Friedman, B3
Goleva, E1
Dunlap, A1
Leung, DY2
Yoshimi, Y1
Yasui, M1
Kasahara, K1
Nakao, S1
Beeh, KM2
Rodrigues, RG1
Houghton, CM2
Woodcock, AA2
Pedersen, SE6
Dransfield, MT1
Bailey, WC1
Raftos, J1
Kerr, D1
Rosengarten, P1
Kelly, AM2
Puxeddu, I1
Lack, G1
Smith, SJ1
Levi-Schaffer, F1
Dalonzo, GE1
Jhingran, P2
El-Kassimi, FA2
Politiek, MJ2
Nizet, TA1
Baker, JW3
Kaplan, MS1
Pearlman, DS11
Bird, S1
Hustad, C1
Edelman, J1
Quinn, C1
Sekhsaria, S1
Alam, M1
Sait, T1
Starr, B1
Parekh, M1
Bye, MR1
Schweizer, C1
Saugy, M1
Kamber, M1
Haddad, S1
Arabi, Y1
Shimemeri, AA1
Benito-Fernández, J1
González-Balenciaga, M1
Capapé-Zache, S1
Vázquez-Ronco, MA1
Mintegi-Raso, S1
Guill, MF1
Barnes, NC3
Mirza, N1
Kasper Schwartz, S1
Antin-Ozerkis, D1
Cowan, LM1
Saini, B1
Krass, I1
Armour, C1
Strand, AM1
Luckow, A1
Pifferi, M1
Caramella, D1
Ragazzo, V1
De Marco, E1
Pietrobelli, A1
Halvorsen, T1
Skadberg, BT1
Eide, GE1
Røksund, OD1
Carlsen, KH4
Bakke, P1
Murray, J1
Rosenthal, R2
Somerville, L2
House, K6
VanderMeer, A3
Geri, P3
Luperini, M1
Maluccio, NM2
Mariani, L2
Marmai, C2
Pistolesi, M3
Fontana, GA3
Pace, E1
Melis, M1
Ferraro, M1
Siena, L1
Gjomarkaj, M2
Tonnel, AB1
Patel, R1
Potter, SJ1
Ung, N1
Nazario, S2
Casal, J2
Torres, A2
Gorman, JD1
Salari, K1
Toscano, M1
Sylvia, JS1
Alioto, M1
Salazar, M1
Gomez, I1
Fagan, JK1
Salas, J1
Lilly, C1
Matallana, H1
Selman, M1
Sheppard, D1
Silverman, EK2
Marogna, M1
Falagiani, P1
Bruno, M1
Massolo, A1
Riva, G1
Asero, R1
Chandra, P1
Paliwal, L1
Parker, AL1
Chew, NY1
Bosnic-Anticevich, SZ1
Chan, HK1
Edwards, L4
Lincourt, W2
ZuWallack, RL6
Busse, W3
Levine, B1
Andriano, K2
Lavecchia, C2
Cockburn, W1
Fishman, R1
Feltis, BN1
Dundas, I1
Chan, EY1
Bridge, PD5
McKenzie, SA5
Peden, D1
Condemi, JJ3
Weinstein, S4
Lau, BH1
Riesen, SK1
Truong, KP1
Lau, EW1
Rohdewald, P1
Barreta, RA1
Ponticiello, A2
Parrella, R2
Reznik, M1
Sharif, I1
Ozuah, PO1
Profita, M1
Di Giorgi, R1
Pompeo, F1
Holt, A1
Weiner, AL1
Holmes, M2
Cavanaugh, R1
Bussamra, MH1
Cukier, A1
Lindgren, B1
Svensson, K1
Berggren, F1
Kruse, M1
Rosenkranz, B1
Dobson, C1
Ayre, G1
Horowitz, A1
Ploin, D1
Rousson, A1
Vitoux-Brot, C1
Nouyrigat, V1
Foucaud, P1
Lemaire, JP1
Chevallier, B1
Bergeron, S1
Martinot, A1
Chéron, G2
Floret, D1
Tobin, A1
Santamaria, J1
Burnell, PK1
Molitor, S1
Liefring, E1
Trautmann, M3
Srichana, T2
Suedee, R2
Muanpanarai, D2
Tanmanee, N2
Chopra, N1
Rimmer, M1
Kahl, L1
Jenkins, M2
Kempsford, R2
Handel, M1
De Silva, M1
Daley-Yates, P1
Dennis, SM2
Altmann, DR1
Lee, TH3
Waring, WS1
Leigh, RB1
Butz, AM1
Donithan, M1
Rand, C1
Thompson, RE1
Carnathan, B1
Sung, J1
Paramore, LC1
Balkrishnan, R1
Nelsen, LM1
Kulkarni, AS1
Pleasants, RA1
Whitmire, JT1
Schechter, MS1
Deykin, A5
Dimango, E3
Leone, F3
Pesola, GR5
Pieters, WR2
Wilson, KK1
Smith, HC1
Tamminga, JJ1
Sondhi, S1
Ayling, J1
Haney, S3
Tamura, G2
Suda, Y1
Ohshima, Y1
Hata, I1
Tsukahara, H1
Omata, N1
Yasutomi, M1
Yamada, A1
Mayumi, M1
Angus, R1
Reagon, R1
Cheesbrough, A1
Zhong, NS2
Zheng, JP2
Cai, BQ1
Xie, CM1
Sun, TY1
Wang, DQ1
Lin, YP1
Tao, JJ1
Kang, J1
Xu, YP1
Guo, XJ1
Chen, XD1
Yin, KS2
Zhang, DP1
Zhou, JY2
Shen, HH1
Qiu, C1
Xiao, BR1
Nabe, T1
Yamauchi, K1
Shinjo, Y1
Niwa, T1
Imoto, K1
Koda, A2
Richmond, NJ1
Silverman, R3
Kusick, M1
Matallana, L1
Winokur, J1
Adcock, IM2
Westerhof, FJ1
Zuidhof, AB1
Kok, L1
Meurs, H1
Zaagsma, J1
Prenner, BM3
van den Toorn, LM1
Prins, JB1
Leman, K1
Hoogsteden, HC2
Overbeek, SE1
Rogeaux, Y1
Moyse, D1
Pello, JY1
Giraud, V1
Boot, JD1
Tarasevych, S1
Schoemaker, RC2
Amin, D1
Cohen, AF2
Diamant, Z1
Small, KM1
Reti, S2
Kasahara, DI1
Perini, A1
Lopes, FD1
Arantes-Costa, FM1
Martins, MA2
Nunes, MP1
Hamilton, LM1
Puddicombe, SM1
Dearman, RJ1
Kimber, I1
Wilson, SJ3
Kallergis, EM1
Manios, EG1
Kanoupakis, EM1
Schiza, SE1
Mavrakis, HE1
Klapsinos, NK1
Vardas, PE1
Kokturk, N1
Kara, P1
Mullaoglu, S1
Yilmaz, F1
Karamercan, A1
Ralston, ME1
Euwema, MS1
Knecht, KR1
Ziolkowski, TJ1
Coakley, TA1
Cline, SM1
Jögi, R1
Haugen, T1
Meren, M1
Loit, HM1
Sairanen, U2
Sandahl, A1
You-Ning, L1
Humphries, M1
Du, X1
Jiang, J1
Gaugris, S1
Kocevar, VS1
Zhang, Q3
Yin, DD1
Epton, MJ1
Kennedy, MA1
Iles, S1
Miller, AL1
Littlejohn, MD1
Hewitt, T1
Swanney, MP1
Brassett, KP1
Qureshi, F3
Zaritsky, A3
Welch, C1
Meadows, T1
Burke, BL1
Lemaigre, V1
Smets, A1
Verleden, GM1
Kukreti, R1
Bhatnagar, P1
B-Rao, C1
Madan, B1
Das, C1
Athavale, AU1
Brahmachari, SK1
Ghosh, B1
Saeki, S1
Balanag, VM1
Yunus, F1
Yang, PC1
McLaughlin, TP2
Hardasmalani, MD1
DeBari, V1
Bithoney, WG1
Gold, N1
Anthracopoulos, MB1
Karatza, AA1
Davlouros, PA1
Chiladakis, JA1
Manolis, AS1
Beratis, NG1
Olaguíbel, JM1
Alvarez-Puebla, MJ1
Anda, M1
Gómez, B1
García, BE1
Tabar, AI1
Arroabarren, E1
Berti, I1
Visintin, S1
Donner, CF2
Reynolds, NA1
Wiseman, LR1
Henderson, WR1
Banerjee, ER1
Chi, EY1
Malone, R1
Nimmagadda, S1
Hellerud, BC1
Kittang, OB1
Vesterhus, P1
Gillies, J1
Brown, J1
Byrnes, C2
Farrell, A1
Graham, D1
James, AL1
Elliot, JG1
Abramson, MJ2
Davies, A1
McNee, W1
Dougherty, S1
Ryskina, KL2
Legorreta, AP5
Lee, DL1
Hsu, CW1
Lee, H6
Chang, HW1
Huang, YC1
Wertheim, D1
Jackson, AC1
Langley, SJ4
Allen, D1
McDonnell, B1
Wheeler, N1
Sharma, RK1
Sykes, A1
Foroughi, S1
Thyagarajan, A1
Cohen, HW1
Chung, V2
Maggiore, D1
Mani, K1
Eryonucu, B2
Uzun, K2
Güler, N2
Tuncer, M1
Sezgi, C1
Oh, SY1
Bahn, JW1
Choi, JY1
Chang, YS1
Kim, YK1
Min, KU1
Kim, YY1
Adler, A1
Uziel, Y1
Mei-Zahav, M1
Horowitz, I1
Brugnami, G1
Curradi, F1
Bandi, V1
Velamuri, S1
Sirgi, C1
Wendt, J1
Wendt, R1
Guntupalli, K1
Lazo-Velásquez, JC1
Lozada, AR1
Cruz, HM1
Moreno-Ancillo, A1
Gil-Adrados, AC1
Domínguez-Noche, C1
Cosmes, PM1
Skoner, DP4
Kim, KT3
Parsey, M2
Hodge, MR1
Baouz, S1
Giron-Michel, J1
Azzarone, B1
Giuliani, M1
Cagnoni, F1
Olsson, S1
Testi, R8
Gabbiani, G1
Lurie, P1
Wolfe, SM1
Nardi, AE1
Jones, D1
Estrada-Reyes, E1
Rosas-Vargas, MA1
Nava-Ocampo, AA1
Pétavy, F1
Phrampus, E1
Pitetti, R1
Saville, A1
Corcoran, T1
Funt, N1
Thompson, A1
D'Urzo, A3
Pauwels, R2
Merino, JM1
Jaspal, M1
Boutet, S1
Karpel, JP4
Noonan, MJ2
Monahan, ME1
Lutsky, B1
Staudinger, H1
Koopmans, JG3
van der Zee, JS5
Prosperini, G2
Arcidiacono, G1
Ciamarra, I2
Polosa, R2
Schreck, DM2
Babin, S1
Bohács, A1
Pállinger, E1
Rigó, J1
Magyar, P1
Losonczy, G1
Tomlinson, HS1
Corlett, SA1
Allen, MB1
Murali, PM1
Rajasekaran, S1
Krishnarajasekar, OR1
Perumal, T1
Nalini, K1
Lakshmisubramanian, S1
Deivanayagam, CN1
Pérez-Francés, C1
Badiola, C1
Lanuza, A1
Bruno, L1
Ferrer, A2
Ankerst, J2
Brodbeck, T1
Majumdar, A1
Town, GI5
Silverman, M7
Suki, B2
Liu, W1
Marriott, C1
Snooks, H1
Halter, M1
Palmer, Y1
Booth, H5
Moore, F1
Nakano, J1
Yano, T1
Yamamura, K1
Yoshihara, H1
Ohbayashi, O1
Yamashita, N1
Ohta, K2
Rivera, ML1
Kim, TY1
Stewart, GM1
Minasyan, L1
Brown, L1
Bourdin, A1
Paganin, F2
Kieseler, D1
Yun, AJ1
Lee, PY1
Doux, JD1
Mathison, DA2
Koziol, JA2
Nishimura, S1
Silva, CS1
Torres, LA1
Rahal, A1
Terra Filho, J1
Vianna, EO1
Gilmore, AS2
Agarwal, R1
Gupta, D1
Parr, JR1
Salama, A1
Sebire, P1
Sannier, N1
Timsit, S1
Cojocaru, B1
Leis, A1
Wille, C1
Garel, D1
Bocquet, N1
Adelroth, E1
Fairall, L1
Lombardi, DM2
English, R1
Ibe, BO2
Portugal, AM1
Raj, JU2
Rubinfeld, AR1
Scicchitano, R1
Hunt, A1
Thompson, PJ2
Van Nooten, A1
Sin, DD1
Man, SF1
Pearse, DB1
Pyrgos, G1
Permutt, S2
Bahnmiller, N1
Li, AM1
Tsang, T1
Wong, E2
Chan, D1
Sung, R1
Ng, PC1
Foster, GC1
Batra, V2
Rybinski, KA1
Cirelli, R2
Tsuruta, D1
Sowa, J1
Kobayashi, H2
Ishii, M1
Rooklin, A2
Verbruggen, SC1
Corel, LJ1
Tiddens, HA1
Carter, K1
Cheung, D3
van Klink, HC1
Atienza, T1
Mihaescu, T1
Duggan, M1
Benito Fernández, J1
Trebolazabala Quirante, N1
Landa Garriz, M1
Mintegi Raso, S1
González Díaz, C1
Mintz, ML1
Hyvärinen, MK1
Reijonen, TM1
Korhonen, K1
Kiviniemi, V2
Yasuda, H1
Yamaya, M1
Taivainen, AH2
Tukiainen, HO2
Manjunath, R1
Jhingran, PM1
Tarsin, WY1
Pearson, SB1
Assi, KH1
Lomia, M1
Tchelidze, T1
Pruidze, M1
Capriles, E1
Do Campo, A1
Verde, O1
Pluchino, S1
Capriles Hulett, A1
Kobiakova, OS1
Nikitina, LIu1
Smetanenko, TV1
Petrovskiĭ, FI1
Georgitis, JW1
Noonan, M4
Ruff, ME1
Johnson, SR1
Marion, AA1
Vrchoticky, T1
Emmanuel, PJ1
Lujan-Zilbermann, J1
Aggarwal, P1
Sharad, S1
Handa, R1
Dwiwedi, SN1
Irshad, M1
Briggs, AH2
Wallace, MV1
Emerman, C1
Parsey, MV2
Gor, D1
Yoxall, S4
Mosen, D1
Stibolt, TB1
Leong, A1
Johnson, MS1
Mendoza, G1
Cook, EF1
Schwabe, A1
Krämer, I1
Aït-Khaled, N4
Enarson, DA3
Rutkowski, R1
Stasiak-Barmuta, A1
Moniuszko, T1
Rutkowska-Rogacz, D1
Woińska, M1
Rutkowski, K1
Sidorczuk, M1
Ameh, V1
Jenner, R1
Jilani, N1
Bradbury, A1
Fromer, L1
McHugh, P1
Duncan, B1
Houghton, F1
Singam, R1
Jena, PK1
Behera, S1
Hellermann, GR1
Lockey, RF2
Ledford, D2
Mohapatra, SS1
Saville, AL2
Sikes, KL1
Corcoran, TE1
Watanasomsiri, A1
Harmanci, K1
Bakirtas, A1
Turktas, I3
Degim, T1
Salpeter, SR1
Buckley, NS1
Ormiston, TM1
Salpeter, EE1
Zagdańska, R2
Grzelewska-Rzymowska, I3
El-Ekiaby, A1
Brianas, L1
Galan, G4
Kaeberlein, FJ1
Villaba, KD1
Lu, XY1
Pines, JM1
Lee, S1
Ismail, T1
Gontijo-Amaral, C1
Ribeiro, MA1
Gontijo, LS1
Condino-Neto, A1
Ribeiro, JD1
Allen-Ramey, FC1
Bukstein, D4
Luskin, A1
Sajjan, SG1
Markson, LE1
Crownover, BK1
Wasserman, RL2
Scott, CA2
Faris, MA1
Johansson, G1
Andreasson, EB1
Larsson, PE1
Vogelmeier, CF1
Davis, WB1
Doherty, DE1
Hamid, Q1
Kavuru, MS1
Reilly, DS1
Stauffer, JL1
Caramori, G1
Egbagbe, EE1
Elusoji, SO1
Akerman, MJ1
Yaegashi, M1
Khiangte, Z1
Murugan, AT1
Abe, O1
Marmur, JD1
Milgrom, H3
Crane, J17
Aslan, S1
Kandiş, H1
Akgun, M1
Cakir, Z1
Inandi, T1
Görgüner, M1
Kuntz, KM1
Paltiel, AD1
Rovati, GE1
Citro, S1
Brichetto, L1
Ravasi, S1
Bell, A1
Conway, PH1
Edwards, S1
Stucky, ER1
Chiang, VW1
Ottolini, MC1
Landrigan, CP1
Sagara, H1
Maier, G1
Rubino, C1
Hsu, R1
Grasela, T1
Fedor, ME1
Rubinstein, A1
Vassiliou, V1
Zipitis, CS1
Spurling, G1
Doust, J1
Bencharif, N2
Boulahdib, F1
Camara, LM2
Dagli, E3
Karadag, B1
Koadag, B1
Ottmani, SE1
Pham, DL2
Sow, O2
Yousser, M2
Zidouni, N2
Aldington, S1
Langley, S1
Jiang, WH1
Deng, L1
Wen, HH1
Yu, JL1
Zeng, Q1
Francavilla, R1
Tesse, R1
Strippoli, A1
Polimeno, L1
Loforese, A1
Miniello, VL1
Armenio, L1
Stănescu, DC2
Pasaoglu, G1
Gok, H1
Sonel, B1
Yalcin, P1
Misirligil, Z1
Holt, EW1
Tan, J1
Hosgood, HD1
Fujimoto, K1
Komatsu, Y1
Yasuo, M1
Urushihata, K1
Kubo, K1
Hartmann, U1
Metzenauer, P1
Stravinskaite, K1
Matsumoto, T1
Matsumura, M1
Tsuda, M1
Kanaya, A1
Moriwaki, A1
Nakanishi, Y1
Williams, C2
Seymour, SM1
Sullivan, EJ1
Meyer, RJ2
Davi, RC1
Fitzgerald, MA1
Lincourt, WR2
Locantore, NW1
Carranza-Rosenzweig, J1
Li, HT1
Zhang, TT1
Zhou, H1
Qu, XJ1
Wu, WM1
Huang, J1
Lavaud, J1
Baitinger, LA1
Bender, BG1
Pedan, A1
Varasteh, LT1
Haidl, P1
Schmidt, F1
Wiese, C1
Koehler, D1
Selvaraj, S1
Jha, G1
Babbar, H1
Walia, B1
Nishiyama, O1
Taniguchi, H2
Kondoh, Y1
Kimura, T2
Kato, K1
Kume, H1
Shimokata, K1
Ohm, R1
Aaronson, LS1
Salo, D1
Tuel, M1
Lavery, RF1
Reischel, U1
Lebowitz, J1
Moore, T1
Marchese, R1
Soresi, S1
Interrante, A1
Keech, ML1
Moore, RH2
Zimmerman, JL1
Miller, CT1
Bag, R1
Sharafkhaneh, A2
Dal Negro, RW2
Micheletto, C1
Tognella, S1
Trevisan, F2
Guerriero, M1
Asher, I1
O'Connell, O1
Hasford, J1
Sugerman, RW1
Ceruti, E1
Maspero, JF1
Kleha, JF1
Lawyer, MC1
Antoniu, SA1
Babb, TG1
Officer, TM1
Sharafkhaneh, H1
Boriek, AM1
Mickleborough, TD1
Turner, LA1
Chakraborti, A1
Lang, DM1
Heldt, G1
Bantje, TA1
Kolbe, J1
D'Urzo, AD4
Janostáková, A1
Jarmila, S1
Zápalka, M1
Hajduch, M1
Naya, IP2
Andersson, TL1
Fardon, T1
Koul, PB1
Minarik, M1
Totapally, BR1
Subramanian, S1
Kumaravel, A1
D'Urzo, TD1
Axelrod, S1
Bielory, L1
Casuso, M1
Rodriguez, JC1
Castro, P1
Varela, NM1
Morero, JL1
Rizzo, OE1
Bertolot, G1
Schiavi, EA2
Albers, JM1
Verblackt, HW1
Costongs, RJ1
Westers, P1
Jantikar, A1
Brashier, B1
Maganji, M1
Raghupathy, A1
Mahadik, P1
Gokhale, P1
Salvi, S1
Jamalvi, SW1
Raza, SJ1
Naz, F1
Shamim, S1
Jamalvi, SM1
Zhang, NF1
Chen, AH1
Chen, RC1
Li, JM1
Bønnelykke, K1
Jespersen, JJ1
Gupta, MK1
Singh, M2
Chaulier, K1
Chalumeau, S1
Ber, CE1
Bret, M1
Rimmelé, T1
Tomcsányi, J1
Somlói, M1
Frész, T1
Arabadzisz, H1
Zsoldos, A1
Vecsey, T1
Simon, LJ1
Yacobov, R1
Edwards, MR1
Haas, J1
Ribeiro de Andrade, C1
Duarte, MC1
Hayasaka, N1
Yaita, T1
Kuwaki, T1
Honma, S1
Honma, K1
Kudo, T1
Shibata, S1
Kemeny, ME1
Rose, RM1
Berg-Smith, SM1
Kline, JN1
Najafizadeh, K1
Sohrab Pour, H1
Ghadyanee, M1
Shiehmorteza, M1
Jamali, M1
Majdzadeh, S1
Kobayashi, Y1
Yasuba, H1
Kudou, M1
Kharitonov, SA3
Trachsel, D1
Newth, CJ3
Hammer, J1
Anthonisen, N1
Maestrelli, P1
Pozzi, E1
Morelli, P1
Shepard, JA1
Mark, EJ1
Richardson, CH2
Hosker, H1
Mukherjee, R1
Wong, I1
Thomas, M1
Stamuli, E1
Tabberer, M1
Gosden, T1
Rudge, H1
Kolpakova, AF1
Alzoghaibi, MA1
Bahammam, AS1
Bagdonas, A1
Gibbs, MR1
Jee, R1
Brownlow, H1
Fredenburgh, LE1
Campion, EW1
Lovén, J1
Svitacheva, N1
Jerre, A1
Miller-Larsson, A1
Korn, SH1
Gross, NJ1
Karkoulias, K1
Charokopos, N1
Kaparianos, A1
Sampsonas, F1
Tsiamita, M1
Spiropoulos, K1
Stanković, I2
Pejcić, T1
Milenković, B1
Jovanović, D1
Rancić, M1
Bonabel-Chone, C1
Lawson, N1
Borrill, ZL1
Wixon, CL1
Tee, AK1
Irving, LB1
Banik, N1
Tews, JT1
Nowak, D3
Black, PN2
Zitt, MJ1
Rachelefsky, GS7
Terracciano, L1
Fiocchi, A2
Bouygue, GR1
Franssen, E2
Perrio, MJ1
Dahiya, B1
Arandelović, M1
Nikolić, M1
M'buila, C1
Bados, A1
Peiffer, C2
Bernard, A1
Zaccaria, I1
Denjean, A1
Harkins, M1
Esparham, A1
Cowie, RL1
Keith, PK1
Bonniaud, P1
Favrolt, N1
Collet, E1
Dumas, JP1
Guilloux, L1
Pauli, G1
Camus, P1
Hulme, J1
Bogacka, E1
Bocheńska-Marciniak, M1
Sterchaluk-Grzyb, E1
Tworek, D1
Parker, D1
Rice, L1
Brown, AD1
Bunnage, ME1
Glossop, PA1
Holbrook, M1
Jones, RD1
Lane, CA1
Lewthwaite, RA1
Mantell, S1
Perros-Huguet, C1
Price, DA1
Webster, R1
Blitz, S1
Diner, B1
Mackey, D1
Ross, S1
Senthilselvan, A1
Kawai, M1
Pullerits, T1
Takaori, S1
Takemoto, Y1
Chan, CK1
Okell, M1
O'Byrne, P1
Bai, T1
Quiralte, J1
Martinez-Aguilar, NE1
Carlsheimer, A1
Macklem, P1
Mitchell, H1
Noble, P1
McFawn, P1
Mazhar, SH1
Ismail, NE1
Newton, DA1
Brixner, DI1
Lenhart, G1
Young, DC1
Samuelson, WM1
Benninger, C1
Mastronarde, JG1
Exline, MC1
Huang, DD1
Zheng, JY1
Hardie, GE1
Brown, JK1
Gold, WM1
Stern, T1
Dawson, N1
Tsai, HJ1
Frith, L3
Thompson-Figueroa, J1
Klein, J1
Flynn, F1
Lang, S1
Bourassa, L1
Burns, S1
Liu, CT1
Wang, YM1
Tan, CW1
Pang, YM1
Eigen, H2
Montgomery, GS1
Amaro, S1
Liao, O1
Bohn, D2
Curran-Everett, D1
Camiciottoli, G1
Brookman, LJ1
Knowles, LJ1
Barbier, M1
Elharrar, B1
Seed, MJ1
Agius, RM2
Wangsuppasawad, N1
Kiatboonsri, C1
Choothakan, S1
Sag, C1
Ozden, FO1
Acikgoz, G1
Anlar, FY1
Horvath, G1
Campos, M1
Loza, MJ1
Foster, S1
Penn, RB1
Lawrance, RM1
Ambrose, HJ1
Cooray, M1
Mills, G1
O'Callaghan, C5
White, J1
Jackson, J1
Crosby, D1
Dougill, B1
Bland, H1
Soltani, A1
Wolzt, M1
de la Peña, A1
Berclaz, PY1
Tibaldi, FS1
Gates, JR1
Muchmore, DB1
Goryachkina, L1
Hamilos, DL1
Levy, RJ1
Marcus, M1
Hooimeijer, HL1
van der Deure, J1
de Langen, JJ1
Wepner, U1
Reddy, PJ1
Aksoy, MO1
Li, XX1
Ji, R1
Kelsen, SG3
Kaplan, A1
Wang, MT1
Skrepnek, GH1
Armstrong, E1
Sherrill, DL1
Harris, RB1
Tsai, CL1
Malone, DC1
Lacy, BE1
Mathis, C1
DesBiens, J1
Manrique, HA1
Muñoz, PA1
Peña, AM1
Barberà, JA3
Roca, J6
Salyer, JW1
Crotwell, DN1
Cowan, CA1
Carter, ER2
Liu, H1
Zhou, LF1
Qian, FH1
Huang, M1
Zhang, XL1
Lee, BH1
Kim, SH1
Chou, V1
Ogawa, Y1
Murray, JJ6
Wolfe, J5
Andersen, L1
Stauffer, J1
Leo, HL1
Dombkowski, KJ1
Clark, NM1
Melani, AS1
Song, TW1
Kim, KW1
Kim, ES1
Park, JW1
Sohn, MH1
Kim, KE1
Plotnick, L1
Savdie, C1
Kudirka, D1
Meng, L1
Ward, JE1
Bamford, T2
Mast, A1
Pain, MC1
Smallwood, D1
Tran, T1
Wilson, J1
Stewart, AG1
Babl, FE1
Sheriff, N1
Borland, M1
Acworth, J1
Neutze, J1
Krieser, D1
Ngo, P1
Schutz, J1
Thomson, F1
Cotterell, E1
Jamison, S1
Francis, P1
Chen, ZG1
Li, M1
Chen, YF1
Chen, FH1
Ji, JZ1
Abdallah, MF1
Singhania, N1
Dhamija, R1
Gravina, LP1
Grenoville, M1
Luigi, DB1
Emanuel, DT1
Federica, DB1
Fabrizio, DT1
Ishihara, K1
Sano, Y2
Nakashima, M1
Karpel, J1
Cassino, C1
Johnson, P1
Conoscenti, CS1
Poon, AH1
Lazarus, R1
Lasky-Su, J1
Lange, C1
Creagh-Brown, BC1
Stuhlman, K1
Broski, SE1
Amundson, DE1
Joos, S1
Miksch, A1
Wieseler, B1
Grouven, U1
Kaiser, T1
Hampel, FC1
Mezzanotte, WS1
Shah, SR1
Kontra, KM1
Bailey, W1
Matz, J2
Dransfield, M1
ten Hacken, NH1
Zhao, HJ1
Cai, SX1
Tong, WC1
Li, WJ1
Reinhardt, D5
Zehmisch, T2
Becker, B2
Nagel-Hiemke, M2
Dyson, AJ2
Mackay, AD3
Howarth, NJ1
Gadsby, R1
Guerrin, F1
Robin, H1
Lahoutte, C1
Voisin, C1
Falliers, CJ2
Morell Brotad, F1
Anto Boque, JM1
Oriol Sabater, J1
Orriols Martínez, R1
Ingemann-Hansen, T1
Bundgaard, A4
Halkjaer-Kristensen, J1
Siggaard-Andersen, J1
Weeke, B1
Misra, NP1
Tiwari, UC1
Khemchandani, GT1
Dollery, CT3
Svedmyr, K4
Youngchaiyud, P2
Liebhart, E5
Suchnicka, R2
Krasnowska, M8
Löfdahl, CG13
Bengtsson, B2
Svedmyr, N21
Lehtonen, A1
Viikari, J1
Sallinen, VP1
Elo, J2
Pride, NB2
Lillington, AW1
Campbell, AN1
Poulier, RA1
Bierman, CW5
Sly, RM4
Horn, CR4
Cochrane, GM9
Oosterhuis, B1
Braat, MC1
van Boxtel, CJ1
Basran, GS1
Paul, W1
Morley, J10
Manresa, F2
Rodriguez, B1
Sabaté, I1
Romero, P2
Tschopp, JM1
Turner-Warwick, M1
Jones, G1
Tarlo, SM2
Dolovich, J6
Hargreave, FE14
Tomioka, K1
Ida, H1
Bryant, DH2
Pui, A1
Brown, MJ1
Tomita, Y1
Masaki, T1
Sugimoto, H1
Matsunaga, M1
Yamada, S1
Arai, Y3
Mishima, T1
Shioda, H2
Posner, V1
Posner, B1
Miraglia Del Giudice, M6
Capristo, A4
Maiello, N1
Thiessen, B4
Bell, R1
Sahay, JN3
Barber, PV1
Chatterjee, SS4
Jolobe, OM4
Leahy, BC1
Gomm, SA1
Allen, SC1
Stokes, GM4
Hodges, IG2
Flint, K1
Hockley, B4
Johnson, NM6
Flint, KC1
Scheinmann, P3
Benoist, MR1
Meyer, B1
Paupe, J2
Baños Hidalgo, P1
Ramos Martos, A1
Cabrera Moreno, R1
Luque Leal, J1
Palacios Giner, A1
Naeraa, N1
Lyager, S1
Hilberg, C1
Fischbacher, CM1
Milroy, R1
Monie, RD4
Cox, ID1
Hughes, DT1
McDonnell, KA1
Vázquez, C3
Fidalgo, I1
Virto, MC1
Labayru, MT2
Casas, C1
Yamada, Y1
Kawai, T1
Onaka, A1
Kamo, T1
Ajisawa, A1
Conolly, ME4
Yamato, T1
Yamagishi, M1
Mizuki, M1
Morita, M1
Kitamura, S1
Ishihara, Y1
Hartley, JP7
Davies, CJ1
Charles, TJ1
Nogrady, SG4
Winson, MD1
Kamei, H1
Hirano, M1
Kawano, K1
Imanishi, H1
Kawaguchi, H1
Hui, KK1
Littner, MR2
Wolfe, RN1
Ikemori, R2
Motojima, S2
Tattersfield, AE16
Harvey, JE4
Gribbin, HR1
Titinchi, S1
Al Shamma, M1
Patel, KR6
Kerr, JW4
Clark, B1
Andersson, P2
Olsson, OA1
Waldeck, B1
Schiffer, R1
Grimwood, K2
Fergusson, DM5
Dawson, KP10
Towns, SJ1
Sharota, E1
Simpson, SJ1
Mellis, CM3
Alanko, K5
Sahlström, K2
Muers, M1
Dawkins, K1
Bolle, R3
Holt, J2
Stiell, IG1
Rivington, RN2
Williams, RI1
Fergusson, RJ3
Carmichael, J4
Rafferty, P2
Higgs, CM2
Laszlo, G3
Bianco, S4
Robuschi, M1
Damonte, C1
Sturani, C1
Schiavina, M1
Tosi, I1
Gunella, G1
Pounsford, JC2
Fuller, RW7
Saunders, KB3
Spector, SL7
Whitsett, TL1
George, RB4
Dwek, JH1
Izquierdo, R1
Evans, HE5
Nakhosteen, JA2
Hirche, H1
Lahdensuo, A6
Repsher, LH2
Anderson, JA1
Bush, RK4
Kass, I1
Kemp, JP16
Reed, C1
Siegel, S1
Webb, DR2
Sil'vestrov, VP2
Surovov, IuA2
Pakulin, IA2
Larin, NV1
Plit, M1
Pover, GM4
Snashall, PD4
Maesen, FP9
Smeets, JJ9
Bernsen, R1
Cornelissen, PJ2
Beskow, R1
Ericsson, CH1
Grönneberg, R1
Skedinger, M1
Brenner, BE1
Svenonius, E4
Kautto, R2
Arborelius, M9
Tullett, WM1
Davies, JG1
Dhillon, P2
Cole, P1
Levison, H14
Isles, A1
Gregg, I2
Gunawardena, KA3
Patel, B1
Campbell, IA2
MacDonald, JB1
Smith, AP3
Al-Hillawi, AH1
Hayward, R1
Boe, J5
Inui, H1
Nagakura, T1
Iikura, Y2
Kalloghlian, A1
Jenkins, J1
Edmonds, J1
Barker, G1
Srivastava, N1
Gupta, SP2
Srivastava, LM1
Burge, PS2
Harries, MG1
l'Anson, E1
Kaik, G3
Kaik, B2
Laggner, A2
Ward, MJ4
Fentem, PH1
Smith, WH1
Davies, D2
Baur, X4
Rasmussen, FV2
Madsen, L1
Firstater, E1
Mizrachi, E1
Topilsky, M3
Groggins, RC2
Ullah, MI1
Newman, GB1
Gayrard, P5
Orehek, J9
Hedlin, G2
Freyschuss, U2
Turpeinen, M1
Kuokkanen, J1
Backman, A1
Ljungholm, K1
Lever, AM1
Gibson, GJ5
Giulekas, D3
Tsakalos, N1
Christaki-Kukuriku, P1
Kotsopoulos, T1
Antoniou, D1
Tal, A2
Pasterkamp, H2
Leahy, F1
Pomari, C2
Turco, P2
Zoccatelli, D1
Gupta, SC1
Mathur, RN1
Swaroop, AK1
Goyal, RK1
Krauss, S1
Spitz, E2
Krauss, A1
Grizotzki, B1
Clement, S1
Kraemer, R4
Geubelle, F1
Aebischer, JC1
Benoit, RC1
Scherrer, M6
Mann, DW1
Sadler, WA1
Yukawa, T1
Numao, T1
Shimizu, T3
Hayashi, T1
Nitta, K2
Shida, T2
Andersson, L2
Boëthius, G1
Benfield, GF2
Charpin, D4
Beaupre, A2
Louridas, G1
Kakoura, M1
Galanis, N1
Patakas, D3
Kastritsi, K1
Richards, IM1
Eady, RP1
Jackson, DM1
Orr, TS1
Vendy, K1
Masters, NJ1
Francis, PW3
Kelly, CA1
Zimmerman, PV1
Brown, PJ1
Greville, HW1
Finucane, KE1
Lamarre, A4
Lapierre, JG1
Rousseau, E2
Gauthier, M2
van Doesburg, N1
Anderson, PB3
Goude, A1
Peake, MD1
Webb, J1
Johnson-Barrett, JJ1
Taylor, B1
Lönnerholm, G2
Foucard, T2
Lindström, B2
Paterson, IC2
Diaz, P1
Kay, AB3
Clark, CJ2
Boyd, G4
Moran, F1
Mattson, K1
Poppius, H6
Ahonen, A2
Hurme, R1
Maasilta, P1
Muittari, A7
Venho, K1
Jones, RS2
Hasham, F1
Kennedy, JD1
Gale, AE1
Hughes, D1
Mindorff, C1
Saltz, H1
Bearman, J1
Newth, CV1
Turner, JA1
Becker, AB5
Nelson, NA1
Simons, FE6
Blumenthal, I3
Shiner, RJ1
Molho, MI1
Rochat, T3
Vonwil, A1
Bachofen, H3
Dalén, G1
Kjellman, B3
Siegel, SC7
Katz, R1
Zychowicz, C1
Ryan, G2
Latimer, KM3
Grassi, C2
Rampulla, C4
Zanon, P1
Cerveri, I1
Mastroberardino, M1
Mustchin, CP1
Sterling, GM1
Kyd, K2
Swinburn, PD1
Sexton, M1
Pullan, CR1
Martin, AJ1
Sinclair, V1
Fairfax, AJ1
McNabb, WR1
Davies, HJ3
Spiro, SG10
Croner, S2
Hedenskog, S1
Kjellman, NI3
Odelram, H1
Bakran, I2
Vrhovac, B2
Plavsić, F1
Evans, WV2
Crimmins, J1
Seaton, A6
Lawford, P3
Dowd, DE1
Palmer, KN7
Kabiraj, MU1
Rolf, C1
Simonsson, BG1
Shepherd, GL3
Hetzel, MR4
Latimer, K1
Jenkinson, SG2
Light, RW3
Spector, S1
Kanto, J2
Allonen, H1
Kulmala, T1
Mäntylä, R1
Tala, E1
Frith, PA3
Cockroft, A1
Griffiths, T1
Rocchiccioli, K1
Davies, BH4
Jagodziński, J3
Woźniakowska, U3
Webber, BA2
Collins, JV1
Branthwaite, MA1
Yates, T1
Dubin, B1
Bell-Jesion, C1
Yahav, Y1
Katznelson, D1
Benzaray, S2
Katz, RM5
Pratt, HF1
O'Doherty, K1
Cauberghs, M1
Van de Woestijne, KP1
Forsell, P1
Holroyde, MC1
Smith, SY1
Holme, G1
Abdurrahman, MB1
Taqi, AM1
Berg, IM1
Berg, T2
Ringqvist, I1
LEE, HS2
Chryssidis, E1
Frewin, DB1
Rebuck, AS6
Contreras, M1
Bevan, M1
Roberts, R1
Anderson, SD5
Schoeffel, RE1
Liubchenko, LN1
Strongina, EI1
Ardashnikova, SN1
Baskakova, NV1
Heinzen, P1
Roelli, HJ1
Meister, B1
Rossi, E1
Morgan, B1
Keyes, SJ1
Weissen, A1
Smith, SC1
Connolly, CK2
Muller, N1
Bryan, AC2
Christensson, P3
Lilja, B5
Bangham, CR1
Hope, RA1
Baldwin, CJ1
Wood, PJ1
Alberti, KG1
Madsen, BW2
Murphy, BP1
Tarala, RA3
Jankowska, R1
Racineux, JL2
Troussier, J1
Turcant, A1
Tuchais, E1
Allain, P1
Miller, TD1
Smith, S1
Tomashefski, JF2
König, P10
Godfrey, S10
Edmunds, AT2
Handslip, PD3
Dart, AM1
Iaia, E2
Cagnazzo, R1
Digilio, VS1
Scoditti, A1
Sevieri, GP1
Quartieri, F2
Del Bono, N3
Tandon, MK1
Gurwitz, D1
Stemmann, EA2
Wolff, GE1
Velardocchio, JM2
Grimaud, C3
Collier, JG1
Dobbs, RJ1
Williams, I1
Imhof, K1
Krastins, IR1
Santo, M1
Sidi, Y1
Pinkhas, Y1
Peel, ET1
Pincus, R1
Bannister, OM1
Paterson, JW7
Beck, PD1
Ormerod, LP1
Thomson, RA1
Anderson, CM1
Stableforth, DE2
Tollig, H1
Wettrell, G1
Robichaud, A1
Michoud, MC2
Hamet, P1
du Souich, P2
Skorodin, MS1
Ackerman, V1
Carpi, S1
Bellini, A1
Vassalli, G1
Marini, M1
Mattoli, S1
Nehmiz, G1
Wald, FD1
Seltzer, JM2
Chervinsky, P14
Alexander, WJ1
Liddle, R4
Mills, R1
Cook, T1
Stone, G1
Abroug, F2
Nouira, S3
Bchir, A1
Boujdaria, R2
Elatrous, S3
Bouchoucha, S2
Wheatley, G1
Walden, S1
Ng, HW1
Perrin-Fayolle, M3
Hyland, ME5
Crocker, GR1
Barry, PW2
Cracco, A1
Tormena, F1
Novello, A1
Fuglsang, G2
Agertoft, L2
Vikre-Jørgensen, J2
Bhagat, R7
Subratty, AH2
Russell, G1
Williams, DA1
Weller, P2
Price, JF6
Habbick, B3
Baker, MJ1
McNutt, M3
Kalra, S3
Rutten-van Mölken, MP2
Custers, F1
van Doorslaer, EK2
Jansen, CC1
Heurman, L1
Bommer, AM2
Raaijmakers, JA3
Lødrup Carlsen, KC2
Halvorsen, R1
Ahlstedt, S1
Wellman, JJ1
Johnston, P1
Krakovsky, D1
Mark, S1
Keller, KA1
Newman, SP4
Watson, JP1
Lewis, RA1
Kostianev, S1
Onadeko, BO1
Bamidele, EO1
Ekweani, CN1
Erabor, GE1
Zerah, F2
Lorino, AM2
Lorino, H2
Harf, A2
Macquin-Mavier, I1
Lai, CK3
Chan, CH1
Ho, SS1
Hui, AC1
Lai, KN2
Grove, A3
Salmeron, S2
Ellrodt, A1
Taravella, O1
Wong, C2
Ayson, M1
Rajasingham, S1
Scheen, AJ1
van Schayck, CP12
Dompeling, E6
Folgering, H6
Akkermans, RP2
van den Broek, PJ1
van Weel, C11
Williams, AJ2
Weiner, C1
Reiff, D1
Hughes, JM2
Reisner, C4
Kotch, A1
Dworkin, G1
Gunn, SD1
Ayres, JG6
McConchie, SM1
Dockhorn, R1
Vanden Burgt, JA1
Ekholm, BP9
Donnell, D1
Cullen, MT1
Beck, R3
Huang, D2
Nicodemus, CF2
Schanker, HM1
Langton Hewer, S1
Hobbs, J1
French, D1
Małlolepszy, J1
Passowicz-Muszyńska, E2
van Essen-Zandvliet, EE9
Kolendowicz, R1
Punthakee, Z1
Harris, TA1
Yiallouros, PK2
Saeed, SA1
Ali, N1
Saleem, S1
Callahan, S3
Canny, G6
Tjørnum, TE1
Devoy, MA1
Palmer, JB12
Hesse, IF1
Yang, CT1
Huang, TJ1
Shieh, WB1
Engel, AM1
Haanaes, OC1
Shaheen, MZ1
Benincasa, C1
Quadrelli, S1
Roncoroni, AJ1
Montiel, GC1
Gawlik, R1
Sachs, K1
Oldaeus, G1
Kubista, J1
Ståhl, E8
Parkin, PC3
Saunders, NR1
Diamond, SA1
Winders, PM1
Macarthur, C3
Buck, ML1
Robertson, CF3
Mellis, C2
Staugas, R1
Isles, AF1
Landau, LI4
Chand, N2
Achterrath-Tuckermann, U1
Szelenyi, I1
Sofia, RD2
Rutten, MP1
van den Boom, G1
Malo, JL15
L'Archevêque, J6
Ghezzo, H8
Grant, JA1
Findlay, SR2
Glovsky, MM1
Grossman, J8
Kaiser, H1
Mitchell, DQ1
Selner, J1
Bartfield, JM2
Boenau, IB1
Lozon, J1
Raccio-Robak, N2
Manolitsas, ND1
Devalia, JL1
Trigg, CJ2
McAulay, AE1
Davies, RJ4
Fedoseev, GB1
Emel'ianov, AV1
Sinitsina, TM1
Goncharova, VA1
Lin, RY7
Newman, TG1
Sauter, D2
Sirleaf, J2
Walters, J3
Fox, S1
Tavakol, M2
Willenbrock, U1
Jörres, R4
Nolte, D2
Penna, AC4
Manglick, P3
Bloch, H1
Mancherje, N1
Grant, S1
Jagminas, L1
Scharf, SM1
Ohe, M1
Munakata, M2
Itoh, A1
Doi, I1
Yamaguchi, E1
Homma, Y2
Kawakami, Y2
Taggart, SC1
Custovic, A1
Santamaria, F1
Villa, MP1
Werner, B1
Barreto, M1
Ronchetti, R1
Kamada, AK2
Worsley, DF1
Alavi, A1
Kim, E1
Palevsky, HI1
Jones, K2
Johnston, PR2
Borkhoff, CM2
Guyatt, GH1
Haukioja, A1
Brussino, L2
Ohnishi, H1
Maeda, H2
Nishimura, Y2
Takenaka, K1
Yahata, T1
Takatsuki, K1
Yokoyama, M2
Perrin, B1
Curran, MA2
Pellicer Ciscar, C1
Perpiña Tordera, M1
de Diego Damia, A1
Macián Gisbert, V1
Baldwin, DR1
Sivardeen, Z1
Knox, AJ2
Rodrigo, G10
Staehr, P1
Vestbo, I1
Côté, J3
Kreisman, H5
Small, DI1
Alexander, M2
Day, A1
Harsanyi, Z1
Darke, AC1
Aldrey, OE1
Añez, H1
Deibis, L1
Tassinari, P1
Isturiz, G1
Bianco, NE1
Chou, KJ1
Cunningham, SJ1
Needleman, JP1
Kaifer, MC1
Nold, JT1
Shuster, PE1
Redding, MM1
Gladstein, J1
Furukawa, CT4
Henochowicz, SI1
Marcoux, JP1
Gross, GN2
Hudson, LD2
Myers, DJ1
Steinberg, P1
Jakubowska-Najnigier, M1
Liszewska-Pfejfer, D1
Jaworski, A3
Tadeusiak, W3
Droszcz, W11
Rubin, ID1
Lanes, R1
Duran, Z1
Aguirre, J1
Espina, L1
Alvarez, W1
Villaroel, O1
Zdanowicz, M1
Visitsuntorn, N1
Wichienwattanachai, V1
Kerdsomnuk, S1
Tuchinda, M1
Yan, MY1
Shun, LH1
Hebe, A1
Soomaree, V1
Taylor, IK2
Sorooshian, M1
Wangoo, A1
Haynes, AR1
Kotecha, S1
Mitchell, DM2
Shaw, RJ1
Solèr, M1
Joos, L1
Bolliger, CT1
Elsasser, S1
Perruchoud, AP1
Robertson, W1
Simkins, J1
O'Hickey, SP1
Freeman, S1
Cayton, RM4
López-Guillen, A1
López-Llorente, MT1
Pastor, E1
Figueras, A1
Löfroos, AB1
Pietinalho, A1
Riska, H2
Newnham, DM2
Clark, RA8
Dhillon, DP7
Winter, JH1
McDevitt, DG8
Stewart, CM1
Wathen, CG2
Moffat, R1
Senn, S2
Vidgren, M5
Silvasti, M10
Korhonen, P2
Kinkelin, A1
Frischer, B1
Stern, K1
Udezue, E2
D'Souza, L1
Mahajan, M1
Meyer, JM1
Wenzel, CL1
Kradjan, WA2
Lebecque, P1
Vliers, S1
De Saint-Moulin, T1
Godding, V1
Hughes, MD3
Waalkens, HJ5
Bronsky, EA5
Orgel, HA5
Tinkelman, DG5
van As, A2
Liddle, RF2
D'Alonzo, GE3
Henochowicz, S1
Morris, RJ4
Rennard, SI1
Bone, RC1
Kesten, S6
Szalai, JP1
Northfield, M1
Shaw, G1
Shale, DJ1
Kenyon, CA1
Jacobs, PA1
Kok-Jensen, A3
Alessandro, F1
Zuccotti, GV1
Vincenzo, ZG1
Sala, M1
Marco, S1
Giovannini, M1
Marcello, G1
Riva, E1
Enrica, R1
Chastang, C1
Georges, D3
Bertin, L2
Bauer, K1
Ramage, L1
Cree, IA1
Gardiner, PV2
Allison, A1
Hendrick, DJ7
Burgess, CD3
Bremner, P3
Thomson, CD1
Siebers, RW2
Odhiambo, JA1
Nganga, LW1
Gikonyo, BM1
Adalioglu, G2
Saraçlar, Y2
Tuncer, A2
Clive, J2
O'Donnell, M1
Garippa, RJ1
Rinaldi, N1
Selig, WM1
Tocker, JE1
Tannu, SA1
Wasserman, MA1
Welton, A1
Bolin, DR1
Finkelstein, FN1
Simon, OR1
Mann, RD2
Brzostek, D2
Piotrowska, B2
Małolepszy, J6
Goodman, DE1
Rosenberg, M1
Johnston, R1
Weersink, EJ3
Koëter, GH6
Kauffman, HF1
Woodman, K3
Pacor, ML2
Biasi, D1
Cortina, P1
Maleknia, T1
Lunardi, C1
Gautrin, D1
D'Aquino, LC1
Gagnon, G1
Benbow, AG1
Filiz, A1
Ekinci, E1
Dikensoy, O1
Bulgur, D1
Oz, M1
Franchi, L1
Jones, KP3
Weiss, SJ1
Anand, P1
Ernst, AA1
Orgeron, D1
May, WL1
Wang, CR1
Yeh, TS1
Chuang, CY1
Chen, CY1
Fjellbirkeland, L1
Gulsvik, A1
Hulks, G2
Colagrande, P1
Bertó, JM1
Camps, B1
Pérez, MJ1
Brochard, L1
Mal, H1
Tenaillon, A1
Henry-Amar, M1
Renon, D2
Duroux, P2
Simonneau, G1
Poriadin, GV1
Salmasi, ZhM1
Busarova, EA1
Zhuravleva, NE1
Twentyman, OP5
Taylor, MR2
Clarke, JR1
Aston, H1
Schnapf, BM1
Santeiro, ML1
Davison, AG1
Hawkins, ER1
Newman Taylor, AJ1
Schachter, J1
Kuwahara, B1
Goresky, GV1
Dor, A1
Azzabi, M1
Holmgren, D3
Sixt, R3
Bennett, JA1
Smyth, ET2
Wilding, PJ1
Rayburn, WF1
Atkinson, BD1
Gilbert, K1
Turnbull, GL1
Verberne, AA6
Bos, AB1
Wong, CS3
Wisniewski, AF3
Williams, J2
Castle, W1
Fuller, R2
Hall, J1
Palmer, J2
Inman, WH1
Bunney, R1
Flaten, O1
Kokubu, H1
Beach, JR2
Young, CL1
Harkawat, R2
Avery, AJ2
Coward, GA1
Pedersen, B3
Larsen, BB1
Wahedna, I1
McParland, CP1
Britto, SA1
Rutherford, BC1
Nyberg, A2
Laurikainen, K4
Tam, J1
de Jong, JW1
Teengs, JP1
van der Mark, TW2
Harrison, JE4
Rooney, SM1
Nolan, KW1
De Vine, CL1
Jakubicki, RG1
Pillar, J1
Diamantis, W1
Boivin, JF2
Horwitz, RI2
Spitzer, WO2
Desmond, KJ1
Demizio, DL1
Allen, PD1
MacDonald, ND1
Strauss, RE1
Wertheim, DL1
Bonagura, VR1
Valacer, DJ1
Connett, GJ3
Warde, C1
Wooler, E1
Veale, D2
Cooper, BG1
Griffiths, CJ1
Anantharaman, V1
Brand, PL3
van der Bruggen-Bogaarts, BA1
Hall, SK1
Elias, M1
Lindsay, DA3
Russell, NL1
Thompson, JE1
Warnock, TH1
Shellshear, ID1
Buchanan, PR1
Imagawa, J1
Kamei, K1
Yoshida, S1
Sugo, I1
Koga, T1
Nabata, H1
Spence, DP1
Calverley, PM1
Higgins, C1
Ramhamadany, E1
Turner, S1
Winning, A1
Winter, J1
Osundwa, VM1
Dawod, ST1
Ehlayel, MS1
Nieminen, MM4
Järvinen, M1
Liippo, K2
Tammivaara, R1
Vetto, TA1
Moore, GP1
Watson, WT2
Shuckett, EP1
Galoppin, L1
Azevedo, I1
Vargaftig, BB3
Bachelet, M3
Ginko, T1
Fischer, M1
Voss, W1
Knutsen, R1
Bøhmer, T1
Falch, J1
Zainudin, BM4
Ismail, O1
Yusoff, K1
Dolovich, MB2
Kazim, F2
Madl, ML1
Rudnitsky, GS1
Eberlein, RS1
Schoffstall, JM1
Mazur, JE1
Spivey, WH1
Newman, T1
Gerritsen, J2
Knol, K1
Rubin, P1
Pierson, W1
Tinkelman, D3
Segal, AT1
Fish, J1
Kaiser, HB2
Wenzel, S1
Cohn, J1
Lanni, C1
Pearlman, H1
Karahalios, P1
O'Brien, RG1
Harman, E2
Aull, L1
Reents, S1
Visser, J1
Shieh, G2
Coleridge, J1
Cameron, P1
Teichtahl, H1
Essex, E3
Volans, GN1
Eda, R1
Okada, C1
Bewtra, AK1
Townley, RG2
Arvidsson, P5
Larsson, S8
Vondra, V1
Reisová, M1
Malý, M1
Sovijärvi, AR2
Paajanen, E1
Piirilä, P1
Katila, T1
Coppola, M1
Westfall, M1
Nelson, MS1
Staudinger, HW1
Haas, JF1
Munro, NC1
Castle, WM1
Hall, JR1
Fishwick, K2
Devereux, G1
Taskar, VS1
Mahashur, AA2
John, PJ1
Kolhatkar, VP1
Menon, L1
Bijur, S1
Packe, GE2
Freeman, W2
Melchor, R1
Mak, VH1
Short, MD1
Connett, G1
Tang, CB1
Quan, BW1
Wang, XF1
Xiong, YX1
Wu, GH1
Oberklaid, F1
Souëf, PN1
Maccarrone, AL1
Finnerty, JP5
O'Brodovich, H1
Reisman, J3
Canny, GJ3
Rosenhall, L3
Melander, B5
Oenbrink, RJ1
Trudeau, C5
Chinet, TC1
Ramoska, EA1
Henretig, F1
Joffe, M1
Spiller, HA1
Sakamoto, K1
Houya, I1
Inoue, K1
Kiuchi, H1
Sakamoto, Y2
Yamamoto, K1
Dohi, Y1
Colacone, A3
Afilalo, M3
Wolkove, N3
Malerba, M3
Politi, A2
Filippi, B2
Boni, E1
Grassi, V4
Kaliner, MA2
Schlegel, J1
Turk, B1
Kienast, K1
Ferlinz, R1
Angus, RM2
McCallum, MJ1
Sams, VR1
Church, MK3
Hutson, PA2
Ferrari, M1
Romito, D1
Adami, S1
Olivieri, M1
Squassante, L1
Prior, M1
Lo Cascio, V1
Smolik, K1
Cloutier, M1
Labrecque, G1
Rivard, GB1
Bonnin, AJ1
Richmond, GW2
Musto, PK1
Volgman, AS1
Fuchs, SM2
Nager, AL1
Shane, SA1
Katz, RW1
Crowley, MR1
Grad, R1
McWilliams, BC1
Murphy, SJ2
Smith, AJ1
Hergenroeder, P1
Fink, G1
Kaye, C1
Blau, H1
Spitzer, SA1
Jain, NK1
Sharma, SD1
Garg, VK1
Sharma, TN1
Devpura, K1
Scalabrin, DM2
Naspitz, CK3
Herdman, MJ1
Ferguson, H1
Thomas, K1
DiGiulio, GA1
Krug, SE2
Alpert, SE1
Marx, CM1
Carter, E1
Cruz, M1
Chesrown, S1
Reilly, K1
Campbell, AM2
Couret, I1
Michel, FB5
Stenius-Aarniala, B2
Kiviranta, K1
Cocchetto, DM2
Turner, DJ1
LeSouëf, PN5
Olshaker, J1
Jerrard, D1
Barish, RA1
Brandt, G1
Hooper, F1
Clarke, SW8
Patel, SR1
Print, CG2
Lake, DC2
Yates, DM1
Lucas, MK1
Rawlinson, DW1
Lyttle, BD1
Hollestelle, AM1
Bancalari, L2
Carrara, M1
Giuntini, C2
Clark, CE1
Ferguson, AD1
Siddorn, JA1
Pavia, D1
Vora, H1
Behr, N1
Morley, TE1
Ghigo, E1
Valetto, MR1
Gaggero, L1
Visca, A1
Valente, F1
Bellone, J1
Castello, D2
Camanni, F1
Gibson, P1
Henry, D1
Francis, L2
Cruickshank, D1
Dupen, F1
Higginbotham, N1
Henry, R1
Sutherland, D2
Knol, KK1
Meijer, GG1
van Aalderen, WM1
Fisher, JD1
Vinci, RJ1
Shaughnessy, AF2
Slawson, DC1
Wlodarczyk, JH1
Borgas, T1
Inman, MD3
Koller, DY1
Herouy, Y1
Götz, M1
Hagel, E1
Urbanek, R1
Eichler, I1
Di Lorenzo, G2
Morici, G2
Norrito, F1
Mansueto, P1
Melluso, M1
Purello D'Ambrosio, F2
Barbagallo Sangiorgi, G1
Flüge, T3
Fabel, H2
Wagner, TO2
Schneider, B4
Forssmann, WG3
Szczeklik, A4
Mastalerz, L2
Nizankowska, E3
Cmiel, A2
Targhetta, R1
Chavagneux, R1
Ayoub, J1
Lemerre, C1
Bourgeois, JM1
Balmes, P1
Hermansson, BA1
Jenkins, RJ2
Aubert, B1
Bons, J2
Hall, CM1
Louw, SJ1
Joubert, G1
Lilley, LL1
Guanci, R1
Kubota, K1
Pearce, G1
Wilton, L1
Gayer, D1
Barbero, GJ1
Shaffer, J1
Van Keimpema, AR1
Ariaansz, M1
Nauta, JJ1
Postmus, PE1
Kleerup, EC2
Cline, AC1
Keatings, V1
Thomas, PS1
Ahmad, HR2
Khan, MA3
Memon, M1
Khan, MN1
Shrestha, M2
Gourlay, S2
Robertson, S1
Bidadi, K2
Wainscott, M1
Hayes, J2
Woolcock, A2
Jacques, LA1
Leatherman, JW1
Fluegel, WL1
David, WS1
Davies, SF1
Iber, C1
Boltansky, H1
Kobayashi, RH1
Shapiro, G3
Trochelmann, LM1
Lorber, RR1
Siebers, R1
Sitenga, GL1
Ing, EB1
Van Dellen, RG1
Younge, BR1
Leavitt, JA1
Creyghton, FB1
van Rooij, RW1
van den Berg, M1
Millar, EA2
Chalmers, GW4
Kelso, TM1
Abou-Shala, N2
Heilker, GM1
Arheart, KL1
Portner, TS1
Self, TH4
Desager, KN2
van Bever, HP3
Vermeire, PA1
Wendel, PJ1
Ramin, SM1
Barnett-Hamm, C1
Rowe, TF1
Cunningham, FG1
Swystun, UA1
Ringbaek, TJ1
Søes-Petersen, U1
Christensen, M1
Iversen, ET2
Garner, SS1
Wiest, DB1
Bradley, JW1
Lesher, BA1
Habib, DM1
Schoenwetter, WF1
Munk, ZM2
Schaberg, A2
Kellerman, DJ4
de Benedictis, FM2
Martinati, LC1
Solinas, LF1
Tuteri, G2
Kidney, JC1
Wong, BJ1
Morris, MM2
Efthimiadis, A1
Anderson, R1
Feldman, C1
Theron, AJ1
Ramafi, G1
Cole, PJ2
Wilson, R1
Gioulekas, D1
Papakosta, D2
Vordoyianni, P1
Baloti, H1
Vamvalis, C2
Turner, CR1
Andresen, CJ1
Smith, WB1
Watson, JW1
Kakhnovskiĭ, IM2
Marinin, VF2
Sorokina, LA2
Markova, ZS1
Leblanc, P1
Knight, A4
Reisine, ST2
Willard, A2
Wells, M2
Metersky, M1
McNally, D1
Lawrence, M2
Tomasko, M1
Baker, KA1
Facchini, G1
Antonicelli, L1
Cinti, B1
Bonifazi, F1
Massei, V1
Mannino, F4
Kishida, M2
Suzuki, I2
Koshibu, T2
Matsumoto, H1
Uchiyama, Y1
Kabayama, H2
Nagayama, T1
Sasamoto, A2
Aoki, T3
Gustafson, T1
Boman, K1
Wester, PO1
Giustina, A1
Bresciani, E1
Desenzani, P1
Licini, M1
Zaltieri, G1
Fish, JE8
Sorkness, C2
Mochizuki, H1
Tokuyama, K1
Morikawa, A1
Costa, JC1
Plácido, JL1
Silva, JP1
Vaz, M1
Trinquet, G1
Harper, AE1
Dagg, KD2
Thomson, LJ2
Ramsay, SG1
Kee, ST1
Chen, DR1
Gamsu, G1
McCallum, AL1
Abboud, RT2
Bowie, DM1
Hodder, RV1
Paré, PD2
Mesic-Fuchs, H1
Molfino, NA3
Schacter, EN1
Fanta, C1
Levey, D1
Spiro, P1
Aldrich, T1
Menjoge, SS1
Witek, TJ2
Ebbutt, A1
Jenkins, MM2
Garnier, P1
Fajac, I1
Dessanges, JF1
Dall'Ava-Santucci, J1
Lockhart, A3
Dinh-Xuan, AT1
Wolstenholme, RJ2
Kane, GC1
Tolino, M1
Pollice, M1
Hand, CH1
Bradley, C1
Matsumoto, I1
Walker, S1
Phagoo, SB1
Wilson, NM1
Lebel, B1
Arnoux, B1
Bougeard, YH1
Daures, JP2
Takamatsu, I1
Inoue, T1
Toyoshima, K1
Mahadewsingh, JV1
Hamersma, WB1
Schreurs, AJ2
Williams, JR1
Bothner, JP1
Swanton, RD1
Blum, PS1
Chambe, MT1
Tool, AT1
Mul, FP1
Knol, EF1
Verhoeven, AJ1
Roos, D1
Forsch, R1
Romano, L1
Zofra, S1
DiLeva, A1
Bariffi, F2
Steffensen, I1
Humbert, M1
Robinson, DS1
Assoufi, B1
Durham, SR3
Rayani, HH1
Vellani, CW1
Zaidi, SR1
Pallares, DE1
Pilarski, BR1
Rodriguez, JL1
Leickly, FE1
Dottorini, ML1
Tantucci, C1
Peccini, F1
Sorbini, CA3
Pazzelli, P1
Niccoli, A1
Mezzetti, D1
Vaccaro, R1
Bagnato, GF1
Mileto, A1
Gulli, S1
Oriti, S1
Di Cesare, E1
Cinquegrani, M1
Bonaiuto, M1
Saitta, A1
D'Angelo, E1
Milic-Emili, J2
Marazzini, L3
Gong, H3
Linn, WS1
Shamoo, DA1
Anderson, KR1
Nugent, CA1
Clark, KW1
Lin, AE1
Khine, H1
Alvarez Sintes, R2
Alvarez Castro, MR1
Merigian, K1
Blaho, K1
Meriste, S2
Marran, S2
Märtson, T2
Sillastu, H2
Tomaç, N1
Horikoshi, S1
Ogawa, C1
Couper, FJ3
Drummer, OH3
Whitehead, F1
Solé, D2
Strachan, DP2
Griffiths, JM1
Johnston, ID2
Anderson, HR3
Arledge, TE2
Rossing, TH2
Whitehead, J1
Carletti, A1
Connell, JM1
Dimond, JP1
Palazzo, MG1
Selby, C1
Engleman, HM1
Fitzpatrick, MF3
Sime, PM1
Mackay, TW1
Douglas, NJ2
Boucher, S1
Hébert, J2
Singhi, SC1
Jayashree, K1
Sarkar, B1
Friberg, K3
Balter, MS1
Hyland, RH3
Peters, S1
Jennings, BH1
Lakkis, H1
Barnett, PL1
Caputo, GL1
Baskin, M1
Kuppermann, N1
Lucena, MI1
Almagro, J1
Andrade, RJ1
Hidalgo Sanchez, R1
Sanchez de la Cuesta, F1
Penna, AS1
Phung, X1
Soo, M1
Spiers, R1
Strauss, L3
Hejal, R2
Dixon, L3
Mariette, C1
Pollard, SJ2
Prenner, B1
Howland, WC2
Calderon, P1
Lins, R1
Rosillon, D1
Stricker, W3
Botto, A1
Kundu, S1
Zhang, J1
Quebe-Fehling, E2
Brambilla, R2
Bromly, CL2
Grunfeld, A1
Levy, RD1
Hodder, R1
Wong, AG1
O'Shaughnessy, AD1
Walker, CM1
Díaz, JE1
Dubin, R1
Gaeta, TJ1
Pelczar, P1
Bradley, K1
Zahger, D1
Rosen, JP2
Goldsobel, AB1
White, MV4
Lotner, GZ1
Bodenheimer, S1
Parkes, SN1
Bersten, AD1
Wildhaber, JH4
Hayden, MJ1
Summers, QA3
Song, P1
Rehder, K1
Douma, RR1
Hamedani, AG2
Eggleston, PA1
Williamson, IJ1
Reid, A1
Fennerty, AG1
Rimmer, EM1
Bettinger, CM1
Margo, K1
Hedner, J4
Lunde, H2
Mandahl, A1
Affleck, G1
Tennen, HA1
Barrows, E1
Reid, RW1
Wilding, P1
Clark, M1
Thompson Coon, J1
Lewis, S1
Rushton, L1
Bennett, J3
Oborne, J1
Cooper, S2
Plaut, TF1
Westby, L1
Koper, I1
Braun, H1
Leutz, M1
Schlimmer, P1
Sybrecht, GW1
Sohal, T1
Jones, JI1
Upchurch, FC1
Nakanishi, AK1
Lamb, BM1
Foster, C1
Rubin, BK1
Maury, E1
Ioos, V1
Lepecq, B1
Guidet, B1
Offenstadt, G1
elSanadi, N1
McFadden, CB1
Shoemaker, L1
Gilbert, L1
Warren, E1
Hammonds, T1
Finkelstein, F1
Rihmer, Z1
Raimondi, AC2
Schottlender, J1
Lombardi, D1
Díaz, O1
Marrades, R1
Wong, HH2
Castro, A2
Pandozi, C1
Bianconi, L1
Toscano, S1
Santini, M1
Meier, CR1
Jick, H1
Tan, KS2
Jack, D1
Adkins, JC2
McTavish, D1
Tolep, KA1
Shindo, K1
Koide, K1
Fukumura, M1
Aldrich, TK1
Prezant, DJ1
Guguchev, K1
Gaitan-Salas, A1
Pathiparti, R1
Everts, KB1
Shaver, JR1
Zangrilli, J1
Pollice, MB1
Garrett, JE3
Rodwell, P1
Marrades, RM1
de Jover, L1
MacNee, W1
Jokic, R2
Marciniuk, DD1
Vir, R1
Shah, A1
Frost, C2
Roorda, RJ1
van der Laag, H1
Boczkowski, J1
Murciano, D2
Pichot, MH1
Ferretti, A1
Pariente, R1
Worsdell, M1
Graf Bigler, U1
Casaulta Aebischer, C1
Weder, M1
Birrer, P1
Levy, S1
Smith, JA1
Feiss, G1
Farrar, JR1
Haimovici, R1
Gragoudas, ES1
Duker, JS1
Sjaarda, RN1
Eliott, D1
Ford, LB1
Ayars, GH1
Rogenes, PR2
Pepsin, PJ3
Klig, JE1
Hodge, D2
Rutherford, MW1
van Zomeren, EH1
Sethi, GR3
Sachdev, HP1
Hill, MR7
Vaughan, LM5
Ostrom, NK1
Crowther, SD3
Costello, JF3
Peterson, GM1
McLean, S1
Westfal, RE3
Bakalchuk, L3
Freyberg, CW2
Cataquet, D2
Heyl, GT3
Kurzawa, R1
Barliński, J1
Bootsma, GP1
Dekhuijzen, PN2
Festen, J1
Amemiya, M1
Myou, S2
Mizuguchi, M1
Matsuda, T2
Salome, C1
Li, Z1
Yu, R1
Jartti, TT2
Kaila, TJ2
Tahvanainen, KU2
Kuusela, TA2
Vanto, TT2
Välimäki, IA2
Graves, PE1
Baldini, M1
Solomon, S1
Erickson, R1
Mandelberg, A2
Chen, E1
Noviski, N1
Priel, IE2
Słomka, A1
Stremler, N1
Mely, L1
Bruguerolle, B2
Taylor, DA1
Jensen, MW1
Aikman, SL1
Harris, JG1
O'Connor, BJ3
Gauvreau, GM1
Jordana, M1
Watson, RM2
Cockroft, DW1
Reynolds, PL1
Bondesson, E3
Carlsson, LG1
Hörnblad, Y2
Jemsby, P1
Källén, A1
Ullman, A4
Werner, S1
Palmqvist, M6
Persson, G3
Lazer, L1
Dzyngel, B1
Tarlo, S1
Slutsky, AS2
Baker, EK1
Willsie, SK1
Marinac, JS1
Salzman, GA1
Kozlik-Feldmann, R1
Harris, AG1
Aaronson, D1
Beaucher, W1
Berkowitz, R2
Bronsky, E4
Cohen, R2
Fourre, J1
Meltzer, E1
Pedinoff, A1
Wanderer, A1
Ushkow, BS1
Reicho, PR1
Slawson, JG1
Flynn, CA1
Chyrek-Borowska, S2
Kowal, K1
Swiebocka, E1
Grubek-Jaworska, H2
Hermanowicz-Salomon, J1
Ritz, M1
Thorens, JB1
Arnold-Ketterer, M1
Chevrolet, JC1
Rubinfeld, A1
Morgan, JP1
Drotar, DE1
Davis, EE1
Higham, MA1
Sharara, AM1
Wilson, P1
Glendenning, GA1
Larsson, L1
Dickinson, J1
Hutton, S1
Atkin, A1
Breitigan, JM1
Klinger, NM6
Slade, HB2
Handley, DA4
McCullough, JR1
Wilcke, JT2
Cook, DA1
Incaudo, GA1
Kalberg, C9
Pendino, JC2
Nannini, LJ2
Slutsky, A1
Clark, DJ3
Seldon, PM1
Stevens, DA1
Yernault, JC1
Demedts, MG1
Geusens, P1
Sung, L1
Osmond, MH2
Aziz, I4
Hamilton, AL1
Khan, A1
Strayhorn, V1
Leeper, K1
Tolley, E1
Self, T1
Montoya, C1
Weissburg, A1
Zuckerman, LH1
Edell, D2
Bruce, E1
Hale, K1
Khoshoo, V1
Bernstein, DI1
Ginchansky, E1
Pedinoff, AJ1
Winder, JA1
Krouwels, FH1
Hol, BE1
Bruinier, B1
Bast, A1
Out, TA3
Smirnova, ZV1
Arkhipova, SV1
Crossland, L1
Finnerty, J1
Baki, A2
Karagüzel, G2
Pirie, J1
Cox, P1
Rakhmanina, NY1
Kearns, GL1
Farrar, HC1
Norden, MA1
Fitzgerald, DA1
Connor, FL1
Van Asperen, PP3
Cooper, PJ1
Allen, HD1
Tolep, K1
Uhereczky, G1
Gács, E1
Jákly, A1
Göndöcs, R1
Durante, S1
Borrello, G1
Dykewicz, MS1
Ledford, DK1
Nana, A1
Maranetra, N1
Davies, B1
Brooks, G1
Devoy, M1
la Rosa, M1
Kaad, PH1
Moorat, A1
Soliman, S1
Elidrissi, H1
Trabelsi, H1
Boussarsar, M2
Ouannes, L1
Bouzouita, K1
Abroug, MF1
Hewer, SL2
Kargul, B1
Tanboga, I1
Ergeneli, S1
Karakoc, F1
Lumry, W4
Manning, M1
Cox, F3
Masterson, CM2
Batty, EP2
Magrì, S1
Pagano, C1
Paolino, G1
Santonocito, G1
Milot, J4
Rossinen, J1
Partanen, J1
Nieminen, MS1
Kumar, SD1
Emery, MJ1
Atkins, ND1
Danta, I2
Grol, MH1
Nutini, S1
Martini, T1
Righi, R1
Weinstein, AG1
Golish, J1
Curtis-McCarthy, P1
McCarthy, K1
Kavuru, M2
Wagner, W2
Beck, G1
Eng, P1
Oddoze, C1
Weinstein, SF1
Byrne, A1
Arledge, T3
Brophy, C1
Ahmed, B1
Bayston, S1
Arnold, A1
McGivern, D1
Greenstone, M1
Proud, D1
Reynolds, CJ1
Lichtenstein, LM1
Kagey-Sobotka, A1
Lanes, SF2
Wentworth, CE2
Turcotte, H3
Mangat, HS1
D'Souza, GA1
Jacob, MS1
Hellinckx, J1
Bande-Knops, J1
van der Poel, M1
Demedts, M1
Malozowski, S1
Stadel, BV1
Pian, LP1
Moy, ML2
Lantin, ML1
Harver, A1
Schwartzstein, RM1
Wever, AM1
de GOEIJ, JA1
de GRAAFF, CS1
Steen, H1
Lanza, LL1
Turner, MO1
Hussack, P1
Vachier, I2
Chiappara, G1
Altieri, E1
Térouanne, B1
Vic, P1
Sellers, J1
Greene, S1
Flaster, E1
Colice, G1
Kou, M1
Phil, M1
Kumana, CR1
Ip, MS1
Lauder, IJ1
Lam, WK1
Chan, JC1
Mincewicz, G1
Sopel, R1
Kozłowki, M1
Kurowski, W1
Pestian, J1
Davis, P1
Dworski, R2
Prokop, A1
Oates, JA1
Garrett, J1
Williams, S2
Holdaway, D1
Zou, JP1
Gu, FQ1
Liao, WJ1
Johnson, C1
Beckerman, RC1
Davis, GM1
Adinoff, AD1
Schwartz, HJ2
Swearingen, BE1
Seppälä, OP1
Kari, E1
Löyttyniemi, E1
Kunkel, G3
Jenne, JW2
Kerac, M1
Montgomery, H1
Johnson, N1
Crago, S1
Coors, L1
Lapidus, JA1
Sapien, R1
Samaranayake, SW1
Dalphin, JC1
Dubiez, A1
Monnet, E1
Gora, D1
Westeel, V1
Pernet, D1
Polio, JC1
Gibey, R1
Laplante, JJ1
Depierre, A1
Corne, JM1
Linaker, CH1
Merrett, T1
Beasely, R1
Church, M1
Caussade, D1
Sanchez, P1
Berjaud, J1
Ducassé, JL1
DiSantostefano, R1
DeGraw, S2
Reasner, DS2
Rollins, TE2
Rubin, PD1
Vervloet, D2
Ekström, T2
Pela, R1
Duce Gracia, F1
Kopp, C1
Silvert, BD1
Di Benedetto, G2
Wrońska, J1
Mazurek, J1
Dawson, KL1
Kaczka, DW1
Ingenito, EP4
Kim, JT1
Kim, CK1
Koh, YY1
Buchwald, A1
Hochhaus, G1
Henderson, SO1
Acharya, P1
Kilaghbian, T1
Perez, J1
Korn, CS1
Chan, LS1
Goh, SY1
Arulanandam, S1
Ho, CL1
Goh, DY1
Chew, FT1
Lee, BW1
Cargill, K1
Wolfe, S1
Darby, H1
Hamid, S1
Kumaradevan, J1
Minkwitz, MC1
Simonson, SG1
Bonuccelli, CM1
Chu, DM1
Wang, CL1
Yang, KD1
Bieler, S1
Guttman, A1
Dankoff, J1
Tselios, C1
Stern, E2
Basran, G1
Schiraldi, G1
Eivindson, A1
Jamieson, AH1
Olsson, H1
Wakita, S1
Chatkin, J1
Ansarin, K1
Caramori, M1
McClean, P1
Rushby, I1
Scullion, J1
Morgan, MD1
Dawson, C1
Weiss, S1
Stubbing, D1
Fairbarn, MS1
Vermetten, FA1
Boermans, AJ1
Luiten, WD1
Schleufe, P1
Reiffen, HP1
Piepenbrock, S1
Goldberg, P1
Galant, S1
Welch, MB2
Petrocella, V2
Langley, PC1
Sill, V1
Bartuschka, B1
Villiger, B1
Ortland, C1
Domej, W1
Li, JT2
Woodring, A3
van Bavel, J1
Finn, A2
Brown, A1
Harding, SM3
Chong, BT1
Agrawal, DK1
Romero, FA1
Pusic, MV1
Lebet, R1
Duggan, AK1
Naumann, PF1
Wong, GA1
Raabe, OG1
Sculpher, MJ1
Buxton, MJ1
Stãlhammar, NO1
Peters, DH1
Faulds, D2
Laursen, LC1
Mackowiak, J1
Yung, M1
Harrison, TW1
Gawchik, SM1
Saccar, CL1
DeGraw, SS1
Tunaoğlu, FS1
Olguntürk, R1
Demirsoy, S1
Löwhagen, O2
Ekström, L1
Holmberg, S1
Wennerblom, B1
Rosenfeldt, M1
Nantel, NP1
Chambers, CB1
Pratt, B1
Parry-Billings, M1
Dewar, AL1
Stewart, A1
Cogswell, JJ1
Dow, AM1
Tenenbaum, C1
Curry, A1
Geoffroy, P1
Lalonde, RL2
Clarke, W1
Goldstein, S1
Nocker, RE2
de Riemer, MJ2
Noppen, M3
Van Muylem, A1
Berkowitz, RB2
Tinkelman, DA1
Scuotri, L1
Grootendorst, DC1
van den Bos, JW1
Romeijn, JJ1
Veselic-Charvat, M1
Vrijlandt, EJ1
Roldaan, AC1
Boothman-Burrell, D1
Hancox, B1
Harré, E1
Laubscher, K1
Linscott, V1
Ramsay, CM2
Richards, G1
Mol, SJ1
Raphael, GD1
Lanier, RQ1
Baker, J1
Casale, TB1
Norhaya, MR1
Yap, TM1
Thomason, DB1
Mohamed, MH2
Eberle, LV2
Johnson, JA2
Rogers, DF2
Zietkowski, Z2
Rogalewska, A1
Razzouk, H2
dos Santos, L1
Giudicelli, J1
Queirós, M1
de Lurdes Chieira, M1
Ramos, C1
Lindbladh, C2
Wiegand, L1
Mende, CN1
Zaidel, G1
Zwillich, CW2
Petrocella, VJ1
Massasso, DH1
Seale, JP3
Woolcock, AJ3
Bryan, S1
Ibsen, T1
Mellén, A2
Parameswaran, KN1
Summers, E1
Tymińska, K2
Kroczyńska-Bednarek, J2
Kwiatkowska, S2
Winders, P1
Dore, ND1
Wilson, JM1
Spencer, CM1
Jarvis, B2
Pinnas, JL1
Müller, HH1
Schäfer, H1
Matthys, H2
Sauer, R1
Schauer, P1
Menz, G1
Malmström, K2
Sorva, R1
Gordon, S1
Vizel', AA1
Khabibullin, KA1
Sander, N1
Costello, J1
Handley, D1
Cowan, J1
Flannery, E1
McLachlan, C1
Anderson, TJ2
Parashchak, MR2
Burke, CM2
Watson, SA2
Turbitt, ML2
Wallaert, B1
Brun, P1
Ostinelli, J1
Champel, F1
Blaive, B1
Montané, F1
Kamio, Y1
Ishiura, Y1
Tachibana, H1
Hirose, T1
Hashimoto, T2
Beaucher, WN1
Kiechel, F1
Sublett, JL1
LaVallee, N1
Shilstone, J1
Stormon, MO1
Kilham, HA1
Rosenthal, RR1
Baraniuk, J1
Srebro, S1
Korosec, M1
Novak, RD1
Myers, E1
Skowronski, M1
Ciccolella, DE1
Brennan, K1
Criner, GJ1
Singhi, S1
Kumar, L1
Jayshree, M1
Clarke, WR1
Dockhorn, RJ2
Lux, C2
Han, SH2
Durham, S1
Roberts, JA2
Britten, KM2
Walls, AF2
Gratziou, C1
Aldridge, RE1
McLachlan, CR2
Kotani, Y1
Burschtin, O1
Mentz, P1
Forssmann, K1
Meyer, M1
Smith, P1
Jackson, L1
Begishvilli, B1
Jamieson, A1
Everts, B1
Möller, CS1
Ouellet, D1
Kimanani, EK1
Potvin, D1
Sheikh, S1
Goldsmith, LJ1
Howell, L1
Eid, N1
Jacobson, K1
Kane, RE2
Banerji, D2
Uryniak, T1
Bouros, D1
Bachlitzanakis, N1
Kottakis, J2
Pfister, P1
Polychronopoulos, V1
Papadakis, E1
Constantopoulos, S1
Froudarakis, M1
Sichletidis, L2
Siafakas, N1
Holz, O1
Mücke, M1
Schneider, LC1
Lester, MR1
Li, X2
Bao, X1
Bailey, M1
Wilson, JW4
Haydn Walters, E2
Welch, M1
Bernstein, D1
Hughes, DA1
Walley, T1
Grutters, JC1
Brinkman, L1
Aslander, MM1
van den Bosch, JM1
Koenderman, L1
Garcia-Rodríguez, LA1
Pérez-Gutthann, S1
Agostinis, L1
Cattaruzi, C1
Troncon, MG1
Gumbhir-Shah, K1
Koch, P1
Jusko, WJ1
DeGraff, AC2
O'Riordan, TG1
Herrle, MR1
Stahl, EG1
Choy, DK1
Ko, F1
Li, ST1
lp, LS1
Leung, R1
Hui, D1
Weksler, N1
Brill, S1
Tarnapolski, A1
Gurman, GM1
Anderson, AJ1
Koester, J1
Snider, ME2
Gluckman, TJ1
Corbridge, T1
Church, NL1
Gillman, SA1
Lanier, BQ2
Brieva, JL1
Redington, AE1
Rees, PJ4
Rogalewska, AM1
Madsen, F1
Schlösser, NJ1
Steinmetz, KO1
Jones, SL2
Gershman, NH1
Liu, JT1
Little, SA2
MacLeod, KJ2
McSharry, C2
Rosi, E1
Scano, G1
Hamzaoui, A1
Hamzaoui, K1
Salah, H1
Chabbou, A1
Hidi, R1
Timmermans, S1
Liu, E1
Schudt, C1
Dent, G1
Stewart, BA1
Carrier, S1
Frosolono, M1
Milavetz, G3
Corna, RA1
Mannarino, S1
Quispe, R1
Mutlu, GM1
Moonjelly, E1
Chan, L1
Olopade, CO1
Boccuzzi, SJ1
Wogen, J1
Roehm, JB1
Okamura, D1
Nagamine, J1
Boychuk, RB1
Halm, B1
Yee, LL1
Dellamary, LA1
Tarara, TE1
Smith, DJ1
Woelk, CH1
Adractas, A1
Costello, ML1
Gill, H1
Weers, JG1
Auregan, G1
Djankine, K1
Keita, B1
Ky, C1
Mahi, S1
Ngoran, K1
Kreitzer, S1
Reilly, D1
Davis, S2
Leversha, AM1
Campanella, SG1
Aickin, RP1
Asher, MI2
Hernández, M1
Salmen, S1
Berrueta, L1
Navas, M1
Sánchez, B1
Muñoz, J1
Delgado, R1
Romano, E1
Rangel, A1
Fowler, SJ4
Dempsey, OJ3
Wilson, AM2
Mistry, C1
Jang, AS1
Choi, IS1
Park, CS1
Horner, SD1
Small, RC1
Chiu, P1
Cook, SJ1
Foster, RW1
Isaac, L1
Hausen, T1
Sato, R1
Gutglass, DJ1
Hampers, L1
Roosevelt, G1
Teoh, D1
Nimmagadda, SR1
Karras, DJ1
Sammon, ME1
Terregino, CA1
Lopez, BL1
Griswold, SK1
Arnold, GK1
Callahan, CW2
Tsehori, S1
Houri, S1
Gilad, E1
Morag, B1
Arshad, H1
Fink, J1
Shrewsbury, S4
Pyke, S2
Britton, M1
Mícheli, F1
Cersósimo, MG1
Scorticati, MC1
Velez, M1
Gonzalez, S2
Ventura, R2
Segura, J2
Bergés, R2
Fitch, KD3
Morton, AR2
Berruezo, S1
Jiménez, C1
Healy, MJ1
Melamed, J1
Grady, J1
Stevens, A1
Duke, S1
Harding, S1
Milano, M1
Reining, U1
Mattes, J1
Storm van's Gravesande, K1
Ihorst, G1
Kühr, J1
Peterson, D1
Pang, L1
Caron, J1
Hilliard, TN1
Witten, H1
Male, IA1
Seddon, PC1
Richter, B1
Bender, R1
Berger, M1
Davis, EB1
Lindsay, MA1
Moilanen, E1
Rosenberg, NM2
Posner, JC1
Waltzman, ML1
Bhende, M1
Whittaker, AR1
Lucas, M1
Carter, R1
Cooper, DM1
Kunselman, S1
McLean, DE1
Yandava, CN2
Sharp, SJ1
Vickers, MR1
Frost, CD1
Horiuchi, T1
Baumgarten, CR1
Dorow, P1
Gebhardt, R1
Kettner, J1
Sykes, AP4
Salat, D1
Popov, D1
Joshi, A1
Sah, SP1
Agrawal, S1
Agarwalla, A1
Jacob, M1
Seberová, E1
Andersson, A1
Greening, A1
Ossip, MS1
Hederos, CA1
Anttila, H1
Ribeiro, BL1
Davies, PI1
Saarelainen, P1
Thwaites, RM1
Jones, R1
Payne, JE1
Wolford, JP1
Adelglass, J1
Clifford, DP1
Duke, SP1
Wire, PD1
Faris, M1
Shelledy, DC1
Lawson, RW1
Davis, CP1
LeGrand, TS1
Stephens, MB1
Balzano, G1
Battiloro, R1
Biraghi, M1
Fuschillo, S1
Gaudiosi, C1
De Angelis, E1
Besbes-Ouanes, L1
Knani, J1
Waterer, GW1
Hills, BA1
Chen, Y1
Farré, M1
Mas, M1
de La Torre, X1
Wade, D1
Hirai, R1
Nolop, K1
Laurent, F1
Latrabe, V1
Raherison, C1
Tunon-de-Lara, JM1
Rho, DS1
Blomgren, A1
Boonyavorakul, C1
Thakkinstian, A1
Charoenpan, P1
Ozaras, R1
Tahan, V1
Turkmen, S1
Talay, F1
Besirli, K1
Aydin, S1
Uzun, H1
Cetinkaya, A1
Lee, T1
Dennis, S1
Jébrak, G1
Maslow, AD1
Regan, MM1
Darvish, A1
Mehrez, M1
Boughton, R1
Loring, SH1
Beckett, P1
Niu, T1
Rogus, JJ1
Wang, B1
Yang, J2
Xu, X1
Frei, SP1
Noschese, P1
D'Amato, M1
D'Amato, G2
Karch, AM1
Karch, FE1
Duane, M1
Chandran, L1
Morelli, PJ1
Church, N1
Murray, A3
Barnhart, F2
Kamachi, A1
Nasuhara, Y1
Ohtsuka, Y1
Amishima, M1
Zetterström, O1
Lähelmä, S1
Keski-karhu, J2
Ostling-kulling, E1
Markham, A2
Sherman, J1
Becker, JM1
Iskandrian, S1
Conkling, J1
Barraza, CH1
Suárez-Chacón, R1
Harnest, U1
Martinez Morales, G1
Nolop, KB1
Visser, S1
Lutsky, BN1
Oudesluys-Murphy, AM1
Janssens, HM1
Hop, W1
Brinkman, JG1
Sukhai, RN1
Brieva, J1
Beckman, O1
Peterson, S1
Fishwick, D1
Bradshaw, L1
Macdonald, C1
Gash, D1
Shapiro, GS1
McRae, W1
Koskela, T1
Peltola, S1
Ojima, F1
Ebihara, M1
Shoji, T1
Tomike, H1
Nakagawa, Y1
Chuffart, AA1
Sennhauser, FH1
Lapidus, RJ1
Levine, BE1
Kiselev, P1
Bourcereau, J1
Leynadier, F1
Ben-Joseph, RH1
Bailey, MJ1
Driver, JS1
Forbes, AB1
McNeil, JJ2
Sanguinetti, CM1
Silins, V1
Bogolubov, M1
Singhal, T1
Garg, H1
Arora, HS1
Tesarowski, D1
Huang, MT1
Yang, YH1
Lin, YT1
Lu, MY1
Wang, LH1
Tsai, MJ1
Chiang, BL1
Anstead, MI1
Hunt, TA1
McConnell, JW1
Burki, NK1
Chakir, J1
Boutet, M1
Liam, CK1
Lim, KH1
Wong, CM1
Dunn, CJ1
Goa, KL1
Clayton, RA1
McGrath, JC1
Hinton, KL1
Kratzenberg, JJ1
Dubé, L1
Noveck, R1
Linder, JA1
Stafford, RS1
Leone, FT1
Mauger, EA1
Ford, J1
McGeady, SJ1
Romano, F1
Recchia, G1
Staniscia, T1
Bonitatibus, A1
Villa, M1
Nicolosi, A1
De Carli, G1
Mannino, S1
Panicker, J1
Sehgal, V1
Eisner, MD1
Chi, F1
Capra, AM1
Mendoza, GR1
Selby, JV1
Blanc, PD1
Chavis, C1
Majori, M1
Farce, M1
Cloosterman, SG4
Bijl-Hofland, ID4
van Den Elshout, FJ2
Blais, R1
Grégoire, JP1
Bouchard, J1
Martin, RM1
Shakir, S1
Chuchalin, AG1
O'Brien, K1
Mitsufuji, H1
Imasaki, T1
Ichikawa, T1
Kawakami, T1
Tomita, T1
Jensen, A1
Atileh, H1
Burggraaf, J1
Westendorp, RG1
in't Veen, JC1
Blauw, GJ1
Rebrov, AP1
Karoli, NA1
Orsida, BE1
Stone, BD1
Elias-Todd, T1
Parrino, J1
Zieba, M1
Keogh, KA1
Arseneault, R1
Tennis, O1
Bacal, L1
Bilge, M1
Boone, R1
Goraya, JS1
Virdi, VS1
Wang, SW1
Liu, X1
Wiener, DJ2
Sennett, C1
Bowers, BW1
Scalfaro, P1
Sims, C1
Habre, W1
Naedele-Risha, R1
Mircetić, RN1
Dodig, S1
Raos, M1
Petres, B1
Cepelak, I1
Kips, JC1
Wood, R1
Jones, PD1
Hankin, R1
Simpson, J1
Cash, R1
Blonski, J1
Cates, C1
Eliseeva, EV2
Romanova, NA1
Maistrovskaya, YV1
Maloney, A1
Ventresca, GP1
Morris, A1
Centanni, S1
Boveri, B1
Di Marco, F1
Santus, P1
Simpson, JL1
Hensley, MJ1
Abisheganaden, J1
Chee, CB1
Goh, SK1
Yeo, LS1
Prabhakaran, L1
Earnest, A1
Wang, YT2
Armstrong, TJ2
Britton, TB2
Forand, PE2
Pillari, A1
Corona-Hernández, L1
Fragoso-Ríos, R1
Berber, A1
Torres-Alcántara, S1
Cuairán-Ruidíaz, V1
Goggin, N1
McDonald, DM1
Coskun, S2
Tikiz, H1
Danahaliloğlu, S1
Mallmann, F1
Fernandes, AK1
Avila, EM1
Nogueira, FL1
Steinhorst, AM1
Saucedo, DZ1
Machado, FJ1
Raymundi, MG1
Dalcin, PT1
Menna Barreto, SS1
Mallol, J1
Aguirre, V1
Rhem, R1
Rodriguez, J1
Dolovich, M1
Botkin, JR1
Clayton, E1
Nelson, R1
Wilfond, B1
Munger, MA1
Miller, FG1
Shorr, AF1
Friedman Ross, L1
Polat, M1
Onag, A1
Marosi, A1
Stiesmeyer, J1
Hallett, C1
Stevens, AL1
Vandermeer, AK1
Garris, T1
Seppälä, OR1
Aalto, E1
Hakonen, T1
Lukkari-Lax, E1
Jouhikainen, T1
Liipp, K1
Walter, SD1
Cohn, JR1
Sataloff, RT1
Branton, C1
Hellier, JP1
Baudrimont, M1
Dussaule, JC1
Berenbaum, F1
Slattery, D1
Wong, SW1
Colin, AA1
Dyer, CA1
Singh, SJ1
Stockley, RA1
Sinclair, AJ1
Hill, SL1
Baty, JD1
Baumgarten, C1
Geldszus, R1
Behre, U1
Peslis, N1
Mylonopoulou, M1
Everard, ML1
Hiller, EJ4
Ross-Russell, R1
O'Keefe, P1
Stoloff, S1
Poinsett-Holmes, K1
Madan, A1
Wiewrodt, R1
Punin, AA1
Bogachev, RS1
Zubkov, SK1
Kozyrev, OA1
Khokhlova, IuA1
Loader, P1
Bracken, M1
Lieberman, AK1
Bowers, B1
van der Elshout, FJ1
Trieu, L1
O'Donnell, JC2
Meyer, JW1
van den Hoogen, H1
Nie, HX1
Hu, SP1
Wu, XJ1
Vatsa, HK1
Gaur, SN1
Delaisi, B1
Newman, KB1
Milne, S1
Hamilton, C1
Hall, K1
Newton, MF1
Hunter, CJ1
Woltmann, G1
Wardlaw, AJ1
Love, JG1
Hayday, K1
Stevermer, JJ1
Tsoĭ, AN1
Apkhipov, VV1
Medvedeva, IV1
Lapik, SV1
Gur'eva, SA1
Savina, IA1
Kress, JP1
Noth, I1
Gehlbach, BK1
Barman, N1
Pohlman, AS1
Miller, A1
Morgan, S1
Hall, JB1
Lloyd, A1
Hutchinson, J1
Plumb, J1
Drago, A1
Esposito-Pellitteri, M1
Candore, G1
Lo Bianco, C1
Caruso, C1
Bessmertny, O1
DiGregorio, RV1
Becker, E1
Looney, D1
Golden, J1
Kohl, L1
Johnson, T1
Phillips, B1
Schmitt, BD1
Grella, E1
Mazzarella, G1
Izawa, M1
Takeshita, Y1
Kurita, F1
Okada, M1
Shinomiya, N1
Perneger, TV1
Sudre, P1
Muntner, P1
Uldry, C1
Courteheuse, C1
Naef, AF1
Jacquemet, S1
Nicod, L1
Assal, JP1
Vialatte, J1
Mancini, G1
Tellini, M1
D'Ambrosio, R1
Blasi, A1
Marzo, C1
Hills, EA1
Davies, S1
Geary, M1
Salorinne, Y2
Stenius, B1
Tukiainen, P2
Pinder, RM1
Brogden, RN3
Speight, TM2
Avery, GS2
Panico, D1
Shotter, MV1
Morris, HG1
Rusnak, SA1
Selner, JC2
Barnes, J1
Von Graffenried, B1
Lindsay, D1
Milledge, JS4
Morris, J2
Gonsior, E1
Meier-Sydow, J1
Cooper, W1
Nizankowski, R1
Mruk, J1
Connellan, SJ1
Wilson, RS1
Bacon, CJ1
Green, C1
Uffholtz, H1
Sadoul, P1
Lempereur, L1
Sentissi, M1
Fitzgerald, JD1
Killian, DN1
Mellon, JJ1
Lightbody, IM1
Ingram, CG1
Legge, JS3
Johnston, RN1
Nascimbene, T1
Marcus, HI1
Charpin, J5
Bonelli, J1
Hitzenberger, G1
Magometschnigg, D1
Griffiths, AD1
Germouty, J1
Bonnaud, F2
Gay, G1
Greenacre, JK2
Raij K-Alanko, K1
Härkönen, M1
Ikemori, K1
Kashima, T1
Reinert, M1
Biro, G1
Retiene, K1
Kallenbach, J1
Joffe, BI2
Zwi, S2
Seftel, HC2
Leifer, KN1
Wittig, HJ1
Turner, P3
Bülow, K3
Cristensson, P1
Schindl, R3
Safirstein, BH3
Dhakhwa, RB1
Gelb, B1
Fontunato, FD1
Boye, NP1
Vale, JR1
Neville, A1
Gaddie, J3
May, CS2
Murchison, LE1
Femi-Pearse, D3
George, WO1
Ilechukwu, ST1
Elegbeleye, OO3
Afonja, AO2
Goldgraber, MB1
Kamburoff, PL3
Prime, FJ3
Schmidt, OP1
Garza Gomez, M1
Picchioni, P1
Minelli, P1
Thompson, P1
Friedman, M2
Mahajan, VK1
Huber, GL1
Raine, D1
Doner, HC1
Posey, WC1
Jones, BJ1
Anderson, G1
Wilkins, E1
Cimbritz, H1
Jungquist, G1
Bennis, J1
Huhti, E1
Poukkula, A1
Cummiskey, J1
Keelan, P1
Gray, P1
Cox, GA1
Beumer, HM2
Mills, JG1
Sharpe, PC1
Hill, A1
Middleton, H1
Momen, M1
Prescott, RJ2
Schonell, M1
Harris, M1
McMiken, D1
Jenne, H1
Evers, R2
Capecchi, V1
Cavalli, F1
Falcoone, F1
Fasano, E1
Jonderko, G1
Kwiatek, R1
Bierowiec, J1
Górnisiewicz, J1
Kapela-Lachowicz, B1
Olak, Z1
Webber, B1
Poddar, SP1
Nath, S1
Wood, DO1
Chandler, D1
Dugdale, AE1
Obminski, G1
Bloomfield, P1
Petrie, GR2
Jewell, NP1
Leopold, D2
Handslip, P1
Pierce, RJ1
Allen, CJ1
Campbell, AH2
Pasotti, C1
Capra, A1
Vibelli, C2
Honeybourne, D1
Guleria, JS3
Vasu, KV1
Hambleton, G2
Stone, MJ1
Hanna, CJ1
Eyre, P1
Harris, MR2
Schonell, ME1
McMiken, DF1
Tormey, WP1
Duncan, D1
Kingsley, PJ1
Hobday, JD1
Bateson, M1
Leméshkina, VS1
Shiriaéva, IS1
Monie, R1
Liang, A1
Macfie, AE1
Harris, EA1
Whitlock, RM1
Olusi, SO1
Ojutiku, OO1
Jessop, WJ1
Iboko, MI1
Wemeau, J1
Bonniere, B1
Pihlajamäki, K1
Bhalla, JS1
Klumpp, JA1
Rutland, J1
Verstraeten, JM1
Houston, K1
McEvoy, A1
Pavicic, F1
Duraković, Z1
Razon, S1
Knoop, U1
Lin, MT1
Collins-Williams, C2
Johnson, AJ5
Pidgeon, J2
Bateman, S1
Brørs, O1
Williams, KO1
Hugues, FC1
Julien, D1
Budmiger, H1
Holmes, PW1
Barter, CE1
Hurst, NP1
Lecerof, H1
Fruhmann, G1
Wildbolz, U1
Février, D1
Sillett, RW1
Dash, CH2
McNicol, MW2
Coady, TJ2
Stewart, CJ1
Davis, HJ1
Blackhall, MI1
Dauth, M1
Mahoney, M1
O'Donnell, SR1
Tribe, AE2
Wong, RM1
Robinson, JS1
Williams, SJ2
Graham, JD1
Graff-Lonnevig, V2
Donevan, RE1
Copland, GM1
Pasqua, F1
Giammarruto, R1
Ancetti, A1
Caputo, G1
Spiro, S1
Rubin, AH1
Mansur, A1
Schey, G1
Shahor, Y1
Bruderman, I1
Tuttle, CB1
Sidorov, J1
Gemelli, M8
De Lucia, F1
Barberio, G8
Franchina, A7
Tickner, TR1
Cramp, DG1
Foo, AY1
Bateman, SM1
Wills, MR1
Ruggerini, R1
Romitti, M1
Sprocato, S1
Bianco, F1
Hawkins, R1
Pepys, J2
Bell, GM1
Rawlins, MD1
Komarov, FI1
Daniliak, IG1
Da Costa, JL1
Goh, BK1
Teoh, PC1
Fawcett, IW1
Erooga, MA1
Semple, PD2
Habeshaw, T1
Del Torre, L1
Fiore, G1
Macluso, S1
Pesce, L1
De Luca, F5
Petraglia, A1
De Cataldis, G1
Tarantino, O1
Materazzi, F1
Choo-Kang, YF3
Renovanz, HD1
Nonhoff, R1
Avner, SE1
Taeger, D1
Arnaud, A4
Autran, P1
Tricard, P1
Goldman, HI1
Haynes, DR1
Parrish, RW1
Fitchett, DH1
Riordan, JF1
D'Arcangelo, GV1
Arca, S1
Miletto, A1
Kennedy, MC1
Posner, E1
Tomasi, L3
Todisco, T2
Ansidei, V1
Miele, N1
Porcellati, C1
Shenfield, GM3
Hodson, ME1
Lewis, HE1
Bhatia, SP1
Ingram, J1
Skinner, C4
Barnes, P1
Kieselstein-Gross, E1
Abrahamov, A1
Sarsfield, JK1
Liberti, R1
Cicconetti, CA1
Gentili, G1
Ingrao, F1
Ingianna, O1
Spadoni, M1
Melillo, G1
Cocco, G1
Brancaccio, L1
Murano, G1
Paroli, M1
Zanotelli, F1
Serembe, M1
Camerota, G1
Pontiggia, P1
Curti, PC1
Fantera, A1
Brettoni, B1
De Paola, E1
Baccini, A1
Bruscoli, G1
Orlandi, O1
Banaudi, C1
Bruna, S1
Dolcetti, A1
Perino, B1
Boschetti, E1
Valenti, S1
Mirabelli, S1
DeLuca, F2
Guideri, A1
Dotti, A1
Grasso Caprioli, G1
Quadri, A1
Rovetta, A1
Spedini, C1
Carnimeo, N1
Maiorano, V1
Cesco, G1
Tansini, GC1
Gandola, L1
Soccini, F1
MacKenzie, AM1
Zieliński, J2
Koziorowski, A2
Maszczyk, Z2
Underwood, SL1
Lewis, SA1
Raeburn, D1
Płusa, T1
Zaraś, E1
Kruszewski, J1
Hoppe, M1
Toumi, M1
Marsac, J3
O'Brien, J1
Sparrow, D1
Fanta, CH2
Murphy, S2
Pacheco, Y1
Hosni, R1
Chabannes, B1
Gormand, F1
Moliere, P1
Piperno, D1
Lagarde, M1
Geddes, DM1
Cockcroft, D1
Hilton, CJ2
O'Shaughnessy, KM1
Choudry, NB1
Midgren, B1
Balder, B1
Wåhlander, L3
Brémont, F1
Moisan, V1
Dutau, G1
Pappo, M2
Muir, JF2
Storms, WW2
Bodman, SF1
Greenstein, SM1
Jackson, R2
Haffner, CA1
Kendall, MJ1
Meyer, CR1
Boman, G4
Takahashi, S1
Beusenberg, FD1
Van Amsterdam, JG1
Hekking, PR2
Brouwers, JW1
Schermers, HP1
Bonta, IL1
Timmers, MC2
Zwinderman, AH2
Dijkman, JH2
Southern, DL1
Brown, PH1
Lenney, J1
Armstrong, S1
Ning, AC1
Soni, NR1
Cifelli, AT1
Broder, I3
Mazza, JA3
Moote, DW2
Small, P2
Wilkinson, JR1
Sprogøe-Jakobsen, U1
Viktrup, L1
Davidsen, O1
Viskum, K1
Törnqvist, H1
Douglass, JA1
Tuxen, DV1
Horne, M1
Scheinkestel, CD1
Weinmann, M1
Czarny, D1
Bowes, G2
Frazier, CA1
Rogers, P1
Wiebe, RA1
Anaya, C1
Chang, RK1
Chang, MA1
Terada, AM1
Bray, ML1
Ching, CY1
Kim, MY1
Shinsato, ET1
Morice, A1
Gleason, MC1
Gromova, OA1
Gusel', VA1
Yamada, N1
Kadowaki, S1
Umezu, K1
Tan, WC2
Chan, TB2
Ang, SM2
Bodenhamer, J1
Bergstrom, R1
Brown, D1
Gabow, P1
Marx, JA1
Lowenstein, SR1
Trussard, V1
Seneterre, E1
Giron, J1
Sénac, JP1
Cogo, AL1
Turati, C1
Waler, JA1
Mann, MC1
Eliasson, O1
Patel, K1
Akkermans, R1
van Grunsven, PM1
Britton, MG1
Earnshaw, JS2
Drblik, SP1
Lapierre, G2
Marcotte, JE1
Bourgeois, M1
Mueller, GA1
Bjure, J1
Engström, I1
Sten, G1
Wennergren, G1
Banks, J1
Buchanan, K1
Cheong, B2
Waterhouse, JC1
Simmons, JL1
Wray, H1
Howard, P1
O'Driscoll, BR4
Kay, EA2
Taylor, RJ3
Weatherby, H1
Chetty, MC1
Bernstein, A3
Dickinson, ET1
O'Connor, RE1
Megargel, R1
Iakovlev, VN1
Nechaev, DF1
Mironov, MB1
Semenova, TA1
Marshall, S1
Lowenthal, D1
Khilnani, G1
Parchani, H1
Toshniwal, G1
Bronstein, M1
Deutsch, M1
Reinikainen, K1
Freudenthal, Y1
Gaddy, JN1
Margolskee, DJ1
Williams, VC1
Lüthke, M1
Wiessmann, J1
Zambruni, U1
Verver, S1
Cisteró, A1
Abadías, M1
Lleonart, R1
Lafuente, V1
Pintó, E1
Torrent, J1
Jané, F1
Cohen, BM1
Mathieu, M1
Lellouche, N1
Sartene, R1
De Stefano, G2
Piacentini, GL2
Bonizzato, C1
Sette, L2
Banfi, F1
Hindi-Alexander, MC1
Wempe, JB1
Breederveld, N1
Alting-Hebing, D1
Reed, CE1
Driesner, NK1
Abuan, TH1
Emmick, G1
Schoene, RB1
Green, SM1
Rothrock, SG1
Speelberg, B1
Roche, WR1
Wassermann, K1
Pothoff, G1
Bahra, J1
Hilger, HH1
Guss, S1
Portnoy, J1
Lødrup, KC1
Svindland, A1
Refvem, OK1
Derom, EY1
Van der Straeten, ME1
Raper, R1
Fisher, M1
Bihari, D1
Mossberg, B2
Suda, H1
Nagai, H1
Iwama, T1
Rooda, HM1
Van Daele, P1
Van den Elshout, FM1
Decramer, M1
Buntinx, A1
De Lepeleire, I1
Fleisher, GR1
Surpure, JS1
Kulick, R1
Vázquez Cordero, C1
Corera Sánchez, M1
Molinuevo Alvaro, J1
Seto, W1
Wong, M1
Mitchell, EA1
Ward, AJ1
Kassem, N1
Evans, JM1
Moxham, J1
Ganderton, D1
Ellis, EF1
Eigen, HN1
Hemstreet, MP1
Bogin, RM2
Ballard, RD2
Kozlik, R1
Sarin, S1
Shami, S1
Cheatle, T1
de Kock, JC1
Hui, KP1
Ramsdale, EH1
Otis, J1
Kline, PA1
Gontovnick, LS1
Jenkins, WJ1
Alexander, J1
Coward, G1
Upchurch, F1
Okiyama, M1
Fujiwara, H1
Kudo, M1
Simizu, M1
Maeda, M1
Yamada, M1
Toshimitsu, Y1
Gongora, HC1
Völkl, KP1
Kroll, VM1
Wiesemann, HG1
Weaving, PG1
Henderson, A1
Ryberg, M2
Möller, C2
Ericson, T2
Walajtys-Rode, E1
Madalinska, M1
Vincent, D1
Havet, N1
Marrash-Chahla, R1
Pradalier, A2
Dry, J1
Shields, MD1
Reisman, JJ1
Fakhoury, K1
Pedder, L1
Menon, PK1
Stankus, RP1
Rando, RJ1
Salvaggio, JE1
Lehrer, SB1
Le Roux, AM1
Kotze, D1
Wium, CA1
Van Jaarsveld, PP1
Weisz, AW1
Talaee, N2
Eiser, N2
Talini, D1
Mapp, CE1
Frans, A1
Garin, P1
Van den Eeckhaudt, J1
Brune, J1
Jobanputra, P1
Ford, A1
Gomm, PJ1
Osselton, MD1
Broster, CG1
Upton, K1
Llupiá, J1
Fernández, AG1
Berga, P1
Gristwood, RW1
Tukiainen, H4
Harbers, H1
Maas, KL1
Higgins, BG1
Powell, RM1
Schauer, U1
Dippel, E1
Gieler, U1
Bräuer, J1
Jung, T1
Heymanns, J1
Rieger, CH1
Verbeek, AL1
van der Hoogen, HJ1
Vidgren, P1
Paronen, P1
Lehti, H1
Ratner, PH2
Pak, J1
Solopov, VN1
Lunichkina, IV1
Li, ZG1
Narang, NK1
Meratwal, S1
Toshniwal, GL1
Richardson, WN1
Shaw, M1
Bibi, H1
Montgomery, M1
Chernick, V1
Domagala, B1
Pinis, G1
Basomba, A1
Burches, E1
Almodovar, A1
de Rojas, DH1
Amsler, B1
Tarayre, JP1
Aliaga, M1
Barbara, M1
Tisseyre, N1
Vieu, S1
Tisne-Versailles, J1
Effron, D1
Lukens, TW1
Gershman, H1
Boehm, SP1
Charlton, I2
Charlton, G2
Broomfield, J2
Mullee, MA2
Quessy, SN1
Larsen, JS1
Weisberg, SC1
Halverson, PC1
Green, CP1
Hoskyns, EW1
Thomson, A1
Decker, E1
Hutchins, A1
Simpson, H1
Clearihan, L1
Mizuno, H1
Takahashi, Y1
Ohno, H1
Misawa, M1
Gubbelmans, HL2
Zweers, PG3
Dauphinee, B1
Djahed, B1
Wu, TC1
Pelucchi, A2
Sher, E1
Mastropasqua, B2
Diedenhofen, A1
Mazza, P1
Cavigioli, G1
Browaldh, L1
Stein, R1
Brittain, RT1
Aldons, PM1
Maesen, F1
Greefhorst, A1
Prins, J1
Tan, Y1
Zweers, P1
Windom, HH1
Purdie, G1
Graafsma, SJ1
Visch, MB1
Tsukioka, K1
Nakamata, M1
Kondo, A1
Shovlin, CL1
Tam, FW1
Harris, A1
Jenkins, MA1
Hurley, SF1
Gontovnick, L1
Britton, JR1
Halpern, GM1
Mackay, T1
Driver, H1
Gay, PC1
Patel, HG1
Nelson, SB1
Gilles, B1
Hubmayr, RD1
Leduc, T1
Proulx, F1
Perreault, S1
Duranceau, A1
Amyot, R1
Joliat, TL1
Weber, RW1
White, KD1
Fitzsimons, T1
Patterson, R1
Patterson, DR1
Plaut, T1
Cammell, JS1
Holdaway, MD1
Smith, NA1
Kornberg, AE1
Zuckerman, S1
Welliver, JR1
Mezzadri, F1
Aquino, N1
Costongs, R1
Brombacher, PJ1
Bendefy, IM1
Pennington, WT1
Bardin, PG1
Bishop, J1
Nolan, T1
Navajas, D1
Agusti, AG1
Wagner, PD3
Hayes, JP1
Lambourn, L1
Hopkirk, JA1
Taylor, AJ1
Gathua, SN1
Aluoch, JA1
Varghese, J1
Gerblich, A1
Salik, H1
Schuyler, M1
Zanconato, S1
Santuz, P1
Magagnin, G1
Zacchello, F1
Jones, A1
Moncrieff, CS1
Brown, HM1
Schwarz, YA1
Kivity, S1
Ilfeld, DN1
Schlesinger, M1
Greif, J2
Garty, MS1
Hussein, A3
Harrie, K1
Kussau, D1
Patrick, DM1
Dales, RE1
Stark, RM1
Laliberte, G1
Dickinson, G1
Suzuki, S1
Miyashita, A1
Matsumoto, Y1
Okubo, T1
Barros, MJ1
Stevens, WJ2
Philip-Joet, F2
Reynaud-Gaubert, M1
Jirou-Najou, JL1
Kallenbach, JM1
Panz, VR1
Jankelow, D1
Soares, FJ1
Cluzel, M1
Clauzel, AM1
Godard, PH1
Pierson, WE2
Bell, TD1
MacCosbe, PE1
Sykes, RS1
Phillips, GD1
James, RW1
Masters, IB1
Levy, N1
Bearman, JE1
Sladek, WA1
Sur, S2
Kwong, T2
Flatt, A2
Reider, MJ1
Pender, E1
Forbes, T1
Tan, YK2
Bailey, D1
Mohs, E2
Chavarría, F2
Luo, ZY1
Luo, DF1
Richards, JG1
Mauger, P1
Le Dune, P1
Mohiuddin, AA1
Burns, R1
Stewart, CF1
Ellis, RF1
Tsiu, SJ1
Kellermann, AL1
Guarnaccia, S1
Pasquali, M1
Acerbis, F1
Pedrali, M1
Duse, M1
Ugazio, AG1
Wiebicke, W1
Carrington, D1
Hollingworth, J1
Gleeson, JG2
Loftus, BG3
Schuddinck, L1
Wojciechowski, M1
Prasher, VP1
Corbett, JA1
Vanmaele, L1
Impens, N1
Schandevyl, W1
Rosenthal, TM1
Voss, KR1
Willsie-Ediger, SK1
Pyszczynski, DR1
Breeden, CC2
Ballester, E2
Ramis, L1
Thompson, LM1
Ingram, RH2
Kelkel, E1
Pison, C1
Pin, I2
Paramelle, B1
Connolly, MJ2
Jarvis, EH1
Habib, RH1
Dorkin, HL1
Wall, MA1
Meyer, A1
Jacobsen, P1
McLaren, M1
Susanna, V1
Loffreda, A1
Servodio, R1
Filippelli, A1
Santagata, A1
Montanaro, C1
Carapella, N1
Marmo, E1
Mazer, B1
Figueroa-Rosario, W1
Bender, B1
Mihatsch, W1
Biddiscombe, M1
Tolfree, SE3
Short, M3
Bastianon, V1
Di Fazio, A1
Colloridi, V1
Marzano, MC1
Ferrucci, A1
Pucci, S1
Bernardini, L1
Coletta, F1
Sorbara, N1
Businco, L1
Martelli, NA1
Lazzari, JO1
Valdés Cuadrado, L1
Salgueiro Rodriguez, M1
Alvarez-Calderón Prat, P1
Arias Castells, MR1
Berdugo Oviedo, M1
Rabuñal Rey, R1
Ventosa Rial, J1
Rodríguez Suarez, JR1
Pelikan, Z1
Pelikan-Filipek, M1
Karnik, AM1
Medhat, M1
Farah, S1
Tennina, S1
Johnson, MA1
Bloom, R1
Crespo Notario, JA1
Sobradillo Peña, V1
Garnacho López, E1
Ansola Zubiaurre, PM1
Mazo Echániz, J1
Georgopoulos, D2
Ilonidis, G1
Shettar, SP1
Jindal, SK1
Kaur, SJ1
Chaieb, J1
Belcher, N1
Chen, L1
Deng, K1
Ye, YQ1
Masliah, J1
Malanchère, E1
Lefort, J1
Bereziat, G1
Neijens, HJ1
Raatgeep, HC1
Degenhart, HJ1
Recaldin, S1
Smith, F2
White, PT1
Pharoah, CA1
Freeling, P1
Ball, M1
Martelli, A1
Otero, C1
Gil, B1
Horsley, MG1
Chambers, DK1
Summers, Q1
Tarala, R1
Sigvaldasson, A1
Skoogh, BE1
Epelbaum, S1
Benhamou, PH1
Pautard, JC1
Devoldere, C1
Kremp, O1
Piussan, C1
Hill, P1
Bogaard, JM1
Slingerland, R1
Verbraak, AF1
Lim, R1
Walshaw, MJ1
Saltissi, S1
Hind, CR1
Phanichyakarn, P1
Mansfield, LE1
Reese, ME2
Tierce, JC1
Meller, W1
Berlow, B1
Gerth, WC1
Charter, MK1
Moreland, TA1
Struthers, AD2
Clark, GA1
Wouters, EF1
Polko, AH1
Visser, BF1
Bâ, M1
Bennati, D1
Peroni, DG1
DaCruz, D1
Holburn, C1
Crockett, AJ1
Blight, MM1
Henry, DA1
Benton, G1
Thomas, RC1
Nickerson, BG1
McQuitty, JC1
Okikawa, J1
Croft, RD1
Fraser, CG1
Meslier, N1
Six, P1
Døssing, M1
Evald, T1
Lange, P1
Christensen, HR1
Sheehan, GJ1
Kutzner, MR1
Chin, WD1
Lowe, RS1
Kersey, J1
Reyes, A1
Guitart, R1
Lim, TK1
Anani, A1
Higgins, AJ1
Osborne, J1
Valentine, J1
Cocksedge, S1
Milner, A1
Kinnear, G1
Körholz, D1
Seeger, K1
Griese, M1
Wahn, V1
Reifenhäuser, A1
Gove, RI1
Brown, RA1
Verini, M1
Ansaloni, A1
Di Vincenzo, MG1
Napoleone, M1
Morgese, G1
Bianchi, G1
DiPalma, JR1
Corsico, R1
Majani, U1
Lodola, E1
Crowe, MJ1
Counihan, HE1
O'Malley, K1
Scremin, S1
Caprioglio, L1
Gustafsson, M1
Säwedal, L1
De Candussio, G1
Franchi, D1
Manini, G2
Arossa, W1
Billing, B1
Dahlqvist, R1
Leideman, T1
Skareke, L1
Ripe, E1
Storr, J3
Barrell, E2
Barry, W1
Hatcher, G1
Fleming, DM1
Whittington, RM1
Joad, J1
Morin, D1
Cookson, WO1
Herjavecz, I1
Böszörményi-Nagy, G1
Szeitz, A1
Debreczeni, LA1
Brodde, OE1
Howe, U1
Egerszegi, S1
Konietzko, N1
Michel, MC1
Manazza, P1
Colombo, ML1
Zoia, MC1
Gould, CA1
Ollier, S1
Aurich, R1
Williams, WR1
Kagamimori, S1
Kakiuchi, H1
Naruse, Y1
Diamant, B1
Madsen, PL1
Vilkka, V1
Parkin, P1
Rajan, A1
Healy, R1
Rieder, M1
Soldin, SJ1
Galdès-Sebaldt, M1
Delnitz, D1
Rozniecki, J1
Macfarlane, JT1
Birch, MJ1
Evans, NA1
Gamble, S1
Bidat, E1
Johnson, CE1
Belfield, PW1
Cooke, NJ2
Spencer, A1
Davies, JA1
Ioli, F1
Fracchia, C1
Patessio, A1
Spada, EL1
Vecchio, C1
Antoniadou, H1
Sotiropoulou, E1
Niero, E1
Vallone, G2
Gaburro, D1
Del Bono, L1
Fontana, G1
Mugnai, M1
Cresci, F1
Panuccio, P1
Mazzei, JA1
Torres, J1
Ebden, P2
Farrow, PR1
Cookson, JB2
Moneret-Vautrin, DA1
Trechot, P1
Maria, Y1
Rayner, RJ1
Cartlidge, PH1
Upton, CJ1
Gribaldo, E1
Ardizzi, A1
Oliaro, A1
Galietti, F1
Giorgis, GE1
Miravalle, C1
Richards, R1
Galdes-Sebalt, M1
Stewart, DE1
Gillies, AJ2
Wiberg, R1
Ekberg, P1
Hanley, SP1
Garrett, HV1
Hadfield, JW2
Ryan, CA1
Wherrett, BA1
Higgins, RM1
Stradling, JR1
Lane, DJ1
Larsson, K1
Bevegård, S1
Grandordy, BM1
Thomas, V1
de Lauture, D2
Petty, TL1
Brandon, ML1
Schoenweter, W1
Mazza, J1
Jaakkola, J1
Torkko, M1
Terho, EO2
Steedman, DJ1
Robertson, CE1
Green, S1
Jeyasingh, K1
Teo, J1
Kwang, LW1
Yip, WC1
Osman, J1
Blainey, AD1
Mazzoni, L1
Sanjar, S1
von der Hardt, H1
Müller, W1
Schell, SM1
Voy, RO1
Murdock, KY1
Rohr, AS2
Lanier, R1
Thorne, KJ1
Richardson, BA1
Butterworth, AE1
Hay, I1
Higenbottam, TW1
Taytard, A1
Beaumont, D1
Pujet, JC1
Sapene, M1
Lewis, PJ1
Reynolds, SR1
Rajan, G1
Forderer, A1
Abelitis, M1
Koch, I1
Wesołowski, S1
Carey, OJ1
Quinton, D1
Rivero, A1
Dal-Re, R1
Azanza, JR1
Montserrat, JM1
Lloberas, P1
Serra, J1
Luengo, M1
Agusti-Vidal, A3
Schindlbeck, NE1
Heinrich, C1
Huber, RM1
Müller-Lissner, SA1
Schöni, MH1
Bruderer, K1
Morley, TF1
Marozsan, E1
Zappasodi, SJ1
Gordon, R1
Griesback, R1
Giudice, JC1
Kaneshige, H1
Suzuki, H1
Takagi, H1
Akisawa, T1
Narushima, M1
Tonozuka, H1
Tanaka, K1
Nakagami, K1
McDonald, C1
Maruchin, JE1
Beauvoir, C1
Sissman, J1
Mussell, MJ1
Maniki, E2
Tsara, V2
Daskalopoulou, E1
Carpentiere, G1
Marino, S1
Castello, F1
Bonanno, CT1
Baldanza, C1
Littenberg, B1
Kelly, C1
Harris, JB1
Annis, L1
Ries, R1
Dascalopoulou, E1
Grandordy, B1
Belmatoug, N1
Morelle, A1
Román, L1
Azcarate, MJ1
Rodriguez Soriano, J1
Graham, AN1
Maling, TJ1
Castillo, JA1
Schinca, N1
Pujades, M1
Ordinas, A1
Coronas, A1
Verbeek, PR1
Gareau, AB1
Rubes, CJ1
Brunette, MG1
Lands, L1
Thibodeau, LP1
Yan, K1
Barbera, JM1
Middleton, HB1
Eby, DM1
Shellshear, I1
Sinopal'nikov, AI1
Efimov, AV1
Alekseev, VG1
Brighenti, C1
Schiassi, M1
Miglioranzi, P1
Richelli, C1
Pincemaille, O1
Jouk, PS1
Bost, M1
Amitai, Y1
Ishizaki, T1
Minegishi, A1
Morishita, M1
Odajima, Y1
Kanagawa, S1
Nagai, T1
Yamaguchi, M1
Montserrat, J1
Bellamy, D1
Penketh, A1
Asai, S1
Watanabe, T1
Hayashida, M1
Miura, N1
Yamasaki, H1
Inuyama, M1
Kiya, T1
Izumikawa, K1
Orphanidou, D1
Myers, MJ1
Al-Suhali, AR1
Henderson, B1
Renard, RL1
Mendelson, LM2
Selcow, JE1
Noyes, JH1
Dubey, GR1
Dabholkar, SV1
Kamat, SR2
Shah, SP1
Sonaje, AG1
Athawale, SS1
Zellweger, JP1
Clottu, R1
Crittin, A1
Dottrens, A1
Heinzer, F1
Stinghe, R1
Vodoz, JM1
Unter, CE2
Allan, J2
Greenough, A1
Pool, J1
Joad, JP2
Lindgren, SD2
Weinberger, MM2
Kirby, JG1
Herkert, A1
Molho, M2
Gruzman, C1
Katz, I1
Lidgi, M1
Chaniac, A1
Bucholtz, GA1
Condemi, J1
Ghafouri, MA1
Hudson, L1
Lakshminarayan, S1
Lockey, R1
Lidji, M1
Karasik, A1
Steir, S1
Baum, GL1
Mikhail, JR1
Daly, S3
Gupta, SK3
Mitra, K1
Faucon, B1
Francomme, P1
Parise, M1
Lindsjö, M1
Strandberg, K1
Wiholm, BE1
Solomon, MA1
Ferrés Mataró, J1
Mangues Bafalluy, MA1
Farré Riba, R1
Juliá Brugues, A1
Bonal de Falgas, J1
Banerjee, DK1
Lee, GS1
Malik, SK1
Mackenzie, HM1
Lewis, H1
Holli, H1
Karvonen, J1
Isawa, T1
Teshima, T1
Ebina, A1
Anazawa, Y1
Konno, K1
Sinclair, BL1
Clark, DW1
Coupe, MO1
Guly, U1
Brown, E1
Church, SE1
Gupta, A1
Bhatnagar, OP1
Jain, AK1
Djurhuus, S1
Rohold, A1
Medici, R1
Vadstrup, S1
Couriel, JM1
Demis, T1
Olinsky, A1
Rodríguez Sanchón, B1
Cardona, MJ1
Gilmartin, JJ1
Adams, PC1
Chudwin, DS1
Strub, M1
Golden, HE1
Frey, C1
Luskin, AT1
Schwartzstein, RS1
Greger, G1
Kaspar, P1
Beswick, KB1
Sampson, S1
Giner, MT1
Nevot, S1
Sierra, JI1
Plaza, A1
Coma, G1
Youssef, W1
Williams, MH1
Küng, M1
Croley, SW1
Phillips, BA1
Blot, P1
Carson, JW2
Hey, AA1
Jones, P1
Tanser, AR1
Burger, G1
Shephard, E1
Markovitz, L1
Dunn, C1
Greenstein, S1
Ozenne, G1
Moore, ND1
Leprevost, A1
Tardif, C1
Boismare, F1
Pasquis, P1
Lemercier, JP1
Pearce, JL1
Wesley, HM1
Hedenstierna, G1
Mackay, M1
Currie, DC1
Cobos Barroso, N1
Schwartz, E1
Grunstein, M1
Chai, H1
Windebank, WJ1
Bateman, JR1
Douglas, JG2
Leslie, MJ1
Yamate, M1
Biedermann, AA1
Chu, TJ1
Bouslama, A1
Grandory, B1
Bozzoni, M1
Longhini, E1
Claybo, R1
Lacroix, J1
Shelton, D1
Maisey, MN1
Monego, A1
Cambria, S1
Cocksedge, SH1
Jackson, MB1
Williamson, L1
Cain, AR1
Osborne, JP1
Hordvik, NL1
Sunderrajan, EV1
Luu, M1
Maillard, D1
Boureau, F1
Franklin, W1
Ulmer, WT1
Krieger, E1
Mutina, ES1
Benatar, SR1
Hönig, P1
Cameron, SJ1
Cooper, EJ1
Hoare, MV2
Reilly, BJ1
Orange, RP1
Thiruvengadam, KV1
Subramanian, N1
Narasimhan, SV1
Nalini, S1
Murray, AB1
Hardwick, DF1
Pirie, GE1
Fraser, BM1
Cornia, G1
Gramiccioni, E1
Tekeres, M1
Mezey, B1
Kellényi, L1
Dirksen, H1
dos Santos, ML1
Romaldini, H1
Nery, LE1
Bogossian, M1
Ratto, OR1
Evans, ME1
Walker, SR2
Epstein, SW1
Barnard, JA1
Zsotér, TT1
Hanan, ME1
Kerr, JA1
Cromptom, GK1
Holst, PE1
O'Donnell, TV1
Martin, PD1
Gebbie, T1
Salmond, CE1
Das, S1
Dübi, B1
Studer, A1
Ferrara, M1
Srivastava, BN1
Shrivastava, VK1
Rao, VS1
Vas, GP1
Mehta, GS1
Kochar, AS2
Store, SD1
Warrier, NV1
Sanghavi, B1
Kulkarni, PS1
Sheth, UK1
Veneskoski, T1
Batra, GK1
Mattila, MJ1
Singh, A1
Singh, P1
Hodgson, SV1
McPherson, A1
Jorde, W1
MacDonald, HL1
Horne, NW1
Williams, FM1
Draffan, GH1
Wise, G1
Sahyoun, H1
Phelan, PD1
Stocks, JG1
Kersten, W1
Koivikko, A1
Leinonen, L1

Clinical Trials (204)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older Wit[NCT03769090]Phase 33,132 participants (Actual)Interventional2018-12-13Completed
Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes[NCT01323010]119 participants (Actual)Interventional2011-09-30Completed
Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient a Randomized Controlled Trial[NCT02774941]220 participants (Actual)Interventional2016-08-31Completed
Seinäjoki Adult Asthma Study: A 12-year Real-life Follow-up Study of New-onset Asthma Diagnosed at Adult Age and Treated in Primary and Specialized Care. Finnish Title: Diagnoosista Hoitotasapainoon: Voidaanko Aikuisen Astman Hoitotasapainoa Ennustaa Diag[NCT02733016]259 participants (Actual)Observational [Patient Registry]1999-10-31Completed
Magnesium Nebulization Utilization in Management of Pediatric Asthma[NCT01429415]Phase 2818 participants (Actual)Interventional2011-09-26Completed
An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control[NCT03380429]Phase 4437 participants (Actual)Interventional2018-01-31Completed
FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody Therapy[NCT04512521]40 participants (Anticipated)Observational2020-05-04Recruiting
200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component[NCT02164539]Phase 2338 participants (Actual)Interventional2014-07-01Completed
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130]60 participants (Anticipated)Observational [Patient Registry]2017-01-01Recruiting
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT01225913]Phase 450 participants (Anticipated)Interventional2007-10-31Recruiting
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT00576069]60 participants (Anticipated)Observational2007-10-25Recruiting
The Efficacy of Intravenous Magnesium in Acute Wheezy Bronchitis in Small Children - a Randomized, Controlled Study[NCT01383655]61 participants (Actual)Interventional2011-03-31Completed
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations[NCT02066129]Phase 3254 participants (Actual)Interventional2014-07-31Completed
Effect of Forward-leaning Position on Vital Signs, Pain and Anxiety of Children With Acute Asthma Attacks: A Randomized Controlled Study[NCT05318885]86 participants (Actual)Interventional2019-10-15Completed
Asthma Express Intervention to Bridge Emergency to Primary Care for High Risk Children With Asthma[NCT01981564]222 participants (Actual)Interventional2013-04-15Completed
A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma[NCT02427165]Phase 229 participants (Actual)Interventional2015-04-30Completed
A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®)[NCT00901368]Phase 4431 participants (Actual)Interventional2009-05-31Completed
"A Two-arm, Placebo-controlled Randomized Clinical Trial to Evaluate the Effect of Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma With a T2 Immune Signature"[NCT03884842]Phase 324 participants (Actual)Interventional2019-07-01Completed
Single-centre Study Exploring the Utility of Hyperpolarized 129Xe Magnetic Resonance Imaging in Healthy Volunteers and Patients With Lung Disease[NCT03455686]60 participants (Anticipated)Interventional2018-04-19Recruiting
A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics[NCT00831376]Phase 430 participants (Actual)Interventional2009-01-31Completed
A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adu[NCT01147848]Phase 3810 participants (Actual)Interventional2010-06-30Completed
A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00683449]Phase 229 participants (Actual)Interventional2008-06-30Terminated (stopped due to Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more appropriate dosing scheme for MN-221 in subjects with asthma.)
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone[NCT01248975]Phase 2145 participants (Actual)Interventional2010-12-31Completed
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeter[NCT01156792]Phase 2162 participants (Actual)Interventional2010-09-30Completed
Video-based Teach-to-goal Intervention on Inhaler Technique on Adults With Asthma and COPD: a Randomized Controlled Trial[NCT05664347]154 participants (Actual)Interventional2020-03-09Completed
A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry P[NCT01494610]Phase 1/Phase 260 participants (Actual)Interventional2010-10-25Completed
Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)[NCT00565266]Phase 3210 participants (Actual)Interventional2008-05-31Completed
Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)[NCT00231114]297 participants (Actual)Interventional2005-09-30Completed
Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma[NCT00401986]14 participants (Actual)Observational2007-01-31Completed
48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age[NCT00861926]Phase 32,079 participants (Actual)Interventional2009-03-31Completed
FeNO Result Prediction Factors in Children With Allergic Diseases[NCT00815984]800 participants (Actual)Observational2009-01-31Completed
Comparasion of Efficacy of Nebulized Magnesium Sulphate With Intravenous Magnesium Sulphate in Children With Acute Asthma[NCT04497766]Phase 4148 participants (Actual)Interventional2019-10-01Completed
A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5[NCT00652002]Phase 3450 participants (Anticipated)Interventional2002-07-31Completed
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease[NCT00889837]Phase 153 participants (Actual)Interventional2009-06-30Completed
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma[NCT00890175]Phase 152 participants (Actual)Interventional2009-05-31Completed
A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in [NCT01181895]Phase 3348 participants (Actual)Interventional2010-09-01Completed
Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador[NCT01795742]Phase 2110 participants (Actual)Interventional2012-08-31Completed
A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers[NCT02777125]980 participants (Actual)Interventional2014-10-31Completed
Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961]24 participants (Actual)Interventional2018-09-20Active, not recruiting
Asthma Mobile Health Application 2.0[NCT03248869]7,752 participants (Actual)Interventional2015-03-15Completed
MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00838591]Phase 2176 participants (Actual)Interventional2009-03-31Completed
Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma[NCT01210170]22 participants (Actual)Interventional2010-10-31Completed
Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial[NCT02584738]Phase 4152 participants (Anticipated)Interventional2015-09-30Recruiting
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)[NCT01584726]400 participants (Anticipated)Interventional2012-12-31Recruiting
Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus[NCT04929626]Phase 1126 participants (Actual)Interventional2022-01-01Completed
The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and Dyspnea is Associated to the Improvement in Small Airway Dysfunction in COPD Patients. A Pilot Study (IOSCOPD20161102)[NCT04421742]43 participants (Actual)Observational2017-05-31Completed
Measurement of Breathing Parameters of Asthma and COPD Patients With Different Degrees of Disease Severity for the Computer Simulation of Lung Deposition of Aerosol Drugs[NCT05445349]200 participants (Anticipated)Observational2022-09-01Recruiting
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma[NCT01424813]Phase 3158 participants (Actual)Interventional2012-12-31Completed
A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma[NCT01747629]Phase 3160 participants (Actual)Interventional2012-12-31Completed
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma[NCT01698320]Phase 3364 participants (Actual)Interventional2012-10-31Completed
Clinical Assessment of Acupuncture for the Treatment of Asthma: A Randomized, Multicenter, Double-blind, Parallel-group Controlled Trial[NCT01931696]200 participants (Actual)Interventional2013-07-31Completed
Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea[NCT01573364]450 participants (Actual)Observational2011-02-28Completed
Blacks and Exacerbations on LABA vs. Tiotropium (BELT)[NCT01290874]Phase 31,070 participants (Actual)Interventional2011-03-30Completed
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter[NCT01857323]Phase 3317 participants (Actual)Interventional2013-05-31Completed
A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Stud[NCT00818454]Phase 2226 participants (Actual)Interventional2008-12-31Completed
A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma[NCT01899144]Phase 261 participants (Actual)Interventional2013-07-31Completed
A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics[NCT02126839]Phase 3186 participants (Actual)Interventional2014-05-31Completed
Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915]107 participants (Actual)Observational2012-11-28Completed
Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease[NCT01280994]Phase 2445 participants (Anticipated)Interventional2011-01-31Recruiting
Individualized Therapy For Asthma in Toddlers[NCT01606306]Phase 3300 participants (Actual)Interventional2013-02-28Completed
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And Chronic Obstructive Pulmonary Disease (COPD) Patients[NCT02447575]23 participants (Actual)Interventional2015-02-28Completed
Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations in Children: A Randomized Controlled Trial[NCT02494076]Phase 452 participants (Actual)Interventional2014-10-31Completed
Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule[NCT00940927]Phase 481 participants (Actual)Interventional1993-07-31Completed
Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia[NCT02447250]Phase 414 participants (Actual)Interventional2013-10-24Completed
Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator[NCT02678949]105 participants (Anticipated)Interventional2016-03-31Not yet recruiting
Randomised, Double-blind, Double-dummy, Parallel-group, Comparative Study of Salmeterol/FP 50/100mcg bd Inhalation Powder Via Diskus With Oral Montelukast (5mg QD) Chewable Tablets in Children 6-14 Years[NCT00328718]Phase 3526 participants Interventional2005-10-31Completed
Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)[NCT00471809]Phase 4210 participants Interventional2006-03-31Terminated (stopped due to The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a futility analysis with 55 randomized children.)
A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma[NCT00476268]Phase 3824 participants (Actual)Interventional2004-02-29Completed
SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea[NCT00480649]Phase 4424 participants (Actual)Interventional2004-01-31Completed
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma[NCT00736801]35 participants (Actual)Interventional2005-09-30Completed
Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children[NCT02409277]926 participants (Actual)Interventional2013-08-31Completed
Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve[NCT04267965]48 participants (Actual)Observational [Patient Registry]2017-08-01Completed
Implementing a Guidelines-Based M-Health Intervention for High Risk Asthma Patients[NCT03842033]370 participants (Actual)Interventional2019-03-04Active, not recruiting
Individualized Interventions to Improve Asthma Adherence[NCT00115323]397 participants (Actual)Interventional2005-05-31Completed
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics[NCT00575861]Phase 419 participants (Actual)Interventional2005-09-30Completed
Methods to Identify and Treat Severe Asthma Patients Project 1: GSNOR Phenotyping and GSNO Challenge[NCT03926741]Early Phase 160 participants (Anticipated)Interventional2019-04-30Recruiting
Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Bec[NCT00497523]Phase 3283 participants (Actual)Interventional2006-03-31Completed
Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma[NCT02758873]241 participants (Actual)Interventional2016-02-29Completed
Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma[NCT00315744]Phase 4285 participants (Actual)Interventional2004-11-04Completed
Randomized, Double-Blind Comparison of Advair 100/50 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARG/ARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone[NCT00102882]Phase 4547 participants (Actual)Interventional2004-10-31Completed
A Prospective Open Randomized Clinical Trial Comparing Bilevel Positive Airway Pressure (BiPAP) Therapy Against Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma Unresponsive to Inhaled Bronchodilators.[NCT02347462]0 participants (Actual)Interventional2015-04-30Withdrawn (stopped due to we were not able to work through the logistics of the study to support enrolment in ER)
A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma.[NCT03296579]100 participants (Anticipated)Interventional2018-06-30Not yet recruiting
Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)[NCT00200967]Phase 387 participants (Actual)Interventional2004-12-31Completed
Tel-Me-Box: Validating and Testing a Novel, Low-cost, Real-time Monitoring Device With Hair Level Analysis Among Adherence-challenged Patients[NCT03086655]131 participants (Actual)Interventional2021-08-13Completed
A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age [NCT00646594]Phase 31,200 participants (Anticipated)Interventional2003-11-30Completed
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study[NCT04129931]Phase 2600 participants (Anticipated)Interventional2019-12-19Recruiting
Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)[NCT00395304]Phase 3182 participants (Actual)Interventional2007-03-31Completed
A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only[NCT00351143]Phase 4274 participants (Actual)Interventional2005-07-26Completed
A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementar[NCT00272753]Phase 420 participants Interventional2004-04-30Completed
A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years[NCT00127166]Phase 3154 participants (Actual)Interventional2005-12-31Completed
A Multicentre, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Product (Seretide®) 50/100 mcg With Fluticasone Propionate (Flixotide® ) 200 mcg, Both Delivered Twice Daily [NCT00197106]Phase 4176 participants (Actual)Interventional2005-06-30Completed
Does the Use of a New Written Action Plan Increase Short-term Adherence to Prescribed Medication and Asthma Control in Children Treated for an Asthma Attack in the Emergency Department: A Randomized Controlled Trial.[NCT00381355]Phase 4218 participants (Actual)Interventional2006-10-31Completed
An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma[NCT00073840]Phase 3386 participants (Actual)Interventional2002-12-31Completed
[NCT00046644]0 participants Observational2002-06-30Completed
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial[NCT00156819]Phase 4500 participants (Actual)Interventional2003-06-30Completed
Autonomic Nervous System Role in Uncontrolled ASTHMA and the Paucigranulocitic Phenotype[NCT02836691]40 participants (Actual)Interventional2016-05-31Completed
An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asth[NCT03084718]Phase 2610 participants (Actual)Interventional2017-07-28Completed
Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control[NCT00163358]Phase 3630 participants Interventional2003-09-30Completed
Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients[NCT03611699]Phase 415 participants (Actual)Interventional2019-01-24Completed
Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma[NCT02566902]118 participants (Actual)Interventional2015-10-31Completed
Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)[NCT00394329]Phase 3288 participants (Actual)Interventional2006-11-30Completed
School-Based Asthma Therapy: Stage 2 Effectiveness Study[NCT01175369]530 participants (Actual)Interventional2006-08-31Completed
A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma[NCT00583947]Phase 253 participants (Actual)Interventional2008-01-31Completed
[NCT00476073]Phase 3228 participants (Actual)Interventional2007-04-30Completed
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients[NCT02415179]52 participants (Actual)Interventional2015-05-31Completed
A Randomized, Double-Blind, Cross-Over Study to Demonstrate Superiority of Fluticasone/Salmeterol Over Double the Dose of Fluticasone on Methacholine Hyper-Reactivity in Patients With Persistent, Mild to Moderate Asthma[NCT00830505]Phase 438 participants (Actual)Interventional2009-04-30Completed
A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol F[NCT00350207]Phase 2388 participants (Actual)Interventional2006-07-31Completed
Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway[NCT01231230]14 participants (Actual)Interventional2007-05-31Completed
Reversal of Acute β-Blocker Induced Bronchoconstriction[NCT01070225]Phase 414 participants (Actual)Interventional2010-03-31Completed
Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)[NCT02148796]Phase 2822 participants (Actual)Interventional2017-01-03Active, not recruiting
Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?[NCT02318043]84 participants (Actual)Interventional2007-01-31Completed
DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®)[NCT00394368]Phase 3180 participants Interventional2004-11-30Completed
Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial[NCT00900874]Phase 478 participants (Anticipated)Interventional2009-01-31Recruiting
Assessing the Use of Digital Therapeutic in Adult Asthma Patients: A Remote Observational Study[NCT03103880]104 participants (Actual)Interventional2017-04-21Completed
Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 mcg + Formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500[NCT00497237]Phase 3382 participants (Anticipated)Interventional2007-04-30Completed
Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma[NCT04651777]Phase 330 participants (Anticipated)Interventional2022-08-08Recruiting
A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype[NCT00655616]64 participants (Actual)Interventional2007-08-31Completed
Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset[NCT01338311]Phase 415 participants (Actual)Interventional2011-03-31Completed
Childhood Asthma Management Program[NCT00000575]Phase 31,041 participants (Actual)Interventional1991-09-30Completed
A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma[NCT00643578]37 participants (Actual)Interventional2008-03-31Completed
Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation[NCT01012050]39 participants (Actual)Interventional2007-06-30Completed
The Effect of Bi-PAP at Individualized Pressures on the Postoperative Pulmonary Recovery of Morbidly Obese Patients (MOP) Undergoing Open Bariatric Surgery (OBS) and Possible Placebo Device-related Effects (Sham-Bi-PAP)[NCT03438383]48 participants (Actual)Interventional2011-05-23Completed
Quantifying Delivery Of Radio Labeled Aerosol During Noninvasive Ventilation To Stable Moderate And Severe Asthmatics: A Randomized, Cross-Over Clinical Trial[NCT01823926]13 participants (Actual)Interventional2011-10-31Completed
IN VIVO ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION IN STABLE COPD: A RANDOMIZED CROSSOVER CLINICAL TRIAL[NCT02247856]9 participants (Actual)Interventional2013-01-31Completed
Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma?[NCT01239199]86 participants (Actual)Interventional2010-01-31Completed
Adherence Feedback for Improving Respiratory Medication Use[NCT00459368]2,698 participants (Actual)Interventional2007-05-31Completed
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015]Phase 4102 participants (Actual)Interventional2005-07-31Terminated (stopped due to Difficulty in recruitment)
A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations[NCT00116402]Phase 115 participants (Actual)Interventional2005-01-31Completed
Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital[NCT06141161]200 participants (Anticipated)Observational2023-11-01Recruiting
Asthma Clinical Research Network (ACRN)[NCT00000577]Phase 30 participants (Actual)Interventional1993-09-30Withdrawn (stopped due to Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.)
The Pharmacokinetics of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols[NCT00692978]Phase 430 participants (Actual)Interventional2008-08-31Completed
The Clinical Effect in Asthma of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols[NCT01662778]Phase 421 participants (Actual)Interventional2011-12-31Completed
[NCT00575445]100 participants (Anticipated)Observational2007-11-30Terminated (stopped due to Nitric Oxide analyzer not functioning properly)
A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects[NCT03086460]Phase 267 participants (Actual)Interventional2017-09-08Completed
A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)[NCT01457261]Phase 110 participants (Actual)Interventional2012-04-30Completed
Effect of Anti-IL5 and Anti-IgE on Alternative Functions of Eosinophils in Severe Asthma[NCT04520165]50 participants (Anticipated)Observational2020-09-01Recruiting
A Comparative, Multicenter and Randomized Study Evaluating the Safety and Efficacy of RESPIMER® Netiflow® Versus Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy in the Treatment of Nasal Polyposis.[NCT02559284]189 participants (Actual)Interventional2015-04-30Completed
A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population[NCT01141465]815,377 participants (Actual)Observational2001-01-31Completed
Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study[NCT01620099]Phase 460 participants (Anticipated)Interventional2011-11-30Completed
A 12 Week, Randomized, Double-blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compar[NCT05292586]Phase 3580 participants (Anticipated)Interventional2022-10-05Recruiting
A Prospective Observational Study in a Tertiary Pediatric Hospital in Beijing to Understand the Accuracy of Bronchodilator Response (BDR) in Chinese Controller Naive Asthmatic Children Between the Age of 4~12 Years Old[NCT01500525]587 participants (Actual)Observational2011-12-31Completed
Nebulizer Intervention for Minority Children With Asthma[NCT00218816]Phase 3221 participants (Actual)Interventional2000-08-31Completed
The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils[NCT02140541]130,248 participants (Actual)Observational2013-02-28Active, not recruiting
Evaluation of the Usefulness of Induced Sputum Eosinophilia, eNO and Bronchial Hyperresponsiveness in Predicting the Failure of Inhaled Corticosteroids Dose Reduction in Children and Adolescents With Stable Asthma[NCT03788057]50 participants (Anticipated)Interventional2016-02-01Recruiting
The Various Effects of Gaseous Albuterol on Serum Lactate[NCT02073747]28 participants (Actual)Interventional2015-04-30Completed
Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/[NCT00479739]Phase 4700 participants (Actual)Interventional2002-11-30Completed
Effectiveness of a Mobile Health Intervention in Improving the Technique of Inhaled Medications Among Children With Asthma: A Pilot Study[NCT03615248]Early Phase 130 participants (Actual)Interventional2021-01-01Completed
Novel Nano-vesicles of Salbutamol Sulphate in Metered Dose Inhalers: Formulation, Characterization, In Vitro and In Vivo Evaluation[NCT03059017]Phase 120 participants (Actual)Interventional2017-02-05Completed
A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus[NCT00410150]Phase 242 participants (Actual)Interventional2006-04-30Terminated (stopped due to Study was stopped after interim analysis and slow enrollment.)
Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD)[NCT01721291]Phase 465 participants (Actual)Interventional2012-10-01Completed
Evaluation of Exercise Induced Bronchoconstriction by Field Test Using Lung Function and a Novel Automated Digital Clinical Decision System[NCT04275648]60 participants (Anticipated)Interventional2020-12-01Recruiting
Fluctuation of Airway Function in Children With Asthma Phenotype as a Predictor of Outcome[NCT02252289]120 participants (Actual)Observational2014-09-30Completed
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma[NCT00595361]30 participants (Actual)Interventional2008-01-31Completed
Functional Evaluation of Distal Airways by Forced Oscillations: Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation[NCT02902471]110 participants (Actual)Interventional2011-06-30Completed
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)[NCT03137303]Phase 3402 participants (Actual)Interventional2017-07-01Completed
Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma Managed in the Emergency Department: A Randomized Controlled Trial[NCT04016220]Phase 160 participants (Anticipated)Interventional2019-05-20Recruiting
Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Carbamazepine Efficacy in Moderate Persistent and Severe Asthma Therapy[NCT00153296]Phase 468 participants Interventional2004-08-31Completed
Identification of Biomarkers in Exhaled Breath Condensates From Asthmatic Patients[NCT00635271]19 participants (Actual)Observational2008-02-29Terminated
Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy: A Pilot Study[NCT02982824]60 participants (Actual)Interventional2016-09-30Completed
Daily Supplementation of Magnesium Citrate in Moderate-severe Chronic Obstructive Pulmonary Disease: a Randomized, Controlled, Double-blind Trial[NCT02680769]76 participants (Anticipated)Interventional2016-03-31Recruiting
Metacholine-provocation of Mablet-treated Asthmatics[NCT01118923]12 participants (Actual)Interventional2010-10-31Completed
Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics[NCT01113151]5 participants (Actual)Interventional2011-04-30Completed
Daily Mablet-treatment of Patients With COPD[NCT01118936]11 participants (Actual)Interventional2010-10-31Completed
Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion[NCT01113138]10 participants (Actual)Interventional2012-12-31Completed
Feasibility and Safety of Immunoglobulin (Ig) Prophylactic Treatment in COPD Patients With Frequent Exacerbations: A Pilot Study[NCT02690038]Phase 248 participants (Actual)Interventional2016-09-30Completed
Efficacy of an Education Protocol in the Correction of Inhalation Techniques in Patients With Chronic Obstructive Pulmonary Disease[NCT03144557]61 participants (Actual)Interventional2017-01-02Completed
Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.[NCT00382889]Phase 3480 participants Interventional2002-08-31Completed
Adjustment of Asthma Treatment in Children Based on an Indirect Hyperresponsiveness Test - a Randomized Trial[NCT04509921]108 participants (Actual)Interventional2018-07-02Completed
A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.[NCT01144910]0 participants (Actual)Observational2011-05-31Withdrawn (stopped due to Due to few capacities 2011 to 2016 the study was withdrawn.)
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered[NCT00268216]Phase 36,228 participants (Actual)Interventional2000-09-30Completed
Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily[NCT00370591]Phase 448 participants (Actual)Interventional2002-12-31Completed
Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-[NCT00242775]Phase 32,100 participants Interventional2005-05-31Completed
A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DI[NCT00920543]Phase 4464 participants (Actual)Interventional2003-02-28Completed
A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids[NCT00096616]Phase 2113 participants (Actual)Interventional2004-11-30Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 10[NCT00102765]Phase 4479 participants (Actual)Interventional2004-11-30Completed
Effects of Bronchodilation on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent: Comparisons Between CT Scans Obtained Before and After Bronchodilation and Relationships With Pulmonary Function Tests.[NCT01142531]20 participants (Actual)Observational2010-03-31Completed
Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care Unit[NCT03900624]Phase 492 participants (Actual)Interventional2019-04-21Completed
Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies[NCT04006964]579 participants (Actual)Observational2018-10-18Completed
Effectiveness and Costs of Albuterol Delivered by MDI With Spacer Versus Nebulizer in Children Hospitalized With Moderate and Severe Asthma Exacerbations[NCT00623688]11 participants (Actual)Interventional2008-02-29Completed
"Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?"[NCT00798616]0 participants (Actual)InterventionalWithdrawn (stopped due to We were unable to enroll a sufficient number of patients due to manpower.)
A Multi-centre Randomised Trial of Lay-led Individualised Self-management Education for Adults With Asthma[NCT00129987]567 participants (Actual)Interventional2003-11-30Completed
Single Dose Dexamethasone is as Effective as Two Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department[NCT02192827]Phase 3318 participants (Actual)Interventional2015-04-30Completed
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513458]Phase 1/Phase 20 participants (Actual)Interventional2020-09-30Withdrawn (stopped due to [The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.)
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513471]Phase 1/Phase 20 participants (Actual)Interventional2019-08-09Withdrawn (stopped due to The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.)
Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study[NCT02780479]Phase 46 participants (Actual)Interventional2017-03-20Terminated (stopped due to insufficient number of participants met the enrollment criteria.)
[NCT00005475]0 participants Observational1996-08-31Completed
Budesonide Inhalation Suspension for Acute Asthma in Children[NCT00393367]Phase 4179 participants (Actual)Interventional2006-12-31Completed
Initiating Inhaled Corticosteroid Therapy at Discharge From the Pediatric Emergency Department to Prevent Asthma Relapse: A Randomized Control Trial[NCT03369847]Phase 443 participants (Actual)Interventional2017-09-10Completed
Epinephrine Inhalation Aerosol USP, an HFA-MDI CLINICAL STUDY-B2 FOR ASSESSMENT OF PHARMACOKINETICS (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)[NCT01188577]Phase 1/Phase 223 participants (Actual)Interventional2010-08-31Completed
CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers[NCT01255709]Phase 224 participants (Actual)Interventional2010-12-31Completed
Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs[NCT01147835]39 participants (Actual)Interventional2009-09-23Terminated (stopped due to Study was stopped and not completed)
A Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Crossover Dose-ranging Study of A006 in Adult Asthma Patients[NCT01581177]Phase 223 participants (Actual)Interventional2012-04-30Completed
Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)[NCT02210806]Phase 222 participants (Actual)Interventional2014-07-31Completed
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults)[NCT02271334]Phase 222 participants (Actual)Interventional2014-08-31Completed
A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus[NCT02872597]Phase 130 participants (Actual)Interventional2016-09-05Completed
Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide[NCT01219738]20 participants (Actual)Interventional2008-07-31Completed
Double-blind, Crossover, Placebo-controlled Evaluation of the Effect of Levalbuterol (R-albuterol) on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma[NCT00320034]Phase 215 participants (Anticipated)Interventional2006-04-30Completed
Prophylactic Racemic Epinephrine for the Prevention of Dysphagia in Patients Undergoing Anterior Cervical Discectomy and Fusion: A Randomized Control Trial[NCT02724761]90 participants (Anticipated)Interventional2016-09-30Not yet recruiting
[NCT00005537]0 participants Observational1997-07-31Completed
Assessment of the Severity of Acute Asthma Exacerbation in Children Attending the Emergency Departments to Predict Outcomes by Modified Pulmonary Index Score[NCT03190759]1 participants (Anticipated)Observational2017-11-11Not yet recruiting
Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism[NCT00116324]Phase 3150 participants Interventional2003-04-30Completed
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients - a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population[NCT01877954]2,654 participants (Actual)Observational2011-02-28Completed
Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge[NCT00595491]Phase 1313 participants (Anticipated)Interventional2008-01-31Recruiting
A Randomized, Double Blind, Placebo-controlled Three-way Crossover Study in Mild Asthmatics to Evaluate the Effect of Smoking Status on the Attenuation by Inhaled Corticosteroids of the Allergen-induced Asthmatic Response.[NCT01400906]Phase 236 participants (Actual)Interventional2011-07-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Annualized Severe Exacerbation Rate

The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable. (NCT03769090)
Timeframe: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

InterventionSevere exacerbations per year (Least Squares Mean)
BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)0.45
AS MDI 180 μg (Full Analysis Set; >=12 Years)0.59
BDA MDI 80/180 μg (Full Analysis Set)0.49
AS MDI 180 μg (Full Analysis Set)0.61

Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24

The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5. (NCT03769090)
Timeframe: From baseline to Week 24

InterventionParticipants (Count of Participants)
BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)677
AS MDI 180 μg (Full Analysis Set; >=12 Years)630
BDA MDI 80/180 μg (Full Analysis Set)681
AS MDI 180 μg (Full Analysis Set)650

Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24

The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5. (NCT03769090)
Timeframe: From baseline to 24 weeks

InterventionParticipants (Count of Participants)
BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)508
BDA MDI 80/180 μg (Full Analysis Set; >=12 Years)489
AS MDI 180 μg (Full Analysis Set; >=12 Years)461

Number of Participants With a Severe Asthma Exacerbation Event

Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy. (NCT03769090)
Timeframe: From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

InterventionParticipants (Count of Participants)
BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)207
AS MDI 180 μg (Full Analysis Set; >=12 Years)266
BDA MDI 80/180 μg (Full Analysis Set)241
AS MDI 180 μg (Full Analysis Set)276

Total Annualized Dose of Systemic Corticosteroid (SCS)

This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period. (NCT03769090)
Timeframe: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

InterventionMilligram(s) (Mean)
BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)86.2
AS MDI 180 μg (Full Analysis Set; >=12 Years)129.3
BDA MDI 80/180 μg (Full Analysis Set)95.5
AS MDI 180 μg (Full Analysis Set)127.1

Admission Rates in Patients With and Without Any Virus Detected

Admission rates in patients with and without any of the following viruses detected by PCR in nasal lavage samples: Adenovirus; Bocavirus; Coronavirus; Enterovirus (Echovirus); Influenza (A H3N2, A H1N1/2009, B and C); Metapneumovirus (subtypes A and B); Parainfluenza 1, 2, 3 and 4 (subtypes A and B); Rhinovirus; Respiratory Syncytial Virus type A and Respiratory Syncytial Virus type B. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionpercentage of participants (Number)
Virus Detected12.3
No Virus Detected22.7

Admission Rates in Patients With and Without Rhinovirus Detect

Admission rates in patients with and without rhinovirus detected by PCR in nasal lavage samples. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionpercentage of participants (Number)
Rhinovirus Detected10.2
No Rhinovirus Detected20.6

Admission Rates in Patients With the Arg16Gly Polymorphisms

Admission rates in patients with the Arg16Gly polymorphisms of the beta-2 adrenergic receptor (Arg16Gly, Arg16Arg and Gly16Gly genotypes). (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionparticipants (Number)
Arg16Gly Patients1
Gly16Gly Patients1
Arg16Arg Patients7

Albuterol Determination in the Plasma

Albuterol determination in the plasma was carried out at at discharge or hospital admission (up to 4 hours post treatment), dosage was accomplished by High Performance Liquid Chromatography. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionng/ml (Median)
Albuterol - Higher Dose (Experimental)2.57
Albuterol - Lower Dose (Control)1.08

Change in PRAM Score After One Hour

"Change in the Pediatric Respiratory Assessment Measure (PRAM) score one hour post-treatment in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured one hour post treatment and the PRAM score at baseline (PRAM score 1 hour - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -8 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -8 maximum value of the difference (Albuterol - Lower Dose, control group): 0" (NCT01323010)
Timeframe: One hour post-treatment

Interventionunits on a scale (Mean)
Albuterol - Higher Dose (Experimental)-3
Albuterol - Lower Dose (Control)-4

Change in Pulse Oximetry One Hour Post-treatment

Change in pulse oximetry one hour post-treatment in comparison with baseline (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline

Interventionpercentage of oxygen saturation (Mean)
Albuterol - Higher Dose (Experimental)1.54
Albuterol - Lower Dose (Control)1.39

Changes in Bicarbonate Serum Levels

Changes in bicarbonate serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

Interventionmmol/L (Mean)
Albuterol - Higher Dose (Experimental)-1.75
Albuterol - Lower Dose (Control)-1.44

Changes in Glucose Serum Levels

Changes in glucose serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

Interventionmg/dL (Mean)
Albuterol - Higher Dose (Experimental)34.73
Albuterol - Lower Dose (Control)22.90

Changes in Heart Rate After One Hour

Change in heart rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline

Interventionbeats per minute (Mean)
Albuterol - Higher Dose (Experimental)1.75
Albuterol - Lower Dose (Control)-1.47

Changes in Heart Rate at Discharge or Hospital Admission

Changes in heart rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionbeats per minute (Mean)
Albuterol - Higher Dose (Experimental)-0.263
Albuterol - Lower Dose (Control)-0.65

Changes in Potassium Serum Levels

Changes in potassium serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

InterventionmEq/L (Mean)
Albuterol - Higher Dose (Experimental)-0.38
Albuterol - Lower Dose (Control)-0.59

Changes in PRAM Score at Discharge or Hospital Admission

"Change in the Pediatric Respiratory Assessment Measure (PRAM) score at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured at discharge or admission and the PRAM score at baseline (PRAM score discharge or admission - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -9 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -9 maximum value of the difference (Albuterol - Lower Dose, control group): 1" (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

Interventionunits on a scale (Median)
Albuterol - Higher Dose (Experimental)-4.5
Albuterol - Lower Dose (Control)-5

Changes in Pulse Oximetry at Discharge or Hospital Admission.

Changes in pulse oximetry at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

Interventionpercentage of oxygen saturation (Mean)
Albuterol - Higher Dose (Experimental)2.14
Albuterol - Lower Dose (Control)1.59

Changes in Respiratory Rate After One Hour

Change in respiratory rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline

Interventionbreaths per minute (Mean)
Albuterol - Higher Dose (Experimental)-2.08
Albuterol - Lower Dose (Control)-4.31

Changes in Respiratory Rate at at Discharge or Hospital Admission.

Changes in respiratory rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.

Interventionbreaths per minute (Mean)
Albuterol - Higher Dose (Experimental)-2.92
Albuterol - Lower Dose (Control)-5.76

Electrocardiogram at Baseline

Electrocardiogram performed at baseline (NCT01323010)
Timeframe: at baseline

Interventionparticipants with ECG abnormalities (Number)
Albuterol - Higher Dose (Experimental)0
Albuterol - Lower Dose (Control)0

Electrocardiogram at Discharge or Hospital Admission

Electrocardiogram at discharge or hospital admission to identify possible rhythm disturbances. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionparticipants with ECG abnormalities (Number)
Experimental Group0
Control Group0

Electrocardiogram One Hour Post-treatment.

Electrocardiogram one hour post-treatment to identify possible rhythm disturbances. (NCT01323010)
Timeframe: One hour post-treatment

Interventionparticipants with ECG abnormalities (Number)
Albuterol - Higher Dose (Experimental)0
Albuterol - Lower Dose (Control)0

Forced Expiratory Volume in the First Second

Change in FEV1 one hour post-treatment in comparison with baseline. Spirometry was performed only in subjects older than 6 years and who could perform the maneuver properly. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline

Interventionpercentage of predicted (Mean)
Albuterol - Higher Dose (Experimental)14.67
Albuterol - Lower Dose (Control)11.3

Hospital Admission

Hospital admission was defined as the need to stay in the emergency room for more than 4 hours, due to the failure to meet the discharge criteria (PRAM score ≤ 3 and pulse oximetry, ≥ 92%) (NCT01323010)
Timeframe: Starting at 4 hours post-treatment

Interventionparticipants (Number)
Albuterol - Higher Dose (Experimental)11
Albuterol - Lower Dose (Control)8

Lengths of Stay in the Emergency Room

lengths of stay in the emergency room for discharged patients (NCT01323010)
Timeframe: one to four hours

Interventionhours (Median)
Albuterol - Higher Dose (Experimental)1.50
Albuterol - Lower Dose (Control)1.40

Need for Additional Therapies

The need for additional therapies such as magnesium sulphate or intravenous albuterol were recorded (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)

Interventionparticipants (Number)
Albuterol - Higher Dose (Experimental)0
Albuterol - Lower Dose (Control)0

Number of Subjects Hospitalized

The primary outcome measure is rate of hospitalization between the two treatment groups overall (NCT02774941)
Timeframe: Within emergency department visit time frame (no more than 12 hours)

InterventionParticipants (Count of Participants)
Control - Jet Nebulizer22
Study - Vibrating Mesh Nebulizer15

Number of Treatments Required to Achieve Mild Asthma Score - Discharge Criteria

(NCT02774941)
Timeframe: Within emergency department visit time frame (no more than 12 hours)

Interventionnumber of treatments (Median)
Control - Jet Nebulizer3.0
Study - Vibrating Mesh Nebulizer2

"Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 4 and Month 6 as Determined by the Maintenance Sensor for Arms; (Cohort 1: Data on Maintenance Use Supplied to Participant and HCP andCohort 5: no Data Supplied to Participant or HCP)"

Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 anti-meridiem (a.m.) each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Analysis was carried out by Analysis of Covariance (ANCOVA) model. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 4 and 6 was determined by the maintenance sensor daily adherence over the last three months of the study period (between months 4 to 6). The daily adherence to ELLIPTA maintenance therapy when both the participant and the HCP were supplied with data from the maintenance sensor (Cohort 1) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6

InterventionPercentage of ELLIPTA doses (Least Squares Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP80.9
Cohort 5: No Data Supplied to Par or HCP69.0

Change From Baseline in Asthma Control Test (ACT) Total Score

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Change from Baseline was calculated as post-dose visit value minus the Baseline value. (NCT03380429)
Timeframe: Baseline and Month 6

InterventionScores on a Scale (Least Squares Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP3.4
Cohort 2: Data on Maintenance Use Supplied to Par4.3
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP4.7
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par4.2
Cohort 5: No Data Supplied to Par or HCP3.9

Number of Doses of Rescue Medication Use Between Month 4 and Month 6 as Determined by the Rescue Medication Sensor

Data for rescue medication use was collected by the clip-on sensor for salbutamol MDI which records time and date when the MDI was actuated. Total rescue use was determined by the rescue sensor records of date, time and number of inhaler actuations. The mean number of doses of rescue medicines between Months 4 and 6 when maintenance data was supplied to both the participant and the HCP (Cohort 1); maintenance data was only supplied to participants (Cohort 2); rescue and maintenance data were supplied to participant and HCP (Cohort 3) and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6

InterventionDoses of rescue medication (Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP55.3
Cohort 2: Data on Maintenance Use Supplied to Par40.6
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP29.5
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par27.0
Cohort 5: No Data Supplied to Par or HCP55.8

Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 1 and Month 3 as Determined by the Maintenance Sensor

Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 1 and 3 was determined by the maintenance sensor daily adherence. The effect on daily adherence to maintenance therapy when maintenance data was supplied to both the participant and the HCP (Cohort 1), maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 1 to Month 3

InterventionPercentage of ELLIPTA doses (Least Squares Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP85.7
Cohort 2: Data on Maintenance Use Supplied to Par84.2
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP82.0
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par79.2
Cohort 5: No Data Supplied to Par or HCP76.4

Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 1 and Month 6 as Determined by the Maintenance Sensor

Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 1 and 6 was determined by the maintenance sensor daily adherence. The effect on daily adherence to maintenance therapy when maintenance data was supplied to both the participant and the HCP (Cohort 1), maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 1 to Month 6

InterventionPercentage of ELLIPTA doses (Least Squares Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP81.5
Cohort 2: Data on Maintenance Use Supplied to Par78.8
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP77.7
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par75.2
Cohort 5: No Data Supplied to Par or HCP71.8

Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 4 and Month 6 as Determined by the Maintenance Sensor

Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 4 and 6 was determined by the maintenance sensor daily adherence over the last three months of the study period (between months 4 to 6). The effect on daily adherence to maintenance therapy when maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6

InterventionPercentage of ELLIPTA doses (Least Squares Mean)
Cohort 2: Data on Maintenance Use Supplied to Par77.2
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP78.3
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par77.1
Cohort 5: No Data Supplied to Par or HCP69.0

Percentage of Participants Attaining Asthma Control (Percentage of Participants With an ACT Total Score >=20) at Month 6

Percentage of participants attaining asthma control was defined as participants with an ACT total score >=20 at Month 6. The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Percentage of participants who attained asthma control at Month 6 is presented. (NCT03380429)
Timeframe: Month 6

InterventionPercentage of participants (Number)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP52
Cohort 2: Data on Maintenance Use Supplied to Par66
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP55
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par53
Cohort 5: No Data Supplied to Par or HCP62

Percentage of Participants Who Have Either an ACT Total Score of >=20 and/or an Increase From Baseline >=3 in ACT Total Score at Month 6

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Percentage of participants who had either an ACT total score of >=20 and/or an increase from Baseline >=3 in ACT total score at Month 6 is presented. (NCT03380429)
Timeframe: Baseline and Month 6

InterventionPercentage of participants (Number)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP66
Cohort 2: Data on Maintenance Use Supplied to Par75
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP65
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par67
Cohort 5: No Data Supplied to Par or HCP70

Percentage of Participants With an Increase From Baseline >=3 in ACT Total Score at Month 6

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Percentage of participants with an increase from Baseline >=3 in ACT total score at Month 6 is presented. (NCT03380429)
Timeframe: Baseline and Month 6

InterventionPercentage of participants (Number)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP61
Cohort 2: Data on Maintenance Use Supplied to Par69
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP65
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par63
Cohort 5: No Data Supplied to Par or HCP64

Percentage of Rescue Free Days Between Month 4 and Month 6 as Determined by the Rescue Medication Sensor

Data for rescue medication use was collected by the clip-on sensor for salbutamol MDI which records time and date when the MDI was actuated. Percentage of rescue free days were determined by the rescue sensor records of date, time and number of inhaler actuations. Least Square mean percentage of rescue free days between Months 4 and 6 when maintenance data was supplied to both the participant and the HCP (Cohort 1); maintenance data was only supplied to participants (Cohort 2); rescue and maintenance data were supplied to participant and HCP (Cohort 3) and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6

InterventionPercentage of rescue free days (Least Squares Mean)
Cohort 1: Data on Maintenance Use Supplied to Par and HCP81.1
Cohort 2: Data on Maintenance Use Supplied to Par81.2
Cohort 3: Data on Maintenance and Rescue Use to Par and HCP85.6
Cohort 4: Data on Maintenance and Rescue Use Supplied to Par83.7
Cohort 5: No Data Supplied to Par or HCP76.4

Change From Baseline in Clinic Trough Forced Expiratory Volume in One Second (FEV1) at the End of Treatment Phase A (Visit 6/Day 29)

FEV1 is defined as forced expiratory volume in one second and measured in the morning at Visits 1 through 8 between 6:00 and 11:00 electronically by spirometry. Change from Baseline in trough FEV1 is defined as the difference in the value obtained at Visit 6 (24 hours post-dose on Visit 5) and the last acceptable/borderline acceptable value obtained prior to randomization (from Visit 2 pre-bronchodilator or Visit 3 pre-dose). Trough FEV1 is defined as the acceptable/borderline acceptable FEV1 value obtained at Visit 6, approximately 24 hours after morning dosing on Visit 5. ITT population is comprised of all participants randomized to treatment who received at least one dose of randomized study medication in the treatment period. All comparisons for statistical purposes are with the FF 100 µg arm. (NCT02164539)
Timeframe: Baseline and Day 29

InterventionLiters (Mean)
FF 100 µg0.047
FF/UMEC 100/15.6 µg0.146
FF/UMEC 100/62.5 µg0.193
FF/UMEC 100/125 µg0.175
FF/UMEC 100/250 µg0.143
FF/VI 100/25 µg0.121

Change From Baseline in Daily Morning (AM) PEF (Pre-dose and Pre-rescue Bronchodilator) Measured at Home and Averaged Over the Last 21 Days of Treatment Phase A

Peak expiratory flow (PEF) stability limit was calculated from AM PEF measurements on the 7 days preceding Visit 3 as mean AM PEF from the available 7 days preceding Visit 3 x 80%. PEF stability limit serves as a benchmark of the participants run-in COPD status and used for comparison during the treatment phase to assess subject safety. Change from Baseline over the last 21 days of Treatment Phase A is the difference between the last 21 days of Treatment Phase A and the appropriate Baseline week. The last 21 days of Treatment Phase A include the AM assessments on the date of Visit 6. AM assessments include the date of Visit 6 and the 20 consecutive days preceding the date of Visit. Analysis performed using analysis of covariance with covariates of treatment, age, sex, Baseline AM PEF, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization (NCT02164539)
Timeframe: Baseline and from Day 8 through Day 29

InterventionLiters per minute (L/min) (Least Squares Mean)
FF 100 µg-14.2
FF/UMEC 100/15.6 µg3.9
FF/UMEC 100/62.5 µg7.6
FF/UMEC 100/125 µg5.5
FF/UMEC 100/250 µg10.5
FF/VI 100/25 µg4.3

Change From Trough in Clinic Forced Expiratory Volume (FEV1) at 3 Hours Post-study Treatment at Visit 5/Day 28

FEV1 was measured in the morning by spirometry. At Visit 5, after trough FEV1 is measured, subject received investigational product. 3 hours post-dose, spirometry was repeated and subject then received 2 puffs of albuterol/salbutamol. After 30 minutes,spirometry was repeated.. Change from Baseline in clinic trough (pre-dose) FEV1 is the difference in the trough value at 3 hours post-dose peak FEV1 and the Baseline value. If the trough value or the Baseline was missing, then change from Baseline was considered as missing. Baseline value of clinic FEV1 is the last acceptable/borderline acceptable (pre-dose) FEV1 value obtained prior to randomization (from Visit 3 pre-dose or from Visit 2 pre-bronchodilator). Analysis done using analysis of covariance with covariates of treatment, age, sex, baseline clinic trough FEV1, pre-dose trough FEV1 at Visit 5, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. (NCT02164539)
Timeframe: Baseline and Day 28

InterventionLiters (L) (Least Squares Mean)
FF 100 µg0.048
FF/UMEC 100/15.6 µg0.093
FF/UMEC 100/62.5 µg0.088
FF/UMEC 100/125 µg0.072
FF/UMEC 100/250 µg0.052
FF/VI 100/25 µg0.124

Change in Clinic FEV1 Following 2 Puffs of Albuterol/Salbutamol Given 3 Hours Post-study Treatment Dose at Visit 5/Day 28

FEV1 is defined as forced expiratory volume in one second and measured in the morning at Visits 1 through 8 between 6:00 and 11:00 electronically by spirometry. Reversibility was measured at Visit 1 and Visit 2 for study eligibility by change in clinic FEV1 within 20 to 60 minutes following 4 inhalations of albuterol/salbutamol and again measured 3 hours after dosing at Visit 5 by change in clinic FEV1 30 minutes following 2 inhalations of albuterol/salbutamol. Baseline value of clinic FEV1 is the last acceptable/borderline acceptable (pre-dose) FEV1 value obtained prior to randomization (either from Visit 3 pre-dose or from Visit 2 pre-bronchodilator). Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline clinic trough FEV1, pre-albuterol/salbutamol FEV1 at Visit 5, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. (NCT02164539)
Timeframe: Baseline and Day 28

InterventionLiters (L) (Least Squares Mean)
FF 100 µg0.249
FF/UMEC 100/15.6 µg0.161
FF/UMEC 100/62.5 µg0.159
FF/UMEC 100/125 µg0.160
FF/UMEC 100/250 µg0.189
FF/VI 100/25 µg0.087

Mean Change From Baseline in E-RS Total Scores at the End of Treatment Phase A

A daily symptoms score for exacerbations of chronic pulmonary disease tool - Respiratory Symptoms (E-RS) is derived by summing the 11 item-level E-RS scores and has a theoretical range of 0-40, with higher values indicating more severe respiratory symptoms. The Baseline E-RS score is defined as the mean within-subject daily score over the 7 days prior to randomization, with data present for a minimum of 4 of the 7 days. Change from Baseline at the end of Treatment Phase is the difference between the end of Treatment Phase value and the appropriate Baseline week. Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline score, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization. All comparisons for statistical purposes are with the FF 100 µg arm. (NCT02164539)
Timeframe: Baseline and End of Treatment Phase A (The end of Treatment Phase A was defined as the last 7 days of Treatment Phase A, including the AM assessments on the date of Visit 6)

InterventionScore on scale (Least Squares Mean)
FF 100 µg0.5
FF/UMEC 100/15.6 µg-2.6
FF/UMEC 100/62.5 µg-2.5
FF/UMEC 100/125 µg-1.5
FF/UMEC 100/250 µg-1.5
FF/VI 100/25 µg-1.1

Mean Change From Baseline in Rescue Medication Use at the End of Treatment Phase A

All participants received the albuterol/salbutamol via MDI as a rescue medication on an as-needed basis. Total daily rescue medication use for a given day is the sum of daytime albuterol/salbutamol use recorded in PM and nighttime albuterol/salbutamol use recorded in AM the next day. The number of puffs of albuterol (salbutamol) MDI used in the last 12 hours for relief of symptoms were recorded morning and evening in the eDiary by the participants. End of Treatment Phase A is the last 7 days of Treatment Phase A. Change from Baseline at the end of Treatment Phase is the difference between the end of Treatment Phase value and the appropriate baseline week. Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline rescue medication use, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization (NCT02164539)
Timeframe: Baseline and End of Treatment Phase A (The end of Treatment Phase A was defined as the last 7 days of Treatment Phase A, including the AM assessments on the date of Visit 6)

InterventionPuffs (Least Squares Mean)
FF 100 µg0.6
FF/UMEC 100/15.6 µg-0.4
FF/UMEC 100/62.5 µg-0.5
FF/UMEC 100/125 µg0.0
FF/UMEC 100/250 µg-0.2
FF/VI 100/25 µg-0.1

Asthma Exacerbations

The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period

Interventionexacerbations per year (Least Squares Mean)
Fluticasone 44 mcg0.37
Fluticasone 220 mcg0.48

Number of Participants Hospitalized for Asthma

Number of participants hospitalized for asthma during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period

InterventionParticipants (Count of Participants)
Fluticasone 44 mcg0
Fluticasone 220 mcg4

Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma

Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period

Interventionvisits per year (Least Squares Mean)
Fluticasone 44 mcg0.47
Fluticasone 220 mcg0.64

Yellow Zone Albuterol Use

Use of albuterol rescue medication during 7-day yellow zone episodes. (NCT02066129)
Timeframe: end of 48 week treatment period

Interventionnumber of albuterol puffs (Least Squares Mean)
Fluticasone 44 mcg13
Fluticasone 220 mcg15

Yellow Zone Asthma Symptoms

Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days. (NCT02066129)
Timeframe: end of 48 week treatment period

Interventionunits on a scale (Least Squares Mean)
Fluticasone 44 mcg20
Fluticasone 220 mcg23

Emergency Department (ED) Visits for Asthma

Number of emergency department visits for asthma in the past 3 months (NCT01981564)
Timeframe: 3 months

Interventionvisits (Mean)
Asthma Express Intervention0.64
Standard Asthma Education Control Group0.62

Symptom Days

Symptom days for asthma during past 14 days (NCT01981564)
Timeframe: 3 months

Interventionsymptom days over past 14 days (Mean)
Asthma Express Intervention6.24
Standard ASthma Education Control Group4.82

Change From Baseline in Asthma Control Test (ACT) Scores at Day 168

"The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, How much of the time did your asthma keep you from getting as much done at work, school or at home?, How often have you had shortness of breath?, How often did your asthma symptoms wake you up at night or earlier than usual in the morning?, How often have you used your rescue inhaler or nebulizer medication (such as albuterol)? and How would you rate your asthma control? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value." (NCT01147848)
Timeframe: Baseline and Day 168

InterventionScores on a scale (Least Squares Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD2.3
Fluticasone Propionate/Salmeterol 250/50 µg BID2.0

Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)

"The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates total impairment; a value of 7 indicates no impairment. The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates total impairment) to 7 (indicates no impairment). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment." (NCT01147848)
Timeframe: Baseline and Day 168

InterventionScores on a scale (Least Squares Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD0.46
Fluticasone Propionate/Salmeterol 250/50 µg BID0.37

Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168

"The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled best imaginable health state and worst imaginable health state anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment." (NCT01147848)
Timeframe: Baseline and Day 168

Interventionscores on a scale (Least Squares Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD5.5
Fluticasone Propionate/Salmeterol 250/50 µg BID4.1

Change From Baseline in Trough FEV1 at Day 168

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value. (NCT01147848)
Timeframe: Baseline and Day 168

InterventionLiters (Least Squares Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD0.281
Fluticasone Propionate/Salmeterol 250/50 µg BID0.300

Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168

The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Day 168

InterventionLiters (Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD0.360
Fluticasone Propionate/Salmeterol 250/50 µg BID0.394

Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)

The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Randomization

InterventionLiters (Least Squares Mean)
FFluticasone Furoate/Vilanterol 100/25 µg OD0.316
Fluticasone Propionate/Salmeterol 250/50 µg BID0.346

Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Day 168/Week 24

InterventionLiters (Least Squares Mean)
Fluticasone Furoate/Vilanterol 100/25 µg OD0.341
Fluticasone Propionate/Salmeterol 250/50 µg BID0.377

"Percentage of Participants With No Problems in the EQ-5D Descriptive System Dimensions at Day 168/Week 24"

"The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their own health state today for each of the five dimensions." (NCT01147848)
Timeframe: Day 168/Week 24

,
Interventionpercentage of participants (Number)
MobilitySelf careUsual activitiesPain/DiscomfortAnxiety/Depression
Fluticasone Furoate/Vilanterol 100/25 µg OD8698867078
Fluticasone Propionate/Salmeterol 250/50 µg BID8498826681

Baseline FEV1 by Completion Status

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. (NCT01147848)
Timeframe: Baseline

,
InterventionLiters (Mean)
All Participants, n=401, 401Completers, n=359, 355Withdrawals, n=42, 46
Fluticasone Furoate/Vilanterol 100/25 µg OD2.0112.0131.996
Fluticasone Propionate/Salmeterol 250/50 µg BID2.0482.0432.091

Number of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168

All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward [GW] or the intensive care unit [ICU]) that were associated with asthma exacerbations were recorded. (NCT01147848)
Timeframe: Baseline to Day 168

,
Interventionvisits per participant (Mean)
Number of Home Visits during the DayNumber of Home Visits during the NightNumber of Physician Office/Practice VisitsNumber of Urgent Care/Outpatient Clinic VisitsNumber of Emergency Room VisitsNumber of Inpatient Hospitalization (ICU) DaysNumber of Inpatient Hospitalization (GW) Days
Fluticasone Furoate/Vilanterol 100/25 µg OD0.00.00.00.00.00.00.0
Fluticasone Propionate/Salmeterol 250/50 µg BID0.00.00.00.00.00.00.0

Number of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1

The number of participants obtaining a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168. (NCT01147848)
Timeframe: Baseline and Day 168

,
Interventionparticipants (Number)
12 hours post-dose, n=356,35424 hours post-dose, n=354, 354
Fluticasone Furoate/Vilanterol 100/25 µg OD199181
Fluticasone Propionate/Salmeterol 250/50 µg BID178176

Number of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1

Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement. (NCT01147848)
Timeframe: Baseline to Day 1

,
Interventionparticipants (Number)
5 minutes15 minutes30 minutes1 hour2 hours3 hours4 hoursCensored
Fluticasone Furoate/Vilanterol 100/25 µg OD100414032191711140
Fluticasone Propionate/Salmeterol 250/50 µg BID85515539291212118

Serial FEV1 (0-24 Hours)

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized. (NCT01147848)
Timeframe: Day 168

,
InterventionLiters (Mean)
Pre-dose, n=359,3535 minutes, n=356, 34415 minutes, n=355, 34730 minutes, n=357, 3511 hour, n=358, 3532 hours, n=359, 3533 hours, n=357, 3534 hours, n=357, 35411 hours, n=359, 34712 hours, n=356, 35412.5 hours, n=357, 35213 hours, n=354, 35414 hours, n=356, 35316 hours, n=354, 35020 hours, n=355, 35223 hours, n=354, 35324 hours, n=354, 354
Fluticasone Furoate/Vilanterol 100/25 µg OD0.3040.3200.3230.3390.3440.3620.3730.3560.3050.3300.3300.3430.3570.3510.3210.3100.304
Fluticasone Propionate/Salmeterol 250/50 µg BID0.3230.3390.3540.3660.3900.4090.4190.4170.3190.3380.3800.3960.4260.4190.3760.3440.340

Change of FEV1 (Forced Expiratory Volume in 1 Second) Expressed as Percent of Predicted After Two Doses of Albuterol (5 mg Each) and Ipratropium (0.5 mg Each) When Compared to FEV1 at Hour 2 After the Start of the Infusion of MN-221 or Placebo.

The primary efficacy summary was change from Baseline in FEV1 (percent predicted), at Hour 2. Baseline was defined as FEV1 (percent predicted) after two doses of albuterol (5 mg each) and ipratropium (0.5 mg each) and FEV1 (percent predicted) FEV1 at Hour 2 was defined as the FEV1 (percent predicted) at 2 hours after the start of the infusion of MN-221 or placebo. Change from Baseline in FEV1 (percent predicted), was summarized by treatment group at Hour 2. (NCT00683449)
Timeframe: Baseline and Hour 2

InterventionFEV1 (percent of predicted) (Mean)
240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes16.57
MN-221 Placebo i.v. Infusion3.88
1,000-1,080 μg MN-221 i.v.3.03
450 μg MN-221 i.v. for 15 Minutes4.27
1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes-0.82

FEV1 (L) The Forced Expiratory Volume in One Second as Measured in Liters Per Second.

FEV1 (L) was determined over time using a spirometer. Measure the mean change in FEV1 (L) from Baseline. (NCT00683449)
Timeframe: Baseline to Hour 2

Interventionliters per second (Mean)
MN-221 at 16.0 μg/Min for 15 Min (Total 240 μg)0.60
Placebo Administered Intravenously0.10
450 μg MN-221 Given i.v.0.12
1,000-1,080 μg MN-221 Given i.v. for 15 Minutes0.10
1,995 MN-221 Administered i.v. for 15 Minutes and 25 Minutes-0.02

Hospital Admission Rate During Visit 1

After a patient in the emergency department (ED) presents with an acute exacerbation of asthma, the hospital proceeds with SOC procedures for this condition. Despite treatment in the ED, it is sometimes necessary to admit the patient into the hospital. In the study described here, the rate of hospital admissions was recorded. (NCT00683449)
Timeframe: Hour -1.5 through Hour 5

Interventionparticipants (Number)
240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes0
MN-221 Placebo i.v. Infusion7
1,000-1,080 μg MN-221 i.v.0
450 μg MN-221 i.v. for 15 Minutes3
1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes1

Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups

The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every morning and evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily average of morning and evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. This outcome measure explored the efficacy between GSK2190915 and montelukast due to the dosing time difference. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionL/min (Least Squares Mean)
FP + GSK2190915 100 mg352.37
FP + GSK2190915 300 mg356.16
FP + Montelukast356.52

Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period

Daytime and night time asthma symptoms were recorded every evening at bedtime and every morning upon rising, respectively, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on scales ranging from '0' (implying no symptoms) to either 5 (for daytime symptoms) or 4 (for night time symptoms) (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. 24-hour period asthma symptom scores were averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionScore on a scale (Least Squares Mean)
FP + Placebo2.26
FP + GSK2190915 100 mg2.26
FP + GSK2190915 300 mg2.15
FP + Montelukast2.22
FP / Salmeterol2.25

Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period

The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionL/min (Least Squares Mean)
FP + Placebo354.06
FP + GSK2190915 100 mg355.71
FP + GSK2190915 300 mg359.16
FP + Montelukast358.88
FP / Salmeterol364.35

Daily Rescue Short-acting beta2-agonist (SABA) Use Averaged Over the Last 3 Weeks of the 6-week Treatment Period

A SABA (albuterol) was provided to participants as a rescue medication, to use as needed for symptomatic relief of asthma symptoms. Participants were required to record their albuterol use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The daily rescue SABA use was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionNumber of inhalations (Least Squares Mean)
FP + Placebo2.17
FP + GSK2190915 100 mg2.14
FP + GSK2190915 300 mg2.03
FP + Montelukast2.09
FP / Salmeterol2.08

Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period

The PEF is a measure of lung function and measures how fast a person can breathe out. Trough PEF was measured every morning prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily electronic diary (eDiary). Daily trough morning PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionLiters/minute (L/min) (Least Squares Mean)
FP + Placebo349.19
FP + GSK2190915 100 mg350.14
FP + GSK2190915 300 mg354.96
FP + Montelukast354.17
FP / Salmeterol361.33

Number of Participants Withdrawn Due to Lack of Efficacy During the Last 3 Weeks of the 6-week Treatment Period

Participants were withdrawn if they met any of the following three criteria for 'lack of efficacy': 1) Clinic FEV1 below the FEV1 'Stability Limit' value, 2) During any consecutive 7-day period, the participant experienced PEF fallen below the PEF 'Stability Limit' for more than 3 days, or if >= 12 inhalations per day of albuterol were used for more than 2 days, and 3) Ashtma exacerbation. The number of withdrawals due to lack of efficacy were summarized for each treatment and Fisher's Exact test was used for comparison with placebo add-on. Withdrawals occurring during active washout periods are not included. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionNumber of participants (Number)
FP + Placebo9
FP + GSK2190915 100 mg5
FP + GSK2190915 300 mg3
FP + Montelukast7
FP / Salmeterol5

Percentage of Nights Without Awakenings Due to Asthma During the Last 3 Weeks of the 6-week Treatment Period

Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale: 0 = no symptoms during the night, 1 = symptoms causing to wake once, 2 = symptoms causing to wake twice or more, 3 = symptoms causing to be awake most of the night, 4 = could not sleep due to severe symptoms. Participants recorded the symptoms in a daily eDiary. The number of nights with no awakenings due to asthma during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionPercentage of nights (Least Squares Mean)
FP + Placebo37.21
FP + GSK2190915 100 mg38.22
FP + GSK2190915 300 mg40.55
FP + Montelukast37.70
FP / Salmeterol38.47

Percentage of Rescue-free Days During the Last 3 Weeks of the 6-week Treatment Period

"Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of days when rescue medication was not used (rescue-free days) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionPercentage of days (Least Squares Mean)
FP + Placebo40.44
FP + GSK2190915 100 mg42.43
FP + GSK2190915 300 mg42.59
FP + Montelukast42.77
FP / Salmeterol41.96

Percentage of Rescue-free Nights During the Last 3 Weeks of the 6-week Treatment Period

"Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of nights when rescue medication was not used (rescue-free nights) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionPercentage of nights (Least Squares Mean)
FP + Placebo45.12
FP + GSK2190915 100 mg45.69
FP + GSK2190915 300 mg48.79
FP + Montelukast45.32
FP / Salmeterol43.98

Percentage of Symptom-free Days During the Last 3 Weeks of the 6-week Treatment Period

"Daytime asthma symptoms were recorded every evening at bedtime, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 6-point scale ranging from '0' (implying no symptoms) to 5 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of days when symptoms were not experienced (symptom-free days) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionPercentage of days (Least Squares Mean)
FP + Placebo30.84
FP + GSK2190915 100 mg33.51
FP + GSK2190915 300 mg36.14
FP + Montelukast34.88
FP / Salmeterol35.45

Percentage of Symptom-free Nights During the Last 3 Weeks of the 6 Week Treatment Period

"Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale ranging from '0' (implying no symptoms) to 4 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of nights when symptoms were not experienced (symptom-free nights) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6

InterventionPercentage of nights (Least Squares Mean)
FP + Placebo37.21
FP + GSK2190915 100 mg38.22
FP + GSK2190915 300 mg40.55
FP + Montelukast37.70
FP / Salmeterol38.47

Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically using spirometry, prior to study medication and any rescue albuterol (bronchodilator) use. At the end of the 6-week treatment period, FEV1 was measured approximately 24 hours after the participant's last morning dose of study medication and approximately 12 hours after the evening dose of study medication. Trough FEV1 was analyzed using mixed effect analysis of covariance (ANCOVA) model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effect of participant. Intent-to-Treat Population is defined as all participants who were randomized and received at least one dose of study drug. (NCT01156792)
Timeframe: End of Week 6

InterventionLiters (L) (Least Squares Mean)
FP + Placebo2.36
FP + GSK2190915 100 mg2.39
FP + GSK2190915 300 mg2.40
FP + Montelukast2.42
FP / Salmeterol2.43

Maximum and Weighted Mean Over 0 to 4 Hours Post Dose of the QT Interval Corrected According to Bazett's Formula (QTc[B]) and the QT Interval Corrected According to Fridericia's Formula (QTc[F])

The electrocardiogram (ECG) of the participants was taken, and the maximum and weighted mean of QTc(B) and QTc(F) was measured. Weighted mean was calculated by using all values of QTc(B) and QTc(F) at the indicated timepoint contributing to the calculation of the mean but with different weightage. The ECG helps in the assessment of the condition of the heart. The QT interval gives the measure of the heart rate, and the cQT interval gives the corrected value. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 3 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionMilliseconds (msec) (Mean)
Max, QTc(B) interval, Asthma + COPD; n=57, 57Max, QTc(B) interval, Asthma; n=33, 33Max, QTc(B) interval, COPD; n=24, 24Weighted mean QTc(B), Asthma + COPD; n=57, 57Weighted mean QTc(B), Asthma; n=33, 33Weighted mean QTc(B), COPD; n=24, 24Max QTc(F), Asthma + COPD; n=57, 57Max QTc(F), Asthma; n=33, 33Max QTc(F), COPD; n=24, 24Weighted mean QTc(F), Asthma + COPD; n=57, 57Weighted mean QTc(F), Asthma; n=33, 33Weighted mean QTc(F), COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler434.4424.7447.6416.8406.3431.3422.6413.7434.9410.1401.3422.3
FP/Salmeterol From MDPI434.0423.7448.1416.8405.7431.9422.5413.5434.9410.3401.2422.9

Mean Albumin and Total Protein

"The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventiong/L (Mean)
Albumin, 1st admin, Asthma; n=33, 33Albumin, 2nd admin, Asthma; n=31, 33Albumin, 1st admin, COPD; n=25, 25Albumin, 2nd admin, COPD; n=25, 25Total protein, 1st admin, Asthma; n=33, 33Total protein, 2nd admin, Asthma; n=31, 33Total protein, 1st admin, COPD; n=25, 25Total protein, 2nd admin, COPD; n=25, 25
FP/Salmeterol From Capsule-based Inhaler42.341.841.440.066.064.864.963.5
FP/Salmeterol From MDPI43.042.040.940.866.865.464.764.6

Mean Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST), and Gama Glutamyl Transferase (GGT)

"Blood samples of participants were collected for the evaluation of AP, ALT, AST, and GGT. All of these parameters are measured to help assess the condition of the liver. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionInternational units per liter (IU/L) (Mean)
AP, 1st admin, Asthma; n=33, 33AP, 2nd admin, Asthma; n=31, 33AP, 1st admin, COP ; n=25, 25AP, 2nd admin, COPD; n=25, 25ALT, 1st admin, Asthma; n=33, 33ALT, 2nd admin, Asthma; n=31, 33ALT, 1st admin, COPD; n=25, 25ALT, 2nd admin, COPD; n=25, 25AST, 1st admin, Asthma; n=33, 33AST, 2nd admin, Asthma; n=31, 33AST, 1st admin, COPD; n=25, 25AST, 2nd admin, COPD; n=25, 25GGT, 1st admin, Asthma; n=33, 33GGT, 2nd admin, Asthma; n=31, 33GGT, 1st admin, COPD; n=25, 25GGT, 2nd admin, COPD; n=25, 25
FP/Salmeterol From Capsule-based Inhaler63.463.969.968.420.419.123.421.221.620.124.721.121.021.044.029.6
FP/Salmeterol From MDPI64.665.069.669.820.121.521.220.921.220.722.722.521.322.736.931.8

Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP

Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionPicogram hours per milliliter (pg*h/mL) (Geometric Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler573.1559.1593.0
FP/Salmeterol From MDPI376.9350.5416.4

Mean AUC(0-tlast) for FP

Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tlast). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionpg*h/mL (Geometric Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler580.9558.4613.2
FP/Salmeterol From MDPI380.1355.7416.5

Mean Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell (WBC) Count

"Blood samples of participants were collected for the evaluation of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and WBC count. Data are reported for the first (1st) and second (2nd) administration (admin) of FP/salmeterol via MDPI or capsule-based inhaler. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionGiga (10^9) cells/L (Mean)
Basophils, 1st admin, Asthma; n=33, 33Basophils, 2nd admin, Asthma; n=31, 33Basophils, 1st admin, COPD; n=25, 25Basophils, 2nd admin, COPD; n=24, 25Eosinophils, 1st admin, Asthma; n=33, 33Eosinophils, 2nd admin, Asthma; n=31, 33Eosinophils, 1st admin, COPD; n=25, 25Eosinophils, 2nd admin, COPD; n=24, 25Lymphocytes, 1st admin, Asthma; n=33, 33Lymphocytes, 2nd admin, Asthma; n=31,33Lymphocytes, 1st admin, COPD; n=25, 25Lymphocytes, 2nd admin, COPD; n=24, 25Monocytes, 1st admin, Asthma; n=33, 33Monocytes, 2nd admin, Asthma; n=31, 33Monocytes, 1st admin, COPD; n=25, 25Monocytes, 2nd admin, COPD; n=24, 25TN, 1st admin, Asthma; n=33, 33TN, 2nd admin, Asthma; n=31, 33TN, 1st admin, COPD; n=25, 25TN, 2nd admin, COPD; n=24, 25Platelet count, 1st admin, Asthma; n=33, 33Platelet count, 2nd admin, Asthma; n=31, 33Platelet count, 1st admin, COPD; n=24, 24Platelet count, 2nd admin, COPD; n=23, 24WBC count, 1st admin, Asthma; n=33, 33WBC count, 2nd admin, Asthma; n=31, 33WBC count, 1st admin, COPD; n=25, 25WBC count, 2nd admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler0.060.040.040.040.330.310.230.261.921.861.721.680.550.520.600.633.373.283.483.75223.9230.8226.6240.16.1825.9766.0366.312
FP/Salmeterol From MDPI0.050.040.070.040.370.310.250.251.961.901.701.750.540.540.640.633.283.303.703.45225.1230.7230.6235.16.1456.0716.3406.092

Mean Calcium, Chloride, Glucose, Potassium, Sodium, Carbon Dioxide (CO2) Content/Bicarbonate (Bicar), and Urea/Blood Urea Nitrogen (BUN)

"Blood samples of participants were collected for the evaluation of calcium, chloride, glucose, potassium, sodium, carbon dioxide (CO2) content/bicarbonate, and urea/BUN. All of these parameters are measured to help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionµmol/L (Mean)
Calcium, 1st admin, Asthma; n=33, 32Calcium, 2nd admin, Asthma; n=31, 33Calcium, 1st admin, COPD; n=25, 25Calcium, 2nd admin, COPD; n=25, 25Chloride, 1st admin, Asthma; n=33, 33Chloride, 2nd admin, Asthma; n=31, 33Chloride, 1st admin, COP; n=25, 25Chloride, 2nd admin, COPD n=25, 25Glucose, 1st admin, Asthma; n=33, 33Glucose, 2nd admin, Asthma; n=31, 33Glucose, 1st admin, COPD; n=25, 25Glucose, 2nd admin, COPD; n=25, 25Potassium, 1st admin, Asthma; n=32, 33Potassium, 2nd admin, Asthma; n=31, 33Potassium, 1st admin, COPD n=25, 25Potassium, 2nd admin, COPD; n=25, 25Sodium, 1st admin, Asthma; n=33, 33Sodium, 2nd admin, Asthma; n=31, 33Sodium, 1st admin, COPD n=25, 25Sodium, 2nd admin, COPD n=25, 25CO2 content/bicar, 1st admin, Asthma; n=33, 33CO2 content/bicar, 2nd admin, Asthma; n=31, 33CO2 content/bicar, 1st admin, COPD; n=25, 25CO2 content/bicar, 2nd admin, COPD; n=25, 25Urea/BUN, 1st admin, Asthma; n=33, 33Urea/BUN, 2nd admin, Asthma; n=31, 33Urea/BUN, 1st admin, COPD; n=25, 25Urea/BUN, 2nd admin, COPD; n=25, 25
FP/Salmeterol From Capsule-based Inhaler2.1782.1702.1892.190104.8105.3104.0104.45.065.155.375.454.054.024.084.11140.5140.4140.5140.225.626.027.327.25.415.436.096.12
FP/Salmeterol From MDPI2.1912.1902.2052.206104.7104.5104.4104.15.065.065.365.634.154.064.164.10140.5140.1140.5140.126.126.227.227.35.345.315.985.90

Mean Corpuscle Volume (MCV)

"Blood samples of participants were collected for the evaluation of MCV. MCV is a measure of the average red blood cell size that is reported as part of a standard complete blood count. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionFemtoliters (fL; 10^-15 L)/cell (Mean)
1st admin, Asthma; n=33, 332nd admin, Asthma; n=31, 331st admin, COPD; n=25, 252nd admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler89.4189.7790.3790.64
FP/Salmeterol From MDPI89.6589.5290.2190.76

Mean Corpuscule Hemoglobin (MCH)

"Blood samples of participants were collected for the evaluation of MCH. MCH is the average mass or amount of hemoglobin per red blood cell in a sample of blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionpicograms (pg)/cell (Mean)
1st admin, Asthma; n=33, 332nd admin, Asthma; n=31, 331st admin, COPD; n=25, 252nd admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler29.8629.9229.7229.83
FP/Salmeterol From MDPI29.9929.8029.7229.73

Mean Direct Bilirubin (DB), Total Bilirubin (TB), Creatinine, and Uric Acid

"Blood samples of participants were collected for the evaluation of DP, TB, creatinine, and uric acid. DB and TB are measures that help assess the condition of the liver, and creatinine and uric acid are measures that help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionMicromoles per liter (µmol/L) (Mean)
DB, 1st admin, Asthma; n=33, 33DB, 2nd admin, Asthma; n=31, 33DB, 1st admin, COPD; n=25, 25DB, 2nd admin, COPD; n=25, 25TB, 1st admin, Asthma; n=33, 33TB, 2nd admin, Asthma; n=31, 33TB, 1st admin, COPD; n=25, 25TB, 2nd admin, COPD; n=25, 25Creatinine, 1st admin, Asthma; n=33, 33Creatinine, 2nd admin, Asthma; n=31, 33Creatinine, 1st admin, COPD; n=25, 25Creatinine, 2nd admin, COPD; n=25, 25Uric acid, 1st admin, Asthma n=33, 33Uric acid, 2nd admin, Asthma; n=31, 33Uric acid, 1st admin, COPD; n=25, 25Uric acid, 2nd admin, COPD; n=25, 25
FP/Salmeterol From Capsule-based Inhaler2.72.62.82.99.98.69.48.475.875.277.779.4331.5325.6348.3352.0
FP/Salmeterol From MDPI3.23.02.92.79.59.98.78.577.276.979.479.6328.9338.4354.2361.7

Mean Hematocrit

"Blood samples of participants were collected for the evaluation of hematocrit. The hematocrit is the percentage of the RBCs in the blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionpercentage of RBCs (Mean)
1st admin, Asthma; n=33, 332nd admin, Asthma; n=31, 331st admin, COPD; n=25, 252nd admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler0.4050.3960.4050.391
FP/Salmeterol From MDPI0.4130.3990.4050.400

Mean Hemoglobin and Mean Corpuscular Hemoglobin (MCH) Concentration

"Blood samples of participants were collected for the evaluation of mean hemoglobin (mean level of hemoglobin in the whole blood sample) and MCH concentration. The MCH concentration is the average concentration of hemoglobin in a red blood cell. Hemoglobin is the red pigment in the blood, and it is reponsible for carrying oxygen. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionGrams per liter (g/L) (Mean)
Hemoglobin, 1st admin, Asthma; n=33, 33Hemoglobin, 2nd admin, Asthma; n=31, 33Hemoglobin, 1st admin, COPD; n=25, 25Hemoglobin, 2nd admin, COPD; n=24, 25MCH concentration, 1st admin, Asthma; n=33, 33MCH concentration, 2nd admin, Asthma; n=31, 33MCH concentration, 1st admin, COPD; n=,25, 25MCH concentration, 1st admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler135.4132.3133.1128.5334.0333.2328.5328.8
FP/Salmeterol From MDPI138.2133.0133.3130.6334.7333.0329.0327.4

Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) for Salmeterol

Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of Salmeterol in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionpg/mL (Geometric Mean)
Cmax, Asthma + COPD; n=57, 57Cmax, Asthma; n=33, 33Cmax, COPD; n=24, 24Cmin, Asthma + COPD; n=57, 57Cmin, Asthma; n=33, 33Cmin, COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler92.27110.2172.2714.35414.63413.978
FP/Salmeterol From MDPI59.2864.9752.2612.75212.67612.857

Mean Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of FP

Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of FP in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum, respectively. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionPicograms per milliliter (pg/mL) (Geometric Mean)
Cmax, Asthma + COPD; n= 57, 57Cmax, Asthma; n=33, 33Cmax, COPD; n=24, 24Cmin, Asthma + COPD; n=57, 57Cmin, Asthma; n=33, 33Cmin, COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler105.79109.98100.2921.54718.86625.866
FP/Salmeterol From MDPI54.6453.6656.0215.90413.63519.654

Mean of Maximum Heart Rate Over 0 to 4 Hours Post Dose for Salmeterol

The maximum observed value of heart rate was measured from the time of the morning dose on Day 10 to 4 hours post dose. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionbpm (Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler74.373.575.4
FP/Salmeterol From MDPI73.072.374.0

Mean Plasma AUC(0-tau) and Plasma AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-tlast]) for Salmeterol

Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tau) and AUC(0-tlast). AUC(0-tau) is a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionpg*h/mL (Geometric Mean)
AUC(0-tau), asthma + COPD; n=57, 57AUC(0-tau), asthma; n=33, 33AUC(0-tau), COPD; n=24, 24AUC(0-t), asthma + COPD; n=57, 57AUC(0-t), asthma; n=33, 33AUC(0-t), COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler345.1356.4330.1345.0356.4330.0
FP/Salmeterol From MDPI300.2305.8292.7303.5305.2301.2

Mean Terminal Phase Half-life (t1/2) for FP

Blood samples of participants were collected for evaluating t1/2. The t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionhours (Geometric Mean)
Asthma + COPD; n=54, 55Asthma; n=30, 32COPD; n=24, 23
FP/Salmeterol From Capsule-based Inhaler5.8445.2386.806
FP/Salmeterol From MDPI6.6605.9067.740

Mean Terminal Phase Half-life (t1/2) for Salmeterol

Blood samples of participants were collected for evaluating t1/2. t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionhours (Geometric Mean)
Asthma + COPD; n=56, 56Asthma; n=32, 32COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler7.2607.5386.905
FP/Salmeterol From MDPI6.5766.4296.776

Mean Urine Cortisol Excretion Over 0 to 24 Hours Post Dose for FP

Urine samples of participants were collected to evaluate urine cortisol excretion over 0-24 hours post treatment dose. A 24-hour urine cortisol sample was used to measure the total amount of cortisol excreted in urine in 24 hours. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in the amount of cortisol excreted in the urine. (NCT01494610)
Timeframe: 0-24 hours post dose on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionnmol (Geometric Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler59.6666.2851.62
FP/Salmeterol From MDPI63.5372.8652.62

Minimum Diastolic Blood Pressure (DBP), Maximum Systolic Blood Pressure (SBP), and Weighted Mean for DBP and SBP Over 0 to 4 Hours Post Dose

The diastolic and systolic blood pressure of the participants was measured. The maximum and minimum observed values from the time of the morning dose on Day 10 to 4 hours post dose were measured for SBP and DBP. The weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. Weighted mean was calculated by using all values of DBP and SBP at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionmillimeters of mercury (mmHg) (Mean)
DBP, Asthma + COPD; n=57, 57DBP, Asthma; n=33, 33DBP, COPD; n=24, 24Weighted mean DBP, Asthma + COPD; n=57, 57Weighted mean DBP, Asthma; n=33, 33Weighted mean DBP, COPD; n=24, 24SBP, Asthma + COPD; n=57, 57SBP, Asthma; n=33, 33SBP, COPD; n=24, 24Weighted mean SBP, Asthma + COPD; n=57, 57Weighted mean SBP, Asthma; n=33, 33Weighted mean SBP, COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler66.262.671.272.268.877.0129.3122.1139.1120.3114.6128.2
FP/Salmeterol From MDPI64.761.669.171.168.075.4128.0119.9139.1118.8112.9126.9

Number of Participants With an Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01494610)
Timeframe: Randomization (Day 1) up to Follow-up (Days 47-50)

,
Interventionparticipants (Number)
1st admin, Asthma; n=33, 342nd admin, Asthma; n=31, 331st admin, COPD; n=26, 252nd admin, COPD; n=25, 25
FP/Salmeterol From Capsule-based Inhaler13151111
FP/Salmeterol From MDPI1312149

Red Blood Cell (RBC) Count and Reticulocytes

"Blood samples of participants were collected for the evaluation of RBC and reticulocytes count. Reticulocytes are immature red blood cells. Normally, about 1% to 2% of the red blood cells in the blood are reticulocytes. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionTrillion (10^12) cells/L (Mean)
RBC, 1st admin, Asthma; n=33, 33RBC, 2nd admin, Asthma; n=31, 33RBC, 1st admin, Asthma, COPD; n=25, 25RBC, 2nd admin, COPD; n=24, 25Reticulocytes, 1st admin, Asthma ; n=33, 32Reticulocytes, 2nd admin, Asthma; n=31, 33Reticulocytes, 1st admin, COPD; n=25, 25Reticulocytes, 2nd admin, COPD; n=24, 25
FP/Salmeterol From Capsule-based Inhaler4.5424.4244.5304.3580.0500.0500.0540.061
FP/Salmeterol From MDPI4.6084.4604.5234.4380.0490.0510.0540.059

Serum Cortisol Minimum (Cmin) for FP

Blood samples of participants were collected for the evaluation of minimum serum cortisol. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in serum cortisol concentrations. (NCT01494610)
Timeframe: Day 10 of each study period (Periods 1-4); Study Day 10 (+/-1) (reference day is Study Day 1 or Randomization day), Period 1; Study Day 20 (+/-1), Period 2; Study Day 30 (+/-1), Period 3; Study Day 40 (+/-1), Period 4

,
Interventionnmol/L (Geometric Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler79.670.094.9
FP/Salmeterol From MDPI88.679.8102.4

Time of Occurrence of Cmax (Tmax) for FP

Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionhours (Median)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler0.5300.3350.673
FP/Salmeterol From MDPI1.0451.0001.173

Tmax for Salmeterol

Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionhours (Median)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler0.0800.0800.080
FP/Salmeterol From MDPI0.7500.3351.000

Weighted Mean Over 0 to 4 Hours Post Dose and Maximum Plasma Glucose

Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the maximum plasma glucose level. Weighted mean was calculated by using all values of plasma glucose at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionmmol/L (Mean)
Weighted mean, Asthma + COPD; n=57, 57Weighted mean, Asthma; n=33, 33Weighted mean, COPD; n=24, 24Max, Asthma + COPD; n=57, 57Max, Asthma; n=33, 33Max, COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler5.955.806.167.196.967.50
FP/Salmeterol From MDPI5.855.676.116.946.647.36

Weighted Mean Over 0 to 4 Hours Post Dose of Heart Rate for Salmeterol

The heart rate (number of heartbeats per unit of time, typically expressed as beats per minute [bpm]) of the participants was monitored for evaluating the weighted mean over the course of 0 to 4 hours post dose. The Capsule-MDPI difference for heart rate was calculated for each participant, and the weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. The weighted mean was calculated by using all values at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
Interventionbpm (Mean)
Asthma + COPD; n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler66.765.768.1
FP/Salmeterol From MDPI66.264.868.2

Weighted Mean Over 0 to 4 Hours Post Dose of Plasma Potassium and Minimum (Min) Plasma Potassium

Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the minimum plasma potassium level. Weighted mean was calculated by using all values of plasma potassium at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionMillimoles per liter (mmol/L) (Mean)
Weighted mean, Asthma + COPD; n=56, 57Weighted mean, Asthma; n=32, 33Weighted mean, COPD; n=24, 24Min, Asthma + COPD; n=57, 57Min, Asthma; n=33, 33Min, COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler4.114.104.133.903.893.92
FP/Salmeterol From MDPI4.114.114.113.913.923.89

Weighted Mean Serum Cortisol (SC) Over 0 to 12 Hours Post Dose

Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body's ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval. (NCT01494610)
Timeframe: At pre-morning dose; 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively

,
InterventionNanomoles per liter (nmol/L) (Geometric Mean)
Asthma + COPD;n=57, 57Asthma; n=33, 33COPD; n=24, 24
FP/Salmeterol From Capsule-based Inhaler178.3166.6195.6
FP/Salmeterol From MDPI193.5187.3202.4

Change Between Week 14 and Week 0 in Asthma Symptoms

"Asthma symptoms were recorded as 0 (absent = no symptom )~(mild = symptom was minimally troublesome, i.e. not sufficient to interfere with normal daily activity or sleep)~(moderate = symptom was sufficiently troublesome to interfere with normal daily activity or sleep)~(severe = symptom was so severe as to prevent normal activity and/or sleep )" (NCT00565266)
Timeframe: Asthma symptoms were measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionunits on a scale (Least Squares Mean)
Tio + 1xICS-0.09
LABA + 1xICS-0.04
2xICS0.03

Change Between Week 14 and Week 0 in the Albuterol Rescue Puffs Per Day

Total number of puffs from the albuterol (rescue) inhaler during the previous 24 hours (excluding those puffs for preventive use). (NCT00565266)
Timeframe: Albuterol rescue puffs were measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionpuffs per day (Least Squares Mean)
Tio + 1xICS-0.11
LABA + 1xICS-0.16
2xICS-0.07

Change Between Week 14 and Week 0 in the Asthma Control Questionnaire Score

Scores on the Asthma Control Questionnaire range from 0 to 6, with a higher score indicating worse asthma control. (NCT00565266)
Timeframe: The asthma control questionnaire score was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionunits on a scale (Least Squares Mean)
Tio + 1xICS-0.22
LABA + 1xICS-0.31
2xICS-0.03

Change Between Week 14 and Week 0 in the Asthma Quality-of-life Questionnaire Score

Scores on the Asthma Quality-of-Life Questionnaire range from 1 to 7, with a higher score indicating a better quality of life. (NCT00565266)
Timeframe: The asthma quality-of-life questionnaire score was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionunits on a scale (Least Squares Mean)
Tio + 1xICS0.15
LABA + 1xICS0.28
2xICS0.05

Change Between Week 14 and Week 0 in the Forced Expiratory Volume in One Second (FEV1)

(NCT00565266)
Timeframe: FEV1 was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionliters (Least Squares Mean)
Tio + 1xICS0.12
LABA + 1xICS0.01
2xICS0.02

Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF)

(NCT00565266)
Timeframe: AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

InterventionLiters per minute (Least Squares Mean)
Tio + 1xICS24.4
LABA + 1xICS18.0
2xICS-1.4

Change Between Week 14 and Week 0 in the Proportion of Asthma Control Days

An asthma control day was defined as a day in which there were no symptoms and no albuterol (rescue) puffs. (NCT00565266)
Timeframe: An asthma control day was determined daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionproportion of asthma control days (Least Squares Mean)
Tio + 1xICS0.13
LABA + 1xICS0.14
2xICS0.05

Asthma Control Questionnaire (ACQ) Score (Change From Baseline)

Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient's FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionUnits on a scale (Mean)
Alair-0.82
Sham-0.77

Days Lost From Work/School/Other Activities Due to Asthma

(NCT00231114)
Timeframe: 12 Months

InterventionDays/Subject/Year (Mean)
Alair1.32
Sham3.9

Emergency Room Visits for Respiratory Symptoms

(NCT00231114)
Timeframe: 12 Months

InterventionEvents/Subject/Year (Mean)
Alair0.07
Sham0.43

Hospitalizations for Respiratory Symptoms

(NCT00231114)
Timeframe: 12 Months

InterventionEvents/Subject/Year (Number)
Alair0.04
Sham0.13

Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)

"Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the Integrated AQLQ Score." (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionUnits on a scale (Mean)
Alair1.35
Sham1.16

Morning Peak Expiratory Flow (amPEF) (Change From Baseline)

Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionL/Min (Mean)
Alair27.8
Sham22.3

Number of Puffs of Rescue Medication Used (Change From Baseline)

Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPuffs/7 Days (Mean)
Alair-6.0
Sham-4.3

Percent Days Rescue Medication Used (Change From Baseline)

Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPercent Change (Mean)
Alair-24.0
Sham-22.0

Percent Symptom-Free Days (Change From Baseline)

Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPercent Change (Mean)
Alair24.4
Sham21.0

Percentage of Subjects With Severe Exacerbations Requiring Systemic Corticosteroids

Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPercent of Subjects (Number)
Alair26.3
Sham39.8

Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)

Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPercent Change (Mean)
Alair-2.8
Sham-2.4

Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)

Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionPercent Change (Mean)
Alair-1.4
Sham-0.1

Rate of Severe Exacerbations Requiring Systemic Corticosteroids

Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionEvents/Subject/Year (Mean)
Alair0.48
Sham0.70

Total Symptom Score (Change From Baseline)

Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control. (NCT00231114)
Timeframe: Baseline, 12 Months

InterventionUnits on a scale (Mean)
Alair-1.7
Sham-1.6

Unscheduled Physician Office Visits for Respiratory Symptoms

(NCT00231114)
Timeframe: 12 Months

InterventionEvents/Subject/Year (Mean)
Alair0.28
Sham0.36

Emergency Room Visits for Respiratory Symptoms

Pull down menu does not have a rate unit. Rate of Emergency Room Visits for Respiratory Symptoms (number of Events/number of Subjects/year) (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure

InterventionNumber of events/number of subject/Year (Number)
Year 2, n=14Year 3, n=14Year 4, n=12Year 5, n=12
Alair Group0.3000.1

Hospitalizations for Respiratory Symptoms

Pull down menu does not have a rate unit. Rate of Hospitalizations for Respiratory Symptoms (number of Events/number of Subject/year) (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure

InterventionNumber of events/number of subject/Year (Number)
Year 2, n=14Year 3, n=14Year 4, n=12Year 5, n=12
Alair Group0.40.20.10.1

Percentage of Subjects With Respiratory Adverse Events (AEs) in Annual Increments

The respiratory-related adverse event profile for the Alair group was analyzed on an annual basis in order to highlight trends in adverse occurrence. (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure

Interventionpercentage subjects with respiratory AEs (Number)
Year 2, n=14Year 3, n=14Year 4, n=12Year 5, n=12
Alair Group78.685.783.3100

Respiratory Adverse Events

Pull down menu does not have a rate unit. Numbers reported represents Rate of Respiratory Adverse (number of Events/number of Subject/year). (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure

InterventionNumber of events/number of subject/Year (Number)
Year 2, n=14Year 3, n=14Year 4, n=12Year 5, n=12
Alair Group1.42.41.72.4

Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12

InterventionLiters per minute (L/min) (Least Squares Mean)
Placebo14.2
Vilanteral 25 µg OD28.0
Salmeterol 50 µg BID23.6

Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12

InterventionLiters per minute (L/min) (Least Squares Mean)
Placebo11.0
Vilanteral 25 µg OD24.9
Salmeterol 50 µg BID18.8

Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period

The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12

InterventionPercentage of rescue-free 24-hr periods (Least Squares Mean)
Placebo14.6
Vilanteral 25 µg OD21.7
Salmeterol 50 µg BID22.9

Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period

Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12

InterventionPercentage of symptom-free 24-hr periods (Least Squares Mean)
Placebo12.7
Vilanteral 25 µg OD19.4
Salmeterol 50 µg BID19.5

Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12

FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Week 12

InterventionLiters (Least Squares Mean)
Placebo0.289
Vilanteral 25 µg OD0.359
Salmeterol 50 µg BID0.283

Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points

FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point. (NCT01181895)
Timeframe: Baseline and Week 12

,,
InterventionLiters (Least Squares Mean)
Predose, n=97,104,1015 min, n=95,100,9815 min, n=96, 101, 9930 min, n=,96,101,10060 min, n=96, 101, 1002 hours, n=96, 100, 993 hours, n=96, 101, 1004 hours, n=96, 101, 1005 hours, n=96, 100, 10011 hours, n=94, 99, 9612 hours, n=93,98,9512.5 hours, n=96, 97, 9813 hours, 96, 98, 10014 hours, n=95, 99, 9916 hours, n=95, 98, 9720 hours, n= 94, 101, 9923 hours, 94, 101, 9924 hours, n= 95, 101, 100
Placebo0.3020.3130.3080.3220.3360.3130.3040.3110.2920.1950.2500.2700.3120.3410.3640.3180.3100.301
Salmeterol 50 µg BID0.2330.2140.2570.2720.2960.3350.3160.2930.2790.1790.2170.2820.3040.3590.3570.2960.2710.275
Vilanteral 25 µg OD0.2720.3010.3240.3440.3520.3690.3740.3590.3680.3120.3410.3370.3410.4010.3710.3710.3450.330

Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12

At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often. (NCT01181895)
Timeframe: Week 4 and Week 12

,,
InterventionParticipants (Number)
Week 4, AS: Much better, n=110, 109, 110Week 4, AS: Somewhat better, n=110, 109, 110Week 4, AS: A little better, n=110, 109, 110Week 4, AS: The same, n=110, 109, 110Week 4, AS: A little worse, n=110, 109, 110Week 4, AS: Somewhat worse, n=110, 109, 110Week 4, AS: Much worse, n=110, 109, 110Week 4, RMU: Much less often, n=110, 109, 110Week 4, RMU: Somewhat less often, n=110, 109, 110Week 4, RMU: A little less often, n=110, 109, 110Week 4, RMU: The same, n=110, 109, 110Week 4, RMU: A little more often, n=110, 109, 110Week 4, RMU: Somewhat more often, n=110, 109, 110Week 4, RMU: Much more often, n=110, 109, 110Week 12, AS: Much better, n=100, 105, 101Week 12, AS: Somewhat better, n=100, 105, 101Week 12, AS: A little better, n=100, 105, 101Week 12, AS: The same, n=100, 105, 101Week 12, AS: A little worse, n=100, 105, 101Week 12, AS: Somewhat worse, n=100, 105, 101Week 12, AS: Much worse, n=100, 105, 101Week 12, RMU: Much less often, n=100, 105, 101Week 12, RMU: Somewhat less often, n=100, 105, 101Week 12, RMU: A little less often, n=100, 105, 101Week 12, RMU: The same, n=100, 105, 101Week 12, RMU: A little more often, n=100, 105, 101Week 12, RMU: Somewhat more often, n=100, 105, 101Week 12, RMU: Much more often, n=100, 105, 101
Placebo25352417621184018264223135131244125311323242
Salmeterol 50 µg BID34342116320283620177203534161141032291321420
Vilanteral 25 µg OD374314131013331231830152319921140321611501

Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)

The number of participants with a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a >=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a >=12% and >=200 mL increase from Baseline in FEV1 over this time period were considered censored. (NCT01181895)
Timeframe: Day 1 and Week 12

,,
InterventionParticipants (Number)
Day 1, 5 min, n=113, 115, 116Day 1, 15 min, n=113, 115, 116Day 1, 30 min, n=113, 115, 1116Day 1, 1 hr, n=113, 115, 116Day 1, 2 hr, n=113, 115, 116Day 1, Censored, n=113, 115, 116Week 12, 5 min, n=96, 101, 100Week 12, 15 min, n=96, 101, 100Week 12, 30 min, n=96, 101, 100Week 12, 1 hr, n=96, 101, 100Week 12, 2 hr, n=96, 101, 100Week 12, Censored, n=96, 101, 100
Placebo2323357739621345
Salmeterol 50 µg BID1811136115730785446
Vilanteral 25 µg OD33118765042224744

Number of Participant's Admitted to the Hospital for Further Treatment

Patient disposition is measured as subjects requiring further treatment and being admitted to hospital. We record the number of patients in each cohort that required admission to the hospital after being evaluated and treated in the Emergency Department. (NCT02777125)
Timeframe: 6 hours

InterventionParticipants admitted to the Hospital (Number)
Albuterol by Metered Dose Inhaler53
Albuterol Breath Actuated Nebulizer57

Number of Participants Requiring Repeat Visits

Defined as a repeat visit to the Emergency Department for a complaint related to their wheezing, within 7 days of initial enrollment in the study. (NCT02777125)
Timeframe: Within 7 days of initial presentation

InterventionParticipants (Count of Participants)
Albuterol by Metered Dose Inhaler5
Albuterol Breath Actuated Nebulizer4

Number of Patients Requiring Ondansetron Dosing

Defined as a patient needing ondansetron for symptomatic relief of their nausea after initiating therapy in the Emergency Department. (NCT02777125)
Timeframe: 6 hours

InterventionParticipants (Count of Participants)
Albuterol by Metered Dose Inhaler14
Albuterol Breath Actuated Nebulizer18

Number of Patients With Tachycardia After Treatment

Defined as anytime after initiation of therapy when the patient's heart rate exceeded age adjusted normal sinus rhythm heart rates for their age. Not uncommonly, patient's experience tachycardia as an unintended side effect of receiving albuterol. Tachycardia can result in a patient requiring further observation in the Emergency department and therefore increasing Emergency Department length of stay. We want to determine if indeed tachycardia is unavoidable, or if its presence suggests that patients are receiving too much albuterol or if albuterol is being given by the wrong appliance. (NCT02777125)
Timeframe: 6 hours

InterventionParticipants (Count of Participants)
Albuterol by Metered Dose Inhaler101
Albuterol Breath Actuated Nebulizer141

Emergency Department Length of Stay

Emergency department length of stay is defined as the point of time when the patient checked into the Emergency Department to the time of final disposition. (NCT02777125)
Timeframe: 6 hours

,
Interventionminutes (Mean)
Mild severityModerate severity
Albuterol Breath Actuated Nebulizer197245
Albuterol by Metered Dose Inhaler192232

Albuterol Induced Percent Change in Qaw

Qaw will be measured before and 15 min after albuterol inhalation (NCT01210170)
Timeframe: change in Qaw 15 minutes after albuterol inhalation

Interventionpercent change in Qaw (Mean)
400 mcg Mometasone 30 Minutes Before Albuterol18
Mometasone Placebo 30 Minutes Before Albuterol0
400 mcg Mometasone and Albuterol Simultaneously30
Mometasone Placebo and Albuterol Simultaneously-2
400 mcg Mometasone 60 Minutes Before AlbuterolNA
Mometasone Placebo 60 Minutes Before AlbuterolNA
200 mcg Mometasone and Albuterol SimultaneouslyNA
200 mcg Mometasone 60 Minutes Before AlbuterolNA
200 mcg Mometasone 30 Minutes Before AlbuterolNA

Albuterol-induced Change in FEV1

FEV1 will be measured before and after inhalation of 180 mcg albuterol. (NCT01210170)
Timeframe: 15 minutes after albuterol inhalation

Interventionliters (Mean)
All Participants Received 400 mcg Mometasone-30 Min0.27
All Participants Received Placebo 30 Minutes Before Albuterol0.18
All Participants Received 400 mcg Mometasone Simultaneous0.32
All Participants Received Placebo Simultaneously With Albutero0.20
All Participants Received 200 mcg Mometasone-30 Min0.23
All Participants Received 400 mcg -60 MinNA
All Participants Received Placebo -60 MinNA
All Participants Received 200 mcg Mometasone SimultaneousNA
All Participants Received 200 mcg -60 MinNA

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 1.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 1

InterventionL*hr (Mean)
Placebo MDPI0.52
Albuterol MDPI1.58

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 8.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 8

InterventionL*hr (Mean)
Placebo MDPI0.26
Albuterol MDPI0.99

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 85.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 85

InterventionL*hr (Mean)
Placebo MDPI0.06
Albuterol MDPI0.74

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) of FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 1, Day 8 and Day 85

InterventionL*hr (Mean)
Placebo MDPI0.28
Albuterol MDPI1.11

Participants With Adverse Events

Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01424813)
Timeframe: Day 1 to Day 92

,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventsTreatment-related AEDeathsOther serious AEsWithdrawn from study due to AEs
Albuterol MDPI2211000
Placebo MDPI2511000

Participants With Clinically Significant Vital Sign Assessments

"For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 ± 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 ± 5 and -5 minutes, then post-dose at 30 (±5) minutes, 1hr (± 10 min), 2hr (± 10 min), 3hr (± 10 min), 4hr (± 10 min), 5hr (± 10 min) and 6 hr (± 10 min).~Serial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:~Systolic blood pressure: > 160 beats/minute Diastolic blood pressure: >100 beats/minute Heart rate: >120 beats/minute" (NCT01424813)
Timeframe: Day 8, Day 85

,
Interventionparticipants (Number)
Systolic blood pressure - highDiastolic blood pressure - highHeart rate - high
Albuterol MDPI011
Placebo MDPI330

Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group

Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint HEENT = head, eyes, ears, nose, throat (NCT01424813)
Timeframe: Day 1 (Baseline), Day 85

,
Interventionparticipants (Number)
General appearance Normal/NormalGeneral appearance Normal/AbnormalGeneral appearance Abnormal/NormalGeneral appearance Abnormal/AbnormalHEENT Normal/NormalHEENT Normal/AbnormalHEENT Abnormal/NormalHEENT Abnormal/AbnormalChest and Lungs Normal/NormalChest and Lungs Normal/AbnormalChest and Lungs Abnormal/NormalChest and Lungs Abnormal/abnormalHeart Normal/NormalHeart Normal/AbnormalHeart Abnormal/NormalHeart Abnormal/AbnormalAbdomen Normal/NormalAbdomen Normal/AbnormalAbdomen Abnormal/NormalAbdomen Abnormal/AbnormalMusculoskeletal Normal/NormalMusculoskeletal Normal/AbnormalMusculoskeletal Abnormal/NormalMusculoskeletal Abnormal/AbnormalSkin Normal/NormalSkin Normal/AbnormalSkin Abnormal/NormalSkin Abnormal/AbnormalLymph nodes Normal/NormalLymph nodes Normal/AbnormalLymph nodes Abnormal/NormalLymph nodes Abnormal/AbnormalNeurological Normal/NormalNeurological Normal/AbnormalNeurological Abnormal/NormalNeurological Abnormal/Abnormal
Albuterol MDPI76011505121167470770107701076110731407800078000
Placebo MDPI76010461211866821760107510174030750207700076100

Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose(AUC0-24) for Albuterol on Day 8

Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Day 8

Interventionpg*hr/mL (Mean)
Albuterol MDPI3605

Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Infinity Post-dose(AUC0-inf) for Albuterol on Day 1

Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Day 1

Interventionpg*hr/mL (Mean)
Albuterol MDPI2278

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 1

InterventionL*hr (Mean)
Placebo MDPI0.58
Albuterol MDPI1.63

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 8

InterventionL*hr (Mean)
Placebo MDPI0.37
Albuterol MDPI1.15

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 85

InterventionL*hr (Mean)
Placebo MDPI0.20
Albuterol MDPI1.12

Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period

"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 1, Day 8 and Day 85

InterventionL*hr (Mean)
Placebo MDPI0.38
Albuterol MDPI1.30

Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (AUC0-t) for Albuterol on Days 1 and 8

"Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min).~AUC0-t on Day 8 is not from pre-dose but at steady state." (NCT01747629)
Timeframe: Days 1 and 8

Interventionpg*hr/mL (Mean)
Day 1Day 8
Albuterol MDPI17472165

Area Under the Concentration-time Curve From Time 0 (Pre-dose) up to 6 Hours Post-dose (AUC0-6) for Albuterol on Days 1 and 8

"Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min).~AUC0-6 on Day 8 is not from pre-dose but at steady state." (NCT01747629)
Timeframe: Days 1 and 8

Interventionpg*hr/mL (Mean)
Day 1Day 8
Albuterol MDPI13252163

Maximum Observed Plasma Drug Concentration (Cmax) for Albuterol on Days 1 and 8

Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8

Interventionpg/mL (Mean)
Day 1Day 8
Albuterol MDPI347.2499.1

Participants With Adverse Events

Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01747629)
Timeframe: Day 1 to Day 93

,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious adverse eventWithdrawn from study due to adverse event
Albuterol MDPI2211022
Placebo MDPI3632001

Participants With Clinically Significant Vital Sign Assessments

"For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 ± 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 ± 5 and -5 minutes, then post-dose at 30 (±5) minutes, 1hr (± 10 min), 2hr (± 10 min), 3hr (± 10 min), 4hr (± 10 min), 5hr (± 10 min) and 6 hr (± 10 min).~Serial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:~Systolic blood pressure: > 160 beats/minute Diastolic blood pressure: >100 beats/minute Heart rate: >120 beats/minute" (NCT01747629)
Timeframe: Days 8 and 85

,
Interventionparticipants (Number)
Systolic blood pressure - highDiastolic blood pressure - highHeart rate - high
Albuterol MDPI320
Placebo MDPI220

Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group

Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint. HEENT = head, eyes, ears, nose, throat. (NCT01747629)
Timeframe: Day 1 (Baseline), Day 85

,
Interventionparticipants (Number)
General appearance Normal/NormalGeneral appearance Normal/AbnormalGeneral appearance Abnormal/NormalGeneral appearance Abnormal/AbnormalHEENT Normal/NormalHEENT Normal/AbnormalHEENT Abnormal/NormalHEENT Abnormal/AbnormalChest and Lungs Normal/NormalChest and Lungs Normal/AbnormalChest and Lungs Abnormal/NormalChest and Lungs Abnormal/AbnormalHeart Normal/NormalHeart Normal/AbnormalHeart Abnormal/NormalHeart Abnormal/AbnormalAbdomen Normal/NormalAbdomen Normal/AbnormalAbdomen Abnormal/NormalAbdomen Abnormal/AbnormalMusculoskeletal Normal/NormalMusculoskeletal Normal/AbnormalMusculoskeletal Abnormal/NormalMusculoskeletal Abnormal/AbnormalSkin Normal/NormalSkin Normal/AbnormalSkin Abnormal/NormalSkin Abnormal/AbnormalLymph nodes Normal/NormalLymph nodes Normal/AbnormalLymph nodes Abnormal/NormalLymph nodes Abnormal/AbnormalNeurological Normal/NormalNeurological Normal/AbnormalNeurological Abnormal/NormalNeurological Abnormal/Abnormal
Albuterol MDPI7210152251564370701037110272101631467400074000
Placebo MDPI8100259171676232820018200181101695278300083000

Terminal Plasma Half-life (t1/2) for Albuterol on Days 1 and 8

Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8

Interventionhour (Mean)
Day 1Day 8
Albuterol MDPI4.75.7

Time to Observed Peak Plasma Concentration (Tmax) for Albuterol on Days 1 and 8

Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8

Interventionhour (Median)
Day 1Day 8
Albuterol MDPI0.480.44

Change From Baseline in Blood Pressure Measurements to Week 12 and Week 52

"Participants were seated at least 2 minutes before blood pressure measurements were obtained by either an electronic or manual sphygmomanometer.~Week 12 values represent change from Week 0. Week 52 values represent change from Week 12." (NCT01698320)
Timeframe: Week 0, Week 12 and Week 52

,
InterventionmmHg (Mean)
Systolic BP Week 12 (n=166, 155)Systolic BP Week 52 (n=159, 155)Diastolic BP Week 12 (n=166, 155)Diastolic BP Week 52 (n=159, 155)
Albuterol MDPI-Albuterol MDPI0.20.70.31.0
Placebo MDPI-Albuterol MDPI1.0-0.40.00.2

Change From Baseline in Pulse Measurements to Week 12 and Week 52

"Participants were seated at least 2 minutes before pulse measurements were obtained by radial pulse.~Week 12 values represent change from Week 0. Week 52 values represent change from Week 12." (NCT01698320)
Timeframe: Week 0, Week 12 and Week 52

,
Interventionbeats/minute (Mean)
Pulse Week 12 (n=166, 155)Pulse Week 52 (n=159, 155)
Albuterol MDPI-Albuterol MDPI0.9-0.3
Placebo MDPI-Albuterol MDPI-0.1-0.4

Electrocardiogram (ECG) Results At Weeks 0, 12, and 52

A standard 12-lead ECG was performed at screening, week 12, and week 52 or early termination/discontinuation. The ECG recording methods were centralized and standardized across all study participants. A centralized cardiologist was responsible for providing all ECG interpretations. (NCT01698320)
Timeframe: Weeks 0 (screening visit), 12, and 52

,
Interventionparticipants (Number)
Week 0: NormalWeek 0: Abnormal, not clinically relevantWeek 0: Abnormal, clinically relevantWeek 12: Normal (n=166, 155)Week 12: Abnormal, not clinically relevantWeek 12: Abnormal, clinically relevantWeek 52: Normal (n=152, 161)Week 52: Abnormal, not clinically relevantWeek 52: Abnormal, clinically relevant
Albuterol MDPI-Albuterol MDPI154140140150148130
Placebo MDPI-Albuterol MDPI151190143230138231

Participants With Abnormal and Clinically Relevant Physical Exam Findings at Weeks 0, 12 and 52

"The physical exam was performed by a qualified healthcare professional, and when possible, the same qualified healthcare professional that performed the physical examination at study screening performed all the scheduled physical examinations. Abnormalities and clinical relevance were determined by the qualified healthcare professional.~HEENT = head, eyes, ears, nose, throat" (NCT01698320)
Timeframe: Weeks 0, 12 and 52

,
Interventionparticipants (Number)
General appearance - Week 0 (n=170, 167)General appearance - Week 12 (n=166, 155)General appearance - Week 52 (n=162, 161)HEENT - Week 0 (n=170, 167)HEENT - Week 12 (n=166, 155)HEENT - Week 52 (n=162, 161)Chest and lungs - Week 0 (n=170, 167)Chest and lungs - Week 12 (n=166, 155)Chest and lungs - Week 52 (n=162, 161)Heart - Week 0 (n=170, 167)Heart - Week 12 (n=166, 155)Heart - Week 52 (n=162, 161)Abdomen - Week 0 (n=168, 167)Abdomen - Week 12 (n=166, 155)Abdomen - Week 52 (n=162, 161)Musculoskeletal - Week 0 (n=169, 167)Musculoskeletal - Week 12 (n=166, 155)Musculoskeletal - Week 52 (n=162, 161)Skin - Week 0 (n=169, 167)Skin - Week 12 (n=167, 155)Skin - Week 52 (n=162, 161)Lymph Nodes - Week 0 (n=169, 167)Lymph Nodes - Week 120 (n=166, 155)Lymph Nodes - Week 52 (n=162, 161)Neurological - Week 0 (n=169, 167)Neurological - Week 12 (n=166, 155)Neurological - Week 52 (n=162, 161)Extremities/back - Week 0 (n=169, 167)Extremities/back - Week 12 (n=166, 155)Extremities/back - Week 52 (n=162, 160)
Albuterol MDPI-Albuterol MDPI000012012000001000000000000000
Placebo MDPI-Albuterol MDPI010012013000000000000000000000

Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period)

Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01698320)
Timeframe: Day 1 to Week 12

,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious adverse eventsWithdrawn from treatment due to adverse events
Albuterol MDPI-Albuterol MDPI8435001
Placebo MDPI-Albuterol MDPI10561011

Participants With Adverse Experiences During Weeks 13-52 (Open-Label Period)

Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01698320)
Timeframe: Weeks 13-52

,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious adverse eventsWithdrawn from treatment due to adverse events
Albuterol MDPI-Albuterol MDPI94131042
Placebo MDPI-Albuterol MDPI106122032

Change in Asthma Control Questionnaire (ACQ)

"Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).~The ACQ has six questions regarding symptoms, rescue short-acting β-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled)." (NCT01290874)
Timeframe: from baseline to 12 months

Interventionunits on a scale (Mean)
Tiotropium-0.70
Salmeterol or Formoterol-0.66

Change in Asthma Quality of Life (AQLQ)

"Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).~The AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life." (NCT01290874)
Timeframe: from baseline to 12 months

Interventionunits on a scale (Mean)
Tiotropium1.00
Salmeterol or Formoterol1.02

Change in Asthma Symptom Utility Index (ASUI)

"Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).~The ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.~4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms)." (NCT01290874)
Timeframe: from baseline to 12 months

Interventionunits on a scale (Mean)
Tiotropium0.11
Salmeterol or Formoterol0.10

Change in FEV1

Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months (NCT01290874)
Timeframe: from baseline to 12 months

Interventionliters (Mean)
Tiotropium-0.018
Salmeterol or Formoterol0.003

Change in Rescue Medication Use

Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day. (NCT01290874)
Timeframe: from baseline to 12 months

Interventionunits on a scale (Mean)
Tiotropium-0.92
Salmeterol or Formoterol-0.97

Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)

We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve. (NCT01290874)
Timeframe: evaluated monthly (on average) via questionnaire for 12 months

Interventionevent per person-year (Mean)
Tiotropium0.37
Salmeterol or Formoterol0.42

Absolute Value of Total Discrepancy Size Per Inhaler

"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome is calculated for each inhaler as beginning counter reading minus end counter reading minus patient-recorded number of dose cycles. The total inhaler discrepancy size is an important measure because it provides the most relevant means of ensuring that the inhaler does not exhaust its supply of albuterol before the counter has recorded the labeled 200 doses." (NCT01857323)
Timeframe: Day 1 - Day 50

Interventiondiscrepancies/inhaler (Mean)
Albuterol Spiromax®2.0

Dosing Discrepancies Per 200 Dose Cycles: Count Unknown Dose Cycle

"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter advances (decreases, e.g., 50 to 48) between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is less than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50

Interventiondiscrepancies/200 dose cycles (Number)
Albuterol Spiromax®0.43

Dosing Discrepancies Per 200 Dose Cycles: Count Up Unknown Dose Cycle

"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter counts upwards (number increases, e.g. 50 to 52) rather than downward between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is greater than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50

Interventiondiscrepancies/200 dose cycles (Number)
Albuterol Spiromax®0.17

Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Count Up

"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter reading increases, instead of decreases, after the participant has executed the dose cycle (i.e., the ending counter reading is greater than the beginning counter reading within a dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50

Interventiondiscrepancies/200 dose cycles (Number)
Albuterol Spiromax®2.46

Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count

"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures how often the dose cycle was not counted: the participant completes a full dose cycle (opens the mouthpiece cap, inhales the medication, and closes the mouthpiece cap) but the counter display does not advance (i.e., does not count down) within a dosing session. The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50

Interventiondiscrepancies/200 dose cycles (Number)
Albuterol Spiromax®2.05

Participants With Treatment-Emergent Adverse Events

Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01857323)
Timeframe: Day 1 to Day 50

Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious adverse eventsWithdrawn from study due to adverse event
Albuterol Spiromax®8527021

Asthma Control Questionnaire (Crossover Part of the Study)

Change from baseline after 4 weeks in ACQ score. Worst score - 6(most severe), best score - 0 (no symptoms) (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionScores on scale (Least Squares Mean)
Albuterol HFA-0.25
Combivent CFC-0.25

FEV1 AUC0-6 Response (Crossover Part of the Study)

Change from baseline after 4 weeks in Forced Expiratory Volume Area Under (FEV1 AUC) the Curve from 0 to 6 hours. (NCT00818454)
Timeframe: Test day baseline and test day FEV1 AUC 0-6, after 4 weeks

Interventionliters (Least Squares Mean)
Albuterol HFA0.167
Combivent CFC0.252

FEV1 AUC0-6 Response (Parallel Part of the Study)

Change from baseline after 4 weeks in Forced Expiratory Volume Area Under the Curve from 0 to 6 hours (NCT00818454)
Timeframe: Test day baseline and test day FEV1 AUC 0-6, after 4 weeks

Interventionliters (Least Squares Mean)
Placebo Respimat0.041
Combivent Respimat0.236

Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)

Change from baseline after 4 weeks in Mini-AQLQ score. Worst score - 1 (most severe), best score - 7 (less severe) (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionScores on scale (Least Squares Mean)
Albuterol HFA0.150
Combivent CFC0.220

Peak FEV1 Response

Change from baseline after 4 weeks in peak Forced Expiratory Volume response (NCT00818454)
Timeframe: Test day baseline and test day peak FEV1, after 4 weeks

Interventionliters (Least Squares Mean)
Placebo Respimat0.199
Combivent Respimat0.412

Peak FEV1 Response (Crossover Part of the Study)

Change from baseline after 4 weeks in peak Forced Expiratory Volume response (NCT00818454)
Timeframe: Test day baseline and test day peak FEV1, after 4 weeks

Interventionliters (Least Squares Mean)
Albuterol HFA0.357
Combivent CFC0.434

Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)

Change from baseline in weekly mean of puffs of open-label albuterol used during day (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionPuffs (Least Squares Mean)
Albuterol HFA-2.24
Combivent CFC-2.28

Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)

Change from baseline in weekly mean of puffs of open-label albuterol used during night (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionPuffs (Least Squares Mean)
Albuterol HFA-0.92
Combivent CFC-0.93

Puffs Study Medication Used During Day (Crossover Part of the Study)

Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during day (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionPuffs (Least Squares Mean)
Albuterol HFA-0.49
Combivent CFC-0.53

Puffs Study Medication Used During Night (Crossover Part of the Study)

Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during night (NCT00818454)
Timeframe: Baseline, 4 weeks

InterventionPuffs (Least Squares Mean)
Albuterol HFA-0.10
Combivent CFC-0.12

Baseline-Adjusted Area-Under-The- Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose (FEV1 AUC0-6)

FEV1 AUC0-6 was calculated using the linear trapezoidal rule, and baseline adjustment was made by subtracting the average of the 2 pre-dose FEV1 values from each post-dose FEV1 determination. (NCT01899144)
Timeframe: Treatment visits 1-5 (approximately days 1, 6, 11, 16, and 21); -35 and -5 minutes prior to dosing and 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±5), 120 (±5), 180 (±5), 240 (±5), 300 (±5), and 360 (±5) minutes after the completion of study drug administrati

InterventionL*hour (Mean)
Albuterol Spiromax 90 mcg0.88
Albuterol Spiromax 180 mcg0.93
ProAir HFA 90 mcg0.74
ProAir HFA 180 mcg0.93
Placebo0.48

Baseline-Adjusted Area-Under-The-Percent-Predicted Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose

"Percent predicted FEV1: measured FEV1 as a percent of the predicted values for the patients of similar characteristics. Predicted FEV1 values were computed and adjusted for age, height, and gender for patients aged 4-5 years (Eigen et al 2001) and for patients aged 6-11 years (Quanjer et al 1995) using ATS/European Thoracic Society (ERS) criteria applicable to pediatric patients (ATS/ERS 2007).~The percent predicted FEV1 (PPFEV1) area under the curve (AUC)0-6 was calculated using the linear trapezoidal rule, and baseline adjustment was made by subtracting the average of the 2 pre-dose PPFEV1 values from each post-dose PPFEV1 determination." (NCT01899144)
Timeframe: Treatment visits 1-5 (approximately days 1, 6, 11, 16, and 21); -35 and -5 minutes prior to dosing and 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±5), 120 (±5), 180 (±5), 240 (±5), 300 (±5), and 360 (±5) minutes after the completion of study drug administrati

Intervention%predicted FEV1*hour (Mean)
Albuterol Spiromax 90 mcg46.6
Albuterol Spiromax 180 mcg48.0
ProAir HFA 90 mcg37.9
ProAir HFA 180 mcg49.1
Placebo25.4

Participants With Treatment-Emergent Adverse Events

"Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).~Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes." (NCT01899144)
Timeframe: Day 1 up to Day 35

,,,,
Interventionparticipants (Number)
Treatment-related AESevere TEAERelated TEAEDeathSerious AETEAE leading to withdrawal
Albuterol Spiromax 180 mcg200000
Albuterol Spiromax 90 mcg000000
Placebo100000
ProAir HFA 180 mcg100000
ProAir HFA 90 mcg500000

Baseline Adjusted Peak Expiratory Flow (PEF) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks

Serial PEF measurements were obtained via spirometry. PEF measures for purpose of serial PEF assessment (pre and postdose) were collected from the spirometer assessed PEF, utilizing the values from the efforts selected based on the highest of 3 acceptable FEV1 maneuvers. (NCT02126839)
Timeframe: 30 ±5 and 5 ±2 minutes prior to dosing, and at 5 ±2, 15 ±5, 30 ±5, 45 ±5, 60 ±10, 120 ±10, 240 ±10, and 360 ±10 minutes after completion of dosing on Days 1 and 22

InterventionLiters/min*hour (Least Squares Mean)
Placebo MDPI QID71.52
Albuterol MDPI 180 mcg QID147.85

Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks

Following measurement of the baseline FEV1 and dose administration on Days 1 and 22, FEV1 values (highest of 3 acceptable maneuvers) will be obtained at 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±10), 120 (±10), 240 (±10), and 360 (±10) minutes after the completion of dosing. Predicted FEV1 values were computed and adjusted for age, height, and gender according to Eigen et al (Eigen et al 2001) for participants 4 to 5 years of age and to Quanjer et al (Quanjer et al 1995) for participants aged 6 to 11 years using ATS criteria (American Thoracic Society/European Respiratory Society Statement 2007). (NCT02126839)
Timeframe: 30 ±5 and 5 ±2 minutes prior to dosing, and at 5 ±2, 15 ±5, 30 ±5, 45 ±5, 60 ±10, 120 ±10, 240 ±10, and 360 ±10 minutes after completion of dosing on Days 1 and 22

Intervention% predicted FEV1/hour (Least Squares Mean)
Placebo MDPI QID18.71
Albuterol MDPI 180 mcg QID43.73

Summary of Participants With Adverse Events

"Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).~Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes." (NCT02126839)
Timeframe: 6 Months

,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreatment-related adverse eventDeathsOther serious AEWithdrawn from study due to AE
Albuterol MDPI 180 mcg QID2100000
Placebo MDPI QID2100000

Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.

The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period. (NCT01606306)
Timeframe: The last 14 weeks of each 16-week treatment period

Interventionprobability (Number)
Non-differential respondersResponded best to daily ICSResponded best to daily LTRAResponded best to as-needed ICS
All Evaluable Participants.26.40.18.16

Inhaler Use Correctness

"This is an observational study, the aim is to record a variety of MDI usage techniques performed by patients. The technique is scored out of 7 for the following 7 steps:~Shaking (0 = not shaken, 1 = shaken)~Coordination (0 = MDI actuated before inhalation start, 1 = MDI actuated after inhalation start)~Flow rate (0 = mean inspiratory flow rate <30L/min or greater than 60L/min, 1 = mean inspiratory flow rate between 30-60L/min)~Duration of inhalation (0 = duration of inhalation <3 sec, 1 = duration of inhalation >=3sec)~Orientation of inhaler (0 = inhaler not upright = > 30° from the vertical position, 1 = inhaler upright = within 30° from the vertical position)~Number of exhalation (0 = exhalation during inhaler use, 1 = no exhalations)~Single Actuation (0 = less than 0 or more than 1 inhaler actuation, 1 = exactly 1 inhaler actuation)~The total score is a minimum of 0 correct steps if all the steps are incorrect to a maximum of 7 correct steps." (NCT02447575)
Timeframe: Single event- Outcome measured per inhaler puff, during the single clinic visit.

Interventioncorrect steps (Mean)
MDI Use Evaluation3.52

Change in Pulmonary Asthma Score (PAS)

The primary outcome was the change in asthma severity as determined by change in Pulmonary Asthma Score (PAS) before and after administration of intervention (or control). The same trained, blinded physician assessor, who was not involved in the care of the patient, assessed PAS scores for study subjects before intervention (or control), and 15 minutes after completion of administration. The PAS is a pediatric asthma severity scoring system adapted from previously validated scores, and includes measures of respiratory rate, oxygen saturation, auscultory findings, retractions, and dyspnea. Values from each category are summed producing a total score between 5 and 15. Total scores < 7 correspond with mild asthma exacerbations, while scores ≥ 7 and < 12 indicate moderate asthma, and scores ≥12 to 15 indicate severe asthma. The primary outcome was determined by subtracting the post-intervention score from the pre-intervention score. (NCT02494076)
Timeframe: 0-30 minutes

Interventionmean PAS score (Mean)
EzPAP0.9
Standard Care0.4

Rate of Inpatient Hospitalization

Number of patients in each group requiring hospital admission (NCT02494076)
Timeframe: After intervention or control and until follow-up phone call 72 hours after disposition

InterventionParticipants (Count of Participants)
EzPAP10
Standard Care13

Number of Participants Requiring Second Line Therapies Including Continuous Albuterol, Subcutaneous Terbutaline, IV Magnesium and Supplemental Oxygen After Administration of Intervention or Control

Second line therapies include: continuous albuterol, intravenous magnesium sulfate, subcutaneous or intravenous terbutaline, non-invasive ventilation (BiPAP or CPAP), and supplemental oxygen. The need for these second line therapies will be assessed by the child's treating team in the Emergency Department. (NCT02494076)
Timeframe: participants will be followed for the duration of ED stay, an expected average of 6-8 hours

,
InterventionParticipants (Count of Participants)
Continuous albuterolSubcutaneous or intravenous terbutalineIntravenous magnesiumSupplemental oxygen
EzPAP11012
Standard Care15137

Effect Maximum (Emax)

Maximum percentage of predicted FEV1 effect (NCT00940927)
Timeframe: 15 minutes after each dose

Interventionpercentage of predicted (Number)
Albuterol24.0

Effective Dose 50% (ED50)

ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol (NCT00940927)
Timeframe: 15 minutes after each dose

Interventionug (Number)
Albuterol141

Association of Smoke Exposure During Pregnancy and Neonatal Response to Albuterol

Mothers who smoked cigarettes during pregnancy and the rate of albuterol response of their infants (NCT02447250)
Timeframe: Smoking and second hand smoke exposure history will be obtained at enrollment. Albuterol response will be obtained within one week.

Interventionparticipants (Number)
albuterol responders of mothers who smokedalbuterol responders of non-smoker mothers %
Single Arm: Varied Albuterol Dose Response46

Birth Weight of Albuterol Responders vs Non Responders

birth weight in grams of each subject was recorded at time of enrollment (NCT02447250)
Timeframe: within one week of entering study

Interventiongrams (Mean)
albuterol respondersalbuterol non responders
Single Arm: Varied Albuterol Dose Response847.21147.7

Change in Respiratory Resistance

The primary outcome is the percentage of subjects who show a positive response to each dose of albuterol. A positive response is defined as a greater than or equal to 10% decrease in respiratory resistance (Rrs). The change in RRs was measured at baseline and again after each dose of albuterol. All measurements were taken within a 7 day time frame for each subject such that each subject would have up to 3 results measured during a 7 day period, if he/she were able to complete three sets of PFTs according to study protocol. The change in Rrs was calculated by subtracting the baseline Rrs from the post-albuterol Rrs. (NCT02447250)
Timeframe: Within one week of performing pulmonary function tests

Interventioncm h2o/mL/sec (Mean)
dose 1dose 2dose 3
Single Arm: Varied Albuterol Dose Response0.0110.0060.014

Etiology of Preterm Delivery

Reason for each subject's preterm delivery was classified as either preterm labor or delivery for maternal indications (eg pre-eclampsia). (NCT02447250)
Timeframe: within one week of entering study

InterventionParticipants (Count of Participants)
preterm labor, responsive to albuterolmaternal indicated delivery, responsive to albuter
Single Arm: Varied Albuterol Dose Response46

Family History of Asthma and Likelihood to Respond to Albuterol

Family history was obtained from verbal history by subject's mother at time of enrollment in study. A positive family history was noted if a first degree relative of the subject (infant) had a diagnosis of asthma. (NCT02447250)
Timeframe: History collected at enrollment, albuterol response assessed within one week

Interventionparticipants (Number)
family hx of asthma, respond to albuterolno fam hx asthma, respond to albuterol
Single Arm: Varied Albuterol Dose Response19

Gestational Age at Birth

Average gestational age (GA) in weeks at birth for subjects who responded to albuterol versus subjects without a positive response (NCT02447250)
Timeframe: within one week of entering study

Interventionweeks (Mean)
birth GA albuterol responders, weeksbirth GA albuterol non responders
Single Arm: Varied Albuterol Dose Response26.728.5

Maternal BMI at Time of Pregnancy and Likelihood of Positive Response to Albuterol

Maternal BMI will be obtained from her medial record, and she will be asked about weight gain during pregnancy at time of enrollment. Results will be compared for infants born to women with a normal BMI vs. those with obese BMI (>30). (NCT02447250)
Timeframe: Maternal information collected at enrollment; albuterol response assessed within one week

Interventionkg/m^2 (Mean)
mean BMI mothers of albuterol-responders , any dosmean BMI mothers of albuterol non-responders
Single Arm: Varied Albuterol Dose Response27.427.3

Number of Participants With Positive Response at Different Albuterol Doses

Compare number of subjects who have a positive response (greater than or equal to 10% decrease in respiratory resistance) to each dose of albuterol (NCT02447250)
Timeframe: Data collected 15 minutes after dose in each session. Study includes 3 sessions within a 7 day period.

Interventionparticipants (Number)
positive Rrs response at 180 mcg albuterolpositive Rrs response at 270 mcg albuterolpositive Rrs response at 360 mcg albuterol
Single Arm: Varied Albuterol Dose Response644

ED/Hospital Admission, Early vs Late Starting Clinics (During the 3 Months When Late Starting Clinics Have Not Used the e-AT)

ED and hospital admission evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters. Statistical analysis was not conducted since the numbers of ED/Hospital admissions was very small (2 and 0) in both group (during the 3 months study window). Here we used intent-to-treat analysis and included the overall 325 (rather than 318 used in analysis of other outcomes) participants. (NCT02409277)
Timeframe: 3-month period prior to the late clinics starting the e-AT

Interventionnumber of ED/Hospital admission (Number)
Early Starting Clinics2
Late Starting Clinics0

ED/Hospital Admission, Early vs. Late Patients

ED and hospital admission was evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters. Analyses (at the patient level) comparing the rates of ED/hospital admissions between a 1 year period following initiation of the e-AT for those in both standard and intensive e-AT groups who were enrolled early during the study period (patients with enrollment dates between January 2014 and December 2014) to rates of ED/hospital admissions for patients who started the e-AT later (patients with enrollment dates between January 2015 and December 2015), during a 1-year period prior to the late patient starting the e-AT. (NCT02409277)
Timeframe: 1 year following e-AT use for early and late starting patients

Interventionnumber of ED/Hospital admission (Mean)
Early Starting Patients0.10
Late Starting Patients0.18

ED/Hospital Admissions, e-AT Overall (Pre vs. Post e-AT Use Within Subjects That Received the e-AT Intervention)

ED/hospital re-admission data were compared between prior and post 12 month period (for both intensive and standard interventions overall) when e-AT was administered. (NCT02409277)
Timeframe: 1 year

Interventionnumber of ED/hospital admission (Mean)
Prior e-AT Use0.22
Post e-AT Use0.09

Oral Steroid Use, Early vs Late Starting Clinics (During the 3 Months When Late Starting Clinics Have Not Started the e-AT)

Use of oral steroid was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Statistical analysis was not conducted since the numbers of ED/Hospital admissions was very small (2 and 0) in both group (during the 3 months study window). Here we used intent-to-treat analysis and included the overall 325 (rather than 318 used in analysis of other outcomes) participants (NCT02409277)
Timeframe: 3 month period prior to the late clinics starting the e-AT

Interventionnumber of oral steroid use (Number)
Early Patients4
Late Patients0

Oral Steroid Use, Early vs. Late Patients

"Oral steroid use data was collected through Intermountain Healthcare claims data and clinics prescribing oral steroid.~Oral steroid use was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Analyses (at the patient level) comparing the rates oral steroid use between a 1 year period following initiation of the e-AT for those in both standard and intensive e-AT groups who were enrolled early during the study period (patients with enrollment dates between January 2014 and December 2014) to rates of oral steroid use for patients who started the e-AT later (patients with enrollment dates between January 2015 and December 2015), during a 1-year period prior to the late patient starting the e-AT." (NCT02409277)
Timeframe: 1 year

Interventionnumber of oral steroid use (Mean)
Early Starting Patients0.53
Late Starting Patients0.53

Use of Oral Steroid, Overall

Use of oral steroid was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Comparison was made between prior and post e-AT (both interventions) overall. (NCT02409277)
Timeframe: 1 year

Interventionnumber of oral steroid use (Mean)
Prior e-AT Use0.74
Post e-AT Use0.51

Asthma Control Change, Standard vs Intensive

Asthma control information was collected weekly through the e-AT for 1 year. Asthma control was measured using the Asthma Control Test (ACT), which had a score ranging from 5 to 25, with 5 being poor control and 25 being optimal control. The analysis compared the mean change in scores from baseline to quarters 1, 2, 3, and 4. (NCT02409277)
Timeframe: Average baseline ACT scores compared to average ACT scores at quarter 1, 2, 3 and 4, and between Standard vs. Intensive

,
Interventionmean score (points) change (Mean)
Qtr 1 vs baselineQtr 2 vs baselineQtr 3 vs baselineQtr 4 vs baseline
Intensive e-AT Intervention1.782.182.183.30
Standard e-AT Intervention2.553.093.263.33

Child Asthma Control Overall (Comparing Change of Asthma Control From Baseline to Quarter 1, Quarter 2, Quarter 3 and Quarter 4)

"Asthma control information was collected through the e-AT, comparing change of asthma control from baseline to quarter 1, quarter 2, quarter 3 and quarter 4.~Asthma control was measured using the Asthma Control Test (ACT), which scale ranged from 5-25, with 5=poorly controlled and 25=well controlled.~Each patient submitted an ACT score weekly for 12 months." (NCT02409277)
Timeframe: baseline ACT scores were compared to quarters 1, 2, 3, 4.

InterventionScore (points) ranging from 5-25 (Mean)
BaselineQuarter 1Quarter 2Quarter 3Quarter 4
All e-AT Users18.8522.2822.8222.8122.97

Child Interrupted/Missed School Days, Overall (Longitudinal Changes Overtime)

Number of child interrupted/missed school days were collected longitudinally (information includes mean at baseline, 3, 6, and 12 months in the study). (NCT02409277)
Timeframe: 1 year

InterventionNumber of days (interrupted or missed) (Mean)
Baseline3 Months Follow-up6 Months Follow-up12 Months Follow-up
All e-AT Users1.910.800.520.79

Child Interrupted/Missed School Days, Standard vs Intensive

"Number of child interrupted/missed school days were collected longitudinally at the same time as collecting the QOL scores: baseline, 3, 6, and 12 months in the study.~Number of child interrupted/missed school days during the 3 months prior to baseline, 3, 6, and 12 months follow-up surveys were counted." (NCT02409277)
Timeframe: Interrupted/missed school days were collected at baseline, 3, 6, and 12 month follow-ups

,
InterventionNumber of interrupted/missed school days (Number)
Baseline3 Months Follow-up6 Months Follow-up12 Months Follow-up
Intensive e-AT Intervention129603037
Standard e-AT Intervention43511487129

ED/Hospital Admissions, e-AT vs Usual Care

Non randomized comparison of ED and hospital admissions between e-AT interventions (both intensive and standard) compared usual care (matched control patients drawn from non-participating clinics) in the prior vs. post e-AT intervention time periods. (NCT02409277)
Timeframe: 1 year

,
InterventionRate per 1000-days (Mean)
PriorPost
e-AT Intervention0.590.24
Usual Care (Non-randomized Cohort)0.230.24

Emergency Department (ED)/Hospitalization, Standard vs Intensive

"ED and hospital admissions were evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters.~We evaluated number ED and hospital admissions 12 months prior to intervention and 12 months post intervention" (NCT02409277)
Timeframe: Change in 1 year ED/hospital admission between 12-month prior and 12 month post e-AT use

,
InterventionNumber of ED/hospital admissions (Number)
PriorPost
Intensive e-AT Intervention188
Standard e-AT Intervention5321

Oral Steroid Use, e-AT vs Usual Care

Non randomized comparison of use of oral steroid between e-AT interventions (both intensive and standard) compared usual care (matched control patients drawn from non-participating clinics) in the prior vs. post e-AT intervention time periods. (NCT02409277)
Timeframe: 1 year

,
InterventionRate per 1000-days (Mean)
PriorPost
e-AT Intervention2.021.41
Usual Care (Non-randomized Cohort)1.871.99

Parent Interrupted/Missed Work Days, Overall (Longitudinal Change Overtime)

Number of parent interrupted/missed work days were collected longitudinally at the same time as collecting the QOL scores: Information includes mean at baseline, 3, 6, and 12 months in the study. (NCT02409277)
Timeframe: 1 year

InterventionNumber of days (interrupted or missed) (Mean)
Baseline3 Months Follow-up6 Months Follow-Up12 Months Follow-up
All e-AT Users0.720.270.250.20

Parent Interrupted/Missed Work Days, Standard vs Intensive

"Number of parent interrupted/missed work days were collected longitudinally at the same time as collecting the QOL scores: baseline, 3, 6, and 12 months in the study.~Number of parent interrupted/missed work days during the 3 months prior to baseline, 3, 6, and 12 months follow-up surveys were counted." (NCT02409277)
Timeframe: Interrupted/missed work days were measured baseline 3, 6, and 12 months

,
InterventionNumber of interrupted/missed work days (Number)
Baseline3 Months Follow-up6 Months Follow-up12 Months Follow-up
Intensive e-AT Intervention56141518
Standard e-AT Intervention176444223

Parent Satisfaction With Care, Overall (Change Overtime From Baseline to 12 Months)

"Parent satisfaction data was collected using a modified version of patient satisfaction survey developed and validated by Varni et al. at baseline and at 12 months in the study.~The scale ranged from 1-5, with 1=Very Dissatisfied and 5=Very Satisfied." (NCT02409277)
Timeframe: Satisfaction at 1 year following e-AT use was compared to baseline satisfaction scores

Interventionunits (points) on a scale (from 1-5) (Mean)
Baseline12 months Follow-up
All e-AT Users4.664.46

Parent Satisfaction With Care, Standard vs Intensive

"Parent satisfaction data was collected at baseline and at 12 months in the study.~The scale ranges from 1-5, with 1 being Very Dissatisfied and 5 Very Satisfied." (NCT02409277)
Timeframe: Changes in satisfaction was compared between 12 month follow-up and baseline satisfaction across Standard and Intensive interventions

,
Interventionunits (points) on a scale (from 1-5) (Mean)
Baseline12 months Follow-up
Intensive e-AT Intervention4.634.54
Standard e-AT Intervention4.634.38

Patient Quality of Life (QOL), Compared Mean QOL Change From Baseline at Each Follow-up Assessment Between the Clinics Assigned to the Intensive and Standard e-AT Interventions

"Patient QOL and missed school days was collected longitudinally through surveys of the study population defined above. The QOL questionnaire included the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF) and was used at baseline (at first assessment), 3, 6, and 12 months in the study.~Items within QOL scales are summed and linearly transformed from 0 to 100, with higher scores indicating better functioning." (NCT02409277)
Timeframe: Quality of Life assessed at baseline, then compared to 3 months, 6 months, and 12 months after intervention.

,
InterventionUnits on a scale (Mean)
3 Months Follow-up vs Baseline6 Months Follow-up compared vs Baseline12 Months Follow-up vs Baseline
Intensive e-AT Intervention7.645.789.29
Standard e-AT Intervention8.558.379.39

Patient Quality of Life (QOL), Overall Longitudinal Change (From Baseline) Within All Subjects (Who Received the e-AT Intervention)

Patient QOL and missed school days was collected longitudinally through surveys of the study population defined above. The QOL questionnaire included the Integrated Therapeutics Group Child Asthma Short Form - ITG-CASF and was used at baseline (at first assessment), 3, 6, and 12 months in the study. Items within scales are summed and linearly transformed from 0 to 100, with higher scores indicating better functioning. (NCT02409277)
Timeframe: Average Baseline QOL was compared to QOL scores at 3, 6 and 12 month follow-up QOL

Interventionunits (points) on a scale, range 0-100 (Mean)
Baseline3 Months6 Months12 Months
All e-AT Users79.0790.9890.0490.64

Asthma Control Questionnaire (ACQ)

Change between placebo salmeterol and active salmeterol for ACQ, where ACQ ranges from 0 (best asthma control) to 6 (worst asthma control). (NCT00200967)
Timeframe: Clinic visits at weeks 0 and 18 of each treatment period

Interventionunits on a scale (Least Squares Mean)
B16 Arg/Arg0.13
B16 Gly/Gly0.11

Asthma Symptoms

Change between placebo salmeterol and active salmeterol for asthma symptoms (0=absent, 1=mild, 2=moderate, 3=severe). (NCT00200967)
Timeframe: Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionunits on a scale (Mean)
B16 Arg/Arg0.04
B16 Gly/Gly0.00

Evening (PM) Peak Expiratory Flow (PEF) Rate

Change between placebo salmeterol and active salmeterol for PM PEF rate (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionliters per minute (Least Squares Mean)
B16 Arg/Arg-25
B16 Gly/Gly-24

Exhaled Breath Condensate (EBC)

Change between placebo salmeterol and active salmeterol for EBC (NCT00200967)
Timeframe: Clinic visits at weeks 0, 10, and 18 of each treatment period

InterventionpH (Least Squares Mean)
B16 Arg/Arg-0.10
B16 Gly/Gly-0.03

Exhaled Nitric Oxide (eNO)

Change between placebo salmeterol and active salmeterol for eNO (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionparts per billion (Geometric Mean)
B16 Arg/Arg0.12
B16 Gly/Gly-0.02

Methacholine Provocative Concentration 20 (PC20)

Change between placebo salmeterol and active salmeterol for methacholine PC20 (NCT00200967)
Timeframe: Clinic visits at weeks 0 and 18 of each treatment period

Interventionmilligrams per milliliter (Geometric Mean)
B16 Arg/Arg0.06
B16 Gly/Gly-1.27

Morning (AM) Peak Expiratory Flow (PEF) Rate

Change between placebo salmeterol and active salmeterol for AM PEF rate (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionliters per minute (Least Squares Mean)
B16 Arg/Arg-21
B16 Gly/Gly-22

Peak Expiratory Flow (PEF) Variability

Change between placebo salmeterol and active salmeterol for PEF variability, where PEF variability is defined as 100% x (PM PEF - AM PEF)/(PM PEF) (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionpercentage (Least Squares Mean)
B16 Arg/Arg0.2
B16 Gly/Gly0.7

Rescue Medication (Ipratropium and Albuterol) Use

Change between placebo salmeterol and active salmeterol for rescue medication use (NCT00200967)
Timeframe: Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionpuffs per day (Mean)
B16 Arg/Arg0.2
B16 Gly/Gly0.0

Spirometry Forced Expiratory Volume in One Second (FEV1), Pre-bronchodilator

Change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionliters (Least Squares Mean)
B16 Arg/Arg-0.08
B16 Gly/Gly-0.04

Spirometry Forced Vital Capacity (FVC), Pre-bronchodilator

Change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionliters (Least Squares Mean)
B16 Arg/Arg-0.04
B16 Gly/Gly-0.03

Spirometry Peak Expiratory Flow (PEF) Rate, Pre-bronchodilator

Change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period

Interventionliters per minute (Least Squares Mean)
B16 Arg/Arg-17
B16 Gly/Gly-17

Change From Baseline in Asthma Quality of Life

Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionunits on a scale (Mean)
2xICS0.2
1xICS + LABA0.3
1xICS + LTRA0.3

Change From Baseline in the Asthma Control Test (ACT)

The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionunits on a scale (Mean)
2xICS1.49
1xICS + LABA1.87
1xICS + LTRA1.69

Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS2.84
1xICS + LABA4.87
1xICS + LTRA2.29

Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz

Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

InterventionkiloPascals per liters per second (Mean)
2xICS-0.08
1xICS + LABA-0.09
1xICS + LTRA-0.06

Change From Baseline in the Logarithm Base 2 of the Methacholine PC20

The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventiondoubling dilutions (Mean)
2xICS1.11
1xICS + LABA1.20
1xICS + LTRA1.00

Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS4.44
1xICS + LABA6.26
1xICS + LTRA4.04

Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionnatural logarithm of parts per billion (Mean)
2xICS-0.04
1xICS + LABA-0.05
1xICS + LTRA-0.02

Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability

PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS2.09
1xICS + LABA1.61
1xICS + LTRA1.72

Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS-0.2
1xICS + LABA-1.2
1xICS + LTRA-0.8

Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionratio (Mean)
2xICS0.98
1xICS + LABA2.13
1xICS + LTRA0.55

Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS0.26
1xICS + LABA1.07
1xICS + LTRA-0.84

Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted

(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

Interventionpercentage points (Mean)
2xICS-1.00
1xICS + LABA-1.58
1xICS + LTRA-1.56

Number of Participants With Asthma Exacerbations

An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

InterventionParticipants (Count of Participants)
2xICS49
1xICS + LABA35
1xICS + LTRA37

The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.

One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period

InterventionParticipants (Number)
All Participants161

Area Under the Curve for %-Change From Pre-exercise Baseline FEV1 in Liters (L), From 0 to 20 Minutes (AUC(0-20))

The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the area under the curve from 0 to 20 minutes (AUC0-20) for FEV1 percent change from pre-exercise baseline. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)

InterventionPercent times Minutes (Least Squares Mean)
Montelukast116.04
Salmeterol168.75

Average (Avg) %-Change in FEV1 After First Beta (β)-Agonist Use and Prior to Second β-agonist Use

The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the average percent change in FEV1 after first β-agonist intake and prior to second β-agonist use. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)

InterventionPercent change from baseline (Least Squares Mean)
Montelukast6.51
Salmeterol2.72

Maximum FEV1 % Predicted Following First Beta-agonist Use

The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on short-acting β-agonist bronchodilation as measured by the maximum FEV1 percent predicted following first β-agonist use. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)

InterventionPercent of predicted value (Least Squares Mean)
Montelukast104.03
Salmeterol99.92

Maximum Post-exercise Percent (%) Fall in FEV1

The effect of four weeks of treatment with oral montelukast plus inhaled fluticasone, and inhaled salmeterol plus inhaled fluticasone on EIB as measured by the maximum post-exercise percent fall (relative to pre-exercise baseline) in FEV1. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)

InterventionPercent change from baseline (Least Squares Mean)
Montelukast10.57
Salmeterol13.82

Time to Recovery to Within 5% of Baseline FEV1

The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the time to recovery (to within 5 percent of the pre-exercise baseline FEV1) following a standardized exercise challenge. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)

Interventionminutes (Median)
Montelukast5.9
Salmeterol11.1

Geometric Means of Nitric Oxide (NO) at Week 26

Geometric mean values of NO at week 26 were compared using ANCOVA with adjustment for baseline value of NO, age, gender and center. Analysis of covariance (ANCOVA) is a general linear model with one continuous outcome variable (quantitative) and one or more factor variables. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionparts per billion (Geometric Mean)
Salmeterol/FP 50/100 mcg Plus Placebo8.6
FP 200 mcg10.0

Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 26

Change from Baseline was calculated as the Week 26 value minus the Baseline value. Forced vital capacity is defined as the maximum volume of air that can be forcibly expired from the lungs and is calculated by use of spirometry. The spirometry test is performed by using a device called a spirometer, which measures the amount of air one can blow out maximally. Generally, the participant is asked to take the deepest breath they can, and then exhale into the sensor as hard as possible, for as long as possible. The test is normally repeated three times to ensure reproducibility. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionliters (Mean)
Salmeterol/FP 50/100 mcg Plus Placebo2.28
FP 200 mcg2.28

Mean Change From Baseline in Midexpiratory Flow (MEF 50) at Week 26

Change from Baseline was calculated as the Week 26 value minus the Baseline value. MEF 50 is defined as maximum expiratory flow rate at 50% of vital capacity. Vital capacity is the maximum amount of air that a person can expel from the lungs after first filling the lungs to their maximum extent. Midexpiratory flow was calculated by use of spirometry. The test is normally repeated at least three times in order to ensure reproducibility. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionliters/second (Mean)
Salmeterol/FP 50/100 mcg Plus Placebo2.28
FP 200 mcg2.19

Mean Change From Baseline in Percentage Predicted Forced Expiratory Volume in One Second (FEV1) at Week 26

Change from Baseline was calculated as the Week 26 value minus the Baseline value. The percentage predicted FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath and is corrected for the FEV1 value corresponding with the same age. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionpercent predicted change (Mean)
Salmeterol/FP 50/100 mcg Plus Placebo102.5
FP 200 mcg103.0

Mean Change From Baseline in Provocation Dose (PD20) Causing a 20% Fall in FEV1 at Week 26

PD20 was calculated by using increasing dosages of methacholine. The dosage that caused a 20% fall in FEV1 was used for analysis. The presented data are ratios (month 6/Baseline) of geometric mean PD20 values. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionratio (Log Mean)
Salmeterol/FP 50/100 mcg Plus Placebo2.7
FP 200 mcg1.5

Number of Asthma Exacerbations Per Treatment Group at Week 26

An exacerbation is defined as a worsening of the asthma complaints (commonly referred to as an asthma attack) and is reported by the participant experiencing the event. An exacerbation was verified by the use of asthma rescue medication. (NCT00197106)
Timeframe: Week 26

Interventionnumber of exacerbations (Number)
Salmeterol/FP 50/100 mcg Plus Placebo10
FP 200 mcg7

Percent Change From Baseline in RINT Measurements at Week 26

Change from Baseline was calculated as the Week 26 value minus the Baseline value. Interrupter respiratory resistance (RINT) measurements were calculated by a combined analysis for relation between change from baseline and occurrence of the endpoint. RINT is a technique that is used for evaluating lung function in poorly collaborating patients (e.g., small children). The measurement is performed during tidal breathing (normal breathing) instead of during maximal expiration, as is done by a spirometry test. (NCT00197106)
Timeframe: Baseline and Week 26

Interventionpercent (Number)
Salmeterol/FP 50/100 mcg Plus Placebo-9.1
FP 200 mcg-9.9

Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period

Asthma symptom-free days are defined as days (24 hour period) with no symptoms, as recorded in the participant's diary. (NCT00197106)
Timeframe: Last 10 weeks of the treatment period (Weeks 16-26)

Interventionpercentage of days (Mean)
Salmeterol/FP 50/100 mcg Plus Placebo50.45
FP 200 mcg49.75

Percentage of Symptom-free Days During the Entire Treatment Period

Asthma symptom-free days are defined as days (24 hour period) with no symptoms, as recorded in the participant's diary (NCT00197106)
Timeframe: Baseline to Week 26

,
Interventionpercentage of days (Mean)
Baseline0-6 weeks6-16 weeks16-26 weeks
FP 200 mcg23.0631.5045.2449.75
Salmeterol/FP 50/100 mcg Plus Placebo22.7831.5844.6050.45

Treatment Failure

The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety. (NCT00156819)
Timeframe: 16 weeks

Interventionparticipants (Number)
Fluticasone34
Montelukast50
Fluticasone Plus Salmeterol33

12-lead ECG Parameters - Heart Rate - Change From Baseline

"12-lead electrocardiogram (12-lead ECG) parameter - heart rate (HR) was measured at baseline (Day 1) and Week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;~bpm=Beats per minute;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionbpm (Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.6
Treatment B (CHF 718 pMDI 400 µg TDD)0.2
Treatment C (CHF 718 pMDI 800 µg TDD)0.4
Treatment D (Placebo)1.2
Treatment E (QVAR^®, 320 µg TDD)-0.4

24-hr Creatinine - Change From Baseline.

"24-hr Creatinine - Change From Baseline.~For the evaluation of the 24-hr creatinine excretion, 24-hour urine sample were collected. Creatinine was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionumol/mol (Median)
Treatment A (CHF 718 pMDI 100 µg TDD)0.00
Treatment B (CHF 718 pMDI 400 µg TDD)0.00
Treatment C (CHF 718 pMDI 800 µg TDD)0.00
Treatment D (Placebo)0.00
Treatment E (QVAR^®, 320 µg TDD)0.00

24-hr Urine Free Cortisol - Change From Baseline

"24-hr Urinary Free Cortisol - Change From Baseline.~For the evaluation of the 24-hr Urine-Free cortisol excretion, 24-hour urine samples were collected. Urine-free cortisol was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionnmol/day (Median)
Treatment A (CHF 718 pMDI 100 µg TDD)-3.60
Treatment B (CHF 718 pMDI 400 µg TDD)-5.35
Treatment C (CHF 718 pMDI 800 µg TDD)-4.10
Treatment D (Placebo)1.40
Treatment E (QVAR^®, 320 µg TDD)-3.50

Pre-dose Morning FEV1 at Week 4 - Change From Baseline

"Change from baseline in pre-dose morning FEV1 at Week 4.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4

InterventionLitres (Least Squares Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.021
Treatment B (CHF 718 pMDI 400 µg TDD)0.120
Treatment C (CHF 718 pMDI 800 µg TDD)0.073
Treatment D (Placebo)0.003
Treatment E (QVAR^®, 320 µg TDD)0.077

Pre-dose Morning FEV1 at Week 8 - Change From Baseline

"Change from baseline in pre-dose morning FEV1 (average of pre-dose FEV1 measurements) at Week 8.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 8

InterventionLitres (Least Squares Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.021
Treatment B (CHF 718 pMDI 400 µg TDD)0.090
Treatment C (CHF 718 pMDI 800 µg TDD)0.070
Treatment D (Placebo)-0.023
Treatment E (QVAR^®, 320 µg TDD)0.078

12-lead ECG Parameters - PR, QRS, QTcF - Change From Baseline.

"12-lead electrocardiogram (12-lead ECG) parameters - PR, QRS, QTcF intervals - were measured at baseline (Day 1) and Week 8.~Changes from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0); QTcF=Fridericia-corrected QT interval; msec=Millisecond;" (NCT03084718)
Timeframe: Baseline, Week 8

,,,,
Interventionmsec (Mean)
PRQRSQTcF
Treatment A (CHF 718 pMDI 100 µg TDD)-2.60.11.6
Treatment B (CHF 718 pMDI 400 µg TDD)1.5-1.30.7
Treatment C (CHF 718 pMDI 800 µg TDD)-1.90.90.7
Treatment D (Placebo)-1.3-0.54.6
Treatment E (QVAR^®, 320 µg TDD)1.0-0.31.2

12-lead ECG Parameters - Prolonged QTcF - Change From Baseline

"Number of participants with prolonged QTcF. Change from baseline.~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; QTcF=Fridericia-corrected QT interval;" (NCT03084718)
Timeframe: Baseline, Week 8

,,,,
InterventionParticipants (Count of Participants)
QTcF > 30 msecQTcF > 60 msec
Treatment A (CHF 718 pMDI 100 µg TDD)61
Treatment B (CHF 718 pMDI 400 µg TDD)41
Treatment C (CHF 718 pMDI 800 µg TDD)40
Treatment D (Placebo)92
Treatment E (QVAR^®, 320 µg TDD)31

Asthma Control Questionnaire-7© (ACQ-7) Score at Week 4 and Week 8 - Change From Baseline

"The ACQ consists of 7 items: 6 simple self-administered questions referring to asthma control and rescue treatment usage with 1 week recall, and a 7th item consisting of the percent (%) predicted FEV1 completed by clinic staff. Scoring uses a 7-point scale: 0 = totally controlled and 6 = severely uncontrolled. The ACQ score was calculated as the average of all 7 items.~Definitions:~ACQ-7 score=Asthma Control Questionnaire-7©; Information regarding the American Thoracic Society ACQ questionnaire is also available at: https://member.thoracic.org/members/assemblies/assemblies/srn/questionaires/acq.php; Baseline ACQ-7 score = ACQ score recorded at V2 (Week 0) Day 1, before randomization; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
Interventionscore on a scale (Least Squares Mean)
Week 4Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)-0.43-0.53
Treatment B (CHF 718 pMDI 400 µg TDD)-0.53-0.58
Treatment C (CHF 718 pMDI 800 µg TDD)-0.49-0.66
Treatment D (Placebo)-0.27-0.43
Treatment E (QVAR^®, 320 µg TDD)-0.47-0.64

Average Use of Rescue Medication - Change From Baseline

"Change from baseline in average use of rescue medication, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~Definitions:~Baseline=For the efficacy variable -- average use of rescue medication -- derived from the electronic diary (eDiary), baseline values were the averages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Interventionpuffs/day (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-0.11-0.12-0.11
Treatment B (CHF 718 pMDI 400 µg TDD)-0.27-0.35-0.31
Treatment C (CHF 718 pMDI 800 µg TDD)-0.14-0.25-0.20
Treatment D (Placebo)0.070.010.04
Treatment E (QVAR^®, 320 µg TDD)-0.13-0.18-0.15

Overall Daily Asthma Symptoms Scores - Change From Baseline

"Overall daily asthma symptoms scores - Change From Baseline (am and pm).~Subjects had to record asthma symptom score (overall symptoms, cough, wheeze, chest tightness and breathlessness) in the am (night-time asthma symptom score) and in the pm (daytime asthma symptom score). These data were collected in the subject's diary. Daily asthma symptoms score were performed separately for am score and pm score and also as a total, where the total equals the sum of the am and pm scores. Degree of asthma symptoms by score: 0=None, 1=Mild, 2=Moderate, and 3=Severe.~Baseline=Averages values during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Interventionscore on a scale (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-0.1-0.1-0.1
Treatment B (CHF 718 pMDI 400 µg TDD)-0.1-0.1-0.1
Treatment C (CHF 718 pMDI 800 µg TDD)-0.1-0.1-0.1
Treatment D (Placebo)0.0-0.00.0
Treatment E (QVAR^®, 320 µg TDD)-0.1-0.1-0.1

Percentage (%) of Asthma Control Days - Change From Baseline

"Change from baseline in percentage (%) of asthma control days, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~This outcome measure was calculated according to the following definition: Days with a total daily morning + evening asthma score = 0 AND No rescue medication use.~Definitions:~Baseline=For the efficacy variable -- asthma control days -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of asthma control days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)7.314.310.8
Treatment B (CHF 718 pMDI 400 µg TDD)10.616.313.4
Treatment C (CHF 718 pMDI 800 µg TDD)10.417.513.9
Treatment D (Placebo)5.010.57.7
Treatment E (QVAR^®, 320 µg TDD)12.820.6316.7

Percentage (%) of Asthma Symptoms-free Days - Change From Baseline

"Change from baseline in Percentage (%) of asthma symptoms-free days.~Asthma symptoms-free days is the number of days with a total asthma score=0 (daily morning plus evening asthma score).~Subjects recorded asthma symptom score as described in the Outcome measure #7.~Definitions:~Baseline=For the efficacy variables -- daytime and night-time asthma symptom scores -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of of asthma symptom-free days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)8.616.412.5
Treatment B (CHF 718 pMDI 400 µg TDD)10.517.013.8
Treatment C (CHF 718 pMDI 800 µg TDD)10.117.213.6
Treatment D (Placebo)5.711.78.7
Treatment E (QVAR^®, 320 µg TDD)12.821.217.0

Percentage (%) of Rescue Medication-free Days - Change From Baseline

"Change from baseline in percentage (%) of rescue medication-free days. An increased value indicates improvement from baseline.~Definitions:~Baseline=For the efficacy variable -- percentage (%) of rescue medication-free days -- derived from the electronic diary (eDiary), baseline values were the averages/percentages recorded during the run-in period.~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of rescue medication-free days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)5.98.97.4
Treatment B (CHF 718 pMDI 400 µg TDD)9.013.111.1
Treatment C (CHF 718 pMDI 800 µg TDD)6.110.08.1
Treatment D (Placebo)1.54.12.8
Treatment E (QVAR^®, 320 µg TDD)7.711.29.5

Pre-dose Morning FVC at Week 4 and 8 - Change From Baseline

"Change from baseline in pre-dose morning FVC at Week 4 and 8.~Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FVC were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FVC=Forced vital capacity;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
InterventionLitres (Least Squares Mean)
Week 4Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)0.0360.014
Treatment B (CHF 718 pMDI 400 µg TDD)0.0990.089
Treatment C (CHF 718 pMDI 800 µg TDD)0.0660.036
Treatment D (Placebo)0.023-0.016
Treatment E (QVAR^®, 320 µg TDD)0.0560.063

Pre-dose Peak Expiratory Flow (PEF) (L/Min) (Morning and Evening) - Change From Baseline

"Change from baseline in pre-dose Peak Expiratory Flow (PEF) (Liters/min), morning and evening measurements.~Definitions:~Baseline=For the efficacy variable -- morning and evening PEF -- derived from the eDiary, the baseline values were the averages/percentages recorded during the run-in period; PEF=evening peak expiratory flow;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
InterventionLiters/min (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-2-4-3
Treatment B (CHF 718 pMDI 400 µg TDD)-330.3
Treatment C (CHF 718 pMDI 800 µg TDD)-4-5-4
Treatment D (Placebo)-6-4-4.9
Treatment E (QVAR^®, 320 µg TDD)021

Vital Signs (Systolic and Diastolic Blood Pressure) - Change From Baseline

"Vital signs (systolic and diastolic blood pressure) at baseline, week 4, and week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; DBP=Diastolic blood pressure; SBP=Systolic blood pressure;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
InterventionmmHg (Mean)
SBP, Week 4SBP, Week 8DBP, Week 4DBP, Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)-0.41.0-0.10.8
Treatment B (CHF 718 pMDI 400 µg TDD)1.02.50.21.0
Treatment C (CHF 718 pMDI 800 µg TDD)0.50.8-0.80.3
Treatment D (Placebo)0.60.20.1-0.5
Treatment E (QVAR^®, 320 µg TDD)0.0-0.90.81.2

Change in FEV1 (% Predicted)

Pre-treatment spirometry measurement assessed at the time of study enrollment. Post-treatment spirometry measurement assessed following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in FEV1 calculated as post-treatment FEV1 minus pre-treatment FEV1 (NCT02566902)
Timeframe: 10 minutes

Intervention%predicted (Mean)
T-piece Nebulizer13.8
Breath-Enhanced Nebulizer9.1

Change in Heart Rate (Beats Per Minute)

"Blinded research personnel will assess subject's heart rate by auscultation and/or pulse palpation prior to and immediately following albuterol administration.~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in heart rate calculated as post-treatment heart rate minus pre-treatment heart rate." (NCT02566902)
Timeframe: 10 minutes

Interventionbeats per minute (Mean)
T-piece Nebulizer4.34
Breath-Enhanced Nebulizer15.05

Change in PAS Score (Points on a Scale)

"Based on examination and auscultation of lungs prior to and immediately following albuterol administration.~PAS score is on a scale of 0-10 which is a sum of five separate sub-scores each on a scale of 0-2. The five sub-scores are:~Respiratory rate (6-12yr/>12yr): <=26/23 (0), 27-30/24-27 (1), >31/28 (2)~Oxygenation: >95% (0), 90-95 (1), <90 (2)~Auscultation: clear/end expiratory wheeze (0), expiratory wheeze (1), biphasic wheeze/diminished (2)~Work of Breathing (accessory muscles): <= 1 (0), 2 (1), >=3 (2)~Dyspnea: Full sentences (0), Partial sentences (1), Single words (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PAS calculated as post-treatment PAS minus pre-treatment PAS." (NCT02566902)
Timeframe: 10 minutes

Interventionscore on a scale (Median)
T-piece Nebulizer-1
Breath-Enhanced Nebulizer-2

Change in PASS Score (Points on a Scale)

"Determined by examination and auscultation of lungs to prior to and immediately following albuterol administration.~PASS is a total score on a scale of 0-6 which is calculated as a sum of three sub-scores, each on a scale of 0-2. The sub-scores are:~Wheezing: None or Mild (0), Moderate (1), Severe wheezing or absent wheezing due to poor air exchange (2)~Work of breathing (accessory muscle use or retractions): None or mild (0), Moderate (1), Severe (2)~Prolonged expiration: Normal or mildly prolonged (0), moderately prolonged (1), severely prolonged (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PASS calculated as post-treatment PASS minus pre-treatment PASS." (NCT02566902)
Timeframe: 10 minutes

Interventionscore on a scale (Median)
T-piece Nebulizer-1
Breath-Enhanced Nebulizer-1

Change Respiratory Rate (Breaths Per Minute)

"Respiratory rate will be measured by observation and auscultation over 30 seconds prior to and immediately following albuterol administration~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in respiratory rate calculated as post-treatment respiratory rate minus pre-treatment respiratory rate." (NCT02566902)
Timeframe: 10 minutes

Interventionbreaths/min (Mean)
T-piece Nebulizer-3.1
Breath-Enhanced Nebulizer-3.2

Emergency Department Length of Stay (Minutes)

Total length of stay will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours

Interventionminutes (Mean)
T-piece Nebulizer246.3
Breath-Enhanced Nebulizer246.2

Percentage of Patients Experiencing Medication Side Effects (%)

"Subjects and parents/guardians will be asked whether subjects experienced nausea, vomiting, palpitations, headache, dizziness either during (assessed by non-blinded personnel) or following treatment (assessed by blinded personnel during post-treatment assessment). Subject and parent/guardian will also be asked if any other side effects were experienced." (NCT02566902)
Timeframe: 10 minutes

InterventionParticipants (Count of Participants)
T-piece Nebulizer5
Breath-Enhanced Nebulizer5

Percentage of Patients Requiring Inpatient Hospital Admission (% of Subjects)

Admission rate to inpatient hospital will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours

InterventionParticipants (Count of Participants)
T-piece Nebulizer11
Breath-Enhanced Nebulizer11

Total Quantity of Albuterol Given in the Emergency Department (mg)

Cumulative dose of albuterol in mg will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: up to 24 hours

Interventionmg (Mean)
T-piece Nebulizer18.2
Breath-Enhanced Nebulizer18.7

Change Between Week 44 and Week 0 in Rescue Albuterol Puffs Per Day

(NCT00394329)
Timeframe: Rescue albuterol puffs were measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventioncount of the number of puffs per day (Least Squares Mean)
A: Daily ICS + Rescue ICS0.26
B: Daily ICS0.24
C: Rescue ICS0.26
D: Placebo0.18

Change Between Week 44 and Week 0 in the Asthma Control Days

(NCT00394329)
Timeframe: An asthma control day was determined daily during each of the 44-week treatment periods. The primary analysis constructed the change between week 14 and week 0.

Interventionproportion of asthma control days (Least Squares Mean)
A: Daily ICS + Rescue ICS-0.006
B: Daily ICS-0.021
C: Rescue ICS-0.064
D: Placebo-0.034

Change Between Week 44 and Week 0 in the Asthma Control Test (ACT)

The ACT consisted of five questions, each ranging from 1 (worst) to 5 (best). The five questions were summed to yield an overall score that ranged from 5 (worst) to 25 (best). (NCT00394329)
Timeframe: The ACT was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionunits on a scale (Least Squares Mean)
A: Daily ICS + Rescue ICS0.17
B: Daily ICS-0.15
C: Rescue ICS-0.57
D: Placebo-0.76

Change Between Week 44 and Week 0 in the Asthma-specific Quality of Life Assessment

The asthma-specific quality of life scale ranged from 1 (worst) to 7 (best) (NCT00394329)
Timeframe: The asthma-specific quality of life assessment was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionunits on a scale (Least Squares Mean)
A: Daily ICS + Rescue ICS0.15
B: Daily ICS0.07
C: Rescue ICS0.05
D: Placebo-0.03

Change Between Week 44 and Week 0 in the Evening Peak Expiratory Flow Rate Variability (PEFR)

(NCT00394329)
Timeframe: Evening PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionliters per minute (Least Squares Mean)
A: Daily ICS + Rescue ICS16.2
B: Daily ICS14.9
C: Rescue ICS12.9
D: Placebo20.6

Change Between Week 44 and Week 0 in the Exhaled Nitric Oxide (eNO) Measured in Parts Per Billion

(NCT00394329)
Timeframe: eNO was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionparts per billion (Least Squares Mean)
Daily ICS + Rescue ICS-0.08
Daily ICS0.07
Rescue ICS0.58
Placebo0.34

Change Between Week 44 and Week 0 in the Morning Peak Expiratory Flow Rate (PEFR)

(NCT00394329)
Timeframe: Morning PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionliters per minute (Least Squares Mean)
A: Daily ICS + Rescue ICS17.7
B: Daily ICS16.3
C: Rescue ICS16.5
D: Placebo21.1

Change Between Week 44 and Week 0 in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV!)

(NCT00394329)
Timeframe: Pre-bronchodilator FEV1 was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionliters (Least Squares Mean)
A: Daily ICS + Rescue ICS0.104
B: Daily ICS0.113
C: Rescue ICS0.097
D: Placebo0.063

Change Between Week 44 and Week 0 Peak Expiratory Flow Rate (PEFR) Variability

PEFR variability represents the relative change between the evening and morning PEFR measurements, so it could be a positive or negative number. It was measured daily during the 44-week treatment period. Specifically, the PEFR variability on a specific day is defined as 100% x (evening PEFR - morning PEFR)/{0.5*(evening PEFR + morning PEFR)} (NCT00394329)
Timeframe: PEFR variability was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.

Interventionrelative change (AM and PM peak flow) (Least Squares Mean)
A: Daily ICS + Rescue ICS0.836
B: Daily ICS-0.043
C: Rescue ICS0.098
D: Placebo0.894

Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy

(NCT00394329)
Timeframe: Measured during the 44-week treatment period

Interventionparticipants (Number)
A: Daily ICS + Rescue ICS22
B: Daily ICS20
C: Rescue ICS25
D: Placebo36

Number of Symptom Free Days

The primary outcome variable is the average number of symptom free days over 2 weeks assessed during peak asthma season (data collected during November, December, January and February during the school year). (NCT01175369)
Timeframe: Average Symptom Free Days, over 2 weeks, during peak asthma season (November-February)

InterventionDays (Mean)
Usual Care10.7
School-based Care11.6

Change From Predose in Mean Diastolic Blood Pressure

Mean diastolic blood pressure measured at various timepoints minus the predose diastolic blood pressure (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
InterventionmmHg (Mean)
15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,52,40)
Arformoterol 15 Mcg-1.0-1.9-1.3-2.8-1.9-1.8-1.9-1.1-1.1-1.5-1.3-1.1-1.0-3.7-1.7-3.6
Arformoterol 7.5 Mcg-1.1-0.6-0.70.1-1.1-1.3-1.2-1.1-0.9-0.9-3.5-1.8-2.6-0.0-1.0-0.1
Levalbuterol 0.63 mg-1.1-1.70.8-1.10.80.00.80.80.11.4-1.90.8-0.40.50.2-0.1

Change From Predose in Mean Heart Rate

Heart rate measured at various timepoints minus the heart rate at predose. (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
Interventionbeats per minute (Mean)
15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,51,40)
Arformoterol 15 Mcg2.32.56.55.56.39.59.010.08.38.97.86.47.97.46.95.8
Arformoterol 7.5 Mcg0.52.04.42.84.54.75.68.67.16.65.55.95.14.64.95.3
Levalbuterol 0.63 mg1.63.28.77.810.013.211.98.78.95.66.86.75.96.65.95.0

Change From Predose in Mean Peak Expiratory Flow Rate (PEFR)

PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. Change in PEFR was calculated as postdose value minus the predose value at each visit. (NCT00583947)
Timeframe: predose, various postdose times

,,
Interventionliters/second (Mean)
10 minutes post dose 1 (n=37,38,27)25 minutes post dose 1 (n=37,37,27)10 minutes post dose 2 (n=36,38,27)25 minutes post dose 2 (n=36,38,27)10 minutes post dose 3 (n=34,38,27)25 minutes post dose 3 (n=35,38,26)2 hours post dose 1 (n=36,37,27)4 hours post dose 1 (n=36,38,27)6 hours post dose 1 (n=36,38,27)
Arformoterol 15 Mcg0.2590.2790.3600.4240.5130.4490.5010.4740.451
Arformoterol 7.5 Mcg0.2420.3200.3440.4190.4570.4620.5960.4840.513
Levalbuterol 0.63 mg0.3220.3990.4580.4520.5240.5390.5750.5090.324

Change From Predose in Mean Serum Glucose

Change in mean serum glucose at the specified timepoint minus the predose value. (NCT00583947)
Timeframe: predose, 2 and 6 hours post dose

,,
Interventionmg/dl (Mean)
2 hours post dose 1 (n=48,47,39)6 hours post dose 1 (n=49,48,38)
Arformoterol 15 Mcg32.918.6
Arformoterol 7.5 Mcg22.412.1
Levalbuterol 0.63 mg27.120.3

Change From Predose in Mean Serum Potassium

Change in mean serum potassium at the specified timepoint minus the predose value. (NCT00583947)
Timeframe: predose, 2 and 6 hours post dose

,,
InterventionmEq/L (Mean)
2 hours post dose 1 (n=48,47,38)6 hours post dose 1 (n=48,49,38)
Arformoterol 15 Mcg-0.62-0.39
Arformoterol 7.5 Mcg-0.42-0.31
Levalbuterol 0.63 mg-0.58-0.23

Change From Predose in Mean Systolic Blood Pressure

Mean systolic blood pressure measured at various timepoints minus the mean systolic blood pressure at predose (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
InterventionmmHg (Mean)
15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,52,40)
Arformoterol 15 Mcg2.0-0.32.61.61.41.81.14.42.41.30.71.30.9-0.00.91.6
Arformoterol 7.5 Mcg-0.40.91.1-0.30.8-0.3-0.41.50.31.8-0.00.61.70.61.72.5
Levalbuterol 0.63 mg0.82.63.72.63.34.02.43.51.82.30.43.91.21.32.24.5

Change From Predose of Mean Forced Expiratory Volume in One Second (FEV1)

Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. Change in FEV1 was calculated as postdose value minus the predose value at each visit. (NCT00583947)
Timeframe: predose, various postdose timepoints

,,
Interventionliters (Mean)
10 minutes post dose 1 (n=37,38,27)25 minutes post dose 1 (n=37,37,27)10 minutes post dose 2 (n=36,38,27)25 minutes post dose 2 (n=36,38,27)10 minutes post dose 3 (n=34,38,27)25 minutes post dose 3 (n=35,38,26)2 hours post dose 1 (n=36,37,27)4 hours post dose 1 (n=36,38,27)6 hours post dose 1 (n=36,38,27)
Arformoterol 15 Mcg0.1330.1580.1750.1830.2030.2050.2180.1980.174
Arformoterol 7.5 Mcg0.1170.1420.1690.1620.1790.1880.1940.1700.173
Levalbuterol 0.63 mg0.1600.1590.1990.1940.2260.2260.2160.1630.098

Mean Diastolic Blood Pressure

Diastolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
InterventionmmHg (Mean)
Predose (n=51,52,40)15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,52,40)
Arformoterol 15 Mcg63.662.561.662.360.861.762.361.662.562.562.162.362.562.659.961.960.0
Arformoterol 7.5 Mcg63.262.062.562.563.362.262.062.062.162.362.359.761.460.563.162.263.0
Levalbuterol 0.63 mg62.561.460.863.461.763.162.863.463.563.163.860.763.262.062.962.662.3

Mean Forced Expiratory Volume in One Second(FEV1)

Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. (NCT00583947)
Timeframe: predose, various postdose times

,,
Interventionliters (Mean)
predose (n=37,38,27)10 minutes post dose 1 (n=37,38,27)25 minutes post dose 1 (n=37,37,27)10 minutes post dose 2 (n=36,38,27)25 minutes post dose 2 (n=36,38,27)10 minutes post dose 3 (n=34,38,27)25 minutes post dose 3 (n=35,38,26)2 hours post dose 1 (n=36,37,27)4 hours post dose 1 (n=36,38,27)6 hours post dose 1 (n=36,38,27)
Arformoterol 15 Mcg1.4861.6201.6441.6611.6691.6891.7001.7041.6841.660
Arformoterol 7.5 Mcg1.5521.6681.6951.7211.7141.7311.7401.7541.7221.725
Levalbuterol 0.63 mg1.5541.7141.7121.7411.7351.7751.7821.7841.7321.667

Mean Heart Rate

Heart rate measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
Interventionbeats per minute (Mean)
Predose (n=51,52,40)15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,51,40)
Arformoterol 15 Mcg87.089.489.593.592.593.396.196.197.195.395.994.893.495.094.593.992.9
Arformoterol 7.5 Mcg84.785.286.689.087.588.989.390.393.391.891.290.290.689.889.389.689.8
Levalbuterol 0.63 mg87.689.390.996.495.497.1100.499.296.096.293.094.194.193.394.093.392.4

Mean Peak Expiratory Flow Rate (PEFR)

PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. (NCT00583947)
Timeframe: predose, various postdose times

,,
Interventionliters/second (Mean)
predose (n=37,38,27)10 minutes post dose 1 (n=37,38,27)25 minutes post dose 1 (n=37,37,27)10 minutes post dose 2 (n=36,38,27)25 minutes post dose 2 (n=36,38,27)10 minutes post dose 3 (n=34,38,27)25 minutes post dose 3 (n=35,38,26)2 hours post dose 1 (n=36,37,27)4 hours post dose 1 (n=36,38,27)6 hours post dose 1 (n=36,38,27)
Arformoterol 15 Mcg3.5653.8243.8443.9253.9894.0774.0174.0664.0394.016
Arformoterol 7.5 Mcg3.5463.7883.8773.8903.9644.0034.0074.1784.0294.058
Levalbuterol 0.63 mg3.6043.9264.0034.0534.0474.1564.1764.2214.1553.970

Mean Serum Glucose Values

(NCT00583947)
Timeframe: Predose, 2 and 6 hours post dose 1

,,
Interventionmg/dl (Mean)
Predose (n=51,52,40)2 hours post dose 1 (n=48,47,39)6 hours post dose 1 (n=49,48,38)
Arformoterol 15 Mcg87.6120.6106.3
Arformoterol 7.5 Mcg87.5108.699.0
Levalbuterol 0.63 mg86.4114.5107.6

Mean Serum Potassium Levels

(NCT00583947)
Timeframe: Predose, 2 hours and 6 hours postdose 1

,,
InterventionmEq/L (Mean)
Predose (n=51,52,39)2 hours post dose 1 (n=48,47,38)6 hours post dose 1 (n=48,49,38)
Arformoterol 15 Mcg4.313.713.87
Arformoterol 7.5 Mcg4.273.833.95
Levalbuterol 0.63 mg4.253.673.99

Mean Systolic Blood Pressure

Systolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose

,,
InterventionmmHg (Mean)
Predose (n=51,52,40)15 min post dose 1 (n=51,52,40)30 min post dose 1 (n=51,52,40)60 min post dose 1 (n=51,51,40)15 min post dose 2 (n=50,51,40)30 min post dose 2 (n=47,50,40)60 min post dose 2 (n=46,50,37)30 min post last dose (n=49,52,40)60 min post last dose (n=49,52,40)1.5 hours post last dose (n=48,52,40)2 hours post last dose (n=50,52,40)2.5 hours post last dose (n=49,52,40)3 hours post last dose (n=50,52,40)3.5 hours post last dose (n=50,52,40)4 hours post last dose (n=50,52,40)4.5 hours post last dose (n=50,52,40)5 hours post last dose (n=50,52,40)
Arformoterol 15 Mcg100.6102.6100.3103.2102.1101.9102.9101.6104.9103.0101.8101.3101.9101.4100.5101.5102.1
Arformoterol 7.5 Mcg101.5101.2102.5102.7101.7102.8101.9101.2103.0101.9103.4101.5102.1103.2102.1103.2104.1
Levalbuterol 0.63 mg102.1102.9104.6105.8105.0106.4107.2105.0106.1104.8104.6103.0106.1103.4103.6104.5106.7

Plasma Concentration of (R,R) Formoterol

If the mean plasma concentration was 'below the limit of quantification' (BLQ) which was set as <=0.5 picograms/milliliter, the value is displayed as a zero. (NCT00583947)
Timeframe: predose, various postdose times

,,
Interventionpicogram/milliliter (Mean)
predose (n=51,52,39)25 minutes post dose 1 (n=50,46,36)25 minutes post dose 2 (n=48,47,36)2 hours post dose 1 (n=50,51,38)6 hours post dose 1 (n=50,50,37)
Arformoterol 15 Mcg0.7371.6593.3254.1892.818
Arformoterol 7.5 Mcg02.2361.8451.8850.874
Levalbuterol 0.63 mg0.6462.402000

"Mean Weekly Score for Asthma Control Diary Question Did You Experience Wheeze or Cough During the Day at Week 12"

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.539
Salmeterol1.505
Placebo1.572

"Mean Weekly Score for Asthma Control Diary Question Did You Experience Wheeze or Cough During the Day at Week 16"

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.528
Salmeterol1.515
Placebo1.669

"Mean Weekly Score for Asthma Control Diary Question Did You Experience Wheeze or Cough During the Day at Week 4"

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.679
Salmeterol1.605
Placebo1.652

"Mean Weekly Score for Asthma Control Diary Question Did You Experience Wheeze or Cough During the Day at Week 8"

Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.519
Salmeterol1.56
Placebo1.575

"Mean Weekly Score for Asthma Control Diary Question Did You Wake up During the Night Due to Asthma at Week 12"

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.203
Salmeterol1.194
Placebo1.224

"Mean Weekly Score for Asthma Control Diary Question Did You Wake up During the Night Due to Asthma at Week 16"

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.196
Salmeterol1.135
Placebo1.185

"Mean Weekly Score for Asthma Control Diary Question Did You Wake up During the Night Due to Asthma at Week 4"

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.267
Salmeterol1.22
Placebo1.232

"Mean Weekly Score for Asthma Control Diary Question Did You Wake up During the Night Due to Asthma at Week 8"

Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.182
Salmeterol1.176
Placebo1.21

"Mean Weekly Score for Asthma Control Diary Question How Limited Were You in Your Activities Today Because of Your Asthma at Week 12"

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.458
Salmeterol1.436
Placebo1.52

"Mean Weekly Score for Asthma Control Diary Question How Limited Were You in Your Activities Today Because of Your Asthma at Week 16"

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.446
Salmeterol1.415
Placebo1.593

"Mean Weekly Score for Asthma Control Diary Question How Limited Were You in Your Activities Today Because of Your Asthma at Week 4"

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.549
Salmeterol1.514
Placebo1.583

"Mean Weekly Score for Asthma Control Diary Question How Limited Were You in Your Activities Today Because of Your Asthma at Week 8"

Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.475
Salmeterol1.478
Placebo1.545

"Mean Weekly Score for Asthma Control Diary Question How Much Shortness of Breath Did You Experience During the Day at Week 12"

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.57
Salmeterol1.482
Placebo1.62

"Mean Weekly Score for Asthma Control Diary Question How Much Shortness of Breath Did You Experience During the Day at Week 16"

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.623
Salmeterol1.482
Placebo1.691

"Mean Weekly Score for Asthma Control Diary Question How Much Shortness of Breath Did You Experience During the Day at Week 4"

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.699
Salmeterol1.627
Placebo1.735

"Mean Weekly Score for Asthma Control Diary Question How Much Shortness of Breath Did You Experience During the Day at Week 8"

Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.557
Salmeterol1.571
Placebo1.643

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms During the Day at Week 12"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.572
Salmeterol1.495
Placebo1.682

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms During the Day at Week 16"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.609
Salmeterol1.476
Placebo1.711

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms During the Day at Week 4"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.735
Salmeterol1.637
Placebo1.744

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms During the Day at Week 8"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.603
Salmeterol1.569
Placebo1.699

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms in the Morning at Week 4"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.612
Salmeterol1.486
Placebo1.615

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms This Morning at Week 12"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.519
Salmeterol1.436
Placebo1.542

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms This Morning at Week 16"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.536
Salmeterol1.461
Placebo1.647

"Mean Weekly Score for Asthma Control Diary Question How Were Your Asthma Symptoms This Morning at Week 8"

Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium1.504
Salmeterol1.481
Placebo1.613

Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial

Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit (NCT00350207)
Timeframe: baseline and after 16 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium-3.93
Salmeterol-3.15
Placebo-24.63

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3

Diastolic blood pressure collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment

InterventionmmHg (Mean)
Tiotropium78.62
Salmeterol77.62
Placebo79.34

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4

Diastolic blood pressure collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionmmHg (Mean)
Tiotropium77.88
Salmeterol77.22
Placebo78.29

Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5

Diastolic blood pressure collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionmmHg (Mean)
Tiotropium79.23
Salmeterol77.61
Placebo78.38

Mean PEF Variability at Week 12

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 12 weeks of treatment

Interventionratio expressed in percent (Least Squares Mean)
Tiotropium11.735
Salmeterol11.320
Placebo11.257

Mean PEF Variability at Week 16

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 16 weeks of treatment

Interventionratio expressed in percent (Least Squares Mean)
Tiotropium11.742
Salmeterol10.793
Placebo12.305

Mean PEF Variability at Week 4

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 4 weeks of treatment

Interventionratio expressed in percent (Least Squares Mean)
Tiotropium12.043
Salmeterol10.547
Placebo12.085

Mean PEF Variability at Week 8

PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 8 weeks of treatment

Interventionratio expressed in percent (Least Squares Mean)
Tiotropium13.377
Salmeterol11.252
Placebo12.964

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12

Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.31
Salmeterol2.299
Placebo2.231

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16

Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.343
Salmeterol2.291
Placebo2.215

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4

Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.369
Salmeterol2.318
Placebo2.25

Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8

Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.32
Salmeterol2.301
Placebo2.239

Mean Weekly Evening Peak Expiratory Flow at Week 12

Mean weekly evening peak expiratory flow at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium366.282
Salmeterol362.01
Placebo344.291

Mean Weekly Evening Peak Expiratory Flow at Week 16

Mean weekly evening peak expiratory flow at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium363.657
Salmeterol360.304
Placebo340.099

Mean Weekly Evening Peak Expiratory Flow at Week 4

Mean weekly evening peak expiratory flow at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium374.496
Salmeterol366.219
Placebo348.344

Mean Weekly Evening Peak Expiratory Flow at Week 8

Mean weekly evening peak expiratory flow at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium368.758
Salmeterol359.586
Placebo345.299

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12

Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.256
Salmeterol2.254
Placebo2.156

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16

Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.3
Salmeterol2.278
Placebo2.188

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4

Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.301
Salmeterol2.316
Placebo2.161

Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8

Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.254
Salmeterol2.287
Placebo2.164

Mean Weekly Morning Peak Expiratory Flow at Week 12

Mean weekly morning peak expiratory flow at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium359.05
Salmeterol351.3
Placebo332.808

Mean Weekly Morning Peak Expiratory Flow at Week 16

Mean weekly morning peak expiratory flow at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium355.619
Salmeterol355.799
Placebo334.525

Mean Weekly Morning Peak Expiratory Flow at Week 4

Mean weekly morning peak expiratory flow at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium360.695
Salmeterol359.762
Placebo335.515

Mean Weekly Morning Peak Expiratory Flow at Week 8

Mean weekly morning peak expiratory flow at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment

InterventionL/min (Least Squares Mean)
Tiotropium355.42
Salmeterol350.53
Placebo330.193

Mini-AQLQ Overall Score at Visit 4

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium5.233
Salmeterol5.399
Placebo5.078

Mini-AQLQ Overall Score at Visit 5

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium5.305
Salmeterol5.454
Placebo5.214

Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3

Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 6 weeks of treatment

InterventionUnit on a scale (Least Squares Mean)
Tiotropium5.050
Salmeterol5.259
Placebo5.097

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment (NCT00350207)
Timeframe: After 6 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.471
Salmeterol2.401
Placebo2.299

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.467
Salmeterol2.442
Placebo2.266

Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5

Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium2.439
Salmeterol2.457
Placebo2.29

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3

Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment (NCT00350207)
Timeframe: After 6 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium3.531
Salmeterol3.441
Placebo3.367

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4

Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium3.509
Salmeterol3.495
Placebo3.307

Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5

Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionL (Least Squares Mean)
Tiotropium3.488
Salmeterol3.474
Placebo3.353

Pulse Rate in Conjunction With Spirometry at Visit 3

Pulse rate collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment

Interventionbpm (Mean)
Tiotropium74.7
Salmeterol74.9
Placebo74.2

Pulse Rate in Conjunction With Spirometry at Visit 4

Pulse rate collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment

Interventionbpm (Mean)
Tiotropium74.8
Salmeterol74.6
Placebo74.2

Pulse Rate in Conjunction With Spirometry at Visit 5

Pulse rate collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment

Interventionbpm (Mean)
Tiotropium74.4
Salmeterol75.3
Placebo74.7

Systolic Blood Pressure in Conjunction With Spirometry at Visit 3

Systolic blood pressure collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment

InterventionmmHg (Mean)
Tiotropium124.68
Salmeterol123.11
Placebo126.41

Systolic Blood Pressure in Conjunction With Spirometry at Visit 4

Systolic blood pressure collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment

InterventionmmHg (Mean)
Tiotropium124.81
Salmeterol123.92
Placebo125.18

Systolic Blood Pressure in Conjunction With Spirometry at Visit 5

Systolic blood pressure collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment

InterventionmmHg (Mean)
Tiotropium124.23
Salmeterol123.83
Placebo124.47

Maximum Change From Baseline in Airway Blood Flow (Qaw)

(NCT01231230)
Timeframe: maximum change in Qaw within 240 minutes post drug inhalation

Interventionchange from baseline ( µl/min/ml) (Mean)
Fluticasone-11.0
Placebo14.1
Salmeterol23.9
Fluticasone/Salmeterol25.5

Bronchial Responsiveness to Serial Methacholine Concentrations Inhaled Into the Lungs

Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventionmg/ml of methacholine (Geometric Mean)
1 Budesonide3.0
2 Nedocromil1.8
3 Placebo1.9

Change From Baseline in the Rate of Asthma Free Days

Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventiondays per month (Mean)
1 Budesonide11.3
2 Nedocromil9.3
3 Placebo9.3

Change in Height From Baseline to End of Treatment, 4-6 Years Later

Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventioncm (Mean)
1 Budesonide22.7
2 Nedocromil23.7
3 Placebo23.8

Mortality

Counts of deaths from asthma. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventionparticipants (Number)
1 Budesonide0
2 Nedocromil1
3 Placebo0

Need for Urgent Care for Asthma

Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventionrate per 100 person years (Number)
1 Budesonide12
2 Nedocromil16
3 Placebo22

Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period

Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references. (NCT00000575)
Timeframe: At the end of treatment, 4-6 years from baseline assessment

Interventionpercentage of predicted value (Mean)
1 Budesonide0.6
2 Nedocromil-0.5
3 Placebo-0.1

Standardized Depression Scale -- Children's Depression Inventory

Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression. (NCT00000575)
Timeframe: 4-6 years from baseline

Interventionunits on a scale (Mean)
1 Budesonide-3.2
2 Nedocromil-1.8
3 Placebo-2.2

FEV1

The forced expiratory volume in the first second, expressed as a percent predicted. (NCT00643578)
Timeframe: 1 hour after dose

Interventionpercent predicted (Mean)
12 Mcg of Formoterol88
24 Mcg of Formoterol91

Post-dose PC20

The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second. (NCT00643578)
Timeframe: 3-7 days after visits 1 and 2

Interventionmg/mL (Geometric Mean)
12 Mcg Formoterol7
24 Mcg Formoterol16

Days of Hospitalization

duration of hospitalization, calculated by discharge date minus admission date (NCT03438383)
Timeframe: From day of admission to day of discharge from the hospital

,
Interventiondays (Mean)
Type of OBS: gastroplastyType of OBS: open gastric bypass
Bi-PAP610
Sham Bi-PAP610

Forced Expiratory Volume at One Second (FEV1) Difference

difference in FEV1 value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 h post-operatively

,
InterventionLitres (Mean)
24h before surgery24h post-op48h post-op72h post-op
Bi-PAP3.11.41.71.9
Sham Bi-PAP3.11.31.31.4

Forced Vital Capacity (FVC) Difference

difference in FVC value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively

,
InterventionLitres (Mean)
24h before surgery24h post-op48h post-op72h post-op
Bi-PAP3.51.62.02.3
Sham Bi-PAP3.41.31.51.9

Number of Participants With Atelectasis

occurrence of atelectasis as defined by chest X-ray (CXR) post-operatively with CXR before surgery as baseline (NCT03438383)
Timeframe: At 24, 48 and 72 hours post-operatively

,
InterventionParticipants (Count of Participants)
24h post-op48h list-op72h post-op
Bi-PAP000
Sham Bi-PAP333

Number of Participants With Hypoxemia

occurrence of hypoxemia, considered as SpO2<90%, post-operatively (NCT03438383)
Timeframe: At 24, 48 and 72 hours post-operatively

,
InterventionParticipants (Count of Participants)
24h post-op48h post-op72h post-op
Bi-PAP000
Sham Bi-PAP500

Peak Expiratory Flow Rate (PEFR) Difference

difference in PEFR value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively

,
InterventionLitres/minute (Mean)
24h before surgery24h post-op48h post-op72h post-op
Bi-PAP325.3137.4195.7247.5
Sham Bi-PAP376.9146.9166.0190.1

Post-operative Pain

Intensity of pain was assessed post-operatively by Numerical Rating Scale (NRS) (0-10, 0=no pain, 10=worst pain imaginable) (NCT03438383)
Timeframe: right before spirometry, at 24, 48 and 72 h post-operatively

,
Interventionscore on a scale (Mean)
24h post-op48h post-op72h post-op
Bi-PAP6.55.33.5
Sham Bi-PAP6.54.53.3

SpO2 Difference

difference in SpO2 value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively

,
Interventionpercentage of SpO2 (Mean)
24h before surgery24h post-op48h post-op72h post-op
Bi-PAP96.992.695.296.8
Sham Bi-PAP96.991.692.492.5

Patient Adherence to Inhaled Corticosteroids (ICS)

Adherence to ICS medication was measured during the last 3 months of the intervention (i.e., for the time period of 9-12 months post-randomization). Adherence was measured using pharmacy claims data, and represents the percent of prescribed medication taken. The normal range for this value is 0-100%. (NCT00459368)
Timeframe: 1 year

InterventionPercent of ICS medication taken (Mean)
Patient Medication Adherence Feedback21.3
Usual Care23.3

Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.24
Fluticasone Propionate + Placebo-0.14

Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.52
Fluticasone Propionate + Placebo-0.29

Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.22
Fluticasone Propionate + Placebo-0.25

Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.41
Fluticasone Propionate + Placebo-0.47

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-1.66
Fluticasone Propionate + Placebo-2.21

AUC Fluticasone Propionate (FP)

The main outcome measure is the concentration of Fluticasone Propionate in blood following inhalation of the dose. This will be found by calculating the area under the curve of concentration versus time 0 and 12 hours. (NCT00692978)
Timeframe: 12 hours

Interventionpg.h/ml (Median)
FP From Active 250 ug MDI Inhaler Asthma188.2
FP 50ug 1.5um Asthma756
FP 50ug 3um Asthma978
FP 50ug 6um Asthma380.5
FP From Active 250 ug MDI Inhaler HV172.3
FP 50ug 1.5um HV740
FP 50ug 3um HV934.6
FP 50ug 6um HV250.4

AMP Challenge Test PC20

The concentration of Adenosine Monophosphate (AMP), measured in mg/ml, required to see a 20% fall in the patient's forced expiratory volume in 1 second (FEV1) is measured after taking FP aerosol. AMP is a bronchoconstrictor agent (ie it narrows the airways. We would expect that more would be necessary to produce the same 20% fall in FEV1 after receiving the FP than before due to the reduction in airways inflammation. This change is the primary outcome measure. (NCT01662778)
Timeframe: 2 hours

Interventionmg/ml (Mean)
Monodisperse FP 1.5um79.21
Monodisperse FP 6.0um79.74
Placebo STAG62.69
MDI FP92.1

The Concentration of Fluticasone Propionate

The concentration of Fluticasone Propionate in blood following inhalation of the dose will be measured. Cmax will be measured. (NCT01662778)
Timeframe: 4 hours

Interventionpg/ml (Mean)
Monodisperse Fluticasone Propionate 6.0 Microns283.4
Monodisperse Fluticasone Propionate 1.5microns636
Placebo STAG0
Metered Dose Inhaler of Fluticasone Propionate86.94

FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14

"Spirometry used to measure FEV1, was performed according to internationally accepted standards. Results show the change from baseline in FEV1 AUC(0-12h), normalized by time on Day 14; it was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Definitions:~AUC=Area under the curve; AUC(0-12h)=AUC between 0 and 12 h; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period; FEV1=Forced expiratory volume in the 1st second;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.174
Treatment B0.221
Treatment C0.197
Treatment D0.231
Treatment E0.064
Treatment F0.208

FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1

"Spirometry used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.181
Treatment B0.221
Treatment C0.260
Treatment D0.282
Treatment E0.067
Treatment F0.239

Patients Achieving Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1

"Patients achieving onset of action, defined as a change from baseline in post-dose FEV1 ≥12% and ≥200 mL, on Day 1. These are the subjects who contributed to the results, reported as median and 95% CI for 'Time to onset of action' presented in the Outcome Measure 13, above.~For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.~Definitions:~Onset of action=Change from baseline in post-dose FEV1 ≥12% and ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose);" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose

InterventionParticipants (Count of Participants)
Treatment A23
Treatment B22
Treatment C30
Treatment D29
Treatment E11
Treatment F31

Pre-dose Morning FEV1 (L) -- Change From Baseline to Post Dose Day 14

"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.071
Treatment B0.102
Treatment C0.073
Treatment D0.149
Treatment E0.037
Treatment F0.126

Pre-dose Morning FVC -- Change From Baseline to Post Dose Day 14

"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.048
Treatment B0.044
Treatment C0.048
Treatment D0.114
Treatment E0.053
Treatment F0.114

Sensitivity Analysis 1: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14

"The primary analysis was repeated, considering patients as randomized and including only the first instance of each treatment.~Patients receiving the same treatment in more than one period were included in the analysis with only data from the first instance of each treatment." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.169
Treatment B0.224
Treatment C0.196
Treatment D0.232
Treatment E0.058
Treatment F0.206

Sensitivity Analysis 2: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14

"The primary analysis was repeated, considering only patients and treatment periods for which treatment was assigned on or after the randomization error occurred.~The number of patients shown represents those with at least one post-baseline assessment available." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.129
Treatment B0.180
Treatment C0.159
Treatment D0.179
Treatment E-0.006
Treatment F0.170

Sensitivity Analysis 3: FEV1 AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 14

"Patients receiving the same treatment during two treatment periods are considered twice in the ANCOVA model (once for each period attended).~Patients considered in this analysis are those with at least one available post-baseline assessment." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

InterventionLitres (Least Squares Mean)
Treatment A0.144
Treatment B0.194
Treatment C0.170
Treatment D0.198
Treatment E0.037
Treatment F0.184

Time to Onset of Action -- Change From Baseline in Post-dose FEV1 ≥12% and ≥200 mL to Post Dose Day 1

"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.~Definitions:~Time to onset of action=The time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose

Interventionminutes (Median)
Treatment A358.8
Treatment B60.3
Treatment C33.6
Treatment D44.3
Treatment ENA
Treatment F45.5

12-lead ECG Parameter -- Heart Rate (HR) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"Results are shown by treatment group, as change from baseline (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionbpm (Mean)
Day 1, 30 min post-doseDay 1, 1h post-doseDay 1, 4h post-doseDay 1, 8h post-doseDay 1, 12h post-doseDay 14, pre-doseDay 14, 30 min post-doseDay 14, 1h post-doseDay 14, 4h post-doseDay 14, 8h post-doseDay 14, 12h post-dose
Treatment A0.3-1.32.15.05.12.52.91.92.85.57.4
Treatment B1.20.31.52.45.50.1-0.8-1.22.33.57.5
Treatment C1.72.73.35.05.53.11.61.66.74.96.7
Treatment D2.51.55.33.97.62.04.33.23.43.85.4
Treatment E-2.4-1.80.20.52.40.7-1.5-1.21.81.60.5
Treatment F-0.3-1.23.22.15.20.41.30.42.32.65.1

12-lead Electrocardiogram (ECG) Parameter (PR Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionmsec (Mean)
Day 1, 30 min post-doseDay 1, 1h post-doseDay 1, 4h post-doseDay 1, 8h post-doseDay 1, 12h post-doseDay 14, pre-doseDay 14, 30 min post-doseDay 14, 1h post-doseDay 14, 4h post-doseDay 14, 8h post-doseDay 14, 12h post-dose
Treatment A-0.11.1-1.2-1.9-3.41.3-0.21.0-1.5-2.6-5.0
Treatment B1.62.21.6-0.5-2.33.74.55.72.51.51.7
Treatment C-1.3-1.1-1.5-3.0-3.8-1.7-1.50.1-2.5-3.2-4.8
Treatment D-3.6-0.7-4.0-2.6-3.0-2.9-3.1-1.6-3.2-5.4-1.4
Treatment E1.00.4-1.6-2.4-2.60.13.45.20.8-1.10.1
Treatment F3.22.01.9-0.0-1.72.25.16.11.30.8-0.3

12-lead Electrocardiogram (ECG) Parameter (QRS Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionmsec (Mean)
Day 1, 30 min post-doseDay 1, 1h post-doseDay 1, 4h post-doseDay 1, 8h post-doseDay 1, 12h post-doseDay 14, pre-doseDay 14, 30 min post-doseDay 14, 1h post-doseDay 14, 4h post-doseDay 14, 8h post-doseDay 14, 12h post-dose
Treatment A1.21.31.20.60.50.51.41.32.00.70.8
Treatment B1.21.02.10.91.01.01.60.91.81.20.4
Treatment C1.71.22.21.31.0-0.50.50.40.60.10.3
Treatment D1.11.62.10.50.91.72.42.32.81.41.4
Treatment E0.81.01.0-0.20.4-0.9-0.30.0-0.2-0.8-1.0
Treatment F1.31.41.10.50.80.81.71.01.10.90.5

12-lead Electrocardiogram (ECG) Parameter (QTcF Interval) -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionmsec (Mean)
Day 1, 30 min post-doseDay 1, 1h post-doseDay 1, 4h post-doseDay 1, 8h post-doseDay 1, 12h post-doseDay 14, pre-doseDay 14, 30 min post-doseDay 14, 1h post-doseDay 14, 4h post-doseDay 14, 8h post-doseDay 14, 12h post-dose
Treatment A3.92.12.52.42.01.54.44.03.83.43.7
Treatment B3.81.41.51.10.9-0.41.01.00.91.71.7
Treatment C2.73.90.80.6-0.31.63.51.91.11.7-0.9
Treatment D4.94.22.40.81.15.810.47.75.02.23.7
Treatment E-0.20.4-2.4-0.2-1.5-2.31.90.9-1.11.5-0.6
Treatment F1.4-0.9-1.3-2.4-2.21.21.70.6-1.10.4-1.6

FEV1 AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14

"Spirometry used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
InterventionLitres (Least Squares Mean)
Day 1Day 14
Treatment A0.2200.214
Treatment B0.2500.251
Treatment C0.2700.231
Treatment D0.3170.278
Treatment E0.0470.061
Treatment F0.2880.259

FEV1 Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14

"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
InterventionLitres (Least Squares Mean)
Day 1Day 14
Treatment A0.3590.346
Treatment B0.3700.373
Treatment C0.3930.349
Treatment D0.4300.389
Treatment E0.1780.183
Treatment F0.4160.367

FVC AUC(0-12h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14

"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
InterventionLitres (Least Squares Mean)
Day 1Day 14
Treatment A0.1110.103
Treatment B0.1560.134
Treatment C0.1600.120
Treatment D0.1820.142
Treatment E0.0590.060
Treatment F0.1720.134

FVC AUC(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14

"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
InterventionLitres (Least Squares Mean)
Day 1Day 14
Treatment A0.1580.135
Treatment B0.1860.146
Treatment C0.1590.136
Treatment D0.2150.194
Treatment E0.0360.050
Treatment F0.2130.177

FVC Peak(0-4h), Normalized by Time -- Change From Baseline to Post Dose Day 1 and Day 14

"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
InterventionLitres (Least Squares Mean)
Day 1Day 14
Treatment A0.3310.310
Treatment B0.3470.331
Treatment C0.3540.304
Treatment D0.3670.350
Treatment E0.2160.198
Treatment F0.3850.340

Heart Rate (HR) AUC(0-4h) and Peak(0-4h), Normalized by Time -- Change From Pre-dose to Post Dose Day 14

"Heart rate (HR) AUC(0-4h) and HR peak(0-4h), normalized by time (in bpm).~Results are shown as change from pre-dose on Day 14 (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~Definitions:~HR=Heart rate; HR AUC(0-4h)=Area under the curve between 0 and 4 h for heart rate; HR peak(0-4h)=The maximum observed value over 4 h after dosing;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose

,,,,,
Interventionbpm (Mean)
HR AUC(0-4h)HR peak(0-4h)
Treatment A-0.43.5
Treatment B0.55.1
Treatment C0.45.1
Treatment D1.35.3
Treatment E-0.24.3
Treatment F0.94.8

Heart Rate (HR) AUC(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"Heart rate HR AUC(0-4h) normalized by time. Results are shown by treatment group, as change from baseline (in bpm).~The HR AUC(0-4h) normalized by time is calculated based on the actual times, using the linear trapezoidal rule.~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionbpm (Mean)
Day 1Day 14
Treatment A0.22.3
Treatment B0.80.2
Treatment C2.73.5
Treatment D3.03.3
Treatment E-1.0-0.1
Treatment F0.31.2

Heart Rate (HR) Peak(0-4h), Normalized by Time -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"Heart rate (HR) peak(0-4h) normalized by time.~Results are shown by treatment group, as change from baseline (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.~Definitions:~HR=Heart rate; HR peak(0-4h)=The maximum observed value over 4 hours following dosing;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionbpm (Mean)
Day 1Day 14
Treatment A4.76.1
Treatment B4.44.8
Treatment C6.58.3
Treatment D7.57.3
Treatment E2.94.4
Treatment F5.15.2

Serum Glucose -- Change From Baseline to Post-dose Day 1 and Day 14

"Serum glucose level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionmmol/L (Mean)
Day 1; 1.5h post-doseDay 1; 3h post-doseDay 1; 5h post-doseDay 1; 7h post-doseDay 1; 11h post-doseDay 14; pre-doseDay 14; 1.5h post-doseDay 14; 3h post-doseDay 14; 5h post-doseDay 14; 7h post-doseDay 14; 11h post-dose
Treatment A0.490.450.830.810.98-0.340.090.090.04-0.040.39
Treatment B0.340.541.120.421.080.000.260.770.900.601.30
Treatment C0.571.101.111.241.890.490.971.311.120.731.50
Treatment D1.191.791.581.371.420.491.211.511.161.091.47
Treatment E0.470.260.510.841.400.370.350.250.320.251.03
Treatment F-0.060.390.440.610.90-0.03-0.030.160.530.180.68

Serum Potassium -- Change From Baseline Post-dose to Post Dose Day 1 and Day 14

"Serum potassium level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose

,,,,,
Interventionmmol/L (Mean)
Day 1; 1.5h post-doseDay 1; 3h post-doseDay 1; 5h post-doseDay 1; 7h post-doseDay 1; 11h post-doseDay 14; pre-doseDay 14; 1.5h post-doseDay 14; 3h post-doseDay 14; 5h post-doseDay 14; 7h post-doseDay 14; 11h post-dose
Treatment A-0.01-0.06-0.14-0.020.070.06-0.02-0.04-0.020.050.11
Treatment B-0.05-0.08-0.03-0.000.02-0.02-0.03-0.09-0.050.060.05
Treatment C-0.08-0.23-0.12-0.05-0.080.08-0.10-0.13-0.010.090.03
Treatment D-0.17-0.28-0.19-0.16-0.10-0.14-0.23-0.24-0.26-0.19-0.06
Treatment E-0.060.03-0.040.040.010.05-0.03-0.000.000.020.01
Treatment F-0.18-0.21-0.20-0.14-0.13-0.13-0.15-0.15-0.15-0.09-0.02

Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) -- Change From Baseline for Post-dose on Day 1 and on Day 14

"Vital signs -- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured at pre-specified times (at baseline - pre dose and on Day 14 of each treatment period or on the day of early study termination).~Results are shown by treatment group, as change from baseline (in mmHg).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~Definitions:~For safety variables, the baseline for each treatment period was defined as pre-dose measurements on Day 1 of each treatment period; Day 14=The day of the last dosing of a treatment period. Day 14 of the second, third, and fourth treatment periods (day of last dosing); treatments were separated by a 2-week wash-out interval;" (NCT03086460)
Timeframe: Baseline, Day 1 and Day 14 post-dose

,,,,,
InterventionmmHg (Mean)
SBP, Day 1, 30 min post-doseSBP, Day 1, 1 h post-doseSBP, Day 1, 4 h post-doseSBP, Day 1, 8 h post-doseSBP, Day 1, 12 h post-doseSBP, Day 14, pre-doseSBP, Day 14, 30 min post-doseSBP, Day 14, 1 h post-doseSBP, Day 14, 4 h post-doseSBP, Day 14, 8 h post-doseSBP, Day 14, 12 h post-doseDBP, Day 1, 30 min post-doseDBP, Day 1, 1 h post-doseDBP, Day 1, 4 h post-doseDBP, Day 1, 8 h post-doseDBP, Day 1, 12 h post-doseDBP, Day 14, pre-doseDBP, Day 14, 30 min post-doseDBP, Day 14, 1 h post-doseDBP, Day 14, 4 h post-doseDBP, Day 14, 8 h post-doseDBP, Day 14, 12 h post-dose
Treatment A-1.2-0.11.70.81.81.00.30.10.90.71.2-2.10.0-0.6-1.5-0.5-1.2-0.2-0.3-1.0-1.10.0
Treatment B0.20.50.40.22.1-1.8-3.1-1.80.11.31.0-1.5-1.9-1.4-0.9-0.10.1-2.1-2.4-1.5-1.0-0.7
Treatment C-0.8-0.6-0.91.13.00.0-0.7-1.8-1.41.11.5-1.2-0.4-0.4-0.40.41.1-0.8-0.5-1.70.30.7
Treatment D-1.2-0.60.90.71.4-0.4-0.7-1.91.00.64.4-2.0-1.6-1.0-1.9-1.0-0.1-2.9-2.4-2.5-2.6-0.6
Treatment E-0.5-0.80.20.5-0.1-2.5-3.6-1.7-0.5-3.3-0.3-0.3-2.5-1.6-1.7-0.3-0.6-1.5-1.80.4-1.71.4
Treatment F-0.8-0.80.52.53.4-0.3-2.5-1.1-0.80.62.5-1.2-1.7-1.00.40.0-0.7-2.0-1.6-2.3-1.3-0.1

Bronchodilator Response in Asthmatic Children

"To observe bronchodilator response(BDR) distribution curve for Chinese non-asthmatic children from 4-12 years, BDR calculated as: (FEV 1 L post-bronchodilator - FEV 1 L pre-bronchodilator)/FEV 1 L pre-bronchodilator × 100%.~To observe BDR distribution curve for Chinese controller-naïve asthmatic children from 4-12 years~To compare BDR values between non-asthmatic group and controller-naïve asthmatic group, and analyze appropriate cut-off point value" (NCT01500525)
Timeframe: 3 years

Interventionpercentage of BDR (Mean)
Asthmatic Children9.45
Non-asthmatic Children3.30

Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment.

We powered our study to detect a difference of 0.5 mmol/L between pre and post-treatment lactate levels, but hypothesize that the difference will be greater than 1.0 mmol/L. (NCT02073747)
Timeframe: Change in serum lactate from baseline to 1 hour

Interventionmmol/L (Mean)
Normal Saline Control Group-0.15
Albuterol Trial Group0.77

Length of Stay

Time to discharge eligibility (hours) (NCT00410150)
Timeframe: Hospital discharge

Interventionhours (Mean)
Heliox Group66.2
Control Group63.4

ANALYSIS OF LUNG DEPOSITION - Penetration Index

Images of the lungs will be taken for radiolabelled salbutamol treatment. The images will be processed using computer software and the lungs divided into central airways (C - region) and peripheral airways (P -region). We will analyse the amount of radiolabelled salbutamol in each region and calculate how deep into the lungs the inhaled salbutamol has reached by using the ratio C/P which is known as the Penetration Index. (NCT01721291)
Timeframe: 5 MINUTES AFTER INHALATION OF SALBUTAMOL

Interventionratio (Mean)
Healthy_1.5um Slow0.8
Healthy_1.5um Fast0.72
COPD 1_1.5um Slow0.69
COPD1_1.5um Fast0.58
Healthy_3um Slow0.75
Healthy_3um Fast0.63
COPD_3um Slow0.65
COPD_3um Fast0.48
Healthy_6um Slow0.51
Healthy_6um Fast0.46
COPD_6um Slow0.37
COPD_6um Fast0.32

Comparison of the Maximum Percent Fall in FEV1 After 1st Dose of Salmeterol to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Subjects

(NCT00595361)
Timeframe: 2 weeks after 1st dose of Salmeterol

Intervention% fall FEV1 (Mean)
Arg/Arg-12.6
Gly/Gly-16.5

Comparison of the Maximum Percent Fall in FEV1 After Exercise Challenge at the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients

(NCT00595361)
Timeframe: 2 weeks after exercise challenge

Intervention% fall FEV1 (Mean)
Arg/Arg12.6
Gly/Gly16.5

Comparison of the Maximum Percent Fall in FEV1 From Pre-salmeterol Baseline to the End of the 2-week Treatment Period Between Arg/Arg and Gly/Gly Patients

(NCT00595361)
Timeframe: 2 weeks from pre-salmeterol baseline

Intervention% fall FEV1 (Mean)
Arg/Arg5.9
Gly/Gly4.3

Total Number of Healthcare Visits

Determine differences in healthcare visits which include all-cause and respiratory related, acute care outpatient visits, emergency department visits, and hospitalizations between groups (NCT03137303)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Emergency room visit72551318Emergency room visit72551317Hospitalization72551317Hospitalization72551318Acute outpatient visit72551318Acute outpatient visit72551317Routine primary care visits72551317Routine primary care visits72551318New diagnostic tests72551318New diagnostic tests72551317
NoMissingYes
Patient Subject Usual Care111
Patient-Subject Intervention76
Patient Subject Usual Care119
Patient-Subject Intervention93
Patient Subject Usual Care1
Patient Subject Usual Care48
Patient-Subject Intervention17
Patient Subject Usual Care182
Patient-Subject Intervention152
Patient Subject Usual Care61
Patient-Subject Intervention35
Patient Subject Usual Care169
Patient-Subject Intervention134
Patient Subject Usual Care198
Patient-Subject Intervention138
Patient Subject Usual Care32
Patient-Subject Intervention31
Patient-Subject Intervention2
Patient Subject Usual Care126
Patient-Subject Intervention72
Patient Subject Usual Care104
Patient-Subject Intervention97

Duration of Continuous Nebulized Albuterol

Duration (in days) of continuous nebulized albuterol. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week

Interventiondays (Median)
Methylprednisolone Arm - Standard Care1
Dexamethasone Arm - Interventional Arm0.8

Length of Stay

Hospital length of stay measured in days. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week

Interventiondays (Mean)
Methylprednisolone Arm - Standard Care2.9
Dexamethasone Arm - Interventional Arm2.9

Number of Participants Receiving an Adjunctive Asthma Therapy

"Number of participants receiving an adjunctive therapy:~use of non-invasive ventilation (NIV)~terbutaline~inhaled helium~inhaled anesthetic gas~mechanical ventilation~extracorporeal life support" (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week

InterventionParticipants (Count of Participants)
Methylprednisolone Arm - Standard Care41
Dexamethasone Arm - Interventional Arm16

Corticosteroid-related Adverse Events

Rates of known corticosteroid-related adverse events including clinically-relevant gastrointestinal bleeding, gastritis, ventilator associated pneumonia, necrotizing enterocolitis, hypertension, hyperglycemia, altered mentation (including hallucinations and delirium), and adrenal insufficiency observed prior to hospital discharge. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week

,
InterventionParticipants (Count of Participants)
HyperglycemiaHypertensionAdrenal insufficiencyAltered mentationClinically-relevant gastrointestinal bleedingGastritisNecrotizing enterocolitisVentilator associated pneumonia
Dexamethasone Arm21000000
Methylprednisolone Arm71220000

Number of Participants With Unscheduled Use of Healthcare

Healthcare consists of one or other of hospital admission, emergency department attendance, unscheduled consultation with a GP (NCT00129987)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Nurse Group61
Lay Educator Group65

Number of Participants With Use of Asthma Medication

Number of participants with courses of steriod tablets (NCT00129987)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Nurse Group60
Lay Educator Group62

Number of Participants Returning to Care Following Discharge From the Emergency Department

The investigators will determine if each patient had any unscheduled visits to the emergency room, urgent care or primary care physician. (NCT02192827)
Timeframe: 5 days

InterventionParticipants (Count of Participants)
Single Dose Dexamethasone14
Two Dose Dexamethasone12

Reported Number of Days Until Symptom Resolution

Will determine number of days to symptom resolution, including missed school days. (NCT02192827)
Timeframe: 5 days

InterventionDays (Mean)
Single Dose Dexamethasone2.4
Two Dose Dexamethasone2.5

Reported Side Effects Experienced by Participants

The investigators will determine during phone follow up if patient experienced any side effects related to the Dexamethasone, including vomiting, mood swings, behavior changes, appetite changes, sweating or headache. (NCT02192827)
Timeframe: 5 days

,
InterventionParticipants (Count of Participants)
No side effectsDecreased AppetiteDifficulty SleepingMood swings/AgitationHeadacheOtherMultiple
Single Dose Dexamethasone714973517
Two Dose Dexamethasone837031418

Change in Mean Heart Rate

Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol (NCT00393367)
Timeframe: From the initial heart rate to heart rate 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionBeats per minute (Mean)
Budesonide Inhalation Suspension (BIS)12
Placebo (Normal Saline)13

Mean Change in Asthma Score at 2 Hours

The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator

InterventionUnits on a scale (Mean)
Budesonide Inhalation Suspension (BIS)-2.9
Placebo (Normal Saline)-3.0

Mean Change in Respiratory Rate.

Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator. (NCT00393367)
Timeframe: Initial rate, minus rate taken 2 hours after budesonide/albuterol intervention or saline/albuterol comparator

InterventionBreaths per minute (Mean)
Budesonide Inhalation Suspension (BIS)-6
Placebo (Normal Saline)-6

Median Change in Asthma Score 2 Hours After Intervention

The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator

InterventionUnits on a scale (Median)
Budesonide Inhalation Suspension (BIS)-3
Placebo (Normal Saline)-3

Number of Patients Hospitalized

The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician. (NCT00393367)
Timeframe: within 4 hours after the budesonide/albuterol intervention or saline/albuterol placebo

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)56
Placebo (Saline)55

Number of Subjects Moving From the Severe Asthma to Mild Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)8
Placebo (Normal Saline)10

Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)22
Placebo (Normal Saline)11

Number of Subjects Remaining in the Severe Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)4
Placebo (Normal Saline)4

Oxygen Saturation.

Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment. (NCT00393367)
Timeframe: 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator

InterventionPercent Hemoglobin Saturation (Mean)
Budesonide Inhalation Suspension (BIS)1.0
Placebo (Normal Saline)1.0

Relapse / Readmission Numbers.

Participants admitted to the hospital within 5 days of the ED visit (NCT00393367)
Timeframe: within 5 days of ED visit

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)2
Placebo (Normal Saline)2

Number of Participants With Adverse Events (Non-serious).

(NCT00393367)
Timeframe: within 30 days of the ED visit

,
InterventionParticipants (Number)
RhinorrheaHeadacheDiarrheaSore throatCoughHyperglycemia
Budesonide Inhalation Suspension (BIS)653422
Placebo (Normal Saline)1197330

Serious Adverse Events

Serious Adverse Events (NCT00393367)
Timeframe: 0-5 days

,
Interventionparticipants (Number)
Return within 5 days with hosptial admissionIncreased level of care
Budesonide Inhalation Suspension (BIS)21
Placebo (Saline)20

Area Under the Curve From Time Zero to 6 Hours Post-dose (AUC[0-6]) for Total Epinephrine

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Area under the curve from time zero to 6 hours post-dose (AUC[0-6]) was calculated using the trapezoidal rule. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose

Interventionpg*min/mL (Mean)
Treatment T8498
Treatment C6191

Baseline Concentration (C0) of Total Epinephrine

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at Baseline (prior to dosing) in each treatment period following a specified washout period (3-14 days), and were analyzed using an established analysis method. Baseline concentration (C0) is the concentration of epinephrine measured in the plasma at this time point. (NCT01188577)
Timeframe: 0 to 30 minutes prior to dosing

Interventionpg/mL (Mean)
Treatment T2.6
Treatment C4.3

Half-life (t1/2) of Total Epinephrine

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Half-life (t1/2) is the amount of time it takes for epinephrine to decrease to half the peak concentration in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose

Interventionmin (Mean)
Treatment T145.9
Treatment C289.8

Peak Concentration (Cmax) of Total Epinephrine From Time Zero to 6 Hours Post-dose

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Peak (maximum) concentration (Cmax) is the highest concentration of epinephrine measured in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose

Interventionpg/mL (Mean)
Treatment T862
Treatment C190

Time to Reach Peak Concentration (Tmax) for Total Epinephrine

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Tmax is the amount of time it takes for epinephrine to reach peak concentration in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose

Interventionmin (Mean)
Treatment T2.3
Treatment C3.4

Concentration vs. Time for Total Epinephrine From Time Zero to 6 Hours Post-dose

Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose

,
Interventionpg/mL (Mean)
0 min (Baseline)2 min post-dose5 min post-dose7.5 min post-dose10 min post-dose12.5 min post-dose15 min post-dose20 min post-dose25 min post-dose30 min post-dose45 min post-dose60 min post-dose90 min post-dose120 min post-dose240 min post-dose360 min post-dose
Treatment C4.3189.099.148.839.733.932.030.120.317.719.813.211.26.917.717.2
Treatment T2.6861.5379.4186.6118.375.646.822.910.910.510.58.73.56.516.117.1

Airway Blood Flow (Qaw)

Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days. (NCT01219738)
Timeframe: participants will be followed for 6 hours after budesonide dose

Interventionpercentage of change from baseline (Mean)
Budesonide 360ug22.3
Budesonide 720ug29.4
Budesonide 1440ug34.1
Budesonide 720ug 4 Times28.2
Placebo5.1

Forced Expiratory Volume in 1 Second (FEV1)

FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days. (NCT01219738)
Timeframe: participant will be followed up to 6 hours after budesonide dose

Interventionpercentage of change from baseline (Mean)
Budesonide 360 ug0.1
Budesonide 720 ug3.2
Budesonide 1440 ug1.6
720ug of Budesonide 4 Times3.2
Placebo0.8

LAR - Non-smokers: Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 4-10 hours post-allergen challenge is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)

InterventionLiters (Least Squares Mean)
Placebo-1.034
FP 100 µg-0.396
FP 500 µg-0.373

LAR - Non-smokers: Absolute Change From Saline in WM FEV1 Between 4-10 Hrs Following Post-treatment Allergen Challenge on Day 6 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 6. The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. LAR WM FEV1 was measured at 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 6. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)

InterventionLiters (Least Squares Mean)
Placebo-0.688
FP 100 µg-0.212
FP 500 µg-0.158

LAR - Smokers: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following Post-treatment Allergen Challenge on Day 6 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 6. The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. LAR WM FEV1 was measured at 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 6. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)

InterventionLiters (Least Squares Mean)
Placebo-0.364
FP 100 µg-0.188
FP 500 µg-0.198

Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 4-10 hours post-allergen challenge is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)

InterventionLiters (Least Squares Mean)
Placebo-0.592
FP 100 µg-0.420
FP 500 µg-0.431

Absolute Change From Baseline in FEV1 Post-dose on Day 1, Day 6 (Prior to Allergen Challenge), and Day 7

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline FEV1 was measured on Day 1 pre-dose administration. FEV1 was measured on Day 1 post-dose, on Day 6 (prior to allergen challenge), and on Day 7 pre dose administration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Baseline, Day 1, Day 6, and Day 7

,,
InterventionLiters (Least Squares Mean)
Day 1, Smokers, n=17, 17, 17Day 6, Smokers, n=16, 17, 17Day 7, Smokers, n=17, 17, 17Day 1, Non-smokers, n=16, 18, 17Day 6, Non-smokers, n=18, 18, 18Day 7, Non-smokers, n=18, 18, 18
FP 100 µg0.2160.016-0.0830.2370.114-0.079
FP 500 µg0.1770.032-0.0530.2170.0580.012
Placebo0.156-0.081-0.1230.201-0.028-0.341

Concentration of Exhaled Nitric Oxide (eNO) on Day 6 and Day 7 of Each Treatment Period

The concentration of eNO was measured on Day 6 pre-dose and on Day 7 post-study medication administration. eNO was measured 3 times at each time point, and all 3 measurements were recorded. The mean of the 3 measurements was calculated and was used in the derivation of summary statistics. (NCT01400906)
Timeframe: Day 6 and Day 7 of each treatment period (up to 11 weeks)

,,
InterventionParts per billion (Mean)
Day 6, Pre-dose, Smokers, n=16, 17, 17Day 7, Post-dose, Smokers, n=17, 17, 17Day 6, Pre-dose, Non-smokers, n=17, 18, 18Day 7, Post-dose, Non-smokers, n=18, 18, 18
FP 100 µg12.71816.60237.25242.869
FP 500 µg14.04916.29832.57234.989
Placebo21.11745.16762.98098.837

Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 and WM FEV1 Between 0-2 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes [min], 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs). The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)

,,
InterventionLiters (Least Squares Mean)
Minimum FEV1, Smokers, n=16, 17, 17Minimum FEV1, Non-smokers, n=18, 18, 18WM FEV1, Smokers, n=16, 17, 17WM FEV1, Non-smokers, n=18, 18, 18
FP 100 µg-0.769-0.743-0.303-0.349
FP 500 µg-0.817-0.676-0.362-0.311
Placebo-0.799-0.984-0.423-0.531

Neutrophil and Eosinophil Cell Counts in Induced Sputum on Day 7 of Each Treatment Period

Sputum induction was performed using hypertonic saline solution to collect an adequate sample of secretions from lungs. The collected sputum was analyzed for neutrophil and eosinophil counts. Sputum induction was performed after methacholine challenge and post-dose administration on Day 7. Zero values are imputed to 0.001 for this analysis. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 7 of each treatment period (up to 11 weeks)

,,
Intervention10^4 cells per gram of sputum (Geometric Mean)
Eosinophil count, Smokers, n=7, 7, 5Eosinophil count, Non-smokers, n=11, 11, 10Neutrophil count, Smokers, n=7, 7, 5Neutrophil count, Non-smokers, n=11, 11, 10
FP 100 µg0.4890.87850.31349.532
FP 500 µg0.4590.14487.69936.561
Placebo0.4006.91196.23178.768

Provocative Concentration of Methacholine Resulting in a 20% Reduction in FEV1 (PC20) on Day 7 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a >=20% decrease in FEV1 from the post-saline value was achieved. (NCT01400906)
Timeframe: Day 7 of each treatment period (up to 11 weeks)

,,
Interventionmilligrams per milliliter (Geometric Mean)
Smokers, n=16, 17, 17Non smokers, n=18, 17, 18
FP 100 µg1.2331.488
FP 500 µg1.4392.080
Placebo0.5790.514

Reviews

291 reviews available for albuterol and Asthma

ArticleYear
Recent Advances in β
    Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24

    Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle

2020
The environmental impact of inhalers for asthma: A green challenge and a golden opportunity.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:7

    Topics: Administration, Inhalation; Albuterol; Asthma; Dry Powder Inhalers; Environment; Greenhouse Gases; H

2022
Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis.
    Chinese medical journal, 2021, Nov-15, Volume: 134, Issue:24

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic

2021
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
    CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Doping in Sports; Humans; Substance Abuse Detection

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Salbutamol in the Management of Asthma: A Review.
    International journal of molecular sciences, 2022, Nov-17, Volume: 23, Issue:22

    Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors

2022
Pharmacists' perspectives on school stock inhaler access for children.
    Journal of public health policy, 2023, Volume: 44, Issue:3

    Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers; Pharmacists; Surveys and Questionnaires

2023
Asthma Care Protocol Implementation in the Pediatric Intensive Care Unit.
    Critical care nursing clinics of North America, 2023, Volume: 35, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Hospitalization; Humans; Intensive Care Units, Pedi

2023
Breathe easy: inhalational therapy for feline inflammatory airway disease.
    Journal of feline medicine and surgery, 2023, Volume: 25, Issue:9

    Topics: Albuterol; Animals; Asthma; Bronchitis, Chronic; Cat Diseases; Cats; Emotions; Humans; Veterinarians

2023
BET 1: Efficacy of different techniques using a metered-dose inhaler with Spacer to relieve symptoms in children with acute asthma.
    Emergency medicine journal : EMJ, 2019, Volume: 36, Issue:11

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Equipment Design; Female; Hu

2019
Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis.
    Pediatric pulmonology, 2020, Volume: 55, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Disease

2020
A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Polymorphism, Single Nucleotide; Receptors, Adrene

2021
Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2021
A compendium and review of pediatric pulmonary function testing assessment opportunities for asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2022, Volume: 59, Issue:8

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans; Respi

2022
Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.
    Drug safety, 2018, Volume: 41, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreacti

2018
Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).
    Pulmonary pharmacology & therapeutics, 2018, Volume: 53

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volu

2018
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2018, 12-03, Volume: 12

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Age Factors; Albute

2018
[Asthmatic attack].
    MMW Fortschritte der Medizin, 2018, Volume: 160, Issue:21-22

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Middle Aged; Respiratory Sounds

2018
Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
    Sports medicine (Auckland, N.Z.), 2019, Volume: 49, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Albuterol; Asthma; Athletes; Bronch

2019
Tolerance & resistance to β₂-agonist bronchodilators.
    Paediatric respiratory reviews, 2013, Volume: 14, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents;

2013
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Ast

2013
Clinical Practice. Mild asthma.
    The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Algorithms; Anti-Asthmatic Agents;

2013
Development of the siriraj clinical asthma score.
    Asian Pacific journal of allergy and immunology, 2013, Volume: 31, Issue:3

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; In

2013
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.
    The Cochrane database of systematic reviews, 2014, Feb-06, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy,

2014
[Pregnancy and bronchial asthma].
    Arerugi = [Allergy], 2014, Volume: 63, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A

2014
[Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD].
    Pneumonologia i alergologia polska, 2014, Volume: 82, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosol Propellants; Aerosols; Albuterol; Asth

2014
Intravenous salbutamol for childhood asthma: evidence-based medicine?
    Archives of disease in childhood, 2014, Volume: 99, Issue:9

    Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Evid

2014
COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Respiratory medicine, 2014, Volume: 108, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma

2014
What is the role of tiotropium in asthma?: a systematic review with meta-analysis.
    Chest, 2015, Volume: 147, Issue:2

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Cholinergic Antagonists; Disease Progression; Drug Thera

2015
[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].
    Revue des maladies respiratoires, 2014, Volume: 31, Issue:8

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinati

2014
Advances in acute asthma.
    Current opinion in pulmonary medicine, 2015, Volume: 21, Issue:1

    Topics: Acute Disease; Adrenergic beta-1 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents;

2015
Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
    Expert opinion on drug delivery, 2015, Volume: 12, Issue:6

    Topics: Albuterol; Androstadienes; Asthma; Beclomethasone; Drug Combinations; Dry Powder Inhalers; Ethanolam

2015
Anticholinergics for treatment of asthma.
    Journal of investigational allergology & clinical immunology, 2015, Volume: 25, Issue:2

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agen

2015
Salmeterol Xinafoate.
    Profiles of drug substances, excipients, and related methodology, 2015, Volume: 40

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Biotran

2015
Question 2: Blast from the past: is oral salbutamol useful in resource-poor settings?
    Archives of disease in childhood, 2015, Volume: 100, Issue:8

    Topics: Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents;

2015
In brief: a new albuterol inhaler (ProAir RespiClick) for asthma.
    The Medical letter on drugs and therapeutics, 2015, Oct-26, Volume: 57, Issue:1480

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Forced Expiratory Volume; Humans; M

2015
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.
    The Cochrane database of systematic reviews, 2015, Nov-24, Issue:11

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast

2015
Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:9

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Ap

2016
Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma.
    The Cochrane database of systematic reviews, 2017, 01-11, Volume: 1

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Atropine; Cholinergic

2017
Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events.
    Annals of internal medicine, 2008, Jul-01, Volume: 149, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br

2008
[Causes of prolonged and chronic cough].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr

2008
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
    The Cochrane database of systematic reviews, 2008, Jul-16, Issue:3

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Drug Combination

2008
Regular treatment with salmeterol for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2008, Jul-16, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ca

2008
Regular treatment with formoterol for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2008, Oct-08, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Chron

2008
The risk of asthma mortality with inhaled long acting beta-agonists.
    Postgraduate medical journal, 2008, Volume: 84, Issue:995

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic A

2008
Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review.
    Pulmonary pharmacology & therapeutics, 2009, Volume: 22, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

2009
Safety of long-acting beta2-agonists in the treatment of asthma.
    Therapeutic advances in respiratory disease, 2007, Volume: 1, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2007
Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.
    Therapeutic advances in respiratory disease, 2008, Volume: 2, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Budesonide; Disease Progressi

2008
Use of dry powder inhalers in acute exacerbations of asthma and COPD.
    Therapeutic advances in respiratory disease, 2009, Volume: 3, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Ethanolamin

2009
Seretide: a pharmacoeconomic analysis.
    Journal of medical economics, 2008, Volume: 11, Issue:3

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol

2008
[Asthma therapy: combination of topical glucocorticosteroids and theophylline].
    Medizinische Klinik (Munich, Germany : 1983), 1997, Volume: 92 Suppl 5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; B

1997
[Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].
    Medizinische Klinik (Munich, Germany : 1983), 1997, Volume: 92 Suppl 5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Ant

1997
Safety of long-acting beta-agonists: are new data really required?
    Chest, 2009, Volume: 136, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; De

2009
Should salmeterol be used for long-term asthma control?
    American family physician, 2009, Jun-01, Volume: 79, Issue:11

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Evidence-Based Medicine; Female; Humans;

2009
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agen

2009
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast

2009
Current options in the treatment of acute bronchospasm.
    Postgraduate medicine, 2005, Volume: 118, Issue:6 Suppl Ac

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; A

2005
Review article: management of acute severe and near-fatal asthma.
    Emergency medicine Australasia : EMA, 2009, Volume: 21, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Albuterol; Amino

2009
Salmeterol/fluticasone propionate: a review of its use in asthma.
    Drugs, 2009, Volume: 69, Issue:13

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Drug Combination

2009
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma;

2009
Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Androst

2009
[Do fixed combinations increase effectiveness in asthma bronchiale?].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134 Suppl 10

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmati

2009
[Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134 Suppl 10

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm

2009
Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy.
    Thorax, 2010, Volume: 65, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodila

2010
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast

2010
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:1

    Topics: Acetates; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Mass Index; Cyclopro

2010
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Clinical therapeutics, 2009, Volume: 31, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al

2009
Stopping long-acting beta-2 agonists.
    The Medical letter on drugs and therapeutics, 2010, Mar-22, Volume: 52, Issue:1334

    Topics: Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol;

2010
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.
    The Cochrane database of systematic reviews, 2010, May-12, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al

2010
Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic

2010
Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000-2009 period.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:9

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bude

2010
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma.
    The Cochrane database of systematic reviews, 2010, Sep-08, Issue:9

    Topics: Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Cromolyn Sodium; Et

2010
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    Sao Paulo medical journal = Revista paulista de medicina, 2010, Volume: 128, Issue:5

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Ethanolamines; Formoterol Fumarate; Glu

2010
[Bronchial asthma in children].
    Arerugi = [Allergy], 2011, Volume: 60, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2011
(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:7

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Pulmonary Dis

2011
Safe use of long-acting β-agonists: what have we learnt?
    Expert opinion on drug safety, 2011, Volume: 10, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Ethanolamines; Formoterol Fum

2011
Controversies regarding long-acting β2-agonists.
    Current opinion in allergy and clinical immunology, 2011, Volume: 11, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asth

2011
Safety of formoterol in adults and children with asthma: a meta-analysis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 107, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Child,

2011
[What helps for persistent symptoms of asthma during inhalative steroid therapy?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:42

    Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists;

2011
Single maintenance and reliever therapy (SMART) for asthma.
    Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol;

2011
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Drug

2011
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2012, Mar-14, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Asthmatic Agent

2012
Anticholinergic therapy for acute asthma in children.
    The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albutero

2012
Regular treatment with formoterol for chronic asthma: serious adverse events.
    The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Chron

2012
[Salbutamol in asthma treatment: with nebulizer or inhaler?].
    Tuberkuloz ve toraks, 2012, Volume: 60, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery Systems

2012
Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature.
    Clinical pediatrics, 2012, Volume: 51, Issue:12

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenal Insufficiency; Albuterol; Androstadiene

2012
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews.
    The Cochrane database of systematic reviews, 2012, Oct-17, Volume: 10

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Therapy, Combination; Ethanolamines; Formotero

2012
Management of asthma during pregnancy.
    Therapeutic advances in respiratory disease, 2013, Volume: 7, Issue:2

    Topics: Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, M

2013
Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.
    Pulmonary pharmacology & therapeutics, 2013, Volume: 26, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Stereoiso

2013
Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.
    The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12

    Topics: Acetamides; Acute Disease; Administration, Inhalation; Administration, Intravenous; Adrenal Cortex H

2012
Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
    Respiratory medicine, 2012, Volume: 106 Suppl 1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Ast

2012
Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis.
    Chest, 2002, Volume: 122, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Confidence Intervals; D

2002
[symbol: see text] Seretide and [symbol: see text] Symbicort in asthma management.
    Drug and therapeutics bulletin, 2002, Volume: 40, Issue:8

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Ast

2002
Antagonism of long-acting beta2-adrenoceptor agonism.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla

2002
Safety of sputum induction.
    The European respiratory journal. Supplement, 2002, Volume: 37

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage;

2002
Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:12

    Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Clinical Trials

2002
beta2-Agonists in acute asthma: the evolving state of the art.
    Pediatric emergency care, 2002, Volume: 18, Issue:6

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Infusions

2002
The long and short of beta2-agonists.
    Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2002
From adrenaline to formoterol: advances in beta-agonist therapy in the treatment of asthma.
    International journal of clinical practice, 2002, Volume: 56, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Etha

2002
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.
    The Cochrane database of systematic reviews, 2002, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Ethanolamines; For

2002
Single-isomer levalbuterol: a review of the acute data.
    Current allergy and asthma reports, 2003, Volume: 3, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Humans

2003
Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD.
    Drugs of today (Barcelona, Spain : 1998), 2002, Volume: 38, Issue:9

    Topics: Administration, Inhalation; Albuterol; Area Under Curve; Asthma; Biological Availability; Bronchodil

2002
[Milestones in inhalation therapy of airway diseases].
    Medizinische Klinik (Munich, Germany : 1983), 2002, Dec-15, Volume: 97 Suppl 2

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Aerosols; Albuterol;

2002
[State of the art of the inhalation therapy of asthma].
    Medizinische Klinik (Munich, Germany : 1983), 2002, Dec-15, Volume: 97 Suppl 2

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Albuterol; All

2002
Mechanisms of asthma.
    The Journal of allergy and clinical immunology, 2003, Volume: 111, Issue:3 Suppl

    Topics: Adenine; Adult; Albuterol; Asthma; Bronchodilator Agents; Chemokines; Child; Cytokines; Disease Prog

2003
Long-term management of asthma.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:1

    Topics: Administration, Inhalation; Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bro

2003
Salmeterol (Serevent) asthma trial halted early.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Mar-18, Volume: 168, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Black People; Humans; Multicente

2003
Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids.
    QJM : monthly journal of the Association of Physicians, 2003, Volume: 96, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanol

2003
Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Rela

2003
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:1

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Drug Synergism; Drug Therapy, Combina

2003
Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
    The Cochrane database of systematic reviews, 2003, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio

2003
[Pharmacological action and clinical aspects of salmeterol].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2003, Volume: 122, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2003
Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    PharmacoEconomics, 2003, Volume: 21, Issue:13

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Drug Combinations;

2003
Inhaled long acting beta agonists for stable chronic asthma.
    The Cochrane database of systematic reviews, 2003, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumara

2003
Novolizer: a multidose dry powder inhaler.
    Drugs, 2003, Volume: 63, Issue:22

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agent

2003
State of the art in beta2-agonist therapy: a safety review of long-acting agents.
    International journal of clinical practice, 2003, Volume: 57, Issue:8

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Drug

2003
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.
    British journal of clinical pharmacology, 2004, Volume: 57, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Ethanolamines; Forced Expiratory Volu

2004
Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.
    American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Do

2002
Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma?
    Emergency medicine journal : EMJ, 2004, Volume: 21, Issue:1

    Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans; Infusions, Intravenous

2004
[Fixed combination of inhalant steroids and long-acting beta(2) agonists].
    Deutsche medizinische Wochenschrift (1946), 2004, Jan-30, Volume: 129, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2004
[Recent study on pathogenesis of bronchial asthma and the therapeutic strategy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Mar-10, Volume: 93, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Anti-Inflamm

2004
Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:8

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Br

2004
Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.
    The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Molecular Structure; Pulmonary Disease, Chronic Ob

2004
The cost effectiveness of levalbuterol versus racemic albuterol.
    The American journal of managed care, 2004, Volume: 10, Issue:5 Suppl

    Topics: Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Humans; Stereoisomerism; United Sta

2004
Combination therapy in asthma--fixed or variable dosing in different patients?
    Current medical research and opinion, 2004, Volume: 20, Issue:11

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Budesonide; Bu

2004
The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma.
    Respiratory medicine, 2004, Volume: 98, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Drug Administration Schedule;

2004
[Treatment of exacerbation of asthma: what are today's issues?].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005, Volume: 12, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aeroso

2005
What is new with the beta2-agonists: issues in the management of asthma.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Clin

2005
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
    Drugs, 2005, Volume: 65, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2005
Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
    Drugs, 2005, Volume: 65, Issue:12

    Topics: Acetates; Administration, Inhalation; Albuterol; Androstadienes; Asthma; Asthma, Exercise-Induced; B

2005
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
    Thorax, 2005, Volume: 60, Issue:9

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent

2005
Advances in pediatric asthma and atopic dermatitis.
    Current opinion in pediatrics, 2005, Volume: 17, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Calcineurin Inhibitors; Child; Dermatitis, Atopic; Dermato

2005
Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:9

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And

2005
Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    European journal of pharmacology, 2006, Mar-08, Volume: 533, Issue:1-3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; A

2006
Beta-adrenoceptor responses of the airways: for better or worse?
    European journal of pharmacology, 2006, Mar-08, Volume: 533, Issue:1-3

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory

2006
Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2006, Volume: 5, Issue:4

    Topics: Acetylcysteine; Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Anti-Bacterial Agents;

2006
Asthma pathophysiology and evidence-based treatment of severe exacerbations.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, May-15, Volume: 63, Issue:10 Suppl 3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Disease Progression; Evidence-Based Medicine; Humans; S

2006
Managing acute attacks of asthma.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2006, Volume: 10, Issue:5

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2006
Best evidence topic reports. Beta-agonists with or without anti-cholinergics in the treatment of acute childhood asthma?
    Emergency medicine journal : EMJ, 2006, Volume: 23, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilat

2006
Long-acting beta-agonists role in asthma management.
    The Journal of family practice, 2006, Volume: Suppl

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; C

2006
Heliox-driven albuterol nebulization for asthma exacerbations: an overview.
    Respiratory care, 2006, Volume: 51, Issue:6

    Topics: Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Delivery Systems;

2006
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.
    Annals of internal medicine, 2006, Jun-20, Volume: 144, Issue:12

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch

2006
[Comparison of different vehicles for nebulized salbutamol in treatment of bronchial asthma exacerbations: a Meta-analysis].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2006, Volume: 35, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Female; Humans; Magnesium Sulfate; Male; Nebulizers and

2006
Long-acting beta2-agonists in asthma: not so SMART?
    Drug safety, 2006, Volume: 29, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2006
[Right and wrong of salmeterol/fluticasone propionate combination].
    Arerugi = [Allergy], 2006, Volume: 55, Issue:7

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone; Humans; Sa

2006
Review of guidelines and the literature in the treatment of acute bronchospasm in asthma.
    Pharmacotherapy, 2006, Volume: 26, Issue:9 Pt 2

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchial Spasm; Bronchodil

2006
Managing bronchospasm with short-acting beta(2)-agonists.
    The Nurse practitioner, 2006, Volume: 31, Issue:9

    Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Asth

2006
Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe.
    Primary care respiratory journal : journal of the General Practice Airways Group, 2006, Volume: 15, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As

2006
Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma.
    Respiration; international review of thoracic diseases, 2007, Volume: 74, Issue:1

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Controlled Cli

2007
Formoterol as a rescue medication for asthma.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doub

2006
The controversy over long-acting beta agonists: examining the evidence.
    Cleveland Clinic journal of medicine, 2006, Volume: 73, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Black or African American;

2006
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Chronic Disease; E

2007
Evidence based review on levosalbutamol.
    Indian journal of pediatrics, 2007, Volume: 74, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Child;

2007
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13

    Topics: Adrenergic beta-Agonists; Aerosol Propellants; Albuterol; Asthma; Atmosphere; Bronchodilator Agents;

2007
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
    Current medical research and opinion, 2007, Volume: 23, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast

2007
Levalbuterol for asthma: a better treatment?
    Current allergy and asthma reports, 2007, Volume: 7, Issue:4

    Topics: Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Clinical Trials as Top

2007
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.
    The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio

2007
Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma.
    Respiratory medicine, 2008, Volume: 102, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; A

2008
beta-Adrenergic receptor polymorphisms: relationship to the beta-agonist controversy and clinical implications.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:18

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Genotype

2007
Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2008
Safety of long-acting beta-agonists in asthma: a review.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
The role of magnesium sulfate in the acute and chronic management of asthma.
    Current opinion in pulmonary medicine, 2008, Volume: 14, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu

2008
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.
    Lancet (London, England), 2007, Dec-22, Volume: 370, Issue:9605

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Budesonide; Ethanolamines; Female; Formoterol Fu

2007
Vascular remodelling in asthma.
    Current opinion in allergy and clinical immunology, 2008, Volume: 8, Issue:1

    Topics: Adolescent; Albuterol; Animals; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Matr

2008
Inhalatory therapy training: a priority challenge for the physician.
    Acta bio-medica : Atenei Parmensis, 2007, Volume: 78, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aerosols; Aged; Albuterol; Androstadiene

2007
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review.
    Thorax, 2008, Volume: 63, Issue:5

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists;

2008
Pharmacogenetic response to albuterol among asthmatics.
    Pharmacogenomics, 2008, Volume: 9, Issue:5

    Topics: Albuterol; Asthma; Genetic Variation; Humans; Pharmacogenetics; Receptors, Adrenergic, beta-2

2008
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
    Medizinische Klinik (Munich, Germany : 1983), 2008, May-15, Volume: 103, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb

2008
Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
    Naunyn-Schmiedeberg's archives of pharmacology, 2008, Volume: 378, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And

2008
Adrenergic drugs.
    Clinical reviews in allergy, 1983, Volume: 1, Issue:1

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Catecholamines; Chemical Phenomena; Chemistry

1983
[Preventive treatment of asthma due to exertion in children: comparative study of 4 drugs].
    La Pediatria, 1981, Dec-31, Volume: 89, Issue:4

    Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Beclomethasone; Child; Cromolyn S

1981
Adrenergic agents in acute asthma: valuable new alternatives.
    Annals of emergency medicine, 1983, Volume: 12, Issue:8

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Epinephrine; Humans; Iso

1983
Bronchial asthma in adults: presentation to the emergency department. Part II: Sympathomimetics, respiratory failure, recommendations for initial treatment, indications for admission, and summary.
    The American journal of emergency medicine, 1983, Volume: 1, Issue:3

    Topics: Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Emergencies; Epinephrine; Humans; Hydroge

1983
Response: asthma in childhood.
    The Journal of allergy and clinical immunology, 1983, Volume: 72, Issue:5 Pt 2

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aerosols; Albuterol; Asthma; Bronchodilator Agents; C

1983
[Inhalation provocation tests in the diagnosis of bronchial asthma].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1982, Aug-02, Volume: 37, Issue:26

    Topics: Albuterol; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Carbachol; Evaluation Studies as

1982
Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance.
    The Journal of allergy and clinical immunology, 1981, Volume: 68, Issue:5

    Topics: Aerosols; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Cold Temperatu

1981
Salmeterol for the treatment of asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chro

1995
Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?
    Chest, 1995, Volume: 107, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol F

1995
Administration of albuterol by continuous nebulization.
    AACN clinical issues, 1995, Volume: 6, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers

1995
Salmeterol: its place in asthma management.
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Sche

1994
Salmeterol in the management of paediatric asthma.
    Respiratory medicine, 1994, Volume: 88, Issue:9

    Topics: Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-Induced; Bronchodilator

1994
Salmeterol: a novel, long-acting beta 2-agonist.
    The Annals of pharmacotherapy, 1993, Volume: 27, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Clinic

1993
Beta-agonist inhaler causing hallucinations.
    Pediatric emergency care, 1994, Volume: 10, Issue:2

    Topics: Albuterol; Animals; Asthma; Child; Chlorofluorocarbons, Methane; Hallucinations; Humans; Male; Nebul

1994
Beta 2-agonists as anti-inflammatory therapies in the lung.
    Agents and actions. Supplements, 1993, Volume: 41

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchitis; Ca

1993
Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.
    Lung, 1993, Volume: 171, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity;

1993
Evolution of asthma treatments.
    Annals of allergy, 1993, Volume: 71, Issue:3

    Topics: Albuterol; Asthma; Beclomethasone; Humans

1993
Efficacy and safety of salmeterol in childhood asthma.
    European journal of pediatrics, 1995, Volume: 154, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A

1995
[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Allergic Agents; Asthma; Bronchi; Bronchial Hyperreactivit

1996
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote

1996
Bronchodilators: new drugs and controversies.
    Current opinion in pulmonary medicine, 1997, Volume: 3, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bron

1997
A paradoxical effect of bronchodilators.
    Chest, 1997, Volume: 111, Issue:6

    Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents;

1997
Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?
    Drug safety, 1997, Volume: 16, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bro

1997
Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.
    Drugs, 1997, Volume: 54, Issue:2

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans;

1997
Salmeterol in the treatment of chronic asthma.
    American family physician, 1997, Volume: 56, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Humans; Salmeterol Xinafoate

1997
Long-acting beta 2-agonists. Role in primary care asthma treatment.
    Canadian family physician Medecin de famille canadien, 1997, Volume: 43

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Ethanolamines; Formoterol

1997
New developments in bronchodilator therapy.
    Current opinion in pulmonary medicine, 1996, Volume: 2, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-Agonists;

1996
Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant?
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 80, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Age

1998
Long-acting beta(2)-agonists: how are they used in an optimal way?
    Respiratory medicine, 1997, Volume: 91, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule; Dr

1997
Sympathomimetic enantiomers and asthma.
    Chirality, 1998, Volume: 10, Issue:3

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Clinical Trials as Topic; Humans; Isoprot

1998
Long-acting inhaled beta2-agonists in asthma therapy.
    Chest, 1998, Volume: 113, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Spasm; Ethanolamines; Formoterol Fum

1998
Salmeterol: a long-acting beta 2-agonist.
    The Journal of the American Osteopathic Association, 1998, Volume: 98, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist

1998
Bronchodilator therapy in asthma.
    Acta microbiologica et immunologica Hungarica, 1998, Volume: 45, Issue:1

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; Treat

1998
Recent findings in asthma likely to impact patient care.
    Comprehensive therapy, 1998, Volume: 24, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Gastroesophageal Reflux; Humans;

1998
The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Fe

1998
An overview of nine clinical trials of salmeterol in an asthmatic population.
    Respiratory medicine, 1998, Volume: 92, Issue:5

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administration Sch

1998
[Inhaler therapy for adults with obstructive lung diseases: powder or aerosol?].
    Nederlands tijdschrift voor geneeskunde, 1998, Jun-13, Volume: 142, Issue:24

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Human

1998
Inhaled beta2-agonists and airway responses to allergen.
    The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:5

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens;

1998
A steroid-induced acute psychosis in a child with asthma.
    Pediatric pulmonology, 1998, Volume: 26, Issue:5

    Topics: Acute Disease; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; Dose-Respo

1998
Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate

1998
Newer therapeutic agents for asthma.
    Advances in internal medicine, 1999, Volume: 44

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadi

1999
Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.
    PharmacoEconomics, 1995, Volume: 7, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Drug Costs; Humans; Quality

1995
Newer therapeutic agents for asthma.
    Disease-a-month : DM, 1999, Volume: 45, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator A

1999
Salmeterol/fluticasone propionate combination.
    Drugs, 1999, Volume: 57, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast

1999
[Established combinations of inhaled corticoids and long-acting beta 2-symphathomimetics for long-term therapy of bronchial asthma. Position of an expert panel study].
    Pneumologie (Stuttgart, Germany), 1999, Volume: 53, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

1999
Contrasting properties of albuterol stereoisomers.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 2

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstriction; Bronchodilator Agents; Dr

1999
Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Lung Disea

1999
The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 2

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchoconstriction; Bronchodilator A

1999
Clinical experience with levalbuterol.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as

1999
Long-acting beta 2-agonists: the new symptom controllers for asthma.
    The Medical journal of Australia, 1999, Sep-06, Volume: 171, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Alg

1999
A meta-analysis of the effects of ipratropium bromide in adults with acute asthma.
    The American journal of medicine, 1999, Volume: 107, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc

1999
[A rational combination for the treatment of asthma. Salmeterol and fluticasone in one preparation].
    Pneumologie (Stuttgart, Germany), 1999, Volume: 53, Issue:9

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations;

1999
Atopic diseases and upper respiratory infections.
    Current opinion in pediatrics, 1999, Volume: 11, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child

1999
Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
    Thorax, 1999, Volume: 54, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Chlorofluorocarbons; Clinical Trials as Topic; Drug Del

1999
New millennium bronchodilators for asthma: single-isomer beta agonists.
    Current opinion in pulmonary medicine, 2000, Volume: 6, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchoconstrictor Agents; Bronchodilator Agen

2000
Management of respiratory failure in patients with asthma.
    Current opinion in pulmonary medicine, 2000, Volume: 6, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Calcium Channel Blockers; Gluc

2000
Long-acting inhaled beta 2-agonists in the management of asthma: recent advances and current recommendations.
    International journal of clinical practice, 1998, Volume: 52, Issue:7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Forced Expiratory

1998
Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?
    Pharmacotherapy, 2000, Volume: 20, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Huma

2000
Association of sputum parameters with clinical and functional measurements in asthma.
    Thorax, 2000, Volume: 55, Issue:3

    Topics: Albuterol; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Eosinophils; Forced Expirato

2000
Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
    Pediatric pulmonology, 2000, Volume: 29, Issue:3

    Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Asth

2000
Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
    PharmacoEconomics, 1999, Volume: 16 Suppl 2

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

1999
Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio

2000
Bronchodilator resuscitation in the emergency department. Part 2 of 2: dosing strategies.
    Respiratory care, 2000, Volume: 45, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Airway Obstruction; Albuterol; Asthm

2000
Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).
    BMJ (Clinical research ed.), 2000, May-20, Volume: 320, Issue:7246

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule; Drug Ther

2000
The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma.
    Clinics in chest medicine, 2000, Volume: 21, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chronic D

2000
The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol.
    Respiratory care, 2000, Volume: 45, Issue:7

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cholinergic Agents;

2000
The expanding role of long-acting beta-agonists.
    Chest, 2000, Volume: 118, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2000
The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients.
    Respiratory medicine, 2000, Volume: 94 Suppl F

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Chronic Disea

2000
The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients.
    Respiratory medicine, 2000, Volume: 94 Suppl F

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla

2000
Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Drugs, 2000, Volume: 60, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2000
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:2

    Topics: Administration, Inhalation; Adrenergic Agents; Albuterol; Androstadienes; Asthma; Bronchodilator Age

2001
Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    PharmacoEconomics, 2000, Volume: 18, Issue:6

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations;

2000
The pharmacokinetics of levosalbutamol: what are the clinical implications?
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Animals; Area

2001
Single-isomer beta-agonists.
    Pharmacotherapy, 2001, Volume: 21, Issue:3 Pt 2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Age

2001
Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
    Drugs, 2001, Volume: 61, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Child

2001
[Use of glucocorticosteroids in asthmatic conditions (review)].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:3

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Algorithms; Asthma; Bronchodilator Agents

2001
Pharmacological similarities and differences between beta2-agonists.
    Respiratory medicine, 2001, Volume: 95 Suppl B

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Blood Glucose; Blood Pressure; Bronchodilator

2001
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
    MedGenMed : Medscape general medicine, 2001, Jul-05, Volume: 3, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A

2001
Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
    The Journal of the American Osteopathic Association, 2001, Volume: 101, Issue:9

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2001
What's new: newly approved drugs for children.
    Pediatrics in review, 2001, Volume: 22, Issue:10

    Topics: Adolescent; Age Factors; Albuterol; Androstadienes; Anticonvulsants; Asthma; Atovaquone; Attention D

2001
Long-acting inhaled beta(2)-agonist therapy in asthma.
    American journal of respiratory and critical care medicine, 2001, Sep-15, Volume: 164, Issue:6

    Topics: Administration, Topical; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Androstadienes; An

2001
Clinical efficacy with formoterol in the absence of a response to salmeterol: a review.
    International journal of clinical practice, 2001, Volume: 55, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Forced Expiratory Volume; Formoterol Fumara

2001
[Long-acting beta 2-stimulants].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenerg

2001
[Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-2 Receptor Agonists; Adrenergic

2001
Chronic asthma.
    BMJ (Clinical research ed.), 2001, Oct-27, Volume: 323, Issue:7319

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Chronic Dis

2001
Levalbuterol hydrochloride.
    Pediatric pulmonology, 2002, Volume: 33, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Eos

2002
Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.
    Pharmacotherapy, 2002, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2002
[Inhalation therapy].
    Annales de medecine interne, 2001, Volume: 152, Issue:8

    Topics: Adrenergic beta-Antagonists; Aerosols; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; A

2001
Does adding ipratropium to salbutamol (albuterol) help children with asthma?
    Archives of disease in childhood, 2001, Volume: 85, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therapy, Combination; Female; Humans; Ipratrop

2001
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation.
    Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Relationship, Drug;

2002
Rimiterol: a review of its pharmacological properties and therapeutic efficacy in asthma.
    Drugs, 1977, Volume: 14, Issue:2

    Topics: Absorption; Administration, Oral; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Catec

1977
Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration.
    Acta medica Scandinavica. Supplementum, 1977, Volume: 608

    Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; E

1977
[Pulmonary function tests with the bronchodilator Terbutaline].
    Acta medica Austriaca. Supplement, 1979, Volume: 14

    Topics: Administration, Oral; Adult; Aged; Albuterol; Asthma; Atropine; Clenbuterol; Epinephrine; Female; Fe

1979
On the action of combination bronchodilators.
    Agents and actions, 1979, Volume: 9, Issue:4

    Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Dogs; Drug Combinations; Drug Synergism; Ephedrin

1979
Inhibition of exercise-induced asthma by different pharmacological pathways.
    Thorax, 1976, Volume: 31, Issue:2

    Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Chil

1976
Beta-adrenergic bronchodilators.
    Pediatric clinics of North America, 1975, Volume: 22, Issue:1

    Topics: Administration, Oral; Aerosols; Albuterol; Animals; Anisoles; Asthma; Bronchi; Bronchial Spasm; Bron

1975
Beta 2 agonist therapy: oral versus inhaled delivery.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1992, Volume: 29, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Human

1992
[Bronchodilator effect of salmeterol and inhibition of bronchial hyperreactivity].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests;

1992
Metabolic effects of beta 2-agonists.
    Journal of clinical pharmacy and therapeutics, 1992, Volume: 17, Issue:3

    Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Female; Glucose; Human

1992
[Variety of pharmacological action of beta agonists].
    Arerugi = [Allergy], 1992, Volume: 41, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provocati

1992
Long-acting beta 2-agonists.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1992, Volume: 22, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Drug Tolerance; Ethanol

1992
Pediatric pulmonary function testing in asthma.
    Pediatric clinics of North America, 1992, Volume: 39, Issue:6

    Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Humans; Infant; Re

1992
The beta-agonist controversy: fact or fiction?
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1992, Volume: 22, Issue:7

    Topics: Albuterol; Animals; Asthma; Blood Pressure; Bronchoconstriction; Double-Blind Method; Fenoterol; Hum

1992
[Comparison of treatment of acute asthma attacks in children with salbutamol dispensed by the Volumatic dispenser or by a nebulizer].
    Anales espanoles de pediatria, 1992, Volume: 36, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Child; Dose-Response Relationship, Dru

1992
The challenge of long-acting beta-adrenoceptor agonists.
    Respiratory medicine, 1991, Volume: 85, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol

1991
Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma.
    The European respiratory journal, 1991, Volume: 4, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Ethanolamines; Formoterol Fum

1991
Salmeterol: a novel drug for the treatment of asthma.
    Agents and actions. Supplements, 1991, Volume: 34

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator

1991
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Drugs, 1991, Volume: 42, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictio

1991
[Isolated cough and bronchial asthma].
    Revue de pneumologie clinique, 1991, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Chronic Dis

1991
The current place of beta 2-agonists in the management of asthma.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchia

1990
Basic pharmacology of new long-acting sympathomimetics.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Asthma;

1990
Long-term studies on long-acting sympathomimetics.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; D

1990
[Current concepts in the treatment of asthma (in the United States)].
    Allergie et immunologie, 1990, Volume: 22, Issue:8

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchial Spasm; Costs and

1990
Controlled--release salbutamol tablets.
    Drug and therapeutics bulletin, 1990, Jul-23, Volume: 28, Issue:15

    Topics: Administration, Oral; Albuterol; Asthma; Delayed-Action Preparations; Humans

1990
[Treatment of the severe asthma attack and status asthmaticus].
    Fortschritte der Medizin, 1989, Oct-20, Volume: 107, Issue:30

    Topics: Airway Resistance; Albuterol; Asthma; Drug Therapy, Combination; Fenoterol; Humans; Prednisolone; St

1989
The effect of theophylline and beta 2 agonists on airway reactivity.
    Chest, 1987, Volume: 92, Issue:1 Suppl

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Test

1987
Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs.
    Chest, 1987, Volume: 92, Issue:1 Suppl

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchitis; Clinical Trials as Topic;

1987
Aminophylline treatment in severe, acute asthma. A meta-analysis.
    JAMA, 1988, Mar-18, Volume: 259, Issue:11

    Topics: Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Epinephrine; Glucocorticoids; Humans; M

1988
In-vivo and in-vitro responsiveness of bronchial smooth muscle.
    Bulletin europeen de physiopathologie respiratoire, 1986, Volume: 22 Suppl 7

    Topics: Airway Resistance; Albuterol; Animals; Asthma; Atropine; Atropine Derivatives; Bronchi; Carbachol; D

1986
Treatment of severe asthma.
    The New England journal of medicine, 1974, Jun-27, Volume: 290, Issue:26

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Aminophylline; Asthma

1974
Antiasthmatic drugs I: pathophysiological and clinical pharmacological aspects.
    Drugs, 1974, Volume: 7, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Albuterol; Amines; Asthma; Autacoids; Bradykin

1974
[Treatment of bronchial asthma].
    Klinicheskaia meditsina, 1974, Volume: 52, Issue:12

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchitis; C

1974
Asthma: current concepts.
    Pediatric clinics of North America, 1974, Volume: 21, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Carboxylic Acids; Child; Child

1974

Trials

1634 trials available for albuterol and Asthma

ArticleYear
Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children.
    Pediatric pulmonology, 2021, Volume: 56, Issue:12

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin

2021
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.
    BMJ open respiratory research, 2021, Volume: 8, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Budesonide; Child; Drug Combinatio

2021
Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: A comparative study.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 9), Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Pres

2021
As-Needed Use of Short-Acting β
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child

2022
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
    The New England journal of medicine, 2022, 06-02, Volume: 386, Issue:22

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Budesonide; Child; Child, Preschoo

2022
Efficacy of a loading dose of IV salbutamol in children with severe acute asthma admitted to a PICU: a randomized controlled trial.
    European journal of pediatrics, 2022, Volume: 181, Issue:10

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Intensive Care

2022
Nebulized Salbutamol with or without Magnesium Sulphate in the Management of Acute Asthma in Children in India: A Randomized Controlled Trial.
    Journal of tropical pediatrics, 2022, 08-04, Volume: 68, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Double-B

2022
Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1).
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:10

    Topics: Administration, Inhalation; Albuterol; Asthma; Bayes Theorem; Bronchodilator Agents; Humans; Nebuliz

2022
Optimising intravenous salbutamol in children: a phase 2 study.
    Archives of disease in childhood, 2023, Volume: 108, Issue:4

    Topics: Administration, Intravenous; Albuterol; Asthma; Child; Emergency Service, Hospital; Humans; Prospect

2023
Comparative Efficacy of Levosalbutamol and Racemic Salbutamol in the Treatment of Acute Exacerbation of Asthma.
    Mymensingh medical journal : MMJ, 2023, Volume: 32, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bangladesh; Bronchodilator Agen

2023
Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial.
    Pediatric pulmonology, 2023, Volume: 58, Issue:6

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Child; Dexamethasone; Humans; Methylprednisolone; Prospe

2023
Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation.
    Asian Pacific journal of allergy and immunology, 2022, Volume: 40, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2022
Impact of sleep opportunity on asthma outcomes in adolescents.
    Sleep medicine, 2020, Volume: 65

    Topics: Adolescent; Albuterol; Asthma; Child; Cross-Over Studies; Female; Humans; Male; Quality of Life; Sle

2020
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.
    Pulmonary pharmacology & therapeutics, 2020, Volume: 60

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Fema

2020
Clinical Efficacy of Vibrating Mesh and Jet Nebulizers With Different Interfaces in Pediatric Subjects With Asthma.
    Respiratory care, 2020, Volume: 65, Issue:10

    Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C

2020
The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial.
    Respirology (Carlton, Vic.), 2021, Volume: 26, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bisoprolol; Bronchod

2021
Randomized pilot trial of ipratropium versus placebo in children with critical asthma.
    Pediatric pulmonology, 2020, Volume: 55, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2020
Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.
    JAMA, 2020, 11-24, Volume: 324, Issue:20

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; B

2020
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients.
    The European respiratory journal, 2021, Volume: 57, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

2021
Bronchodilatory effects of B-type natriuretic peptide in acute asthma attacks: a randomized controlled clinical trial.
    Advances in respiratory medicine, 2020, Volume: 88, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fe

2020
Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study.
    Pulmonary pharmacology & therapeutics, 2021, Volume: 68

    Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Heparin, Lo

2021
Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma: Secondary Analysis of a Randomized Clinical Trial.
    JAMA network open, 2021, 07-01, Volume: 4, Issue:7

    Topics: Acute Disease; Administration, Inhalation; Administration, Intravenous; Adolescent; Albuterol; Anti-

2021
Nurse-Driven Clinical Pathway for Inpatient Asthma: A Randomized Controlled Trial.
    Hospital pediatrics, 2017, Volume: 7, Issue:4

    Topics: Albuterol; Asthma; Attitude of Health Personnel; Bronchodilator Agents; Canada; Child; Child, Presch

2017
Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial.
    NPJ primary care respiratory medicine, 2017, May-11, Volume: 27, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide, Formoterol

2017
Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2018, Volume: 55, Issue:3

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge

2018
Effect of extending the time after bronchodilator administration on identifying bronchodilator responsiveness in a pediatric pulmonary clinic.
    Pediatric pulmonology, 2017, Volume: 52, Issue:8

    Topics: Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilator Agents; Child; Female; For

2017
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Respiratory medicine, 2017, Volume: 131

    Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzen

2017
Effect of Nebulized 3% Hypertonic Saline with Salbutamol on Management of Acute Asthma in Outpatient Adults: A Double-blind, Randomized Clinical Trial in Emergency Department.
    Iranian journal of allergy, asthma, and immunology, 2017, Volume: 16, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Ambulatory Care; Asthma; Disease Manage

2017
Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?
    The European respiratory journal, 2017, Volume: 50, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Age Distribution; Aged; Albuterol; Anti-Asthmatic Agents

2017
Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial.
    The European respiratory journal, 2018, Volume: 51, Issue:2

    Topics: Acute Disease; Administration, Intravenous; Albuterol; Asthma; Bronchodilator Agents; Child, Prescho

2018
Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, Feb-15, Volume: 24

    Topics: Adult; Albuterol; Asthma; Cholinergic Antagonists; Female; Humans; Inflammation; Interleukin-13; Mal

2018
Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations.
    The New England journal of medicine, 2018, Mar-08, Volume: 378, Issue:10

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Dose-

2018
A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers.
    The Journal of emergency medicine, 2018, Volume: 55, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Equipment Design; Fem

2018
Comparison of the Clinical Efficacy of Salbutamol with Jet and Mesh Nebulizers in Asthmatic Children.
    Pulmonary medicine, 2018, Volume: 2018

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child;

2018
MDI with DIY Spacer versus Nebulizer for Bronchodilator Therapy in Children Admitted with Asthmatic Attack.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2016, Volume: 99 Suppl 4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2016
Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial.
    Respiratory medicine, 2018, Volume: 140

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Bronch

2018
Comparison of two methods of determining lung de-recruitment, using the forced oscillation technique.
    European journal of applied physiology, 2018, Volume: 118, Issue:10

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Pulmonary

2018
Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma.
    Canadian respiratory journal, 2018, Volume: 2018

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Fluticasone; Humans; Infant; Inhalation Spacers; M

2018
Analysis of the advantages and disadvantages in application of oxygen-driven aerosol and aerosol inhalation by air compressor for the pediatric asthma.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:6(Special)

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Budesonide; Child; Compressed Air; Female;

2018
Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial.
    Pediatric pulmonology, 2019, Volume: 54, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Cannula; Child; Child, Preschool; Emergency Se

2019
Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection.
    Pediatric pulmonology, 2019, Volume: 54, Issue:5

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over

2019
Characteristics of inner-city children with life-threatening asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2019, Volume: 122, Issue:4

    Topics: Adult; Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Caregivers; Child; Child, Preschool; Cot

2019
Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial.
    Allergology international : official journal of the Japanese Society of Allergology, 2019, Volume: 68, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Doubl

2019
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
    The New England journal of medicine, 2019, 05-23, Volume: 380, Issue:21

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bro

2019
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
    Pulmonary pharmacology & therapeutics, 2019, Volume: 58

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie

2019
Mesh nebulizer is as effective as jet nebulizer in clinical practice of acute asthma in children
    Turkish journal of medical sciences, 2019, 08-08, Volume: 49, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; For

2019
Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma.
    Immunotherapy, 2013, Volume: 5, Issue:2

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bacterial Vaccines; Child; Child, Pre

2013
Comparison of salbutamol with normal saline and salbutamol with magnesium sulphate in the treatment of severe acute asthma.
    Mymensingh medical journal : MMJ, 2013, Volume: 22, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents;

2013
Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
    Pulmonary pharmacology & therapeutics, 2013, Volume: 26, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclome

2013
Non-inferiority trial between two dry-powder inhalers containing fluticasone/salmeterol in asthmatic patients.
    Drug research, 2013, Volume: 63, Issue:6

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Dry Powder Inhal

2013
Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Pulmonary pharmacology & therapeutics, 2014, Volume: 27, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadie

2014
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me

2013
Perception of bronchoconstriction: a complementary disease marker in children with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:6

    Topics: Adolescent; Albuterol; Androstadienes; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Bron

2013
Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma.
    Mymensingh medical journal : MMJ, 2013, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Albuterol, Ipratropium Drug Combination; Asthma; Bronc

2013
Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics.
    Pulmonary pharmacology & therapeutics, 2013, Volume: 26, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammato

2013
[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2013, Volume: 15, Issue:6

    Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female;

2013
Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients.
    Clinical science (London, England : 1979), 2014, 01-01, Volume: 126, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol;

2014
Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
    Chest, 2013, Volume: 144, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Chil

2013
Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
    Respiratory medicine, 2013, Volume: 107, Issue:10

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Cost-Benefit Analysis; Dos

2013
Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma.
    Chest, 2014, Volume: 145, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Ther

2014
Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma.
    Respiratory investigation, 2013, Volume: 51, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol;

2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
    Current medical research and opinion, 2013, Volume: 29, Issue:12

    Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2

2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
    Current medical research and opinion, 2013, Volume: 29, Issue:12

    Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2

2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
    Current medical research and opinion, 2013, Volume: 29, Issue:12

    Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2

2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
    Current medical research and opinion, 2013, Volume: 29, Issue:12

    Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2

2013
Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.
    Drugs in R&D, 2013, Volume: 13, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2013
Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Aged; Albuterol; A

2014
Metrics of salbutamol use as predictors of future adverse outcomes in asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2013, Volume: 43, Issue:10

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Drug Overdose; Female; Humans; Male;

2013
Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Chest, 2013, Volume: 144, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents;

2013
[Observation on the effects of the treatment of sillicosis merger asthma].
    Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 2013, Volume: 31, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Flu

2013
Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.
    The Journal of allergy and clinical immunology, 2014, Volume: 133, Issue:2

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; As

2014
Predictors of response to tiotropium versus salmeterol in asthmatic adults.
    The Journal of allergy and clinical immunology, 2013, Volume: 132, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator

2013
Inhaled salbutamol does not affect athletic performance in asthmatic and non-asthmatic cyclists.
    British journal of sports medicine, 2015, Volume: 49, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Athletic Performance; Bicycling; Bronchodilato

2015
Safety of bronchial thermoplasty in patients with severe refractory asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch

2013
Safety of bronchial thermoplasty in patients with severe refractory asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch

2013
Safety of bronchial thermoplasty in patients with severe refractory asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch

2013
Safety of bronchial thermoplasty in patients with severe refractory asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch

2013
Childhood asthma clusters and response to therapy in clinical trials.
    The Journal of allergy and clinical immunology, 2014, Volume: 133, Issue:2

    Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Asthmatic

2014
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Ag

2013
Effect of inhaled MgSO4 on FEV1 and PEF in children with asthma induced by acetylcholine: a randomized controlled clinical trail of 330 cases.
    Journal of tropical pediatrics, 2014, Volume: 60, Issue:2

    Topics: Acetylcholine; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, P

2014
Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy
    Pulmonary pharmacology & therapeutics, 2014, Volume: 27, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmati

2014
Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anticonvulsants; Asthma; Bronchodi

2013
Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2014, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child;

2014
Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma.
    Lung, 2014, Volume: 192, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aerosol Propellants; Aged; A

2014
Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2014, Volume: 51, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadie

2014
The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:5

    Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Cyclopropan

2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth

2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth

2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth

2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth

2014
[A multi-center, randomized, double-blind, positive controlled clinical trial of salbutamol sulfate MDI without CFC in the treatment of asthma].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:2

    Topics: Albuterol; Asthma; Double-Blind Method; Forced Expiratory Volume; Humans; Metered Dose Inhalers

2014
Comparison between the effects of generic and original salmeterol/fluticasone combination (SFC) treatment on airway inflammation in stable asthmatic patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2014, Volume: 97 Suppl 3

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cross-

2014
Eczema and race as combined determinants for differential response to step-up asthma therapy.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:2

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Black or African Ame

2014
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.
    Respirology (Carlton, Vic.), 2014, Volume: 19, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Budes

2014
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids.
    Journal of negative results in biomedicine, 2014, Jun-13, Volume: 13, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Alb

2014
Treatment of asthma exacerbations with the human-powered nebuliser: a randomised parallel-group clinical trial.
    NPJ primary care respiratory medicine, 2014, Jun-26, Volume: 24

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Child

2014
Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial.
    Journal of paediatrics and child health, 2015, Volume: 51, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bro

2015
Dependence of bronchoconstrictor and bronchodilator responses on thoracic gas compression volume.
    Respirology (Carlton, Vic.), 2014, Volume: 19, Issue:7

    Topics: Adult; Aged; Albuterol; Asthma; Body Height; Bronchial Provocation Tests; Bronchoconstrictor Agents;

2014
Lung deposition of 99mTc-radiolabeled albuterol delivered through a pressurized metered dose inhaler and spacer with facemask or mouthpiece in children with asthma.
    Journal of aerosol medicine and pulmonary drug delivery, 2014, Volume: 27 Suppl 1

    Topics: Administration, Inhalation; Aerosols; Age Factors; Albuterol; Asthma; Child, Preschool; Cross-Over S

2014
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2014
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2014
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2014
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2014
Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation.
    Respiratory medicine, 2014, Volume: 108, Issue:9

    Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents;

2014
Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma.
    Respiratory medicine, 2014, Volume: 108, Issue:10

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies;

2014
Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2015, Volume: 52, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc

2015
Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma.
    Chest, 2015, Volume: 147, Issue:4

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Res

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
    Pediatric pulmonology, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2015
Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.
    The Journal of allergy and clinical immunology, 2015, Volume: 136, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Airway Obstruction; Albuterol; Anti-As

2015
High-Dose Inhaled Salbutamol Does Not Improve 10-km Cycling Time Trial Performance.
    Medicine and science in sports and exercise, 2015, Volume: 47, Issue:11

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Athletic Performance; Bicycling; Body Weight;

2015
Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2015, Volume: 52, Issue:8

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asian People; Asthma; Bronchodila

2015
Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Jun-15, Volume: 72, Issue:12

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hospitalization; Humans;

2015
A Randomized Controlled Trial of 2 Inhalation Methods When Using a Pressurized Metered Dose Inhaler With Valved Holding Chamber.
    Respiratory care, 2015, Volume: 60, Issue:12

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Breath Holding; Bronchodilator Agents; Ch

2015
Reversibility of pulmonary function after inhaling salbutamol in different doses and body postures in asthmatic children.
    Respiratory medicine, 2015, Volume: 109, Issue:10

    Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Cross-Over St

2015
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2016
Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial.
    Trials, 2015, Sep-23, Volume: 16

    Topics: Acupuncture Therapy; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2

2015
Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.
    JAMA, 2015, Oct-27, Volume: 314, Issue:16

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Black or African

2015
Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies.
    Clinical drug investigation, 2016, Volume: 36, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dou

2016
Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
    Respiratory research, 2015, Dec-24, Volume: 16

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bicycling

2015
Formoterol as reliever medication in asthma: a post-hoc analysis of the subgroup of the RELIEF study in East Asia.
    BMC pulmonary medicine, 2016, Jan-12, Volume: 16

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol;

2016
Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Child, Preschool; Drug Tolerance; Dry Powder Inhalers;

2016
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma.
    Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol;

2016
Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2016
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Administration, Inhalation; Administration, Sublingual; Adolescent; Adrenal Cortex Hormones; Adrener

2016
Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
    BMC pulmonary medicine, 2016, Apr-30, Volume: 16, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A

2016
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female;

2016
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female;

2016
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female;

2016
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female;

2016
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.
    American journal of respiratory and critical care medicine, 2017, 02-01, Volume: 195, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Biomarkers; Body Mass Index; Breath Tests; Bronchodilator Agen

2017
Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Prescho

2016
Individualized therapy for persistent asthma in young children.
    The Journal of allergy and clinical immunology, 2016, Volume: 138, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Child, Preschool; Female; Fo

2016
Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy.
    Current drug delivery, 2017, Volume: 14, Issue:4

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Biological Availability; Cross-Over Studies; Glucans

2017
Parental decision making associated with pediatric emergency department use for asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2016, Volume: 117, Issue:5

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Child, Preschool; Cluster Analys

2016
Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β
    Clinical therapeutics, 2016, Volume: 38, Issue:12

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Aged; Albuterol; Anti

2016
Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.
    Allergy and asthma proceedings, 2017, Jan-28, Volume: 38, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Pr

2017
Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial.
    The Journal of pediatrics, 2017, Volume: 185

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Combined Modality Therapy; Emergency Service, Hospi

2017
Use of long-acting beta2 agonists in arginine-16 homozygous patients with asthma.
    Thorax, 2008, Volume: 63, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bu

2008
Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2008,Summer, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents

2008
Temporal strength changes from resistance exercise and albuterol on unloaded muscle.
    Journal of strength and conditioning research, 2008, Volume: 22, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Ergometry; Female; Humans; Male; M

2008
Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study.
    Allergy, 2008, Volume: 63, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents

2008
Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study.
    Respiratory medicine, 2008, Volume: 102, Issue:8

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Ast

2008
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
    Clinical therapeutics, 2008, Volume: 30 Spec No

    Topics: Acute Disease; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hospital Costs; Hospitalizati

2008
Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease.
    Thorax, 2009, Volume: 64, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchial Diseases; Bronchodilator Agents; Case-Control Studies; Chil

2009
A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.
    The Journal of allergy and clinical immunology, 2008, Volume: 122, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

2008
Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Clinical therapeutics, 2008, Volume: 30, Issue:8

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Androstadienes; A

2008
Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down".
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2008, Volume: 45, Issue:8

    Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Dose-Response Rel

2008
Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study.
    The Journal of allergy and clinical immunology, 2008, Volume: 122, Issue:6

    Topics: Acetates; Adolescent; Albuterol; Anti-Bacterial Agents; Asthma; Azithromycin; Bronchodilator Agents;

2008
Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
    Respiratory medicine, 2009, Volume: 103, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Broncho

2009
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children.
    The Journal of allergy and clinical immunology, 2008, Volume: 122, Issue:4

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child

2008
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma.
    The Journal of allergy and clinical immunology, 2008, Volume: 122, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Preschool; Cohort Studies; Femal

2008
Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea.
    Current medical research and opinion, 2008, Volume: 24, Issue:12

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asian People; Asthma; Bronchodilator Agents; Fem

2008
Asthma control over 3 years in a real-life study.
    Respiratory medicine, 2009, Volume: 103, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth

2009
Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months.
    The Journal of emergency medicine, 2009, Volume: 37, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therap

2009
Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma.
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:4

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Biomarkers; Child; Cyclopropanes; Double-Bl

2009
Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment.
    The Journal of emergency medicine, 2011, Volume: 40, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cost-

2011
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma.
    The European respiratory journal, 2009, Volume: 33, Issue:6

    Topics: Adenosine; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Androstadienes; Anti-Allergic A

2009
Determining the time to maximal bronchodilator response in asthmatic children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Human

2009
Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study.
    Current medical research and opinion, 2009, Volume: 25, Issue:2

    Topics: Acetates; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Belgium; Budesonide; Cycl

2009
Adverse effects of salmeterol in asthma: a neuronal perspective.
    Thorax, 2009, Volume: 64, Issue:9

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Androst

2009
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2009, Volume: 20, Issue:8

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila

2009
Patient-reported outcomes among omalizumab and salmeterol/fluticasone combination therapy patients.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:2

    Topics: Activities of Daily Living; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Antibodies, Ant

2009
Influence of ambulatory inhaled treatment with different devices on the duration of acute asthma findings in children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Metered Dose

2009
A comparative study of efficacy of salbutamol via metered dose inhaler with volumatic spacer and via dry powder inhaler, easyhaler, to nebulization in mild to moderate severity acute asthma exacerbation in childhood.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91 Suppl 3

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child

2008
Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma.
    Nuclear medicine communications, 2009, Volume: 30, Issue:3

    Topics: Adenosine; Aged; Albuterol; Asthma; Bronchial Spasm; Case-Control Studies; Female; Humans; Male; Myo

2009
In vivo performance testing of the novel Medspray wet aerosol inhaler.
    Journal of aerosol medicine and pulmonary drug delivery, 2009, Volume: 22, Issue:4

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cross-Over St

2009
Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 102, Issue:4

    Topics: Administration, Inhalation; Adult; Aerosol Propellants; Albuterol; Androstadienes; Asthma; Bronchodi

2009
Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2009, Volume: 58, Issue:3

    Topics: Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Drug Combinations; Eosinophils;

2009
High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial.
    The Journal of pediatrics, 2009, Volume: 155, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Blood Glucose; Bronchodilator Agents; Child; Dose-Response Relationsh

2009
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
    Pulmonary pharmacology & therapeutics, 2009, Volume: 22, Issue:6

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; As

2009
Bronchodilator effects of exercise hyperpnea and albuterol in mild-to-moderate asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2009, Volume: 107, Issue:2

    Topics: Adaptation, Physiological; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchoconstriction

2009
Home use of albuterol for asthma exacerbations.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 102, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Child, Preschool; Cross-Sectional Studi

2009
Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence.
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:2

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Albuterol; Allergens; Androstadienes; Anti-Asthmatic

2009
Evidence for adverse phonatory change following an inhaled combination treatment.
    Journal of speech, language, and hearing research : JSLHR, 2010, Volume: 53, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Drug Combinations;

2010
Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2010, Volume: 21, Issue:2 Pt 1

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone;

2010
Regular vs prn nebulized treatment in wheeze preschool children.
    Allergy, 2009, Volume: 64, Issue:10

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator

2009
Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).
    Pediatric pulmonology, 2009, Volume: 44, Issue:11

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

2009
Does parental involvement in pediatric emergency department asthma treatment affect home management?
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:8

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Se

2009
Interaction of ambient air pollution with asthma medication on exhaled nitric oxide among asthmatics.
    Archives of environmental & occupational health, 2009,Fall, Volume: 64, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Air Pollutants; Air Polluti

2009
Transient expiratory flow interruptions (TEFI) increase expiratory flow in acute asthma exacerbation.
    Medicina, 2009, Volume: 69, Issue:5

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Female; Forced Expirator

2009
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.
    American journal of respiratory and critical care medicine, 2010, Apr-01, Volume: 181, Issue:7

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadiene

2010
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
    Lancet (London, England), 2009, Nov-21, Volume: 374, Issue:9703

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros

2009
Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma.
    Respiratory medicine, 2010, Volume: 104, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator

2010
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma.
    The European respiratory journal, 2010, Volume: 35, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anxiety; Ast

2010
Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma.
    Indian journal of pediatrics, 2009, Volume: 76, Issue:11

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Metho

2009
Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma.
    Allergy, 2010, Volume: 65, Issue:7

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclome

2010
Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes.
    International journal of sports medicine, 2010, Volume: 31, Issue:4

    Topics: Albuterol; Analysis of Variance; Asthma; Bronchoconstriction; Bronchodilator Agents; Caffeine; Centr

2010
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:10

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Area Under Curve

2010
Providing feedback on adherence increases use of preventive medication by asthmatic children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:2

    Topics: Adolescent; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Drug Combinations; Feed

2010
Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Drug

2010
Plasma concentrations of salbutamol in the treatment of acute asthma in a pediatric emergency. Could age be a parameter of influence?
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Body Weight;

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al

2010
Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11.
    The clinical respiratory journal, 2008, Volume: 2, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bioma

2008
Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial.
    The clinical respiratory journal, 2009, Volume: 3, Issue:3

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Denmark; Drug Therapy, Combination;

2009
Respiratory impedance and response to salbutamol in asthmatic Vietnamese children.
    Pediatric pulmonology, 2010, Volume: 45, Issue:4

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Respiratory Function Tes

2010
Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist.
    Respiratory medicine, 2010, Volume: 104, Issue:8

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Dose-Response Relations

2010
Effect of salmeterol/fluticasone propionate combination on airway hyper-responsiveness in patients with well-controlled asthma.
    Respiratory medicine, 2010, Volume: 104, Issue:8

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth

2010
Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
    Respiratory research, 2010, May-28, Volume: 11

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Ast

2010
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group st
    Clinical drug investigation, 2010, Volume: 30, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A

2010
A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma.
    Allergy, 2010, Volume: 65, Issue:11

    Topics: Acute Disease; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Brazil; Child;

2010
Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010, Volume: 104, Issue:6

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchoconstriction;

2010
Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Clinical drug investigation, 2010, Volume: 30, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2010
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.
    Respiratory medicine, 2010, Volume: 104, Issue:11

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross

2010
Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma.
    American journal of respiratory and critical care medicine, 2010, Nov-15, Volume: 182, Issue:10

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Ch

2010
Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control.
    American journal of respiratory and critical care medicine, 2011, Jan-15, Volume: 183, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Advance Care Planning; Albuterol; Androstadienes; Asthma; Bronc

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
    American journal of respiratory and critical care medicine, 2011, Feb-15, Volume: 183, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil

2011
Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline

2010
Multidetector row computed tomography to assess changes in airways linked to asthma control.
    Respiration; international review of thoracic diseases, 2011, Volume: 81, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchi; Bronchography; Drug C

2011
Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control.
    Chest, 2011, Volume: 139, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Allergic Agents; Anti-Asthmatic Agents; Ast

2011
Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial.
    Trials, 2010, Dec-15, Volume: 11

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Chronic Disease; Clinical Protocols; Dru

2010
[Comparative observation on therapeutic effect of chronic persistent bronchial asthma treated with heat-sensitive moxibustion and medication].
    Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2010, Volume: 30, Issue:11

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Chronic Disease; Drug Combinations; Fema

2010
Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:2

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Double-Blind Method; Emer

2011
Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2011, Feb-19, Volume: 377, Issue:9766

    Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents;

2011
Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combinati

2011
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
    Respiratory care, 2011, Volume: 56, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2011
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
    Respiratory care, 2011, Volume: 56, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2011
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
    Respiratory care, 2011, Volume: 56, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2011
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
    Respiratory care, 2011, Volume: 56, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2011
Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model.
    Veterinary journal (London, England : 1997), 2012, Volume: 192, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Allergens; Androstadienes; Animals; Ant

2012
Comparison of high-dose salmeterol/fluticasone and moderate-dose salmeterol/fluticasone plus low-dose mometasone in patients with severe persistent asthma.
    Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:5

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma

2011
Randomized controlled trial to improve care for urban children with asthma: results of the School-Based Asthma Therapy trial.
    Archives of pediatrics & adolescent medicine, 2011, Volume: 165, Issue:3

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cotinine; Counsel

2011
Lung function response to bronchodilator nebulization via hood in wheezy infants: a pilot study.
    The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:1

    Topics: Administration, Inhalation; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Female; Func

2011
Comparison of salbutamol efficacy in children--via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer--in mild to moderate asthma exacerbation: a multicenter, randomized study.
    Asian Pacific journal of allergy and immunology, 2011, Volume: 29, Issue:1

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dry Po

2011
Urine concentrations of repetitive doses of inhaled salbutamol.
    International journal of sports medicine, 2011, Volume: 32, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Case-Cont

2011
A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma.
    Pediatric pulmonology, 2011, Volume: 46, Issue:8

    Topics: Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator Agents; Child; Child, Preschool; Cr

2011
Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity.
    Thorax, 2011, Volume: 66, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Analysis of Varia

2011
Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:6

    Topics: Adult; Albuterol; Asthma; Body Mass Index; Body Weight; Emergency Service, Hospital; Hospitalization

2011
Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
    BMC pulmonary medicine, 2011, May-23, Volume: 11

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat

2011
Effect of bronchoconstriction on airway remodeling in asthma.
    The New England journal of medicine, 2011, 05-26, Volume: 364, Issue:21

    Topics: Adult; Albuterol; Animals; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstriction; Bronch

2011
Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma.
    Pulmonary pharmacology & therapeutics, 2011, Volume: 24, Issue:5

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; Etha

2011
Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke.
    Chest, 2012, Volume: 141, Issue:2

    Topics: Adult; Albuterol; Androstadienes; Asthma; Cross-Over Studies; Double-Blind Method; Drug Combinations

2012
Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
    Journal of aerosol medicine and pulmonary drug delivery, 2011, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cross-Over Studies; Fem

2011
Components of asthma control and treatment response of individual control criteria in children: analysis of the PEACE study.
    Pediatric pulmonology, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; A

2011
Active albuterol or placebo, sham acupuncture, or no intervention in asthma.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Acupuncture Therapy; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Diagnostic

2011
Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2011, Volume: 18, Issue:7

    Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents;

2011
Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
    The Journal of allergy and clinical immunology, 2011, Volume: 128, Issue:2

    Topics: Administration, Inhalation; Albuterol; Arginine; Asthma; Bronchodilator Agents; Double-Blind Method;

2011
The effect of airway remodelling on airway hyper-responsiveness in asthma.
    Respiratory medicine, 2011, Volume: 105, Issue:12

    Topics: Adult; Airway Remodeling; Airway Resistance; Albuterol; Androstadienes; Asthma; Bronchial Hyperreact

2011
Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice.
    The Medical journal of Australia, 2011, Aug-15, Volume: 195, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Comorbid

2011
Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity.
    The Journal of allergy and clinical immunology, 2011, Volume: 128, Issue:5

    Topics: Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child;

2011
Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children.
    Italian journal of pediatrics, 2011, Aug-22, Volume: 37

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Beclo

2011
Impact of race on asthma treatment failures in the asthma clinical research network.
    American journal of respiratory and critical care medicine, 2011, Dec-01, Volume: 184, Issue:11

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Biomedical Research; Bl

2011
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.
    Respiratory medicine, 2012, Volume: 106, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2012
[Dynamics of functional parameters in different schemes for bronchial asthma therapy: results of the STRELA-ACT multicentre study].
    Klinicheskaia meditsina, 2011, Volume: 89, Issue:4

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory

2011
The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study.
    International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:10

    Topics: Acute Disease; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Carbon Dio

2011
Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.
    Chest, 2012, Volume: 141, Issue:5

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Androstadienes; Anti-Asthmatic Agen

2012
Bronchodilator responsiveness in wheezy infants and toddlers is not associated with asthma risk factors.
    Pediatric pulmonology, 2012, Volume: 47, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Female; Humans; Infant; Male; Prevalence

2012
Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction.
    British journal of clinical pharmacology, 2012, Volume: 73, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Anti-Inflammatory Agents;

2012
Salmeterol or doxycycline do not inhibit acute bronchospasm and airway inflammation in cats with experimentally-induced asthma.
    Veterinary journal (London, England : 1997), 2012, Volume: 192, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; An

2012
Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Albuterol; Asthma; Bronchodilator Age

1976
Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.
    European journal of applied physiology, 2012, Volume: 112, Issue:9

    Topics: Acceleration; Administration, Oral; Adult; Albuterol; Asthma; Athletes; Bronchodilator Agents; Cross

2012
Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents.
    The Journal of allergy and clinical immunology, 2012, Volume: 129, Issue:3

    Topics: Adolescent; Adult; Albuterol; Algorithms; Asthma; Disease Progression; Drug Utilization; Female; Fol

2012
Efficacy of salbutamol by nebulizer versus metered dose inhaler with home-made non-valved spacer in acute exacerbation of childhood asthma.
    Mymensingh medical journal : MMJ, 2012, Volume: 21, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Disease Progression; Equipment De

2012
Predicting asthma treatment outcome at diagnosis: the role of symptom perception during a histamine challenge test.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2012, Volume: 49, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Diagnostic Self Evaluation; Female; Forced Ex

2012
The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
    Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 2012, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; A

2012
Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial.
    BMC pediatrics, 2012, Mar-07, Volume: 12

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Bud

2012
Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2012, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Budesonide; Drug Subs

2012
Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:10

    Topics: Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Arteries; Asthma; Bronchoconstrict

2012
Oral versus intravenous steroids in acute exacerbation of asthma--randomized controlled study.
    The Journal of the Association of Physicians of India, 2011, Volume: 59

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronc

2011
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics.
    European annals of allergy and clinical immunology, 2012, Volume: 44, Issue:1

    Topics: Adolescent; Albuterol; Androstadienes; Asthma; Asthma, Exercise-Induced; Bronchial Hyperreactivity;

2012
Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2012, Volume: 49, Issue:5

    Topics: Acetates; Administration, Inhalation; Age Factors; Aged; Aged, 80 and over; Albuterol; Anti-Asthmati

2012
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Clinical drug investigation, 2012, Jul-01, Volume: 32, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2012
Salmeterol and fluticasone in young children with multiple-trigger wheeze.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Asthma;

2012
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial.
    Respiratory research, 2012, Jun-25, Volume: 13

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Beclomethasone; Bronchodilator Agents; D

2012
The reliability and patient acceptability of the SmartTrack device: a new electronic monitor and reminder device for metered dose inhalers.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2012, Volume: 49, Issue:6

    Topics: Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Drug Monit

2012
Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma.
    Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:5

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Spasm; Cross-Over Studies; Double-Blind Method;

2012
Original salbutamol versus similar salbutamol in children with asthma exacerbation: a randomized, controlled, double-blind study.
    Archivos argentinos de pediatria, 2012, Volume: 110, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Disease Progression; Double-Blind Metho

2012
Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol.
    Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:8

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Eosinophilia; Female; Fluticasone;

2012
Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients.
    Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:6

    Topics: Adult; Airway Obstruction; Albuterol; Arginine; Asthma; Biomarkers; Bronchial Provocation Tests; Bro

2012
[Comparative study on effect of acupoint heat-sensitive moxibustion and Seretide on the symptoms of bronchial asthma at chronic persistent stage].
    Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2012, Volume: 32, Issue:7

    Topics: Acupuncture Points; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Chronic Disease; Drug Comb

2012
Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2012, Volume: 23, Issue:7

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Hum

2012
Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
    Advances in therapy, 2012, Volume: 29, Issue:11

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Confide

2012
Effects of low-dose fluticasone propionate/salmeterol combination therapy on exhaled nitric oxide and nitrite/nitrate in breath condensates from patients with mild persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:1

    Topics: Adult; Albuterol; Androstadienes; Asthma; Breath Tests; Bronchial Provocation Tests; Bronchodilator

2013
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:8

    Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma

2013
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:8

    Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma

2013
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:8

    Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma

2013
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:8

    Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma

2013
Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:6

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Airway Resistance; Albuterol; Asthma;

2012
Salbutamol tolerance to bronchoprotection: course of onset.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction

2012
Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma.
    Respiratory medicine, 2013, Volume: 107, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Circadian Rhythm;

2013
Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
    Health technology assessment (Winchester, England), 2013, Volume: 17, Issue:4

    Topics: Absenteeism; Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho

2013
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients.
    Respiratory medicine, 2002, Volume: 96, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Dru

2002
The combination of nebulized sodium cromoglycate and salbutamol in the treatment of moderate-to-severe asthma in children.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2002, Volume: 13, Issue:3

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cromolyn S

2002
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma.
    The European respiratory journal, 2002, Volume: 20, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Beclomethasone; Blood

2002
One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2002
Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program.
    The Journal of allergy and clinical immunology, 2002, Volume: 110, Issue:3

    Topics: Albuterol; Allergens; Asthma; Bronchodilator Agents; Child; Disease Progression; Female; Forced Expi

2002
Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodila

2002
Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2002, Volume: 39, Issue:5

    Topics: Administration, Inhalation; Adult; Aging; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studi

2002
Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects.
    Chest, 2002, Volume: 122, Issue:3

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol

2002
Metal versus plastic spacers: an in vitro and in vivo comparison.
    International journal of pharmaceutics, 2002, Oct-01, Volume: 245, Issue:1-2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dos

2002
Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma.
    Pharmacogenetics, 2002, Volume: 12, Issue:7

    Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic A

2002
The effects of inhaled albuterol and salmeterol in 2- to 5-year-old asthmatic children as measured by impulse oscillometry.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2002, Volume: 39, Issue:6

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child Welfare; Child, P

2002
Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma.
    Chest, 2002, Volume: 122, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Confidenc

2002
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    PharmacoEconomics, 2002, Volume: 20, Issue:13

    Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Chronic

2002
Importance of drug delivery system in steroid aerosol therapy via nebulizer.
    Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:5

    Topics: Adult; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchoconstrictor Agents;

2002
Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
    Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method

2002
Efficacy and safety of a home-made non-valved spacer for bronchodilator therapy in acute asthma.
    Acta paediatrica (Oslo, Norway : 1992), 2002, Volume: 91, Issue:9

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; C

2002
A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers.
    The Journal of allergy and clinical immunology, 2002, Volume: 110, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bayes Th

2002
Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients wit
    Respiratory medicine, 2002, Volume: 96, Issue:11

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Doubl

2002
Clinical equivalence between salbutamol hydrofluoroalkane pMDI and salbutamol Turbuhaler at the same cumulative microgram doses in paediatric patients.
    Respiratory medicine, 2002, Volume: 96, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over Studies; Double-Blind Method

2002
Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross

2002
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma.
    The European respiratory journal, 2002, Volume: 20, Issue:5

    Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Age

2002
Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital.
    Thorax, 2002, Volume: 57, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Drug Therapy, Combin

2002
A randomized controlled trial of intravenous montelukast in acute asthma.
    American journal of respiratory and critical care medicine, 2003, Feb-15, Volume: 167, Issue:4

    Topics: Acetates; Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Varianc

2003
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
    American journal of respiratory and critical care medicine, 2003, May-01, Volume: 167, Issue:9

    Topics: Acetates; Adenosine Monophosphate; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmati

2003
Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation.
    Anesthesiology, 2002, Volume: 97, Issue:6

    Topics: Adult; Airway Resistance; Albuterol; Anesthetics, Local; Asthma; Bronchial Provocation Tests; Bronch

2002
Comparison of single 7.5-mg dose treatment vs sequential multidose 2.5-mg treatments with nebulized albuterol in the treatment of acute asthma.
    Chest, 2002, Volume: 122, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Emergencies; Female; Forced Expiratory Volume;

2002
[Comparative efficiency of nebulized adrenaline and salbutamol in severe acute asthma. A randomized, controlled prospective study].
    Annales francaises d'anesthesie et de reanimation, 2002, Volume: 21, Issue:9

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma

2002
Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study.
    The European respiratory journal, 2002, Volume: 20, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Bronchoalveolar

2002
Children with mild asthma: do they benefit from inhaled corticosteroids?
    The European respiratory journal, 2002, Volume: 20, Issue:6

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchial P

2002
[A comparison between the effects of albuterol and isoproterenol in bronchodilation test].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 2001, Volume: 32, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Max

2001
Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness.
    Clinical physiology and functional imaging, 2003, Volume: 23, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Hyperreact

2003
The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma.
    Respiratory medicine, 2003, Volume: 97, Issue:3

    Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Cyclopro

2003
Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office.
    Clinical pediatrics, 2003, Volume: 42, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Ch

2003
Salbutamol and/or beclomethasone diproprionate in asthma.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:2

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; Child,

2003
Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial.
    Thorax, 2003, Volume: 58, Issue:4

    Topics: Abdominal Pain; Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthm

2003
Efficacy of a consensus protocol therapy in adults with acute, severe asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:3

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
    Chest, 2003, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi

2003
Creatininuria in asthmatic children treated with a combination of glucocorticoid and beta-agonist.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Becl

2003
Metabolism of salbutamol differs between asthmatic patients and healthy volunteers.
    Pharmacology & toxicology, 2003, Volume: 92, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Area Under Curve; Asthma; Bron

2003
Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Drug Overdose; Drug The

2003
Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma.
    Respiratory medicine, 2003, Volume: 97, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agen

2003
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
    International archives of allergy and immunology, 2003, Volume: 130, Issue:4

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm

2003
Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:1

    Topics: Adenosine Monophosphate; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal;

2003
A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
    Pulmonary pharmacology & therapeutics, 2003, Volume: 16, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator

2003
Bronchodilator tolerance: the impact of increasing bronchoconstriction.
    The European respiratory journal, 2003, Volume: 21, Issue:5

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provo

2003
Triple inhaled drug protocol for the treatment of acute severe asthma.
    Chest, 2003, Volume: 123, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc

2003
Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.
    The European respiratory journal, 2003, Volume: 21, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchoalveolar

2003
Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation.
    Respiratory medicine, 2003, Volume: 97, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Eosinoph

2003
Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma.
    Respiratory medicine, 2003, Volume: 97, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind

2003
Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2003,Summer, Volume: 16, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Female; Humans; Male;

2003
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial.
    Lancet (London, England), 2003, Jun-21, Volume: 361, Issue:9375

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Calci

2003
Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance.
    International journal of clinical pharmacology research, 2002, Volume: 22, Issue:3-4

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; Me

2002
Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:1

    Topics: Adult; Airway Obstruction; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Cromolyn Sodium; Doub

2003
Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Double-Blind

2003
Effects of salmeterol on smooth muscle versus inflammatory outcomes.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:1

    Topics: Albuterol; Androstadienes; Asthma; Cross-Over Studies; Drug Therapy, Combination; Fluticasone; Human

2003
Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.
    British journal of clinical pharmacology, 2003, Volume: 56, Issue:1

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchi; Bronchoconstrictor Agents; Bronchodilator Agents;

2003
Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids.
    Chest, 2003, Volume: 124, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As

2003
[The comparative effects of aminophylline and salbutamol on the treatment of infant allergic cough].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2003, Volume: 15, Issue:7

    Topics: Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Cough; Humans; Treatment Outcome

2003
Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!
    Archives of disease in childhood, 2003, Volume: 88, Issue:8

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery System

2003
Electrostatic charge on spacer devices and salbutamol response in young children.
    International journal of pharmaceutics, 2003, Aug-11, Volume: 261, Issue:1-2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agent

2003
Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response.
    The European respiratory journal, 2003, Volume: 22, Issue:1

    Topics: Adult; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodilator Agents;

2003
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 95, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

2003
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 95, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

2003
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 95, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

2003
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 95, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

2003
Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:5-6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Delivery Systems; F

2003
Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
    Clinical therapeutics, 2003, Volume: 25, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Ethanolamines; Female; Formoter

2003
[Fixed-dose fluticasone-salmeterol combination: at least effective and better tolerated than open-dose combinations].
    Revue de pneumologie clinique, 2003, Volume: 59, Issue:3

    Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Female; Fl

2003
Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.
    Respiratory medicine, 2003, Volume: 97, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Anti-Asthmatic

2003
Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:5

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Albuterol; Anti-Asthmatic Agents; Asthma

2003
Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilato

2003
Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2003
Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat

2003
Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:3

    Topics: Acetates; Administration, Inhalation; Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Ag

2003
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
    BMJ (Clinical research ed.), 2003, Oct-18, Volume: 327, Issue:7420

    Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho

2003
Tolerance to the protective effect of salmeterol in mild untreated asthmatics.
    Pulmonary pharmacology & therapeutics, 2003, Volume: 16, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; B

2003
Effects of ambient air pollution on symptom severity and medication use in children with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:4

    Topics: Adolescent; Air Pollutants; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Carbon Monoxide

2003
Effect of inhalation of salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in some patients with chronic stable bronchial asthma.
    The Indian journal of medical research, 2003, Volume: 117

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Broncho

2003
Effects of respiratory timing and cheek support on resistance measurements, before and after bronchodilation in asthmatic children using the interrupter technique.
    Pediatric pulmonology, 2003, Volume: 36, Issue:6

    Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents

2003
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial.
    The European respiratory journal, 2003, Volume: 22, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2003
Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents;

2003
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
    British journal of clinical pharmacology, 2003, Volume: 56, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2003
Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
    The Journal of pediatrics, 2003, Volume: 143, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double

2003
Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27.
    British journal of clinical pharmacology, 2004, Volume: 57, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Forced Expir

2004
[A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination].
    European annals of allergy and clinical immunology, 2003, Volume: 35, Issue:9

    Topics: Acetates; Administration, Inhalation; Adult; Aerosols; Albuterol; Androstadienes; Anti-Asthmatic Age

2003
Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma.
    American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat

2002
Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing.
    Pediatric pulmonology, 2004, Volume: 37, Issue:2

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bone and Bones; Bronchodilator Agents

2004
Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma.
    Swiss medical weekly, 2004, Jan-24, Volume: 134, Issue:3-4

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth

2004
Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma.
    Thorax, 2004, Volume: 59, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents

2004
Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial.
    Indian pediatrics, 2004, Volume: 41, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator A

2004
Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2004, Volume: 15, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over

2004
Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2004, Volume: 15, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

2004
Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
    Current medical research and opinion, 2004, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Analysis of Variance; Androstadienes; Asthma;

2004
Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies.
    International journal of clinical pharmacology research, 2003, Volume: 23, Issue:2-3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agen

2003
Nebulized salbutamol vs salbutamol and ipratropium combination in asthma.
    Indian journal of pediatrics, 2004, Volume: 71, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Schedule; Drug Ther

2004
One week treatment with salmeterol does not prevent early and late asthmatic responses and sputum eosinophilia induced by allergen challenge in asthmatics.
    Pulmonary pharmacology & therapeutics, 2004, Volume: 17, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cross-O

2004
Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
    Pulmonary pharmacology & therapeutics, 2004, Volume: 17, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronchoconstriction;

2004
Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study.
    The American journal of medicine, 2004, Jun-01, Volume: 116, Issue:11

    Topics: Albuterol; Antiviral Agents; Asthma; Bronchodilator Agents; Female; Follow-Up Studies; Hepatitis C,

2004
Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate.
    Respirology (Carlton, Vic.), 2004, Volume: 9, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Female;

2004
Response to inhaled albuterol during nocturnal asthma.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over

2004
Inhaled corticosteroids and growth of airway function in asthmatic children.
    The European respiratory journal, 2004, Volume: 23, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Analysis of Variance; As

2004
Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Pulmonary pharmacology & therapeutics, 2004, Volume: 17, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-Acti

2004
Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma.
    The Journal of emergency medicine, 2004, Volume: 27, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Cal

2004
Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 92, Issue:6

    Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cyclopr

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil

2004
Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol.
    Thorax, 2004, Volume: 59, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies;

2004
Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
    Respiratory medicine, 2004, Volume: 98, Issue:9

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator

2004
Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study.
    Respiratory medicine, 2004, Volume: 98, Issue:9

    Topics: Acetates; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over;

2004
Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:3

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Blood Proteins; Bre

2004
Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone.
    Respiratory medicine, 2004, Volume: 98, Issue:10

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; D

2004
Montelukast and airway remodeling in children with chronic persistent asthma: an open study.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2004, Volume: 15, Issue:5

    Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Ch

2004
Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi

2004
Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
    British journal of clinical pharmacology, 2004, Volume: 58, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Area Under Curve; Asthma; Bronchoconstriction; Broncho

2004
[Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study].
    Revue de pneumologie clinique, 2004, Volume: 60, Issue:4

    Topics: Adult; Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Fluticasone-Salmeterol Drug Com

2004
Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma.
    Indian journal of pediatrics, 2004, Volume: 71, Issue:11

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Confidence Intervals; Dose-Respons

2004
Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p
    Clinical therapeutics, 2004, Volume: 26, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2004
Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics.
    British journal of clinical pharmacology, 2005, Volume: 59, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

2005
BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist.
    Respirology (Carlton, Vic.), 2004, Volume: 9, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2004
Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.
    European journal of clinical pharmacology, 2005, Volume: 60, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agent

2005
Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:8

    Topics: Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Inf

2004
Pycnogenol as an adjunct in the management of childhood asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:8

    Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antioxidants; Asthma; Bronch

2004
Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma.
    Pulmonary pharmacology & therapeutics, 2005, Volume: 18, Issue:2

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-A

2005
Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma.
    Chest, 2005, Volume: 127, Issue:2

    Topics: Adolescent; Adult; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents;

2005
Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain.
    International journal of clinical practice, 2005, Volume: 59, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2005
Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Pulmonary pharmacology & therapeutics, 2005, Volume: 18, Issue:3

    Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Doubl

2005
[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment].
    Pneumologie (Stuttgart, Germany), 2005, Volume: 59, Issue:3

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy,

2005
The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers.
    Journal of pharmaceutical sciences, 2005, Volume: 94, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; Chromatography, High Pre

2005
Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma.
    Respiratory medicine, 2005, Volume: 99 Suppl A

    Topics: Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Chemical Phe

2005
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
    Respiratory medicine, 2005, Volume: 99 Suppl A

    Topics: Adolescent; Adult; Aerosol Propellants; Albuterol; Anti-Asthmatic Agents; Asthma; Chemical Phenomena

2005
Increase in daytime symptoms is a sensitive and specific criterion for predicting corticosteroid-treated exacerbations in a clinical asthma trial.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:3

    Topics: Acute Disease; Administration, Oral; Albuterol; Asthma; Drug Administration Schedule; Follow-Up Stud

2005
Haemodynamic responses to salbutamol and isometric exercise are altered in young adults with mild asthma.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Cros

2005
Monitoring nebulizer use in children: comparison of electronic and asthma diary data.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:3

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Femal

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi

2005
The 24 h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler.
    Respiratory medicine, 2005, Volume: 99, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age

2005
[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2005, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug

2005
Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2005
Benefit from anti-inflammatory treatment during clinical remission of atopic asthma.
    Respiratory medicine, 2005, Volume: 99, Issue:6

    Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic Agents; Anti-Infl

2005
Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide.
    Respiratory medicine, 2005, Volume: 99, Issue:6

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Androstadienes; Anti-Inflammatory Agents; As

2005
Reversal of the late asthmatic response increases exhaled nitric oxide.
    Respiratory medicine, 2005, Volume: 99, Issue:12

    Topics: Adult; Albuterol; Allergens; Asthma; Breath Tests; Bronchial Provocation Tests; Bronchodilator Agent

2005
Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways.
    Human molecular genetics, 2005, Jun-15, Volume: 14, Issue:12

    Topics: Adenylyl Cyclases; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-

2005
The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast
    Clinical therapeutics, 2005, Volume: 27, Issue:4

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Double-Blind Method; Dr

2005
A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks.
    Pulmonary pharmacology & therapeutics, 2005, Volume: 18, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Bronchodilator Agents; Calcium Channe

2005
Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
    The Journal of emergency medicine, 2005, Volume: 29, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi

2005
Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Female; Humans; Male; Middle Aged

2005
Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
    International journal of clinical practice, 2005, Volume: 59, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aerosol Propellants; Aged; A

2005
Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.
    Annals of emergency medicine, 2005, Volume: 46, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2005
Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Delayed-Action Preparations; D

2006
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon

2006
Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.
    Pediatric emergency care, 2005, Volume: 21, Issue:7

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Gas Analysis; Bronchodilator Agents; Child; Child, Presc

2005
Effects of two nebulization regimens on heart rate variability during acute asthma exacerbations in children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma;

2005
Comparative analysis of the bronchodilator response measured by impulse oscillometry (IOS), spirometry and body plethysmography in asthmatic children.
    Journal of investigational allergology & clinical immunology, 2005, Volume: 15, Issue:2

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Oscill

2005
The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Blood Pressure; Child; Child, Preschool

2005
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:2

    Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agen

2005
Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2005, Volume: 12, Issue:9

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dy

2005
The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study.
    Clinical therapeutics, 2005, Volume: 27, Issue:7

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconstrictor Agent

2005
Regular vs ad-lib albuterol for patients hospitalized with acute asthma.
    Chest, 2005, Volume: 128, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Doubl

2005
Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients.
    Chest, 2005, Volume: 128, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Ethanolamines; Femal

2005
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Respiratory research, 2005, Sep-16, Volume: 6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio

2005
Formoterol induces tolerance to the bronchodilating effect of Salbutamol following methacholine-provocation test in asthmatic children.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Blood Cell Count; Bronchial Provocation Tests; Bronchodilator Agents;

2006
Does an asthma education program improve quality of life? A two-year randomized trial.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:7

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Measurements; Mal

2005
Deposition pattern of heliox-driven bronchodilator aerosol in the airways of stable asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:7

    Topics: Administration, Inhalation; Adult; Aerosol Propellants; Albuterol; Asthma; Biological Availability;

2005
Evaluation of severity of bronchial asthma through an exercise bronchial challenge.
    Pediatric pulmonology, 2005, Volume: 40, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Child, Pre

2005
Alterations in T-lymphocyte subsets in the airways of asthmatic patients with active hepatitis C virus infection.
    Respiration; international review of thoracic diseases, 2006, Volume: 73, Issue:3

    Topics: Albuterol; Antiviral Agents; Asthma; Bronchodilator Agents; CD4-CD8 Ratio; Drug Therapy, Combination

2006
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    American journal of respiratory and critical care medicine, 2005, Dec-15, Volume: 172, Issue:12

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H

2005
Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma.
    Pediatric pulmonology, 2005, Volume: 40, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Dose-Response Relationship, Drug; Double

2005
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:3

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Alb

2005
[Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study].
    Ugeskrift for laeger, 2005, Sep-19, Volume: 167, Issue:38

    Topics: Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag

2005
Co-administration of salbutamol and fluticasone for emergency treatment of children with moderate acute asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005, Volume: 16, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory A

2005
Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate.
    Respiratory medicine, 2006, Volume: 100, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat

2006
Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.
    Pediatrics, 2005, Volume: 116, Issue:5

    Topics: Acute Disease; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child;

2005
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
    The European respiratory journal, 2005, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma

2005
Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Br

2005
Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils.
    The Journal of allergy and clinical immunology, 2005, Volume: 116, Issue:5

    Topics: Administration, Inhalation; Albuterol; Allergens; Androstadienes; Asthma; Bronchodilator Agents; Cro

2005
Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Ana

2006
Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
    British journal of clinical pharmacology, 2005, Volume: 60, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricto

2005
Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline.
    Respiration; international review of thoracic diseases, 2006, Volume: 73, Issue:4

    Topics: Administration, Oral; Adult; Albendazole; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Comb

2006
Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:5

    Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Airway Resistance; Albuterol; Androstadienes; Asth

2005
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
    Nature, 2005, Dec-01, Volume: 438, Issue:7068

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random

2005
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
    Nature, 2005, Dec-01, Volume: 438, Issue:7068

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random

2005
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
    Nature, 2005, Dec-01, Volume: 438, Issue:7068

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random

2005
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
    Nature, 2005, Dec-01, Volume: 438, Issue:7068

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random

2005
beta-Adrenergic receptor polymorphisms and response to salmeterol.
    American journal of respiratory and critical care medicine, 2006, Mar-01, Volume: 173, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Drug Therapy, Combin

2006
The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation.
    Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Biological Availability; Bronchodilator Agents

2007
Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Androstadienes; Asthma; Bronchodilator Agen

2006
Aminophilline suppress the release of chemical mediators in treatment of acute asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Aminophylline; Anti-Inflammatory

2006
Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial.
    The American journal of emergency medicine, 2006, Volume: 24, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2006
Comparison of morning and afternoon exercise training for asthmatic children.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2006, Volume: 39, Issue:1

    Topics: Abdominal Muscles; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Budesonide; Case-

2006
[Metered-dose inhaler with spacer vs nebulization for severe and potentially severe acute asthma treatment in the pediatric emergency department].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:3

    Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronch

2006
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Chest, 2006, Volume: 129, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2006
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Chest, 2006, Volume: 129, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2006
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Chest, 2006, Volume: 129, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2006
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Chest, 2006, Volume: 129, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2006
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol.
    Respiratory research, 2006, Jan-24, Volume: 7

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Doubl

2006
Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.
    Thorax, 2006, Volume: 61, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic A

2006
Formoterol Turbuhaler as reliever medication in patients with acute asthma.
    The European respiratory journal, 2006, Volume: 27, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Australia; Bronchodilator Agents; Dose-Re

2006
The structural basis of airways hyperresponsiveness in asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2006, Volume: 101, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchoconstriction;

2006
Bronchodilator effect of salbutamol from two different spacer devices.
    Pediatric pulmonology, 2006, Volume: 41, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cross-Over Studies; Equipment Design; Female; Fo

2006
Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use.
    Respiratory research, 2006, Feb-15, Volume: 7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cell Adhesion Molecules; Humans;

2006
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Clinical therapeutics, 2006, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma;

2006
Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus.
    Pediatric pulmonology, 2006, Volume: 41, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Clinical Protocols; Connecticut; Female; Hospita

2006
Improved lung function and symptom control with formoterol on demand in asthma.
    The European respiratory journal, 2006, Volume: 27, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Ethanolami

2006
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down.
    The Journal of allergy and clinical immunology, 2006, Volume: 117, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmat

2006
[Bronchodilators via metered-dose inhaler with spacer in the pediatric emergency department: what is the dosage?].
    Anales de pediatria (Barcelona, Spain : 2003), 2006, Volume: 64, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

2006
Responses to inhaled bronchodilators in infancy are not linked with asthma in later childhood.
    Pediatric pulmonology, 2006, Volume: 41, Issue:5

    Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Child, Preschool; Cross-Over S

2006
Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction.
    Respiratory medicine, 2006, Volume: 100, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchocons

2006
Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
    International journal of pharmaceutics, 2006, Jun-19, Volume: 316, Issue:1-2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Anti-As

2006
Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine.
    Respiratory medicine, 2006, Volume: 100, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Anticonvulsa

2006
Once-daily ciclesonide in children: efficacy and safety in asthma.
    The Journal of pediatrics, 2006, Volume: 148, Issue:3

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-Res

2006
Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study.
    Emergency medicine journal : EMJ, 2006, Volume: 23, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru

2006
Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.
    Allergy, 2006, Volume: 61, Issue:5

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method

2006
A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
    The American journal of emergency medicine, 2006, Volume: 24, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of V

2006
EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb

2006
Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data.
    The Journal of allergy and clinical immunology, 2006, Volume: 117, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Pharmacy Information System

2006
Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:5

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2006
Oral montelukast treatment of preschool-aged children with acute asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:5

    Topics: Acetates; Acute Disease; Administration, Oral; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodila

2006
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary

2007
Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:6

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Height; Bronchodilator Agents; Child,

2006
Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
    PharmacoEconomics, 2006, Volume: 24, Issue:7

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asth

2006
Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Bronchoalveolar Lavage Fluid; Fe

2006
Bronchodilator effect of infused B-type natriuretic peptide in asthma.
    Chest, 2006, Volume: 130, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expirato

2006
Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial.
    Current medical research and opinion, 2006, Volume: 22, Issue:6

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Relations

2006
The effect of nebulized NaHCO3 treatment on "RADS" due to chlorine gas inhalation.
    Inhalation toxicology, 2006, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Air Pollutants; Albuterol; Asthma; Chlorine; Double-Blind Method; Drug Therapy, C

2006
Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma.
    Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Area Under Curve; Asthma; Bronchodi

2007
Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma.
    Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:5

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Cross-O

2006
Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
    Respiratory research, 2006, Aug-18, Volume: 7

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic

2006
Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study.
    Rheumatology international, 2006, Volume: 27, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And

2006
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2006, Volume: 43, Issue:7

    Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Inflammatory Agents

2006
Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Sch

2007
Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline.
    Respiration; international review of thoracic diseases, 2007, Volume: 74, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Bronchodilator

2007
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.
    American journal of respiratory and critical care medicine, 2007, Feb-01, Volume: 175, Issue:3

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists;

2007
Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction.
    International journal of clinical practice, 2006, Volume: 60, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2006
Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilato

2006
Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:4

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 an

2006
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:11

    Topics: Administration, Cutaneous; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Femal

2006
A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma.
    The Journal of emergency medicine, 2006, Volume: 31, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Humans;

2006
The correlation between asthma control and health status: the GOAL study.
    The European respiratory journal, 2007, Volume: 29, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age

2007
The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:5

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronc

2007
The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
    European annals of allergy and clinical immunology, 2006, Volume: 38, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adu

2006
Ventolin to Salamol--a crossover study in New Zealand.
    The New Zealand medical journal, 2006, Oct-27, Volume: 119, Issue:1244

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Equipment

2006
Asthmatics: too drunk to drive? The time curve of exhaled ethanol levels after use of Salamol in normal subjects.
    The New Zealand medical journal, 2006, Oct-27, Volume: 119, Issue:1244

    Topics: Administration, Inhalation; Adult; Albuterol; Alcoholic Intoxication; Asthma; Breath Tests; Bronchod

2006
Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
    The Journal of pediatrics, 2006, Volume: 149, Issue:5

    Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Asthma; Bronchodilator A

2006
Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma.
    Indian journal of pediatrics, 2006, Volume: 73, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Therapy, Comb

2006
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.
    The Journal of allergy and clinical immunology, 2007, Volume: 119, Issue:1

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Height; Child;

2007
Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
    Respiratory research, 2006, Dec-04, Volume: 7

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconst

2006
Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma.
    Clinical drug investigation, 2006, Volume: 26, Issue:6

    Topics: Acetates; Administration, Intranasal; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchod

2006
A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:6

    Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Breath Tests; Bronchodilator Agents; Cross-Over Stud

2007
Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Family practice, 2007, Volume: 24, Issue:2

    Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Dose-Response Relationship, D

2007
Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
    Respiratory medicine, 2007, Volume: 101, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O

2007
Management of acute asthma in children using metered dose inhaler and small volume nebulizer.
    JPMA. The Journal of the Pakistan Medical Association, 2006, Volume: 56, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc

2006
Age dependent systemic exposure to inhaled salbutamol.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:2

    Topics: Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child

2007
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.
    Respiratory research, 2007, Mar-06, Volume: 8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cholinergic Antagoni

2007
Formoterol turbuhaler is as effective as salbutamol diskus in relieving adenosine-induced bronchoconstriction in children.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2007,Spring, Volume: 20, Issue:1

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol

2007
Placebo response in asthma: a robust and objective phenomenon.
    The Journal of allergy and clinical immunology, 2007, Volume: 119, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Cross-Over Studies; Double-Blind Me

2007
A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.
    Emergency medicine journal : EMJ, 2007, Volume: 24, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Me

2007
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:2

    Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albute

2007
Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity.
    Chest, 2007, Volume: 131, Issue:5

    Topics: Adult; Albuterol; Asthma; Breath Tests; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents;

2007
Randomized comparison of strategies for reducing treatment in mild persistent asthma.
    The New England journal of medicine, 2007, May-17, Volume: 356, Issue:20

    Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic A

2007
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
    The New England journal of medicine, 2007, May-17, Volume: 356, Issue:20

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2007
Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.
    Pharmaceutical research, 2007, Volume: 24, Issue:11

    Topics: Administration, Inhalation; Albuterol; Asthma; Biological Availability; Chemistry, Pharmaceutical; C

2007
[Effects of combined therapy with domestic inhalational anti-asthmatic drugs on oxidant status of patients with bronchial asthma].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Antioxidants; Asthma; Budesonid

2007
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
    The European respiratory journal, 2007, Volume: 30, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br

2007
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
    The European respiratory journal, 2007, Volume: 30, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br

2007
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
    The European respiratory journal, 2007, Volume: 30, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br

2007
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
    The European respiratory journal, 2007, Volume: 30, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br

2007
Lipid peroxides in stable asthmatics receiving inhaled steroids and long-acting beta2 -agonists.
    Respirology (Carlton, Vic.), 2007, Volume: 12, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Budeson

2007
Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone.
    Primary care respiratory journal : journal of the General Practice Airways Group, 2007, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents

2007
Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
    Respiratory research, 2007, Jul-04, Volume: 8

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; B

2007
Is there any point in a corticosteroid treatment of intermittent asthma?
    TheScientificWorldJournal, 2007, Jul-03, Volume: 7

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Drug Combi

2007
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
    Respiratory research, 2007, Jul-14, Volume: 8

    Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason

2007
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
    Respiratory research, 2007, Jul-14, Volume: 8

    Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason

2007
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
    Respiratory research, 2007, Jul-14, Volume: 8

    Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason

2007
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
    Respiratory research, 2007, Jul-14, Volume: 8

    Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason

2007
Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials.
    Respiratory medicine, 2007, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Double-Bli

2007
Randomized trial of spacers in asthma.
    Indian journal of pediatrics, 2007, Volume: 74, Issue:7

    Topics: Adolescent; Adrenergic alpha-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presc

2007
Swimming and persons with mild persistant asthma.
    TheScientificWorldJournal, 2007, Aug-17, Volume: 7

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Femal

2007
Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction.
    Pharmacotherapy, 2007, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Albuterol; Area Under Curve; Asthma; Breath Tests; Bronchial Provocation Tests; B

2007
Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Clinical therapeutics, 2007, Volume: 29, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Alkanes; Androstadienes; Asthma; Bronc

2007
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
    Allergy, 2007, Volume: 62, Issue:10

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen

2007
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
    Allergy, 2007, Volume: 62, Issue:10

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen

2007
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
    Allergy, 2007, Volume: 62, Issue:10

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen

2007
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
    Allergy, 2007, Volume: 62, Issue:10

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen

2007
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:104

    Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho

2005
Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
    Respiratory research, 2007, Sep-27, Volume: 8

    Topics: Acetates; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma;

2007
Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2007, Volume: 14, Issue:10

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be

2007
Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics.
    Respiratory medicine, 2007, Volume: 101, Issue:12

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albuterol; Analysis of Varianc

2007
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Respiratory medicine, 2007, Volume: 101, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2007
Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study.
    The Journal of allergy and clinical immunology, 2007, Volume: 120, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albuterol; Androstadienes; Anti-Allergic Agents;

2007
Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma

2007
[A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2007, Volume: 30, Issue:7

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivi

2007
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation.
    Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 104, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; B

2008
Agreement between two methods for assessing bioequivalence of inhaled salbutamol.
    Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc

2008
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Current medical research and opinion, 2007, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator Agents; El

2007
Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Respiratory medicine, 2008, Volume: 102, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Ov

2008
Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Volume: 33, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Algorithms; Asthma; Biological Availability; Bronchodi

2008
The effects of combination treatment with a long-acting beta2-agonist and a corticosteroid on salivary flow rate, secretory immunoglobulin A, and oral health in children and adolescents with moderate asthma: a 1-month, single-blind clinical study.
    Clinical therapeutics, 2007, Volume: 29, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

2007
Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Thera

2008
Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand.
    The New Zealand medical journal, 2007, Dec-14, Volume: 120, Issue:1267

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies;

2007
AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma.
    Diabetes care, 2008, Volume: 31, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Blood Glucose; Cross-Ov

2008
Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
    Respiratory medicine, 2008, Volume: 102, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A

2008
Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
    Clinical drug investigation, 2008, Volume: 28, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator

2008
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 99, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; F

2007
Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids.
    Clinical drug investigation, 2008, Volume: 28, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie

2008
The effects of nebulized albuterol on esophageal function in asthmatic patients.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:10

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Dru

2008
Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilato

2008
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
    Respiratory medicine, 2008, Volume: 102, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A

2008
[Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:3

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Ch

2008
Salmeterol vs. formoterol: a comparison of rapid bronchodilator effect in a randomized controlled trial.
    Indian pediatrics, 2008, Volume: 45, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Etha

2008
Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients.
    Respiratory medicine, 2008, Volume: 102, Issue:7

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; D

2008
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma.
    Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Cross-Ov

2008
Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma.
    Pharmacogenetics and genomics, 2008, Volume: 18, Issue:5

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Bli

2008
Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:6

    Topics: Acetates; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Breath Tests; Bronchodil

2008
Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2008, Volume: 45, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budeson

2008
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Child

2008
Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone.
    Current medical research and opinion, 2008, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Black or African American; Bronchodilator Agen

2008
Ketotifen in adult asthma.
    British medical journal, 1980, Feb-09, Volume: 280, Issue:6211

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Doubl

1980
Double-blind crossover study of carbuterol and salbutamol in bronchial asthma.
    The Journal of international medical research, 1981, Volume: 9, Issue:4

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Trial

1981
Inhaled prazosin in asthma.
    Thorax, 1981, Volume: 36, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Metho

1981
Comparison of cardiorespiratory effects of procaterol and salbutamol in asthmatic patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1982, Volume: 65, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cardiovascular System; Clinical Tria

1982
Two new beta 2-adrenoceptor agonists, D-2343 and QH 25, studied in asthmatic patients.
    Allergy, 1982, Volume: 37, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Animals; Asthma; Bronchodilator Agents; Depression

1982
Pirbuterol.
    Lancet (London, England), 1984, Apr-07, Volume: 1, Issue:8380

    Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Double-Blind Method; Et

1984
Selectivity of beta-adrenergic stimulating and blocking agents.
    European journal of respiratory diseases. Supplement, 1984, Volume: 136

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Resistance; Albuterol; Asthma; Bronchi

1984
Aminophylline for morning dips in chronic asthma.
    Lancet (London, England), 1984, Jul-07, Volume: 2, Issue:8393

    Topics: Albuterol; Aminophylline; Asthma; Beclomethasone; Circadian Rhythm; Clinical Trials as Topic; Double

1984
A therapeutic comparison of ipratropium bromide and salbutamol in asthmatic patients.
    Current medical research and opinion, 1982, Volume: 8, Issue:4

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Drug Tolerance; Fema

1982
Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma.
    British journal of diseases of the chest, 1983, Volume: 77, Issue:2

    Topics: Acute Disease; Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Female; Humans; Iprat

1983
Nebulised ipratropium bromide in wheezy infants and young children.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Administration, Intranasal; Age Factors; Airway Resistance; Albuterol; Asthma; Atropine Derivatives;

1983
Salbutamol versus Duovent (a combination of fenoterol and ipratropium bromide) in asthma.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Drug Combinations; E

1983
A comparison between a combination of ipratropium bromide plus fenoterol in a single metered dose inhaler (Duovent) and salbutamol in asthma.
    Postgraduate medical journal, 1983, Volume: 59, Issue:697

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Chronic Disease; Drug Combinations; Ethanolami

1983
[Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma].
    Revista clinica espanola, 1983, Nov-30, Volume: 171, Issue:4

    Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Chronic Disease; Double-Blind Method;

1983
Comparison of Duovent and salbutamol inhalers in chronic stable asthma.
    Postgraduate medical journal, 1984, Volume: 60 Suppl 1

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Chronic Disease; Clinical Trials as

1984
Ipratropium bromide in patients with nocturnal asthma.
    Postgraduate medical journal, 1984, Volume: 60, Issue:706

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Female; Humans; Ipra

1984
[Effectiveness of disodium cromoglycate, salbutamol, and ipratropium bromide in the inhibition of exercise-induced bronchospasm].
    Anales espanoles de pediatria, 1984, Volume: 20, Issue:8

    Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Bronchial Spasm; Child; Clinical

1984
Combination of salbutamol inhalational powder and tablets in asthma.
    Archives of disease in childhood, 1983, Volume: 58, Issue:4

    Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-B

1983
Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma.
    The Medical journal of Australia, 1983, Jun-25, Volume: 1, Issue:13

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchi; Child; Child, Preschool; Clinical Trials as Topic;

1983
Comparison of bronchodilator effects of oral salbutamol and theophylline and their combination with hydroxyzine.
    Annals of clinical research, 1983, Volume: 15, Issue:1

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug

1983
A 21-day double-blind study of the effect of adding sustained-release theophylline (Nuelin SA) to inhaled salbutamol in patients with asthma.
    British journal of diseases of the chest, 1983, Volume: 77, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind

1983
Effect of a timed interval between inhalation of beta-agonist and corticosteroid aerosols on the control of chronic asthma.
    Thorax, 1983, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Chronic Disease; Clinical Tria

1983
[Inhalation therapy with fenoterol powder in children with bronchial asthma].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1983, Apr-20, Volume: 103, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Ethanolamines; Female; Fenoterol; Hu

1983
Chamber assisted inhalant treatment (CAIR).
    Annals of allergy, 1983, Volume: 51, Issue:3

    Topics: Albuterol; Asthma; Beclomethasone; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant

1983
Nebulized salbutamol in life-threatening asthma: is IPPB necessary?
    British journal of diseases of the chest, 1983, Volume: 77, Issue:3

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method;

1983
The duration of protection from exercise-induced asthma by inhaled salbutamol, and a comparison with inhaled reproterol.
    British journal of diseases of the chest, 1983, Volume: 77, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Drug Combi

1983
Bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children.
    British journal of diseases of the chest, 1983, Volume: 77, Issue:3

    Topics: Albuterol; Asthma; Bronchi; Child; Child, Preschool; Chlorpheniramine; Clemastine; Clinical Trials a

1983
Drug effect on bronchial response to PGF2 alpha and water inhalation.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 1)

    Topics: Albuterol; Asthma; Benzothiazoles; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Clin

1983
Comparison of inhaled fenoterol and salbutamol in the prevention of exercise-induced asthma.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced

1983
A cumulative dose response study of oxitropium bromide (Ba 253) in asthmatics.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fe

1983
Fenoterol versus salbutamol nebuliser solution in asthma.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Administration, Intranasal; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Doub

1983
The bronchodilator response to inhalation of increasing doses of aerosolized albuterol.
    The Journal of allergy and clinical immunology, 1983, Volume: 72, Issue:4

    Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Age

1983
Cardiac response to oral and aerosol administration of beta agonists.
    The Journal of pediatrics, 1983, Volume: 103, Issue:4

    Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Hear

1983
Fenoterol versus salbutamol nebulization in asthma.
    Postgraduate medical journal, 1983, Volume: 59, Issue:694

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamin

1983
[Effect, tolerance and dose dependence of salbutamol powder inhalations].
    Die Medizinische Welt, 1983, Nov-04, Volume: 34, Issue:44

    Topics: Administration, Intranasal; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response

1983
Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol.
    Chest, 1984, Volume: 85, Issue:1

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Double-Blin

1984
[Effect of treatment with ventolin and becotide on ventilation and hemodynamics in patients with bronchial asthma].
    Klinicheskaia meditsina, 1983, Volume: 61, Issue:12

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Drug Therapy, Combination; He

1983
Assessment of a new combination inhaler containing salbutamol and beclomethasone dipropionate in the management of asthmatic patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1984, May-12, Volume: 65, Issue:19

    Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Child; Clinical Trials as Topic; Double-Blind

1984
Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism.
    Clinical science (London, England : 1979), 1984, Volume: 66, Issue:6

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Atropine; Bronchi; Chlorpheniramine; Dose-Response Rela

1984
Comparative study of the bronchospasmolytic effect of fenoterol (0.2 mg) salbutamol (0.4 mg) as powder inhalations in 20 patients with reversible bronchial obstruction.
    Respiration; international review of thoracic diseases, 1984, Volume: 45, Issue:3

    Topics: Administration, Intranasal; Adult; Airway Resistance; Albuterol; Asthma; Clinical Trials as Topic; D

1984
A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma.
    European journal of respiratory diseases, 1984, Volume: 65, Issue:7

    Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind

1984
Isosorbide dinitrate and isoxsuprine in exercise induced asthma.
    British medical journal (Clinical research ed.), 1983, Jun-18, Volume: 286, Issue:6382

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cromolyn Sodium; Forced Expiratory V

1983
Simple drug delivery system for use by young asthmatics.
    British medical journal (Clinical research ed.), 1983, Jun-25, Volume: 286, Issue:6383

    Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Therapy

1983
Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma.
    British medical journal (Clinical research ed.), 1984, Feb-04, Volume: 288, Issue:6414

    Topics: Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; Female; Humans; Male; M

1984
Comparison of atropine with ipratropium bromide in patients with reversible airways obstruction unresponsive to salbutamol.
    British journal of diseases of the chest, 1980, Volume: 74, Issue:3

    Topics: Adult; Albuterol; Asthma; Atropine; Atropine Derivatives; Clinical Trials as Topic; Dose-Response Re

1980
Effect of freon inhalation on maximal expiratoryflows and heart rhythm after treatment with salbutamol and ipratropium bromide.
    European journal of respiratory diseases, 1980, Volume: 61, Issue:3

    Topics: Adult; Aerosol Propellants; Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; Atropine Derivatives;

1980
[Clinical pharmacological trials of a new metered dose inhaler, IK-6, a combination of the bronchodilators fenoterol and ipratropium bromide (author's transl)].
    Wiener medizinische Wochenschrift (1946), 1980, Jun-15, Volume: 130, Issue:11

    Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Drug Combinations; Ethanolami

1980
Ipratropium bromide in acute asthma.
    British medical journal (Clinical research ed.), 1981, Feb-21, Volume: 282, Issue:6264

    Topics: Acute Disease; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical

1981
[Bronchial asthma induced by exercise (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Mar-06, Volume: 106, Issue:10

    Topics: Airway Resistance; Albuterol; Asthma; Cromolyn Sodium; Humans; Ipratropium; Physical Exertion

1981
Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets.
    Allergy, 1980, Volume: 35, Issue:8

    Topics: Administration, Oral; Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Clin

1980
Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma.
    Archives of disease in childhood, 1981, Volume: 56, Issue:5

    Topics: Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Child, Preschool;

1981
Adrenaline and nebulized salbutamol in acute asthma.
    Archives of disease in childhood, 1984, Volume: 59, Issue:7

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Epinephrine; Female; Humans; Injections; Male

1984
[Pirbuterol and salbutamol aerosol for exercise-induced bronchoconstriction].
    Schweizerische medizinische Wochenschrift, 1984, Nov-17, Volume: 114, Issue:46

    Topics: Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Ethanolamines;

1984
Deep-inspiration induced bronchoconstriction: a mechanism for beclomethasone aerosol intolerance.
    European journal of respiratory diseases, 1983, Volume: 64, Issue:7

    Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial Spasm; Cough; Humans; Prem

1983
Bronchodilatory effect of inhaled versus oral salbutamol in bronchial asthma.
    Respiration; international review of thoracic diseases, 1983, Volume: 44, Issue:6

    Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expi

1983
Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children.
    Australian paediatric journal, 1983, Volume: 19, Issue:4

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Maximal M

1983
Effects of oral theophylline and oral salbutamol in the treatment of asthma.
    Archives of disease in childhood, 1982, Volume: 57, Issue:9

    Topics: Adolescent; Albuterol; Asthma; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Drug

1982
Comparison of salbutamol given by intermittent positive-pressure breathing and pressure-packed aerosol in chronic asthma.
    Thorax, 1982, Volume: 37, Issue:8

    Topics: Aerosols; Albuterol; Asthma; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans;

1982
A comparison of the effects of different methods of administration of beta-2-sympathomimetics in patients with asthma.
    British journal of diseases of the chest, 1982, Volume: 76, Issue:4

    Topics: Administration, Oral; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Resp

1982
Salbutamol: tablets, inhalational powder, or nebuliser?
    British medical journal (Clinical research ed.), 1981, Jan-10, Volume: 282, Issue:6258

    Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method;

1981
Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma.
    British medical journal (Clinical research ed.), 1981, Mar-28, Volume: 282, Issue:6269

    Topics: Adolescent; Albuterol; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Delayed-Action Prep

1981
Bronchodilator effect of sodium cromoglycate and its clinical implications.
    British medical journal (Clinical research ed.), 1981, Jun-13, Volume: 282, Issue:6280

    Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Cromolyn Sodium; Female; Humans;

1981
Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma.
    Clinical allergy, 1981, Volume: 11, Issue:3

    Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Cromolyn Sodium; Female; Humans; Ketotifen; Male; Middle

1981
Actions of salbutamol, disodium cromoglycate, and placebo administered as aerosols in acute asthma.
    Archives of disease in childhood, 1981, Volume: 56, Issue:9

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Cromolyn Sodium; Dr

1981
The immediate effect of sodium cromoglycate on the airway.
    Annals of allergy, 1982, Volume: 48, Issue:1

    Topics: Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Cromolyn Sodium; Female; Humans

1982
A double blind crossover trial of lithium carbonate in asthma.
    Annals of allergy, 1982, Volume: 49, Issue:3

    Topics: Adult; Albuterol; Asthma; Double-Blind Method; Female; Humans; Lithium; Lithium Carbonate; Male; Mid

1982
Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study.
    Australian and New Zealand journal of medicine, 1982, Volume: 12, Issue:3

    Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic

1982
Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children.
    The Journal of pediatrics, 1983, Volume: 102, Issue:3

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Gas Analysis; Child; Double-Blind Method; Epinep

1983
Comparison between an alpha-adrenergic antagonist and a beta 2-adrenergic agonist in bronchial asthma.
    Chest, 1983, Volume: 83, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Drug Evaluation; Drug Therapy, Combination; Female; Human

1983
Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children.
    Annals of allergy, 1983, Volume: 50, Issue:5

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Blood Pressure; Child; Double-Blind Method; Female; Heart;

1983
Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects.
    Thorax, 1983, Volume: 38, Issue:3

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Relationship

1983
The effect of powder aerosol compared to pressurized aerosol.
    European journal of respiratory diseases. Supplement, 1982, Volume: 119

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Humans; Powders; Pressure; Random Allocation; Respirato

1982
Protective effect of inhaled salbutamol powder in children assessed by histamine challenge.
    British medical journal, 1980, Feb-09, Volume: 280, Issue:6211

    Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Child; Clinical Trials as Topic; Double-

1980
Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma.
    Archives of disease in childhood, 1980, Volume: 55, Issue:3

    Topics: Administration, Oral; Airway Resistance; Albuterol; Asthma; Child, Preschool; Clinical Trials as Top

1980
Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels.
    Thorax, 1980, Volume: 35, Issue:7

    Topics: Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Chronic Disease; Circadian Rhythm; Clinic

1980
Salbutamol by powder or spray inhalation in childhood asthma.
    Allergy, 1980, Volume: 35, Issue:7

    Topics: Administration, Intranasal; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials

1980
Aminophylline vs. salbutamol in exercise-induced asthma.
    International journal of clinical pharmacology, therapy, and toxicology, 1980, Volume: 18, Issue:10

    Topics: Adult; Albuterol; Aminophylline; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Forced

1980
Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma.
    British journal of diseases of the chest, 1980, Volume: 74, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Drug A

1980
A comparison of the duration of action of fenoterol and salbutamol in asthma.
    Current medical research and opinion, 1981, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamines;

1981
Regular versus symptomatic aerosol bronchodilator treatment of asthma.
    British journal of diseases of the chest, 1981, Volume: 75, Issue:2

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Admini

1981
How important is the sequence of administration of inhaled beclomethasone dipropionate and salbutamol in asthma.
    British journal of diseases of the chest, 1981, Volume: 75, Issue:3

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Double-Blind Met

1981
Clinical effects of albuterol aerosol in the treatment of asthma.
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Humans; Isoproterenol; Middle Ag

1981
Tolerance to beta-adrenergics and results of rising dose studies of albuterol, isoproterenol and placebo.
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Spasm; Clinical Trials as Topic; Dose-Response Relatio

1981
Interaction between proxyphylline and salbutamol.
    International journal of clinical pharmacology, therapy, and toxicology, 1981, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Albuterol; Aminophylline; Animals; Asthma; Bronchodilator Agents; Clinical Trials

1981
Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels.
    Thorax, 1981, Volume: 36, Issue:8

    Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male;

1981
[Broncholytic effect of salbutamol, ventolin and berotec aerosols in bronchial asthma].
    Pneumonologia polska, 1981, Volume: 49, Issue:10

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Clinical Trials as T

1981
Severe acute asthma: a comparison of three methods of inhaling salbutamol.
    British journal of diseases of the chest, 1982, Volume: 76, Issue:1

    Topics: Acute Disease; Albuterol; Asthma; Heart Rate; Humans; Intermittent Positive-Pressure Breathing; Maxi

1982
A comparison of isoetharine and albuterol: report of changes in pulmonary functions over 1 hour.
    The Journal of the American Osteopathic Association, 1982, Volume: 81, Issue:8

    Topics: Albuterol; Amino Alcohols; Asthma; Bronchial Spasm; Bronchodilator Agents; Clinical Trials as Topic;

1982
Oral albuterol in the treatment of childhood asthma.
    Pediatrics, 1982, Volume: 69, Issue:4

    Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Female; Forced Expi

1982
Salbutamol in the treatment of asthmatic children. A comparison of oral and inhalation therapy alone and in combination.
    European journal of respiratory diseases, 1982, Volume: 63, Issue:4

    Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Female; F

1982
Albuterol by aerosol and orally administered theophylline in asthmatic children.
    The Journal of pediatrics, 1982, Volume: 101, Issue:4

    Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Humans; Pulmonary Ventilation;

1982
Salbutamol: comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects.
    Canadian Medical Association journal, 1982, Nov-01, Volume: 127, Issue:9

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Forced Expirator

1982
Albuterol syrup in the treatment of the young asthmatic child.
    Annals of allergy, 1981, Volume: 47, Issue:3

    Topics: Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Fe

1981
Pulmonary function and airways resistance studies on chronic stabilized asthma: comparison of acute and long-term effects of albuterol and isoproterenol aerosols.
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Acute Disease; Airway Resistance; Albuterol; Asthma; Female; Heart Rate; Humans; Isoproterenol; Male

1981
Cardiovascular response during severe acute asthma and its treatment in children.
    Thorax, 1981, Volume: 36, Issue:7

    Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Blood Pressure; Cardiac Output; Cardiov

1981
Intravenous salbutamol and aminophylline in asthma: a search for synergy.
    Thorax, 1981, Volume: 36, Issue:10

    Topics: Albuterol; Aminophylline; Asthma; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Co

1981
Corticosteroids in status asthmaticus.
    The Journal of pediatrics, 1980, Volume: 96, Issue:3 Pt 2

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Child; Evaluation Studies as

1980
Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction.
    British journal of clinical pharmacology, 1980, Volume: 9, Issue:3

    Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Humans; Tachycardia; Time Factors

1980
Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm.
    Pediatrics, 1980, Volume: 66, Issue:1

    Topics: Administration, Intranasal; Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Asthma, E

1980
A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma.
    The Journal of international medical research, 1980, Volume: 8, Issue:6

    Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Delayed-Action Preparations; Dose-Response Rela

1980
Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol.
    Allergy, 1980, Volume: 35, Issue:7

    Topics: Acute Disease; Administration, Intranasal; Adolescent; Albuterol; Asthma; Child; Dose-Response Relat

1980
Plasma atrial natriuretic peptide during spontaneous bronchoconstriction in asthmatics.
    Peptides, 1995, Volume: 16, Issue:4

    Topics: Acute Disease; Adult; Albuterol; Analysis of Variance; Asthma; Atrial Natriuretic Factor; Bronchi; F

1995
Effect of zatebradine, a novel 'sinus node inhibitor', on pulmonary function compared to placebo.
    Pulmonary pharmacology, 1994, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Benzazepines; Bronchial Hyperreactivity; Cardiovascular

1994
Safety of salmeterol in the maintenance treatment of asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Chronic Disease; Double

1995
A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma.
    Intensive care medicine, 1995, Volume: 21, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Blood Gas Analysis; Bronchodila

1995
Salbutamol in the treatment of asthma.
    Lancet (London, England), 1995, Oct-21, Volume: 346, Issue:8982

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Double-Blind Method; Forced E

1995
Validation of an asthma quality of life diary in a clinical trial.
    Thorax, 1995, Volume: 50, Issue:7

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cross-Sectional S

1995
The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children.
    Allergy, 1995, Volume: 50, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin

1995
Influence of budesonide on the response to inhaled terbutaline in children with mild asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 1995, Volume: 6, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child;

1995
Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine.
    American journal of respiratory and critical care medicine, 1995, Volume: 152, Issue:5 Pt 1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Analysis of Varia

1995
The assessment of dyspnea in bronchial asthma.
    International journal of clinical pharmacology and therapeutics, 1995, Volume: 33, Issue:7

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Forced

1995
Salmeterol xinafoate in children on high dose inhaled steroids.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

1995
Rapid onset of tolerance to the bronchoprotective effect of salmeterol.
    Chest, 1995, Volume: 108, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agen

1995
Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.
    The European respiratory journal, 1995, Volume: 8, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl

1995
Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1995, Volume: 32, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Eq

1995
An open multi-centre study to assess the efficacy of inhaled salmeterol in bronchial asthma in Nigeria.
    African journal of medicine and medical sciences, 1994, Volume: 23, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Femal

1994
Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.
    Chest, 1995, Volume: 108, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Cr

1995
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.
    Lancet (London, England), 1995, Jul-22, Volume: 346, Issue:8969

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cros

1995
Efficacy of a simple DIY spacer with a metered dose inhaler in asthma.
    The New Zealand medical journal, 1995, Jun-28, Volume: 108, Issue:1002

    Topics: Administration, Inhalation; Albuterol; Asthma; Cross-Over Studies; Equipment Design; Female; Humans;

1995
Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1995, Volume: 45, Issue:394

    Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Female; Follow-Up Studies; Hu

1995
Comparison of the effect of inhaled selective and non-selective adrenergic agonists on cardiorespiratory parameters in chronic stable asthma.
    Pulmonary pharmacology, 1994, Volume: 7, Issue:4

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Chronic Disease; Cross-Over Studies; Dou

1994
Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:1

    Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Injections, Intravenous; Male; Pe

1995
Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group.
    European journal of clinical pharmacology, 1995, Volume: 48, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O

1995
Regular use of inhaled albuterol and the allergen-induced late asthmatic response.
    The Journal of allergy and clinical immunology, 1995, Volume: 96, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Asthma; Cross-Over Studies; Double-Blind Me

1995
Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.
    The Journal of allergy and clinical immunology, 1995, Volume: 96, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Chlorofluorocarbons; Cross-Over St

1995
Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma.
    The Journal of allergy and clinical immunology, 1995, Volume: 96, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Drug

1995
Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma.
    Respiratory medicine, 1995, Volume: 89, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Chronic Disease; Double-Blind Method

1995
[Bronchial reactivity after regular inhalation of salbutamol].
    Pneumonologia i alergologia polska, 1995, Volume: 63, Issue:3-4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Rel

1995
Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

1995
Long-term intervention in childhood asthma: the Dutch study results. Dutch Chronic Nonspecific Lung Disease Study Group.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1995, Volume: 50, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc

1995
Some technical factors influencing the induction of sputum for cell analysis.
    The European respiratory journal, 1995, Volume: 8, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cell Count; Cross

1995
High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group.
    The European respiratory journal, 1995, Volume: 8, Issue:4

    Topics: Aerosols; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Budesonide; Double-Blind Meth

1995
Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma.
    The Journal of pediatrics, 1995, Volume: 126, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Analysis of Variance; Asthma; Child; Child, Preschool; Double-

1995
Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies.
    Allergy, 1994, Volume: 49, Issue:10

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Cross-Over Studies; Dose-Re

1994
Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients.
    The European respiratory journal, 1994, Volume: 7, Issue:12

    Topics: Aerosol Propellants; Age Factors; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Dou

1994
Comparison of Bricanyl Turbuhaler and Ventolin Rotahaler in children with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:1

    Topics: Albuterol; Asthma; Child; Child, Preschool; Cross-Over Studies; Drug Tolerance; Female; Humans; Lung

1995
Randomised trial spacer v nebuliser for acute asthma.
    Archives of disease in childhood, 1995, Volume: 72, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Drug Delivery Systems; Drug Therapy

1995
The influence of an inhaled steroid on quality of life in patients with asthma or COPD.
    Chest, 1995, Volume: 107, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volume; Hea

1995
The reversibility of airway obstruction to an inhaled beta 2-adrenergic agent is less satisfactory after methacholine testing in asthmatic subjects.
    Chest, 1995, Volume: 107, Issue:5

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Method

1995
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial.
    The Journal of allergy and clinical immunology, 1995, Volume: 95, Issue:5 Pt 1

    Topics: Adolescent; Adult; Albuterol; Asthma; Cetirizine; Double-Blind Method; Ephedrine; Humans; Male; Plac

1995
Comparison of metered dose inhaler and oral administration of albuterol in the outpatient treatment of infants and children.
    The American journal of emergency medicine, 1995, Volume: 13, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Female

1995
Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma.
    American journal of respiratory and critical care medicine, 1995, Volume: 151, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Proteins; Bronchi; Bronchial Provocation

1995
[Duration of the effect of inhaled corticosteroids on lung function and sensitivity of the respiratory tract in patients with bronchial asthma].
    Medizinische Klinik (Munich, Germany : 1983), 1995, Apr-15, Volume: 90, Issue:4

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial P

1995
[Asthma is asthma, is asthma...].
    Medizinische Klinik (Munich, Germany : 1983), 1995, Apr-15, Volume: 90, Issue:4

    Topics: Administration, Inhalation; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial Provocat

1995
A randomized comparison of 100-mg vs 500-mg dose of methylprednisolone in the treatment of acute asthma.
    Chest, 1995, Volume: 107, Issue:6

    Topics: Acute Disease; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Huma

1995
Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma.
    Chest, 1995, Volume: 107, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Combined Modality Therapy; Double-Blind M

1995
GR106642X: a new, non-ozone depleting propellant for inhalers.
    BMJ (Clinical research ed.), 1995, Jun-24, Volume: 310, Issue:6995

    Topics: Aerosol Propellants; Albuterol; Asthma; Bronchial Hyperreactivity; Cross-Over Studies; Double-Blind

1995
The effect of transfusion on pulmonary function in patients with thalassemia major.
    Pediatric pulmonology, 1994, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; beta-Thalassemia; Child; Erythrocyte Transfusion; Female; Huma

1994
Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.
    American journal of respiratory and critical care medicine, 1995, Volume: 151, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchod

1995
Effect of inhaled norepinephrine on the nitroglycerin-induced bronchodilatation in asthmatics.
    Chest, 1995, Volume: 107, Issue:1

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Cross-Over Studies; Double-Blin

1995
[Effect of an inhaled beta-2-adrenergic agent administered at the time of delayed bronchial reactions to occupational agents].
    Revue des maladies respiratoires, 1994, Volume: 11, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Meth

1994
[Contribution of the bronchodilator test in the study of bronchial reversibility].
    Archivos de bronconeumologia, 1994, Volume: 30, Issue:10

    Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchitis; Diagnosis, Differential;

1994
Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.
    Thorax, 1994, Volume: 49, Issue:11

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Cross-Over Studies; Culture Techniques; Dose-Response

1994
High-dose MDI salbutamol treatment of asthma in the ED.
    The American journal of emergency medicine, 1995, Volume: 13, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Emergencies; Female;

1995
[Salmeterol improves control in asthmatic patients treated in general practice. A comparative study of salmeterol (Serevent) and salbutamol (Ventoline) in patients with mild to moderate asthma].
    Ugeskrift for laeger, 1995, Jan-02, Volume: 157, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Doubl

1995
Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids.
    American journal of respiratory and critical care medicine, 1995, Volume: 151, Issue:2 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Budesonide

1995
A double-blind, cross-over study using salbutamol, beclomethasone, and a combination of both in bronchial asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1995, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Child; Cross-Over

1995
Early administration of hydrocortisone in the emergency room treatment of acute asthma: a controlled clinical trial.
    Respiratory medicine, 1994, Volume: 88, Issue:10

    Topics: Acute Disease; Adult; Albuterol; Asthma; Double-Blind Method; Drug Administration Schedule; Drug The

1994
Metered-dose inhalers with spacers vs nebulizers for pediatric asthma.
    Archives of pediatrics & adolescent medicine, 1995, Volume: 149, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Dru

1995
Theophylline does not shorten hospital stay for children admitted for asthma.
    Archives of pediatrics & adolescent medicine, 1995, Volume: 149, Issue:2

    Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Double-Blind Method; Drug The

1995
Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol.
    The Journal of allergy and clinical immunology, 1995, Volume: 95, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronch

1995
Nebulized salbutamol (Asmasal) in Thai children with asthma: comparison of three doses.
    Asian Pacific journal of allergy and immunology, 1994, Volume: 12, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Cross-Over Studies; Dose-Response Relationship

1994
Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction.
    The European respiratory journal, 1994, Volume: 7, Issue:11

    Topics: Adenosine Monophosphate; Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchocons

1994
Does single dose salmeterol affect exercise capacity in asthmatic men?
    The European respiratory journal, 1994, Volume: 7, Issue:11

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Exercise T

1994
Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma.
    Thorax, 1994, Volume: 49, Issue:12

    Topics: Albuterol; Asthma; Chlorofluorocarbons; Dose-Response Relationship, Drug; Double-Blind Method; Drug

1994
Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.
    Thorax, 1995, Volume: 50, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Pressure; Cross-Over Studies; Dose-Respo

1995
Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol.
    Arzneimittel-Forschung, 1995, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-O

1995
[The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study].
    Revue des maladies respiratoires, 1994, Volume: 11, Issue:1

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Me

1994
Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group.
    The European respiratory journal, 1994, Volume: 7, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc

1994
A 1-week dose-ranging study of inhaled salmeterol in patients with asthma.
    Chest, 1994, Volume: 105, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

1994
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    JAMA, 1994, May-11, Volume: 271, Issue:18

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

1994
Regular vs as-needed inhaled salbutamol in asthma control.
    Lancet (London, England), 1994, Jun-04, Volume: 343, Issue:8910

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Ad

1994
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.
    Lancet (London, England), 1994, Jul-23, Volume: 344, Issue:8917

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Double-Blin

1994
Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 1994, Volume: 3, Issue:2

    Topics: Activities of Daily Living; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind M

1994
Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.
    Allergy, 1994, Volume: 49, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Delayed-Action Preparations; D

1994
Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors.
    Hypertension (Dallas, Tex. : 1979), 1994, Volume: 24, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Atenolol; Double-

1994
Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels.
    International archives of allergy and immunology, 1994, Volume: 105, Issue:2

    Topics: Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Interleukins; Lum

1994
Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics.
    American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lav

1994
Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma.
    International journal of clinical pharmacology and therapeutics, 1994, Volume: 32, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Albuterol; Asthma; Double-Blind Method; Female

1994
Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer.
    Chest, 1994, Volume: 106, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Double-Blind Met

1994
Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi.
    East African medical journal, 1994, Volume: 71, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Femal

1994
A clinical study of colchicine in childhood asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1994, Volume: 31, Issue:5

    Topics: Albuterol; Asthma; Child; Colchicine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male;

1994
[Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:7-8

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Drug Therapy, Combination; Fema

1994
[Inhalation corticosteroid therapy and nonspecific bronchial responsiveness enhanced with salbutamol].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:7-8

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Hista

1994
Partial inhibition of the early and late asthmatic response by a single dose of salmeterol.
    American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:5 Pt 1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Animals; Antigens, Dermatophagoides; Asthma; Blood Prote

1994
Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients.
    Delaware medical journal, 1994, Volume: 66, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Drug Combinations; Female; Fenoter

1994
Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide.
    Pediatric pulmonology, 1994, Volume: 18, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Analysis of Variance; Asthma; Child; Chronic Dise

1994
Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group.
    Thorax, 1994, Volume: 49, Issue:10

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-

1994
Effect of out-of-hospital albuterol inhalation treatments on patient comfort and morbidity.
    Annals of emergency medicine, 1994, Volume: 24, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Cohort Studies; Confidence Inte

1994
Salbutamol in treatment of bronchial asthma--comparison of controlled release tablet with standard tablet.
    Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology, 1993, Volume: 26, Issue:3

    Topics: Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Mal

1993
The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.
    Respiratory medicine, 1994, Volume: 88, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cros

1994
High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects.
    The European respiratory journal, 1994, Volume: 7, Issue:9

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchoconstriction

1994
Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma.
    Magnesium research, 1994, Volume: 7, Issue:2

    Topics: Adult; Aged; Albuterol; Analysis of Variance; Asthma; Blood Pressure; Cross-Over Studies; Double-Bli

1994
Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study.
    American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance;

1994
Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness.
    Archives of disease in childhood, 1993, Volume: 69, Issue:1

    Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Double-Blind Method; Equi

1993
Protective effect of albuterol delivered via a spacer device (Babyhaler) against methacholine induced bronchoconstriction in young wheezy children.
    Pediatric pulmonology, 1994, Volume: 17, Issue:5

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Child, Preschool; Double-Blind

1994
Bronchodilator treatment in asthma and bronchitis.
    BMJ (Clinical research ed.), 1994, Jul-23, Volume: 309, Issue:6949

    Topics: Albuterol; Asthma; Bronchitis; Chronic Disease; Humans; Ipratropium; Lung; Random Allocation; Respir

1994
Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").
    Thorax, 1994, Volume: 49, Issue:8

    Topics: Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Humans; Middle Aged; Nebulizers and Vaporizer

1994
Systemic effects of salbutamol and salmeterol in patients with asthma.
    Thorax, 1994, Volume: 49, Issue:8

    Topics: Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response Relationship, Drug; D

1994
Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children.
    The Journal of allergy and clinical immunology, 1993, Volume: 91, Issue:1 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Ast

1993
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
    BMJ (Clinical research ed.), 1993, Feb-27, Volume: 306, Issue:6877

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method; Drug Administra

1993
Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
    BMJ (Clinical research ed.), 1993, Apr-17, Volume: 306, Issue:6884

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br

1993
Effect on airway responsiveness of six weeks treatment with salmeterol.
    Pulmonary pharmacology, 1993, Volume: 6, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug

1993
The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X.
    Allergy, 1993, Volume: 48, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Blood Proteins; Bronchial Provocation

1993
Asthma control during and after cessation of regular beta 2-agonist treatment.
    The American review of respiratory disease, 1993, Volume: 148, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma

1993
Regular inhaled salbutamol and airway responsiveness to allergen.
    Lancet (London, England), 1993, Oct-02, Volume: 342, Issue:8875

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation T

1993
A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses.
    Annals of allergy, 1994, Volume: 72, Issue:2

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Male; Middle Aged; Nebulizers and

1994
Nedocromil sodium versus albuterol in the management of allergic asthma.
    American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocati

1994
Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations.
    Pediatrics, 1994, Volume: 93, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Double-Blind M

1994
Prednisolone and salbutamol in the hospital treatment of acute asthma.
    Archives of disease in childhood, 1994, Volume: 70, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr

1994
Prednisolone and salbutamol in the hospital treatment of acute asthma.
    Archives of disease in childhood, 1994, Volume: 70, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr

1994
Prednisolone and salbutamol in the hospital treatment of acute asthma.
    Archives of disease in childhood, 1994, Volume: 70, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr

1994
Prednisolone and salbutamol in the hospital treatment of acute asthma.
    Archives of disease in childhood, 1994, Volume: 70, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr

1994
The effect of controlled-release salbutamol on sleep and nocturnal oxygenation in patients with asthma and chronic obstructive pulmonary disease.
    Respiratory medicine, 1994, Volume: 88, Issue:2

    Topics: Albuterol; Asthma; Delayed-Action Preparations; Double-Blind Method; Female; Forced Expiratory Volum

1994
Therapeutic regimes for acute bronchial asthma.
    Singapore medical journal, 1993, Volume: 34, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Protocols; Epinephrine;

1993
Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.
    Thorax, 1993, Volume: 48, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Bronchial

1993
A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions.
    The European respiratory journal, 1994, Volume: 7, Issue:2

    Topics: Aerosols; Albuterol; Asthma; Child; Female; Hot Temperature; Humans; Humidity; Male; Middle Aged; Ne

1994
The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma.
    American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:5

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Azepin

1994
Easyhaler, a novel multiple dose powder inhaler: clinically equivalent to salbutamol metered dose inhaler and easier to use.
    Respiration; international review of thoracic diseases, 1994, Volume: 61, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Double-Blind Method; Female; Force

1994
Effect of nebulized ipratropium bromide on intraocular pressures in children.
    Chest, 1994, Volume: 105, Issue:5

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; Fema

1994
[Reference controlled, randomized double-blind study of the effectiveness of salbutamol/DNCG DA combination in bronchial hyperreactivity in comparison with salbutamol DA alone (parallel group comparison)].
    Pneumologie (Stuttgart, Germany), 1994, Volume: 48, Issue:3

    Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn Sodium; Double-B

1994
Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma.
    Thorax, 1994, Volume: 49, Issue:3

    Topics: Adolescent; Adult; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Humans; Middle Aged;

1994
Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
    Chest, 1994, Volume: 105, Issue:6

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchoconstriction; Dose-Response Relation

1994
Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department.
    Annals of emergency medicine, 1993, Volume: 22, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Emergency Service, Hospital; Fe

1993
Continuous versus intermittent albuterol nebulization in the treatment of acute asthma.
    Annals of emergency medicine, 1993, Volume: 22, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Emergency Service, Hospital; Fe

1993
Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group.
    The American review of respiratory disease, 1993, Volume: 148, Issue:5

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Prov

1993
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Annals of internal medicine, 1993, Dec-01, Volume: 119, Issue:11

    Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory

1993
Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma?
    Annals of internal medicine, 1993, Dec-15, Volume: 119, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Double-Blind Met

1993
Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators.
    Australian and New Zealand journal of medicine, 1993, Volume: 23, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Bronchodilator A

1993
Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1993, Volume: 30, Issue:6

    Topics: Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Double-Blind Method; Ethanolamines; Female;

1993
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.
    Thorax, 1993, Volume: 48, Issue:11

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Double-Blind Method; Female; F

1993
Anti-inflammatory action of steroid inhalers.
    The Journal of the Association of Physicians of India, 1993, Volume: 41, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Chronic Disease; Female; Human

1993
Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma.
    Annals of emergency medicine, 1994, Volume: 23, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Double-Blind Method;

1994
A comparison of a bodyweight dose versus a fixed dose of nebulised salbutamol in acute asthma in children.
    The Medical journal of Australia, 1993, Jun-07, Volume: 158, Issue:11

    Topics: Administration, Inhalation; Albuterol; Asthma; Body Weight; Child; Child, Preschool; Double-Blind Me

1993
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
    The Journal of pediatrics, 1993, Volume: 123, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method

1993
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
    The Journal of pediatrics, 1993, Volume: 123, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method

1993
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
    The Journal of pediatrics, 1993, Volume: 123, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method

1993
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
    The Journal of pediatrics, 1993, Volume: 123, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method

1993
Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.
    Thorax, 1993, Volume: 48, Issue:6

    Topics: Administration, Inhalation; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents

1993
Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma.
    The Journal of allergy and clinical immunology, 1993, Volume: 92, Issue:3

    Topics: Administration, Inhalation; Adult; Air; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agent

1993
A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.
    Chest, 1993, Volume: 104, Issue:3

    Topics: Acute Disease; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Double-Blind Method; Fema

1993
[Reference controlled, randomized double-blind study of the effectiveness of a salbutamol/DNCG DA combination in bronchial hyperreactivity in comparison with salbutamol DA alone (parallel group comparison)].
    Pneumologie (Stuttgart, Germany), 1993, Volume: 47, Issue:7

    Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn Sodium; D

1993
Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma.
    The American review of respiratory disease, 1993, Volume: 147, Issue:5

    Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Blood Pressure; Bronchi; Cyclic GMP; Double-Bli

1993
Albuterol and nedocromil sodium affect airway and leukocyte responses to allergen.
    The American review of respiratory disease, 1993, Volume: 147, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Analysis of Variance; Anti-Infl

1993
Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients.
    Respiration; international review of thoracic diseases, 1993, Volume: 60, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Cyclic AMP; Double-Blind Metho

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
    Pediatrics, 1993, Volume: 92, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl

1993
Is combined therapy of sympathomimetics and theophylline indicated?
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1993, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Drug Therapy, Combination; Female; Forced Expirat

1993
Efficacy and side effects of salbutamol in acute asthma in children: comparison of oral route and two different nebulizer systems.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1993, Volume: 30, Issue:1

    Topics: Acute Disease; Administration, Oral; Adolescent; Albuterol; Asthma; Blood Pressure; Child; Female; F

1993
The effect of salbutamol controlled release on airways responsiveness to inhaled methacholine in mild asthmatic subjects.
    Respiratory medicine, 1993, Volume: 87, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Delayed-Action Pre

1993
Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid.
    The Journal of pediatrics, 1993, Volume: 122, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Met

1993
Efficacy of intravenously administered theophylline in children hospitalized with severe asthma.
    The Journal of pediatrics, 1993, Volume: 122, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Drug Administ

1993
Evaluation of a new spacer device for drug inhalation.
    European journal of clinical pharmacology, 1993, Volume: 44, Issue:2

    Topics: Adult; Albuterol; Asthma; Double-Blind Method; Evaluation Studies as Topic; Female; Humans; Male; Mi

1993
Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring.
    Annals of allergy, 1993, Volume: 70, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Bronchodilato

1993
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
    Thorax, 1993, Volume: 48, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchoconstriction; Double-Blind

1993
Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
    Thorax, 1993, Volume: 48, Issue:2

    Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Chemistry, Pharmaceutical; Double-Bl

1993
Duration of preventive effect of inhaled salbutamol on early airway response to allergen in asthmatic subjects.
    Respiratory medicine, 1993, Volume: 87, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchial Hyperreactivi

1993
Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma.
    Thorax, 1993, Volume: 48, Issue:3

    Topics: Aged; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Lung; Male;

1993
Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma.
    The American review of respiratory disease, 1993, Volume: 147, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests

1993
Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids.
    American journal of respiratory and critical care medicine, 1995, Volume: 152, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tes

1995
MDI with spacer vs nebulizer in pediatric asthma.
    The Journal of family practice, 1996, Volume: 42, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Infant; Nebulizers and V

1996
Drug delivery in asthma: a comparison of spacers with a jet nebuliser.
    Australian and New Zealand journal of medicine, 1995, Volume: 25, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Deliv

1995
The effect of regular inhaled albuterol on exercise-induced bronchoconstriction.
    American journal of respiratory and critical care medicine, 1996, Volume: 153, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Air; Albuterol; Analysis of Variance; A

1996
Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1995, Volume: 25, Issue:10

    Topics: Adult; Albuterol; Asthma; Blood Proteins; Cell Count; Cross-Over Studies; Eosinophil Granule Protein

1995
Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects.
    European journal of clinical investigation, 1995, Volume: 25, Issue:10

    Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agents; Double-Blind Method; Fem

1995
Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma.
    American journal of respiratory and critical care medicine, 1996, Volume: 153, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Alprostadil; Aspirin; Asthma; Br

1996
Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response.
    The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:1 Pt 1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tes

1996
Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
    The European respiratory journal, 1995, Volume: 8, Issue:9

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged;

1995
Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics.
    Regulatory peptides, 1995, Nov-10, Volume: 59, Issue:3

    Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Blood Pressure; Bronchodilator Agents; Dose-Res

1995
A 4-week comparison of salmeterol and terbutaline in adult asthma.
    Allergy, 1995, Volume: 50, Issue:7

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume;

1995
Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Cromoly

1996
Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1995, Volume: 85, Issue:11

    Topics: Acute Disease; Adult; Albuterol; Aminophylline; Anti-Inflammatory Agents; Asthma; Bronchodilator Age

1995
Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report.
    Pediatric pulmonology, 1995, Volume: 20, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi;

1995
Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1996, Volume: 33, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies;

1996
Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma.
    Chest, 1996, Volume: 109, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Chlorofl

1996
Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma.
    The European respiratory journal, 1995, Volume: 8, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance;

1995
Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects.
    The American journal of medicine, 1996, Volume: 100, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-B

1996
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
    American journal of respiratory and critical care medicine, 1996, Volume: 153, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthm

1996
Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Child; Delayed-Action Preparations; Double-Blind Method; Female; Huma

1996
Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
    Chest, 1996, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents;

1996
Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol.
    Chest, 1996, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents;

1996
An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group.
    The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Chronic

1996
Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma.
    The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:4

    Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child;

1996
Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP).
    Thorax, 1996, Volume: 51, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agen

1996
Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans.
    The American journal of the medical sciences, 1996, Volume: 311, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Black or A

1996
Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults.
    Chest, 1996, Volume: 110, Issue:1

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Drug Administration Sch

1996
Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler.
    Lancet (London, England), 1996, Jul-20, Volume: 348, Issue:9021

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Chlorofluorocarbons; Do

1996
Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
    Thorax, 1996, Volume: 51, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationshi

1996
Asthma treatment in pregnancy: a randomized controlled study.
    American journal of obstetrics and gynecology, 1996, Volume: 175, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon

1996
[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily].
    Ugeskrift for laeger, 1996, Jul-01, Volume: 158, Issue:27

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie

1996
A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1996, Volume: 33, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi

1996
Nebulized flunisolide in infants and young children with asthma: a pilot study.
    Pediatric pulmonology, 1996, Volume: 21, Issue:5

    Topics: Airway Resistance; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child, Presch

1996
Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
    The European respiratory journal, 1996, Volume: 9, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Anti-Asthmatic Ag

1996
A comparison of the clinical efficacy and patient acceptability of terbutaline Turbuhaler and salbutamol Rotahaler, in adult patients with asthma.
    Respiratory medicine, 1996, Volume: 90, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Female; Follow-Up S

1996
A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma.
    American journal of respiratory and critical care medicine, 1996, Volume: 154, Issue:2 Pt 1

    Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Ast

1996
The effect of inhaled albuterol in moderate to severe asthma.
    The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie

1996
Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 77, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Androstadienes

1996
[A comparison of two delivery methods on the bronchodilator effects of beta 2-stimulant].
    Arerugi = [Allergy], 1996, Volume: 45, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin

1996
Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma.
    Clinical science (London, England : 1979), 1996, Volume: 90, Issue:3

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchoconstriction; Bronchodilator Agents; Cromolyn Sodiu

1996
Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.
    Journal of endocrinological investigation, 1995, Volume: 18, Issue:11

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Aged; Albuterol; A

1995
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.
    The New England journal of medicine, 1996, Sep-19, Volume: 335, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; D

1996
Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group.
    The European respiratory journal, 1996, Volume: 9, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammator

1996
Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients.
    Thorax, 1996, Volume: 51, Issue:8

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Fe

1996
Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.
    Chest, 1996, Volume: 110, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A

1996
A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.
    Chest, 1996, Volume: 110, Issue:3

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Bli

1996
Efficacy and safety of salmeterol in childhood asthma.
    European journal of pediatrics, 1995, Volume: 154, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A

1995
Relative efficacy of three different inhalers containing salbutamol in patients with asthma.
    European journal of clinical pharmacology, 1996, Volume: 50, Issue:6

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Female; Forced Expiratory

1996
Delivery of albuterol in a pediatric emergency department.
    Pediatric emergency care, 1996, Volume: 12, Issue:4

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Colorado; Emergency

1996
Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.
    The European respiratory journal, 1996, Volume: 9, Issue:8

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Double-Bli

1996
Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
    The European respiratory journal, 1996, Volume: 9, Issue:8

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Ag

1996
Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma.
    Allergy, 1996, Volume: 51, Issue:8

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Biomarkers; Blood Proteins; Bronchi

1996
Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group.
    The European respiratory journal, 1996, Volume: 9, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Ag

1996
A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 77, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Child; Female; Humans;

1996
Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol.
    International journal of clinical pharmacology and therapeutics, 1996, Volume: 34, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma

1996
Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses.
    The European respiratory journal, 1996, Volume: 9, Issue:10

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchoconstric

1996
Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1996, Volume: 51, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1996
Effects of bronchomotor tone and gas density on time dependence of forced expiratory vital capacity maneuver.
    American journal of respiratory and critical care medicine, 1996, Volume: 154, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Helium; Humans; Lung Diseases, Obstru

1996
Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects.
    Chest, 1996, Volume: 110, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Air; Air Pollutants; Albuterol; Asthma;

1996
Continuous vs intermittent nebulized albuterol for emergency management of asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1996, Volume: 3, Issue:11

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female

1996
Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
    The American journal of emergency medicine, 1996, Volume: 14, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Glucose; Bronchodilator Agents; Double-Bli

1996
[Sympathomimetics and theophylline: combined use?].
    Anales de medicina interna (Madrid, Spain : 1984), 1995, Volume: 12, Issue:9

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug

1995
Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma.
    The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:5 Pt 2

    Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchitis; Chronic Disease; Double-Blind Metho

1996
Efficacy of salmeterol in the treatment of childhood asthma.
    Acta paediatrica Japonica : Overseas edition, 1996, Volume: 38, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C

1996
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote

1996
Salmeterol tachyphylaxis in steroid treated asthmatic subjects.
    Thorax, 1996, Volume: 51, Issue:11

    Topics: Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents;

1996
Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1996, Volume: 33, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator

1996
An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.
    American journal of respiratory and critical care medicine, 1996, Volume: 154, Issue:6 Pt 1

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Albuterol; Ant

1996
Salmeterol does not cause tolerance during long-term asthma therapy.
    The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:6 Pt 1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Drug Tolerance; Humans; Salmeterol

1996
Tolerance to the protective effect of salmeterol on allergen challenge.
    Chest, 1996, Volume: 110, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tes

1996
The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma.
    Chest, 1997, Volume: 111, Issue:1

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Angiotensin II; Asthma; Cross-Over Studies; Double-Bl

1997
Inhaled salmeterol or oral theophylline in nocturnal asthma?
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol;

1997
A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study.
    The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:1 Pt 1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1997
Hypokalaemia following nebulized salbutamol in children with acute attack of bronchial asthma.
    Journal of paediatrics and child health, 1996, Volume: 32, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child

1996
Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 78, Issue:1

    Topics: Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fem

1997
Efficacy of nebulized ipratropium in severely asthmatic children.
    Annals of emergency medicine, 1997, Volume: 29, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind M

1997
Intravenous versus oral corticosteroids in the management of acute asthma in children.
    Annals of emergency medicine, 1997, Volume: 29, Issue:2

    Topics: Administration, Oral; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents

1997
Oral fenoterol versus sustained release theophylline in adult asthmatics.
    International journal of clinical pharmacology and therapeutics, 1997, Volume: 35, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; C

1997
Randomised trial of intravenous salbutamol in early management of acute severe asthma in children.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Acute Disease; Aerosols; Albuterol; Anti-Inflammatory Agents; Asthma; Australia; Bronchodilator Agen

1997
A one-week dose-ranging study of inhaled salmeterol in children with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1997, Volume: 34, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-

1997
Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Area Under Curve; Asthma; Bronc

1997
Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.
    Thorax, 1997, Volume: 52, Issue:1

    Topics: Acetates; Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Cross-O

1997
The duration of action of inhaled formoterol dry powder.
    The British journal of clinical practice, 1996, Volume: 50, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1996
The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group.
    Chest, 1997, Volume: 111, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Combin

1997
Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
    The European respiratory journal, 1997, Volume: 10, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction

1997
Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1997, Volume: 4, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Atropine; Blood Pressure; Bronchodilator Agents;

1997
The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control.
    The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchia

1997
Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask.
    Thorax, 1997, Volume: 52, Issue:2

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Combined Modality Therapy; Dose-Response Rela

1997
Hospitalization patterns in severe acute asthma in children.
    Pediatric pulmonology, 1997, Volume: 23, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

1997
Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers.
    Pediatric pulmonology, 1997, Volume: 23, Issue:3

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Infant; Nebu

1997
Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma.
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:4

    Topics: Adenosine Monophosphate; Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonis

1997
Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 78, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast

1997
Generic inhaled salbutamol versus branded salbutamol. A randomised double-blind study.
    Postgraduate medical journal, 1997, Volume: 73, Issue:857

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Double-Blind Method; Drug Delivery

1997
The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
    Chest, 1997, Volume: 111, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchoalveolar Lavage Fluid; Br

1997
Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction.
    Pulmonary pharmacology, 1996, Volume: 9, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O

1996
Salmeterol versus theophylline in the treatment of asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 78, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

1997
Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study.
    BMJ (Clinical research ed.), 1997, May-17, Volume: 314, Issue:7092

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1997
[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance].
    Pneumologie (Stuttgart, Germany), 1997, Volume: 51, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Do

1997
The Spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic spacer device.
    Respiratory medicine, 1997, Volume: 91, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug

1997
Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children.
    Chest, 1997, Volume: 111, Issue:6

    Topics: Acute Disease; Administration, Oral; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Squar

1997
Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder.
    Chest, 1997, Volume: 112, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cost Control; Costs and

1997
Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients.
    The European respiratory journal, 1997, Volume: 10, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Breath Tes

1997
Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Cros

1997
Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered?
    Chest, 1997, Volume: 112, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchodil

1997
Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma.
    The Journal of allergy and clinical immunology, 1997, Volume: 100, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc

1997
Nebulized glutathione induces bronchoconstriction in patients with mild asthma.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:2 Pt 1

    Topics: Adult; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchoconstriction; Bronchodilator Agents

1997
The current dilemma with spirometric inclusion criteria for asthma drug trials.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middle

1997
Sleep disturbances in clinically stable young asthmatic adults.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Female; Humans; India; Male; Peak

1997
One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:3 Pt 1

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Body Height; Bronchial Prov

1997
Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:3 Pt 1

    Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivi

1997
Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants.
    Respiration; international review of thoracic diseases, 1997, Volume: 64, Issue:5

    Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Asthma; Beclomethasone; Bronchodilator

1997
Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma.
    Chest, 1997, Volume: 112, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Anti-I

1997
Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma.
    The Journal of allergy and clinical immunology, 1997, Volume: 100, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Androstadienes; Anti-Asthm

1997
Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1997, Volume: 34, Issue:5

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Albuterol; Anti-Inflammat

1997
Treatment of nocturnal airway obstruction improves daytime cognitive performance in asthmatics.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:4 Pt 1

    Topics: Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Androstadienes; Anti-Asthmatic Age

1997
Comparative efficacy of jet nebulizer and metered dose inhaler with spacer device in the treatment of acute asthma.
    Indian pediatrics, 1997, Volume: 34, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, P

1997
Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:4

    Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C

1997
Varied effects of regular salbutamol on airway responsiveness to inhaled spasmogens.
    Lancet (London, England), 1997, Nov-15, Volume: 350, Issue:9089

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Humans

1997
Early parenteral corticosteroid administration in acute asthma.
    The American journal of emergency medicine, 1997, Volume: 15, Issue:7

    Topics: Acute Disease; Adult; Aerosols; Airway Obstruction; Albuterol; Anti-Asthmatic Agents; Anti-Inflammat

1997
[Better control of asthma symptoms with salmeterol].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 2, Issue:11

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans

1997
A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
    The New England journal of medicine, 1997, Dec-04, Volume: 337, Issue:23

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone;

1997
Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma.
    The European respiratory journal, 1997, Volume: 10, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Analysis of Variance; A

1997
Altered cardiovascular autonomic regulation after 2-week inhaled salbutamol treatment in asthmatic children.
    European journal of pediatrics, 1997, Volume: 156, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Autonomic Nervous System; B

1997
Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine.
    Thorax, 1997, Volume: 52, Issue:10

    Topics: Adult; Akathisia, Drug-Induced; Albuterol; Asthma; Bronchoconstriction; Bronchoconstrictor Agents; B

1997
Nebulized wet aerosol treatment in emergency department--is it essential? Comparison with large spacer device for metered-dose inhaler.
    Chest, 1997, Volume: 112, Issue:6

    Topics: Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Double-Blind Meth

1997
[Evaluation of the effectiveness and safety of salmeterol in children with nocturnal dyspnea].
    Pneumonologia i alergologia polska, 1997, Volume: 65 Suppl 1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

1997
[Inhaled salmeterol or oral theophylline in nocturnal asthma?].
    Pneumologie (Stuttgart, Germany), 1997, Volume: 51, Issue:9

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Cross-Ov

1997
[Influence of the inhaler device on bronchodilatation in the asthmatic child].
    Revue des maladies respiratoires, 1997, Volume: 14, Issue:3

    Topics: Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child

1997
Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:6

    Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation T

1997
Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Blood Pro

1997
Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction.
    The European respiratory journal, 1997, Volume: 10, Issue:11

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Respo

1997
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    The European respiratory journal, 1997, Volume: 10, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator

1997
Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma.
    European journal of medical research, 1996, Jul-25, Volume: 1, Issue:10

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodi

1996
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
    The Journal of allergy and clinical immunology, 1997, Volume: 100, Issue:6 Pt 1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E

1997
Single-breath counting for the assessment of bronchospastic patients in the ED.
    The American journal of emergency medicine, 1998, Volume: 16, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Humans; Peak Expira

1998
[Evaluation of combined therapy efficacy with disodium cromoglycate and salmeterol in children with atopic bronchial asthma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 3, Issue:16

    Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Cromolyn Sodium;

1997
[The effect of salmeterol on the number of hypodense eosinophils, eosinophilic cationic protein levels ECP in serum, bronchial hyperresponsiveness and lung function test in patients with bronchial asthma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 3, Issue:16

    Topics: Adult; Albuterol; Asthma; Blood Proteins; Bronchi; Bronchial Provocation Tests; Bronchodilator Agent

1997
Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack.
    Intensive care medicine, 1997, Volume: 23, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Fe

1997
Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial.
    Annals of emergency medicine, 1998, Volume: 31, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Combinations; E

1998
Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 80, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchi; Bronchia

1998
Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
    Thorax, 1997, Volume: 52, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio

1997
Proventil HFA and ventolin have similar safety profiles during regular use.
    Chest, 1998, Volume: 113, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Aged;

1998
Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.
    Chest, 1998, Volume: 113, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Age Fa

1998
Effect of salmeterol is independent of previously inhaled salbutamol: a clinical controlled study.
    Lung, 1998, Volume: 176, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies;

1998
Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.
    The Journal of allergy and clinical immunology, 1998, Volume: 101, Issue:2 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag

1998
Effect of inhaled furosemide in acute asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1998, Volume: 35, Issue:1

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Furosemide;

1998
Inhaled flunisolide for acute severe asthma.
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:3 Pt 1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A

1998
Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:3 Pt 1

    Topics: Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadiene

1998
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1998, Volume: 5, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm

1998
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1998, Volume: 5, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm

1998
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1998, Volume: 5, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm

1998
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 1998, Volume: 5, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm

1998
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    The Journal of allergy and clinical immunology, 1998, Volume: 101, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al

1998
Elevation of peak expiratory flow by a "spitting" maneuver: measured with five peak flowmeters.
    Chest, 1998, Volume: 113, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Peak Expiratory Flow Rate; Rhe

1998
A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma.
    The Journal of allergy and clinical immunology, 1998, Volume: 101, Issue:4 Pt 1

    Topics: Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Double-Blind Method; Drug Administration Schedul

1998
[The effect of salben on the rheological properties of the bronchial secretion].
    Terapevticheskii arkhiv, 1998, Volume: 70, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Benzoates; Benzoic Acid; Bronchi; Bronch

1998
Treatment of acute asthma: salbutamol via jet nebuliser vs spacer and metered dose inhaler.
    Journal of paediatrics and child health, 1998, Volume: 34, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child

1998
Short-term cardiovascular effects of salmeterol.
    Chest, 1998, Volume: 113, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bron

1998
Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method;

1998
A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; Asthma; Bronchoconstrictor Ag

1998
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule;

1998
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule;

1998
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule;

1998
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:2

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule;

1998
[Dose-effect of adrenaline nebulization in asthma: comparative study with salbutamol].
    Revue de pneumologie clinique, 1997, Volume: 53, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations

1997
Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma.
    Pediatric pulmonology, 1998, Volume: 25, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child;

1998
Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 80, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilat

1998
Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo.
    The European respiratory journal, 1998, Volume: 11, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-

1998
Bronchodilator response to salbutamol after spontaneous recovery from nonspecific bronchial provocation tests in asthma.
    The European respiratory journal, 1998, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Female; Fo

1998
Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids.
    The European respiratory journal, 1998, Volume: 11, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al

1998
Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:1

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents; Child; Double-Blind

1998
Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation.
    The European respiratory journal, 1998, Volume: 11, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Blood P

1998
Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.
    Respiratory medicine, 1998, Volume: 92, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dela

1998
Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer, and Rotahaler device--a comparison of efficacy and safety.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1998, Volume: 35, Issue:4

    Topics: Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Double-Blind Me

1998
Possible interaction between exposure to environmental tobacco smoke and therapy in children with asthma.
    Clinical science (London, England : 1979), 1998, Volume: 95, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Biomarkers; Bronchial Hyperreactivity; Bronchial Provocation Tests; B

1998
Comparison of two dosage regimens of albuterol in acute asthma.
    The American journal of medicine, 1998, Volume: 105, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Res

1998
Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 81, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chronic Disease; Double-Blind Met

1998
Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.
    British journal of clinical pharmacology, 1998, Volume: 46, Issue:1

    Topics: Absorption; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Equipment D

1998
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Pulmonary pharmacology & therapeutics, 1997, Volume: 10, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi

1997
Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma.
    Acta paediatrica Japonica : Overseas edition, 1998, Volume: 40, Issue:3

    Topics: Adolescent; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma

1998
How long should Atrovent be given in acute asthma?
    Thorax, 1998, Volume: 53, Issue:5

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Bli

1998
Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children.
    Clinical physiology (Oxford, England), 1998, Volume: 18, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Autonomic Nervous System; Blood Pressure;

1998
Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1998, Volume: 28, Issue:7

    Topics: Administration, Intranasal; Adrenergic beta-Agonists; Albuterol; Asthma; Capillary Permeability; Cel

1998
The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
    Chest, 1998, Volume: 114, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Al

1998
Influence of beclomethasone and salmeterol on the perception of methacholine-induced bronchoconstriction.
    Chest, 1998, Volume: 114, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchoconstrictio

1998
Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial.
    The European respiratory journal, 1998, Volume: 12, Issue:2

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind

1998
Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchial P

1998
Potential masking effects of salmeterol on airway inflammation in asthma.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

1998
Comparison of the Maxair Autohaler to wet nebulizer in patients with acute asthma.
    Chest, 1998, Volume: 114, Issue:3

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents

1998
Bronchodilator responses to salbutamol using diskhaler versus metered-dose inhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1998, Volume: 35, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-

1998
[Evaluation of the efficacy of nebulized salbutamol in exacerbation of chronic asthma].
    Pneumonologia i alergologia polska, 1997, Volume: 65, Issue:11-12

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Ambulatory Care; Asthma; Chronic Disease; Female; Humans

1997
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
    The New England journal of medicine, 1998, Oct-08, Volume: 339, Issue:15

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method;

1998
Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Aspirin; Asthma; Bronchial P

1998
Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid.
    Archives of disease in childhood, 1998, Volume: 79, Issue:1

    Topics: Acute Disease; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Child; Cross-Over Studies;

1998
[Clinical study on treating asthma of cold type with wenyang tongluo mixture].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1996, Volume: 16, Issue:9

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethason

1996
Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma.
    The Journal of pediatrics, 1998, Volume: 133, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-R

1998
Salmeterol compared with current therapies in chronic asthma.
    The Journal of family practice, 1998, Volume: 47, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Double-

1998
Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer.
    Arzneimittel-Forschung, 1998, Volume: 48, Issue:9

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method;

1998
A low cost spacer device used for asthma treatment in a Calcutta street clinic to improve efficacy of metered dose inhalers.
    Tropical doctor, 1998, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Doub

1998
Paper spacers coupled to metered dose inhalers in family practice.
    The Ceylon medical journal, 1998, Volume: 43, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Child; Developing Countries; Doubl

1998
Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo.
    The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method; Female; Humans; Hypersensit

1998
Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer.
    The American journal of emergency medicine, 1998, Volume: 16, Issue:7

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Emergency Servi

1998
Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.
    The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:6 Pt 1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Child; Female;

1998
A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease.
    Respiratory medicine, 1998, Volume: 92, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Et

1998
[Treatment with salmeterol and quality of life in patients with asthma].
    Pneumonologia i alergologia polska, 1998, Volume: 66, Issue:3-4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; Middle A

1998
Airway and lung tissue mechanics in asthma. Effects of albuterol.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator

1999
Serum levels of soluble interleukin-2 receptor at acute asthma exacerbation: relationship with severity of exacerbation and bronchodilator response.
    International archives of allergy and immunology, 1998, Volume: 117, Issue:4

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Hu

1998
Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 81, Issue:6

    Topics: Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Chlorofluorocarbons; Cross-Over Studies; Dose-R

1998
A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:1 Pt 1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio

1999
Use of heliox-driven nebulizer therapy in the treatment of acute asthma.
    Annals of emergency medicine, 1999, Volume: 33, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Forced Expiratory Volu

1999
Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma.
    Chest, 1999, Volume: 115, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asth

1999
Single centre open study to compare patient recording of PRN salbutamol use on a daily diary card with actual use as recorded by the MDI compliance monitor.
    Respiratory medicine, 1998, Volume: 92, Issue:10

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Mal

1998
An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:2 Pt 1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents;

1999
Hypokalemia and salbutamol therapy in asthma.
    Pediatric pulmonology, 1999, Volume: 27, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Age Factors; Albuterol; Asthma; Bl

1999
Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma.
    Chest, 1999, Volume: 115, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Eq

1999
The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group.
    Controlled clinical trials, 1999, Volume: 20, Issue:1

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Preschool

1999
Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: a randomized clinical trial.
    Annals of emergency medicine, 1999, Volume: 33, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Anti-A

1999
Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged;

1999
Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br

1999
As-required versus regular nebulized salbutamol for the treatment of acute severe asthma.
    The European respiratory journal, 1999, Volume: 13, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A

1999
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic

1999
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic

1999
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic

1999
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic

1999
Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Pro

1999
Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:2

    Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Bro

1999
Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Infla

1999
Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:1

    Topics: Adult; Aerosol Propellants; Albuterol; Asthma; Chlorofluorocarbons; Chlorofluorocarbons, Methane; Fe

1999
Effective application of bronchodilator aerosols from metered-dose inhalers (MDI) via resuscitator-bag and adapter.
    Resuscitation, 1998, Volume: 39, Issue:3

    Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; E

1998
Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge.
    Chest, 1999, Volume: 115, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomet

1999
Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial.
    Chest, 1999, Volume: 115, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cardiovascular System; Child;

1999
Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.
    Chest, 1999, Volume: 115, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Fe

1999
[Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
    Pneumologie (Stuttgart, Germany), 1999, Volume: 53, Issue:1

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Etha

1999
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Androst

1999
Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes;

1999
Ipratropium bromide added to asthma treatment in the pediatric emergency department.
    Pediatrics, 1999, Volume: 103, Issue:4 Pt 1

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflammatory Agents; A

1999
Clinical comparison of Gentle-Haler Actuator and Aerochamber Spacer for Metered Dose Inhaler (MDI) use by asthmatics.
    Respiratory care, 1992, Volume: 37, Issue:12

    Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; California; Child; Double-Blind Method;

1992
The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.
    PharmacoEconomics, 1993, Volume: 4, Issue:5

    Topics: Albuterol; Asthma; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Ethanolamines; Femal

1993
Clinical evaluation of CFC-free metered dose inhalers.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 1995,Spring, Volume: 8 Suppl 1

    Topics: Adult; Aerosol Propellants; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila

1995
Randomised controlled trial of aminophylline for severe acute asthma.
    Archives of disease in childhood, 1998, Volume: 79, Issue:5

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Aminophylline; Asthma; Bronch

1998
A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction.
    Respiratory medicine, 1998, Volume: 92, Issue:12

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provoca

1998
Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma.
    Respiratory medicine, 1998, Volume: 92, Issue:12

    Topics: Administration, Inhalation; Adult; Albuterol; Anesthetics, Local; Asthma; Bronchial Hyperreactivity;

1998
The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross

1999
Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children.
    Pediatrics international : official journal of the Japan Pediatric Society, 1999, Volume: 41, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Cardiac Output; Chil

1999
Safety of long-term treatment with HFA albuterol.
    Chest, 1999, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Aerosols; Albutero

1999
Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates.
    Chest, 1999, Volume: 115, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator

1999
A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital.
    Archives of disease in childhood, 1999, Volume: 80, Issue:5

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child

1999
Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study.
    Annals of emergency medicine, 1999, Volume: 33, Issue:5

    Topics: Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Adm

1999
Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Female;

1999
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag

1999
A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:5 Pt 1

    Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflamma

1999
Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:5 Pt 1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Ove

1999
Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline-induced sputum in asthmatic subjects.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1999, Volume: 29, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchial Provocation Tests; Bro

1999
Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity.
    The European respiratory journal, 1999, Volume: 13, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Biomarkers; Blood Proteins; Bronchial Provocation Tests; Cell Count;

1999
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
    Thorax, 1998, Volume: 53, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronc

1998
Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
    Thorax, 1999, Volume: 54, Issue:3

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Dose-Response Relat

1999
Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.
    Thorax, 1999, Volume: 54, Issue:2

    Topics: Administration, Inhalation; Administration, Topical; Adolescent; Airway Obstruction; Albuterol; Anti

1999
A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:5 Pt 1

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Beclomethasone; Dose-Response Relationsh

1999
Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
    The American journal of managed care, 1998, Volume: 4, Issue:11

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Pla

1998
Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma.
    Respirology (Carlton, Vic.), 1999, Volume: 4, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Thera

1999
Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.
    PharmacoEconomics, 1998, Volume: 14, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Et

1998
Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:6

    Topics: Adenosine Diphosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchial Provoc

1999
[The effect of salmeterol on specific and non-specific bronchial response in allergic asthma patients].
    Pneumonologia i alergologia polska, 1998, Volume: 66, Issue:9-10

    Topics: Adult; Albuterol; Animals; Asthma; Blood Proteins; Bronchi; Bronchial Provocation Tests; Bronchodila

1998
[Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients].
    Pneumonologia i alergologia polska, 1998, Volume: 66, Issue:9-10

    Topics: Adult; Albuterol; Animals; Asthma; Bronchodilator Agents; Female; Humans; Male; Mites; Respiratory F

1998
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged;

1999
A comparison of the bronchodilatory effect of 50 and 100 microg salbutamol via Turbuhaler and 100 microg salbutamol via pressurized metered dose inhaler in children with stable asthma.
    International journal of pharmaceutics, 1999, Apr-15, Volume: 180, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Chronic Disease; Cross-Over Studies; Dose-Response

1999
Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects.
    Thorax, 1999, Volume: 54, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma; Blood Proteins

1999
Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
    Chest, 1999, Volume: 115, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

1999
Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Bronch

1999
Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio

1999
[The influence of salmeterol and salbutamol on bronchial constriction in patients with bronchial asthma].
    Pneumonologia i alergologia polska, 1998, Volume: 66, Issue:11-12

    Topics: Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Double-Blind Method; Dru

1998
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
    The Journal of pediatrics, 1999, Volume: 135, Issue:1

    Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool;

1999
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
    The Journal of pediatrics, 1999, Volume: 135, Issue:1

    Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool;

1999
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
    The Journal of pediatrics, 1999, Volume: 135, Issue:1

    Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool;

1999
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
    The Journal of pediatrics, 1999, Volume: 135, Issue:1

    Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool;

1999
Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children.
    The Journal of pediatrics, 1999, Volume: 135, Issue:1

    Topics: Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Inf

1999
A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Child; Double-Bli

1999
Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
    The European respiratory journal, 1999, Volume: 13, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Cr

1999
Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma.
    European journal of clinical pharmacology, 1999, Volume: 55, Issue:5

    Topics: Adenosine Monophosphate; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Over Studie

1999
A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
    Respiratory medicine, 1999, Volume: 93, Issue:7

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Cell Count; Collagen;

1999
Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma.
    Respiratory medicine, 1999, Volume: 93, Issue:7

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Biopsy; Female;

1999
A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group.
    Respiratory medicine, 1999, Volume: 93, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol;

1999
A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
    Respiratory medicine, 1999, Volume: 93, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1999
Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Age

1999
Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 83, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Amenorrhea; Asthma; Cross-Over Studi

1999
Outcome evaluation of early discharge of asthmatic children from hospital: a randomized control trial.
    Journal of quality in clinical practice, 1999, Volume: 19, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Administration Schedule; Fem

1999
Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Chest, 1999, Volume: 116, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchial

1999
Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.
    Chest, 1999, Volume: 116, Issue:3

    Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ag

1999
Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents

1999
Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma.
    Acta paediatrica (Oslo, Norway : 1992), 1999, Volume: 88, Issue:8

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Anti-Inflamma

1999
Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Broncho

1999
Long acting inhaled beta2-agonists: anti-inflammatory effects not evident during treatment of day to day asthma.
    The European respiratory journal, 1999, Volume: 14, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator

1999
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
    The European respiratory journal, 1999, Volume: 14, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Bronch

1999
Tolerance to beta-agonists during acute bronchoconstriction.
    The European respiratory journal, 1999, Volume: 14, Issue:2

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; B

1999
Bronchodilation using combined urodilatin - albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial.
    European journal of medical research, 1999, Oct-15, Volume: 4, Issue:10

    Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agents; Cyclic AMP; Double-Blind

1999
A comparison of the bronchodilator effect of salbutamol inhaled via Turbuhaler as two consecutive doses or as two divided doses at different time intervals.
    International journal of pharmaceutics, 1999, Nov-10, Volume: 190, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; C

1999
Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1999, Volume: 117, Issue:10

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; C

1999
Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.
    Journal of pharmacokinetics and biopharmaceutics, 1999, Volume: 27, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Computer Simulation; Cross-Ove

1999
Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 83, Issue:4

    Topics: Absenteeism; Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Asthma; Child; Cross

1999
Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 83, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aerosols; Aged; Albuterol; Anti-

1999
Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma.
    The European respiratory journal, 1999, Volume: 14, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Aged; Albuterol;

1999
An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:5 Pt 1

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents

1999
A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group.
    Chest, 1999, Volume: 116, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho

1999
Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.
    The European respiratory journal, 1999, Volume: 14, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Beclomethasone; Blood Proteins; Bronc

1999
Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects.
    Pulmonary pharmacology & therapeutics, 1999, Volume: 12, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Area Under Curve; Asthma; Blood Glucose; B

1999
A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; B

1999
Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:8

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Beclo

1999
Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration.
    Chest, 2000, Volume: 117, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As

2000
[The effect of sputum induction on spirometry parameters in patients with bronchial asthma].
    Pneumonologia i alergologia polska, 1999, Volume: 67, Issue:7-8

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricti

1999
Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics.
    Respiratory medicine, 1999, Volume: 93, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents;

1999
Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
    Respiratory medicine, 1999, Volume: 93, Issue:12

    Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ag

1999
Use of fluticasone in asthma.
    Chest, 2000, Volume: 117, Issue:2

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bias; Dose-Res

2000
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:2 Pt 1

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag

2000
Low- and high-dose fluticasone propionate in asthma; effects during and after treatment.
    The European respiratory journal, 2000, Volume: 15, Issue:1

    Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Asthmati

2000
Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin.
    Chest, 2000, Volume: 117, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Biological Availability; Bronchial Provocation Tests; Cr

2000
Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma.
    The American journal of medicine, 2000, Feb-15, Volume: 108, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-B

2000
Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
    PharmacoEconomics, 1999, Volume: 16 Suppl 2

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

1999
Comparison of different long-term asthma treatments in subjects with mild-to-moderate asthma.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1999, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchial Provoca

1999
Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Met

2000
Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma.
    The Journal of pediatrics, 2000, Volume: 136, Issue:4

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child, Preschool; Cost-Benefit Analysis; Do

2000
[Control of inhaled triggering factors decreases prolonged drug therapy requirements in patients with asthma].
    Investigacion clinica, 2000, Volume: 41, Issue:1

    Topics: Adolescent; Albuterol; Allergens; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Beclometh

2000
Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids.
    Chest, 2000, Volume: 117, Issue:4

    Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Oral; Adrenergic beta

2000
Immunohistochemically stained activated eosinophils in sputum in patients with asthma.
    Respiration; international review of thoracic diseases, 2000, Volume: 67, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Antibodies, Monoclonal; Antibody Specificity; Asthma;

2000
A low dose of albuterol by metered-dose inhaler with a spacer was as effective as higher doses by metered-dose inhaler or low doses by nebulizer in children with mild acute asthma.
    The Western journal of medicine, 2000, Volume: 172, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans

2000
Undiluted albuterol aerosols in the pediatric emergency department.
    Pediatrics, 2000, Volume: 105, Issue:5

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administr

2000
Wet nebulization in acute asthma: the last refrain?
    Chest, 2000, Volume: 117, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-

2000
Is nebulized aerosol treatment necessary in the pediatric emergency department?
    Chest, 2000, Volume: 117, Issue:5

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Chil

2000
The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
    Chest, 2000, Volume: 117, Issue:5

    Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial

2000
Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
    The Journal of allergy and clinical immunology, 2000, Volume: 105, Issue:5

    Topics: Adenosine Monophosphate; Administration, Inhalation; Albuterol; Anti-Inflammatory Agents; Asthma; Br

2000
First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.
    American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:6

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Do

2000
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
    The Journal of allergy and clinical immunology, 2000, Volume: 105, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2000
Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids.
    The Journal of allergy and clinical immunology, 2000, Volume: 105, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie

2000
Induced sputum and bronchoalveolar lavage as tools for evaluating the effects of inhaled corticosteroids in patients with asthma.
    The Journal of laboratory and clinical medicine, 2000, Volume: 136, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Blood P

2000
Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2000, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relat

2000
Effects of on-demand beta2-agonist inhalation in moderate-to-severe asthma. A randomized controlled trial.
    Journal of internal medicine, 2000, Volume: 247, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-As

2000
Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol.
    The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:1 Pt 1

    Topics: Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Chymases; C

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype;

2000
Short-acting inhaled beta-agonists: to be taken regularly or as needed?
    Lancet (London, England), 2000, May-13, Volume: 355, Issue:9216

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedule; Humans; Peak Expiratory F

2000
Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework.
    Lancet (London, England), 2000, May-13, Volume: 355, Issue:9216

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Disease Progre

2000
Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
    Respiratory medicine, 2000, Volume: 94 Suppl B

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuter

2000
Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
    Respiratory medicine, 2000, Volume: 94 Suppl B

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho

2000
Equivalent therapeutic ratio of salbutamol given by Turbuhaler and Diskus.
    Respiratory medicine, 2000, Volume: 94, Issue:6

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie

2000
Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI.
    Respiratory medicine, 2000, Volume: 94, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind

2000
Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Respiratory medicine, 2000, Volume: 94, Issue:6

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; A

2000
Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma.
    Pediatric pulmonology, 2000, Volume: 30, Issue:2

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator

2000
Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma.
    Respiratory medicine, 2000, Volume: 94, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Inflammatory Agents; Ast

2000
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
    Respiratory medicine, 2000, Volume: 94, Issue:7

    Topics: Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Budesonid

2000
A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma.
    Chest, 2000, Volume: 118, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi

2000
Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
    Chest, 2000, Volume: 118, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi

2000
A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma.
    Chest, 2000, Volume: 118, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Al

2000
Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
    Chest, 2000, Volume: 118, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist

2000
Is there a clinical difference in outcomes when beta-agonist therapy is delivered through metered-dose inhaler (MDI) with a spacing device compared with standard nebulizer treatments in acutely wheezing children?
    The Journal of family practice, 2000, Volume: 49, Issue:8

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Double-Blind Method; Humans; Infant;

2000
Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2000,Spring, Volume: 13, Issue:1

    Topics: Administration, Inhalation; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; C

2000
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.
    Thorax, 2000, Volume: 55, Issue:9

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Met

2000
Salmeterol in paediatric asthma.
    Thorax, 2000, Volume: 55, Issue:9

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Cross-Over Studies

2000
Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial.
    Annals of emergency medicine, 2000, Volume: 36, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronc

2000
Reducing electrostatic charge on spacer devices and bronchodilator response.
    British journal of clinical pharmacology, 2000, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind

2000
Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
    Clinical chemistry, 2000, Volume: 46, Issue:9

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronc

2000
Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma.
    The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Drug Delivery Syste

2000
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
    The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Circadian Rhythm; Drug Adminis

2000
Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
    European journal of clinical pharmacology, 2000, Volume: 56, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator

2000
The efficacy of nebulized racemic epinephrine in children with acute asthma: a randomized, double-blind trial.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2000, Volume: 7, Issue:10

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2000
Intravenous magnesium sulfate in acute severe asthma.
    Respirology (Carlton, Vic.), 2000, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Anti-Inflammatory Agents; Asthma; Bronchod

2000
Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma.
    Anesthesiology, 2000, Volume: 93, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Anesthesia, Inhalation; Anesthetics, Inhalation; Anest

2000
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
    The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:6

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androst

2000
Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.
    Archives of pediatrics & adolescent medicine, 2000, Volume: 154, Issue:12

    Topics: Aerosols; Albuterol; Alkanes; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; Child; Child

2000
Salbutamol via Easyhaler is at least as effective as salbutamol via Turbuhaler in the treatment of histamine-induced bronchoconstriction.
    Respiratory medicine, 2000, Volume: 94, Issue:11

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocati

2000
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
    The European respiratory journal, 2000, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Budeson

2000
Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.
    Archives of disease in childhood, 2001, Volume: 84, Issue:2

    Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; C

2001
Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
    Pulmonary pharmacology & therapeutics, 2001, Volume: 14, Issue:1

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; B

2001
Regular inhaled salbutamol : effect on airway responsiveness to methacholine and adenosine 5'-monophosphate and tolerance to bronchoprotection.
    Chest, 2001, Volume: 119, Issue:2

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Ast

2001
Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma.
    American journal of respiratory and critical care medicine, 2001, Volume: 163, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

2001
Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2000, Volume: 37, Issue:8

    Topics: Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chlorofluoro

2000
The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2000, Volume: 37, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Amino Acid Sequence; Asthma; Bronchodilator Agents

2000
Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow.
    Respiratory medicine, 2000, Volume: 94, Issue:12

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over Studies; Double

2000
Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers.
    Swiss medical weekly, 2001, Jan-12, Volume: 131, Issue:1-2

    Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Ch

2001
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 86, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br

2001
Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.
    Respiratory medicine, 2001, Volume: 95, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Adm

2001
Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
    Respiratory medicine, 2001, Volume: 95, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; Androstadienes;

2001
Efficacy of a home-made spacer with acute exacerbation of bronchial asthma: a randomized controlled trial.
    Indian journal of pediatrics, 2001, Volume: 68, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cost Control; Humans;

2001
Effectiveness and safety of salmeterol in nonspecialist practice settings.
    Chest, 2001, Volume: 119, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind

2001
Effects of therapeutic doses of albuterol on beta2-adrenergic receptor density and metabolic changes.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2001, Volume: 38, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female;

2001
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2001, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-B

2001
Acceptance of the Accuhaler, a multi-dose powder inhaler, among asthmatic patients: a comparison with the pressurized metered-dose inhaler.
    Asian Pacific journal of allergy and immunology, 2000, Volume: 18, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Anti-Asthmatic Agents; Ast

2000
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man.
    Pulmonary pharmacology & therapeutics, 2001, Volume: 14, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fe

2001
The effect of salmeterol on markers of airway inflammation following segmental allergen challenge.
    American journal of respiratory and critical care medicine, 2001, Volume: 163, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Analysis of Varia

2001
Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 86, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilator

2001
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
    Chest, 2001, Volume: 119, Issue:4

    Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Topical; Adrenergic b

2001
Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
    Indian pediatrics, 2001, Volume: 38, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dose-Response Relationship,

2001
Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations.
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2001
A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients.
    Chest, 2001, Volume: 119, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Animals; Asthma; Bronchial Hyperreactivity; D

2001
Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma.
    Current opinion in pulmonary medicine, 2001, Volume: 7 Suppl 1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Humans; Lung Diseases, Obstructive; Nebulizers

2001
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.
    The European respiratory journal, 2001, Volume: 17, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agent

2001
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    Thorax, 2001, Volume: 56, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchia

2001
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients.
    Thorax, 2001, Volume: 56, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma

2001
Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma.
    American journal of respiratory and critical care medicine, 2001, Jul-01, Volume: 164, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoscopy; Collagen; Double-Blind Method; Fem

2001
[The evaluation of efficacy and tolerability of salbutamol administered by nebulization in patients with stable severe bronchial asthma].
    Pneumonologia i alergologia polska, 2001, Volume: 69, Issue:1-2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Heart

2001
Comparison of the acute effects of salbutamol and terbutaline on heart rate variability in adult asthmatic patients.
    The European respiratory journal, 2001, Volume: 17, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Autonomic Nervous System; Cross-Over Studies;

2001
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
    Chest, 2001, Volume: 120, Issue:2

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists;

2001
Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
    The European respiratory journal, 2001, Volume: 18, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction

2001
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
    American journal of respiratory and critical care medicine, 2001, Sep-01, Volume: 164, Issue:5

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmat

2001
Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma.
    American journal of respiratory and critical care medicine, 2001, Sep-01, Volume: 164, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammator

2001
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
    MedGenMed : Medscape general medicine, 2001, Jul-05, Volume: 3, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A

2001
Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children.
    Anesthesia and analgesia, 2001, Volume: 93, Issue:4

    Topics: Adolescent; Airway Resistance; Albuterol; Algorithms; Anesthesia, Inhalation; Anesthetics, Inhalatio

2001
Long-acting bronchodilators in premenstrual exacerbation of asthma.
    Respiratory medicine, 2001, Volume: 95, Issue:9

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Age

2001
In patients with asthma that is not well controlled with inhaled steroids, does salmeterol (Serevent) or montelukast (Singulair) offer better symptom relief?
    The Journal of family practice, 2001, Volume: 50, Issue:9

    Topics: Acetates; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

2001
The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.
    The Journal of allergy and clinical immunology, 2001, Volume: 108, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationshi

2001
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Respiration; international review of thoracic diseases, 2001, Volume: 68, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Over

2001
Implementing randomization procedures in the asthma clinical research network.
    Controlled clinical trials, 2001, Volume: 22, Issue:6 Suppl

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Female; Humans; Male; Quality Contro

2001
Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone;

2001
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
    Archives of pediatrics & adolescent medicine, 2001, Volume: 155, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma;

2001
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
    Archives of pediatrics & adolescent medicine, 2001, Volume: 155, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma;

2001
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
    Archives of pediatrics & adolescent medicine, 2001, Volume: 155, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma;

2001
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
    Archives of pediatrics & adolescent medicine, 2001, Volume: 155, Issue:12

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma;

2001
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.
    Pediatrics international : official journal of the Japan Pediatric Society, 2001, Volume: 43, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Arrhythmias, Cardiac; Asthma; Bron

2001
Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.
    The Journal of allergy and clinical immunology, 2001, Volume: 108, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-

2001
Therapeutic equivalence of three metered-dose inhalers containing salbutamol (Albuterol) in protecting against methacholine-induced bronchoconstriction in children with asthma.
    Pediatric pulmonology, 2001, Volume: 32, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconstrictor

2001
Lower arrythmogenic risk of low dose albuterol plus ipratropium.
    Indian journal of pediatrics, 2001, Volume: 68, Issue:10

    Topics: Albuterol; Arrhythmias, Cardiac; Asthma; Bronchodilator Agents; Female; Humans; Infant; Ipratropium;

2001
The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices.
    Respiratory medicine, 2001, Volume: 95, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance;

2001
The incremental shuttle walking test in elderly people with chronic airflow limitation.
    Thorax, 2002, Volume: 57, Issue:1

    Topics: Administration, Inhalation; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Drug

2002
Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    European journal of medical research, 2002, Jan-29, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Drug

2002
Salbutamol dry powder inhaler: efficacy, tolerability, and acceptability study.
    Pediatric pulmonology, 2002, Volume: 33, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cross-Ov

2002
Subcutaneous epinephrine vs nebulized salbutamol in asthma.
    Indian journal of pediatrics, 2001, Volume: 68, Issue:12

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Developing Cou

2001
[Cardiovascular and metabolic effects in nebulizer therapy of bronchial asthma].
    Klinicheskaia meditsina, 2002, Volume: 80, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Heart Rate; Hemodynamics; Humans; Male; Middle Age

2002
Bronchodilator therapy and hyperactivity in preschool children.
    Archives of disease in childhood, 2002, Volume: 86, Issue:3

    Topics: Administration, Inhalation; Akathisia, Drug-Induced; Albuterol; Asthma; Bronchodilator Agents; Child

2002
Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 88, Issue:2

    Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agen

2002
Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
    The European respiratory journal, 2002, Volume: 19, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial

2002
Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department.
    Critical care medicine, 2002, Volume: 30, Issue:2

    Topics: Adolescent; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child,

2002
Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
    Respiratory medicine, 2002, Volume: 96, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Double-Blind Method;

2002
Comparative evaluation of market spacer and home made spacer in the management of bronchial asthma.
    The Journal of the Association of Physicians of India, 2002, Volume: 50

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment Design; Female; Humans

2002
Development of an economic model to assess the cost effectiveness of asthma management strategies.
    PharmacoEconomics, 2002, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents;

2002
Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Dose-Response Relationship, Drug

2002
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma].
    Terapevticheskii arkhiv, 2002, Volume: 74, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug

2002
[Clinical and biochemical aspects of flixotide administration in patients with moderate bronchial asthma].
    Terapevticheskii arkhiv, 2002, Volume: 74, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; alpha-Tocopherol; Androstadienes; Anti-Inflammatory Agen

2002
The utility of albuterol nebulized with heliox during acute asthma exacerbations.
    American journal of respiratory and critical care medicine, 2002, May-01, Volume: 165, Issue:9

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Drug Combinations; Emergencies; Female; Forced

2002
Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.
    Respiratory medicine, 2002, Volume: 96, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cost-Benefit Analysis; Drug Costs; E

2002
Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
    Chest, 2002, Volume: 121, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind

2002
Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator response.
    International archives of allergy and immunology, 2002, Volume: 127, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchodilator Agent

2002
A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults.
    Annals of emergency medicine, 2002, Volume: 39, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Analgesics; Asthma; Bronchodilator Agents; Double-Blin

2002
A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 88, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilato

2002
Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
    The Journal of allergy and clinical immunology, 2002, Volume: 109, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Androstadienes;

2002
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction.
    Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:2

    Topics: Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Cross-Over Studies; Dou

2002
Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2002, Volume: 39, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment D

2002
Effect of patient education on self-management skills and health status in patients with asthma: a randomized trial.
    The American journal of medicine, 2002, Volume: 113, Issue:1

    Topics: Adult; Albuterol; Asthma; Attitude to Health; Bronchodilator Agents; Female; Hospitalization; Humans

2002
Salmefamol and Salbutamol in exercise-induced asthma in children.
    British journal of diseases of the chest, 1976, Volume: 70, Issue:2

    Topics: Adolescent; Adrenergic Agonists; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topi

1976
Double-blind cross-over comparison of clenbuterol and salbutamol tablets in asthmatic out-patients.
    European journal of clinical pharmacology, 1975, Apr-04, Volume: 8, Issue:3-4

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Ethanolamines; F

1975
Rimiterol: a review of its pharmacological properties and therapeutic efficacy in asthma.
    Drugs, 1977, Volume: 14, Issue:2

    Topics: Absorption; Administration, Oral; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Catec

1977
Further studies of rimiterol and salbutamol administered by intermittent positive-pressure ventilation, and an important observation on the technique of using the Bennett ventilator.
    British journal of clinical pharmacology, 1977, Volume: 4, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Catechols; Female; Forced Expiratory Volume; Heart Rate; Humans; Int

1977
Diminished leukocyte cyclic AMP responses to adrenergic stimulation after therapeutic administration of beta-adrenergic agonists.
    Chest, 1978, Volume: 73, Issue:6 Suppl

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Trials as Topic; Cyclic AMP; Double-Bli

1978
[Competitive effects of pindolol and salbutamol on airway resistance in asthmatics].
    La Nouvelle presse medicale, 1978, Sep-20, Volume: 7, Issue:31

    Topics: Adrenergic beta-Antagonists; Adult; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchi; Drug Th

1978
A comparison of slow-release salbutamol with slow-release aminophylline in nocturnal asthma.
    The Journal of international medical research, 1979, Volume: 7 Suppl 1

    Topics: Adult; Aged; Albuterol; Aminophylline; Asthma; Delayed-Action Preparations; Female; Humans; Male; Mi

1979
[Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1979, Aug-03, Volume: 104, Issue:31

    Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Cromolyn Sodi

1979
Letter: Alpha-receptor-blocking drugs in bronchial asthma.
    Lancet (London, England), 1975, Feb-08, Volume: 1, Issue:7902

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Airway Obstruction; Airway Resistance; Albut

1975
Combined therapy with salbutamol and beclomethasone inhalers in chronic asthma.
    Lancet (London, England), 1978, Jul-08, Volume: 2, Issue:8080

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Bronchi; Chronic Disease; Circadian Rhythm

1978
A comparison of the bronchodilator activity of Sch 1000 and salbutamol.
    The Journal of allergy and clinical immunology, 1977, Volume: 59, Issue:2

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Clinical Trials as Topic; Drug Eva

1977
Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis.
    British journal of diseases of the chest, 1978, Volume: 72, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Chronic Disease; Drug

1978
Comparison of ipratropium bromide and salbutamol in a long-term trial in asthmatic and bronchitic patients in a cold climate.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Clinical Trials as Topic; Cold Climate; D

1979
A double blind cross-over study of maximal expiratory flows and arterial blood gas tensions in normals, asthmatics and bronchitics after salbutamol and ipratropin.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Albuterol; Asthma; Atropine Derivatives; Bronchitis; Carbon Dioxide; Clinical Trials as Topic; Doubl

1979
SCH 1000 in psychogenic asthma.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blind Method; Dr

1979
The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients.
    International journal of clinical pharmacology and biopharmacy, 1975, Volume: 12, Issue:1-2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronchi; Bronchodilator Agents;

1975
Effect in bronchial asthma of a new beta-adrenergic blocking drug atenolol (ICI 66, 082).
    European journal of clinical pharmacology, 1977, Volume: 11, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Atenolol; Clinical Trials as Topic; Drug Interactions; Female; Human

1977
Metabolic effects of salbutamol: comparison of aerosol and intravenous administration.
    British medical journal, 1977, Feb-12, Volume: 1, Issue:6058

    Topics: Adult; Aerosols; Albuterol; Asthma; Blood Glucose; Bronchi; Chronic Disease; Clinical Trials as Topi

1977
Comparison of intravenous aminophylline and salbutamol in severe asthma.
    British medical journal, 1977, Feb-19, Volume: 1, Issue:6059

    Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Humans; Injections, Intravenous

1977
Terbutaline: an effective bronchodilator by inhalation.
    Annals of allergy, 1977, Volume: 38, Issue:2

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Female; Humans; Male;

1977
The bronchodilator effect of NAB 365.
    British journal of clinical pharmacology, 1977, Volume: 4, Issue:1

    Topics: Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Ethan

1977
Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols.
    The Journal of allergy and clinical immunology, 1977, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Cardiomyopathy, Hypertrophic; Clinica

1977
[Clinical experimentation with salbutamol in bronchial obstructive diseases of early infancy].
    Minerva pediatrica, 1977, Feb-18, Volume: 29, Issue:5

    Topics: Albuterol; Asthma; Bronchial Spasm; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Fem

1977
Comparison of terbutaline and salbutamol aerosols.
    Australian and New Zealand journal of medicine, 1977, Volume: 7, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Force

1977
Intramuscular salbutamol in treatment of acute exacerbations of childhood asthma.
    Archives of disease in childhood, 1977, Volume: 52, Issue:7

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Hum

1977
Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma.
    Annals of allergy, 1977, Volume: 39, Issue:5

    Topics: Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Is

1977
Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.
    The American review of respiratory disease, 1977, Volume: 116, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Clinical Trials as Topic; Dose-Response Relationship,

1977
Comparison of albuterol and isoproterenol aerosols in bronchial asthma.
    Annals of allergy, 1977, Volume: 39, Issue:6

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response Relati

1977
Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma.
    British medical journal, 1978, Jan-14, Volume: 1, Issue:6105

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method;

1978
A trial of clenbuterol in bronchial asthma.
    Thorax, 1977, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clenbuterol; Clinical Trials as Topic; Double-Blind Meth

1977
Effect of salbutamol with IPPB and physiotherapy for three days.
    Scandinavian journal of respiratory diseases. Supplementum, 1977, Volume: 101

    Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Force

1977
A controlled comparison of salbutamol and terbutaline inhaled by IPPV in asthmatic patients: a dose-response study.
    Scandinavian journal of respiratory diseases. Supplementum, 1977, Volume: 101

    Topics: Adult; Albuterol; Asthma; Bronchitis; Clinical Trials as Topic; Dose-Response Relationship, Drug; Do

1977
A comparison of two modes of administering beta2-adrenoceptor stimulants in asthmatics: tablets and metered aerosol.
    Scandinavian journal of respiratory diseases. Supplementum, 1977, Volume: 101

    Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Dose-Re

1977
Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study.
    Chest, 1978, Volume: 73, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Eval

1978
Comparison of NAB 365 and salbutamol tablets in chronic bronchitis and asthma.
    Irish medical journal, 1978, Mar-18, Volume: 71, Issue:4

    Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic;

1978
Comparative study of carbuterol and salbutamol from metered aerosols in bronchial asthma.
    Respiration; international review of thoracic diseases, 1978, Volume: 35, Issue:4

    Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Ethanol

1978
Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis.
    The Medical journal of Australia, 1977, Dec-17, Volume: 2, Issue:25

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Clinical Trials as T

1977
Comparison of terbutaline and salebutamol aerosols in patients with bronchial asthma.
    International journal of clinical pharmacology and biopharmacy, 1978, Volume: 16, Issue:7

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Female; Forced Expiratory

1978
Comparison of salbutamol and ephedrine in oral bronchodilator combinations with theophylline and hydroxyzine: their effects on asthmatics.
    Annals of clinical research, 1977, Volume: 9, Issue:5

    Topics: Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Clinical Trials as

1977
[Effect of joint administration of antagonists of serotonin, histamine and acetylcholine on ventilatory disorders in asthma].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1978, Jul-31, Volume: 33, Issue:31

    Topics: Acetylcholine; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Female; Histamine Antagonis

1978
Two methods of administering nebulized salbutamol: a controlled study.
    Australian paediatric journal, 1978, Volume: 14, Issue:3

    Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant, Newb

1978
Aerosol salbutamol administration by IPPB: lowest effective dose.
    Thorax, 1978, Volume: 33, Issue:6

    Topics: Adult; Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Administrati

1978
Problems of inhalation therapy.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Forced Expiratory Volume; Humans; Placebos; Pr

1979
Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma.
    British medical journal, 1979, Mar-31, Volume: 1, Issue:6167

    Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Hum

1979
An evaluation of a controlled-release aminophylline tablet (Phyllocontin Continus) as a concomitant therapy in patients receiving salbutamol.
    The Journal of international medical research, 1979, Volume: 7 Suppl 1

    Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Humans

1979
Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves.
    The Journal of international medical research, 1979, Volume: 7 Suppl 1

    Topics: Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Dose-Response Relatio

1979
A comparative study of atropine methonitrate, salbutamol, and their combination in airways obstruction.
    Thorax, 1979, Volume: 34, Issue:1

    Topics: Aerosols; Aged; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topi

1979
Albuterol and isoproterenol in bronchial asthma. Efficacy and toxicity of drugs administered via intermittent positive pressure breathing.
    Archives of internal medicine, 1979, Volume: 139, Issue:6

    Topics: Adult; Aged; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Force

1979
NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial.
    International journal of clinical pharmacology and biopharmacy, 1979, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clenbuterol; Clinical Trials as Topic; Double-Blind Meth

1979
Nebulised salbutamol in life-threatening asthma.
    British medical journal, 1979, May-12, Volume: 1, Issue:6173

    Topics: Acute Disease; Albuterol; Asthma; Clinical Trials as Topic; Humans; Injections, Intravenous; Intermi

1979
Nebulised salbutamol in life-threatening asthma.
    British medical journal, 1979, May-12, Volume: 1, Issue:6173

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Humans; Injections, Intra

1979
Double-blind, crossover comparison of carbuterol and salbutamol.
    Annals of allergy, 1979, Volume: 43, Issue:2

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Clinical Trials as Topi

1979
Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma.
    International journal of clinical pharmacology and biopharmacy, 1979, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topi

1979
Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood.
    Archives of disease in childhood, 1979, Volume: 54, Issue:5

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Clinical Trials as Topic;

1979
Controlled clinical trial of oral hexoprenaline in bronchial asthma.
    The Medical journal of Australia, 1979, Nov-17, Volume: 2, Issue:10

    Topics: Albuterol; Asthma; Clinical Trials as Topic; Forced Expiratory Volume; Hexoprenaline; Humans; Phenet

1979
Comparison of IV salbutamol with IV aminophylline in severe acute asthma.
    Archives of disease in childhood, 1979, Volume: 54, Issue:12

    Topics: Albuterol; Aminophylline; Asthma; Child; Clinical Trials as Topic; Double-Blind Method; Humans; Inje

1979
Salbutamol in the treatment of asthma.
    The Practitioner, 1979, Volume: 223, Issue:1338

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Female; Forced Expir

1979
Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients.
    British journal of diseases of the chest, 1979, Volume: 73, Issue:3

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Hum

1979
Continuous and intermittent salbutamol tablet administration in asthmatic children.
    British journal of diseases of the chest, 1979, Volume: 73, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Double-Blind Method; Drug Administra

1979
A comparison of controlled-release aminophylline (Phyllocontin Continus tablets) and sympathomimetic bronchodilators.
    The Journal of international medical research, 1979, Volume: 7 Suppl 1

    Topics: Albuterol; Aminophylline; Asthma; Delayed-Action Preparations; Forced Expiratory Volume; Humans; Met

1979
Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma.
    Current medical research and opinion, 1979, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Clenbuterol; Ethanolamines; Female; Hemodynam

1979
[Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients].
    Revue de l'Institut d'hygiene des mines, 1978, Volume: 33, Issue:4

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Evaluation Studies a

1978
Comparison of salbutamol Rotahaler with conventional pressurized aerosol.
    Clinical allergy, 1977, Volume: 7, Issue:6

    Topics: Administration, Intranasal; Adult; Aerosols; Aged; Albuterol; Asthma; Forced Expiratory Volume; Huma

1977
Intravenous infusion of salbutamol in severe acute asthma.
    British medical journal, 1978, Apr-22, Volume: 1, Issue:6119

    Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory Volume; Humans; In

1978
[The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer].
    Schweizerische medizinische Wochenschrift, 1978, Aug-05, Volume: 108, Issue:31

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Fenoterol; Humans; Hypoxia; Male; Met

1978
Bronchodilatation after inhalation of the antihistamine clemastine.
    Thorax, 1978, Volume: 33, Issue:4

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Clemastine; Forced Expiratory Volume; Humans; Mid

1978
[Comparison of Tyloxapol (Tacholiquin, Alevaire) with physiological saline as inhalation carrier solutions].
    Schweizerische medizinische Wochenschrift, 1975, Jun-21, Volume: 105, Issue:25

    Topics: Albuterol; Asthma; Clinical Trials as Topic; Drug Synergism; Expectorants; Humans; Respiratory Thera

1975
Beta-adrenergic function in airways of healthy and asthmatic subjects.
    Thorax, 1975, Volume: 30, Issue:6

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Cardiovascular System; Clinical Trials as Topi

1975
Comparison of salmefamol with salbutamol aerosols in asthamatics.
    European journal of clinical pharmacology, 1976, Feb-06, Volume: 9, Issue:4

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Female; Forced E

1976
Determination of the optimum dose of subcutaneous salbutamol in asthmatic patients.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:2

    Topics: Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Evaluation; Electrocardiography; Female; Fo

1976
Inhalation of fenoterol (Berotec) by asthmatic children: A clinical comparison with salbutamol, orciprenaline and isoprenaline.
    The Medical journal of Australia, 1976, Sep-18, Volume: 2, Issue:12

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Ethanolamines; Female; Fen

1976
The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes.
    Scandinavian journal of respiratory diseases, 1976, Volume: 57, Issue:5

    Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Circadian Rhythm; Clinical Trials as Topic

1976
A controlled trial of intravenous salbutamol and aminophylline in acute asthma.
    The Medical journal of Australia, 1976, Nov-13, Volume: 2, Issue:20

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic;

1976
Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.
    Thorax, 1976, Volume: 31, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Dronabinol; Female; Humans; Male

1976
Double-blind trial with standard doses of fenoterol and salbutamol in asthmatic children.
    Acta allergologica, 1976, Volume: 31, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Et

1976
Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children.
    Pediatrics, 1975, Volume: 56, Issue:5 pt-2 sup

    Topics: Adolescent; Albuterol; Asthma; Atropine; Child; Child, Preschool; Cromolyn Sodium; Female; Humans; M

1975
Carbuterol: a double-blind clinical trial comparing carbuterol and salbutamol.
    Current therapeutic research, clinical and experimental, 1976, Volume: 19, Issue:2

    Topics: Adult; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Bronchitis; Bronchodilator Agents; Cli

1976
Inhibition of exercise-induced asthma by different pharmacological pathways.
    Thorax, 1976, Volume: 31, Issue:2

    Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Chil

1976
Studies of new sympathomimetic beta-receptor stimulating drugs in asthmatic patients. IV Acomparative trial of subcutaneous terbutaline (Bricanyl) and salbutamol (Ventolin).
    Singapore medical journal, 1976, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Female; Heart Rate; Humans; Male; Middle Aged; Te

1976
Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma.
    British medical journal, 1975, Feb-22, Volume: 1, Issue:5955

    Topics: Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Atropine; Atropine Derivatives;

1975
Comparison of two methods of administering bronchodilator aerosol to asthmatic patients.
    British medical journal, 1975, Apr-19, Volume: 2, Issue:5963

    Topics: Adult; Aerosols; Aged; Airway Resistance; Albuterol; Asthma; Chronic Disease; Clinical Trials as Top

1975
[Level of lactates and examinations of tremor under Clenbuterol (NAB 365)].
    Wiener medizinische Wochenschrift. Supplement, 1975, Volume: 23

    Topics: Albuterol; Analysis of Variance; Aniline Compounds; Asthma; Clinical Trials as Topic; Drug Evaluatio

1975
[Testing of the bronchodilator NAB 365 in a double blind trial author's transl].
    Medizinische Klinik, 1975, Jun-13, Volume: 70, Issue:24

    Topics: Airway Resistance; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Carbon Dioxide; Clinical Tr

1975
[Letter: Study of the delay of action of an injected corticoid on bronchial obstruction in asthmatics. Comparison with an inhaled beta-stimulating agent].
    La Nouvelle presse medicale, 1975, Apr-19, Volume: 4, Issue:16

    Topics: Adrenal Cortex Hormones; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials

1975
The measurement of response to beclomethasone dipropionate treatment for asthma.
    Postgraduate medical journal, 1975, Volume: 51 Suppl 4

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Huma

1975
Comparison of intravenous aminophylline and salbutamol in severe asthma.
    British medical journal, 1975, Dec-20, Volume: 4, Issue:5998

    Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Drug Evaluation; Humans

1975
Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
    Current medical research and opinion, 1975, Volume: 3, Issue:1

    Topics: Adult; Aerosols; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Bronchi; Bronchitis; Broncho

1975
Intravenous treatment with rimiterol and salbutamol in asthma.
    British medical journal, 1975, Jun-28, Volume: 2, Issue:5973

    Topics: Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Catechols; Dose-Response Relationship, Dru

1975
Evaluation of tolerance after continuous and prolonged oral administration of salbutamol to asthmatic patients.
    British journal of clinical pharmacology, 1975, Volume: 2, Issue:5

    Topics: Albuterol; Asthma; Delayed-Action Preparations; Drug Evaluation; Drug Tolerance; Female; Humans; Mal

1975
Effect of intravenous injection of salbutamol in asthma.
    British journal of clinical pharmacology, 1975, Volume: 2, Issue:6

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Female; Forced Expiratory Volume; Heart Ra

1975
The effect of intramuscular salbutamol in asthmatics.
    British journal of clinical pharmacology, 1975, Volume: 2, Issue:3

    Topics: Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Injections, Int

1975
Evaluation of a breath actuated pressurized aerosol.
    Clinical allergy, 1976, Volume: 6, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Evaluation Studies as Topic; Humans; Respiratory Therapy

1976
Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation.
    Chest, 1992, Volume: 101, Issue:2

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Relationship, Drug; Female; For

1992
Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
    The Journal of allergy and clinical immunology, 1992, Volume: 89, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Cold Temperatur

1992
A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion.
    The Journal of allergy and clinical immunology, 1992, Volume: 89, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Bronchial Hyperreactivity; Bronchial Provoca

1992
Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects.
    Chest, 1992, Volume: 101, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Ag

1992
Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist.
    The Journal of allergy and clinical immunology, 1992, Volume: 89, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Etha

1992
[Salmeterol and prolonged treatment of asthma: international clinical data].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Tole

1992
[Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction

1992
[Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Ther

1992
The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1992, Volume: 29, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Circadian Rhy

1992
Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma?
    Annals of allergy, 1992, Volume: 69, Issue:2

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middl

1992
Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.
    The American review of respiratory disease, 1992, Volume: 146, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

1992
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
    The New England journal of medicine, 1992, Oct-22, Volume: 327, Issue:17

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction

1992
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.
    The New England journal of medicine, 1992, Nov-12, Volume: 327, Issue:20

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Do

1992
Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists.
    The European respiratory journal, 1992, Volume: 5, Issue:9

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Chronic Diseas

1992
Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma.
    The Journal of allergy and clinical immunology, 1992, Volume: 90, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Fema

1992
Sustained improvement in asthma with long-term use of formoterol fumarate.
    Annals of allergy, 1992, Volume: 69, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Ethanolam

1992
Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler.
    BMJ (Clinical research ed.), 1992, Oct-17, Volume: 305, Issue:6859

    Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator

1992
[Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
    Ugeskrift for laeger, 1992, Nov-16, Volume: 154, Issue:47

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1992
Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma.
    Chest, 1992, Volume: 102, Issue:3

    Topics: Aerosols; Albuterol; Asthma; Bronchoconstriction; Double-Blind Method; Female; Forced Expiratory Vol

1992
Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
    Singapore medical journal, 1992, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Delayed-Action Preparations; Dose-Response Relationship, Drug;

1992
Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers.
    Arzneimittel-Forschung, 1992, Volume: 42, Issue:7

    Topics: Adult; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Bronchodilator Agents; Ethanolamines

1992
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.
    The European respiratory journal, 1992, Volume: 5, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl

1992
Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma.
    The Quarterly journal of medicine, 1992, Volume: 82, Issue:297

    Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Blood Glucose; Glucagon; Glucocorticoids; Hu

1992
Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction.
    Respiration; international review of thoracic diseases, 1992, Volume: 59, Issue:3

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Double-Blind Method; Forced Expiratory Volume; H

1992
Increased inhaled bronchodilator vs increased inhaled corticosteroid in the control of moderate asthma.
    Chest, 1992, Volume: 102, Issue:6

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Bronchodilator Agent

1992
A long-term prospective assessment of home nebulizer treatment.
    Respiratory medicine, 1992, Volume: 86, Issue:4

    Topics: Adult; Aged; Albuterol; Ambulatory Care; Asthma; Bronchodilator Agents; Drug Combinations; Humans; I

1992
Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics.
    Respiratory medicine, 1992, Volume: 86, Issue:5

    Topics: Adult; Albuterol; Asthma; Cardiovascular System; Double-Blind Method; Female; Fenoterol; Forced Expi

1992
Intravenous theophylline after beta 2-agonist treatment in severe acute asthma. Effect on patients who are not pre-treated with theophylline.
    Upsala journal of medical sciences, 1992, Volume: 97, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Drug Therapy,

1992
Facemasks versus mouthpieces for aerosol treatment of asthmatic children.
    Pediatric pulmonology, 1992, Volume: 14, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Humans; Masks; Respiratory Function T

1992
Hypomagnesemia due to beta 2-agonist use in bronchial asthma.
    The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:5

    Topics: Administration, Oral; Albuterol; Asthma; Humans; Injections, Subcutaneous; Magnesium; Potassium; Ter

1992
Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. French Multicentre Study Group.
    The European respiratory journal, 1992, Volume: 5, Issue:10

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Bronch

1992
Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction--a placebo-controlled study.
    Respiration; international review of thoracic diseases, 1992, Volume: 59, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchoconstriction; Bronchodilator

1992
Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.
    The American review of respiratory disease, 1992, Volume: 146, Issue:2

    Topics: Adult; Airway Obstruction; Albuterol; Analysis of Variance; Asthma; Double-Blind Method; Drug Therap

1992
Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; D

1992
[Changes in the heart rhythm and slow-release beta-2 agonist therapy (peroral) in asthmatic patients. A Holter study].
    Recenti progressi in medicina, 1992, Volume: 83, Issue:12

    Topics: Administration, Oral; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; E

1992
Effect of astemizole on allergic asthma.
    Annals of allergy, 1992, Volume: 69, Issue:2

    Topics: Adolescent; Adult; Albuterol; Astemizole; Asthma; Bronchial Provocation Tests; Double-Blind Method;

1992
Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDI) and a "Diskhaler".
    European journal of clinical pharmacology, 1992, Volume: 42, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory

1992
Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma.
    The Journal of allergy and clinical immunology, 1992, Volume: 89, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchial

1992
Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma.
    Annals of allergy, 1992, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-R

1992
Effect of age on bronchodilator response.
    Chest, 1992, Volume: 101, Issue:6

    Topics: Adolescent; Adult; Aging; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response Re

1992
Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization.
    Annals of emergency medicine, 1992, Volume: 21, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; California; C

1992
The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours.
    The Journal of allergy and clinical immunology, 1992, Volume: 89, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc

1992
Bronchodilator intake and plasma levels on admission for severe acute asthma.
    The European respiratory journal, 1992, Volume: 5, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Pressure; Dose-Resp

1992
Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients.
    Pulmonary pharmacology, 1992, Volume: 5, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations

1992
A clinically relevant modification to existing inhaler therapy.
    Respiratory medicine, 1992, Volume: 86, Issue:3

    Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Carriers; Female; Forced Expiratory Volume; Huma

1992
Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma.
    The Journal of allergy and clinical immunology, 1992, Volume: 90, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Asthma; Beclomethasone; Chi

1992
Treatment of nocturnal asthma with pulsed-release albuterol.
    Chest, 1992, Volume: 102, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Double-Bl

1992
Dose of inhaled beta 2-agonists in asthma.
    Lancet (London, England), 1991, Mar-16, Volume: 337, Issue:8742

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Drug Evaluation; Female;

1991
Exacerbations of asthma in patients on salmeterol.
    Lancet (London, England), 1991, Apr-13, Volume: 337, Issue:8746

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate

1991
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.
    Lancet (London, England), 1991, May-04, Volume: 337, Issue:8749

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchoconstriction; Double

1991
Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms.
    Lancet (London, England), 1991, Jun-08, Volume: 337, Issue:8754

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Follow-Up Studies; Humans; Salmeterol

1991
Asthma specific quality of life scale in a study of salmeterol hydroxynaphthoate.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1991, Volume: 41, Issue:346

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Humans; Quality of Life; Salmetero

1991
A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects.
    The American review of respiratory disease, 1991, Volume: 144, Issue:3 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pr

1991
Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler.
    Arzneimittel-Forschung, 1991, Volume: 41, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Ethanolamines; Femal

1991
Inhaled formoterol during one year in asthma: a comparison with salbutamol.
    The European respiratory journal, 1991, Volume: 4, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Beclomethasone

1991
A study with cumulative doses of formoterol and salbutamol in children with asthma.
    The European respiratory journal, 1991, Volume: 4, Issue:10

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response

1991
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.
    The European respiratory journal, 1991, Volume: 4, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Do

1991
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Drugs, 1991, Volume: 42, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictio

1991
Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma.
    Pediatrics, 1992, Volume: 89, Issue:1

    Topics: Acute Disease; Administration, Intranasal; Albuterol; Asthma; Double-Blind Method; Female; Heart Rat

1992
[Treatment of asthma in the adult using a combination of salbutamol 100 micrograms--beclomethasone 50 micrograms. Results of a study on 1917 patients seen in general medicine].
    Allergie et immunologie, 1991, Volume: 23, Issue:7

    Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Drug Combin

1991
Asthmatic responses to passive cigarette smoke: persistence of reactivity and effect of medications.
    The Journal of allergy and clinical immunology, 1991, Volume: 88, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cromolyn Sodium; Female; Humans; Hypersensiti

1991
Inhaled and oral salbutamol: how effective in the prophylaxis of asthma?
    Respiration; international review of thoracic diseases, 1991, Volume: 58, Issue:3-4

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Animals; Antigens; A

1991
The effect of a beta 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen.
    Respiratory medicine, 1991, Volume: 85, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Animals; Antigens; Asthma; Bronchial Provocation Tests

1991
Salbutamol plus beclomethasone dipropionate, but not salbutamol alone, completely prevent early and late asthmatic responses to allergen.
    Respiratory medicine, 1991, Volume: 85, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Double-Blind Meth

1991
Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma.
    European journal of clinical pharmacology, 1991, Volume: 41, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asian People; Asthma; Delayed-Action Preparation

1991
[Delayed-release salbutamol, a new beta-mimetic with prolonged action. Results of a comparative study against theophylline L.A].
    Allergie et immunologie, 1991, Volume: 23, Issue:8

    Topics: Adolescent; Aged; Albuterol; Asthma; Delayed-Action Preparations; Female; Humans; Male; Maximal Expi

1991
Inhaled procaterol versus salbutamol in bronchial asthma.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Ethan

1991
Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis.
    Thorax, 1991, Volume: 46, Issue:5

    Topics: Age Factors; Albuterol; Asthma; Bronchitis; Chronic Disease; Female; Humans; Hypersensitivity; Iprat

1991
Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis.
    The European respiratory journal, 1991, Volume: 4, Issue:4

    Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchitis; Bronchoc

1991
Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.
    BMJ (Clinical research ed.), 1991, Dec-07, Volume: 303, Issue:6815

    Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Drug Administration Schedule;

1991
In vitro inhalation behaviour and therapeutical response of salbutamol particles administered from two metered dose aerosols.
    Die Pharmazie, 1991, Volume: 46, Issue:1

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Particle Size; Peak Exp

1991
Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma.
    Pediatrics, 1991, Volume: 88, Issue:2

    Topics: Administration, Oral; Albuterol; Asthma; Child; Drug Administration Schedule; Female; Forced Expirat

1991
The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.
    Thorax, 1991, Volume: 46, Issue:1

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchoconstriction; Dose-Response Relationship,

1991
A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.
    The American review of respiratory disease, 1991, Volume: 144, Issue:3 Pt 1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl

1991
A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma.
    Annals of emergency medicine, 1991, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Isoetharine; Male; M

1991
The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma.
    The American review of respiratory disease, 1991, Volume: 144, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Asthma; Bronchial Hyperreactivity; Bronchia

1991
Bronchodilator effect of salbutamol via the Volumatic in children.
    Respiratory medicine, 1991, Volume: 85, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Nebulizers and Vapo

1991
Effect of controlled release salbutamol on nocturnal cough in asthma.
    Archives of disease in childhood, 1991, Volume: 66, Issue:10

    Topics: Adolescent; Albuterol; Asthma; Child; Cough; Delayed-Action Preparations; Double-Blind Method; Femal

1991
[Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline].
    Revue de pneumologie clinique, 1991, Volume: 47, Issue:3

    Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Drug E

1991
Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours.
    Chest, 1990, Volume: 97, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as

1990
Nebulized or intravenous beta 2 adrenoceptor agonist therapy in acute asthma?
    The European respiratory journal, 1990, Volume: 3, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Clinical Trials a

1990
Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:3

    Topics: Administration, Oral; Adult; Albuterol; Allergens; Asthma; Asthma, Exercise-Induced; Bronchi; Bronch

1990
Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.
    Thorax, 1990, Volume: 45, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aerosols; Aged; A

1990
Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1990, Volume: 20, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodila

1990
Can a new beta 2-agonist reduce the mortality of asthma?
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albutero

1990
Acute and long-term effectiveness of tulobuterol inhaler, a new beta 2-agonist, in the treatment of asthma.
    Lung, 1990, Volume: 168 Suppl

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-

1990
Long-term studies on long-acting sympathomimetics.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; D

1990
Long-term efficacy of formoterol compared to salbutamol.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Al

1990
Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma.
    Lung, 1990, Volume: 168 Suppl

    Topics: Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Te

1990
Efficacy of formoterol metered aerosol in children.
    Lung, 1990, Volume: 168 Suppl

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asth

1990
Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis.
    The American review of respiratory disease, 1990, Volume: 142, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Dose-Response

1990
The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma.
    Clinical pharmacology and therapeutics, 1990, Volume: 48, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodil

1990
Formoterol in the treatment of nocturnal asthma.
    Chest, 1990, Volume: 98, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Double-

1990
Protection against allergen-induced asthma by salmeterol.
    Lancet (London, England), 1990, Dec-01, Volume: 336, Issue:8727

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma

1990
Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
    The American review of respiratory disease, 1990, Volume: 142, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchoconstri

1990
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.
    Lancet (London, England), 1990, Dec-08, Volume: 336, Issue:8728

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; D

1990
Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.
    BMJ (Clinical research ed.), 1990, Dec-15, Volume: 301, Issue:6765

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

1990
Metered dose inhalers for bronchodilator delivery in intubated, mechanically ventilated patients.
    Chest, 1991, Volume: 99, Issue:1

    Topics: Aerosols; Aged; Albuterol; Asthma; Costs and Cost Analysis; Female; Humans; Intubation, Intratrachea

1991
Effect of salbutamol on gastroesophageal reflux in healthy volunteers and patients with asthma.
    The Journal of allergy and clinical immunology, 1991, Volume: 87, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Female; Gastroesophageal Reflux; Humans; Male

1991
Occupational asthma and rhinoconjunctivitis from inhalation of crystalline bovine serum albumin powder.
    Annals of allergy, 1991, Volume: 66, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Conjunctivitis; Crystallization; Double-Blind

1991
Improved stability in oral delivery of albuterol provides less variability in bronchodilation in adults with asthma.
    Annals of allergy, 1991, Volume: 66, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Res

1991
Management of childhood asthma--addition of oral controlled release salbutamol to an inhaled treatment regimen.
    The New Zealand medical journal, 1991, Apr-24, Volume: 104, Issue:910

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Delaye

1991
Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children.
    Pediatric emergency care, 1991, Volume: 7, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Drug Therapy, Combination; E

1991
The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations.
    Chest, 1991, Volume: 99, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Electrocardiography; Ethanolamines; F

1991
Inhaled beta-stimulants--a study of high-dose v. conventional-dose treatment in asthmatic outpatients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1991, Jun-01, Volume: 79, Issue:11

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests;

1991
The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya.
    East African medical journal, 1990, Volume: 67, Issue:12

    Topics: Adult; Albuterol; Asthma; Consumer Behavior; Delayed-Action Preparations; Female; Humans; Male; Midd

1990
Antigen-induced T-cell changes: modulation by pharmacologic agents.
    Lung, 1990, Volume: 168, Issue:2

    Topics: Administration, Inhalation; Albuterol; Antigens; Asthma; Bronchi; Bronchial Provocation Tests; Const

1990
Nebulized ipratropium in the treatment of acute asthma.
    Chest, 1990, Volume: 97, Issue:2

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchodilator

1990
A clinical and immunologic study of colchicine in asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Chronic Disease; Colchicine; Conc

1990
[Effects of ipratropium bromide and salbutamol on isolated lung hyperinflation in symptom-free intervals in asthmatic children].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1990, Volume: 138, Issue:3

    Topics: Administration, Inhalation; Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives;

1990
Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy.
    Chest, 1990, Volume: 98, Issue:2

    Topics: Administration, Inhalation; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Atropine Deriva

1990
Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice.
    BMJ (Clinical research ed.), 1990, Dec-15, Volume: 301, Issue:6765

    Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Child; Family Practice; Humans; Office Vis

1990
Home nebulizers: can optimal therapy be predicted by laboratory studies?
    Respiratory medicine, 1990, Volume: 84, Issue:6

    Topics: Adult; Aged; Albuterol; Asthma; Double-Blind Method; Female; Humans; Ipratropium; Lung Diseases, Obs

1990
Comparison of Berodual and salbutamol in asthma: a multicenter evaluation.
    Respiration; international review of thoracic diseases, 1990, Volume: 57, Issue:6

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Combinations; Evaluation Studies as Topic;

1990
High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine.
    The European respiratory journal, 1990, Volume: 3, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Drug Therapy, Combination; Female; Humans; Infusions,

1990
Ambulatory long-term subcutaneous salbutamol infusion in chronic severe asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Ambulatory Care; Asthma; Chronic Disease; Double-Blind Me

1990
Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Capsules; Delayed-Action Preparations; Double-Blind Method; Hu

1990
Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:4

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Aerosols; Albuterol; Asthma;

1990
Single breath versus panting technique in salbutamol delivery through a 750 mL spacing device.
    Pediatric pulmonology, 1990, Volume: 8, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Male; Maximal Midex

1990
Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial.
    Pediatrics, 1990, Volume: 86, Issue:3

    Topics: Acute Disease; Albuterol; Asthma; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; D

1990
Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma.
    Chest, 1990, Volume: 98, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Bronchi; Child; Double-Blind Method; Drug Thera

1990
Nebulized albuterol in acute childhood asthma: comparison of two doses.
    Pediatrics, 1990, Volume: 86, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Drug Administration Sch

1990
A random double-blind trial of the combination of nebulized atropine methylnitrate and albuterol in nocturnal asthma.
    Annals of allergy, 1990, Volume: 65, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchodilat

1990
Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit?
    Chest, 1990, Volume: 98, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Amino

1990
[Clinico-functional evaluation of flunisolide + salbutamol combination (VAL 679/A) vs salbutamol in pediatric patients].
    Minerva pediatrica, 1990, Volume: 42, Issue:6

    Topics: Administration, Topical; Albuterol; Anti-Inflammatory Agents; Asthma; Child; Double-Blind Method; Dr

1990
Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.
    European journal of clinical pharmacology, 1990, Volume: 39, Issue:3

    Topics: Adult; Albuterol; Asthma; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blin

1990
Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:6 Pt 1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Airway Resistance; Albuterol; Asthma; Beclometh

1990
Placebo controlled trial of systemic corticosteroids in acute childhood asthma.
    Acta paediatrica Scandinavica, 1990, Volume: 79, Issue:11

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Heart Rate; Humans

1990
Aerosolized budesonide in asthmatic infants: a double blind study.
    Pediatric pulmonology, 1990, Volume: 9, Issue:3

    Topics: Administration, Intranasal; Albuterol; Asthma; Budesonide; Double-Blind Method; Drug Evaluation; Glu

1990
Continuous nebulization of albuterol (salbutamol) in acute asthma.
    Chest, 1990, Volume: 97, Issue:3

    Topics: Acute Disease; Adult; Albuterol; Asthma; Drug Administration Schedule; Female; Forced Expiratory Vol

1990
[Effect of nebulized salbutamol in 26 patients hospitalized for asthma attack].
    Revue des maladies respiratoires, 1990, Volume: 7, Issue:2

    Topics: Adult; Albuterol; Asthma; Drug Tolerance; Female; Hospitalization; Humans; Injections, Intravenous;

1990
Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study.
    Respiratory medicine, 1990, Volume: 84, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Fem

1990
A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma.
    Respiratory medicine, 1990, Volume: 84, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Ethanolamines; Female

1990
The effect of albuterol aerosol on fine-motor performance in children with chronic asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Met

1990
Asthma, cardiac arrhythmias, and albuterol aerosol.
    Chest, 1986, Volume: 89, Issue:2

    Topics: Adult; Aerosols; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Cardiac Complexes, Premature; Clinic

1986
The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics.
    Journal of cardiovascular pharmacology, 1986, Volume: 8 Suppl 11

    Topics: Adrenergic beta-Antagonists; Aged; Albuterol; Asthma; Bisoprolol; Blood Pressure; Bronchial Provocat

1986
Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges.
    The Journal of allergy and clinical immunology, 1989, Volume: 83, Issue:5

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Cromolyn Sodium; Female; F

1989
Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition.
    Chest, 1989, Volume: 96, Issue:1

    Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Dose-Response Relationship, Drug; Female;

1989
[Comparative study of procaterol and salbutamol in single inhaled doses].
    Revista clinica espanola, 1989, Volume: 184, Issue:6

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Female; Humans; Lung Volum

1989
Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm.
    Chest, 1989, Volume: 96, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronchial S

1989
Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma.
    Respiration; international review of thoracic diseases, 1989, Volume: 55, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic

1989
Relative bronchodilatory responsiveness attributable to sympathetic and parasympathetic activity in bronchial asthma.
    Respiration; international review of thoracic diseases, 1989, Volume: 56, Issue:1-2

    Topics: Administration, Intranasal; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchi; Drug Therapy, C

1989
[Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack].
    Zhonghua nei ke za zhi, 1989, Volume: 28, Issue:11

    Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Therapy, Combination; Fema

1989
Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.
    Allergy, 1989, Volume: 44, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Dose-Res

1989
Randomized controlled trial of small group education on the outcome of chronic asthma in general practice.
    The Journal of the Royal College of General Practitioners, 1989, Volume: 39, Issue:322

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Child, Preschool; Chronic Disease; Education, Med

1989
Fenoterol and serum potassium.
    Lancet (London, England), 1989, May-27, Volume: 1, Issue:8648

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Female; Fenoterol; Humans; Male; Middle Aged;

1989
Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction.
    Lancet (London, England), 1989, Jun-24, Volume: 1, Issue:8652

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Atropine Derivatives;

1989
Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment.
    Respiration; international review of thoracic diseases, 1989, Volume: 55 Suppl 2

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Doubl

1989
Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
    The Journal of allergy and clinical immunology, 1989, Volume: 84, Issue:6 Pt 1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relation

1989
Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics.
    Pharmatherapeutica, 1989, Volume: 5, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Forced Expir

1989
Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.
    Thorax, 1989, Volume: 44, Issue:11

    Topics: Adult; Albuterol; Asthma; Exercise Test; Forced Expiratory Volume; Heart Rate; Humans; Male; Nebuliz

1989
Comparison of subcutaneous injections of terbutaline, salbutamol and adrenaline in acute asthmatic attacks in children.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1989, Volume: 72, Issue:12

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Epinephrine;

1989
Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol.
    The Journal of allergy and clinical immunology, 1989, Volume: 83, Issue:3

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Dose-Response Rela

1989
Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma.
    European journal of clinical pharmacology, 1989, Volume: 37, Issue:1

    Topics: Adult; Albuterol; Asthma; Delayed-Action Preparations; Double-Blind Method; Female; Forced Expirator

1989
Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.
    European journal of clinical pharmacology, 1989, Volume: 37, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Administration, Sublingual; Adult; Aged; Albuterol

1989
Wet nebulizer versus spacer and metered dose inhaler via tidal breathing.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1989, Volume: 26, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Female; Human

1989
Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1989, Volume: 26, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Bronchi; Child; Drug Combinations; Female; Forced Exp

1989
A comparative bronchodilator study of salbutamol and salbutamol sulphate that were administered by metered-dose inhalers.
    The Medical journal of Australia, 1989, Mar-06, Volume: 150, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Double-Blind Method; Female; Humans; Male; Middle Aged; Nebulizers a

1989
Effect of theophylline and salbutamol on hepatic drug metabolism.
    Human toxicology, 1989, Volume: 8, Issue:3

    Topics: Adult; Albuterol; Antipyrine; Asthma; Coffee; Female; Humans; Liver; Male; Middle Aged; Respiratory

1989
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
    The American review of respiratory disease, 1989, Volume: 140, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Dose-Response Relationship, Dru

1989
Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects.
    The American review of respiratory disease, 1989, Volume: 140, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Child; Cold Temperature; Female

1989
Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma.
    Pediatric pulmonology, 1989, Volume: 7, Issue:2

    Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C

1989
Effects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:6

    Topics: Adrenal Glands; Adult; Albuterol; Asthma; Beclomethasone; Blood Glucose; Bronchi; Dose-Response Rela

1988
The effects of ketotifen on beta-adrenergic activity in asthmatics.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Double-Blind Method; Female; Humans; Ipra

1988
Evaluation of reproterol's effectiveness in preventing exercise-induced bronchospasm in children.
    The Journal of international medical research, 1985, Volume: 13, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child;

1985
Treatment of asthma syndromes in pediatric patients using a combination of a beta 2-stimulant drug and a histamine antagonist.
    International journal of clinical pharmacology, therapy, and toxicology, 1985, Volume: 23, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Auscultation; Child; Child, Preschool; Clinical Trials

1985
Broxaterol: a double-blind clinical trial comparing broxaterol and salbutamol.
    Respiration; international review of thoracic diseases, 1985, Volume: 47, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Pressure; Bronchitis; Clinical Trial

1985
Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide.
    International journal of clinical pharmacology research, 1986, Volume: 6, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Drug Combinations

1986
Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy.
    Allergy, 1986, Volume: 41, Issue:5

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Prescho

1986
Duration of oral procaterol protection from methacholine-induced bronchial obstruction.
    International journal of clinical pharmacology research, 1986, Volume: 6, Issue:5

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Child; Ethanolamines; Female; Humans

1986
Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy.
    European journal of respiratory diseases, 1987, Volume: 70, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Chronic Disease; Clinical Trials as Topic;

1987
Effect of a single oral dose of prednisolone in acute childhood asthma.
    Lancet (London, England), 1987, Apr-18, Volume: 1, Issue:8538

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child, Preschool

1987
The effect of theophylline and beta 2 agonists on airway reactivity.
    Chest, 1987, Volume: 92, Issue:1 Suppl

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Test

1987
Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs.
    Chest, 1987, Volume: 92, Issue:1 Suppl

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchitis; Clinical Trials as Topic;

1987
Comparative trials including a beta 2 adrenergic agonist, a methylxanthine, and a mast cell stabilizer.
    Annals of allergy, 1988, Volume: 60, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Attention; Child; Cromolyn Sodium; Dose-Response Relati

1988
A comparison of the bronchodilator effects of broxaterol and salbutamol.
    International journal of clinical pharmacology, therapy, and toxicology, 1988, Volume: 26, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Pressure

1988
Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
    Thorax, 1988, Volume: 43, Issue:9

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Blood Pressure; Clini

1988
A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness.
    British journal of clinical pharmacology, 1988, Volume: 26, Issue:5

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Method; Female; Histamine H1 Ant

1988
Ergogenic effect of inhaled beta 2-agonists in asthmatics.
    International journal of sports medicine, 1988, Volume: 9, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Double-Blind Method; E

1988
The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma.
    Annals of allergy, 1989, Volume: 62, Issue:1

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Eva

1989
High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma.
    Pediatrics, 1989, Volume: 83, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Nebuliz

1989
Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma.
    The Journal of pediatrics, 1985, Volume: 107, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Atropine Derivatives; Child; Clinical Trials as Topic;

1985
[Pharmacological prevention of exercise-induced bronchospasm in patients with asthma].
    Pneumonologia polska, 1985, Volume: 53, Issue:4

    Topics: Adult; Aerosols; Albuterol; Aminophylline; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents;

1985
A place for ipratropium bromide in the treatment of severe acute asthma.
    British journal of diseases of the chest, 1985, Volume: 79, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as

1985
Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects.
    Thorax, 1985, Volume: 40, Issue:9

    Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Citrates; Citric Acid; Cough;

1985
Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma.
    The American review of respiratory disease, 1985, Volume: 132, Issue:5

    Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Chemotactic Factors; Cr

1985
Nebulized salbutamol and ipratropium bromide in asthmatic children.
    British journal of diseases of the chest, 1986, Volume: 80, Issue:1

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschool; Dose-Respons

1986
Nebulised ipratropium and salbutamol in asthma.
    Archives of disease in childhood, 1986, Volume: 61, Issue:6

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschoo

1986
Single dose comparison of salbutamol and a fenoterol/ipratropium combination from metered aerosols in patients with asthma.
    The New Zealand medical journal, 1986, Jun-11, Volume: 99, Issue:803

    Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blind Met

1986
Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol.
    Thorax, 1986, Volume: 41, Issue:4

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; beta-Thromboglobulin; Blood Platelets; Cromolyn

1986
A new bronchodilating agent, procaterol, in preventing exercise-induced asthma.
    International journal of clinical pharmacology research, 1986, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; Ethano

1986
Influence of pindolol on asthmatics and effect of bronchodilators.
    Respiration; international review of thoracic diseases, 1986, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Child; Female; Forced

1986
Salbutamol and ipratropium bromide solution in the treatment of bronchospasm in asthmatic children.
    Annals of allergy, 1987, Volume: 58, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Child; Drug Therapy, Combinati

1987
Cold-air isocapnic hyperventilation test in the study of the effects and duration of action of Duovent. Comparison with fenoterol, salbutamol, disodium cromoglycate and placebo.
    Respiration; international review of thoracic diseases, 1986, Volume: 50 Suppl 2

    Topics: Adolescent; Adult; Air; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronch

1986
Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients.
    Respiration; international review of thoracic diseases, 1986, Volume: 50 Suppl 2

    Topics: Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronchial S

1986
Single-dose comparison of salbutamol and Duovent-Berodual in asthma.
    Respiration; international review of thoracic diseases, 1986, Volume: 50 Suppl 2

    Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Drug Combinations; Female; Fenoterol; Forced Expirat

1986
Blind randomized cross-over comparative study of salbutamol and the combination fenoterol-ipratropium IK6 in patients with bronchial asthma.
    Respiration; international review of thoracic diseases, 1986, Volume: 50 Suppl 2

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Combinat

1986
75 deaths in asthmatics prescribed home nebulizers.
    British medical journal (Clinical research ed.), 1987, Apr-11, Volume: 294, Issue:6577

    Topics: Albuterol; Asthma; Humans; Ipratropium; Nebulizers and Vaporizers

1987
Salbutamol and ipratropium in acute asthma.
    Archives of disease in childhood, 1987, Volume: 62, Issue:8

    Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschool; Clinical Trials as Top

1987
[Ultrasonic spray protection against bronchospasm. Comparison of fenoterol and a combination of salbutamol and ipratropium bromide].
    Minerva medica, 1987, Oct-31, Volume: 78, Issue:20

    Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Therapy, Combina

1987
Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects.
    British journal of clinical pharmacology, 1987, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Forced Expira

1987
Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children.
    The Journal of allergy and clinical immunology, 1988, Volume: 81, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Atropine Derivatives; Child; Drug Synergism; Forced E

1988
A dose response study comparing Duovent vs salbutamol.
    The New Zealand medical journal, 1987, Dec-09, Volume: 100, Issue:837

    Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Bronchodilator Agents; Chronic

1987
Prevention of exercise-induced asthma by drugs inhaled from metered aerosols.
    Allergy, 1988, Volume: 43, Issue:4

    Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Child

1988
Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma.
    Thorax, 1988, Volume: 43, Issue:4

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Dose-

1988
Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?
    Chest, 1988, Volume: 94, Issue:4

    Topics: Acute Disease; Adult; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blin

1988
Posture-induced airflow limitation in asthma: relationship to plasma catecholamines and an inhaled anticholinergic agent.
    The European respiratory journal, 1988, Volume: 1, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Aged; Airway Resistance; Albuterol; Asthma; A

1988
Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma.
    The European respiratory journal, 1988, Volume: 1, Issue:6

    Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Dose-Response Relationship, Drug; Drug Interactions;

1988
A comparison of oral procaterol and albuterol in reversible airflow obstruction.
    The American review of respiratory disease, 1988, Volume: 138, Issue:6

    Topics: Administration, Oral; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials

1988
Comparison between oral procaterol and salbutamol in patients with bronchial asthma.
    Current medical research and opinion, 1988, Volume: 11, Issue:4

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug

1988
Air or oxygen as driving gas for nebulised salbutamol.
    Archives of disease in childhood, 1988, Volume: 63, Issue:8

    Topics: Acute Disease; Air; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Female; Hu

1988
An inexpensive spacer for use with metered-dose bronchodilators in young asthmatic children.
    Pediatric pulmonology, 1988, Volume: 5, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Do

1988
[Intravenous infusion of reproterol (a beta-2-mimetic agent) in the therapy of severe asthma attacks in childhood].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1986, Volume: 134, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Carbon Dioxide; Child; Child, Preschool; Combi

1986
Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.
    The Journal of allergy and clinical immunology, 1987, Volume: 79, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Beclomethasone; Bronchi

1987
A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm.
    Annals of allergy, 1987, Volume: 59, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Child; C

1987
Treatment of bronchial asthma with terfenadine; a randomized controlled trial.
    British journal of clinical pharmacology, 1987, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Benzhydryl Compounds; Child; Clinical Trials as Topic; Double-

1987
Intravenous beta agonist in severe acute asthma.
    BMJ (Clinical research ed.), 1988, Aug-13, Volume: 297, Issue:6646

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Female; Humans; Infusions, Intravenous; M

1988
[The role of anticholinergic drugs in the treatment of bronchospastic conditions].
    Pneumonologia polska, 1985, Volume: 53, Issue:1

    Topics: Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Bronchitis; Clinical Trials as Topic; Huma

1985
Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:4

    Topics: Adult; Albuterol; Asthma; Drug Evaluation; Fenoterol; Humans; Middle Aged; Random Allocation; Respir

1988
Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers.
    JAMA, 1988, Dec-02, Volume: 260, Issue:21

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Esophagus; Female; Gastro

1988
Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma.
    Current medical research and opinion, 1988, Volume: 11, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Drug Combina

1988
Effect of ketotifen on the bronchodilation induced by salbutamol.
    Respiration; international review of thoracic diseases, 1988, Volume: 54, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchi; Dilatation, Pathologic; Female; Forced Expiratory Volume; Humans;

1988
Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma.
    The Journal of allergy and clinical immunology, 1987, Volume: 79, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Clinical Trials as Topic; Dose-Re

1987
Nifedipine treatment of patients with bronchial asthma.
    The Journal of allergy and clinical immunology, 1987, Volume: 79, Issue:6

    Topics: Adult; Aged; Albuterol; Asthma; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Double-B

1987
Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma.
    Thorax, 1987, Volume: 42, Issue:1

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Betamethasone; Bronchi; Clinical Trials as Topic; Doubl

1987
Oral salbutamol vs fenoterol in childhood asthma.
    Helvetica paediatrica acta, 1987, Volume: 42, Issue:4

    Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Double-Blind M

1987
Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease.
    The New Zealand medical journal, 1987, May-27, Volume: 100, Issue:824

    Topics: Administration, Inhalation; Adult; Albuterol; Aminophylline; Arrhythmias, Cardiac; Asthma; Clinical

1987
Delivery of albuterol aerosol by aerochamber to young children.
    Annals of allergy, 1988, Volume: 60, Issue:5

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Heart Rate

1988
Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children.
    Pediatric pulmonology, 1988, Volume: 4, Issue:4

    Topics: Administration, Oral; Albuterol; Altitude; Asthma; Asthma, Exercise-Induced; Child; Clenbuterol; Dou

1988
A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients.
    Postgraduate medical journal, 1987, Volume: 63, Issue:740

    Topics: Albuterol; Asthma; Dose-Response Relationship, Drug; Fenoterol; Forced Expiratory Volume; Heart Rate

1987
Differing bioavailability of salbutamol metered-dose inhalers.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1987, Volume: 24, Issue:4

    Topics: Aerosols; Albuterol; Asthma; Biological Availability; Double-Blind Method; Drug Administration Sched

1987
Duration of action of oral albuterol in an asthmatic population.
    Annals of allergy, 1986, Volume: 56, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchial Spasm; Child; Clinical Trials

1986
How to use a rotahaler.
    Archives of disease in childhood, 1986, Volume: 61, Issue:1

    Topics: Acute Disease; Adolescent; Aerosols; Age Factors; Albuterol; Asthma; Child; Clinical Trials as Topic

1986
Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma.
    British journal of clinical pharmacology, 1986, Volume: 21, Issue:2

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchodilator Agents; Clinical

1986
Comparison of oral salbutamol with reproterol in reversible airway obstruction.
    The Journal of the Association of Physicians of India, 1986, Volume: 34, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Clini

1986
[Comparative study of the effects of regular or on-demand salbutamol inhalation in the treatment of asthma].
    Schweizerische medizinische Wochenschrift, 1986, Sep-13, Volume: 116, Issue:37

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Do

1986
The response of asthmatic children to the heated nebulization of salbutamol.
    Australian paediatric journal, 1986, Volume: 22, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Child; Clinical Trials as Topic; Female; Forced Expir

1986
Response to bronchodilators assessed by lung mechanics.
    Archives of disease in childhood, 1986, Volume: 61, Issue:10

    Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Female; Functio

1986
Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma.
    The Journal of allergy and clinical immunology, 1986, Volume: 78, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bicarbonates; Calcium; Chron

1986
Inhalation powder and oral salbutamol combination.
    Archives of disease in childhood, 1986, Volume: 61, Issue:11

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Chroni

1986
[Comparative study of anticholinergic and betamimetic agents in the treatment of asthma attacks].
    Revue de pneumologie clinique, 1986, Volume: 42, Issue:6

    Topics: Administration, Inhalation; Albuterol; Asthma; Atropine; Clinical Trials as Topic; Female; Humans; I

1986
Nifedipine in asthma. Dose-related effect on resting bronchial tone.
    Chest, 1987, Volume: 91, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Dose-Response Relationship,

1987
Comparison of inhaled albuterol powder and aerosol in asthma.
    The Journal of allergy and clinical immunology, 1987, Volume: 79, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Child; Clinical Tr

1987
Is twice daily prophylaxis with salbutamol and beclomethasone dipropionate effective in the management of asthma?
    Pharmatherapeutica, 1986, Volume: 4, Issue:10

    Topics: Adult; Aged; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule; Drug Therapy, Combinat

1986
Is the combination inhaler of salbutamol and beclomethasone dipropionate as effective as the same agents from separate inhalers in the management of childhood asthma?
    Current medical research and opinion, 1987, Volume: 10, Issue:8

    Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Child; Double-Blind Method; Drug Combinations; Female

1987
Nebulised adrenaline in acute severe asthma: comparison with salbutamol.
    European journal of respiratory diseases, 1987, Volume: 71, Issue:4

    Topics: Acute Disease; Adult; Albuterol; Asthma; Epinephrine; Female; Humans; Male; Middle Aged; Nebulizers

1987
Lack of cardiac effect from repeated doses of albuterol aerosol. A margin of safety.
    Clinical pediatrics, 1986, Volume: 25, Issue:7

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Forced Expiratory Volume; Heart

1986
A comparative study of the bronchodilating effect of oral fenoterol and salbutamol in children with asthma.
    Australian paediatric journal, 1986, Volume: 22, Issue:1

    Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Fenoterol; Hu

1986
Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols.
    British journal of diseases of the chest, 1986, Volume: 80, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Sc

1986
[Nocturnal asthma: inhalation treatment with high doses of salbutamol and beclomethasone].
    Revista clinica espanola, 1986, Volume: 178, Issue:7

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Circadian Rhythm; Drug Therapy, Combination; Female; Human

1986
Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic.
    The American review of respiratory disease, 1986, Volume: 134, Issue:2

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volum

1986
Comparison of the effects of sequential or simultaneous administration of salbutamol and beclomethasone dipropionate.
    Respiration; international review of thoracic diseases, 1986, Volume: 50, Issue:2

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Double-Blind Method; Drug Administration S

1986
The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment.
    The Journal of allergy and clinical immunology, 1986, Volume: 78, Issue:4 Pt 1

    Topics: Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Theophylline

1986
Long-term regularly inhaled salbutamol.
    Current medical research and opinion, 1986, Volume: 10, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Double-Blind Method; Drug Administration Schedule; Dr

1986
Cough and wheezing from beclomethasone aerosol.
    Chest, 1987, Volume: 91, Issue:2

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Cough; Double-Blind Method; Forced Expiratory Volume; H

1987
Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma.
    The Journal of allergy and clinical immunology, 1987, Volume: 79, Issue:1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Chronic Disease; Drug Administration Schedule; Drug Ther

1987
Evaluation of inhalation aids of metered dose inhalers in asthmatic children.
    Chest, 1987, Volume: 91, Issue:3

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers

1987
Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease.
    European journal of clinical pharmacology, 1986, Volume: 31, Issue:4

    Topics: Adult; Albuterol; Asthma; Biological Availability; Delayed-Action Preparations; Double-Blind Method;

1986
"Cup-Mask' salbutamol in acute asthma in children.
    Irish medical journal, 1985, Volume: 78, Issue:1

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Doubl

1985
Fenoterol administered as an inhaled powder. A comparison with salbutamol powder.
    The New Zealand medical journal, 1985, Feb-13, Volume: 98, Issue:772

    Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamines;

1985
Inhaled albuterol powder for the treatment of asthma--a dose-response study.
    The Journal of allergy and clinical immunology, 1985, Volume: 75, Issue:4

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relat

1985
A trial of tiaramide in asthma.
    Allergy, 1985, Volume: 40, Issue:3

    Topics: Administration, Oral; Adult; Aerosols; Aged; Albuterol; Asthma; Benzothiazoles; Bronchodilator Agent

1985
Treatment of acute bronchoconstriction in children with use of a tube spacer aerosol and a dry powder inhaler.
    Allergy, 1985, Volume: 40, Issue:4

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Dou

1985
Albuterol syrup in the treatment of asthma.
    The Journal of allergy and clinical immunology, 1985, Volume: 76, Issue:2 Pt 1

    Topics: Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Ele

1985
Inhalation therapy during acute asthma. The role of a combined steroid and beta-stimulant preparation.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1985, Sep-14, Volume: 68, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Doubl

1985
Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks.
    Annals of allergy, 1985, Volume: 55, Issue:3

    Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Headache; Heart Rate; Humans; Injections

1985
A comparison of inhaled powders of fenoterol and salbutamol in asthma.
    Australian paediatric journal, 1985, Volume: 21, Issue:2

    Topics: Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Ethanolam

1985
Oxitropium, salbutamol and their combination in asthma.
    European journal of respiratory diseases, 1985, Volume: 67, Issue:1

    Topics: Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Forced Expira

1985
Albuterol nebulizer solution for the treatment of asthma.
    Annals of allergy, 1985, Volume: 55, Issue:6

    Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Isoetharine; Ran

1985
Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo.
    European journal of respiratory diseases, 1985, Volume: 67, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dou

1985
Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate.
    Pediatrics, 1986, Volume: 77, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Forced Expiratory Volume; Hu

1986
Is driving gas flow rate clinically important for nebulizer therapy?
    British journal of diseases of the chest, 1986, Volume: 80, Issue:1

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Random Allocation; Resp

1986
A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma.
    British journal of diseases of the chest, 1986, Volume: 80, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Chronic Disease; Female; Forced Expiratory Volume; Humans; Lung; Male;

1986
Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine.
    Chest, 1986, Volume: 89, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Double-Blind Method; Epinephrine; Female;

1986
Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma.
    The Journal of allergy and clinical immunology, 1985, Volume: 75, Issue:1 Pt 1

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response

1985
Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics.
    JAMA, 1985, Apr-12, Volume: 253, Issue:14

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Double-Blind Method; Fe

1985
Response to frequent low doses of nebulized salbutamol in acute asthma.
    The Journal of pediatrics, 1985, Volume: 106, Issue:4

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Child; Dose-Response Relationship, Drug; Dru

1985
Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe?
    Thorax, 1985, Volume: 40, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Drug Administration Schedule; Female;

1985
Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level.
    European journal of clinical pharmacology, 1985, Volume: 27, Issue:6

    Topics: Aerosols; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Powders;

1985
A comparison of inhaled fenoterol and albuterol in asthma.
    Annals of allergy, 1985, Volume: 55, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fenoterol; Forced Expiratory Volume;

1985
A comparative study of the inhaled dry powders of salbutamol and fenoterol and their delivery systems.
    Australian paediatric journal, 1985, Volume: 21, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female

1985
[Spirometric monitoring of the effects of puncturing thoracic pain points in asthmatic disease].
    Respiration; international review of thoracic diseases, 1985, Volume: 48, Issue:4

    Topics: Acupuncture Therapy; Adult; Airway Resistance; Albuterol; Asthma; Female; Humans; Male; Maximal Expi

1985
[Pulmonary function tests on the bronchospasmolytic effects of the beta-2-adrenergics: salbutamol, terbutaline and NAB 365 (double placebo experiment)].
    Arzneimittel-Forschung, 1974, Volume: 24, Issue:6

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Alcohols; Amines; Asthma; Bronchitis; Chlori

1974
Letter: Alpha-adrenoceptor-blocking drugs in asthma.
    British medical journal, 1974, Nov-16, Volume: 4, Issue:5941

    Topics: Adrenergic beta-Antagonists; Albuterol; Asthma; Drug Synergism; Humans; Receptors, Adrenergic

1974
Demonstration by placebo response in asthma by means of exercise testing.
    Journal of psychosomatic research, 1973, Volume: 17, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Atropine; Child; Child, Preschool; Cromolyn Sodium; Female; Humans; L

1973
Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma.
    British medical journal, 1973, Oct-27, Volume: 4, Issue:5886

    Topics: Administration, Oral; Administration, Topical; Adrenocorticotropic Hormone; Aerosols; Albuterol; Ant

1973
A clinical trial of long-term oral salbutamol in reversible diffuse airway obstruction.
    The American review of respiratory disease, 1973, Volume: 108, Issue:6

    Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchitis; Chronic Disease; Clinica

1973
The role of oral bronchodilator therapy as shown by a comparison between salbutamol and terbutaline.
    Current medical research and opinion, 1973, Volume: 1, Issue:9

    Topics: Administration, Oral; Adult; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Clinical Trials

1973
Response to rimiterol and salbutamol aerosols administered by intermittent positive-pressure ventilation.
    British medical journal, 1974, May-04, Volume: 2, Issue:5913

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Electrocardiography

1974
A controlled trial of beclomethasone dipropionate in asthma.
    The New Zealand medical journal, 1974, Mar-27, Volume: 79, Issue:511

    Topics: 17-Hydroxycorticosteroids; Administration, Topical; Adolescent; Adult; Aerosols; Aged; Albuterol; An

1974
A controlled trial of beclomethasone dipropionate by aerosol in chronic asthmatics.
    The New Zealand medical journal, 1974, Mar-27, Volume: 79, Issue:511

    Topics: Administration, Topical; Aerosols; Albuterol; Anti-Inflammatory Agents; Asthma; Beclomethasone; Clin

1974
Salbutamol.
    Journal of the Indian Medical Association, 1973, Nov-01, Volume: 61, Issue:9

    Topics: Albuterol; Asthma; Clinical Trials as Topic; Ephedrine; Humans

1973
[Double blind test with hexoprenaline (Ipradol)-dosage-aerosol apparatus in bronchial asthma].
    Schweizerische medizinische Wochenschrift, 1974, Jun-08, Volume: 104, Issue:23

    Topics: Adolescent; Adult; Aerosols; Albuterol; Amino Alcohols; Asthma; Blood Pressure; Bronchodilator Agent

1974
[Bronchodilator effect of aerosol salbutamol in infantile bronchial asthma].
    La Pediatria, 1974, Mar-31, Volume: 82, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Fem

1974
Comparative study of modern beta adrenoreceptor stimulation aerosols in asthma.
    The Journal of the Association of Physicians of India, 1973, Volume: 21, Issue:9

    Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Humans; Isoproterenol; Metaproterenol; Placeb

1973
Oral salbutamol in obstructive airway disease.
    The Indian journal of chest diseases, 1974, Volume: 16, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Clinical Trials as Top

1974
[Beclomethasone aerosol in asthma therapy].
    Duodecim; laaketieteellinen aikakauskirja, 1974, Volume: 90, Issue:18

    Topics: Administration, Topical; Adult; Aerosols; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Beclome

1974
Evaluation of orally administered salbutamol in the relief of bronchospasm in bronchial asthma.
    Southern medical journal, 1974, Volume: 67, Issue:11

    Topics: Administration, Oral; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Spasm; Clinical Trials

1974
Bronchodilator effect of oral salbutamol and an ephedrine+theophylline+hydroxyzine combination in asthmatic out-patients.
    Scandinavian journal of respiratory diseases, 1974, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Combinations; Ephedrine; Female

1974
Oral salbutamol in asthma-a preliminary report.
    The British journal of clinical practice, 1974, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Female; Humans; Male

1974
The effect of betamethasone valerate aerosol on exercise-induced asthma in children.
    Postgraduate medical journal, 1974, Volume: 50 suppl 4

    Topics: Aerosols; Albuterol; Asthma; Betamethasone; Betamethasone Valerate; Child; Clinical Trials as Topic;

1974
[Oral therapy of asthma. Studies on the effects of bronchodilators in tabelts].
    Fortschritte der Medizin, 1972, Apr-13, Volume: 90, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Amino Alcohols; Asthma; Bronchodilator Agents; F

1972
A comparison of salbutamol and terbutaline aerosols in bronchial asthma.
    The Practitioner, 1973, Volume: 211, Issue:266

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Heart Rate; Humans; Middle Aged; Spirometr

1973
A comparison of the effects of subcutaneous orciprenaline, salbutamol and terbutaline in asthmatic children.
    Annals of clinical research, 1974, Volume: 6, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Dose-Response Relationship,

1974
A comparative trial of salbutamol and isoprenaline in asthma.
    Annals of clinical research, 1974, Volume: 6, Issue:2

    Topics: Adult; Aerosols; Airway Obstruction; Albuterol; Asthma; Carbon Dioxide; Female; Heart Rate; Humans;

1974

Other Studies

1951 other studies available for albuterol and Asthma

ArticleYear
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
    Journal of medicinal chemistry, 1979, Volume: 22, Issue:3

    Topics: Airway Resistance; Animals; Asthma; Benzyl Alcohols; Benzyl Compounds; Bronchodilator Agents; Chemic

1979
A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.
    Bioorganic & medicinal chemistry letters, 2012, Jan-15, Volume: 22, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Anti-Asthmatic Agents; Asthma; Cell Line; Drug Discove

2012
Prospective Observational Study of Clinical Outcomes After Intravenous Magnesium for Moderate and Severe Acute Asthma Exacerbations in Children.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:5

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Therapy, Combination; Female; H

2022
Inpatient albuterol spacing as an indicator of discharge readiness.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Female; Hospitalizatio

2023
Bronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:1

    Topics: Albuterol; Asthma; Biomarkers; Bronchodilator Agents; Humans

2022
Is the use of a combined FABA/ICS single inhaler for mild asthma effective and safe?
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022, Volume: 52, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Drug Combinations; Drug Therapy, Combination; Humans;

2022
Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:5

    Topics: Aged; Albuterol; Anti-Asthmatic Agents; Asthma; COVID-19; COVID-19 Drug Treatment; Humans; Medicare;

2022
Cost analysis of hospitals performing continuous albuterol in non-intensive care settings.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospital Costs; Hospitals; Humans; Length of

2023
Role of ethnicity/language in documented rates of pediatric asthma prescription refills.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:2

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Ethnicity; Humans; Language; Prescriptions

2023
Variation in Prehospital Protocols for Pediatric Respiratory Distress Management in the United States.
    Pediatric emergency care, 2022, Jul-01, Volume: 38, Issue:7

    Topics: Albuterol; Anaphylaxis; Asthma; Child; Croup; Dyspnea; Emergency Medical Services; Epiglottitis; Epi

2022
[Salbutamol as an indicator of poor asthma control].
    Andes pediatrica : revista Chilena de pediatria, 2021, Volume: 92, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2021
Association between beta-2 adrenergic receptor variants and clinical outcomes in children and adolescents with acute asthma.
    Einstein (Sao Paulo, Brazil), 2022, Volume: 20

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Metered Dose Inhalers; Nebulizers an

2022
Sustained delivery of salbutamol from cubosomal gel for management of paediatric asthma:
    Journal of microencapsulation, 2022, Volume: 39, Issue:3

    Topics: Administration, Cutaneous; Albuterol; Animals; Asthma; Drug Delivery Systems; Drug Liberation; Gels;

2022
Severe lactic acidosis and persistent diastolic hypotension following standard dose of intermittent nebulized salbutamol in a child: a case report.
    Journal of medical case reports, 2022, Apr-22, Volume: 16, Issue:1

    Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Famil

2022
Dexmedetomidine with continuous salbutamol inhalation in the treatment of paediatric near-fatal asthma.
    Acta paediatrica (Oslo, Norway : 1992), 2022, Volume: 111, Issue:9

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Dexmedetomidine; Humans

2022
Quality of acute asthma care: an audit of clinical practice in a Victorian health service.
    Internal medicine journal, 2023, Volume: 53, Issue:6

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Emergency Service, Hospita

2023
School-based Stock Inhaler Programs and Neighborhood Disadvantage.
    Journal of health care for the poor and underserved, 2022, Volume: 33, Issue:2

    Topics: Albuterol; Asthma; Humans; Nebulizers and Vaporizers; Neighborhood Characteristics; Residence Charac

2022
Mind the gap: Mapping variation between national and local clinical practice guidelines for acute paediatric asthma from the United Kingdom and the Netherlands.
    PloS one, 2022, Volume: 17, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Child; Humans; Netherlands; Quality of Health Care; United Kingdom

2022
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Attitude of Health Personnel; Bronchodilator A

2023
Potentiality of impulse oscillometry to evaluate bronchodilator reversibility in untreated adult patients with newly diagnosed asthma.
    Journal of the Chinese Medical Association : JCMA, 2022, 08-01, Volume: 85, Issue:8

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Oscillometry; Re

2022
Pharmacology Focus: Is it Time to Ditch the Albuterol Inhaler? S.M.A.R.T. Treatment for Asthma.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2022, Volume: 75, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporiz

2022
The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:4

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Fluticasone; Fluticasone-Salmeterol

2023
Is Seizure an Adverse Effect of Salbutamol in the Pediatric Population?
    Balkan medical journal, 2022, 09-09, Volume: 39, Issue:5

    Topics: Albuterol; Asthma; Child; Epilepsy; Humans; Retrospective Studies; Seizures

2022
Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation.
    Respiratory care, 2022, Volume: 67, Issue:11

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Length of Stay; Male; Status Asthma

2022
In moderate-to-severe asthma, as-needed albuterol-budesonide reduced severe exacerbations vs. albuterol alone.
    Annals of internal medicine, 2022, Volume: 175, Issue:9

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations;

2022
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
    The New England journal of medicine, 2022, 08-18, Volume: 387, Issue:7

    Topics: Albuterol; Asthma; Budesonide; Humans; Nebulizers and Vaporizers

2022
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. Reply.
    The New England journal of medicine, 2022, 08-18, Volume: 387, Issue:7

    Topics: Albuterol; Asthma; Budesonide; Humans; Nebulizers and Vaporizers

2022
Albuterol: Still first-line in rescue therapy?
    JAAPA : official journal of the American Academy of Physician Assistants, 2022, Oct-01, Volume: 35, Issue:10

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Biological Products; Bronchi

2022
Effects of Different Intervention Factors on Vascular Endothelial Growth Factor-Induced Human Airway Smooth Muscle Cell Migration.
    Canadian respiratory journal, 2022, Volume: 2022

    Topics: Airway Remodeling; Albuterol; Asthma; Budesonide; Humans; Ipratropium; Myocytes, Smooth Muscle; p38

2022
[Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation].
    Terapevticheskii arkhiv, 2022, Aug-12, Volume: 94, Issue:7

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Budesonide, Formot

2022
Evaluating the Clinical Impact of a Novel Pediatric Emergency Medicine Curriculum on Asthma Outcomes in Belize.
    Pediatric emergency care, 2022, Nov-01, Volume: 38, Issue:11

    Topics: Albuterol; Asthma; Belize; Child; Curriculum; Emergencies; Emergency Service, Hospital; Humans; Pedi

2022
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
    The Journal of pediatrics, 2022, Volume: 251

    Topics: Albuterol; Asthma; Humans; Steroids

2022
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
    The Journal of pediatrics, 2022, Volume: 251

    Topics: Albuterol; Asthma; Humans; Steroids

2022
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
    The Journal of pediatrics, 2022, Volume: 251

    Topics: Albuterol; Asthma; Humans; Steroids

2022
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
    The Journal of pediatrics, 2022, Volume: 251

    Topics: Albuterol; Asthma; Humans; Steroids

2022
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:12

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2022
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:12

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2022
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:12

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2022
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:12

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2022
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Feb-01, Volume: 181

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H

2023
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Feb-01, Volume: 181

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H

2023
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Feb-01, Volume: 181

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H

2023
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Feb-01, Volume: 181

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H

2023
Use of Drugs Considering Route of Administration on Drug Prescription Pattern for Bronchial Asthma in a Tertiary Level Hospital.
    Mymensingh medical journal : MMJ, 2023, Volume: 32, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Drug

2023
Assessment and management of asthma exacerbations in an emergency department unit.
    Allergologia et immunopathologia, 2023, Volume: 51, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hosp

2023
Efficacy of Nebulised Salbutamol with Ipratropium Bromide in Magnesium Sulphate Base in Acute Flare-up of Wheeze among Children Aged 1-12 y.
    Indian journal of pediatrics, 2023, Volume: 90, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Ipratropium; Magnesium

2023
Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy.
    The journal of allergy and clinical immunology. In practice, 2023, Volume: 11, Issue:7

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Budes

2023
THE INFLUENCE OF SPELEOTHERAPY ON BRONCHI PASSAGE IN CHILDREN WITH BRONCHIAL ASTHMA USING A PHARMACO-FUNCTIONAL TEST WITH SALBUTAMOL.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2023, Volume: 76, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchi; Child; Humans; Speleotherapy

2023
Regular formoterol plus inhaled corticosteroid vs. salmeterol plus inhaled corticosteroid for asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2023, Volume: 53, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Drug

2023
[Availability and affordability of diagnosis and treatment for asthma and COPD in Ouagadougou, Burkina Faso].
    Revue des maladies respiratoires, 2023, Volume: 40, Issue:5

    Topics: Albuterol; Asthma; Burkina Faso; Costs and Cost Analysis; Cross-Sectional Studies; Health Services A

2023
New Combination Asthma Drug.
    The American journal of nursing, 2023, 05-01, Volume: 123, Issue:5

    Topics: Albuterol; Asthma; Budesonide; Drug Combinations; Humans

2023
Calcium-Sensing Receptor Negative Allosteric Modulators Oppose Contraction of Mouse Airways.
    American journal of respiratory cell and molecular biology, 2023, Volume: 69, Issue:2

    Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Guinea Pigs; HEK293 Cells; Humans; Methacholine C

2023
Comparison of associations of household-level and neighbourhood-level poverty markers with paediatric asthma care utilisation by race/ethnicity in an open cohort of community health centre patients.
    Family medicine and community health, 2023, Volume: 11, Issue:3

    Topics: Albuterol; Asthma; Child; Ethnicity; Humans; Income; Poverty

2023
Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma.
    Respiratory medicine, 2023, Volume: 218

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Obesity; P

2023
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2023, 09-01, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Developing Countries; Humans; Pr

2023
Utilization and Spending With Preventive Drug Lists for Asthma Medications in High-Deductible Health Plans.
    JAMA network open, 2023, 08-01, Volume: 6, Issue:8

    Topics: Adult; Albuterol; Asthma; Case-Control Studies; Deductibles and Coinsurance; Female; Humans; Male

2023
Gamma irradiation effect on some asthma drugs: EPR detection of radiosterilization.
    Radiation protection dosimetry, 2023, Sep-18, Volume: 199, Issue:14

    Topics: Albuterol; Asthma; Electron Spin Resonance Spectroscopy; Gamma Rays; Government Agencies; Humans

2023
Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways.
    Respiratory research, 2023, Oct-31, Volume: 24, Issue:1

    Topics: 1-Methyl-3-isobutylxanthine; Acetylcholine; Albuterol; Amitriptyline; Animals; Asthma; Bronchoconstr

2023
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
    Pediatrics, 2023, Dec-01, Volume: 152, Issue:Suppl 3

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Double-Blind Metho

2023
Clinical significance of the bronchodilator response in children with severe asthma.
    Pediatric pulmonology, 2019, Volume: 54, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Cohort Studies; Cross-Sec

2019
Evaluation of Disposable and Traditional Accessory Devices for Use With a Pressurized Metered-Dose Inhaler.
    Respiratory care, 2020, Volume: 65, Issue:3

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery System

2020
Bronchodilation Test with Inhaled Salbutamol Versus Bronchial Methacholine Challenge to Make an Asthma Diagnosis: Do They Provide the Same Information?
    The journal of allergy and clinical immunology. In practice, 2020, Volume: 8, Issue:2

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Forced Expiratory Volume; Humans; Methacholine Chlor

2020
Case report: Paradoxical responses to short acting beta-agonists in a pediatric patient.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2021, Volume: 58, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans

2021
Anti-inflammatory reliever therapy for asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2020, Volume: 124, Issue:1

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bron

2020
Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.
    The journal of allergy and clinical immunology. In practice, 2020, Volume: 8, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans; Quali

2020
Prehospital management of pediatric asthma patients in a large emergency medical services system.
    Pediatric pulmonology, 2020, Volume: 55, Issue:1

    Topics: Adolescent; Albuterol; Anaphylaxis; Asthma; Child; Emergency Medical Services; Female; Humans; Infus

2020
]Risk of dental caries in pediatric asthmatic patients undergoing treatment with salbutamol and budesonide inhalation therapy, Peru.]
    Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2019, 11-27, Volume: 76, Issue:4

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Case-Control Studi

2019
Incidence of supraventricular tachycardia after inhaled short-acting beta agonist treatment in children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2021, Volume: 58, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Body Mass Index; Child; Child, Preschool; Fe

2021
Telehealth delivery of adherence and medication management system improves outcomes in inner-city children with asthma.
    Pediatric pulmonology, 2020, Volume: 55, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Male; Medication Adhere

2020
Functional characterization of 3D contractile smooth muscle tissues generated using a unique microfluidic 3D bioprinting technology.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020, Volume: 34, Issue:1

    Topics: Albuterol; Asthma; Bioprinting; Cells, Cultured; Humans; Microfluidics; Muscle Contraction; Muscle,

2020
An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles.
    Drug design, development and therapy, 2019, Volume: 13

    Topics: A549 Cells; Albuterol; Animals; Asthma; Drug Delivery Systems; Drug Stability; Humans; Injections, I

2019
Lessons of the month 1: Salbutamol induced lactic acidosis: clinically recognised but often forgotten.
    Clinical medicine (London, England), 2020, Volume: 20, Issue:1

    Topics: Acidosis, Lactic; Administration, Inhalation; Aged, 80 and over; Albuterol; Asthma; Female; Humans

2020
Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country.
    Pediatric pulmonology, 2020, Volume: 55, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Colombia; Cost-Benefit

2020
Asthmatic children and MDI verbal inhalation technique counseling.
    Pulmonary pharmacology & therapeutics, 2020, Volume: 61

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Child; Counseling; Female

2020
Air Trapping Correlates With Increased Frequency of Albuterol Use and Severity of Wheeze in Persistent Asthma.
    Respiratory care, 2020, Volume: 65, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Metered Do

2020
Prevalence of asthma at a school-based health clinic in Nicaragua.
    Journal for specialists in pediatric nursing : JSPN, 2020, Volume: 25, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Hospitalizati

2020
Finger-Prick Blood Sampling for Therapeutic Drug Monitoring: Be Aware of Skin Contamination by Nebulized Drugs.
    Therapeutic drug monitoring, 2020, Volume: 42, Issue:3

    Topics: Albuterol; Asthma; Blood Specimen Collection; Bronchodilator Agents; Child; Drug Monitoring; Humans;

2020
Investigation of the Interaction Mechanism between Salbutamol and Human Serum Albumin by Multispectroscopic and Molecular Docking.
    BioMed research international, 2020, Volume: 2020

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Humans; Molecular Docking Simulation; Recept

2020
Clinical Progress Note: Care of Children Hospitalized for Acute Asthma Exacerbation.
    Journal of hospital medicine, 2020, 07-01, Volume: 15, Issue:7

    Topics: Acute Disease; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; Child, Hos

2020
Novel measure of lung function for assessing disease activity in asthma.
    BMJ open respiratory research, 2020, Volume: 7, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Female; Forced Expirato

2020
Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020, Apr-30, Volume: 147

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodila

2020
Benzalkonium Chloride in Albuterol Solutions: Time for a Change?
    Pediatrics, 2020, Volume: 145, Issue:4

    Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchodilator Agents; Child; Humans; Longitudinal Studie

2020
Continuous Albuterol With Benzalkonium in Children Hospitalized With Severe Asthma.
    Pediatrics, 2020, Volume: 145, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Benzalkonium Compounds; Bronchodilator Ag

2020
Preventing Asthma Emergencies in Schools.
    Pediatrics, 2020, Volume: 145, Issue:4

    Topics: Advisory Committees; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Storage; Emergencies; Gov

2020
Acute salbutamol bronchoprotection against methacholine: Asthma compared with chronic obstructive pulmonary disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2020, Volume: 124, Issue:6

    Topics: Albuterol; Asthma; Bronchoconstrictor Agents; Disease Management; Female; Humans; Male; Methacholine

2020
Prevalence and risk factors for wheeze, decreased forced expiratory volume in 1 s and bronchoconstriction in young children living in Havana, Cuba: a population-based cohort study.
    BMJ open, 2020, 04-22, Volume: 10, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchoconstriction; Broncho

2020
What constitutes a "clinically significant" bronchodilator response in children?
    The European respiratory journal, 2020, Volume: 55, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans

2020
Effect of long-acting β-agonist on bronchodilator response in children with asthma.
    The European respiratory journal, 2020, Volume: 56, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chil

2020
Clinical course of asthma in 4 cases of coronavirus disease 2019 infection.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2020, Volume: 125, Issue:2

    Topics: Acetates; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Betacoronavirus; Black or African America

2020
COVID-19: Time to embrace MDI+ valved-holding chambers!
    The Journal of allergy and clinical immunology, 2020, Volume: 146, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Betacoronavirus; Bronchodilator Agents; Coronavirus I

2020
Thunderstorm asthma medication management during an external emergency (Code Brown): An observational study of the impact of electronic prescribing and clinical documentation.
    Australasian emergency care, 2020, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Documentation; Electronic

2020
Global Initiative for Asthma 2019 Guidelines: New Changes to the Treatment of Mild Asthmatics 12 Years and Older.
    Irish medical journal, 2020, 05-07, Volume: 113, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2020
Relationship between age and bronchodilator response at diagnosis in adult-onset asthma.
    Respiratory research, 2020, Jul-13, Volume: 21, Issue:1

    Topics: Administration, Inhalation; Adult; Age of Onset; Aged; Albuterol; Asthma; Bronchial Provocation Test

2020
Study finds poorer asthma outcomes with preservative-containing nebulization solution.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, 07-23, Volume: 77, Issue:15

    Topics: Administration, Inhalation; Albuterol; Asthma; Benzalkonium Compounds; Humans; Nebulizers and Vapori

2020
Levodopa inhalation powder in a patient with persistent asthma.
    Parkinsonism & related disorders, 2020, Volume: 78

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dopamine Agents; Dry Powder In

2020
A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2021, Volume: 58, Issue:11

    Topics: Adolescent; Albuterol; Altitude; Asthma; Bronchodilator Agents; Child; Female; Humans; Male; Oscillo

2021
Adult Patients with Respiratory Distress: Current Evidence-based Recommendations for Prehospital Care.
    The western journal of emergency medicine, 2020, Jun-25, Volume: 21, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; California; Dyspnea; Emergency Medical Services; Ho

2020
Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma.
    The clinical respiratory journal, 2021, Volume: 15, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Oscillometry; Spirometry

2021
Parental attitude and knowledge towards asthma care measures for their children in Saudi Arabia.
    Pediatric pulmonology, 2020, Volume: 55, Issue:11

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Child; Child, Preschool; Female; Health Education

2020
Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils.
    Minerva pediatrics, 2021, Volume: 73, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Case-Control Studies; Cell Count; Chemokine CC

2021
Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2022, Volume: 59, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospitalization; Humans; Intensive Care Unit

2022
Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma.
    Respiratory care, 2021, Volume: 66, Issue:1

    Topics: Albuterol; Asthma; Child; Hospitalization; Humans; Prospective Studies; Status Asthmaticus

2021
Prevalence and risk factors of lactic acidosis in children with acute moderate and severe asthma, a prospective observational study.
    European journal of pediatrics, 2021, Volume: 180, Issue:4

    Topics: Acidosis, Lactic; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Prevalence; Risk F

2021
CAN BURST VENTOLIN THERAPY BE SAFELY GIVEN AT HOME TO REDUCE EMERGENCY AND HOSPITAL PRESENTATIONS WITH ASTHMA IN CHILDREN?
    Journal of paediatrics and child health, 2020, Volume: 56, Issue:10

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Hospitals; Humans

2020
Clinical Outcomes in People with Difficult-to-Control Asthma Using Electronic Monitoring to Support Medication Adherence.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Drug Combina

2021
Health provider perspectives of electronic medication monitoring in outpatient asthma care: a qualitative investigation using the consolidated framework for implementation research.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2022, Volume: 59, Issue:2

    Topics: Albuterol; Asthma; Child; Electronics; Humans; Outpatients; Primary Health Care; Qualitative Researc

2022
Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program.
    JAMA, 2020, 12-08, Volume: 324, Issue:22

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be

2020
Variability in care for children with severe acute asthma in Latin America.
    Pediatric pulmonology, 2021, Volume: 56, Issue:2

    Topics: Adolescent; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Bronchodilator Agents; Cannula;

2021
Large-volume, preservative-free albuterol concentrate.
    The Medical letter on drugs and therapeutics, 2020, 11-02, Volume: 62, Issue:1610

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Preservatives, Pharmaceutic

2020
Implementation of a Critical Asthma Protocol in a Pediatric ICU.
    Respiratory care, 2021, Volume: 66, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Intensive Car

2021
Managing respiratory emergencies at school: A county-wide stock inhaler program.
    The Journal of allergy and clinical immunology, 2021, Volume: 148, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Arizona; Asthma; Child; Emergencies; Female; Huma

2021
It is high time for the scholarly societies to standardize the bronchodilator responsiveness in children.
    Allergologia et immunopathologia, 2021, Volume: 49, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Methacholine Chloride; Nitric Oxide; Spirom

2021
[Induced asthma and sport].
    La Revue du praticien, 2020, Volume: 70, Issue:9

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Doping in Sports; Humans; Sports

2020
Evaluating the impact of coronavirus disease 2019 on asthma morbidity: A comprehensive analysis of potential influencing factors.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021, Volume: 127, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; California; Child; Child, Preschool; COVID-1

2021
High-Flow Nasal Cannula in Pediatric Critical Asthma.
    Respiratory care, 2021, Volume: 66, Issue:8

    Topics: Adolescent; Albuterol; Asthma; Cannula; Child; Child, Preschool; Humans; Nebulizers and Vaporizers;

2021
Heterogeneity of emergency treatment practices in wheezing preschool children.
    Acta paediatrica (Oslo, Norway : 1992), 2021, Volume: 110, Issue:8

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Cross-Sectional Studies; Emergency Treat

2021
Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:10

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Colombia; C

2021
Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol.
    Journal of health care for the poor and underserved, 2021, Volume: 32, Issue:2

    Topics: Albuterol; Asthma; Child; Humans; Pharmaceutical Services; Schools; Students

2021
Role of social deprivation on asthma care quality among a cohort of children in US community health centres.
    BMJ open, 2021, 06-23, Volume: 11, Issue:6

    Topics: Albuterol; Asthma; Child; Cohort Studies; Community Health Centers; Humans; Residence Characteristic

2021
Is Delivery of Aerosolized Medication via HFNC for Critical Asthma Effective Concurrent Therapy?
    Respiratory care, 2021, Volume: 66, Issue:8

    Topics: Albuterol; Asthma; Humans; Nebulizers and Vaporizers

2021
[Guideline on diagnosis and treatment: bronchial asthma in children ≥ 6 years old. Update 2021].
    Archivos argentinos de pediatria, 2021, Volume: 119, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child

2021
Pharmacology Update: Emergency and Controller Medications for Treatment of Asthma.
    NASN school nurse (Print), 2022, Volume: 37, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Nebulizers and

2022
Asthma in Singapore: Past, Present and Future.
    Annals of the Academy of Medicine, Singapore, 2017, Volume: 46, Issue:3

    Topics: Adrenal Cortex Hormones; Albuterol; Arsenic Poisoning; Asthma; Bronchodilator Agents; Developed Coun

2017
Modeling Seasonal and Spatiotemporal Variation: The Example of Respiratory Prescribing.
    American journal of epidemiology, 2017, Jul-01, Volume: 186, Issue:1

    Topics: Age Distribution; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Uti

2017
Regional Ventilation Changes in the Lung: Treatment Response Mapping by Using Hyperpolarized Gas MR Imaging as a Quantitative Biomarker.
    Radiology, 2017, Volume: 284, Issue:3

    Topics: Adult; Aged; Albuterol; Algorithms; Asthma; Biomarkers; Bronchodilator Agents; Female; Helium; Human

2017
Small airway function before and after cold dry air challenge in pediatric asthma patients during remission.
    Pediatric pulmonology, 2017, Volume: 52, Issue:7

    Topics: Adolescent; Air; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Cold Temperature; Ex

2017
Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma - Impact on salbutamol transport.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Aug-30, Volume: 106

    Topics: Albuterol; Allergens; Asthma; Biological Transport; Bronchi; Bronchodilator Agents; Cell Culture Tec

2017
Free-breathing Functional Pulmonary MRI: Response to Bronchodilator and Bronchoprovocation in Severe Asthma.
    Academic radiology, 2017, Volume: 24, Issue:10

    Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Female; Humans; Image Pr

2017
Value-Based Insurance Design Pharmacy Benefits for Children and Youth With Special Health Care Needs: Principles and Opportunities.
    Pediatrics, 2017, Volume: 139, Issue:Suppl 2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Disabled Children; Drug Costs; Humans; Insurance Co

2017
Self-reported racial/ethnic discrimination and bronchodilator response in African American youth with asthma.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Case-Control Studie

2017
The Weekday Wheezer.
    Clinical pediatrics, 2017, Volume: 56, Issue:9

    Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Child; Diagnosis, Differential; Fluticasone; Guin

2017
Study of pH Stability of R-Salbutamol Sulfate Aerosol Solution and Its Antiasthmatic Effects in Guinea Pigs.
    Biological & pharmaceutical bulletin, 2017, Sep-01, Volume: 40, Issue:9

    Topics: Aerosols; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chemistry, Pharm

2017
Mycoplasma pneumoniae-Associated Bronchiolitis Obliterans Following Acute Bronchiolitis.
    Scientific reports, 2017, 08-16, Volume: 7, Issue:1

    Topics: Albuterol; Asthma; Bronchiolitis; Bronchiolitis Obliterans; Child; Child, Preschool; Female; Humans;

2017
Small airway oscillometry indices: Repeatability and bronchodilator responsiveness in young children.
    Pediatric pulmonology, 2017, Volume: 52, Issue:10

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; Lung; Male; Oscil

2017
Racial/Ethnic Variation in Emergency Department Care for Children With Asthma.
    Pediatric emergency care, 2019, Volume: 35, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross-Sectional Studi

2019
Stevens-Johnson syndrome secondary to isolated albuterol use.
    Cutis, 2017, Volume: 100, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Diagnosis, Differential; Human

2017
Efficacy and usability of a novel nebulizer targeting both upper and lower airways.
    Italian journal of pediatrics, 2017, Sep-29, Volume: 43, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilato

2017
Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma.
    Paediatric and perinatal epidemiology, 2018, Volume: 32, Issue:1

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Et

2018
Many patients labelled as having mild asthma do not have well-controlled asthma.
    Respirology (Carlton, Vic.), 2018, Volume: 23, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans

2018
Breathing pattern recordings using respiratory inductive plethysmography, before and after a physiotherapy breathing retraining program for asthma: A case report.
    Physiotherapy theory and practice, 2018, Volume: 34, Issue:4

    Topics: Albuterol; Anxiety; Asthma; Breathing Exercises; Bronchodilator Agents; Depression; Female; Forced E

2018
Long-term prognosis of chronic cough: a prospective, observational cohort study.
    BMC pulmonary medicine, 2017, Nov-21, Volume: 17, Issue:1

    Topics: Aged; Albuterol; Asthma; Bronchial Provocation Tests; Chronic Disease; Comorbidity; Cough; Female; F

2017
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
    Chest, 2018, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent

2018
Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2018, Volume: 55, Issue:11

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Specimen Collection; Child; Dose

2018
Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective.
    BMC pulmonary medicine, 2017, Dec-08, Volume: 17, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm

2017
Translating Research into Health Policy: Stock Albuterol Legislation.
    Annals of the American Thoracic Society, 2018, Volume: 15, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Health Policy; Humans; Nebulizers and V

2018
Repeated doses of salbutamol and aeroallergen sensitisation both increased salbutamol-induced hypoxia in children and adolescents with acute asthma.
    Acta paediatrica (Oslo, Norway : 1992), 2018, Volume: 107, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi

2018
Food and Drug Administration-mandated Trials of Long-Acting β-Agonist Safety in Asthma. Bang for the Buck?
    American journal of respiratory and critical care medicine, 2018, 04-15, Volume: 197, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Drug

2018
Everyone with asthma should have a metered dose inhaler and a spacer.
    BMJ (Clinical research ed.), 2018, 02-15, Volume: 360

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Metered Dose Inhalers;

2018
Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma.
    American journal of respiratory and critical care medicine, 2018, 06-15, Volume: 197, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Child; Female; Geno

2018
The acute effects of bronchial thermoplasty on FEV
    Respiratory medicine, 2018, Volume: 137

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Albu

2018
Children with severe acute asthma admitted to Dutch PICUs: A changing landscape.
    Pediatric pulmonology, 2018, Volume: 53, Issue:7

    Topics: Acute Disease; Administration, Intravenous; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Ca

2018
Access to asthma medicines at the household level in eight counties of Kenya.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018, 05-01, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Family Characteristics; Female; Health

2018
Sample Size Determination for a 3-Treatment 3-Period Crossover Trial in Frequency Data.
    Therapeutic innovation & regulatory science, 2018, Volume: 52, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Cross-Over Studies; Humans; Mont

2018
Should reversibility be assessed in all asthmatic children with normal spirometry?
    The European respiratory journal, 2018, Volume: 52, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Databases,

2018
Exertional dyspnea and operating lung volumes in asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2018, 09-01, Volume: 125, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Dyspne

2018
Beware of beta! A case of salbutamol-induced lactic acidosis in severe asthma.
    BMJ case reports, 2018, Jun-17, Volume: 2018

    Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al

2018
1064 nm Dispersive Raman Microspectroscopy and Optical Trapping of Pharmaceutical Aerosols.
    Analytical chemistry, 2018, 08-07, Volume: 90, Issue:15

    Topics: Aerosols; Albuterol; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Equipment Design; Fluoresc

2018
Prevalence of paradoxical bronchoconstriction after inhaled albuterol.
    Respiratory medicine, 2018, Volume: 141

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchoconstrict

2018
Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors.
    Clinical and experimental immunology, 2018, Volume: 194, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Cells, Cultured; Cyclic AMP; Disease Progression; Fibrobla

2018
Asthma Severity Pathway in the PICU.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2018, Volume: 19, Issue:8

    Topics: Albuterol; Asthma; Humans; Intensive Care Units, Pediatric; Length of Stay; Retrospective Studies; S

2018
Clinical differences between children with asthma and rhinitis in rural and urban areas.
    Colombia medica (Cali, Colombia), 2018, Jun-30, Volume: 49, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Colombia; Emergency Service, Hospital;

2018
The Usefulness of the Forced Oscillation Technique in the Diagnosis of Bronchial Asthma in Children.
    Canadian respiratory journal, 2018, Volume: 2018

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Pre

2018
Quantifying beta-agonist utilization: Occasions or puffs?
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administr

2019
Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy.
    Journal of liposome research, 2019, Volume: 29, Issue:4

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Delayed-Action Preparations; Drug Compoundi

2019
Paradoxical Bronchoconstriction with Short-Acting Beta Agonist.
    The American journal of case reports, 2018, Oct-09, Volume: 19

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Airway Remodeling; Albuterol; Asthma; Bronchoconstrictio

2018
Free to breathe hard in the Tour de France.
    Lancet (London, England), 2018, 09-29, Volume: 392, Issue:10153

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bicycling; Bronchodilator Agents; Confoundin

2018
Measuring the effects of bronchial thermoplasty using oscillometry.
    Respirology (Carlton, Vic.), 2019, Volume: 24, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Thermoplasty; Broncho

2019
Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017.
    Thorax, 2019, Volume: 74, Issue:7

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Drug Thera

2019
Errors in Aerosol Inhaler Use and Their Effects on Maternal and Fetal Outcomes among Pregnant Asthmatic Women (Subanalysis from QAKCOP Study).
    Canadian respiratory journal, 2018, Volume: 2018

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Budesonide,

2018
Anti-asthmatic activity of alkaloid compounds from Pericarpium Citri Reticulatae (Citrus reticulata 'Chachi').
    Food & function, 2019, Feb-20, Volume: 10, Issue:2

    Topics: Albuterol; Alkaloids; Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Citrus; Female;

2019
The effect of single pretreatment with salbutamol on recovery of bronchoalveolar lavage fluid in horses with suspected or confirmed severe equine asthma.
    Journal of veterinary internal medicine, 2019, Volume: 33, Issue:2

    Topics: Albuterol; Animals; Asthma; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchodilator Age

2019
A Statewide Study of the Epidemiology of Emergency Medical Services' Management of Pediatric Asthma.
    Pediatric emergency care, 2021, Nov-01, Volume: 37, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergency Medical Services; Humans; Ipratrop

2021
How to diagnose and treat acute asthma.
    CJEM, 2019, Volume: 21, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Emergenc

2019
Jailhouse self-induced lesions by misuse of salbutamol inhaler.
    International journal of dermatology, 2019, Volume: 58, Issue:9

    Topics: Aerosols; Albuterol; Asthma; Black or African American; Cold Temperature; Humans; Hypopigmentation;

2019
Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
    Archivos argentinos de pediatria, 2019, 04-01, Volume: 117, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Female; Humans

2019
Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
    Respirology (Carlton, Vic.), 2019, Volume: 24, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2019
A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit.
    Respiratory care, 2019, Volume: 64, Issue:11

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Clinical Protocols; C

2019
Neutrophilic inflammation in asthma and defective epithelial translational control.
    The European respiratory journal, 2019, Volume: 54, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Hyperreactiv

2019
Regional airflow obstruction after bronchoconstriction and subsequent bronchodilation in subjects without pulmonary disease.
    Journal of applied physiology (Bethesda, Md. : 1985), 2019, 07-01, Volume: 127, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricti

2019
Impact of SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of phenylephrine and salbutamol by human SULT1A3 allozymes.
    Pharmacogenetics and genomics, 2019, Volume: 29, Issue:5

    Topics: Albuterol; Arylsulfotransferase; Asthma; Genotype; Humans; Hypotension; Isoenzymes; Kinetics; Mutage

2019
Let Them Breathe: A Plea to Pediatricians to Advocate for Stock Inhaler Policies at School.
    Pediatrics, 2019, Volume: 144, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergencies; Health Policy; Humans; Nebulizers and

2019
Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
    The European respiratory journal, 2019, Volume: 54, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2019
I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements.
    Lung, 2019, Volume: 197, Issue:4

    Topics: Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Female; Forced

2019
Acute effects of salbutamol on systemic vascular function in people with asthma.
    Respiratory medicine, 2019, Volume: 155

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Blood Pre

2019
Ultra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landed.
    Archivos de bronconeumologia, 2013, Volume: 49, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Ethanolamines; F

2013
[Clinical significance of bronchial reversibility test in the treatment of childhood asthma].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2013, Volume: 15, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Asthma; Bronchi; Child; Drug Comb

2013
Volatile anesthetic rescue therapy in children with acute asthma: innovative but costly or just costly?.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2013, Volume: 14, Issue:4

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Anesthesia, Inhalation; Anesthetics, Inh

2013
Evaluating a clinical practice intervention to promote delivery of salbutamol by metered-dose inhalers with holding chambers in a pediatric emergency department.
    CJEM, 2013, Volume: 15, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment Design; Follo

2013
[Cushing's syndrome during HIV treatment: pharmacological interaction during use of ritonavir].
    Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:14

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cushing Syndrome; Cytochrome P-450

2013
Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 110, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Argentina; Asthma; Child; Disease Progre

2013
Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration.
    Current pharmaceutical design, 2013, Volume: 19, Issue:37

    Topics: Absorption; Administration, Oral; Albuterol; Animals; Asthma; Biological Availability; Bronchodilato

2013
Corticosteroid therapy in critically ill pediatric asthmatic patients.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2013, Volume: 14, Issue:5

    Topics: Administration, Intravenous; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Canada;

2013
Teaching corner: Adult asthma in Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2011, Volume: 23, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Clinical Compe

2011
An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005-2011.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Andro

2013
Use of magnesium in moderating tachycardia in acute severe asthma in pregnancy.
    British journal of anaesthesia, 2013, Volume: 110, Issue:6

    Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Female; Humans; Magnes

2013
Role of interactions in pharmacogenetic studies: leukotrienes in asthma.
    Pharmacogenomics, 2013, Volume: 14, Issue:8

    Topics: Albuterol; Alleles; Asthma; Biomarkers, Pharmacological; Bronchodilator Agents; Gene-Environment Int

2013
Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren.
    Pediatric pulmonology, 2014, Volume: 49, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Disease Progression; Emergency Service,

2014
Asthma, steroids, and surveys…science or merely my opinion?
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2013, Volume: 14, Issue:5

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Critical Illness; Humans; Methylprednisolone; Practice P

2013
Long acting β2 agonists in adult asthma.
    BMJ (Clinical research ed.), 2013, Aug-06, Volume: 347

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Drug Monitor

2013
Rapid and severe adverse reaction to adenosine during a pharmacological stress test for a myocardial perfusion scan.
    Clinical nuclear medicine, 2013, Volume: 38, Issue:9

    Topics: Adenosine; Albuterol; Asthma; Electrocardiography; Exercise Test; Humans; Male; Middle Aged; Myocard

2013
[Inadequate use of inhalers among asma patients who use Salbutamol].
    Revista peruana de medicina experimental y salud publica, 2013, Volume: 30, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Medication Errors; Nebulizers and Vaporizers

2013
A genome-wide association study of bronchodilator response in Latinos implicates rare variants.
    The Journal of allergy and clinical immunology, 2014, Volume: 133, Issue:2

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Genome

2014
Management of acute asthma in the emergency department.
    Emergency medicine practice, 2013, Volume: 15, Issue:6

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Humans; Ipratr

2013
Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis.
    Primary care respiratory journal : journal of the General Practice Airways Group, 2013, Volume: 22, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; A

2013
The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
    PharmacoEconomics, 2013, Volume: 31, Issue:11

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Budesonide; Cross-Sectional Studies; Data

2013
Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients.
    Primary care respiratory journal : journal of the General Practice Airways Group, 2013, Volume: 22, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A

2013
Prostaglandin E2 elicits greater bronchodilation than salbutamol in mouse intrapulmonary airways in lung slices.
    Pulmonary pharmacology & therapeutics, 2014, Volume: 28, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchodilator Agents; Calcium; Din

2014
Association between respiratory prescribing, air pollution and deprivation, in primary health care.
    Journal of public health (Oxford, England), 2013, Volume: 35, Issue:4

    Topics: Adult; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Female; Humans;

2013
LABA monotherapy in asthma: an avoidable problem.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2013, Volume: 63, Issue:617

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A

2013
A young girl with apparent treatment-resistant asthma treated at Bambino Gesù children's hospital.
    Thorax, 2014, Volume: 69, Issue:4

    Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child; Diagnosis, Differential; Drug Resistanc

2014
[Lactic acidosis after inhaled beta-2 agonists: about 2 cases].
    Annales francaises d'anesthesie et de reanimation, 2014, Volume: 33, Issue:1

    Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma

2014
The interpretation of exhaled nitric oxide values in children with asthma depends on the degree of bronchoconstriction and the levels of asthma severity.
    Respiratory care, 2014, Volume: 59, Issue:9

    Topics: Adolescent; Albuterol; Asthma; Biomarkers; Breath Tests; Bronchoconstriction; Bronchodilator Agents;

2014
Serum lactate increase during acute asthma treatment: a new piece of the puzzle.
    Chest, 2014, Volume: 145, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male

2014
Salmeterol and lactic acidosis: clinical and educational aspects.
    CJEM, 2014, Volume: 16, Issue:1

    Topics: Acidosis, Lactic; Albuterol; Androstadienes; Asthma; Drug Overdose; Female; Humans; Intention; Lacti

2014
Notes on testing equality and interval estimation in Poisson frequency data under a three-treatment three-period crossover trial.
    Statistical methods in medical research, 2016, Volume: 25, Issue:5

    Topics: Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Least-Squares Analysis;

2016
A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formoterol and salmeterol/fluticasone.
    Allergology international : official journal of the Japanese Society of Allergology, 2014, Volume: 63, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes

2014
Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy.
    World journal of pediatrics : WJP, 2014, Volume: 10, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma;

2014
Bronchial obstruction and reversibility in children: inspiratory or expiratory resistance?
    The European respiratory journal, 2014, Volume: 44, Issue:1

    Topics: Airway Obstruction; Albuterol; Asthma; Bronchial Diseases; Bronchodilator Agents; Case-Control Studi

2014
Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2014, Volume: 112, Issue:5

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Ag

2014
Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients.
    Current medical research and opinion, 2014, Volume: 30, Issue:7

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Andr

2014
Mechanical factors affecting nebulized albuterol aerosol particle sizes for asthma drug delivery.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:6

    Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Nebulizers a

2014
SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels?
    Drug testing and analysis, 2015, Volume: 7, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Arylsulfotransferase; Asthma;

2015
Adrenal suppression with mometasone furoate/formoterol.
    Chest, 2014, Volume: 145, Issue:5

    Topics: Albuterol; Androstadienes; Asthma; Ethanolamines; Female; Humans; Hypothalamo-Hypophyseal System; Ma

2014
Thyrotoxic periodic paralysis triggered by β2-adrenergic bronchodilators.
    CJEM, 2014, Volume: 16, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodi

2014
An unusual mechanism of foreign body aspiration: a vignette from the emergency department.
    BMJ case reports, 2014, May-23, Volume: 2014

    Topics: Albuterol; Asthma; Bronchodilator Agents; Bronchoscopy; Emergency Service, Hospital; Foreign Bodies;

2014
Too much testing?
    Chest, 2014, Volume: 145, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male

2014
Response.
    Chest, 2014, Volume: 145, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male

2014
Nocturnal asthma and the importance of race/ethnicity and genetic ancestry.
    American journal of respiratory and critical care medicine, 2014, Aug-01, Volume: 190, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Black or African American; Body Mass Index; Br

2014
Addressing ethnic disparity in asthma trials.
    Respirology (Carlton, Vic.), 2014, Volume: 19, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Ethanolamines; Female; Formoterol Fumarate; Hu

2014
Understanding nocturnal asthma. The plot thickens.
    American journal of respiratory and critical care medicine, 2014, Aug-01, Volume: 190, Issue:3

    Topics: Albuterol; Asthma; Black or African American; Female; Forced Expiratory Volume; Humans; Male; Pharma

2014
Clinical application of inert gas Multiple Breath Washout in children and adolescents with asthma.
    Respiratory medicine, 2014, Volume: 108, Issue:9

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Breath Tests; Bronchodilator Age

2014
An innovative childhood asthma score predicts the need for bronchodilator nebulization in children with acute asthma independent of auscultative findings.
    Respiratory care, 2014, Volume: 59, Issue:11

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Auscultation; Bronchodilat

2014
The orl rat is more responsive to methacholine challenge than wild type.
    Pulmonary pharmacology & therapeutics, 2014, Volume: 29, Issue:2

    Topics: Administration, Inhalation; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoconstrictor Ag

2014
Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?
    Thorax, 2015, Volume: 70, Issue:1

    Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Child, Pr

2015
Airway obstruction, upper airway artifact and response to bronchodilator in asthmatic and healthy children.
    Pediatric pulmonology, 2015, Volume: 50, Issue:11

    Topics: Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Huma

2015
Peripheral airways dysfunction in obesity reflects increased bronchomotor tone.
    The Journal of allergy and clinical immunology, 2015, Volume: 135, Issue:3

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Obesity; R

2015
Molecular insights into the dynamics of pharmacogenetically important N-terminal variants of the human β2-adrenergic receptor.
    PLoS computational biology, 2014, Volume: 10, Issue:12

    Topics: Albuterol; Asthma; Binding Sites; Humans; Molecular Dynamics Simulation; Pharmacogenetics; Polymorph

2014
[Reaction of population of pulmonary mast cells in rat bronchial asthma under the effect of β-adrenoreceptor antagonists].
    Tsitologiia, 2013, Volume: 55, Issue:7

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alcian Blue; Animals; Anti-Asthmat

2013
Clinical outcomes after bilevel positive airway pressure treatment for acute asthma exacerbations.
    JAMA pediatrics, 2015, Volume: 169, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Continuous Positive A

2015
Identification of high affinity bioactive Salbutamol conformer directed against mutated (Thr164Ile) beta 2 adrenergic receptor.
    Current topics in medicinal chemistry, 2015, Volume: 15, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Amino Acid Substi

2015
Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?
    Archives of disease in childhood. Education and practice edition, 2015, Volume: 100, Issue:4

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Humans

2015
How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up.
    BMC health services research, 2015, Jan-28, Volume: 15

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Chil

2015
Safety of β2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice.
    The AAPS journal, 2015, Volume: 17, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Forced Expiratory Vol

2015
Reversibility after inhaling salbutamol in different body postures in asthmatic children: a pilot study.
    Respiratory medicine, 2015, Volume: 109, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Monito

2015
Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2015, Volume: 52, Issue:7

    Topics: Age Factors; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Child; Child, Preschool; Dose

2015
Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.
    Chest, 2015, Volume: 147, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Black People; Br

2015
Treasure in the chest.
    BMJ case reports, 2015, Apr-09, Volume: 2015

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Diagnosis, Differential; Female; Foreign Bodie

2015
Not Breathing Easier With the US FDA's Ban on Chlorofluorocarbons in Inhalers.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and

2015
On Chlorofluorocarbon Bans and Inhaled Albuterol Prices.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and

2015
The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Chlorofluorocarbons; Fe

2015
A case of pediatric Steven-Johnson Syndrome associated with albuterol consumption.
    International immunopharmacology, 2015, Volume: 27, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Immunoglobulins, Intravenous; Male; Pharmac

2015
Insulin therapy in hyperglycemic children with severe acute asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2015, Volume: 52, Issue:7

    Topics: Acute Disease; Administration, Intravenous; Adolescent; Albuterol; Asthma; Blood Glucose; Bronchodil

2015
Hypokalaemia in children with asthma treated with nebulised salbutamol.
    Archives of disease in childhood, 2015, Volume: 100, Issue:10

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; Hypokalemia; Infa

2015
Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics.
    Inflammation, 2015, Volume: 38, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodi

2015
Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility.
    The clinical respiratory journal, 2017, Volume: 11, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Alb

2017
HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?
    The Journal of family practice, 2015, Volume: 64, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A

2015
Can 'extrafine' dry powder aerosols improve lung deposition?
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 96

    Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C

2015
Can 'extrafine' dry powder aerosols improve lung deposition?
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 96

    Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C

2015
Can 'extrafine' dry powder aerosols improve lung deposition?
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 96

    Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C

2015
Can 'extrafine' dry powder aerosols improve lung deposition?
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 96

    Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C

2015
A Genome-Wide Association Study of Post-bronchodilator Lung Function in Children with Asthma.
    American journal of respiratory and critical care medicine, 2015, Sep-01, Volume: 192, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Carrier Proteins; Child; Cystic Fibrosi

2015
[Emergency checklist: Asthmatic attack].
    MMW Fortschritte der Medizin, 2015, Sep-10, Volume: 157, Issue:15

    Topics: Adult; Albuterol; Asthma; Checklist; Dyspnea; Emergencies; Female; Humans; Medical History Taking; M

2015
Implementation of a Policy Change: Replacement of Nebulizers by Spacers for the Treatment of Asthma in Children.
    The Israel Medical Association journal : IMAJ, 2015, Volume: 17, Issue:7

    Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2015
Spirometry in children with asthma and/or allergic rhinitis: comparison of FEF25-75% with the standard measures.
    Minerva pediatrica, 2019, Volume: 71, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Female; Forced Ex

2019
Impulse oscillometry in acute and stable asthmatic children: a comparison with spirometry.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Female; Forced Expiratory Volume; Humans; Male; Oscillometry;

2016
An explosive side effect of albuterol nebulizers.
    Surgery, 2015, Volume: 158, Issue:5

    Topics: Abdominal Injuries; Aged; Albuterol; Asthma; Bronchodilator Agents; Explosions; Foreign Bodies; Huma

2015
Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea.
    Allergy, 2016, Volume: 71, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Disease Progression; Dyspnea; Female; Forced Expiratory Volume; Huma

2016
The True Environmental Cost of Chlorofluorocarbon-Based Inhalers.
    JAMA internal medicine, 2015, Volume: 175, Issue:11

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and

2015
Second-order Texture Measurements of (3)He Ventilation MRI: Proof-of-concept Evaluation of Asthma Bronchodilator Response.
    Academic radiology, 2016, Volume: 23, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Area Under Curve; Asthma; Bronchial Provocation Tests;

2016
Long-Acting Beta Agonists Enhance Allergic Airway Disease.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anti-Asthmatic Agents; Arrestins; Aspergill

2015
Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors.
    Journal of immunology (Baltimore, Md. : 1950), 2016, Jan-01, Volume: 196, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Benzoxazines; Cell Adhesion Molecule-1; Cell

2016
Bronchodilator response as a marker of poor asthma control.
    Respiratory medicine, 2016, Volume: 112

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Animals; A

2016
Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    International journal of chronic obstructive pulmonary disease, 2016, Volume: 11

    Topics: Administration, Inhalation; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Cros

2016
Implementation and Evaluation of a Stock Albuterol Program for Students with Asthma.
    Annals of the American Thoracic Society, 2016, Volume: 13, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Nebulizers and Vaporizers; Prog

2016
Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?
    Lung, 2016, Volume: 194, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Air

2016
[Asthma-COPD overlap syndrome].
    Tuberkuloz ve toraks, 2015, Volume: 63, Issue:4

    Topics: Adult; Aged; Albuterol; Asthma; Comorbidity; Disease Progression; Female; Humans; Male; Prevalence;

2015
[Effects and significance of methacholine bronchial provocation tests and salbutamol bronchial dilation test on measurements of fractional exhaled nitric oxide in patients with asthma].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2016, Volume: 39, Issue:3

    Topics: Albuterol; Asthma; Breath Tests; Bronchial Provocation Tests; Exhalation; Humans; Methacholine Chlor

2016
Perception of Bronchodilation Assessed by Visual Analog Scale in Asthmatics: A Real-life Study.
    Journal of investigational allergology & clinical immunology, 2016, Volume: 26, Issue:1

    Topics: Adult; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Female;

2016
Utility of impulse oscillometry in patients with moderate to severe persistent asthma.
    The Journal of allergy and clinical immunology, 2016, Volume: 138, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Female;

2016
ADRB2 Polymorphism and Salbutamol Responsiveness in Northern Indian Children with Mild to Moderate Exacerbation of Asthma.
    Indian pediatrics, 2016, Volume: 53, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross-Sectional Studi

2016
It is time to stop prescribing oral salbutamol.
    Australian family physician, 2016, Volume: 45, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Humans;

2016
Salbutamol in paediatrics: pharmacology, prescribing and controversies.
    Archives of disease in childhood. Education and practice edition, 2016, Volume: 101, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Prescriptions; Female; Humans; Infant;

2016
Measurement of intraindividual airway tone heterogeneity and its importance in asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2016, 07-01, Volume: 121, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Functional Residual Capacity; Humans; Lung;

2016
Manual external chest compression in severe pediatric asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2016, Volume: 53, Issue:6

    Topics: Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child;

2016
Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma.
    Journal of aerosol medicine and pulmonary drug delivery, 2016, Volume: 29, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Agammaglobulinaemia Tyrosine Kinase

2016
Smoke and viruses-a hindrance to relaxing the airways?
    Clinical science (London, England : 1979), 2016, 05-01, Volume: 130, Issue:10

    Topics: Albuterol; Animals; Asthma; Humans; Pulmonary Disease, Chronic Obstructive; Smoke; Viruses

2016
Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2016, Volume: 23, Issue:7

    Topics: Albuterol; Arterial Pressure; Asthma; Bronchodilator Agents; Child; Child, Preschool; Disease Manage

2016
Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Sports medicine (Auckland, N.Z.), 2016, Volume: 46, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; A

2016
Conundrum in an asthma exacerbation.
    BMJ case reports, 2016, May-10, Volume: 2016

    Topics: Acidosis, Lactic; Adrenal Cortex Hormones; Aged; Albuterol; Asthma; Humans; Male; Prednisolone; Trea

2016
Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe.
    Pediatric pulmonology, 2016, Volume: 51, Issue:11

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2016
Tidal changes in respiratory resistance are sensitive indicators of airway obstruction in children.
    Thorax, 2016, Volume: 71, Issue:10

    Topics: Airway Resistance; Albuterol; Anthropometry; Asthma; Bronchodilator Agents; Child; Child, Preschool;

2016
Asthma control and bronchodilator response.
    Respiratory medicine, 2016, Volume: 116

    Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans

2016
Bronchodilator response not a significant marker of poor asthma control.
    Respiratory medicine, 2016, Volume: 116

    Topics: Albuterol; Asthma; Biomarkers; Bronchodilator Agents; Forced Expiratory Volume; Humans

2016
Pressurised metered dose inhaler-spacer technique in young children improves with video instruction.
    European journal of pediatrics, 2016, Volume: 175, Issue:7

    Topics: Administration, Inhalation; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pre

2016
Wastewater-based epidemiological evaluation of the effect of air pollution on short-acting beta-agonist consumption for acute asthma treatment.
    Environmental research, 2016, Volume: 150

    Topics: Adrenergic beta-2 Receptor Agonists; Air Pollutants; Albuterol; Asthma; Bronchodilator Agents; Envir

2016
The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Acute Disease; Administration, Inhalation; Airway Obstruction; Albuterol; Asthma; Double-Blind Metho

2016
Effect of Traditional Chinese Medicine on Inflammatory Mediators in Pediatric Asthma.
    Mediators of inflammation, 2016, Volume: 2016

    Topics: Acetates; Albuterol; Asthma; Child, Preschool; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Fem

2016
Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2017, 01-02, Volume: 54, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Hum

2017
Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma.
    Canadian respiratory journal, 2016, Volume: 2016

    Topics: Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Human

2016
Association of Beta 2 adrenergic receptor (Thr164Ile) polymorphism with Salbutamol refractoriness in severe asthmatics from Indian population.
    Gene, 2016, Oct-30, Volume: 592, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control S

2016
A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia.
    CJEM, 2017, Volume: 19, Issue:1

    Topics: Albuterol; Asthma; Child; Child, Preschool; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Eme

2017
Safety of Long-Acting Beta-Agonists in Children with Asthma.
    The New England journal of medicine, 2016, Sep-01, Volume: 375, Issue:9

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm

2016
Using Hyperpolarized
    Academic radiology, 2016, Volume: 23, Issue:12

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Healthy Volunteers; Humans; Lung; Magnetic

2016
Safety Study of Salmeterol in Asthma in Adults.
    The New England journal of medicine, 2016, 09-15, Volume: 375, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2016
Safety Study of Salmeterol in Asthma in Adults.
    The New England journal of medicine, 2016, 09-15, Volume: 375, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2016
Safety Study of Salmeterol in Asthma in Adults.
    The New England journal of medicine, 2016, 09-15, Volume: 375, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2016
Safety Study of Salmeterol in Asthma in Adults.
    The New England journal of medicine, 2016, 09-15, Volume: 375, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2016
Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population.
    Pediatric pulmonology, 2017, Volume: 52, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cohort Studies; Emerg

2017
Association of emergency department albuterol dispensing with pediatric asthma revisits and readmissions.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2017, Volume: 54, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emergency Service, Hospital; Fema

2017
Within-microenvironment exposure to particulate matter and health effects in children with asthma: a pilot study utilizing real-time personal monitoring with GPS interface.
    Environmental health : a global access science source, 2016, 10-10, Volume: 15, Issue:1

    Topics: Adolescent; Air Pollutants; Albuterol; Asthma; Biomarkers; Child; Cities; Colorado; Computer Systems

2016
Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 120, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A

2017
Takotsubo cardiomyopathy following recurrent doses of albuterol due to asthma attack: a very rare case report.
    Future cardiology, 2016, Volume: 12, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Coronary Angiog

2016
Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation.
    BMJ case reports, 2016, Oct-28, Volume: 2016

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Aminophylline; Asthma; Bronchodilator Agents;

2016
Impact of Copayment Changes on Children's Albuterol Inhaler Use and Costs after the Clean Air Act Chlorofluorocarbon Ban.
    Health services research, 2018, Volume: 53, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Chlorofluorocarbons; Cost Sharing; Female; H

2018
Free asthma medications reduces hospital admissions in Brazil (Free asthma drugs reduces hospitalizations in Brazil).
    Respiratory medicine, 2016, Volume: 121

    Topics: Adolescent; Adult; Age Distribution; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Brazi

2016
Salmeterol and Fluticasone Propionate in Children with Asthma.
    The New England journal of medicine, 2016, 12-01, Volume: 375, Issue:22

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator

2016
Salmeterol and Fluticasone Propionate in Children with Asthma.
    The New England journal of medicine, 2016, 12-01, Volume: 375, Issue:22

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator

2016
[Lactic acidosis in a 24-year-old woman with status asthmaticus].
    Ugeskrift for laeger, 2016, Dec-12, Volume: 178, Issue:50

    Topics: Acidosis, Lactic; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; Humans; Lactates;

2016
Long-acting beta agonists do not increase serious asthma-related event risk.
    The Journal of pediatrics, 2017, Volume: 180

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br

2017
Improved Muscular Weakness During Asthma Exacerbation.
    JAMA neurology, 2017, 03-01, Volume: 74, Issue:3

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Diagnosis, Differential; Electromyography; Humans; Lordosi

2017
Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.
    Journal of aerosol medicine and pulmonary drug delivery, 2017, Volume: 30, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Albuterol; Asthma;

2017
Bilateral acute angle closure developing due to use of ipratropium bromide and salbutamol.
    International ophthalmology, 2018, Volume: 38, Issue:1

    Topics: Albuterol; Antihypertensive Agents; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug;

2018
Effect of an Asthma Guideline in 2 Pediatric Emergency Departments and an Urgent Care Center.
    Pediatric emergency care, 2018, Volume: 34, Issue:10

    Topics: Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilator Agents; Child; Child, Pres

2018
Systematic Review on Efficacy of Magnesium (Intravenous or Nebulized) for Acute Asthma Episodes in Children: Evidence-based Medicine Viewpoint.
    Indian pediatrics, 2017, 02-15, Volume: 54, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Evidence-Based

2017
Systematic Review on Efficacy of Magnesium (Intravenous or Nebulized) for Acute Asthma Episodes in Children: Pediatric Pulmonologist's Viewpoint.
    Indian pediatrics, 2017, 02-15, Volume: 54, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Magnesi

2017
WHY ASTHMA STILL KILLS.
    The Ulster medical journal, 2017, Volume: 86, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Drug Utilization Review; Humans; Nebulizers

2017
Drug safety and salmeterol: the controversy continues.
    Annals of internal medicine, 2008, Jul-01, Volume: 149, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br

2008
Albuterol vs. levalbuterol for asthma treatment in children.
    American family physician, 2008, May-01, Volume: 77, Issue:9

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Humans

2008
A survey of pediatricians' knowledge on asthma management in children.
    Iranian journal of allergy, asthma, and immunology, 2008, Volume: 7, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Child; Clinical Competence; Epinephrine; Female;

2008
Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs.
    Archives of pharmacal research, 2008, Volume: 31, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Aerosols; Airway Resistance; Albuterol; Animals; A

2008
Biochemical markers as a response guide for steroid therapy in asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2008, Volume: 45, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Biomarkers; Breath

2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
    Chest, 2008, Volume: 134, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
    Chest, 2008, Volume: 134, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
    Chest, 2008, Volume: 134, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
    Chest, 2008, Volume: 134, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2008
Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Albuterol; Asth

2008
Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Bronchodilat

2008
When should a reversibility test be performed on patients with early stages of asthma and normal spirometry?
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2008, Volume: 45, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female

2008
Increased use of beta-agonists leading to non-ST-segment elevation myocardial infarction in a patient with hemodynamically significant myocardial bridging.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:8

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Coronary Angiography; Coronary Vessel Anomalies; Electr

2008
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma.
    The European respiratory journal, 2008, Volume: 32, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Albuterol; Androstadienes; Asthma; Cohort Studies; Drug Therapy, Comb

2008
Inhalational diesel exhaust exposure in submariners: observational study.
    Military medicine, 2008, Volume: 173, Issue:7

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Inflammatory A

2008
Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways.
    The Journal of allergy and clinical immunology, 2008, Volume: 122, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents;

2008
[The effects of dose of salbutamol and observation time on bronchodilation test].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2008, Volume: 31, Issue:3

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Dose-Response Relations

2008
Validation of Ramathibodi's acute asthma predictive score.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:8

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; M

2008
A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
    International journal of clinical practice, 2008, Volume: 62, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al

2008
An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes .
    Current medical research and opinion, 2008, Volume: 24, Issue:11

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Asthma; Cohort Studies; Disease

2008
Effect of educational and policy interventions on institutional utilization of wet nebulization respiratory drugs and portable inhalers.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2008,Summer, Volume: 15, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Health Services; Hospital Bed

2008
Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
    Respiratory medicine, 2009, Volume: 103, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Ambulatory Care; Androstadienes; Ast

2009
Asthma/Allergy. FDA advises asthma patients to switch to new Albuterol inhalers.
    Child health alert, 2008, Volume: 26

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporizers; United States; United S

2008
Associations between air pollution and peak expiratory flow among patients with persistent asthma.
    Journal of toxicology and environmental health. Part A, 2009, Volume: 72, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Air; Air Pollutants; Albute

2009
A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population.
    Clinical therapeutics, 2008, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Drug Combination

2008
Final count down to hfa albuterol inhalers: are we ready as yet?
    Clinical pediatrics, 2009, Volume: 48, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Humans; Hydrocarbons, Fluorinated; Me

2009
Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations.
    Chest, 2009, Volume: 135, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Disease Progressio

2009
Misconceptions regarding levalbuterol in the treatment of acute asthma exacerbations in children.
    The American journal of emergency medicine, 2009, Volume: 27, Issue:1

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Humans

2009
[Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
    Arerugi = [Allergy], 2008, Volume: 57, Issue:11

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al

2008
Effectiveness of combination therapies in asthma: an observational study.
    Pulmonary pharmacology & therapeutics, 2009, Volume: 22, Issue:3

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchodi

2009
Complex dream-enacting behavior in sleepwalking.
    Psychosomatic medicine, 2009, Volume: 71, Issue:2

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Consciousness Disorders; Diagnosis, Differential; D

2009
Can beta agonists cause dilated cardiomyopathy?
    Heart, lung & circulation, 2009, Volume: 18, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cardiomyopathy,

2009
Reduction in asthma morbidity following a community-based asthma self-management programme in Tonga.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Disease Management; Emergency Service, Hospital; Female

2009
Safety of long-acting beta-agonists: urgent need to clear the air remains.
    The European respiratory journal, 2009, Volume: 33, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Glucocorticoids; Hu

2009
Levalbuterol kinetics.
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod

2009
Metabolic acidosis, respiratory distress, and children with severe acute asthma.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2009, Volume: 10, Issue:1

    Topics: Acidosis; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Pre

2009
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma].
    Pneumologie (Stuttgart, Germany), 2009, Volume: 63, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin

2009
[Rhabdomyolysis in severe acute asthma].
    Annales francaises d'anesthesie et de reanimation, 2009, Volume: 28, Issue:2

    Topics: Acidosis; Acute Disease; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Combined Modal

2009
[Study of personal best value of peak expiratory flow in patients with asthma--comparison of the highest value of daily PEF under good control and the highest value of daily PEF obtained after using repeated inhaled beta2-agonist during high-dose inhaled
    Arerugi = [Allergy], 2008, Volume: 57, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Humans

2008
Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control.
    American journal of respiratory and critical care medicine, 2009, Feb-15, Volume: 179, Issue:4

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Biomarkers; Bronchitis; Bronchodilator Agents; Common Co

2009
Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in disease management.
    Drugs, 2009, Volume: 69, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent

2009
Are we adequately managing children with wheeze using the standard case management guidelines?
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91 Suppl 3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Bacterial Agents; Asthma; Ausc

2008
Socioeconomic, family, and pediatric practice factors that affect level of asthma control.
    Pediatrics, 2009, Volume: 123, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child

2009
Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.
    Current medical research and opinion, 2009, Volume: 25, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Amino Acid Substitution; Androstadienes; Arginine; Asthm

2009
Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.
    International journal of chronic obstructive pulmonary disease, 2008, Volume: 3, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Diagnosis, Differential; Femal

2008
Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona
    Clinical therapeutics, 2009, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Area Under Curve; Asthma; Bronchodilator Agents;

2009
Increased levels of outdoor air pollutants are associated with reduced bronchodilation in children with asthma.
    Chest, 2009, Volume: 136, Issue:6

    Topics: Adrenergic beta-Agonists; Air Pollutants; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Age

2009
Images in cardiology. Acute myocardial infarction due to coronary vasospasm and salbutamol abuse.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:8

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Coronary Vasospasm; Female; Humans; Myocardial Infa

2009
Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats.
    International archives of allergy and immunology, 2009, Volume: 150, Issue:1

    Topics: Albuterol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Cats; Cytokines; Ma

2009
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma].
    Pneumologie (Stuttgart, Germany), 2009, Volume: 63, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin

2009
Adolescents and asthma: why bother with our meds?
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At

2009
Adolescents and asthma: why bother with our meds?
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At

2009
Adolescents and asthma: why bother with our meds?
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At

2009
Adolescents and asthma: why bother with our meds?
    The Journal of allergy and clinical immunology, 2009, Volume: 123, Issue:6

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At

2009
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma. Comment of the German Airway League and the German Respiratory Society].
    Pneumologie (Stuttgart, Germany), 2009, Volume: 63, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Dosage Forms; Ethanolamines; Formoterol Fumarate; Germany;

2009
Fluticasone/salmeterol: labeling change.
    Prescrire international, 2008, Volume: 17, Issue:98

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Approval; Drug Labeling; Drug Therapy

2008
[Lactic acidosis secondary to inhaled salbutamol in children with acute severe asthma].
    Anales de pediatria (Barcelona, Spain : 2003), 2009, Volume: 71, Issue:1

    Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchod

2009
An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.
    Irish medical journal, 2009, Volume: 102, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; As

2009
Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma.
    Pediatric pulmonology, 2009, Volume: 44, Issue:7

    Topics: Adolescent; Albuterol; Aldehyde Oxidoreductases; Asthma; Black or African American; Bronchodilator A

2009
Transdermal delivery of salbutamol sulphate: formulation and evaluation.
    Pharmaceutical development and technology, 2009, Volume: 14, Issue:2

    Topics: Administration, Cutaneous; Adult; Albuterol; Animals; Asthma; Bronchodilator Agents; Drug Delivery S

2009
Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Clinical therapeutics, 2009, Volume: 31, Issue:5

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Combinations

2009
Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 102, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Sectional Studies; Drug Interacti

2009
Love it or lev it: levalbuterol for severe acute asthma--for now, leave it.
    The Journal of pediatrics, 2009, Volume: 155, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Forced Expiratory Volu

2009
Simultaneous determination of beta2-agonists in human urine by fast-gas chromatography/mass spectrometry: method validation and clinical application.
    Biomedical chromatography : BMC, 2010, Volume: 24, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Gas Chromatography

2010
Treatment of acute bronchospasm in elderly patients.
    Postgraduate medicine, 2005, Volume: 118, Issue:6 Suppl Ac

    Topics: Acute Disease; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Aging; Albuterol; Asth

2005
Acute bronchospasm from the patient's perspective.
    Postgraduate medicine, 2005, Volume: 118, Issue:6 Suppl Ac

    Topics: Acute Disease; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm

2005
Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2009, Volume: 35, Issue:7

    Topics: Adolescent; Adult; Aged; Airway Obstruction; Airway Resistance; Albuterol; Analysis of Variance; Ast

2009
Levalbuterol versus albuterol.
    Current allergy and asthma reports, 2009, Volume: 9, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Clinical Trials as

2009
Measuring the assessment and counseling provided with the supply of nonprescription asthma reliever medication: a simulated patient study.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:9

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

2009
Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2009, Volume: 58, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Delivery Systems; Feasibility Studies; Female;

2009
Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis.
    Journal of pediatric psychology, 2010, Volume: 35, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol

2010
The beta2 receptor and airway hyper-responsiveness: are sensory nerves involved?
    Thorax, 2009, Volume: 64, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Humans; Neurons, Afferent; R

2009
[Long acting beta-2 agonists. Discussion of their use in asthma].
    MMW Fortschritte der Medizin, 2009, Apr-09, Volume: 151, Issue:15

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Delayed

2009
Salmeterol and formoterol: asthma aggravation. Use should be restricted.
    Prescrire international, 2009, Volume: 18, Issue:102

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Contraindications;

2009
[Long-acting beta2-agonist bronchodilators safety for asthma treatment].
    Archivos argentinos de pediatria, 2009, Volume: 107, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Delayed-Action Preparatio

2009
Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol.
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Alleles; Ast

2009
[Diagnostic value of peak flow variability in patients with suspected diagnosis of bronchial asthma in general practice].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:41

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronchodilator Agents; Di

2009
Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges.
    Current medical research and opinion, 2009, Volume: 25, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2009
Go and see.
    The New Zealand medical journal, 2009, Oct-09, Volume: 122, Issue:1304

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Clinical Competence; Fatal Outcome; Huma

2009
Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factor.
    The Journal of allergy and clinical immunology, 2010, Volume: 125, Issue:1

    Topics: Albuterol; Asthma; Cell Line; Histamine Release; Humans; Lung; Mast Cells; Potassium Channels, Calci

2010
Implementation of spacer therapy for acute asthma in children.
    Irish medical journal, 2009, Volume: 102, Issue:8

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2009
Adherence to combined montelukast and fluticasone treatment in economically disadvantaged african american youth with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2009, Volume: 46, Issue:9

    Topics: Acetates; Adolescent; Albuterol; Ambulatory Care; Androstadienes; Anti-Allergic Agents; Anti-Asthmat

2009
Pharmacogenetics of beta(2)-agonists in children.
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Ethanolamin

2009
Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes;

2009
Acute severe asthma: new approaches to assessment and treatment.
    Drugs, 2009, Volume: 69, Issue:17

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2009
Acute severe asthma: new approaches to assessment and treatment.
    Drugs, 2009, Volume: 69, Issue:17

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2009
Acute severe asthma: new approaches to assessment and treatment.
    Drugs, 2009, Volume: 69, Issue:17

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2009
Acute severe asthma: new approaches to assessment and treatment.
    Drugs, 2009, Volume: 69, Issue:17

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age

2009
Blood and urinary concentrations of salbutamol in asthmatic subjects.
    Medicine and science in sports and exercise, 2010, Volume: 42, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchodilat

2010
Achieving control of asthma in preschoolers.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2010, Mar-09, Volume: 182, Issue:4

    Topics: Albuterol; Amoxicillin; Anti-Infective Agents; Anti-Inflammatory Agents; Asthma; Beclomethasone; Bro

2010
Evaluation of asthma control using patient based measures and peak expiratory flow rate.
    The West Indian medical journal, 2009, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents;

2009
Regression of giant bullous emphysema.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Hum

2010
An elevated bronchodilator response predicts large airway inflammation in mild asthma.
    Pediatric pulmonology, 2010, Volume: 45, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Biomarkers; Breath Tests; Bronchodilator Agents; California; Child; E

2010
Omalizumab: when the non-responder is a late-responder.
    European annals of allergy and clinical immunology, 2009, Volume: 41, Issue:5

    Topics: Adult; Albuterol; Allergens; Androstadienes; Animals; Anti-Asthmatic Agents; Antibodies, Anti-Idioty

2009
A comparative study of two different metered-dose inhaler-valved holding chambers in the administration of salbutamol.
    Chest, 2010, Volume: 137, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Dose-Response Relati

2010
A 19-month-old boy with recurrent respiratory distress.
    Pediatric emergency care, 2010, Volume: 26, Issue:2

    Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma

2010
Acute exacerbation of asthma complicated by hyperventilation in emergency department.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:2

    Topics: Adult; Albuterol; Asthma; Emergency Service, Hospital; Female; Forced Expiratory Volume; Heart Rate;

2010
Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.
    Respiratory research, 2010, Feb-24, Volume: 11

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Animals; Asthma; Disease Models, Animal; Drug

2010
In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate.
    Chemical & pharmaceutical bulletin, 2010, Volume: 58, Issue:3

    Topics: Acrylic Resins; Adhesiveness; Administration, Buccal; Albuterol; Animals; Anti-Asthmatic Agents; Ast

2010
Choosing asthma step-up care.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Cyclopropanes

2010
Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections.
    Respiratory medicine, 2010, Volume: 104, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Sy

2010
The synergistic anti-asthmatic effects of glycyrrhizin and salbutamol.
    Acta pharmacologica Sinica, 2010, Volume: 31, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Asthmatic Ag

2010
Meeting the obligation to balance bioethics and clinical trial design in asthma.
    American journal of respiratory and critical care medicine, 2010, Apr-01, Volume: 181, Issue:7

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bioethical Issues; Bronchodila

2010
GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:6

    Topics: Albuterol; Aldehyde Oxidoreductases; Asthma; Bronchodilator Agents; Drug Interactions; Genes; Genoty

2010
[Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:4

    Topics: Albuterol; Androstadienes; Asian People; Asthma; Cost-Benefit Analysis; Drug Combinations; Evidence-

2010
Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.
    Federal register, 2010, Apr-14, Volume: 75, Issue:71

    Topics: Air Pollutants; Air Pollution; Albuterol; Anti-Asthmatic Agents; Asthma; Atmosphere; Bronchodilator

2010
Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.
    The Journal of allergy and clinical immunology, 2010, Volume: 125, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Cells, Cultured; Dexamethasone; Dual Specifici

2010
Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cholinergic Antagonists;

2010
Letter: Perioral dermatitis in a child associated with an inhalation steroid.
    Dermatology online journal, 2010, Apr-15, Volume: 16, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cl

2010
Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.
    British journal of pharmacology, 2010, Volume: 160, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodi

2010
Hyperlactic acidosis as metabolic side-effect of albuterol and theophylline in acute severe asthma.
    Klinische Padiatrie, 2010, Volume: 222, Issue:4

    Topics: Acidosis, Lactic; Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inf

2010
beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells.
    BMC pulmonary medicine, 2010, May-14, Volume: 10

    Topics: Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bacterial

2010
Salbutamol modulates the balance of Th1 and Th2 cytokines by mononuclear cells from allergic asthmatics.
    International archives of allergy and immunology, 2010, Volume: 152 Suppl 1

    Topics: Adult; Albuterol; Antigens, Dermatophagoides; Asthma; Chemokine CCL5; Female; Humans; Interferon-gam

2010
[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
    Pneumologie (Stuttgart, Germany), 2010, Volume: 64, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Adverse Drug Reaction Reportin

2010
Salmeterol use and risk of hospitalization among emergency department patients with acute asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010, Volume: 104, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon

2010
Assessment and validation of bronchodilation using the interrupter technique in preschool children.
    Pediatric pulmonology, 2010, Volume: 45, Issue:7

    Topics: Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Child; Child, Preschool; Cough

2010
Step-up therapy for children with uncontrolled asthma.
    The New England journal of medicine, 2010, Jul-01, Volume: 363, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Genotype; Glucocorti

2010
Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma.
    Thorax, 2010, Volume: 65, Issue:7

    Topics: Acute Disease; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Breath Tests; Broncho

2010
TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs.
    European journal of pharmacology, 2010, Sep-01, Volume: 641, Issue:2-3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents;

2010
Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma.
    American journal of respiratory cell and molecular biology, 2011, Volume: 44, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Binding Sites; Bronchodilator Agents; Case-Control Studi

2011
High exposure to passive tobacco smoking and the development of asthma in an adult patient who had never smoked.
    American journal of respiratory and critical care medicine, 2010, Aug-01, Volume: 182, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Cetirizine; Confined Spaces; Female; Histamine

2010
The article by Daley-Yates et al.
    Clinical therapeutics, 2010, Volume: 32, Issue:5

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol

2010
Use of the inhaled corticosteroid to bronchodilator ratio in an audit of the treatment of asthma in an academic family medicine residency programme.
    Journal of primary health care, 2010, Volume: 2, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents; Asthma; Br

2010
The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?
    The Journal of allergy and clinical immunology, 2010, Volume: 126, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Dosage Calculations; Drug

2010
Antiasthmatic action of dibenzylbutyrolactone lignans from fruits of Forsythia viridissima on asthmatic responses to ovalbumin challenge in conscious guinea-pigs.
    Phytotherapy research : PTR, 2011, Volume: 25, Issue:3

    Topics: 4-Butyrolactone; Airway Resistance; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveol

2011
Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2011, Jan-15, Volume: 18, Issue:2-3

    Topics: Airway Resistance; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid;

2011
ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos.
    The Journal of allergy and clinical immunology, 2010, Volume: 126, Issue:4

    Topics: 5-Lipoxygenase-Activating Proteins; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Carrier Pr

2010
Call for withdrawal of LABA single-therapy inhaler in asthma.
    Lancet (London, England), 2010, Sep-04, Volume: 376, Issue:9743

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2010
Impact of an emergency nurse-initiated asthma management protocol on door-to-first-salbutamol-nebulization-time in a pediatric emergency department.
    Journal of emergency nursing, 2010, Volume: 36, Issue:5

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Child; Child, Pres

2010
Rosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle.
    British journal of pharmacology, 2011, Volume: 162, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Carbachol; Cells, Cultured; Dexamet

2011
Lung function in preschool children with a history of wheezing measured by forced oscillation and plethysmographic specific airway resistance.
    Pediatric pulmonology, 2010, Volume: 45, Issue:11

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans

2010
Asthma inhalers and colour coding: universal dots.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2010, Volume: 60, Issue:578

    Topics: Albuterol; Asthma; Bronchodilator Agents; Color; Equipment Design; Humans; Nebulizers and Vaporizers

2010
Response to salbutamol in patients with mild asthma treated with nadolol.
    The European respiratory journal, 2010, Volume: 36, Issue:4

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Asth

2010
No association of catastrophic events with Advair.
    The American journal of medicine, 2010, Volume: 123, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agen

2010
Dr Nathan Tucker's Asthma Specific--a treatment for asthma preceding inhaled steroids and beta-agonists.
    The New Zealand medical journal, 2010, Sep-24, Volume: 123, Issue:1323

    Topics: Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Cocaine; Female; Glucocorticoids; Human

2010
Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2010, Dec-23, Volume: 41, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Force

2010
Airway peroxidases catalyze nitration of the {beta}2-agonist salbutamol and decrease its pharmacological activity.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Ascorbic Acid; Asthma; Breath Tests; Bronchi; Cataly

2011
Products at risk.
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cholinergic An

2010
Anticholinergics for patients with asthma?
    The New England journal of medicine, 2010, Oct-28, Volume: 363, Issue:18

    Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cholinergic An

2010
The improvement of cognitive functions in patients with bronchial asthma after therapy.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:10

    Topics: Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Cognition Disorders;

2010
A 20-year-old woman with severe asthma refractory to Primatene Mist.
    Chest, 2010, Volume: 138, Issue:5

    Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cholinergic

2010
Aerosol inhalation from spacers and valved holding chambers requires few tidal breaths for children.
    Pediatrics, 2010, Volume: 126, Issue:6

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch

2010
Intravenous magnesium sulphate prevents intravenous salbutamol tachycardia in asthma.
    British journal of anaesthesia, 2010, Volume: 105, Issue:6

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Arrhythmia Agents; Asthma; Bronchod

2010
[My private opinion on Asthma Prevention and Management Guideline 2009--chemotherapy plans for long term care of adult asthma patients--with special reference to handling of LABA].
    Arerugi = [Allergy], 2010, Volume: 59, Issue:11

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Practi

2010
Salbutamol misuse or abuse with fatal outcome: a case-report.
    Human & experimental toxicology, 2011, Volume: 30, Issue:11

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Arrhythmogenic Right Ventricular Dysplasia; A

2011
2007 San Diego wildfires and asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; California; Eosinophils; Fires; Forced Expiratory V

2011
Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.
    COPD, 2010, Volume: 7, Issue:6

    Topics: Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Meas

2010
Influence of gene-gene interactions on response to albuterol therapy.
    Pharmacogenomics, 2011, Volume: 12, Issue:1

    Topics: Albuterol; Asthma; Epistasis, Genetic; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Re

2011
Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy.
    Clinical therapeutics, 2010, Volume: 32, Issue:10

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool

2010
Eosinophilic cationic protein: is it useful in assessing control of childhood asthma?
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2010, Volume: 16, Issue:10

    Topics: Albuterol; Androstadienes; Asthma; Biomarkers; Bronchodilator Agents; Case-Control Studies; Child; C

2010
The dilemma of albuterol dosing for acute asthma exacerbations in pediatric patients.
    Chest, 2011, Volume: 139, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans;

2011
Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients.
    Respiratory medicine, 2011, Volume: 105, Issue:7

    Topics: Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Biomarkers; Dyspnea; Exhalation; Female; Forced

2011
Tiotropium step-up therapy in asthma.
    The New England journal of medicine, 2011, 02-10, Volume: 364, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chol

2011
A case of accidental ingestion of a salbutamol sulfate inhalant, Venetlin®.
    The Tokai journal of experimental and clinical medicine, 2009, Sep-20, Volume: 34, Issue:3

    Topics: Accidents, Home; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Nebulizers and

2009
Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2011, Volume: 22, Issue:4

    Topics: Albuterol; Asthma; Azides; Bronchi; Cell Line; Chemokine CCL5; Chemokine CXCL10; Cyclic AMP; Epithel

2011
New insights into the treatment of persistent asthma.
    Lancet (London, England), 2011, Feb-19, Volume: 377, Issue:9766

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator

2011
Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 106, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-

2011
Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Benzoxa

2011
Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma.
    Respiratory research, 2011, Mar-07, Volume: 12

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Analysis of Variance; An

2011
Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition.
    Journal of aerosol medicine and pulmonary drug delivery, 2011, Volume: 24, Issue:3

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Ga

2011
Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department.
    Pediatrics, 2011, Volume: 127, Issue:5

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; British Columbia; Child; Child, Preschool

2011
Effects of salbutamol given by metered-dose inhaler on dispersion of ventricular repolarization.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2011, Volume: 11, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Ch

2011
Induced sputum in children: success determinants, safety, and cell profiles.
    Journal of investigational allergology & clinical immunology, 2011, Volume: 21, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Cell Count; Ch

2011
Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD).
    Drug safety, 2011, Jun-01, Volume: 34, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2011
Treatment of acute asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:7

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; Humans; Male; Nebulizers and Vaporiz

2011
Treatment of mild persistent asthma in children.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents

2011
Device type and real-world effectiveness of asthma combination therapy: an observational study.
    Respiratory medicine, 2011, Volume: 105, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A

2011
Asthma treatment through the beta receptor: lessons from animal models.
    Frontiers in bioscience (Elite edition), 2011, 06-01, Volume: 3, Issue:4

    Topics: Adrenergic beta-Antagonists; Albuterol; Animals; Asthma; Disease Models, Animal; Stereoisomerism

2011
Relationship between bronchial hyperreactivity and bronchodilation in patients with allergic rhinitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 106, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodi

2011
A case of haemorrhagic cystitis by inhaled salbutamol and salmeterol.
    European journal of clinical pharmacology, 2011, Volume: 67, Issue:11

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; As

2011
Effective bronchodilator resuscitation of children in the emergency room: device or interface?
    Respiratory care, 2011, Volume: 56, Issue:6

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerg

2011
Beta agonist use during asthma exacerbations: how much is too much?
    The New Zealand medical journal, 2011, Apr-15, Volume: 124, Issue:1332

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And

2011
Meaningful placebos--controlling the uncontrollable.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Placebo Eff

2011
Airway resistance at maximum inhalation as a marker of asthma and airway hyperresponsiveness.
    Respiratory research, 2011, Jul-15, Volume: 12

    Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Boston; Bronchial Hyperreactivity; Bronchial Provo

2011
Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:7

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agent

2011
Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China.
    Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:8

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Arginine; Asian People; Asthma; Bronchodilator Agent

2011
Spirometric maneuvers and inhaled salbutamol do not affect exhaled nitric oxide measurements among patients with allergic asthma.
    Respiration; international review of thoracic diseases, 2012, Volume: 83, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Breath Tests; Bronchodilator

2012
Asthma challenges: The place of inhaled long-acting beta-agonists.
    The Cochrane database of systematic reviews, 2010, Apr-14, Volume: 2011

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Ethanolamines; Glucocorticoids; Humans

2010
Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids.
    Clinical medicine (London, England), 2011, Volume: 11, Issue:4

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Cushing Syndrome; Drug Combinations;

2011
Will recording of lung function fluctuation open the door to internet-guided treatment of asthma?
    Thorax, 2011, Volume: 66, Issue:12

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Female; Humans; Male; Peak Expiratory Flow Rate; Salmetero

2011
The response of children with asthma to ambient particulate is modified by tobacco smoke exposure.
    American journal of respiratory and critical care medicine, 2011, Dec-15, Volume: 184, Issue:12

    Topics: Adolescent; Albuterol; Asthma; Child; Colorado; Drug Utilization; Environmental Exposure; Female; Hu

2011
Compliance with guidelines in the treatment of asthma exacerbations in primary care.
    Therapeutic advances in respiratory disease, 2011, Volume: 5, Issue:6

    Topics: Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Cross-Sectional Studies; Female; Follow-Up St

2011
Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:18

    Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Humans; Inci

2011
Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 107, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Humans; Linear Models; Middle Age

2011
Placebo and other interventions in asthma.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Placebo Effect;

2011
Placebo and other interventions in asthma.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Placebo Effect;

2011
Placebo and other interventions in asthma.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Placebo Effect

2011
Long-acting β-agonists in asthma management: what is the current status?
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm

2011
Exhaled carbon monoxide levels in preschool-age children with episodic asthma.
    Pediatrics international : official journal of the Japan Pediatric Society, 2012, Volume: 54, Issue:2

    Topics: Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Carbon Monoxide; Cromolyn Sodium; Drug Thera

2012
ProAir(®) HFA delivers warmer, lower-impact, longer-duration plumes containing higher fine particle dose than Ventolin(®) HFA.
    Journal of aerosol medicine and pulmonary drug delivery, 2012, Volume: 25, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Humans; Hydrocarbons, Fluorinated; Meter

2012
Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:4

    Topics: Administration, Oral; Aged; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response

1976
Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells.
    Cellular & molecular immunology, 2012, Volume: 9, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Cells, Cultured; Cytokines; Dendrit

2012
Maternal asthma medication use and the risk of selected birth defects.
    Pediatrics, 2012, Volume: 129, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Albuterol; Anal Canal; Androstadienes; Anti-Asthmatic Agents; An

2012
Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition.
    British journal of pharmacology, 2012, Volume: 167, Issue:4

    Topics: 1-Phosphatidylinositol 4-Kinase; Adenine; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonis

2012
Late-night wheezer: providers respond to pediatric asthma patient.
    JEMS : a journal of emergency medical services, 2012, Volume: 37, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Medical Services; Female; Humans; Nebuliz

2012
Asthma guidelines and smokers: it's time to be inclusive.
    Chest, 2012, Volume: 141, Issue:2

    Topics: Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combinatio

2012
Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
    Clinical drug investigation, 2012, Apr-01, Volume: 32, Issue:4

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Computer Simulation; Cost-

2012
Pharmacogenetics of asthma controller treatment.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:3

    Topics: Acetates; Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents;

2013
Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 108, Issue:3

    Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Anti-Asthmatic Agents; A

2012
Adrenal insufficiency and growth failure secondary to inhaled corticosteroids: a paradoxical complication.
    Clinical pediatrics, 2012, Volume: 51, Issue:12

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenal Insufficiency; Albuterol; Androstadiene

2012
Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems.
    Journal of medical economics, 2012, Volume: 15, Issue:4

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Emergen

2012
Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2012, Volume: 49, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Biomarkers;

2012
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.
    International journal of nanomedicine, 2012, Volume: 7

    Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Animals; Anti-Asthmatic Agents; Anura;

2012
Mycoplasma pneumoniae bronchiolitis mimicking asthma in an adult.
    Respiratory care, 2012, Volume: 57, Issue:11

    Topics: Adult; Albuterol; Anti-Infective Agents; Asthma; Aza Compounds; Bronchiolitis; Bronchodilator Agents

2012
[Cardiogenic pulmonary edema following β2 agonist infusion for acute, severe asthma].
    Annales de cardiologie et d'angeiologie, 2015, Volume: 64, Issue:4

    Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Combined Modality Ther

2015
Magnesium use in asthma pharmacotherapy: a Pediatric Emergency Research Canada study.
    Pediatrics, 2012, Volume: 129, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Prescho

2012
Investigating asthma symptoms in primary care.
    BMJ (Clinical research ed.), 2012, Apr-25, Volume: 344

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Diagnosis, Diff

2012
Long-acting beta-agonists and the risk of intensive care unit admission in children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2012, Volume: 49, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists

2012
Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination.
    Chest, 2012, Volume: 141, Issue:5

    Topics: Airway Resistance; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchodilator

2012
Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 342, Issue:2

    Topics: Albuterol; Animals; Asthma; beta-Alanine; Bronchial Hyperreactivity; Bronchoconstriction; Fingolimod

2012
Treating acute asthma--salbutamol may not always be the right answer.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:2

    Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al

2012
Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 342, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchoconstriction; Bronc

2012
Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations.
    Pediatric pulmonology, 2012, Volume: 47, Issue:10

    Topics: Adrenal Cortex Hormones; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Child; Chil

2012
Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
    Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:4

    Topics: Adenosine Monophosphate; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Benzothiaz

2012
Quantitative analysis of dynamic airway changes after methacholine and salbutamol inhalation on xenon-enhanced chest CT.
    European radiology, 2012, Volume: 22, Issue:11

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchoconstrictor Agents; Female; Force

2012
A case of recurrent acute haemorrhagic cystitis associated with salbutamol and beclomethasone use in a paediatric patient.
    Journal of paediatrics and child health, 2012, Volume: 48, Issue:7

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; Cystitis; Hematuria;

2012
Pitfalls associated with the therapeutic reference pricing practice of asthma medication.
    BMC pulmonary medicine, 2012, Jul-20, Volume: 12

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb

2012
Can a rare form of myasthenia gravis shed additional light on disease mechanisms?
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:5

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Autoantibodies; Calcium Signaling; Carbon Dioxide;

2013
The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?
    Thorax, 2013, Volume: 68, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations;

2013
Response to treatment in individuals with late-onset asthma.
    Journal of the American Geriatrics Society, 2012, Volume: 60, Issue:8

    Topics: Adult; Age of Onset; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Female; Flutica

2012
Regional pulmonary response to a methacholine challenge using hyperpolarized (3)He magnetic resonance imaging.
    Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:8

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronc

2012
Salbutamol with metered dose inhalers with spacers - an established emergency treatment for preschool wheeze.
    Acta paediatrica (Oslo, Norway : 1992), 2012, Volume: 101, Issue:11

    Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Preschool; Drug Administration Schedule

2012
Are we overlooking persistent small airways dysfunction in community-managed asthma?
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Androstadi

2012
The correlation of average monthly ambient sulfur dioxide concentration and the use of inhalation bronchodilators in children.
    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2012, Volume: 9, Issue:2

    Topics: Air Pollutants; Albuterol; Asthma; Bosnia and Herzegovina; Bronchodilator Agents; Child; Child, Pres

2012
Effectiveness of a breath-actuated nebulizer device on asthma care in the pediatric emergency department.
    Clinical pediatrics, 2012, Volume: 51, Issue:12

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2012
Long-acting β-agonist prescribing in people with asthma in primary care.
    Thorax, 2013, Volume: 68, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination;

2013
Practice patterns in asthma discharge pharmacotherapy in pediatric emergency departments: a pediatric emergency research Canada study.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2012, Volume: 19, Issue:9

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Age Factors;

2012
Severe intraoperative bronchospasm treated with a vibrating-mesh nebulizer.
    Anesthesia progress, 2012,Fall, Volume: 59, Issue:3

    Topics: Aerosols; Albuterol; Albuterol, Ipratropium Drug Combination; Anesthesia, Inhalation; Anesthetics, I

2012
Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
    The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:6

    Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Database

2012
Efficacy of budesonide in combination with formoterol in patients with inadequately controlled asthma on fluticasone in combination with salmeterol.
    Allergology international : official journal of the Japanese Society of Allergology, 2012, Volume: 61, Issue:4

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Therapy, Combination; Eth

2012
Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation.
    AJR. American journal of roentgenology, 2012, Volume: 199, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Asthma; Bronchoconstrictor Agent

2012
Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone.
    CJEM, 2012, Volume: 14, Issue:6

    Topics: Acidosis, Lactic; Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albut

2012
An assessment of community pharmacists' responses to hypothetical medical emergency situations.
    The International journal of pharmacy practice, 2012, Volume: 20, Issue:6

    Topics: Adult; Albuterol; Anaphylaxis; Anti-Asthmatic Agents; Asthma; Attitude of Health Personnel; Communit

2012
P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy.
    American journal of respiratory and critical care medicine, 2013, Jan-01, Volume: 187, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Black or African American; Case-Control Studies;

2013
Management of COPD in general practice.
    Australian family physician, 2012, Volume: 41, Issue:11

    Topics: Aged; Albuterol; Asthma; Australia; Bronchodilator Agents; Comorbidity; Female; General Practice; Hu

2012
High exhaled nitric oxide levels may predict bronchial reversibility in allergic children with asthma or rhinitis.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Breath Tests; Child; Cohort Studies; Cross-Sectional Studies; Female;

2013
Research on the molecular mechanism of Seretide treatment to asthma disease.
    European review for medical and pharmacological sciences, 2012, Volume: 16, Issue:12

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Databases, Genetic;

2012
Inappropriate home albuterol use during an acute asthma exacerbation.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Caregivers; Child; Child, Preschool; Cross-Sectional Studies; Emergen

2012
RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients.
    Pediatric pulmonology, 2013, Volume: 48, Issue:10

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Forced Expira

2013
Bronchodilator responsiveness using spirometry in healthy and asthmatic preschool children.
    Archives of disease in childhood, 2013, Volume: 98, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Preschool; Forced Expi

2013
Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powd
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2013, Volume: 50, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Cohort Studi

2013
[Nebulized salbutamol as a possible cause of lactate acidosis in a patient with acute asthma].
    Ugeskrift for laeger, 2013, Jan-14, Volume: 175, Issue:3

    Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al

2013
[Lactic acidosis in a patient with exercabation of asthma receiving inhalation therapy].
    Ugeskrift for laeger, 2013, Jan-14, Volume: 175, Issue:3

    Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol;

2013
Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department.
    Pediatric emergency care, 2013, Volume: 29, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distrib

2013
The dark side of airway management. Forensic cases in EMS advanced airway management.
    EMS world, 2013, Volume: 42, Issue:1

    Topics: Aged; Airway Management; Albuterol; Asthma; Bronchodilator Agents; Clinical Protocols; Emergency Med

2013
Supramaximal flow in asthmatic patients.
    The European respiratory journal, 2002, Volume: 19, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Forced Expiratory Volume

2002
Respiratory impedance response to a deep inhalation in asthmatic children with spontaneous airway obstruction.
    The European respiratory journal, 2002, Volume: 19, Issue:6

    Topics: Adolescent; Airway Obstruction; Airway Resistance; Albuterol; Analysis of Variance; Asthma; Bronchod

2002
Transient lactic acidosis as a side effect of inhaled salbutamol.
    Chest, 2002, Volume: 122, Issue:1

    Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans

2002
Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma.
    The Journal of allergy and clinical immunology, 2002, Volume: 110, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Clinical Trials as Topic;

2002
Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.
    The Journal of allergy and clinical immunology, 2002, Volume: 110, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Consumer Product Safety;

2002
Expression of bronchodilator response: comparison of four indices.
    Respiratory medicine, 2002, Volume: 96, Issue:8

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Bronchospirometry; Female; Forced Expiratory Volume

2002
Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma.
    Pediatric pulmonology, 2002, Volume: 34, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Breath Tests; Child; Humans; Luminescent Me

2002
Achieving guideline-based asthma control: does the patient benefit?
    The European respiratory journal, 2002, Volume: 20, Issue:3

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Fluticasone; Gu

2002
Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness.
    Journal of investigational allergology & clinical immunology, 2002, Volume: 12, Issue:2

    Topics: Acetaldehyde; Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Airway Obstruc

2002
The current landscape of asthma: a new geometry.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:4

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Drug Combinatio

2002
Lung dose of inhaled drugs in children with acute asthma.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2002,Fall, Volume: 15, Issue:3

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child;

2002
Should combination therapy with inhaled corticosteroids and long-acting beta2-agonists be prescribed as initial maintenance treatment for asthma?
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Oct-29, Volume: 167, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Drug Combinations; Drug Therapy, Combin

2002
Dyspnoea worsened by salmeterol.
    Journal of the Royal Society of Medicine, 2002, Volume: 95, Issue:11

    Topics: Adenocarcinoma; Albuterol; Asthma; Breast Neoplasms; Bronchodilator Agents; Diagnosis, Differential;

2002
Question from the clinician: levalbuterol in managing pediatric asthma.
    Pediatrics in review, 2002, Volume: 23, Issue:11

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug

2002
Selecting the best method to evaluate bronchodilation when analysing bronchodilator studies.
    Statistics in medicine, 2002, Dec-15, Volume: 21, Issue:23

    Topics: Age Factors; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Human

2002
In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position.
    Critical care medicine, 2002, Volume: 30, Issue:11

    Topics: Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Drug Delivery Systems; Hum

2002
[Contribution of salmeterol in ambulatory practice to the improvement of asthma and quality of life in childhood].
    Allergie et immunologie, 2002, Volume: 34, Issue:8

    Topics: Adolescent; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Albuterol; Anti-Ast

2002
Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma.
    Respiration; international review of thoracic diseases, 2002, Volume: 69, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agen

2002
[Optimization of asthma control with fluticasone/salmeterol (seretide) combination: new clinical data].
    Revue de pneumologie clinique, 2002, Volume: 58, Issue:3 Pt 2

    Topics: Albuterol; Androstadienes; Asthma; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Force

2002
Occupational rhinoconjunctivitis and asthma in a wool worker caused by Dermestidae spp.
    Allergy, 2002, Volume: 57, Issue:12

    Topics: Adult; Albuterol; Allergens; Animals; Antibody Specificity; Asthma; Bronchial Provocation Tests; Bro

2002
Nonreversible conductive airway ventilation heterogeneity in mild asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 94, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Fem

2003
[Combination of beta-1 agonist and corticosteroid is advantageous not only in asthma. COPD patients spared exacerbations].
    MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadi

2002
Diabetic ketoacidosis associated with oral salbutamol overdose.
    The American journal of medicine, 2002, Dec-01, Volume: 113, Issue:8

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Diabetic Ketoacidosis; Drug Overdose; Female; Follow

2002
Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
    Chest, 2003, Volume: 123, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Female; Hospitalization; Humans; Male; Middle Aged; Pul

2003
Pharmacists helping physicians.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Jan-21, Volume: 168, Issue:2

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol

2003
Clinical and biological heterogeneity in children with moderate asthma.
    American journal of respiratory and critical care medicine, 2003, Jun-01, Volume: 167, Issue:11

    Topics: Adolescent; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Biomarkers; Bronchodilator

2003
Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study.
    Chest, 2003, Volume: 123, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Th

2003
How to design a negative study.
    Chest, 2003, Volume: 123, Issue:2

    Topics: Albuterol; Asthma; Bias; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Formoterol Fu

2003
Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2002,Winter, Volume: 15, Issue:4

    Topics: Aerosols; Albuterol; Analysis of Variance; Androstadienes; Asthma; Bronchodilator Agents; Chromatogr

2002
[The MMW Drug Prize 2002: Prize for a new classic with innovation potential].
    Medizinische Klinik (Munich, Germany : 1983), 2002, Dec-15, Volume: 97 Suppl 2

    Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen

2002
Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:2

    Topics: Albuterol; Asthma; Chemistry, Pharmaceutical; Child; England; Female; Humans; Hydrocarbons, Fluorina

2003
Clarification of salmeterol studies.
    Chest, 2003, Volume: 123, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Powders; Salmeterol Xi

2003
Effect of pharmacist counseling in patients hospitalized with acute exacerbation of asthma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Mar-01, Volume: 60, Issue:5

    Topics: Acetates; Acute Disease; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Anti

2003
Intravenous salbutamol.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2003, Volume: 4, Issue:1

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Emergency Service, Hospital; Humans;

2003
Second line treatment for severe acute childhood asthma.
    Thorax, 2003, Volume: 58, Issue:4

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Child; Drug Combinations;

2003
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
    British journal of pharmacology, 2003, Volume: 138, Issue:6

    Topics: Albuterol; Animals; Antigens, CD34; Apoptosis; Asthma; Cell Division; Female; Humans; Male; Methacho

2003
Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals.
    Pediatric pulmonology, 2003, Volume: 35, Issue:5

    Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Breath Tests; Bronchodilator Agents

2003
Early detection of cardiac disease masquerading as acute bronchospasm: The role of bedside limited echocardiography by the emergency physician.
    Pediatric emergency care, 2003, Volume: 19, Issue:2

    Topics: Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Calcinosis; Cardiomyopathy, Dilated; Chil

2003
Herbal therapy use in a pediatric emergency department population: expect the unexpected.
    Pediatrics, 2003, Volume: 111, Issue:5 Pt 1

    Topics: Adolescent; Adult; Albuterol; Asthma; Caregivers; Child; Child, Preschool; Complementary Therapies;

2003
Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2003,Spring, Volume: 16, Issue:1

    Topics: Adrenergic beta-Agonists; Aerosol Propellants; Albuterol; Area Under Curve; Asthma; Biological Avail

2003
Rapidly repeated intravenous boluses of salbutamol for acute severe asthma.
    Anaesthesia, 2003, Volume: 58, Issue:7

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child

2003
(R,S)-salbutamol plasma concentrations in severe asthma.
    Journal of clinical pharmacy and therapeutics, 2003, Volume: 28, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations

2003
[The effect of time on the perception of dyspnea following inhaled long-acting bronchodilator].
    Harefuah, 2003, Volume: 142, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Forced Expiratory Vol

2003
Asthma, age, and early reversibility testing.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:3

    Topics: Adult; Age Factors; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Case-Control

2003
Prescriber and pharmacist responses to intervention letters for Connecticut Medicaid beneficiaries with asthma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jun-01, Volume: 60, Issue:11

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution;

2003
Funhaler spacer: improving adherence without compromising delivery.
    Archives of disease in childhood, 2003, Volume: 88, Issue:7

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Administration Sch

2003
Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma.
    Allergy, 2003, Volume: 58, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent

2003
Nebulised magnesium in asthma: the right solution for an old remedy?
    Lancet (London, England), 2003, Jun-21, Volume: 361, Issue:9375

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Calcium Channel Blockers; Chem

2003
Prescribing for asthmatic children in primary care. Are we following guidelines?
    Saudi medical journal, 2003, Volume: 24, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch

2003
Outcome evaluation of early discharge from hospital with asthma.
    Respirology (Carlton, Vic.), 2003, Volume: 8, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Australia; Bronchodilator Agents; Child; Child, Preschool; Dose-Respo

2003
Use of intravenous salbutamol in acute severe asthma.
    Anaesthesia, 2003, Volume: 58, Issue:8

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Algorithms; Asthma; Bronchodilator Agents; Human

2003
Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:2

    Topics: Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Child, Presc

2003
Excess mortality with salmeterol as single-agent therapy.
    Prescrire international, 2003, Volume: 12, Issue:66

    Topics: Albuterol; Asthma; Clinical Trials as Topic; Drug Evaluation; Humans; United States; United States F

2003
Occupational asthma due to IgE mediated allergy to the flower Molucella laevis (Bells of Ireland).
    Occupational and environmental medicine, 2003, Volume: 60, Issue:9

    Topics: Air Pollutants, Occupational; Albuterol; Allergens; Asthma; Bronchodilator Agents; Humans; Immunoglo

2003
Exhaled nitric oxide corresponds with office evaluation of asthma control.
    Pediatric pulmonology, 2003, Volume: 36, Issue:4

    Topics: Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Hum

2003
Cardiovascular collapse in a 77-year-old-woman with an asthma exacerbation following bronchodilator treatment.
    Chest, 2003, Volume: 124, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents

2003
Levalbuterol vs racemic albuterol: science or drug company propaganda?
    Chest, 2003, Volume: 124, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Industry; Humans; Propaganda; Racemases and Epimerase

2003
Levalbuterol is not more cost-effective than albuterol for COPD.
    Chest, 2003, Volume: 124, Issue:3

    Topics: Albuterol; Asthma; Bias; Bronchodilator Agents; Cost-Benefit Analysis; Hospitalization; Humans; Pulm

2003
The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey.
    European journal of emergency medicine : official journal of the European Society for Emergency Medicine, 2003, Volume: 10, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Austra

2003
[Theomyl, a new synthetic asthma preparation].
    Svenska lakartidningen, 1962, Nov-15, Volume: 59

    Topics: Albuterol; Asthma; Caffeine; Epinephrine; Ipratropium; Theophylline

1962
Nebulised salbutamol and magnesium sulphate in acute asthma.
    Lancet (London, England), 2003, Sep-27, Volume: 362, Issue:9389

    Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Inhalation; Albuterol; Asthma; Bronchodilato

2003
Nebulised salbutamol and magnesium sulphate in acute asthma.
    Lancet (London, England), 2003, Sep-27, Volume: 362, Issue:9389

    Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Inhalation; Albuterol; Asthma; Bronchodilato

2003
Nebulised salbutamol and magnesium sulphate in acute asthma.
    Lancet (London, England), 2003, Sep-27, Volume: 362, Issue:9389

    Topics: Acute Disease; Adjuvants, Pharmaceutic; Albuterol; Asthma; Humans; Isotonic Solutions; Magnesium Sul

2003
FDA alerts asthmatics to drug safety risk.
    Nature reviews. Drug discovery, 2003, Volume: 2, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Consumer Product Safety; Humans; Product Surveillance,

2003
A response to 'Rapidly repeated intravenous boluses of salbutamol for acute severe asthma' Sellers WFS, Messahel B, Anaesthesia 2003; 58: 680-3.
    Anaesthesia, 2003, Volume: 58, Issue:11

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Infusions

2003
Asthma-like syndrome in a teenager.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2003, Volume: 14, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Albuterol; Amoxicillin; Androstadienes; Anti-Ba

2003
Prescribing for asthmatic children in primary care. Are we following the guidelines?
    Saudi medical journal, 2003, Volume: 24, Issue:11

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Practice Guidelines as Topic; Practice Patt

2003
Mirror images: is levalbuterol the fairest of them all?
    The Journal of pediatrics, 2003, Volume: 143, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Humans; Isomerism; Resear

2003
Asthma variability in patients previously treated with beta2-agonists alone.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Child; Disease

2003
Outcome of occupational asthma in patients with continuous exposure: a 3-year longitudinal study during pharmacologic treatment.
    Chest, 2003, Volume: 124, Issue:6

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Female; Humans; Longitudinal Studie

2003
Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype.
    European journal of clinical pharmacology, 2004, Volume: 59, Issue:11

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Cholinergic Antagonists; Et

2004
Effect of inhaled racemic and (R)-albuterol on airway vascular smooth muscle tone in healthy and asthmatic subjects.
    Lung, 2003, Volume: 181, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Case-Contro

2003
[Bronchial asthma -- to set the measuring rod higher. Combination therapy defines asthma control anew].
    MMW Fortschritte der Medizin, 2003, Nov-13, Volume: 145, Issue:46

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilato

2003
Levalbuterol.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans

2003
[Adding a prolonged action beta-2-agonist].
    Revue de pneumologie clinique, 2003, Volume: 59, Issue:4

    Topics: Acetates; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Cyclo

2003
[Adding an anti-leukotriene: results of the IMPACT study].
    Revue de pneumologie clinique, 2003, Volume: 59, Issue:4

    Topics: Acetates; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Chroni

2003
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:1

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Clinical Trial

2004
Plasma cortisol levels in acute asthma.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:12

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Hydrocortisone; Male

2003
Beta2-agonist eutomers: a rational option for the treatment of asthma?
    American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Asthmatic Ag

2002
Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study.
    The American journal of emergency medicine, 2004, Volume: 22, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Female; Forced

2004
A rare side-effect of intravenous salbutamol.
    Anaesthesia, 2004, Volume: 59, Issue:2

    Topics: Acidosis, Lactic; Albuterol; Asthma; Bronchodilator Agents; Humans; Infusions, Intravenous; Male; Mi

2004
Intravenous magnesium sulphate and salbutamol for asthma.
    Anaesthesia, 2004, Volume: 59, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Magnesiu

2004
Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:1

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Drug Delivery Systems; Female; Human

2004
Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths.
    The Ceylon medical journal, 2003, Volume: 48, Issue:3

    Topics: Albuterol; Asthma; Cause of Death; Clinical Trials as Topic; Female; Humans; Incidence; Male; Multic

2003
Airway responsiveness to beta-adrenergic agonist (salbutamol) in asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Hyperreactivity; Bronch

2003
The use of inhaled and related respiratory medications in Christchurch rest homes.
    The New Zealand medical journal, 2003, Dec-12, Volume: 116, Issue:1187

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aged; Aged, 80 and ov

2003
Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.
    American journal of respiratory cell and molecular biology, 2004, Volume: 31, Issue:1

    Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchi; Cells, Cultured; Cytokines; Dr

2004
Increasing compliance with inhaled corticosteroids through the use of combination therapy.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent

2004
Near-fatal asthma related to menstruation.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Menstru

2004
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:2

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adult; Albuterol; Androstadienes; Anti-A

2004
Long-acting beta agonists in asthma therapy.
    Current allergy and asthma reports, 2004, Volume: 4, Issue:2

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanol

2004
Relationship between quality of life and clinical status in asthma: a factor analysis.
    The European respiratory journal, 2004, Volume: 23, Issue:2

    Topics: Activities of Daily Living; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Al

2004
Point-counterpoint: A comparison of levalbuterol and racemic albuterol in the treatment of pediatric asthma.
    Pediatrics in review, 2004, Volume: 25, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; History, Medieval; Humans; Stereoisomerism

2004
Contamination of dry powder inhalers for asthma with milk proteins containing lactose.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:3

    Topics: Administration, Inhalation; Albuterol; Anaphylaxis; Androstadienes; Asthma; Bronchodilator Agents; C

2004
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2004
HFA inhalers.
    Pediatric pulmonology. Supplement, 2004, Volume: 26

    Topics: Aerosol Propellants; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Glucocorticoids; Huma

2004
Three 20-minute interspaced salbutamol inhalations as a test for the diagnosis of reversible airflow limitation in adult asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:1

    Topics: Administration, Inhalation; Administration, Oral; Aged; Airway Obstruction; Albuterol; Anti-Inflamma

2004
Exhaled nitric oxide.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 92, Issue:3

    Topics: Acetates; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Budesonide; Cyclopropanes; Exhalat

2004
Asthma exacerbations and formoterol.
    Chest, 2004, Volume: 125, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br

2004
Contamination of nebulizer equipment with cockroach allergen: there's a bug in the system!
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 92, Issue:4

    Topics: Adolescent; Albuterol; Allergens; Androstadienes; Animals; Asthma; Bronchodilator Agents; Child; Coc

2004
Evaluation of a physician-focused educational intervention on medicaid children with asthma.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:6

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Drug Ut

2004
[Effect of high doses of broncholytics on the state of cardiovascular system during treatment of sever exacerbation of bronchial asthma].
    Kardiologiia, 2004, Volume: 44, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug

2004
[Lactic acidosis occurring after inhaled beta2 agonists during an asthma attack].
    La Revue de medecine interne, 2004, Volume: 25, Issue:6

    Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Female; H

2004
Pupil blown by a puffer.
    Lancet (London, England), 2004, Jun-05, Volume: 363, Issue:9424

    Topics: Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Combinations; Humans; Ipratropium; M

2004
A response to 'A rare side-effect of intravenous salbutamol', Girgis M and Milner Q, Anaesthesia 2004; 59: 196-7.
    Anaesthesia, 2004, Volume: 59, Issue:7

    Topics: Acidosis, Lactic; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans

2004
Hypercapnia: what is the limit in paediatric patients? A case of near-fatal asthma successfully treated by multipharmacological approach.
    Paediatric anaesthesia, 2004, Volume: 14, Issue:7

    Topics: Acidosis, Respiratory; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therapy, Combination; G

2004
Asthmalike symptoms following intratracheal exposure of Guinea pigs to sulfur mustard aerosol: therapeutic efficacy of exogenous lung surfactant curosurf and salbutamol.
    Inhalation toxicology, 2004, Volume: 16, Issue:8

    Topics: Aerosols; Albuterol; Animals; Asthma; Biological Products; Bronchoalveolar Lavage Fluid; Bronchodila

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
    American journal of respiratory and critical care medicine, 2004, Oct-01, Volume: 170, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl

2004
Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cell C

2004
[Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma].
    Arerugi = [Allergy], 2004, Volume: 53, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Metered Dose Inhalers;

2004
Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals.
    The Journal of laboratory and clinical medicine, 2004, Volume: 144, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Biomarkers; Dithiothreitol;

2004
Steroids and antibiotics for treatment of acute asthma exacerbations in African-American children.
    Journal of the National Medical Association, 2004, Volume: 96, Issue:7

    Topics: Adolescent; Albuterol; Amoxicillin; Asthma; Black or African American; Bronchodilator Agents; Child;

2004
A comparison of lung function methods for assessing dose-response effects of salbutamol.
    British journal of clinical pharmacology, 2004, Volume: 58, Issue:2

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Female; For

2004
Asthma in emergency departments: combined adult and paediatric versus paediatric only centres.
    Journal of paediatrics and child health, 2004, Volume: 40, Issue:8

    Topics: Adolescent; Albuterol; Asthma; Australia; Bronchodilator Agents; Child; Child, Preschool; Emergency

2004
Reduced eosinophil pro-fibrogenic effect in severe childhood asthma compared to mild disease: an effect of corticosteroids?
    Pediatric pulmonology, 2004, Volume: 38, Issue:3

    Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Child; Cyclopropanes; Dexamethasone; Eosino

2004
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    PharmacoEconomics, 2004, Volume: 22, Issue:12

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adult; Albuterol; Androstadienes; Anti-A

2004
Differentiating asthma and COPD patients.
    Chest, 2004, Volume: 126, Issue:2

    Topics: Albuterol; Androstadienes; Asthma; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume;

2004
Tremor side effects of salbutamol, quantified by a laser pointer technique.
    Respiratory medicine, 2004, Volume: 98, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Child; Child,

2004
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2004
Cost of using levalbuterol in the emergency room.
    The Journal of pediatrics, 2004, Volume: 145, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Hospitalization; Human

2004
Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
    Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 2004, Volume: 14, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Doping in Sports; Humans; Male; Sports Medicine;

2004
Hypokalemic paralysis mimicking Guillain-Barré syndrome and causing acute respiratory failure.
    Middle East journal of anaesthesiology, 2004, Volume: 17, Issue:5

    Topics: Acidosis, Respiratory; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Gas Analysis; Diagn

2004
Salbutamol via metered-dose inhaler with spacer versus nebulization for acute treatment of pediatric asthma in the emergency department.
    Pediatric emergency care, 2004, Volume: 20, Issue:10

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Antagonists; Albuterol; Asthm

2004
Asthma update: clinical aspects and management.
    Pediatrics in review, 2004, Volume: 25, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Algorithms; Anti-Asthmatic Agents; Anti-Bacterial Agents; Asthm

2004
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study.
    American journal of respiratory and critical care medicine, 2004, Oct-15, Volume: 170, Issue:8

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Case-Control Studies; Fluticasone; Humans;

2004
Laryngeal findings in users of combination corticosteroid and bronchodilator therapy.
    The Laryngoscope, 2004, Volume: 114, Issue:9

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Andros

2004
Development, implementation, and evaluation of a community pharmacy-based asthma care model.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:11

    Topics: Adult; Albuterol; Asthma; Australia; Bronchodilator Agents; Case-Control Studies; Community Pharmacy

2004
Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study.
    Acta paediatrica (Oslo, Norway : 1992), 2004, Volume: 93, Issue:10

    Topics: Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchopulmon

2004
Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:5

    Topics: Active Transport, Cell Nucleus; Adolescent; Albuterol; Androstadienes; Apoptosis; Asthma; Caspases;

2004
Ten puffs too many.
    Archives of disease in childhood, 2004, Volume: 89, Issue:12

    Topics: Albuterol; Asthma; Bronchodilator Agents; Burns, Chemical; Child; Humans; Male; Nebulizers and Vapor

2004
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma.
    American journal of respiratory and critical care medicine, 2005, Mar-15, Volume: 171, Issue:6

    Topics: Adolescent; Albuterol; Alleles; Asthma; Bronchodilator Agents; Child; Female; Gene Frequency; Genoty

2005
The allergic march in pollinosis: natural history and therapeutic implications.
    International archives of allergy and immunology, 2004, Volume: 135, Issue:4

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; Coho

2004
Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients.
    International archives of allergy and immunology, 2004, Volume: 135, Issue:4

    Topics: Adult; Age Factors; Aged; Albuterol; Allergens; Ambrosia; Asthma; Betula; Bronchodilator Agents; Fem

2004
Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchi

2004
Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:7

    Topics: Administration, Inhalation; Aerosols; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Asthma

2004
Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:6

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and

2004
Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate: comment.
    Respirology (Carlton, Vic.), 2004, Volume: 9, Issue:4

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla

2004
Diagnostic accuracy of bronchodilator responsiveness in wheezy children.
    Thorax, 2005, Volume: 60, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Femal

2005
Rubbing ointments and asthma morbidity in adolescents.
    Journal of alternative and complementary medicine (New York, N.Y.), 2004, Volume: 10, Issue:6

    Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Camphor; Cross-Sectional Studies; Drug Combina

2004
Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.
    Allergy, 2005, Volume: 60, Issue:3

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents; Cells, Cultu

2005
Metered dose inhalers: a need for dose counters.
    Respirology (Carlton, Vic.), 2005, Volume: 10, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Packaging; Equipme

2005
Correspondence regarding levalbuterol and racemic albuterol, July 2004 Supplement.
    The American journal of managed care, 2005, Volume: 11, Issue:1

    Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Emergency Service, Hospital;

2005
Evaluation of particle size distribution of albuterol sulfate hydrofluoroalkane administered via metered-dose inhaler with and without valved holding chambers.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Hydrocarbons, Fluorinated; Meter

2005
Respiratory failure precipitated by salbutamol.
    Internal medicine journal, 2005, Volume: 35, Issue:3

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Ne

2005
Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2005,Spring, Volume: 18, Issue:1

    Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Computer Simulation; Equipment Design; Female;

2005
Combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid as initial maintenance treatment in asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm

2005
A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Protocols; Delayed-Action Preparations; Drug Ther

2005
Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:1

    Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Age

2005
Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Federal register, 2005, Apr-04, Volume: 70, Issue:63

    Topics: Adrenergic beta-Agonists; Air Pollutants; Air Pollution; Albuterol; Asthma; Chlorofluorocarbons; Cos

2005
Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Treatments in respiratory medicine, 2005, Volume: 4, Issue:2

    Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho

2005
Rapid onset of tolerance to beta-agonist bronchodilation.
    Respiratory medicine, 2005, Volume: 99, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Area Under Curve; Asthma; Bronchia

2005
Images in clinical medicine. Airway dilatation after inhalation of a beta-agonist.
    The New England journal of medicine, 2005, Apr-14, Volume: 352, Issue:15

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma;

2005
The GOAL study: designed to favor a long-acting beta2-agonist?
    American journal of respiratory and critical care medicine, 2005, May-01, Volume: 171, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperr

2005
An own GOAL or a real breakthrough?
    American journal of respiratory and critical care medicine, 2005, May-01, Volume: 171, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Therapy, Co

2005
Salivary-type hyperamylasemia in theophylline poisoning.
    Pediatrics international : official journal of the Japan Pediatric Society, 2005, Volume: 47, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans; Hyperamyl

2005
Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination.
    International journal of clinical practice, 2005, Volume: 59, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Andros

2005
Delayed-type asthmatic response induced by repeated intratracheal exposure to toluene-2,4-diisocyanate in guinea pigs.
    International archives of allergy and immunology, 2005, Volume: 137, Issue:2

    Topics: Airway Resistance; Albumins; Albuterol; Allergens; Animals; Asthma; Chromones; Dexamethasone; Diseas

2005
Out-of-hospital administration of albuterol for asthma by basic life support providers.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2005, Volume: 12, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child

2005
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.
    American journal of respiratory and critical care medicine, 2005, Sep-15, Volume: 172, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic

2005
Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity.
    The European respiratory journal, 2005, Volume: 25, Issue:5

    Topics: Albuterol; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Disease Models, Animal; Guinea Pig

2005
Salamol asthma inhaler fails roadside alcohol breath testing.
    The New Zealand medical journal, 2005, May-06, Volume: 118, Issue:1214

    Topics: Albuterol; Alcohol Drinking; Asthma; Automobile Driving; Breath Tests; Bronchodilator Agents; Ethano

2005
Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma.
    Emergency medicine journal : EMJ, 2005, Volume: 22, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Carbon Dioxide; Female; Forced

2005
Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2005, Volume: 38, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Chronic Disease; Disease Models, Animal; Dose-

2005
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium.
    The European respiratory journal, 2005, Volume: 25, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As

2005
Acute electrophysiologic effects of inhaled salbutamol in humans.
    Chest, 2005, Volume: 127, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Atrioventricular Node; Dose

2005
Role of combination inhaled corticosteroids and long acting beta agonists in the treatment of adult asthma.
    Issues in emerging health technologies, 2005, Issue:68

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And

2005
Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected].
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:6

    Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Anti-A

2005
Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma.
    American journal of respiratory and critical care medicine, 2005, Sep-15, Volume: 172, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expi

2005
Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*.
    Pharmacogenomics, 2005, Volume: 6, Issue:4

    Topics: 5' Untranslated Regions; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Ag

2005
Effects of various anti-asthmatic agents on mite allergen-pulsed murine bone marrow-derived dendritic cells.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:7

    Topics: Albuterol; Androstadienes; Animals; Anti-Asthmatic Agents; Antigens, Dermatophagoides; Asthma; Bone

2005
Treatment patterns for pediatric asthma prior to and after emergency department events.
    Pediatric pulmonology, 2005, Volume: 40, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Albuterol; As

2005
Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:5

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents;

2005
Treatment of mild asthma.
    The New England journal of medicine, 2005, Jul-28, Volume: 353, Issue:4

    Topics: Acetates; Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Chil

2005
Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model.
    The Journal of allergy and clinical immunology, 2005, Volume: 116, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Apoptosis; Asthma; Bronchial Hyperreactivity; Disease

2005
[A three-year-old boy with hypoglycaemia].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Aug-11, Volume: 125, Issue:15

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child, Prescho

2005
PHARMAC and Ventolin in New Zealand.
    The New Zealand medical journal, 2005, Aug-12, Volume: 118, Issue:1220

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Industry; Equipment Design; Equipment F

2005
Time to death, airway wall inflammation and remodelling in fatal asthma.
    The European respiratory journal, 2005, Volume: 26, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Death; Female; Humans; Lung; Male; Mucu

2005
PHARMAC responds on salbutamol.
    The New Zealand medical journal, 2005, Aug-26, Volume: 118, Issue:1221

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Industry; Equipment Failure Analysis; H

2005
Adherence to asthma controller medication regimens.
    Respiratory medicine, 2005, Volume: 99, Issue:10

    Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthm

2005
Pressure oscillation amplitude after interruption of tidal breathing as an index of change in airway mechanics in preschool children.
    Pediatric pulmonology, 2005, Volume: 40, Issue:5

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Diagnosis, Computer-A

2005
Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:9

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Child; Female; Haplot

2005
Recognition of asthma in adolescents and young adults: which objective measure is best?
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Antigens; Asthma; Bro

2005
Lupine inhalation induced asthma in a child.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005, Volume: 16, Issue:6

    Topics: Administration, Inhalation; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Chil

2005
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB.
    International immunology, 2005, Volume: 17, Issue:11

    Topics: Actins; Active Transport, Cell Nucleus; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-In

2005
Misleading data analyses in salmeterol (SMART) study.
    Lancet (London, England), 2005, Oct-08, Volume: 366, Issue:9493

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Data Interpreta

2005
Long-acting beta2-agonists in asthma: safety concerns.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Oct-25, Volume: 173, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Randomized

2005
Where are the guidelines for the treatment of asthma with panic spectrum symptoms?
    American journal of respiratory and critical care medicine, 2005, Oct-15, Volume: 172, Issue:8

    Topics: Albuterol; Antidepressive Agents; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; P

2005
Long-acting inhaled bronchodilators for COPD--lack of logic continues.
    The New Zealand medical journal, 2005, Sep-16, Volume: 118, Issue:1222

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Approval; Ethanolamines;

2005
Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED.
    The American journal of emergency medicine, 2005, Volume: 23, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

2005
Clinically masked increases in bronchial inflammation in guideline-treated persistent asthma.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Albuterol; Allergens; Androstadienes; Asthma; Bronchitis; Bronchodilator Agents;

2006
[The management of bronchial asthma during pregnancy--Hungarian experiences].
    Orvosi hetilap, 2005, Nov-06, Volume: 146, Issue:45

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Birth Weight; Budesonid

2005
Hearing half the message? A re-audit of the care of patients with acute asthma by emergency ambulance crews in London.
    Quality & safety in health care, 2005, Volume: 14, Issue:6

    Topics: Acute Disease; Adult; Albuterol; Ambulances; Asthma; Bronchodilator Agents; Child; Clinical Protocol

2005
Nitrogen washout slope in poorly controlled asthma.
    Allergy, 2006, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Case-Control Studies; Fem

2006
Salmeterol and paroxetine: more evidence for paradoxical medicine.
    Medical hypotheses, 2006, Volume: 66, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Clinical Trials

2006
Safety of long-acting beta-agonists--an urgent need to clear the air.
    The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Drug

2005
Utility and efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler for persistent asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma

2005
Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2006, Volume: 126, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

2006
Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age

2005
No role for inhaled magnesium sulfate in the treatment of acute asthma?
    Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:5

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; A

2007
A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia.
    European journal of pediatrics, 2006, Volume: 165, Issue:5

    Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Clinical Competence; Humans; Hypokalemia; I

2006
Beta2 déjà vu.
    Chest, 2006, Volume: 129, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol

2006
Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma.
    International archives of allergy and immunology, 2006, Volume: 139, Issue:3

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchodilator Agents; Cel

2006
Planning ahead. Albuterol & the potential for hypokalemia-induced ventricular tachycardia in prehospital care.
    JEMS : a journal of emergency medical services, 2006, Volume: 31, Issue:2

    Topics: Aged; Albuterol; Ambulatory Care; Asthma; Bronchodilator Agents; Emergency Treatment; Female; Humans

2006
Contact dermatitis around a tracheostoma due to salbutamol sulfate and Aldecin.
    Contact dermatitis, 2006, Volume: 54, Issue:2

    Topics: Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Beclomethasone; Dermatitis, Allergic Contact; D

2006
[Fatal asthma in childhod preventable by recognizing risk factors and presenting features].
    Nederlands tijdschrift voor geneeskunde, 2006, Feb-04, Volume: 150, Issue:5

    Topics: Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child;

2006
Invalid and irrelevant comparisons: apples or oranges?
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:2

    Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Cycloprop

2006
Safety of long-acting beta-agonists.
    The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Dr

2006
A levalbuterol metered-dose inhaler (Xopenex HFA) for asthma.
    The Medical letter on drugs and therapeutics, 2006, Mar-13, Volume: 48, Issue:1230

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Metered Dose Inhalers;

2006
Exhaled carbon monoxide levels in school-age children with episodic asthma.
    Pediatric pulmonology, 2006, Volume: 41, Issue:5

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Breath Tests; Bronchodilator Agents; Carbon

2006
Safety of long-acting beta-agonists.
    The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination; Hum

2006
Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives.
    Current medical research and opinion, 2006, Volume: 22, Issue:3

    Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho

2006
Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
    Current medical research and opinion, 2006, Volume: 22, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Br

2006
Children's asthma and the third world: an approach.
    Journal of investigational allergology & clinical immunology, 2006, Volume: 16, Issue:1

    Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Child Health Services; Chil

2006
[The clinicofunctional characterization of the phenotypes of severe uncontrollable bronchial asthma].
    Klinicheskaia meditsina, 2006, Volume: 84, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agen

2006
Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.
    The Journal of pediatrics, 2006, Volume: 148, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adrenal Insufficiency; Albuterol; Androstadienes; Asthma; Br

2006
Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists.
    The Journal of pediatrics, 2006, Volume: 148, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Female; Forced Expiratory Volu

2006
[CD28 and CTLA-4 costimulatory molecules expression on T lymphocytes and NK cells in nonallergic bronchial asthma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2006, Volume: 20, Issue:116

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differ

2006
Spontaneous pneumopericardium, pneumomediastinum and subcutaneous emphysema: unusual complications of asthma in a 2-year-old boy.
    Emergency medicine journal : EMJ, 2006, Volume: 23, Issue:6

    Topics: Albuterol; Anti-Asthmatic Agents; Anti-Bacterial Agents; Asthma; Child, Preschool; Drug Therapy, Com

2006
Buteyko breathing technique and asthma in children: a case series.
    The New Zealand medical journal, 2006, May-19, Volume: 119, Issue:1234

    Topics: Adolescent; Albuterol; Androstadienes; Asthma; Breathing Exercises; Bronchodilator Agents; Child; Co

2006
Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice.
    Virology journal, 2006, May-23, Volume: 3

    Topics: Albuterol; Allergens; Androstadienes; Animals; Anti-Allergic Agents; Asthma; Bronchoalveolar Lavage;

2006
[FEV1 after three years of observation in patients with bronchial asthma and patients with chronic obstructive pulmonary disease].
    Pneumonologia i alergologia polska, 2005, Volume: 73, Issue:2

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Follow-Up Studies

2005
Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness.
    American journal of respiratory and critical care medicine, 2006, Sep-01, Volume: 174, Issue:5

    Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black or African American; Emerge

2006
Profiles in patient safety: Antibiotic timing in pneumonia and pay-for-performance.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2006, Volume: 13, Issue:7

    Topics: Aged, 80 and over; Albuterol; Anti-Bacterial Agents; Asthma; Chest Pain; Female; Humans; Male; Middl

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
    Thorax, 2006, Volume: 61, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F

2006
Lessons from structure-function studies in asthma: myths and truths about what we teach.
    Journal of applied physiology (Bethesda, Md. : 1985), 2006, Volume: 101, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Forced Expi

2006
Summaries for patients. What are the risks of using inhaled long-acting beta-agonist medications for the relief of asthma?
    Annals of internal medicine, 2006, Jun-20, Volume: 144, Issue:12

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch

2006
Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:4

    Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; C

2006
PP-ICONS--another tool to help interpret asthma utilization studies.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:4

    Topics: Abstracting and Indexing; Acetates; Albuterol; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Drug Th

2006
Telithromycin in acute exacerbations of asthma.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Bacterial Agents; Asthma; Cytoc

2006
Pneumomediastinum and subcutaneous emphysema associated with asthma exacerbation.
    JPMA. The Journal of the Pakistan Medical Association, 2006, Volume: 56, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Male; Mediastinal Emphysema; Nebulizers and

2006
Long-acting beta agonists--prescribe with care.
    The New Zealand medical journal, 2006, Jul-07, Volume: 119, Issue:1237

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2006
Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma.
    Pediatrics, 2006, Volume: 118, Issue:2

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Budeso

2006
Levosalbutamol in the treatment of asthma.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchial Provocation T

2006
Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma.
    Respiratory research, 2006, Jul-28, Volume: 7

    Topics: Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Bronchi; Bronchodilator Agents; Cells, Cultu

2006
SMART therapy.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Aug-01, Volume: 175, Issue:3

    Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Humans;

2006
Variations in management of common inpatient pediatric illnesses: hospitalists and community pediatricians.
    Pediatrics, 2006, Volume: 118, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Albuterol; An

2006
Effects of long-term low-dose corticosteroid therapy on humoral immunity.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:1

    Topics: Acetates; Agammaglobulinemia; Albuterol; Anti-Asthmatic Agents; Antibodies, Bacterial; Antibody Form

2006
Long-acting bronchodilators: time for a re-think.
    Journal of the Royal Society of Medicine, 2006, Volume: 99, Issue:8

    Topics: Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Delayed-Ac

2006
Evidence based answers--is salmeterol safe in asthma?
    Australian family physician, 2006, Volume: 35, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

2006
Treatment outcome of asthma after one year follow-up in health centres of several developing countries.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2006, Volume: 10, Issue:8

    Topics: Adolescent; Adult; Albuterol; Algeria; Ambulatory Care; Asthma; Bronchodilator Agents; Child; Child,

2006
Magnitude of bronchoprotection of albuterol vs methacholine: relationship to baseline airway caliber.
    Chest, 2006, Volume: 130, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchoconstrictor Agents; Forced

2006
[Effects of salbutamo and ipraopium bromide inhalation on pulmonary function in young children with asthmatoid bronchitis].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2006, Volume: 8, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Preschool;

2006
Exhaled breath condensate pH measurement in children with asthma, allergic rhinitis and atopic dermatitis.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2006, Volume: 17, Issue:6

    Topics: Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Budesonide; Case-Control Studies

2006
Life-threatening asthma during treatment with salmeterol.
    The New England journal of medicine, 2006, Aug-24, Volume: 355, Issue:8

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma;

2006
The structural basis of airways hyperresponsiveness in asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2006, Volume: 101, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchoconstriction;

2006
Systemic reaction to omalizumab.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:2

    Topics: Acetates; Adrenal Cortex Hormones; Aged; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents;

2006
The impact of spirometry on pediatric asthma diagnosis and treatment.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2006, Volume: 43, Issue:7

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm

2006
Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:3

    Topics: Acetates; Adolescent; Airway Obstruction; Albuterol; Asthma; Child; Chronic Disease; Cyclopropanes;

2006
Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2006, Volume: 43, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchoconstriction; Dyspnea; Female; Forced Expirato

2006
The Salmeterol Multicenter Asthma Research Trial.
    Chest, 2006, Volume: 130, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Humans

2006
Cause of death in the SMART Trial.
    Chest, 2006, Volume: 130, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Black or African American; Cause of Death; Dose-Respons

2006
Why SMART about second-line treatment when first-line treatment is being ignored?
    Chest, 2006, Volume: 130, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination; Gui

2006
Comments on the Salmeterol Multicenter Asthma Research Trial.
    Chest, 2006, Volume: 130, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug-Related Side Effects and Adverse Reactions; Endpoi

2006
[A move meat beginning...and evolutive].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:12

    Topics: Adolescent; Adrenergic Agonists; Albuterol; Angioedema; Asthma; Bronchial Spasm; Bronchodilator Agen

2006
Adherence and persistence with fluticasone propionate/salmeterol combination therapy.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchod

2006
Peak inspiratory flow rate after methacholine challenge in asthmatic patients and its impact on the effect of formoterol via different inhalers.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2006,Fall, Volume: 19, Issue:3

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchial

2006
Room air entrainment during beta-agonist delivery with heliox.
    Chest, 2006, Volume: 130, Issue:4

    Topics: Adrenergic beta-Agonists; Air; Airway Resistance; Albuterol; Asthma; Dose-Response Relationship, Dru

2006
Symptom perception and adherence to asthma controller medications.
    Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, 2006, Volume: 38, Issue:3

    Topics: Adaptation, Psychological; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Aw

2006
Deep inspiration-induced changes in lung volume decrease with severity of asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstrictor

2007
(R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con].
    American journal of respiratory and critical care medicine, 2006, Nov-01, Volume: 174, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Cost of Illness; Disease Models, Animal; Disea

2006
Treatment with (R)-albuterol has no advantage over racemic albuterol.
    American journal of respiratory and critical care medicine, 2006, Nov-01, Volume: 174, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Cost of Illness; Dose-Resp

2006
Salamol and inequalities in New Zealand.
    The New Zealand medical journal, 2006, Oct-27, Volume: 119, Issue:1244

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Equipment Design; Equipment Failure

2006
Excess mortality in patients with asthma on long-acting beta2-agonists.
    The European respiratory journal, 2006, Volume: 28, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule; Hu

2006
The use of rhinitis medications in children receiving initial controller therapy for asthma.
    Current medical research and opinion, 2006, Volume: 22, Issue:11

    Topics: Acetates; Administration, Intranasal; Adolescent; Adrenal Cortex Hormones; Albuterol; Androstadienes

2006
More on life-threatening asthma and salmeterol.
    The New England journal of medicine, 2006, Nov-16, Volume: 355, Issue:20

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Logistic Models; Occup

2006
The confounding effects of thoracic gas compression on measurement of acute bronchodilator response.
    American journal of respiratory and critical care medicine, 2007, Feb-15, Volume: 175, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Nebulizers and V

2007
Comparative effects of a high-intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes.
    International journal of sports medicine, 2007, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchoconstrictor Agents; Exercise;

2007
[How to make easier the treatment of asthma].
    Revue des maladies respiratoires, 2006, Volume: 23, Issue:4 Pt 2

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Aerosols; Albuterol; Androstadienes

2006
Salamol and asthma in New Zealand.
    The New Zealand medical journal, 2006, Nov-17, Volume: 119, Issue:1245

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethics, Research; Humans; New Zealand; Research Design; Tr

2006
Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management.
    Treatments in respiratory medicine, 2006, Volume: 5, Issue:6

    Topics: Albuterol; Asthma; Budesonide; Drug Combinations; Ethanolamines; Humans; Nebulizers and Vaporizers

2006
Post hoc analysis and claims of superiority in the EXCEL trial.
    Respiratory medicine, 2007, Volume: 101, Issue:3

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therap

2007
Lactic acidosis in children with acute exacerbation of severe asthma.
    European journal of emergency medicine : official journal of the European Society for Emergency Medicine, 2007, Volume: 14, Issue:1

    Topics: Acidosis, Lactic; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Humans; Male; Retr

2007
Is salmeterol safe in asthma?
    Australian family physician, 2006, Volume: 35, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Receptors, Adrenergic, beta-2; Salmeterol Xinaf

2006
Control of airway inflammation.
    The Journal of allergy and clinical immunology, 2007, Volume: 119, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Fluticasone;

2007
Beta2-agonists and paresthesias in multiple sclerosis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 98, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase

2007
[Bronchodilators in acute asthma: metered dose inhalers or wet nebulizations?].
    Medicina, 2006, Volume: 66, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents

2006
Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie

2007
Onset of action of formoterol versus salmeterol.
    Respiratory medicine, 2007, Volume: 101, Issue:4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin

2007
[Expiratory flow limitation detected by negative expiratory pressure in patients with bronchial asthma].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2006, Volume: 29, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Forced Ex

2006
[Metabolic acidosis in a context of acute severe asthma].
    Annales francaises d'anesthesie et de reanimation, 2007, Volume: 26, Issue:4

    Topics: Acidosis, Lactic; Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Middle Ag

2007
[Acute myocardial infarction triggered by salbutamol in asthma bronchiale].
    Orvosi hetilap, 2006, Nov-26, Volume: 147, Issue:47

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Electrocardiography; Femal

2006
A matched crossover design for clinical trials.
    Contemporary clinical trials, 2007, Volume: 28, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Clinical Trials as Topic; Cross-O

2007
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
    The Journal of biological chemistry, 2007, May-25, Volume: 282, Issue:21

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen

2007
beta-adrenergic receptor genotype and response to salmeterol.
    The Journal of allergy and clinical immunology, 2007, Volume: 120, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy, Co

2007
Salmeterol response and beta(2)-adrenergic receptor genotype.
    The Journal of allergy and clinical immunology, 2007, Volume: 120, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Genotype; Humans; Receptors, Adr

2007
Correlations between pulse oximetry and peak expiratory flow in acute asthma.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2007, Volume: 40, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi

2007
Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model.
    Endocrinology, 2007, Volume: 148, Issue:7

    Topics: Acetylcholine; Administration, Inhalation; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Cel

2007
Asthma: fatal exacerbations with long-acting beta2 agonist therapy without concomitant steroid therapy.
    Prescrire international, 2007, Volume: 16, Issue:88

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; Clinical Tria

2007
Adenosine for salbutamol-induced supraventricular tachycardia.
    Intensive care medicine, 2007, Volume: 33, Issue:9

    Topics: Adenosine; Albuterol; Anti-Arrhythmia Agents; Asthma; Bronchodilator Agents; Humans; Male; Tachycard

2007
Case records of the Massachusetts General Hospital. Case 15-2007. A 20-year-old woman with asthma and cardiorespiratory arrest.
    The New England journal of medicine, 2007, May-17, Volume: 356, Issue:20

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Cause of Death; Fatal Outcome; F

2007
Clinical Decisions. Treatment of mild persistent asthma.
    The New England journal of medicine, 2007, May-17, Volume: 356, Issue:20

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2007
The role of the large airways on smooth muscle contraction in asthma.
    Journal of applied physiology (Bethesda, Md. : 1985), 2007, Volume: 103, Issue:4

    Topics: Albuterol; Asthma; Bronchi; Bronchodilator Agents; Humans; Muscle Contraction; Muscle, Smooth

2007
Hyperlactaemia due to nebulised salbutamol.
    Anaesthesia, 2007, Volume: 62, Issue:7

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Nebulizers and Vaporiz

2007
Clinical Decisions. Mild persistent asthma--polling results.
    The New England journal of medicine, 2007, Jul-12, Volume: 357, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Becl

2007
Benefits of long-acting beta2-agonists.
    The Journal of allergy and clinical immunology, 2007, Volume: 120, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; De

2007
Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor.
    The European respiratory journal, 2007, Volume: 30, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Blotting, Western; Bronchi; Bronchodilator Agents; Bude

2007
Albuterol inhalers.
    The New England journal of medicine, 2007, Jun-28, Volume: 356, Issue:26

    Topics: Aerosol Propellants; Albuterol; Asthma; Chlorofluorocarbons; Drugs, Generic; Fees, Pharmaceutical; H

2007
Aseptic femoral head necrosis in a patient receiving long term courses of inhaled and intranasal corticosteroids.
    Tuberkuloz ve toraks, 2007, Volume: 55, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Arthro

2007
Identification of bronchodilator responsiveness by forced oscillation admittance in children.
    Pediatric research, 2007, Volume: 62, Issue:3

    Topics: Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Chi

2007
Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a "real-life" setting.
    European journal of medical research, 2007, Jun-27, Volume: 12, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Th

2007
Reducing asthma treatment.
    The New England journal of medicine, 2007, Aug-02, Volume: 357, Issue:5

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Administration Schedule; Drug Therapy

2007
Beclomethasone and albuterol in mild asthma.
    The New England journal of medicine, 2007, Aug-02, Volume: 357, Issue:5

    Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Drug Combinati

2007
Reducing asthma treatment.
    The New England journal of medicine, 2007, Aug-02, Volume: 357, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

2007
Beclomethasone and albuterol in mild asthma.
    The New England journal of medicine, 2007, Aug-02, Volume: 357, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child;

2007
Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Ant

2007
A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Drug safety, 2007, Volume: 30, Issue:8

    Topics: Adult; Aerosol Propellants; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Com

2007
Interrupter resistance short-term repeatability and bronchodilator response in preschool children.
    Respiratory medicine, 2007, Volume: 101, Issue:12

    Topics: Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child;

2007
Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient.
    Allergy, 2007, Volume: 62, Issue:10

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Drug Hypersensitivit

2007
Hyperlactaemia in asthmatics.
    Anaesthesia, 2007, Volume: 62, Issue:10

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Lactic Acid

2007
Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study.
    Chest, 2007, Volume: 132, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Bo

2007
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.
    Bioorganic & medicinal chemistry letters, 2007, Nov-15, Volume: 17, Issue:22

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Biological Availability; Caco-2 Cells; CHO Cel

2007
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
    Journal of applied physiology (Bethesda, Md. : 1985), 2007, Volume: 103, Issue:4

    Topics: Albuterol; Artifacts; Asthma; Bronchi; Bronchoconstriction; Bronchoconstrictor Agents; Bronchodilato

2007
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
    Journal of applied physiology (Bethesda, Md. : 1985), 2007, Volume: 103, Issue:4

    Topics: Albuterol; Artifacts; Asthma; Bronchi; Bronchoconstriction; Bronchodilator Agents; Humans; Lung Volu

2007
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
    Journal of applied physiology (Bethesda, Md. : 1985), 2007, Volume: 103, Issue:4

    Topics: Albuterol; Animals; Asthma; Bronchi; Bronchodilator Agents; Disease Models, Animal; Humans; Lung Vol

2007
Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation.
    British journal of clinical pharmacology, 2008, Volume: 65, Issue:3

    Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Inhalation Spacers; Lung; Male; Meter

2008
The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations.
    Current medical research and opinion, 2007, Volume: 23, Issue:11

    Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Costs; Drug Therapy, Combination; Dru

2007
A 39-year-old woman with intractable asthma.
    Chest, 2007, Volume: 132, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Female; Forced Expiratory Volume;

2007
[Salmeterol for the treatment of childhood asthma: the experience of 96 cases].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Female; Forced Exp

2007
Adrenergic responsiveness: FEV1 and symptom differences in Whites and African Americans with mild asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black or African American; Bronchial Provocation

2007
Validating a guidelines based asthma decision support system: step one.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:8

    Topics: Albuterol; Asthma; Bronchodilator Agents; Decision Making, Computer-Assisted; Female; Humans; Male;

2007
Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2007, Volume: 44, Issue:8

    Topics: Adolescent; Adult; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Child; Femal

2007
Heterogeneity of bronchoconstriction does not distinguish mild asthmatic subjects from healthy controls when supine.
    Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 104, Issue:1

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provoc

2008
Bronchodilator response: another piece in the asthma mosaic.
    The Journal of pediatrics, 2007, Volume: 151, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Nebulizers and Vaporizer

2007
Value of the bronchodilator response in assessing controller naïve asthmatic children.
    The Journal of pediatrics, 2007, Volume: 151, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Forced Expiratory Volume;

2007
Metabolic acidosis in severe asthma: Is it the disease or is it the doctor?
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2007, Volume: 8, Issue:6

    Topics: Acidosis; Acute Disease; Albuterol; Asthma; Blood Gas Analysis; Bronchodilator Agents; Child, Presch

2007
Paradoxical asthma hazard of short-acting beta2-agonists.
    Allergy, 2008, Volume: 63, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstrictio

2008
A predictive score for unfavorable outcome of acute asthma in the emergency room.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:10

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Female; Health

2007
Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Budesonide; Cells, Cultured; E

2008
Salamol--was it worth it?
    The New Zealand medical journal, 2007, Dec-14, Volume: 120, Issue:1267

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Costs; Drugs, Generic;

2007
The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2007,Winter, Volume: 20, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Carriers; Equipment Desig

2007
[Voiding difficulties in a child attributed to the use of ipratropium and salbutamol].
    Nederlands tijdschrift voor geneeskunde, 2007, Dec-08, Volume: 151, Issue:49

    Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Female; Humans; Ipratropium; Urinat

2007
[More asthma death cases with beta-2-antagonists: with inhaled corticosteroids on the safe side?].
    MMW Fortschritte der Medizin, 2007, Dec-06, Volume: 149, Issue:49-50

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Clinica

2007
Benefits of combination therapy on exacerbations in nonsmoking patients with asthma.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:3

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Fluticasone; Fluticason

2008
Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.
    COPD, 2008, Volume: 5, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Carboxylic Acids; Cells, Cultured; Chemokine CXCL10; Cy

2008
Treatment of mild persistent asthma.
    Primary care respiratory journal : journal of the General Practice Airways Group, 2008, Volume: 17, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm

2008
Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.
    Current medical research and opinion, 2008, Volume: 24, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma

2008
Adenosine 5'-monophosphate in asthma: gas exchange and sputum cellular responses.
    The European respiratory journal, 2008, Volume: 31, Issue:6

    Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation T

2008
The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience.
    Respiratory care, 2008, Volume: 53, Issue:3

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Costs and Cost Analysis

2008
Increased RhoGDI2 and peroxiredoxin 5 levels in asthmatic murine model of beta2-adrenoceptor desensitization: a proteomics approach.
    Chinese medical journal, 2008, Feb-20, Volume: 121, Issue:4

    Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Female; G

2008
Benzalkonium chloride induced bronchoconstriction in patients with stable bronchial asthma.
    The Korean journal of internal medicine, 2007, Volume: 22, Issue:4

    Topics: Adult; Albuterol; Asthma; Benzalkonium Compounds; Bronchial Provocation Tests; Bronchoconstriction;

2007
The economic effect of the hydrofluoroalkane albuterol transition on children with asthma.
    The Journal of allergy and clinical immunology, 2008, Volume: 121, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Hydrocarbons, Fluorinated; Metered Dose Inh

2008
Utility of impulse oscillometry in young children with asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2008, Volume: 19, Issue:8

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Eosinophils; Female; Humans; Immu

2008
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
    The Journal of pediatrics, 2008, Volume: 152, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female

2008
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
    The Journal of pediatrics, 2008, Volume: 152, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female

2008
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
    The Journal of pediatrics, 2008, Volume: 152, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female

2008
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
    The Journal of pediatrics, 2008, Volume: 152, Issue:4

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female

2008
Proliferation is not increased in airway myofibroblasts isolated from asthmatics.
    The European respiratory journal, 2008, Volume: 32, Issue:2

    Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cell Proliferation; Cyclin D1; Fema

2008
Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines.
    Archives of disease in childhood, 2008, Volume: 93, Issue:4

    Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Australia; Child;

2008
Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation.
    International archives of allergy and immunology, 2008, Volume: 146, Issue:4

    Topics: Albuterol; Asthma; Blotting, Western; Bronchodilator Agents; Cell Proliferation; Cyclin-Dependent Ki

2008
Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children.
    Pediatric pulmonology, 2008, Volume: 43, Issue:5

    Topics: Adolescent; Albuterol; Argentina; Asthma; Bronchodilator Agents; Child; Drug Tolerance; Female; Forc

2008
FEF75 in asthma management.
    European annals of allergy and clinical immunology, 2007, Volume: 39, Issue:10

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast

2007
Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Clinical therapeutics, 2008, Volume: 30, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc

2008
An under-recognized complication of treatment of acute severe asthma.
    The American journal of emergency medicine, 2008, Volume: 26, Issue:4

    Topics: Acidosis, Lactic; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Male; Respiration, Artifi

2008
Paradoxical response to levalbuterol.
    The Journal of the American Osteopathic Association, 2008, Volume: 108, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Diseases; Constriction, Pathologic; Hu

2008
Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2008, Volume: 38, Issue:7

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; C

2008
[Influence of education level on self-evaluation and control of patients with bronchial asthma].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Educational Statu

2008
Age-dependency of alpha- and beta-adrenoceptors on thrombocytes and lymphocytes of asthmatic and nonasthmatic children.
    European journal of pediatrics, 1984, Volume: 142, Issue:2

    Topics: Adolescent; Adult; Aging; Albuterol; Asthma; Blood Platelets; Child; Child, Preschool; Humans; Infan

1984
Nebulised salbutamol in general practice.
    Lancet (London, England), 1980, Nov-29, Volume: 2, Issue:8205

    Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Family Practice; Humans; Infant; Methods

1980
Bronchodilating drugs and airway reactivity.
    European journal of respiratory diseases. Supplement, 1980, Volume: 106

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Female; Forced Expirato

1980
Combined vs. sequential vs. single-entity therapy.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1981, Volume: 18, Issue:1

    Topics: Albuterol; Aminophylline; Asthma; Beclomethasone; Drug Therapy, Combination; Ephedrine; Epinephrine;

1981
[Treatment of bronchial asthma].
    Medicina clinica, 1981, Apr-10, Volume: 76, Issue:7

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Cromolyn Sodium

1981
Maximal oxygen consumption rate in patients with bronchial asthma-the effect of beta 2-adrenoreceptor stimulation.
    Scandinavian journal of clinical and laboratory investigation, 1980, Volume: 40, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressu

1980
beta 2-Adrenoceptor stimulants and theophylline in asthma therapy.
    European journal of respiratory diseases. Supplement, 1981, Volume: 116

    Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Albuterol; Aminophylline; Asthma; Bronchod

1981
[Protective effect of adrenergic alpha blockaders on posthistamine bronchial spasm].
    Pneumonologia polska, 1981, Volume: 49, Issue:11

    Topics: Adrenergic alpha-Antagonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchial Spasm

1981
Effect of beta 2-adrenergic stimulation on serum lipids.
    International journal of clinical pharmacology, therapy, and toxicology, 1982, Volume: 20, Issue:11

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cholesterol; Cholesterol, HDL; Cholesterol, LDL;

1982
Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.
    British journal of clinical pharmacology, 1983, Volume: 15, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Forced Expirat

1983
Safe drugs for childhood asthma?
    Lancet (London, England), 1983, Oct-29, Volume: 2, Issue:8357

    Topics: Aerosols; Albuterol; Asthma; Child, Preschool; Humans

1983
Beta-adrenergic drugs in the management of asthma in athletes.
    The Journal of allergy and clinical immunology, 1984, Volume: 73, Issue:5 Pt 2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Dose-Response Relationship, D

1984
Inhaled therapy reduces morning dips in asthma.
    Lancet (London, England), 1984, May-26, Volume: 1, Issue:8387

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Child; Circadian Rhythm; Drug Therap

1984
Analysis of beta-sympathicomimetics in man with high performance liquid chromatography using mode sequencing and electrochemical detection.
    European journal of respiratory diseases. Supplement, 1984, Volume: 135

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Chromatography, High Pressure Liquid; Food; Humans; Kin

1984
Beta-adrenoceptor agonist responses in the skin and lungs of asthmatic subjects.
    European journal of respiratory diseases. Supplement, 1984, Volume: 135

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Endothelium; Forced Expiratory Volume; Histamine

1984
Adrenergic receptors of normal and asthmatic airways.
    European journal of respiratory diseases. Supplement, 1984, Volume: 135

    Topics: Adrenergic alpha-Agonists; Albuterol; Asthma; Bronchial Spasm; Catecholamines; Dose-Response Relatio

1984
Persisting airflow limitation in asthmatics receiving routine self-adjusted medication.
    European journal of respiratory diseases, 1984, Volume: 65, Issue:5

    Topics: Adult; Aerosols; Age Factors; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volume; H

1984
Asthma caused by occupational exposure to a furan-based binder system.
    The Journal of allergy and clinical immunology, 1980, Volume: 66, Issue:6

    Topics: Albuterol; Asthma; Binding Sites; Butanols; Forced Expiratory Volume; Furans; Histamine Release; Hum

1980
Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (BD 40A).
    Archives internationales de pharmacodynamie et de therapie, 1981, Volume: 250, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Ethanolamines; Female; Formoterol Fumarate; Gu

1981
Histamine content of sputum from patients with asthma and chronic bronchitis.
    Clinical allergy, 1982, Volume: 12, Issue:1

    Topics: Albuterol; Animals; Asthma; Bronchitis; Carcinoma, Bronchogenic; Chronic Disease; Guinea Pigs; Hista

1982
Do human mast cells possess functional beta adrenoceptors in vivo?
    Agents and actions. Supplements, 1983, Volume: 13

    Topics: Adult; Albuterol; Asthma; Female; Histamine; Histamine Release; Humans; Male; Mast Cells; Propranolo

1983
Effects of fenoterol hydrobromide on histamine release from human leukocytes.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Albuterol; Allergens; Asthma; Child; Ethanolamines; Fenoterol; Histamine Release; Humans; Leukocytes

1983
A comparison of late reactions to antigen and exercise.
    The Journal of allergy and clinical immunology, 1984, Volume: 73, Issue:5 Pt 2

    Topics: Albuterol; Antigens; Asthma; Asthma, Exercise-Induced; Bronchial Provocation Tests; Chemotactic Fact

1984
Organizing a general-practitioner therapeutical trial.
    The Practitioner, 1982, Volume: 226, Issue:1367

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchitis; Clinical Trials as Topic; Double-Blind M

1982
Maximal expiratory flows and forced vital capacity in normal, asthmatic and bronchitic subjects after salbutamol and ipratropium bromide.
    Respiration; international review of thoracic diseases, 1982, Volume: 43, Issue:4

    Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchi; Bronchitis; Dose-Response Relatio

1982
Impaired atropine responsiveness in asthma: role of atopy.
    Respiration; international review of thoracic diseases, 1983, Volume: 44, Issue:2

    Topics: Adult; Aged; Albuterol; Asthma; Atropine; Atropine Derivatives; Female; Humans; Hypersensitivity, Im

1983
[Asthmatic crises in children. Value of salbutamol nebulization].
    Presse medicale (Paris, France : 1983), 1983, Dec-17, Volume: 12, Issue:46

    Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Respiratory Therapy

1983
Factors determining residual volume in normal and asthmatic subjects.
    European journal of respiratory diseases, 1984, Volume: 65, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Female; Humans; Ipratropium; Lung Volume Measurements; Male; Mid

1984
Reversible airflow obstruction: clinical spectrum and responsiveness to anticholinergic drugs.
    Respiration; international review of thoracic diseases, 1984, Volume: 45, Issue:3

    Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Female; Forced

1984
Asthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs.
    Respiration; international review of thoracic diseases, 1984, Volume: 45, Issue:3

    Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchial Provo

1984
[Influence of sympathomimetic drugs on immediate intradermal reactions induced by allergens].
    Arerugi = [Allergy], 1984, Volume: 33, Issue:11

    Topics: Adult; Albuterol; Asthma; Clenbuterol; Ethanolamines; Humans; Hypersensitivity, Immediate; Intraderm

1984
Cyclic nucleotides, beta receptors, and bronchial asthma.
    Advances in cyclic nucleotide research, 1980, Volume: 12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Albuterol; Asthma; Bronchi; Cyclic AMP; Cyclic GMP; Epinephrine

1980
[The treatment of asthmatic patients using an alpha-adrenoreceptor blocking agents--changes of various pulmonary function tests and plasma cyclic AMP levels (author's transl)].
    Nihon Kyobu Shikkan Gakkai zasshi, 1981, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Female; Humans; Lung Volume Measurements; Ma

1981
Plasma cyclic nucleotide levels in exercise-induced asthma.
    Thorax, 1981, Volume: 36, Issue:11

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cyclic AMP; Cyclic GMP; Humans; Male; Middle Age

1981
Anti-asthmatic activity of BB-1502 by inhalation.
    Japanese journal of pharmacology, 1982, Volume: 32, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Albuterol; Animals; Ascaris; Asthma; Bronchodilator Ag

1982
Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol.
    The Journal of allergy and clinical immunology, 1982, Volume: 70, Issue:6

    Topics: Administration, Intranasal; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Dose-R

1982
Relationships between responsiveness of the bronchi to acetylcholine and cyclic AMP response of lymphocytes to beta 1- and beta 2-adrenergic receptor stimulation in patients with asthma.
    Allergy, 1983, Volume: 38, Issue:1

    Topics: Acetylcholine; Albuterol; Asthma; Bronchi; Cyclic AMP; Humans; Lymphocytes; Norepinephrine; Receptor

1983
Interactions between beta-adrenergic activity and prostaglandin synthesis in control of airways bronchoconstrictor responsiveness.
    Agents and actions. Supplements, 1983, Volume: 13

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Female; Histamine; Humans; Indomethacin; Male;

1983
Is asthma due to partial beta-blockade of airways?
    Agents and actions. Supplements, 1983, Volume: 13

    Topics: Airway Resistance; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Humans; Receptors,

1983
Circadian variation in number and affinity of beta 2-adrenoceptors in lymphocytes of asthmatic patients.
    Clinical science (London, England : 1979), 1984, Volume: 66, Issue:3

    Topics: Albuterol; Asthma; Circadian Rhythm; Forced Expiratory Volume; Humans; Hydrocortisone; Kinetics; Lym

1984
Airway hyperreactivity. Cholinergic and adrenergic receptors.
    European journal of respiratory diseases. Supplement, 1983, Volume: 131

    Topics: Albuterol; Asthma; Bronchi; Humans; Parasympathetic Nervous System; Practolol; Prenalterol; Receptor

1983
Comparison of beta 2-adrenoceptor stimulation in bronchial and skeletal muscle in experimental and clinical studies.
    European journal of respiratory diseases. Supplement, 1984, Volume: 135

    Topics: Albuterol; Animals; Asthma; Bronchi; Cats; Guinea Pigs; Histamine; Humans; Muscle, Smooth; Muscles;

1984
Influence of beta-receptor-agonists and glucocorticoids on alpha- and beta-adrenoceptors of isolated blood cells from asthmatic children.
    Pediatric pharmacology (New York, N.Y.), 1983, Volume: 3, Issue:3-4

    Topics: Adolescent; Albuterol; Asthma; Blood Platelets; Child; Humans; Infant; Lymphocytes; Prednisolone; Ra

1983
Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis.
    Respiration; international review of thoracic diseases, 1984, Volume: 45, Issue:1

    Topics: Albuterol; Asthma; Bronchitis; Ethanolamines; Female; Fenoterol; Humans; Intermittent Positive-Press

1984
Improvement after training of children with exercise-induced asthma.
    Acta paediatrica Scandinavica, 1983, Volume: 72, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Exercise Therapy; F

1983
Addiction to aerosol treatment: the asthmatic alternative to glue sniffing.
    British medical journal (Clinical research ed.), 1983, Nov-19, Volume: 287, Issue:6404

    Topics: Adolescent; Aerosol Propellants; Aerosols; Albuterol; Asthma; Beclomethasone; Female; Humans; Substa

1983
A new treatment for asthma: promotional expediency versus pharmaceutical responsibility.
    British medical journal (Clinical research ed.), 1984, Jan-07, Volume: 288, Issue:6410

    Topics: Albuterol; Asthma; Beclomethasone; Drug Combinations; Humans

1984
Oxygen as a driving gas for nebulisers: safe or dangerous?
    British medical journal (Clinical research ed.), 1984, Jan-28, Volume: 288, Issue:6413

    Topics: Adult; Aerosols; Aged; Air; Albuterol; Asthma; Bronchitis; Carbon Dioxide; Female; Humans; Male; Mid

1984
Illogical warnings on Ventolin inhalers.
    British medical journal (Clinical research ed.), 1984, Apr-21, Volume: 288, Issue:6425

    Topics: Albuterol; Asthma; Drug Labeling; Humans

1984
Domiciliary nebulized beta-agonists. Long-term treatment in asthmatics, and drug intake and plasma levels in acute asthma.
    European journal of respiratory diseases. Supplement, 1984, Volume: 136

    Topics: Adult; Aerosols; Aged; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Human

1984
Decrease of exercise-induced asthma after physical training.
    European journal of respiratory diseases. Supplement, 1984, Volume: 136

    Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Carbon Dioxide; Child; Combined Modality Therapy; Cromo

1984
[Exercise-induced pathophysiological changes in asthmatic children. VII. Late asthmatic response in exercise-induced asthma: changes in chemical mediators and effects of the use of a mask and drugs].
    Arerugi = [Allergy], 1984, Volume: 33, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Chemotactic Factors; Child; Cromolyn Sodium

1984
Intravenous salbutamol in the treatment of status asthmaticus in children.
    Critical care medicine, 1984, Volume: 12, Issue:10

    Topics: Adolescent; Adult; Albuterol; Asthma; Carbon Dioxide; Child; Child, Preschool; Drug Evaluation; Hear

1984
Evaluation of complement (C3) inhibition in vitro by drugs used in the management of bronchial asthma.
    Asian Pacific journal of allergy and immunology, 1984, Volume: 2, Issue:2

    Topics: Adolescent; Adult; Albuterol; Aminophylline; Animals; Asthma; Complement Activation; Complement C3;

1984
Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water.
    European journal of respiratory diseases. Supplement, 1980, Volume: 106

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Cromolyn Sodium; Female; H

1980
The effect of vagolytic drugs on airway obstruction in patients with bronchial asthma.
    Annals of allergy, 1981, Volume: 46, Issue:6

    Topics: Airway Obstruction; Albuterol; Asthma; Atropine; Forced Expiratory Volume; Humans; Ipratropium; Maxi

1981
Influence of age on response to ipratropium and salbutamol in asthma.
    Thorax, 1981, Volume: 36, Issue:7

    Topics: Adult; Aging; Albuterol; Asthma; Atropine Derivatives; Forced Expiratory Volume; Humans; Ipratropium

1981
[Measurement of the effect of a bronchodilator using FEV1: how to express it?].
    Revue des maladies respiratoires, 1984, Volume: 1, Issue:2

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Middle Age

1984
Cardiac output and blood pressure in asthmatic children before and during induced asthma.
    Acta paediatrica Scandinavica, 1984, Volume: 73, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchi; Cardiac Output; Ch

1984
Drug intake and plasma concentrations in acute asthma.
    Respiration; international review of thoracic diseases, 1984, Volume: 45, Issue:4

    Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Ethanolamines; Female; Fenoterol;

1984
Nifedipine enhances the bronchodilator effect of salbutamol.
    Thorax, 1984, Volume: 39, Issue:8

    Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Synergism; Forced Expiratory Volume; Humans; Mal

1984
Atropine resistance in asthma: definition and provisional hypothesis.
    Respiration; international review of thoracic diseases, 1984, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine; Drug Resistance; Female; Forced Expiratory Vol

1984
Safety and efficacy of salbutamol aerosol on Dermatophagoides farinae induced bronchospasm in asthmatic patients.
    Annals of allergy, 1984, Volume: 53, Issue:5

    Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Airway Obstruction; Albuterol; Antigens; As

1984
Arterial oxygen desaturation following salbutamol inhalation in acute asthma.
    Chest, 1984, Volume: 86, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child, Preschool; Female; Humans; Male; Oxygen

1984
Multiparametrical approach to fog-challenge-induced bronchial hyperreactivity in asthmatics--protective effects of salbutamol plus beclomethasone dipropionate.
    International journal of clinical pharmacology, therapy, and toxicology, 1984, Volume: 22, Issue:9

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Humans; Male; Middle Aged; R

1984
Metabolic effects of salbutamol in bronchial asthma.
    The Journal of the Association of Physicians of India, 1984, Volume: 32, Issue:7

    Topics: Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Humans; Potassium

1984
Treatment of hypertension in mild asthmatic patients with atenolol.
    Angiology, 1984, Volume: 35, Issue:12

    Topics: Adult; Albuterol; Asthma; Atenolol; Blood Pressure; Electrocardiography; Exercise Test; Female; Hear

1984
Lung distensibility and airway function in asthmatic children.
    Pediatric research, 1984, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Child; Huma

1984
[Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma].
    Anales espanoles de pediatria, 1984, Nov-30, Volume: 21, Issue:8

    Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Drug Evaluation; Fo

1984
The antidiuretic hormone response to therapy for acute asthma.
    Australian paediatric journal, 1984, Volume: 20, Issue:4

    Topics: Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Fluid Therapy; Humans; Male; Oxyg

1984
[Effective combined therapy of selective beta 1-adrenergic antagonist and selective beta 2-adrenergic agonist in a patient with bronchial asthma and hypertrophic cardiomyopathy].
    Nihon Kyobu Shikkan Gakkai zasshi, 1984, Volume: 22, Issue:4

    Topics: Albuterol; Asthma; Cardiomyopathy, Hypertrophic; Drug Therapy, Combination; Female; Humans; Metoprol

1984
Anti-asthmatic effects and drug tolerance of selective beta 2-adrenergic stimulants in guinea-pigs.
    European journal of respiratory diseases. Supplement, 1983, Volume: 128 (Pt 2)

    Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Drug Tolerance; Ethanolamines; Fenoterol; Guinea

1983
The use of fenoterol powder for the treatment of children with asthma.
    European journal of respiratory diseases. Supplement, 1983, Volume: 130

    Topics: Adolescent; Albuterol; Asthma; Child; Ethanolamines; Female; Fenoterol; Humans; Male; Powders

1983
Effect of domiciliary treatment with nebulized beta 2-stimulants--a retrospective follow-up of 102 patients.
    European journal of respiratory diseases. Supplement, 1984, Volume: 136

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Follow-Up Studies; Humans; Mi

1984
Predicting rapid and slow response to treatment in acute severe asthma.
    British journal of diseases of the chest, 1983, Volume: 77, Issue:3

    Topics: Acute Disease; Adult; Age Factors; Albuterol; Asthma; Female; Humans; Hydrocortisone; Male; Peak Exp

1983
Ascaris-induced bronchoconstriction in primates experimentally infected with Ascaris suum ova.
    Clinical and experimental immunology, 1983, Volume: 54, Issue:2

    Topics: Airway Resistance; Albuterol; Allergens; Animals; Ascariasis; Ascaris; Asthma; Atropine; Benzopyrans

1983
An inexpensive nebuliser for asthmatic patients.
    The Practitioner, 1983, Volume: 227, Issue:1385

    Topics: Aerosols; Aged; Albuterol; Asthma; Child; Female; Humans; Male; Respiratory Therapy

1983
Aerosol bag for administration of bronchodilators to young asthmatic children.
    Pediatrics, 1984, Volume: 73, Issue:2

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Res

1984
Asthma and irreversible airflow obstruction.
    Thorax, 1984, Volume: 39, Issue:2

    Topics: Adult; Age Factors; Albuterol; Asthma; Chronic Disease; Female; Forced Expiratory Volume; Humans; Lu

1984
[Severe status asthmaticus in children: evaluation and treatment].
    L'union medicale du Canada, 1984, Volume: 113, Issue:2

    Topics: Albuterol; Aminophylline; Asthma; Child; Humans; Isoproterenol; Metaproterenol; Respiration, Artific

1984
Corticosteroid resistance in chronic asthma.
    British medical journal (Clinical research ed.), 1981, May-02, Volume: 282, Issue:6274

    Topics: Adrenal Cortex Hormones; Adult; Airway Obstruction; Albuterol; Asthma; Bronchi; Chronic Disease; Cir

1981
Bronchodilator effect of sodium cromoglycate and its clinical implications.
    British medical journal (Clinical research ed.), 1981, Aug-08, Volume: 283, Issue:6288

    Topics: Albuterol; Asthma; Child; Cromolyn Sodium; Humans

1981
Deaths from asthma on holiday.
    British medical journal (Clinical research ed.), 1981, Nov-14, Volume: 283, Issue:6302

    Topics: Aerosols; Albuterol; Asthma; Equipment and Supplies; Humans

1981
Misplaced confidence in nebulised bronchodilators in severe asthmatic attacks.
    British medical journal (Clinical research ed.), 1982, Jan-02, Volume: 284, Issue:6308

    Topics: Adult; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male

1982
Effects of oral theophylline and oral salbutamol in the treatment of asthma.
    Archives of disease in childhood, 1983, Volume: 58, Issue:1

    Topics: Albuterol; Asthma; Child; Humans; Theophylline

1983
[Inhalation of beta-stimulators: comparison of the effects of 6 different inhalation devices].
    Schweizerische medizinische Wochenschrift, 1983, Mar-05, Volume: 113, Issue:9

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Male; Middle Aged; Respiratory Fu

1983
MMEF or FEV1 in estimating bronchial obstruction in asthmatic children.
    Allergy, 1983, Volume: 38, Issue:3

    Topics: Administration, Intranasal; Adolescent; Airway Obstruction; Albuterol; Asthma; Bronchospirometry; Ch

1983
[Therapeutic and preventive procedures in bronchial asthma in children].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1983, Mar-15, Volume: 36, Issue:6

    Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Drug Evaluation; Humans; Metaprotere

1983
Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre.
    Thorax, 1982, Volume: 37, Issue:6

    Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Circadian Rhythm; Female; Forced Expiratory Volume; Histami

1982
A comparison between different methods for detecting bronchial hyperreactivity. Bronchial hyperreactivity: methods of study.
    European journal of respiratory diseases. Supplement, 1980, Volume: 106

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchi; Bronchial Provocation Tests

1980
The response of asthmatic patients and normal subjects to maximum respiratory manoeuvres. Spirometry--induced bronchoconstriction.
    European journal of respiratory diseases. Supplement, 1980, Volume: 106

    Topics: Adult; Albuterol; Asthma; Bronchi; Forced Expiratory Volume; Humans; Maximal Voluntary Ventilation;

1980
[Protection from exercise-induced asthma after salbutamol (Ventolin) in powder form, inhaled with the Rotahaler].
    Schweizerische medizinische Wochenschrift, 1981, Oct-31, Volume: 111, Issue:44

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Male; Midd

1981
Inhaled bronchodilators: a comparison of different methods of inhaling.
    The New Zealand medical journal, 1981, Nov-11, Volume: 94, Issue:695

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male

1981
Clinical use of dry powder systems.
    European journal of respiratory diseases. Supplement, 1982, Volume: 122

    Topics: Albuterol; Asthma; Beclomethasone; Fenoterol; Humans; Powders; Respiratory Therapy

1982
Status asthmaticus--a case history.
    Physiotherapy, 1980, Volume: 66, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Humans; Intermittent Positive-Pressure Breathing; Male; Physical Ther

1980
Drug-induced changes in airways obstruction reflected by forced expiratory flows and airway resistance measured with an oscillometric method using quiet breathing.
    Respiration; international review of thoracic diseases, 1981, Volume: 41, Issue:2

    Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; M

1981
Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma.
    Thorax, 1981, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Female; Forced Exp

1981
Persistent cough a forme-fruste of asthma.
    European journal of respiratory diseases, 1982, Volume: 63, Issue:1

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchial Spasm; Child; Child, Preschool; Cough; Eosinophil

1982
Abuse of salbutamol inhalers in young people.
    Clinical allergy, 1982, Volume: 12, Issue:2

    Topics: Administration, Intranasal; Adolescent; Albuterol; Asthma; Chlorofluorocarbons, Methane; Dose-Respon

1982
Status asthmaticus and the syndrome of inappropriate secretion of antidiuretic hormone.
    Thorax, 1982, Volume: 37, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Vasopress

1982
Failure of body plethysmography in bronchial asthma.
    Journal of applied physiology: respiratory, environmental and exercise physiology, 1982, Volume: 52, Issue:4

    Topics: Acetylcholine; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Spasm; Dilatation; Fal

1982
Bronchodilator tolerance and dosage.
    The Medical journal of Australia, 1982, Jun-12, Volume: 1, Issue:12

    Topics: Albuterol; Asthma; Drug Tolerance; Humans

1982
Analysis of antigen-induced changes in pulmonary mechanics in sensitized inbred rats.
    Canadian journal of physiology and pharmacology, 1982, Volume: 60, Issue:5

    Topics: Albuterol; Aminophylline; Animals; Antigens; Asthma; Female; Forced Expiratory Volume; Lung; Male; M

1982
Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.
    Thorax, 1982, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Dose-

1982
Long-term stability of bronchial responsiveness to histamine.
    Thorax, 1982, Volume: 37, Issue:4

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Bronchial Provocation Tests; Female; Forced Expir

1982
Childhood bronchial asthma in northern Nigeria.
    Clinical allergy, 1982, Volume: 12, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Breast Feeding; Child; Child, Preschool; Feces; Female; Humans; Hydro

1982
Domiciliary monitoring of lung function.
    Australian family physician, 1982, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Humans; Middle Aged; Monitoring, Physi

1982
Intramuscular and intravenous albuterol in the treatment of asthma.
    Clinical therapeutics, 1982, Volume: 5, Issue:1

    Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hemodynamics; Humans; Infusions, Pare

1982
Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment.
    Thorax, 1982, Volume: 37, Issue:6

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Humans; Male

1982
Respiratory heat and water loss during exercise in patients with asthma. Effect of repeated exercise challenge.
    European journal of respiratory diseases, 1982, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Body Temperature; Body Water; Exerci

1982
[Pharmacological testing in assessing bronchial function].
    Pediatriia, 1982, Issue:9

    Topics: Acetylcholine; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Child

1982
[Clinical forms and lung physiology changes in children with bronchial asthma].
    Schweizerische medizinische Wochenschrift, 1982, Sep-11, Volume: 112, Issue:37

    Topics: Airway Resistance; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Humans; Lung Volume M

1982
Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber.
    The American review of respiratory disease, 1982, Volume: 126, Issue:5

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Atropine; Bronchial Provocation Tests; Chlorpheniramine

1982
[A case from practice (12)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1982, Nov-23, Volume: 71, Issue:47

    Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Middle Aged

1982
Cardio-selective beta-adrenergic therapy in a patient with asthma and hypertrophic obstructive cardiomyopathy.
    Chest, 1981, Volume: 80, Issue:1

    Topics: Adult; Albuterol; Asthma; Cardiomyopathy, Hypertrophic; Female; Heart; Humans; Male; Pindolol

1981
The effect of bronchodilators on diurnal rhythms in airway obstruction.
    British journal of diseases of the chest, 1981, Volume: 75, Issue:2

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Circadian Rhythm; Fem

1981
Tonic inspiratory muscle activity as a cause of hyperinflation in asthma.
    Journal of applied physiology: respiratory, environmental and exercise physiology, 1981, Volume: 50, Issue:2

    Topics: Adult; Albuterol; Asthma; Diaphragm; Electromyography; Female; Humans; Intercostal Muscles; Lung Vol

1981
Adrenergic compounds and corticosteroids.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1981, Volume: 18, Issue:1

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aerosols; Albuterol; Asthma; Beclomethasone; Bronchod

1981
Salbutamol inhalation in chronic asthma bronchiale: dose aerosol vs jet nebulizer.
    Chest, 1981, Volume: 79, Issue:4

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Dosage Forms; Female; Forced Expiratory Volume; Humans; Ma

1981
Exercise-induced asthma in Nepalese children.
    Clinical allergy, 1981, Volume: 11, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Child, Preschool; Exercise Test; Fem

1981
Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol.
    Clinical science (London, England : 1979), 1981, Volume: 60, Issue:5

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Dose-Response Relationship, Drug; Humans; Injections, I

1981
Maximum or mean FEV1 for bronchodilator aerosol evaluation in acute asthmatics.
    British journal of clinical pharmacology, 1981, Volume: 11, Issue:6

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Evaluation; Forced Expiratory Volume; Human

1981
Albuterol.
    The Medical letter on drugs and therapeutics, 1981, Sep-18, Volume: 23, Issue:19

    Topics: Aerosols; Albuterol; Asthma; Humans

1981
[Electrocardiographic changes in asthma as affected by various drugs combined with phentolamine (Regitine)].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1981, Jun-08, Volume: 36, Issue:23

    Topics: Adult; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Electrocardiography; Female; Hea

1981
[Comparison of bronchodilator effects of salbutamol and theophylline (author's transl)].
    Bulletin europeen de physiopathologie respiratoire, 1981, Volume: 17, Issue:5

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Injections, Intravenous; Male; M

1981
The lack of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol.
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Adult; Aerosols; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Humans; Isoproterenol;

1981
The use of albuterol for the prevention of exercise-induced bronchospasm.
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Atropine; Child; Humans; Isoproterenol; Theop

1981
Worldwide experience with albuterol (salbutamol).
    Annals of allergy, 1981, Volume: 47, Issue:5 Pt 2

    Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Glucose; Child; Heart Rate; Humans; Inj

1981
Salbutamol powder inhalation for bronchial asthma.
    Allergy, 1981, Volume: 36, Issue:6

    Topics: Administration, Intranasal; Adolescent; Adult; Albuterol; Asthma; Child; Humans; Powders

1981
[Evaluation of the bronchodilating effect of TH 1165 A and of salbutamol in patients with spastic obstructive ventilatory syndrome].
    La Clinica terapeutica, 1981, Dec-15, Volume: 99, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Spasm; Ethanolamines; Fenoterol; Humans; Lung Dis

1981
[Fenoterol in the diagnosis and treatment of reversible bronchospasm].
    La Clinica terapeutica, 1981, Dec-31, Volume: 99, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Ethanolamines; Female; Fenoterol; Humans; Lung Diseases,

1981
Cardiopulmonary effects of fenoterol and salbutamol aerosols.
    Chest, 1980, Volume: 77, Issue:3

    Topics: Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Dose-Response Relationship, Drug;

1980
[Salbutamol in asthmatic children, lung function and plasma levels of free salbutamol after treatment with salbutamol rectally and by pressurized aerosol (author's transl)].
    Monatsschrift fur Kinderheilkunde, 1980, Volume: 128, Issue:2

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Function Tests

1980
Bronchomotor effect of bronchoconstriction-induced deep inspirations in asthmatics.
    The American review of respiratory disease, 1980, Volume: 121, Issue:2

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Carbachol; Constr

1980
[Problems of indication and execution of long-term steroid therapy in advanced disabling bronchial asthma].
    Schweizerische medizinische Wochenschrift, 1980, Feb-09, Volume: 110, Issue:6

    Topics: Adrenal Cortex Hormones; Albuterol; Altitude; Asthma; Beclomethasone; Humans; Prednisone; Respirator

1980
[Significance of reversibility of obstructive respiratory disorders in bronchial asthma for prognosis of the effectiveness of treatment].
    Terapevticheskii arkhiv, 1980, Volume: 52, Issue:3

    Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Humans; Prognosis

1980
Acute myocardial infarction following intravenous salbutamol.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1980, Sep-06, Volume: 58, Issue:10

    Topics: Albuterol; Asthma; Humans; Male; Middle Aged; Myocardial Infarction

1980
Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Drug Tolerance; Female; Forced Expiratory Vol

1980
Teaching patients correct use of asthma aerosols.
    Australian family physician, 1980, Volume: 9, Issue:10

    Topics: Aerosols; Albuterol; Asthma; Humans; Patient Compliance; Physician-Patient Relations; Teaching

1980
The effectiveness of nebulised salbutamol in the management of acute asthma in children.
    Physiotherapy, 1980, Volume: 66, Issue:5

    Topics: Administration, Intranasal; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Prescho

1980
Comparative efficacy of salbutamol by pressurized aerosol and wet nebulizer in acute asthma.
    British journal of clinical pharmacology, 1980, Volume: 10, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Dru

1980
An unusual asthma death.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1981, Feb-21, Volume: 59, Issue:8

    Topics: Albuterol; Asthma; Child; Humans; Male

1981
Reversible airway obstruction in cystic fibrosis.
    Thorax, 1980, Volume: 35, Issue:10

    Topics: Adolescent; Age Factors; Airway Obstruction; Albuterol; Asthma; Child; Child, Preschool; Cystic Fibr

1980
Long-acting beta 2-agonists and their role in asthma management.
    The Western journal of medicine, 1995, Volume: 163, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Salmeterol Xinafoate

1995
Asthma mortality and beta-agonists.
    Chest, 1995, Volume: 108, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate

1995
Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1.
    The Journal of allergy and clinical immunology, 1995, Volume: 96, Issue:5 Pt 1

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Bronchoscopy; Cells, Cultured;

1995
Pediatric asthma--a correlation of clinical treatment and oxygen saturation.
    Hawaii medical journal, 1995, Volume: 54, Issue:7

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Nebulizers and Vaporiz

1995
Paradoxical bronchoconstriction with salbutamol.
    Journal of the Royal Army Medical Corps, 1995, Volume: 141, Issue:2

    Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Child, Preschool; Humans; Male

1995
Bronchodilation subsensitivity to salbutamol after salmeterol.
    Lancet (London, England), 1995, Oct-07, Volume: 346, Issue:8980

    Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Forced Expiratory Volume

1995
Bronchodilation subsensitivity to salbutamol after salmeterol.
    Lancet (London, England), 1995, Oct-07, Volume: 346, Issue:8980

    Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Lung; Peak Expiratory Fl

1995
Bronchodilation subsensitivity to salbutamol after salmeterol.
    Lancet (London, England), 1995, Oct-07, Volume: 346, Issue:8980

    Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Forced Expiratory Volume

1995
Emergency treatment of asthma.
    Thorax, 1995, Volume: 50, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Emergencies; Humans; Terbutaline

1995
Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1995, Nov-15, Volume: 153, Issue:10

    Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ae

1995
Eosinophil cationic protein and tidal flow volume loops in children 0-2 years of age.
    The European respiratory journal, 1995, Volume: 8, Issue:7

    Topics: Albuterol; Asthma; Blood Proteins; Bronchial Provocation Tests; Bronchodilator Agents; Case-Control

1995
Long-acting inhaled beta agonists in the treatment of bronchial asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1995, Volume: 32, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Delayed-Action Preparations

1995
Supraventricular tachycardia: a complication of nebulized albuterol.
    Pediatric emergency care, 1995, Volume: 11, Issue:2

    Topics: Adult; Albuterol; Asthma; Electrocardiography; Female; Humans; Infant; Male; Nebulizers and Vaporize

1995
Generic salbutamol metered dose inhalers.
    Thorax, 1995, Volume: 50, Issue:5

    Topics: Aerosols; Albuterol; Asthma; Drug Delivery Systems; Humans; Lung; Nebulizers and Vaporizers; Time Fa

1995
Generic salbutamol metered dose inhalers.
    Thorax, 1995, Volume: 50, Issue:5

    Topics: Aerosols; Albuterol; Asthma; Drug Delivery Systems; Humans; Lung; Nebulizers and Vaporizers; Time Fa

1995
A new approach to the evaluation of bronchodilatator response.
    Folia medica, 1994, Volume: 36, Issue:2

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Evaluation Studies as Topic; Forced Expiratory Volu

1994
Forced oscillation technique vs spirometry to assess bronchodilatation in patients with asthma and COPD.
    Chest, 1995, Volume: 108, Issue:1

    Topics: Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Lung Diseases, Obstr

1995
Sympathomimetics in severe acute asthma.
    Lancet (London, England), 1995, Jul-22, Volume: 346, Issue:8969

    Topics: Acute Disease; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Injections,

1995
[Pharmacy clinics. Drug of the month. Salmeterol (Serevent)].
    Revue medicale de Liege, 1995, Volume: 50, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate

1995
[Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1995, Volume: 2 Suppl 2

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Child; Drug Therapy, Combination; Emer

1995
Treating acute asthma.
    Chest, 1995, Volume: 108, Issue:2

    Topics: Acute Disease; Aerosols; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Humans; Infusi

1995
Pharmacology of long-acting beta-agonists.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 75, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Receptors, Adr

1995
Effective argon-FRC with a rebreathing technique in children with acute asthma.
    Pediatric pulmonology, 1995, Volume: 19, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Argon; Asthma; Bronchodilator Agen

1995
Differential effects of anti-asthmatic drugs on arachidonic acid and platelet-activating factor.
    Biochemical Society transactions, 1994, Volume: 22, Issue:4

    Topics: Albuterol; Aminophylline; Arachidonic Acid; Asthma; Blood Platelets; Bronchodilator Agents; Humans;

1994
[Statistics: Salmeterol and asthma].
    Ugeskrift for laeger, 1995, Feb-27, Volume: 157, Issue:9

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; Treatment Outcome

1995
Knowledge of asthma and its management in newly qualified doctors in Accra, Ghana.
    Respiratory medicine, 1995, Volume: 89, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Chronic Disease; Clinical Competence; Develo

1995
Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction.
    Respiratory medicine, 1995, Volume: 89, Issue:2

    Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Combined Modality Therapy; Dose-Response Relationship

1995
Tidal breathing analysis and response to salbutamol in awake young children with and without asthma.
    The European respiratory journal, 1994, Volume: 7, Issue:12

    Topics: Albuterol; Asthma; Child, Preschool; Consciousness; Female; Humans; Male; Pulmonary Ventilation; Sig

1994
[Response to bronchodilators among patients with bronchial asthma].
    Medicina, 1994, Volume: 54, Issue:4

    Topics: Albuterol; Asthma; Bronchospirometry; Humans; Retrospective Studies

1994
[Behavior of some parameters of the autonomic nervous system in patients with bronchial asthma].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:11-12

    Topics: Adult; Albuterol; Asthma; Autonomic Nervous System; Cyclic AMP; Female; Humans; Male; Middle Aged; R

1994
Salmeterol xinafoate in children.
    The Medical journal of Australia, 1995, Apr-17, Volume: 162, Issue:8

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child

1995
Synergistic protective effects with azelastine and salbutamol in a guinea pig asthma model.
    Research communications in molecular pathology and pharmacology, 1995, Volume: 87, Issue:2

    Topics: Administration, Oral; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents;

1995
[The therapeutic potentials of Ditec in bronchial asthma patients].
    Terapevticheskii arkhiv, 1995, Volume: 67, Issue:3

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn

1995
Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting.
    Chest, 1994, Volume: 106, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Emergency Service, Ho

1994
Acute asthma, salbutamol and hyperglycaemia.
    Acta paediatrica (Oslo, Norway : 1992), 1995, Volume: 84, Issue:3

    Topics: Acute Disease; Age Factors; Albuterol; Asthma; Blood Glucose; Child; Child, Preschool; Chromatograph

1995
Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma.
    Thorax, 1995, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Alleles; Asthma; Bronchi; Bronchial Provocati

1995
Scintigraphic appearance of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction.
    Clinical nuclear medicine, 1994, Volume: 19, Issue:10

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Female; Humans; Hypoxia; Lung; Pregnancy; Preg

1994
[Bronchial hyperresponsiveness and relaxability in patients with mitral stenosis].
    Nihon Kyobu Shikkan Gakkai zasshi, 1994, Volume: 32, Issue:11

    Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Female; Humans; Male; Met

1994
Salmeterol in the treatment of asthma.
    Australian family physician, 1994, Volume: 23, Issue:10

    Topics: Albuterol; Asthma; Drug Approval; Humans; Salmeterol Xinafoate

1994
[Effect of salbutamol on left ventricular function and selected biochemical parameters in patients with bronchial asthma].
    Polskie Archiwum Medycyny Wewnetrznej, 1994, Volume: 92, Issue:4

    Topics: Adult; Albuterol; Asthma; Creatine Kinase; Echocardiography; Fatty Acids, Nonesterified; Female; Hum

1994
Inhaled salmeterol.
    East African medical journal, 1994, Volume: 71, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Huma

1994
Short- and long-term effect of oral salbutamol on growth hormone secretion in prepubertal asthmatic children.
    Metabolism: clinical and experimental, 1995, Volume: 44, Issue:2

    Topics: Administration, Oral; Albuterol; Asthma; Child; Growth Hormone; Humans; Time Factors

1995
TAME-esterase activity during a prolonged attack of asthma.
    International journal of clinical pharmacology and therapeutics, 1994, Volume: 32, Issue:11

    Topics: Adult; Albuterol; Asthma; Humans; Peptide Hydrolases

1994
Platelet-derived growth factor-beta mRNA in human alveolar macrophages in vivo in asthma.
    The European respiratory journal, 1994, Volume: 7, Issue:11

    Topics: Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Blotting, Northern; Bronchodilator Agents; Budes

1994
Salmeterol-induced vertigo.
    The European respiratory journal, 1994, Volume: 7, Issue:11

    Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Salmeter

1994
Effectiveness of nebulised salbutamol administered in ambulances to patients with severe acute asthma.
    Thorax, 1995, Volume: 50, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Airway Obstru

1995
The AB/BA crossover: past, present and future?
    Statistical methods in medical research, 1994, Volume: 3, Issue:4

    Topics: Albuterol; Analysis of Variance; Asthma; Bayes Theorem; Bias; Cross-Over Studies; Data Interpretatio

1994
Hypokalemia after normal doses of neubulized albuterol (salbutamol).
    The American journal of emergency medicine, 1995, Volume: 13, Issue:2

    Topics: Adult; Albuterol; Asthma; Electrocardiography; Humans; Hypokalemia; Male

1995
Beta-agonists and asthma.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Humans; Methacholine Chloride; Salmet

1993
Salmeterol.
    The Medical letter on drugs and therapeutics, 1994, Apr-29, Volume: 36, Issue:921

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Drug A

1994
A word of caution regarding a new long-acting bronchodilator.
    JAMA, 1994, May-11, Volume: 271, Issue:18

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate

1994
Asthma control.
    Lancet (London, England), 1994, Jul-16, Volume: 344, Issue:8916

    Topics: Albuterol; Asthma; Bronchodilator Agents; Follow-Up Studies; Forced Expiratory Volume; Humans

1994
Asthma control.
    Lancet (London, England), 1994, Jul-16, Volume: 344, Issue:8916

    Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Humans; Sympathomimetics

1994
Respiratory arrests in young asthmatics on salmeterol.
    Respiratory medicine, 1994, Volume: 88, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Male; Respiratory Insufficiency; Salmeterol Xin

1994
Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic.
    The European respiratory journal, 1994, Volume: 7, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol

1994
Asthma control.
    Lancet (London, England), 1994, Jul-30, Volume: 344, Issue:8918

    Topics: Albuterol; Asthma; Humans

1994
Regular versus as-needed inhaled salbutamol in asthma control.
    Lancet (London, England), 1994, Aug-27, Volume: 344, Issue:8922

    Topics: Administration, Inhalation; Albuterol; Asthma; Drug Administration Schedule; Humans

1994
Compliance with pharmacologic prophylaxis and therapy in bronchial asthma.
    Annals of allergy, 1994, Volume: 73, Issue:2

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Ch

1994
Asthma control.
    Lancet (London, England), 1994, Sep-10, Volume: 344, Issue:8924

    Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Administration Schedule; Humans; Salm

1994
Asthma control.
    Lancet (London, England), 1994, Sep-10, Volume: 344, Issue:8924

    Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Tolerance; Humans; Nebulizers and Vap

1994
Common measures of asthma severity lack association for describing its clinical course.
    The Journal of allergy and clinical immunology, 1994, Volume: 94, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Humans; Medical Records; Patie

1994
Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 270, Issue:3

    Topics: Albuterol; Anaphylaxis; Animals; Antigens; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agen

1994
Risks of salmeterol?
    The New England journal of medicine, 1994, Nov-10, Volume: 331, Issue:19

    Topics: Aged; Albuterol; Asthma; Bronchodilator Agents; Fatal Outcome; Humans; Patient Education as Topic; R

1994
Salmeterol: a long-acting beta 2-agonist for asthma.
    The Nurse practitioner, 1994, Volume: 19, Issue:7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate

1994
[Long-acting beta-2-agonists in the treatment of asthma].
    Schweizerische medizinische Wochenschrift, 1994, Oct-01, Volume: 124, Issue:39

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumara

1994
Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs.
    The West Indian medical journal, 1994, Volume: 43, Issue:2

    Topics: Adult; Albuterol; Animals; Asthma; Dogs; Humans; Therapeutic Equivalency

1994
Results of prescription event monitoring study of salmeterol.
    BMJ (Clinical research ed.), 1994, Oct-15, Volume: 309, Issue:6960

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Cause of

1994
[Change of nonspecific bronchial responsiveness and other indices of asthma severity in groups of patients treated with beta2-adrenomimetics "on demand". Test of correlation].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:7-8

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Drug Administration Schedule; Eosinophils; Fe

1994
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.
    American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:5 Pt 1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Asthma; Female; Humans; Inspiratory Capacity

1994
Confounding by severity does not explain the association between fenoterol and asthma death.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1994, Volume: 24, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child

1994
[Efficacy of salmeterol in patients with allergic bronchial asthma].
    La Clinica terapeutica, 1994, Volume: 145, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

1994
Comparison between peak expiratory flow rates (PEFR) and FEV1 in the monitoring of asthmatic subjects at an outpatient clinic.
    Chest, 1994, Volume: 106, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Ambulatory Care Facilities; Asthma; Female; Forced Expiratory Vo

1994
Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance?
    The European respiratory journal, 1994, Volume: 7, Issue:8

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Drug Therapy, Comb

1994
[Relations between nonspecific bronchial hyperreactivity, diurnal variation of peak expiratory flow and medication requirements in patients with mild asthma].
    Archivos de bronconeumologia, 1994, Volume: 30, Issue:9

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Circadian Rh

1994
[Corrective effect of the Russian bronchodilator preparations saventol and troventol on the lymphocyte regulatory function of atopic bronchial asthma patients in vitro].
    Biulleten' eksperimental'noi biologii i meditsiny, 1994, Volume: 117, Issue:2

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchodilator A

1994
Reversibility of the allergen-provoked late asthmatic response by an inhaled beta 2-adrenoceptor agonist.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1994, Volume: 24, Issue:3

    Topics: Adult; Albuterol; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Female; Forced Expiratory

1994
Asthma: audit of peak flow rate guidelines for admission and discharge.
    Archives of disease in childhood, 1994, Volume: 70, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Medical Audit; Patient

1994
Occupational asthma in salbutamol process workers.
    Occupational and environmental medicine, 1994, Volume: 51, Issue:6

    Topics: Adult; Albuterol; Asthma; Drug Industry; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged;

1994
Anaesthetic management of an asthmatic child for appendicectomy.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1994, Volume: 41, Issue:6

    Topics: Adolescent; Albuterol; Anesthesia, Epidural; Appendectomy; Asthma; Beclomethasone; Bupivacaine; Fent

1994
[Effect of vaporizing high doses of ipratropium bromide on lung ventilation in patients with chronic obstructive pulmonary disease and bronchial asthma].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:1-2

    Topics: Albuterol; Asthma; Drug Administration Schedule; Forced Expiratory Flow Rates; Forced Expiratory Vol

1994
[Comparison of the influence of ipratropium bromide and salbutamol on activity of phosphocreatine kinase (CK) and isoenzyme CK-MB].
    Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:1-2

    Topics: Adult; Albuterol; Asthma; Creatine Kinase; Female; Humans; Ipratropium; Isoenzymes; Male; Middle Age

1994
Wet nebulizers vs metered dose inhalers.
    Chest, 1994, Volume: 106, Issue:3

    Topics: Acute Disease; Albuterol; Asthma; Evaluation Studies as Topic; Humans; Nebulizers and Vaporizers

1994
Effects of salbutamol inhalations on transcutaneous blood gases in children during the acute asthmatic attack: from acute deterioration to recovery.
    Acta paediatrica (Oslo, Norway : 1992), 1994, Volume: 83, Issue:5

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Carbon Dioxide;

1994
Effective pulmonary blood flow in children with acute asthma attack requiring hospitalization.
    Pediatric pulmonology, 1994, Volume: 17, Issue:6

    Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Argon; Asthma; Bronchodilator Agents; Case-Control S

1994
Short-term effects of inhaled albuterol on maternal and fetal circulations.
    American journal of obstetrics and gynecology, 1994, Volume: 171, Issue:3

    Topics: Adolescent; Adult; Albuterol; Aorta; Asthma; Blood Circulation; Blood Flow Velocity; Blood Pressure;

1994
Dose equivalence of drugs for asthma.
    BMJ (Clinical research ed.), 1993, Apr-17, Volume: 306, Issue:6884

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans

1993
Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained.
    BMJ (Clinical research ed.), 1993, Jun-12, Volume: 306, Issue:6892

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Product Surveillance, Po

1993
Bronchodilator treatment in asthma. Manufacturers underestimate mortality from asthma.
    BMJ (Clinical research ed.), 1993, Jun-12, Volume: 306, Issue:6892

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate

1993
Bronchodilator treatment in asthma. Regular treatment with beta agonists remains unevaluated.
    BMJ (Clinical research ed.), 1993, Jun-12, Volume: 306, Issue:6892

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Research Design; Salmete

1993
Bronchodilator treatment in asthma. Study too small to detect increase in deaths.
    BMJ (Clinical research ed.), 1993, Jun-12, Volume: 306, Issue:6892

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; St

1993
[A new long-acting asthma spray. Preliminary wait-and-see attitude?].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1993, May-20, Volume: 113, Issue:13

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dela

1993
[Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma].
    Arerugi = [Allergy], 1993, Volume: 42, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoc

1993
Systemic absorption of salbutamol following nebulizer delivery in acute asthma.
    Acta paediatrica (Oslo, Norway : 1992), 1993, Volume: 82, Issue:11

    Topics: Absorption; Acute Disease; Adolescent; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Dose

1993
Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs.
    Allergy, 1993, Volume: 48, Issue:8

    Topics: Albuterol; Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoa

1993
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
    American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:3 Pt 1

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Albute

1994
Effect of salbutamol on gas compression in cystic fibrosis and asthma.
    American journal of respiratory and critical care medicine, 1994, Volume: 149, Issue:3 Pt 1

    Topics: Adolescent; Albuterol; Asthma; Bias; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Human

1994
Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department.
    Annals of emergency medicine, 1994, Volume: 23, Issue:4

    Topics: Acute Disease; Aged; Albuterol; Asthma; Drug Therapy, Combination; Female; Glaucoma, Angle-Closure;

1994
Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?
    Chest, 1994, Volume: 105, Issue:4

    Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Diagnosis, Differential; Forced Expiratory Volu

1994
Patient handling of a multidose dry powder inhalation device for albuterol.
    Chest, 1994, Volume: 105, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Child; Female; Humans; Male;

1994
In vivo bronchodilator action of a novel K+ channel opener, KC 399, in the guinea pig.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 269, Issue:1

    Topics: Administration, Inhalation; Albuterol; Anesthesia; Animals; Antigens; Asthma; Benzopyrans; Bronchoco

1994
Home nebulizer therapy in asthmatics in Qatar.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1994, Volume: 31, Issue:1

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Service, Hospital; Female; Hom

1994
A comparison of "closed" and "open" mouth techniques of inhalation of a salbutamol metered-dose inhaler.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1994, Volume: 31, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Female; Forced Expiratory Volume;

1994
Effect of albuterol nebulization on peripheral WBC counts.
    The American journal of emergency medicine, 1994, Volume: 12, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Emergencies; Female; Humans; Leukocyte Count;

1994
Nonspecific refractoriness to adenylyl cyclase stimulation in alveolar macrophages from infants with recurrent bronchiolitis.
    The Journal of allergy and clinical immunology, 1994, Volume: 93, Issue:5

    Topics: Adenylyl Cyclases; Albuterol; Asthma; Bronchiolitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; Col

1994
Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks.
    Scandinavian journal of clinical and laboratory investigation, 1994, Volume: 54, Issue:2

    Topics: Administration, Oral; Adult; Aged; Albuterol; Asthma; Calcium; Female; Humans; Infusions, Intravenou

1994
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
    Thorax, 1993, Volume: 48, Issue:8

    Topics: Albuterol; Asthma; Child; Forced Expiratory Volume; Humans

1993
[Serevent. Salmeterolxinafoate].
    Wiener klinische Wochenschrift, 1993, Volume: 105, Issue:16

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Austria; Bronchodilator Agen

1993
A study of self poisoning with oral salbutamol--laboratory and clinical features.
    Human & experimental toxicology, 1993, Volume: 12, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child, Preschool; Female; Humans; Male; Middle Aged; Pot

1993
Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation.
    International archives of allergy and immunology, 1993, Volume: 102, Issue:4

    Topics: Adult; Albuterol; Asthma; Blood Proteins; Cell Degranulation; Chemotaxis, Leukocyte; Dose-Response R

1993
[The bronchodilator agent, Ventodisk, in the powdered inhalation form without freon is better].
    Casopis lekaru ceskych, 1993, Oct-25, Volume: 132, Issue:20

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Hu

1993
Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects.
    Chest, 1994, Volume: 105, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Forc

1994
Albuterol protocol.
    The American journal of emergency medicine, 1994, Volume: 12, Issue:1

    Topics: Adult; Albuterol; Asthma; Humans

1994
Albuterol.
    The American journal of emergency medicine, 1994, Volume: 12, Issue:1

    Topics: Adult; Albuterol; Asthma; Humans

1994
Extrapulmonary effects of fenoterol compared to salbutamol in asthmatics.
    Respiratory medicine, 1993, Volume: 87, Issue:8

    Topics: Albuterol; Asthma; Cardiovascular Diseases; Drug Administration Schedule; Fenoterol; Humans

1993
Respiratory arrests in young asthmatics on salmeterol.
    Respiratory medicine, 1993, Volume: 87, Issue:8

    Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Respiratory Insufficien

1993
Bronchodilator treatment in asthma.
    BMJ (Clinical research ed.), 1993, Sep-11, Volume: 307, Issue:6905

    Topics: Adolescent; Adult; Age Distribution; Aged; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle

1993
Rates of change in peak expiratory flow and in diurnal variation in peak flow in patients recovering from acute severe asthma.
    Clinical science (London, England : 1979), 1994, Volume: 86, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Asthma; Circadian Rhythm; Follow-Up Studies; Humans; Lung; Peak Exp

1994
Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.
    Thorax, 1993, Volume: 48, Issue:5

    Topics: Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Lung; Male; Middle Aged; Nebu

1993
Prolonged hypoxaemia after nebulised salbutamol.
    Thorax, 1993, Volume: 48, Issue:5

    Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Humans; Hypoxia; Infant; Nebulizers and V

1993
Influence of airway inflammatory changes on airway hyperresponsiveness in asthmatics.
    Chinese medical journal, 1993, Volume: 106, Issue:4

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Bronchial Provocation Tests; Br

1993
Use of pulse oximetry in the hospital management of acute asthma in childhood.
    Pediatric pulmonology, 1993, Volume: 15, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Hospit

1993
Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline.
    The American review of respiratory disease, 1993, Volume: 148, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoc

1993
Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants.
    The Journal of the American Osteopathic Association, 1993, Volume: 93, Issue:6

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Chlorofluorocarbons, Methane; Dyspnea; Female; Humans; Neb

1993
Management of chronic obstructive pulmonary disease.
    The New England journal of medicine, 1993, Sep-23, Volume: 329, Issue:13

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Humans

1993
Propranolol treatment of albuterol poisoning in two asthmatic patients.
    Annals of emergency medicine, 1993, Volume: 22, Issue:9

    Topics: Adolescent; Albuterol; Asthma; Charcoal; Drug Overdose; Female; Gastric Lavage; Humans; Hypokalemia;

1993
[Improvement of intractable nocturnal asthma treated by therapeutic awakening].
    Arerugi = [Allergy], 1993, Volume: 42, Issue:7

    Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Female; Humans; Wakefulness

1993
[Bronchial hyperreactivity after chronic use of salbutamol].
    Pneumonologia i alergologia polska, 1993, Volume: 61, Issue:3-4

    Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Female; Humans; Male; Spirometry

1993
Controlled-release oral salbutamol and cardiac arrhythmias in asthmatic patients.
    Chest, 1993, Volume: 104, Issue:3

    Topics: Administration, Oral; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; F

1993
Bronchodilator treatment in asthma.
    BMJ (Clinical research ed.), 1993, Aug-14, Volume: 307, Issue:6901

    Topics: Adolescent; Adult; Age Factors; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch

1993
Nedocromil sodium blocks the early and late phases of allergen challenge in a guinea pig model of asthma.
    The Journal of allergy and clinical immunology, 1993, Volume: 92, Issue:1 Pt 2

    Topics: Aerosols; Albuterol; Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalv

1993
[Bronchodilating action of salbutamol depending on route of administration].
    Pneumonologia i alergologia polska, 1993, Volume: 61, Issue:7-8

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Female;

1993
[Effect of corticosteroids on tachyphylaxis induced by beta-2- receptor agonists in patients with bronchial asthma].
    Pneumonologia i alergologia polska, 1993, Volume: 61, Issue:7-8

    Topics: Adult; Albuterol; Asthma; Down-Regulation; Female; Humans; Male; Prednisone; Receptors, Adrenergic,

1993
Chronopharmacology of albuterol in hospitalized asthmatic children.
    Chronobiology international, 1993, Volume: 10, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Child; Circadian Rhythm; Female; Hospitalization; Humans; Male; Pulmo

1993
Repeated inhalation of nebulized albuterol did not induce arrhythmias in a patient with Wolff-Parkinson-White syndrome and asthma.
    Chest, 1993, Volume: 103, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Contraindications; Elect

1993
Safety of continuous nebulized albuterol for bronchospasm in infants and children.
    Pediatrics, 1993, Volume: 92, Issue:5

    Topics: Acute Disease; Albuterol; Asthma; Bronchial Spasm; Bronchiolitis; Bronchopulmonary Dysplasia; Child,

1993
High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol.
    Chest, 1993, Volume: 103, Issue:1

    Topics: Adult; Aerosols; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory Volume; Heart Rate; Hum

1993
Assessment of exercise capacity in asthmatic children with various degrees of activity.
    Pediatric pulmonology, 1993, Volume: 15, Issue:1

    Topics: Adolescent; Albuterol; Anthropometry; Asthma; Child; Exercise Test; Exercise Tolerance; Female; Huma

1993
Functional characteristics of bronchial epithelium obtained by brushing from asthmatic and normal subjects.
    The American review of respiratory disease, 1993, Volume: 147, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Bronchoscopy; Calcimycin; Cell Surv

1993
Nebulized salbutamol (albuterol): systemic absorption could be important in achieving bronchodilatation.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1993, Volume: 30, Issue:2

    Topics: Absorption; Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchi; Dose-Response Rel

1993
The effect of age on bronchodilator responsiveness.
    Pediatric pulmonology, 1993, Volume: 15, Issue:2

    Topics: Aging; Albuterol; Asthma; Bronchi; Child; Child, Preschool; Dose-Response Relationship, Drug; Female

1993
The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks.
    The American journal of emergency medicine, 1993, Volume: 11, Issue:2

    Topics: Acute Disease; Administration, Intranasal; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Emerge

1993
Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler.
    Chest, 1993, Volume: 103, Issue:5

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Male; Middle Aged;

1993
Dose equivalence of drugs for asthma.
    BMJ (Clinical research ed.), 1993, Apr-17, Volume: 306, Issue:6884

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate;

1993
Dose equivalence of drugs for asthma.
    BMJ (Clinical research ed.), 1993, Apr-17, Volume: 306, Issue:6884

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate;

1993
Asthma. Assessment and management in a pediatric hospital.
    Canadian family physician Medecin de famille canadien, 1993, Volume: 39

    Topics: Acute Disease; Albuterol; Asthma; Canada; Child; Child, Preschool; Emergency Medicine; Emergency Ser

1993
Asthma management guidelines.
    BMJ (Clinical research ed.), 1993, Apr-24, Volume: 306, Issue:6885

    Topics: Adult; Albuterol; Asthma; Child; Humans; Practice Guidelines as Topic; Prednisolone

1993
Respiratory arrests in young asthmatics on salmeterol.
    Respiratory medicine, 1993, Volume: 87, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Female; Huma

1993
Treating nocturnal asthma poses challenges.
    The Journal of the American Osteopathic Association, 1993, Volume: 93, Issue:3

    Topics: Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Humans; Peak Expiratory Flow Rate;

1993
Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.
    Journal of endocrinological investigation, 1993, Volume: 16, Issue:4

    Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Growth Hormone;

1993
Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma.
    BMJ (Clinical research ed.), 1993, Jun-05, Volume: 306, Issue:6891

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Cross-Sectional Studies; Drug Pres

1993
Assessment of bronchodilator response in children with asthma. Dutch CNSLD Study Group.
    The European respiratory journal, 1993, Volume: 6, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Forced

1993
Prehospital management of pediatric asthma requiring hospitalization.
    Pediatric emergency care, 1995, Volume: 11, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Boston; Bronchodilator Agents; Child; Child, Preschool; Emergency Med

1995
Clinical value of monitoring eosinophil activity in asthma.
    Archives of disease in childhood, 1995, Volume: 73, Issue:5

    Topics: Albuterol; Asthma; Blood Proteins; Bronchodilator Agents; Budesonide; Child; Child, Preschool; Cysti

1995
[Right diaphragmatic kinetics measured by TM-mode ultrasonography with concomitant spirometry in normal subjects and asthmatic patients. Preliminary results].
    La Revue de medecine interne, 1995, Volume: 16, Issue:11

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Diaphragm; Female; Humans; Lung Volume Measureme

1995
Educate the patient.
    The American journal of nursing, 1996, Volume: 96, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy; Drug Therapy, Combination; Humans; Ma

1996
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
    Journal of clinical epidemiology, 1996, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Albuterol; Asth

1996
Volume history response of airway resistance.
    Advances in experimental medicine and biology, 1995, Volume: 393

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Functional Residual Capacity; Humans

1995
Muscle weakness in mechanically ventilated patients with severe asthma.
    American journal of respiratory and critical care medicine, 1996, Volume: 153, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Atracurium; Bronchodilator Agents; Cohort

1996
Long-acting beta-agonists, tachyphylaxis, and corticosteroids.
    Chest, 1996, Volume: 109, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Broncho

1996
Asthma caused by topical application of ketorolac.
    Ophthalmology, 1996, Volume: 103, Issue:6

    Topics: Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-S

1996
Loss of bronchoprotection with salmeterol.
    Chest, 1996, Volume: 110, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Dru

1996
Determination of post-salbutamol methacholine dose shift.
    Chest, 1996, Volume: 110, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Humans; Methacholine Chlor

1996
Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model.
    Critical care medicine, 1996, Volume: 24, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Disease Models, Animal; Drug Delivery Systems; Drug

1996
Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro.
    British journal of pharmacology, 1996, Volume: 117, Issue:7

    Topics: Adenosine Triphosphate; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma

1996
Characterization of a primate model of asthma using anti-allergy/anti-asthma agents.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1996, Volume: 45, Issue:5

    Topics: Albuterol; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Antigens; Asthma; Bronchoconstri

1996
[Cardiac monitoring in bronchial asthma patients taking salben].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Bronchodilator Age

1996
Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1996, Volume: 51, Issue:3

    Topics: Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchial Spasm; Bronchodilator

1996
Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and Autohaler.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1996, Volume: 51, Issue:3

    Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Lung Disease

1996
Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists.
    The European respiratory journal, 1996, Volume: 9, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Biopsy, Needle; Blood Chemical An

1996
Inhaled beta 2-agonists in the treatment of asthma.
    The New England journal of medicine, 1996, Sep-19, Volume: 335, Issue:12

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedul

1996
Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma.
    Thorax, 1996, Volume: 51, Issue:3

    Topics: Acetates; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodilator

1996
Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy.
    Allergy, 1996, Volume: 51, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Animals; Antigens, Dermatophago

1996
High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers.
    Academic radiology, 1996, Volume: 3, Issue:5

    Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Diseases; Bronchoconstrictor Agents; Bronchodilator Age

1996
Exhaled nitric oxide during acute changes of airways calibre in asthma.
    The European respiratory journal, 1996, Volume: 9, Issue:6

    Topics: Adult; Airway Resistance; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bron

1996
Doping taboos.
    British journal of sports medicine, 1995, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Contraindications; Doping in Spo

1995
Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans.
    Pulmonary pharmacology, 1995, Volume: 8, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Antigens; Asthma; Bronchial

1995
Health beliefs of adults with asthma: toward an understanding of the difference between symptomatic and preventive use of inhaler treatment.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1996, Volume: 33, Issue:5

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Attitude to Health; Beclomethasone; Bronchodilator Agents;

1996
Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology.
    The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; So

1996
The influence of breathhold on peak expiratory flow in normal and asthmatic children.
    The European respiratory journal, 1996, Volume: 9, Issue:7

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Female; Fo

1996
A portable device based on the interrupter technique to measure bronchodilator response in schoolchildren.
    The European respiratory journal, 1996, Volume: 9, Issue:7

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans

1996
Evaluation of a new interrupter device for measuring bronchial responsiveness and the response to bronchodilator in 3 year old children.
    The European respiratory journal, 1996, Volume: 9, Issue:7

    Topics: Airway Resistance; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Bronchial Provocation Te

1996
Ex vivo pharmacologic modulation of basophil histamine release in asthmatic patients.
    Allergy, 1996, Volume: 51, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Infla

1996
[Difference of lung deposition rate of disodium cromoglycate (DSCG) among three kinds of electric nebulizer].
    Arerugi = [Allergy], 1996, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Lung; Middle Aged; Nebulizers

1996
Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma.
    Clinical reviews in allergy & immunology, 1996,Spring, Volume: 14, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Guinea Pigs; Humans

1996
The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils.
    The European respiratory journal. Supplement, 1996, Volume: 22

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chemo

1996
Treating acute asthma in adults.
    The Journal of family practice, 1996, Volume: 43, Issue:4

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Hu

1996
Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks.
    Thorax, 1996, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodila

1996
Bronchodilator response in pulmonary disease at two different states of respiratory mechanics.
    Respiration; international review of thoracic diseases, 1996, Volume: 63, Issue:5

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Female;

1996
The role of pharmacology and forensics in the death of an asthmatic.
    Journal of analytical toxicology, 1995, Volume: 19, Issue:6

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Fatal Outcome; Heroin; Humans; Lung; Male; Mor

1995
Gas chromatographic-mass spectrometric determination of beta 2-agonists in postmortem blood: application in forensic medicine.
    Journal of chromatography. B, Biomedical applications, 1996, Oct-25, Volume: 685, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Autopsy; Calibration; Fenoterol; Forensic Medicine; Gas

1996
Confounding by indication and channeling over time: the risks of beta 2-agonists.
    American journal of epidemiology, 1996, Dec-15, Volume: 144, Issue:12

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; C

1996
Ventilatory function in British adults after asthma or wheezing illness at ages 0-35.
    American journal of respiratory and critical care medicine, 1996, Volume: 154, Issue:6 Pt 1

    Topics: Adolescent; Adult; Age of Onset; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child; Child,

1996
Asthma group issues guidelines for safe use of salmeterol.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Dec-15, Volume: 53, Issue:24

    Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Practice Guidelines as

1996
Sequential designs for equivalence studies.
    Statistics in medicine, 1996, Dec-30, Volume: 15, Issue:24

    Topics: Albuterol; Asthma; Bronchodilator Agents; Confidence Intervals; Humans; Models, Statistical; Randomi

1996
An unconscious man with asthma and a fixed, dilated pupil.
    Lancet (London, England), 1997, Jan-11, Volume: 349, Issue:9045

    Topics: Albuterol; Asthma; Brain Edema; Bronchodilator Agents; Carbon Dioxide; Humans; Hypoxia; Intracranial

1997
CFC-free inhalers.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Albuterol; Asthma; Bronchodilator Agents; Equipment Failure; Humans; Nebulizers and Vaporizers

1997
Observations on the effects of aerosolized albuterol in acute asthma.
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Dose-Response

1997
Oscillatory pressure transients after flow interruption during bronchial challenge test in children.
    The European respiratory journal, 1997, Volume: 10, Issue:1

    Topics: Acoustics; Adolescent; Air; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchial Prov

1997
Respiratory resistive impedance in obstructive patients: linear regression analysis vs viscoelastic modelling.
    The European respiratory journal, 1997, Volume: 10, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Airway Resistance; Albuterol; Asthma; Br

1997
Albuterol in mild asthma.
    The New England journal of medicine, 1997, Mar-06, Volume: 336, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Patient Selection; Randomiz

1997
Lung hyperinflation and flow limitation in chronic airway obstruction.
    The European respiratory journal, 1997, Volume: 10, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Case-Control Studies; Female;

1997
Early management of acute severe asthma.
    Lancet (London, England), 1997, Apr-05, Volume: 349, Issue:9057

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Emergenc

1997
Allergen challenge of passively sensitized human bronchi alters M2 and beta2 receptor function.
    American journal of respiratory and critical care medicine, 1997, Volume: 155, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Allergens; Animals; Asthma; Bronchi; Bronchial Hyp

1997
Are beta-adrenergic bronchodilators safe?
    Pediatrics, 1997, Volume: 99, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Drug

1997
Oral vs i.v. steroids for asthma.
    The Journal of family practice, 1997, Volume: 44, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma;

1997
The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
    Survey of ophthalmology, 1997, Volume: 41 Suppl 2

    Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Aged; Albutero

1997
Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood.
    The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:5

    Topics: Adolescent; Adult; Affect; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Hum

1997
A minimal response to albuterol challenge does not exclude a diagnosis of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1997, Volume: 34, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchitis; Child; Forced Expiratory Volume; Humans; Middle Aged; Nebulize

1997
The influence of parasympatholytics on the resolution of acute attacks of asthma.
    The American journal of medicine, 1997, Volume: 102, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Hospitalization; Humans; Ipr

1997
Isoetherine or albuterol for acute asthma.
    The American journal of medicine, 1997, Volume: 102, Issue:1

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Humans; Isoetharine; Therapeutic Equivalenc

1997
Successful treatment of salbutamol-induced panic disorder with citalopram.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7, Issue:3

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Citalopram; Humans; Male; Middle Aged; Panic Disorder; Psy

1997
Effect of age on bronchodilator response in acute severe asthma treatment.
    Chest, 1997, Volume: 112, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol;

1997
Safety of one method of sputum induction in asthmatic subjects.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Female; Forced Expiratory Volu

1997
Several studies have shown salmeterol to be more potent than salbutamol for systemic effects.
    BMJ (Clinical research ed.), 1997, Jul-12, Volume: 315, Issue:7100

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Delivery Systems; Humans; Salmeterol Xinafoate; Th

1997
[Latent long QT syndrome: discription of a clinical case].
    Giornale italiano di cardiologia, 1997, Volume: 27, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Electrocardiography;

1997
Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.
    Thorax, 1997, Volume: 52, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control

1997
Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients.
    Thorax, 1997, Volume: 52, Issue:7

    Topics: Adenosine Monophosphate; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Varianc

1997
Asthma guidelines.
    Thorax, 1997, Volume: 52, Issue:7

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; B

1997
PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro.
    Biochemical and biophysical research communications, 1997, Aug-08, Volume: 237, Issue:1

    Topics: Adult; Albuterol; Asthma; Cell Separation; Centrifugation, Density Gradient; Chemotaxis, Leukocyte;

1997
Beta 2-agonist-elevated stress response in human bronchial epithelial cells in vivo and in vitro.
    Lung, 1997, Volume: 175, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Biopsy; Bronchi; Bronchial Provocatio

1997
Expiratory flow limitation in stable asthmatic patients during resting breathing.
    American journal of respiratory and critical care medicine, 1997, Volume: 156, Issue:3 Pt 1

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bias; Bronchodilator Agents; Female; Forced Expiratory F

1997
Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids.
    Ophthalmology, 1997, Volume: 104, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Becl

1997
Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy.
    Journal of clinical pharmacy and therapeutics, 1997, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi

1997
Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".
    American journal of epidemiology, 1997, Nov-15, Volume: 146, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Cohort Studies; Confounding Facto

1997
A guinea-pig model of ultrasonically nebulized distilled water-induced bronchoconstriction.
    The European respiratory journal, 1997, Volume: 10, Issue:10

    Topics: Administration, Inhalation; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provoca

1997
Effects of beta-agonists on dose-response curves.
    The European respiratory journal, 1997, Volume: 10, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents;

1997
[The effect of salmeterol on the activity of neutrophil chemotactic factor in patients with asthma].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1996, Volume: 19, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Humans; Interleukin-8; Male; Middle Aged

1996
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
    The Journal of clinical investigation, 1997, Dec-15, Volume: 100, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam

1997
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
    The Journal of clinical investigation, 1997, Dec-15, Volume: 100, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam

1997
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
    The Journal of clinical investigation, 1997, Dec-15, Volume: 100, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam

1997
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
    The Journal of clinical investigation, 1997, Dec-15, Volume: 100, Issue:12

    Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam

1997
Salbutamol enantiomers: early clinical evidence in humans.
    Thorax, 1997, Volume: 52, Issue:10

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Stereoisomerism; Structure-Activity Relationship

1997
Dosing interval with albuterol MDI for asthma.
    The Journal of family practice, 1997, Volume: 45, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru

1997
Defining the asthma phenotype for the purpose of genetic analysis.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1997, Volume: 34, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronch

1997
Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1997, Volume: 34, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Arrhythmia

1997
MDI for acute asthma in children.
    The Journal of family practice, 1998, Volume: 46, Issue:1

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma;

1998
Proventil HFA: a new inhaler for asthma.
    Advance for nurse practitioners, 1997, Volume: 5, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporizers

1997
[Salmeterol, a new long-acting beta 2-agonist in asthma treatment].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 3, Issue:16

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate

1997
The change to non-CFC metered dose inhalers.
    Australian family physician, 1997, Volume: 26, Issue:12

    Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Asthma; Australia; Bronchodilator Agents

1997
Effect of pneumonia and whooping cough in childhood on adult lung function.
    The New England journal of medicine, 1998, Feb-26, Volume: 338, Issue:9

    Topics: Adult; Albuterol; Asthma; Child; Child, Preschool; Cohort Studies; Female; Forced Expiratory Volume;

1998
Relative efficacy of three different inhalers containing salbutamol in patients with asthma.
    European journal of clinical pharmacology, 1997, Volume: 53, Issue:3-4

    Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Humans; Nebulizers and V

1997
Reducing asthma morbidity in the community: the effect of a targeted nurse-run asthma clinic in an English general practice.
    Respiratory medicine, 1997, Volume: 91, Issue:10

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Chil

1997
Counseling about chlorofluorocarbon-free inhalers.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Feb-01, Volume: 55, Issue:3

    Topics: Aerosol Propellants; Albuterol; Anti-Asthmatic Agents; Asthma; Chlorofluorocarbons, Methane; Drug Ca

1998
Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill.
    Chest, 1998, Volume: 113, Issue:2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Area Under Curve; Asthma; Beclome

1998
Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma.
    Chest, 1998, Volume: 113, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A

1998
Effects of airway calibre on lung delivery of nebulised salbutamol.
    Thorax, 1997, Volume: 52, Issue:12

    Topics: Absorption; Administration, Inhalation; Adult; Albuterol; Asthma; Biological Availability; Bronchi;

1997
Inhaled glucocorticoids and acute asthma: therapeutic breakthrough or nonspecific effect?
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:3 Pt 1

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Ag

1998
Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release.
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:3 Pt 1

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Cells,

1998
The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs.
    The Journal of allergy and clinical immunology, 1998, Volume: 101, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic Agents; A

1998
Off-label prescribing for infants.
    Advance for nurse practitioners, 1998, Volume: 6, Issue:2

    Topics: Age Factors; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Humans; Infant; Nurse Pra

1998
Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report.
    Pediatric pulmonology, 1998, Volume: 25, Issue:3

    Topics: Albuterol; Antiviral Agents; Asthma; Bronchial Hyperreactivity; Bronchiolitis; Bronchodilator Agents

1998
Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood.
    American journal of respiratory cell and molecular biology, 1998, Volume: 18, Issue:5

    Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Clone

1998
Long acting beta 2 agonists and the risk of life threatening asthma.
    Thorax, 1998, Volume: 53, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Fenoterol; Humans; Odds Ratio; Salmeterol Xinafoate

1998
Case-control study of salmeterol and near-fatal attacks of asthma.
    Thorax, 1998, Volume: 53, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child,

1998
Adrenal function and physiologic stress during acute asthma exacerbation.
    Annals of emergency medicine, 1998, Volume: 31, Issue:5

    Topics: Acute Disease; Adrenal Glands; Adult; Albuterol; Asthma; Bronchodilator Agents; Cosyntropin; Emergen

1998
Acute bronchodilatory effect of salmeterol on methacholine-induced bronchoconstriction in childhood asthma.
    Acta paediatrica Japonica : Overseas edition, 1998, Volume: 40, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Female; Forced Exp

1998
Changes in treatment and outcomes of children receiving care in the intensive care unit for severe acute asthma.
    Pediatric emergency care, 1998, Volume: 14, Issue:2

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Canada; Child; Cri

1998
Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.
    Pediatric emergency care, 1998, Volume: 14, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Electrocardiography; Humans; Hypokalemia; Male;

1998
Inhalation devices in childhood asthma.
    Acta microbiologica et immunologica Hungarica, 1998, Volume: 45, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bron

1998
How often should beta-agonists be administered?
    Chest, 1998, Volume: 113, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug

1998
Severe childhood asthma.
    Lancet (London, England), 1998, May-30, Volume: 351, Issue:9116

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans;

1998
Inhaler medicament effects on saliva and plaque pH in asthmatic children.
    The Journal of clinical pediatric dentistry, 1998,Winter, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A

1998
Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease.
    Journal of internal medicine, 1998, Volume: 243, Issue:5

    Topics: Administration, Inhalation; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Bronchodi

1998
Airway mucosal blood flow in bronchial asthma.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents

1998
When should your asthmatic patients refill their MDI propelled with chlorofluorocarbons?
    Delaware medical journal, 1998, Volume: 70, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Drug Labeling; Drug Packaging; Humans

1998
Final measurements vs ANOVA for data analysis.
    Chest, 1998, Volume: 114, Issue:1

    Topics: Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Data Interpretation, Statistical; Eq

1998
Bronchodilator response in 3-6.5 years old healthy and stable asthmatic children.
    The European respiratory journal, 1998, Volume: 12, Issue:2

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Body Height; Bronchodilator Agents;

1998
Comparison of beclomethasone, salmeterol, and placebo in children with asthma.
    The New England journal of medicine, 1998, Sep-03, Volume: 339, Issue:10

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Body Height; Child; Humans; Salmeterol Xin

1998
Language of dyspnea in assessment of patients with acute asthma treated with nebulized albuterol.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Acute Disease; Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodila

1998
Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Anti-Asthmatic Agents; Asthma;

1998
Glucocorticoid receptors in bronchial epithelial cells in asthma.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Administration, Oral; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Biopsy; Bronchi; Bro

1998
Young inner-city children visiting the emergency room (ER) for asthma: risk factors and chronic care behaviors.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1998, Volume: 35, Issue:7

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child Welfare; Child, Preschool; Drug Utilization;

1998
Can oral beta2 agonists cause heart failure?
    Lancet (London, England), 1998, Oct-03, Volume: 352, Issue:9134

    Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Coho

1998
About long-acting bronchodilators.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 81, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Delayed-Acti

1998
Prehospital treatment of acute asthma in a rural state.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1998, Volume: 81, Issue:4

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Emergency Medical Technicians; Emergency

1998
Prevalence of asthma and respiratory symptoms in dairy farmers in the French province of the Doubs.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:5 Pt 1

    Topics: Adult; Age Factors; Albuterol; Allergens; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease

1998
[Asthmatic crisis and spontaneous rupture of the esophagus].
    Annales francaises d'anesthesie et de reanimation, 1998, Volume: 17, Issue:9

    Topics: Aged; Albuterol; Asthma; Bronchodilator Agents; Dexamethasone; Diagnosis, Differential; Esophageal D

1998
Awareness of environmental issues and the acceptance of CFC-free inhalers.
    Annals of tropical paediatrics, 1998, Volume: 18, Issue:3

    Topics: Adult; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chlorofluor

1998
Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database.
    Respiratory medicine, 1998, Volume: 92, Issue:11

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies; C

1998
Drugs for asthma.
    The Medical letter on drugs and therapeutics, 1999, Jan-15, Volume: 41, Issue:1044

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr

1999
The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers.
    Clinical therapeutics, 1999, Volume: 21, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cost Savings; Costs and Cost Ana

1999
Inhaled corticosteroid therapy in asthma: a balancing act.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:3

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi

1999
An in vivo model of beta-adrenoceptor desensitization.
    Journal of pharmacological and toxicological methods, 1998, Volume: 40, Issue:2

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictor

1998
Selective airway responsiveness in asthma.
    Trends in pharmacological sciences, 1999, Volume: 20, Issue:1

    Topics: Albuterol; Animals; Asthma; Bradykinin; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Bronch

1999
The cost per treatment success.
    PharmacoEconomics, 1994, Volume: 5, Issue:4

    Topics: Albuterol; Asthma; Cost-Benefit Analysis; Ethanolamines; Humans; Treatment Outcome

1994
Antiasthma drugs: quality-of-life rating scales and sensitivity to longitudinal change.
    PharmacoEconomics, 1994, Volume: 6, Issue:4

    Topics: Albuterol; Asthma; Humans; Longitudinal Studies; Quality of Life; Surveys and Questionnaires

1994
Clinical efficacy and safety of Turbuhaler as compared to pressurized MDIs-beta 2-agonists.
    Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 1994, Volume: 7, Issue:Suppl 1

    Topics: Aged; Albuterol; Asthma; Chlorofluorocarbons; Equipment Design; Humans; Middle Aged; Nebulizers and

1994
Point-of-service outcomes data and its effect on asthma treatment: a salmeterol pilot investigation.
    Medical interface, 1997, Volume: 10, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Outcome Assessment, Health Care; Physician-Patient

1997
Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    The American journal of managed care, 1997, Volume: 3, Issue:11

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Decision Making, Organizational; Fo

1997
Experience of an emergency mobile asthma treatment programme.
    Resuscitation, 1997, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Ambulances; Asthma; Broncho

1997
Evidence of acinar airway involvement in asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:5 Pt 1

    Topics: Adult; Aging; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional

1999
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
    Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Arginine; Asthma; Bronchodilator Agents; Female; Forced

1999
Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children.
    Archives of pediatrics & adolescent medicine, 1999, Volume: 153, Issue:6

    Topics: Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Educationa

1999
Levalbuterol for asthma.
    The Medical letter on drugs and therapeutics, 1999, Jun-04, Volume: 41, Issue:1054

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Digoxin; Drug Interactions; Humans; Isomerism

1999
Perception of bronchodilation in subjects with asthma and smokers with airflow limitation.
    Respirology (Carlton, Vic.), 1999, Volume: 4, Issue:2

    Topics: Aged; Airway Resistance; Albuterol; Asthma; Attitude to Health; Bronchodilator Agents; Female; Force

1999
Salmeterol for nocturnal asthma.
    The Journal of family practice, 1999, Volume: 48, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Hu

1999
Optimization of testing times and critical values in sequential equivalence testing.
    Statistics in medicine, 1999, Jul-30, Volume: 18, Issue:14

    Topics: Albuterol; Asthma; Bronchodilator Agents; Computer Simulation; Humans; Models, Biological; Normal Di

1999
Postmortem stability and interpretation of beta 2-agonist concentrations.
    Journal of forensic sciences, 1999, Volume: 44, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Stability; Fenoterol; Humans; Postmortem Changes;

1999
Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 1999, Volume: 10, Issue:1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres

1999
An in vitro analysis of the output of salbutamol from different nebulizers.
    The European respiratory journal, 1999, Volume: 13, Issue:5

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Humans

1999
A low-cost spacer device.
    Tropical doctor, 1999, Volume: 29, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Ethics, Medical; Humans; India

1999
[Comparative effects of acute tests using ventolin, ventodisk and intal plus in the ambulatory pulmonological practice].
    Problemy tuberkuleza, 1999, Issue:2

    Topics: Albuterol; Ambulatory Care; Asthma; Bronchial Spasm; Bronchitis; Cromolyn Sodium; Humans; Lung Disea

1999
Beta2-agonist enantiomers: is there a glitch with the chiral switch?
    The European respiratory journal, 1999, Volume: 13, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Human

1999
Asthma from the perspective of the patient.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 2

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma

1999
Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma.
    The American journal of medicine, 1999, Volume: 107, Issue:3

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents

1999
Prior use of long-acting beta-agonists: friend or foe in the emergency department?
    The American journal of medicine, 1999, Volume: 107, Issue:3

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Emergency Treatme

1999
Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; B

1999
Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease.
    The European respiratory journal, 1999, Volume: 14, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol;

1999
Salmeterol, inhaled corticosteroids, and tolerance to allergen bronchoprotection.
    Chest, 1999, Volume: 116, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Beclomethasone;

1999
Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population.
    Respiratory medicine, 1999, Volume: 93, Issue:10

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albuterol; Asthma; Child; Chronic Di

1999
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
    The European respiratory journal, 1999, Volume: 14, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; CD4-Po

1999
Intranasal salbutamol instillation in asthma attack.
    The American journal of emergency medicine, 1999, Volume: 17, Issue:7

    Topics: Acute Disease; Administration, Intranasal; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc

1999
Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.
    American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:1

    Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adult; Aged; Albuterol; Androstadie

2000
Salmeterol and tolerance.
    Chest, 2000, Volume: 117, Issue:2

    Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Drug Tolerance; Humans; Long-

2000
Excessive use of inhaled salbutamol: the potential benefits of dose-reduction. A case report.
    The New Zealand medical journal, 1999, Nov-26, Volume: 112, Issue:1100

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Humans; Subs

1999
Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma.
    Thorax, 2000, Volume: 55, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Inflammatory Agents; Asthma

2000
Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet)
    Pediatric pulmonology, 2000, Volume: 29, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity;

2000
Lymphocytes apoptosis in patients with acute exacerbation of asthma.
    Mediators of inflammation, 1999, Volume: 8, Issue:4-5

    Topics: Adult; Aged; Aged, 80 and over; Albuterol; Apoptosis; Asthma; Cells, Cultured; fas Receptor; Humans;

1999
Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients.
    Respiration; international review of thoracic diseases, 2000, Volume: 67, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Ethanolamines; F

2000
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
    The European respiratory journal, 2000, Volume: 15, Issue:2

    Topics: Albuterol; Asthma; Bucladesine; Chemotaxis, Leukocyte; Colforsin; Cyclic AMP; Humans; Interleukin-8;

2000
Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium.
    Mayo Clinic proceedings, 2000, Volume: 75, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction;

2000
Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
    Clinical therapeutics, 2000, Volume: 22, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho

2000
Dispensing home nebulizers for acute wheezing from the hospital is cost-effective.
    The American journal of emergency medicine, 2000, Volume: 18, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilat

2000
Hollow porous particles in metered dose inhalers.
    Pharmaceutical research, 2000, Volume: 17, Issue:2

    Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agent

2000
Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2000, Volume: 4, Issue:3

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Developing Countries; Glucocorticoids; Hum

2000
Drugs for asthma.
    The Medical letter on drugs and therapeutics, 2000, Mar-06, Volume: 42, Issue:1073

    Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta

2000
Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Response Relations

1999
Therapeutic equivalence of inhaled salbutamol.
    Thorax, 2000, Volume: 55, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporiz

2000
Beta-adrenoceptor agonists in bronchial asthma: role of k+-channel opening in mediating their bronchodilator effects.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1993, Volume: 23, Issue:10

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta

1993
[Two out-of-the-ordinary (?) case reports an asthmatic disease].
    Pneumologie (Stuttgart, Germany), 2000, Volume: 54, Issue:3

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Family Practice; Female; Fluocinolone Acet

2000
[The role of beta 2-adrenoceptor gene polymorphisms in asthma].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 2000, Volume: 75, Issue:2

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asian People; Asthma; Down-Regulation; Force

2000
Clinically meaningful changes in quantitative measures of asthma severity.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2000, Volume: 7, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Humans; Logistic Models; Male; Pea

2000
Myoclonus secondary to albuterol (salbutamol) instillation.
    Neurology, 2000, May-23, Volume: 54, Issue:10

    Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug;

2000
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 84, Issue:5

    Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin

2000
Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
    Therapeutic drug monitoring, 2000, Volume: 22, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma

2000
Airway resistance and atopy in preschool children with wheeze and cough.
    The European respiratory journal, 2000, Volume: 15, Issue:5

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Cough; Female; Humans

2000
Increased risk for dental caries in asthmatic children.
    Texas dental journal, 1999, Volume: 116, Issue:9

    Topics: Adolescent; Albuterol; Amoxicillin; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal;

1999
[Reproducibility in induced sputum in children with asthma].
    Pneumologie (Stuttgart, Germany), 2000, Volume: 54, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Feasibility Studies; Forced Expiratory

2000
Treatment of acute asthma in a field environment using albuterol and a large volume spacer.
    Military medicine, 2000, Volume: 165, Issue:6

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Hawaii; Humans; Male; Military Perso

2000
Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.
    American journal of respiratory cell and molecular biology, 2000, Volume: 23, Issue:1

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagoni

2000
Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics.
    Pulmonary pharmacology & therapeutics, 2000, Volume: 13, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black People; Bronchodilator Agents;

2000
Management of acute childhood asthma: a prospective multicentre study.
    The European respiratory journal, 2000, Volume: 15, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Child, Pr

2000
Delayed eosinophil apoptosis in asthma.
    The Journal of allergy and clinical immunology, 2000, Volume: 106, Issue:1 Pt 1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Apoptosis; Asthma; Cells, Cultu

2000
To go by the books.
    Pediatric emergency care, 2000, Volume: 16, Issue:3

    Topics: Accidents, Traffic; Albuterol; Asthma; Bronchodilator Agents; Cervical Vertebrae; Child; Child, Pres

2000
Limitations in the use of median frequency for lung sound analysis.
    Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine, 2000, Volume: 214, Issue:3

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Chil

2000
[C. Kroegel on "Asthma therapy in a double-pack". Compliance next to the toothbrush. Interview by Dr. med. Julia Rautenstrauch].
    MMW Fortschritte der Medizin, 1999, Nov-25, Volume: 141, Issue:47

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Fluticasone; Humans; Ne

1999
The pressurized metered dose inhaler (pMDI) remains the most commonly prescribed device for the delivery of inhaled asthma medications.
    Respiratory medicine, 2000, Volume: 94 Suppl B

    Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Anti-Asthmatic Agents; A

2000
Palmar erythema nodosum.
    The Journal of dermatology, 2000, Volume: 27, Issue:6

    Topics: Aged; Albuterol; Asthma; Drug Therapy, Combination; Erythema Nodosum; Erythromycin; Female; Hand Der

2000
Easier breathing?
    Annals of emergency medicine, 2000, Volume: 36, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent

2000
Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2000, Volume: 30, Issue:9

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Bronchi; Bronchial P

2000
Seattle's breath of fresh air.
    JEMS : a journal of emergency medical services, 2000, Volume: 25, Issue:1

    Topics: Administration, Inhalation; Albuterol; Asthma; Emergency Medical Services; Humans; Lung Diseases, Ob

2000
Persistent asthma: patient characteristics, courses of asthma, and utility of salmeterol.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2000, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Allergens; Animals; Asthma; Bronchodilator Ag

2000
Functional significance of air trapping detected in moderate asthma.
    European radiology, 2000, Volume: 10, Issue:9

    Topics: Administration, Inhalation; Adult; Aged; Air; Albuterol; Asthma; Bronchodilator Agents; Bronchograph

2000
Acute angle-closure glaucoma after albuterol nebulizer treatment.
    American journal of ophthalmology, 2000, Volume: 130, Issue:1

    Topics: Acute Disease; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Gla

2000
Regular use of salbutamol in asthma.
    Lancet (London, England), 2000, Sep-02, Volume: 356, Issue:9232

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans

2000
Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist.
    Respirology (Carlton, Vic.), 2000, Volume: 5, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronch

2000
Short-acting beta2-agonists.
    Lancet (London, England), 2000, Sep-09, Volume: 356, Issue:9233

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; Bro

2000
[Increased dosage of inhaled corticosteroids or addition of salmeterol in symptomatic asthma].
    Presse medicale (Paris, France : 1983), 2000, Sep-23, Volume: 29, Issue:27

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila

2000
Familial aggregation of bronchodilator response: a community-based study.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi;

2000
Cost comparison of bronchodilator delivery methods in Emergency Department treatment of asthma.
    The Journal of emergency medicine, 2000, Volume: 19, Issue:4

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; E

2000
Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.
    Chest, 2000, Volume: 118, Issue:5

    Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists

2000
A spoonful of medicine. Or is it more?
    The American journal of nursing, 2000, Volume: 100, Issue:11

    Topics: Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Treatmen

2000
Recurrent supraventricular tachycardia as a complication of nebulized albuterol treatment.
    Clinical pediatrics, 2000, Volume: 39, Issue:11

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Electrocardiography; He

2000
Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment.
    Chest, 2000, Volume: 118, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agen

2000
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.
    Thorax, 2001, Volume: 56, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Bronchoconstrictor A

2001
Practical pharmacotherapy for pediatric asthma.
    Pediatric annals, 2000, Volume: 29, Issue:12

    Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Budesonide; Child; Glucocorticoi

2000
Fatal and near-fatal asthma in children exposed to fireworks.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2000, Volume: 85, Issue:6 Pt 1

    Topics: Administration, Inhalation; Albuterol; Asthma; Blast Injuries; Child; Child, Preschool; Explosions;

2000
Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects.
    Journal of applied physiology (Bethesda, Md. : 1985), 2001, Volume: 90, Issue:2

    Topics: Administration, Inhalation; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Albuterol; A

2001
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2001, Volume: 121, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Ch

2001
Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
    Respiratory medicine, 2001, Volume: 95, Issue:1

    Topics: Acetates; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Ant

2001
Are asthma medications and management related to deaths from asthma?
    American journal of respiratory and critical care medicine, 2001, Volume: 163, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Fem

2001
New therapeutic approach to persistent asthma.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2000, Volume: 55, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Glucocorticoids; Humans; Salmete

2000
Salmeterol and conventional asthma therapy.
    Chest, 2001, Volume: 119, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Interactions; Humans; Salmeterol Xinafoate

2001
[Salmeterol plus fluticasone--a powerful team. New combined preparation improves compliance].
    MMW Fortschritte der Medizin, 2001, Feb-08, Volume: 143, Issue:6

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinati

2001
Beta2-agonist exerts differential effects on the development of cord blood T cells but not on peripheral blood T cells.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2001, Volume: 12, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cell Division; Female; Fetal Blood; Humans; Immu

2001
[Bronchial asthma. A combination preparation improves patient compliance].
    MMW Fortschritte der Medizin, 2001, Feb-22, Volume: 143, Issue:8

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinati

2001
Clinical predictors of health-related quality of life depend on asthma severity.
    American journal of respiratory and critical care medicine, 2001, Volume: 163, Issue:4

    Topics: Adult; Albuterol; Analysis of Variance; Asthma; Female; Follow-Up Studies; Humans; Hydroxyurea; Male

2001
The diagnosis and treatment of cough.
    The New England journal of medicine, 2001, Apr-05, Volume: 344, Issue:14

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Common Cold; Cough; Diagnost

2001
Fluticasone propionate/salmeterol combination.
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator A

2001
The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research.
    Chest, 2001, Volume: 119, Issue:4

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Area Under Curve; Asthma; False Positive Rea

2001
Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.
    European journal of epidemiology, 2000, Volume: 16, Issue:9

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albutero

2000
A combination of fluticasone and salmeterol for asthma.
    The Medical letter on drugs and therapeutics, 2001, Apr-16, Volume: 43, Issue:1102

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes;

2001
Lidocaine inhalation for cough suppression.
    The American journal of emergency medicine, 2001, Volume: 19, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Anesthetics, Local; Antitussive Agents; Asthma;

2001
Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma.
    The European respiratory journal, 2001, Volume: 17, Issue:2

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma

2001
Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma.
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:5

    Topics: 5-Lipoxygenase-Activating Proteins; Administration, Inhalation; Administration, Oral; Adrenergic bet

2001
Ambulatory use of inhaled beta(2)-agonists for the treatment of asthma in Quebec : a population-based utilization review.
    Chest, 2001, Volume: 119, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag

2001
Formoterol (Foradil Aerolizer) for asthma.
    The Medical letter on drugs and therapeutics, 2001, May-14, Volume: 43, Issue:1104

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma

2001
[Powder inhaler with integrated motor. The anti-asthmatic drug stays fresh].
    MMW Fortschritte der Medizin, 2001, Apr-19, Volume: 143, Issue:16

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Combinations; Humans; Nebulizers and Vapo

2001
Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
    Drug safety, 2001, Volume: 24, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Asthma; Bronc

2001
Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.
    Clinical therapeutics, 2001, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents;

2001
What is "more effective asthma control"?
    The Journal of allergy and clinical immunology, 2001, Volume: 107, Issue:6

    Topics: Acetates; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chronic Disease; Cyclopro

2001
Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment.
    Chest, 2001, Volume: 119, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Broncho

2001
[Precise direction or flexible self-control. How strictly must the asthma patient adhere to medical advice?].
    MMW Fortschritte der Medizin, 2001, May-10, Volume: 143, Issue:19

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Dr

2001
Is overall asthma control being achieved? A hypothesis-generating study.
    The European respiratory journal, 2001, Volume: 17, Issue:4

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations;

2001
Time to consign cromoglycate to history?
    Thorax, 2001, Volume: 56, Issue:6

    Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Cromolyn Sodium; Humans

2001
Acute changes in bronchoconstriction influences exhaled nitric oxide level.
    The Japanese journal of physiology, 2001, Volume: 51, Issue:2

    Topics: Adult; Albuterol; Asthma; Breath Tests; Bronchoconstriction; Bronchoconstrictor Agents; Bronchodilat

2001
Selected contribution: airway caliber in healthy and asthmatic subjects: effects of bronchial challenge and deep inspirations.
    Journal of applied physiology (Bethesda, Md. : 1985), 2001, Volume: 91, Issue:1

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstricti

2001
Revisiting interactions between hypoxaemia and beta2 agonists in asthma.
    Thorax, 2001, Volume: 56, Issue:7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Cardiovascular Diseases; Dose-Response Relationship, Dr

2001
EG-1 positive eosinophils in asthma.
    American journal of respiratory and critical care medicine, 2001, Jul-01, Volume: 164, Issue:1

    Topics: Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Eosinophils; Humans; Salmete

2001
Is there a need for another inhalative beta(2)-agonist besides formoterol in patients with asthma?
    Respiration; international review of thoracic diseases, 2001, Volume: 68, Issue:4

    Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Drug

2001
[Controlling inflammation plus bronchodilation. Advantages of fixed combinations].
    MMW Fortschritte der Medizin, 2001, Jun-14, Volume: 143, Issue:24

    Topics: Adult; Albuterol; Androstadienes; Asthma; Child; Drug Combinations; Fluticasone; Humans; Salmeterol

2001
Predictors of hospitalization in children with acute asthma.
    The Journal of pediatrics, 2001, Volume: 139, Issue:2

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Female; Forced Expiratory

2001
[Bronchial asthma. Patient management still has deficits].
    MMW Fortschritte der Medizin, 2001, Jul-26, Volume: 143, Issue:30

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Drug Synergism; Drug Therapy, Combina

2001
Beta2-agonists--from pharmacological properties to everyday clinical practice.
    Respiratory medicine, 2001, Volume: 95 Suppl B

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Nebulizers

2001
To the editor: Exacerbation of asthma by ibuprofen in a very young child.
    Pediatric pulmonology, 2001, Volume: 32, Issue:3

    Topics: Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator Agents; Child, Preschool;

2001
Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
    The American journal of managed care, 2001, Volume: 7, Issue:9

    Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost of Illness; Drug Therapy, Comb

2001
Magnesium concentration in plasma, leukocytes and urine of children with intermittent asthma.
    Clinica chimica acta; international journal of clinical chemistry, 2001, Volume: 312, Issue:1-2

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Preschool;

2001
The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children.
    American journal of respiratory and critical care medicine, 2001, Oct-01, Volume: 164, Issue:7

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Female; Humans; Male; Saline Solutio

2001
Regulation of NO-producing function of the lungs with salmeterol.
    Bulletin of experimental biology and medicine, 2001, Volume: 132, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator A

2001
Levalbuterol and racemic albuterol: are there therapeutic differences?
    The Journal of allergy and clinical immunology, 2001, Volume: 108, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Spasm; Bronchodila

2001
Childhood asthma.
    The Western journal of medicine, 2001, Volume: 175, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Cholinergic Antagonists; Drug Therapy

2001
Safety of sputum induction with isotonic saline in adults with acute severe asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2001, Volume: 31, Issue:11

    Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Al

2001
[How compliance is improved. Combined treatment of asthma].
    MMW Fortschritte der Medizin, 2001, Oct-18, Volume: 143, Issue:42

    Topics: Albuterol; Androstadienes; Asthma; Delayed-Action Preparations; Drug Therapy, Combination; Ethanolam

2001
Using humanistic health outcomes data in asthma.
    PharmacoEconomics, 2001, Volume: 19 Suppl 2

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Health Status; Hum

2001
Impact of an asthma carepath on the management of acute asthma exacerbations.
    Annals of the Academy of Medicine, Singapore, 2001, Volume: 30, Issue:4 Suppl

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Critical Pathways; Female; Hospitals, Teaching; Hum

2001
The clinical trials in the initial five-year award period of the Asthma Clinical Research Network.
    Controlled clinical trials, 2001, Volume: 22, Issue:6 Suppl

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Area Under

2001
Genetic analysis in the Asthma Clinical Research Network.
    Controlled clinical trials, 2001, Volume: 22, Issue:6 Suppl

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Confidentiality; Ethics Commi

2001
Recruitment strategies in the Asthma Clinical Research Network.
    Controlled clinical trials, 2001, Volume: 22, Issue:6 Suppl

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child

2001
Angiogenesis and remodeling of airway vasculature in chronic inflammation.
    American journal of respiratory and critical care medicine, 2001, Nov-15, Volume: 164, Issue:10 Pt 2

    Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Angiopoietin-1; Animals; Asthma; Bronchitis; Bronchod

2001
Early prediction of poor outcome in patients with acute asthma in the emergency room.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2002, Volume: 35, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service

2002
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    JAMA, 2001, Dec-26, Volume: 286, Issue:24

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child;

2001
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    JAMA, 2001, Dec-26, Volume: 286, Issue:24

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Glucoc

2001
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    JAMA, 2001, Dec-26, Volume: 286, Issue:24

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child;

2001
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
    JAMA, 2001, Dec-26, Volume: 286, Issue:24

    Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Glucoc

2001
Improving pediatric asthma patient outcomes by incorporation of effective interventions.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2001, Volume: 38, Issue:8

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator

2001
When the whole is more than the sum of its parts.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Dr

2001
Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Child,

2001
Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:6

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Chromatograp

2001
Number needed to treat (NNT): estimation of a measure of clinical benefit.
    Statistics in medicine, 2001, Dec-30, Volume: 20, Issue:24

    Topics: Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Humans; Quality of Life; Randomized Co

2001
Response of asthma-related voice dysfunction to allergen immunotherapy: a case report of confirmation by methacholine challenge.
    Journal of voice : official journal of the Voice Foundation, 2001, Volume: 15, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Desensitization, Immunol

2001
Reversible selective beta(2)-adrenoceptor agonist-induced myopathy.
    Rheumatology (Oxford, England), 2002, Volume: 41, Issue:1

    Topics: Administration, Intranasal; Administration, Oral; Adrenergic beta-Antagonists; Aged; Albuterol; Asth

2002
Validation of the pulmonary score: an asthma severity score for children.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002, Volume: 9, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge

2002
Validation of the pulmonary score: an asthma severity score for children.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002, Volume: 9, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge

2002
Validation of the pulmonary score: an asthma severity score for children.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002, Volume: 9, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge

2002
Validation of the pulmonary score: an asthma severity score for children.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002, Volume: 9, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge

2002
Bronchodilator responsiveness and atopy in 5-10-yr-old coughers.
    The European respiratory journal, 2001, Volume: 18, Issue:6

    Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cough; Cross-S

2001
[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].
    Pneumologie (Stuttgart, Germany), 2002, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents

2002
MIASMA: asthma exacerbation reduction with salmeterol.
    Chest, 2002, Volume: 121, Issue:3

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Glucocorticoids; Humans; Sa

2002
Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
    The Journal of allergy and clinical immunology, 2002, Volume: 109, Issue:3

    Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma;

2002
Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects.
    Acta pharmacologica Sinica, 2002, Volume: 23, Issue:3

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; CD4-Positive T-Lymphocytes; Delayed-Action Preparat

2002
[Fixed combination of salmeterol and fluticasone. A mile stone in asthma therapy].
    MMW Fortschritte der Medizin, 2002, Mar-07, Volume: 144, Issue:10

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trial

2002
[Good asthma control is possible. Synergy of 2 soloists].
    MMW Fortschritte der Medizin, 2002, Mar-07, Volume: 144, Issue:10

    Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trial

2002
Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma.
    Chest, 2002, Volume: 121, Issue:4

    Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflamma

2002
A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma.
    Chest, 2002, Volume: 121, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Dose-Response R

2002
Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation.
    Chest, 2002, Volume: 121, Issue:4

    Topics: Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Measu

2002
A comparison of the validity of different diagnostic tests in adults with asthma.
    Chest, 2002, Volume: 121, Issue:4

    Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchod

2002
Bronchodilator reversibility to albuterol predicts bronchodilator response to salmeterol.
    Chest, 2002, Volume: 121, Issue:4

    Topics: Acetates; Administration, Inhalation; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; B

2002
Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma.
    The American journal of medicine, 2002, Apr-15, Volume: 112, Issue:6

    Topics: Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Broncho

2002
In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?
    The Journal of family practice, 2002, Volume: 51, Issue:3

    Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch

2002
[Bronchial asthma. Dual problem--dual therapy].
    MMW Fortschritte der Medizin, 2002, Mar-28, Volume: 144, Issue:13

    Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combination; Fluticasone; Hu

2002
Xopenex. New asthma relief for kids.
    Nursing, 2002, Volume: 32, Issue:5

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Approval; Humans

2002
Preventing unnecessary emergency department visits for "albuterol nebs".
    Archives of pediatrics & adolescent medicine, 2002, Volume: 156, Issue:6

    Topics: Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Humans; Nebulizers and Vapori

2002
[Inducible nitric oxide synthase in rat lungs in experimental bronchial asthma and its status in administering drugs with adrenergic action].
    Tsitologiia, 2002, Volume: 44, Issue:2

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Asthma; Fenote

2002
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
    Chest, 2002, Volume: 121, Issue:6

    Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Ast

2002
[Use of beta-adrenergic drugs in pediatric therapy].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adrenergic beta-Agonists; Age Factors; Albuterol; Asthma; Child; Dyspnea; Humans; Isoproterenol; Met

1976
[Comparative effectiveness of some beta-adrenergic drugs used in the treatment of asthma-like syndromes].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Dyspnea; Humans; Metaproterenol; Respi

1976
[Physiopathological and clinical studies on the use of beta-stimulating drugs].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Humans; Lung Diseases, Obstructive; Pu

1976
[Effect of beta-adrenergic drugs on bronchial secretion].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchitis; Drug Evaluation; Female; Hu

1976
[Comparative study of the effectiveness of beta-adrenergic stimulatin drugs].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Drug Evaluation; For

1976
[Comparative clinical data on the bronchodilating effect of some selective beta-2 stimulating drugs].
    La Pediatria, 1977, Jun-30, Volume: 85, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory

1977
A comparison of rimiterol and salbutamol by inhalation at high and low dose in asthmatic patients.
    Respiration; international review of thoracic diseases, 1978, Volume: 35, Issue:3

    Topics: Aerosols; Albuterol; Asthma; Blood Pressure; Bronchial Spasm; Catechols; Heart Rate; Humans; Peak Ex

1978
Blood eosinophil leucocyte and eosinophil cationic protein. In vivo study of the influence of beta-2-adrenergic drugs and steroid medication.
    Scandinavian journal of respiratory diseases, 1978, Volume: 59, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Asthma; B

1978
Aspects on bronchial beta2-receptor tolerance.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Drug Resistance; Humans; Time Factors

1979
Which bronchodilator-and when?
    Australian family physician, 1979, Volume: 8, Issue:1

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans;

1979
[Bronchospasmolytic agents].
    Polskie Archiwum Medycyny Wewnetrznej, 1979, Volume: 61, Issue:3

    Topics: Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchi; Drug Therapy, Combination; Huma

1979
Granulocyte response in vitro to isoproterenol, histamine, and prostaglandin E1, during treatment with beta-adrenergic aerosols in asthma.
    The American review of respiratory disease, 1979, Volume: 120, Issue:2

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Cyclic AMP; Glucuronidase;

1979
Letter: Intravenous prednisolone in asthma.
    Lancet (London, England), 1976, Feb-21, Volume: 1, Issue:7956

    Topics: Albuterol; Asthma; Drug Interactions; Humans; Hydrocortisone; Injections, Intravenous; Isoproterenol

1976
Myocardial infarction in status asthmaticus.
    Lancet (London, England), 1977, Mar-19, Volume: 1, Issue:8012

    Topics: Albuterol; Aminophylline; Asthma; Female; Humans; Middle Aged; Myocardial Infarction

1977
Intravenous versus inhaled salbutamol.
    Lancet (London, England), 1978, Jan-14, Volume: 1, Issue:8055

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous

1978
Intravenous versus inhaled salbutamol.
    Lancet (London, England), 1978, Feb-04, Volume: 1, Issue:8058

    Topics: Albuterol; Asthma; Evaluation Studies as Topic; Humans; Injections, Intravenous; Intermittent Positi

1978
Nebulised salbutamol in treatment of acute asthma in children.
    Lancet (London, England), 1978, Feb-25, Volume: 1, Issue:8061

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child, Preschool; Cromolyn Sodium; Home Care Services; H

1978
Nebulised salbutamol in adult asthma.
    Lancet (London, England), 1978, Mar-25, Volume: 1, Issue:8065

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Male; Middle Aged

1978
Salbutamol and beclomethasone in chronic asthma.
    Lancet (London, England), 1978, Aug-26, Volume: 2, Issue:8087

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Chronic Disease; Drug Therapy, Combination; Humans

1978
Salbutamol and beclomethasone in chronic asthma.
    Lancet (London, England), 1978, Sep-09, Volume: 2, Issue:8089

    Topics: Albuterol; Asthma; Beclomethasone; Chronic Disease; Drug Therapy, Combination; Humans

1978
Nebulised salbutamol in treatment of acute asthma in children.
    Lancet (London, England), 1978, Jan-21, Volume: 1, Issue:8056

    Topics: Acute Disease; Aerosols; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Ma

1978
A simple standardized approach to childhood asthma.
    The Practitioner, 1979, Volume: 223, Issue:1337

    Topics: Albuterol; Asthma; Beclomethasone; Child; Child Health Services; Child, Preschool; Cromolyn Sodium;

1979
[Value and limitations of salbutamol in the treatment of the obstructive syndrome. Comparative study with a synthetic atropine-like agent].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Female; Humans; Ipratropium; Lung

1976
Protective effect of drugs on histamine-induced asthma.
    Thorax, 1977, Volume: 32, Issue:4

    Topics: Albuterol; Ascorbic Acid; Asthma; Atropine; Choline; Cromolyn Sodium; Female; Histamine; Humans; Ipr

1977
[Effect of an adrenergic-parasympatholytic aerosol combination on the respiratory function].
    Minerva medica, 1979, Jan-28, Volume: 70, Issue:4

    Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Bronchitis; Drug Combinations; D

1979
[Concerning the therapy of exercise-induced asthma (author's transl)].
    Praxis und Klinik der Pneumologie, 1979, Volume: 33, Issue:6

    Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Cromolyn Sodium; Humans; Ipratrop

1979
Clinical pharmacology of a combination of bronchodilators.
    International journal of clinical pharmacology and biopharmacy, 1979, Volume: 17, Issue:6

    Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Bronchodilator Agents; Drug Combinati

1979
Mechanisms of the bronchoconstrictor effects of deep inspiration in asthmatic patients.
    Thorax, 1979, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Constriction, Pathologic; Cromolyn

1979
[Combined inhalation of salbutamol and ipratropin in chronic bronchial obstruction].
    Ugeskrift for laeger, 1979, Jul-23, Volume: 141, Issue:30

    Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Drug Therapy, Combination; Female;

1979
Editorial: Treatment of asthmatic children with steroids.
    British medical journal, 1975, Feb-22, Volume: 1, Issue:5955

    Topics: Adrenocorticotropic Hormone; Aerosols; Albuterol; Asthma; Beclomethasone; Child; Child, Preschool; C

1975
Treatment of a case of allergic asthma with a synthetic human ACTH preparation.
    Clinical allergy, 1976, Volume: 6, Issue:3

    Topics: Adrenocorticotropic Hormone; Albuterol; Asthma; Child; Cromolyn Sodium; Female; Hormones; Humans

1976
[Use of bronchodilators].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1976, Feb-09, Volume: 52, Issue:6

    Topics: Administration, Intranasal; Administration, Oral; Albuterol; Asthma; Bronchial Spasm; Bronchodilator

1976
The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function.
    The Journal of clinical investigation, 1976, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Female; Humans; Isoproterenol; Lymphocytes;

1976
Effect of salbutamol inhalations of plasma and urinary cyclic adenosine monophosphate levels in asthmatics and non-atopic controls.
    Scandinavian journal of respiratory diseases, 1976, Volume: 57, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aerosols; Albuterol; Asthma; Cyclic AMP; Female; Humans; Ma

1976
Comparison of cyclic adenosine monophosphate response of lymphocytes in normal and asthmatic subjects to norepinephrine and salbutamol.
    The Journal of allergy and clinical immunology, 1977, Volume: 59, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Cyclic AMP; Female; Humans; In Vitro

1977
[Plasma cortisol, cyclic adenosine monophosphate and lung function in asthmatic patients].
    MMW, Munchener medizinische Wochenschrift, 1978, Jul-21, Volume: 120, Issue:29-30

    Topics: Adult; Aged; Albuterol; Asthma; Cosyntropin; Cyclic AMP; Female; Humans; Hydrocortisone; Middle Aged

1978
[Broncholytic effect of stimulation of beta-2 adrenergic receptors in asthma, bronchiectasis and pulmonary tuberculosis].
    Pneumonologia polska, 1978, Volume: 46, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchiectasis; Female; Humans; Male; Receptors, Adre

1978
Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma.
    British journal of diseases of the chest, 1978, Volume: 72, Issue:3

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Lymphocyte

1978
Circadian rhythmicity in medicine with special regard to asthmatic patients.
    Scandinavian journal of respiratory diseases. Supplementum, 1979, Volume: 103

    Topics: Adrenocorticotropic Hormone; Albuterol; Asthma; Circadian Rhythm; Corticosterone; Humans; Hydrocorti

1979
Metabolic and cardiovascular effects of salbutamol in atopic subjects with and without asthma.
    Scandinavian journal of respiratory diseases, 1979, Volume: 60, Issue:1

    Topics: Adult; Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Forced Expiratory Volum

1979
Exercise-induced asthma.
    British journal of diseases of the chest, 1975, Volume: 69, Issue:1

    Topics: Acidosis, Respiratory; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Air

1975
[Induced beta-adrenergic stimulation and blockade in asthma bronchomotor effects (author's transl)].
    Respiration; international review of thoracic diseases, 1975, Volume: 32, Issue:4

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Obstruction; Airway Resistance; Albute

1975
Annals of allergy.
    Annals of allergy, 1975, Volume: 35, Issue:2

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Epinephrine; Fenoterol; Hexoprenaline; Isopro

1975
Effect of beta-adrenoreceptor stimulants on exercise-induced asthma.
    Pediatrics, 1975, Volume: 56, Issue:5 pt-2 sup

    Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Child; Epinephrine; Humans; Isoetha

1975
A comparison of oral theophylline and oral salbutamol in exercise-induced asthma.
    Australian and New Zealand journal of medicine, 1977, Volume: 7, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Child; Female; Humans; Male; Peak Expira

1977
Case report: an asthmatic child with a very high consumption of Ventoline respirator solution.
    Scandinavian journal of respiratory diseases. Supplementum, 1977, Volume: 101

    Topics: Adolescent; Albuterol; Asthma; Drug Tolerance; Female; Humans; Respiratory Therapy; Substance-Relate

1977
Volume of trapped gas (VTG) during provoked asthma and after inhalation of salbutamol.
    Scandinavian journal of respiratory diseases. Supplementum, 1977, Volume: 101

    Topics: Albuterol; Asthma; Female; Forced Expiratory Volume; Functional Residual Capacity; Humans; Lung Volu

1977
[Broncholytic aerosols; with special attention to juvenile patients].
    Wiener medizinische Wochenschrift. Supplement, 1978, Volume: 51

    Topics: Adolescent; Aerosols; Age Factors; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Body He

1978
Bronchodilator effects of oral salbutamol and theophylline-salbutamol combinations in chronic steroid-dependent asthmatics.
    The Journal of the Medical Society of New Jersey, 1979, Volume: 76, Issue:13

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Chronic Disease; Double-Bli

1979
Intermittent positive-pressure breathing.
    British medical journal, 1978, May-06, Volume: 1, Issue:6121

    Topics: Adult; Albuterol; Asthma; Female; Humans; Intermittent Positive-Pressure Breathing; Male; Methods; P

1978
A comparison of salbutamol given by pressure-packed aerosol or nebulization via IPPB in acute asthma.
    British journal of diseases of the chest, 1978, Volume: 72, Issue:3

    Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Intermi

1978
Aerosolised bronchodilator therapy with & without IPPR in bronchial asthma--a comparative evaluation.
    The Indian journal of chest diseases & allied sciences, 1978, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Intermittent

1978
Nebulised salbutamol in life-threatening asthma.
    British medical journal, 1979, Jun-16, Volume: 1, Issue:6178

    Topics: Aerosols; Albuterol; Asthma; Humans; Intermittent Positive-Pressure Ventilation

1979
Status asthmaticus in children: a one-year study.
    Archives of disease in childhood, 1979, Volume: 54, Issue:8

    Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Follow-Up Studies; Ho

1979
Effects of exercise on asthma.
    Australian family physician, 1977, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Middle Aged; Physical Exertion

1977
A case of intrinsic asthma.
    British medical journal, 1977, Sep-10, Volume: 2, Issue:6088

    Topics: Albuterol; Asthma; Cromolyn Sodium; Humans

1977
Treatment of asthma in children.
    Australian family physician, 1978, Volume: 7, Issue:2

    Topics: Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Sympathomimetics; Theophylline

1978
Saving asthmatics.
    British medical journal, 1979, Jun-30, Volume: 1, Issue:6180

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans

1979
[Use of ventolin for detection of latent bronchial spasm in the inter-attack period of bronchial asthma in children].
    Pediatriia, 1979, Issue:6

    Topics: Albuterol; Asthma; Bronchi; Bronchial Spasm; Child; Child, Preschool; Humans

1979
Saving asthmatics.
    British medical journal, 1979, Aug-04, Volume: 2, Issue:6185

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans; Kinetics; Random Allocation

1979
Transit-time analysis of the forced expiratory spirogram during clinical remission in juvenile asthma.
    Thorax, 1979, Volume: 34, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Female; Forced Expiratory Flow Rates; Humans; Male; Remission,

1979
Bronchodilator effects of antiasthmatic cigarette smoke (Datura stramonium).
    Thorax, 1979, Volume: 34, Issue:2

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Datura stramonium; Dilatation; Female; Heart R

1979
Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma.
    Clinica chimica acta; international journal of clinical chemistry, 1979, Mar-01, Volume: 92, Issue:2

    Topics: Adult; Age Factors; Albuterol; Ascorbic Acid; Asthma; Body Weight; Cholesterol; Humans; Leukocyte Co

1979
[Prolonged use of salbutamol syrup in 25 aged patients].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1979, Volume: 24, Issue:3

    Topics: Administration, Oral; Aged; Albuterol; Asthma; Bronchial Spasm; Female; Follow-Up Studies; Humans; M

1979
Bronchodilator drugs and young children.
    Archives of disease in childhood, 1979, Volume: 54, Issue:8

    Topics: Age Factors; Albuterol; Asthma; Humans; Infant

1979
Respiratory and circulatory interactions of salbutamol and theophyllamine in asthmatic patients.
    International journal of clinical pharmacology and biopharmacy, 1979, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Albuterol; Asthma; Double-Blind Method; Drug Interactions; Female; Hemodynamics;

1979
A comparison of the bronchodilator efficacy of oral salbutamol and terbutaline.
    The Journal of the Association of Physicians of India, 1979, Volume: 27, Issue:6

    Topics: Adult; Albuterol; Asthma; Female; Humans; Male; Pulmonary Ventilation; Terbutaline

1979
Dose-titration comparison of inhaled salbutamol and oral theophylline in asthma.
    British journal of clinical pharmacology, 1979, Volume: 8, Issue:6

    Topics: Administration, Oral; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Fo

1979
Physiological patterns in early morning asthma.
    Thorax, 1977, Volume: 32, Issue:4

    Topics: Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Helium; Humans; Lung; Middle Aged; Respiratory Fun

1977
Salbutamol-induced ketoacidosis.
    British medical journal, 1977, Oct-29, Volume: 2, Issue:6095

    Topics: Acidosis; Albuterol; Asthma; Female; Humans; Hyperglycemia; Ketosis; Middle Aged

1977
[The controlled administration of salbutamol in asthmatics by means of "Airflometer" (author's transl)].
    Lijecnicki vjesnik, 1977, Volume: 99, Issue:9

    Topics: Albuterol; Asthma; Humans; Respiratory Function Tests

1977
[Clinical evaluation of salbutamol in bronchial asthma in childhood].
    Minerva pediatrica, 1977, Nov-03, Volume: 29, Issue:34

    Topics: Age Factors; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; In

1977
[Management of severe asthma in childhood (author's transl)].
    Monatsschrift fur Kinderheilkunde, 1977, Volume: 125, Issue:11

    Topics: Acetylcysteine; Age Factors; Airway Obstruction; Albuterol; Aminophylline; Asthma; Bromhexine; Child

1977
Intravenous or inhaled salbutamol in severe acute asthma?
    Thorax, 1977, Volume: 32, Issue:5

    Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Injections, Intravenous; Male; Mi

1977
Metabolic effects of intravenous salbutamol in the course of acute severe asthma.
    Thorax, 1977, Volume: 32, Issue:5

    Topics: Acute Disease; Albuterol; Asthma; Fatty Acids, Nonesterified; Humans; Injections, Intravenous; Potas

1977
Oral salbutamol therapy of asthma in young children.
    The Journal of asthma research, 1977, Volume: 15, Issue:1

    Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male

1977
Treatment of severe attacks of asthma in children with nebulized B2 adrenergic agents.
    Annals of allergy, 1978, Volume: 40, Issue:3

    Topics: Administration, Intranasal; Albuterol; Asthma; Auscultation; Child; Child, Preschool; Dyspnea; Human

1978
Management of severe acute asthma.
    British medical journal, 1978, Apr-08, Volume: 1, Issue:6117

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Hospitalization; Humans

1978
[Effect of stimulation of beta-2 adrenergic receptors on the exercise capacity and subjective exercise tolerance in patients with asthma].
    Pneumonologia polska, 1978, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Humans; Male; Physical Exertion

1978
Management of severe acute asthma.
    British medical journal, 1978, May-27, Volume: 1, Issue:6124

    Topics: Acute Disease; Albuterol; Asthma; Humans

1978
[Comparison between intravenous administration of salbutamol and theophylline in asthma].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1978, Apr-30, Volume: 98, Issue:12

    Topics: Albuterol; Asthma; Humans; Theophylline

1978
Intravenous infusion of salbutamol in severe acute asthma.
    British medical journal, 1978, Jun-17, Volume: 1, Issue:6127

    Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans; Infusions, Parenteral; Research Design

1978
Changes in volume of trapped gas in the lungs during provoked asthma followed by beta-2 receptor stimulation.
    Respiration; international review of thoracic diseases, 1978, Volume: 36, Issue:1

    Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Bronchospirometry; Closing Volume; Female; Humans; Lung;

1978
Bronchofiberscopy in asthmatics: a method for minimizing risk of complications.
    Respiration; international review of thoracic diseases, 1978, Volume: 36, Issue:2

    Topics: Adult; Aged; Albuterol; Asthma; Bronchial Spasm; Bronchitis; Bronchoscopy; Female; Forced Expiratory

1978
[Long-term effect and tolerance of broncholytics].
    Wiener medizinische Wochenschrift (1946), 1978, Volume: 128, Issue:48

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Drug Resistance; Drug Tolerance; Fenoterol; Hexoprenaline;

1978
Comparison of the metabolic effects of salbutamol administered in a one-minute bolus and a continuous infusion in patients with bronchial asthma.
    Israel journal of medical sciences, 1978, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Glucose; Female; Heart Rate; Humans; Male; Peak Expirato

1978
[Use of sympathomimetics in the treatment of asthma].
    Le Poumon et le coeur, 1978, Volume: 34, Issue:2

    Topics: Albuterol; Asthma; Bronchodilator Agents; Ephedrine; Epinephrine; Humans; Isoproterenol; Metaprotere

1978
Acute changes of lung volumes and lung mechanics in asthma and in normal subjects.
    Thorax, 1978, Volume: 33, Issue:3

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Functional Residual C

1978
At what age do bronchodilator drugs work?
    Archives of disease in childhood, 1978, Volume: 53, Issue:7

    Topics: Age Factors; Airway Resistance; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Prescho

1978
The volume of trapped gas: a new and sensitive test for the detection of exercise-induced bronchospasm in children.
    Acta paediatrica Scandinavica, 1978, Volume: 67, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Humans; Lung Volume Measurem

1978
[Pathogenesis and prevention of exercise-induced asthma].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1978, Issue:84

    Topics: Airway Obstruction; Albuterol; Asthma; Humans; Physical Exertion

1978
Use of salbutamol powder in childhood asthma.
    Archives of disease in childhood, 1978, Volume: 53, Issue:12

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Powders; Res

1978
Inhalation of beta-stimulants: dose-response relationship.
    Lung, 1978, Volume: 154, Issue:4

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Huma

1978
[The neurovegetative system in the pathogenesis of bronchial spasm].
    Minerva medica, 1977, Jan-14, Volume: 68, Issue:2

    Topics: Albuterol; Aminophylline; Animals; Asthma; Atropine; Autonomic Nervous System; Bronchial Spasm; Dogs

1977
[Use of a new Bronchodilator agent in the prevention and control of bronchial spasm induced by surface anesthesin].
    Minerva anestesiologica, 1977, Volume: 43, Issue:1

    Topics: Adult; Aged; Albuterol; Anesthesia; Anesthetics; Asthma; Bronchial Spasm; Bronchodilator Agents; Fem

1977
Metabolic and cardiotoxic effects of salbutamol.
    British medical journal, 1977, Mar-19, Volume: 1, Issue:6063

    Topics: Albuterol; Asthma; Heart; Humans

1977
Reversibility of small airway obstruction after therapy with salbutamol. Studies in asymptomatic asthmatic patients after inhalation of pressurized aerosol.
    Chest, 1977, Volume: 71, Issue:4

    Topics: Adolescent; Adult; Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Female; Force

1977
Correct use of aerosol inhalers.
    Canadian Medical Association journal, 1977, Jul-09, Volume: 117, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Lung Diseases; Methods

1977
[Clinical evaluation of beta-sympathomimetics in the treatment of infantile allergic asthma].
    Minerva pediatrica, 1977, Mar-03, Volume: 29, Issue:7

    Topics: Albuterol; Asthma; Child; Drug Evaluation; Humans; Infant

1977
Metabolic response to intravenous salbutamol therapy in acute asthma.
    Thorax, 1977, Volume: 32, Issue:2

    Topics: Acute Disease; Adult; Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Humans;

1977
[Salbutamol in the treatment of severe broncho-asthmatic attacks].
    Minerva anestesiologica, 1977, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Lung Diseases, Obstruct

1977
Studies in chronic allergic bronchopulmonary aspergillosis. 1. Clinical and physiological findings.
    Thorax, 1977, Volume: 32, Issue:3

    Topics: Adult; Aged; Albuterol; Aspergillosis; Asthma; Chronic Disease; Female; Humans; Lung Diseases, Funga

1977
A case of intrinsic asthma.
    British medical journal, 1977, Jul-23, Volume: 2, Issue:6081

    Topics: Aged; Albuterol; Asthma; Beclomethasone; Humans; Male; Prednisone

1977
[Respiratory function data in juvenile bronchial asthma].
    Wiener medizinische Wochenschrift (1946), 1977, Jul-15, Volume: 127, Issue:14

    Topics: Albuterol; Asthma; Bronchi; Child; Child, Preschool; Humans; Plethysmography, Whole Body; Prognosis;

1977
Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics.
    The American review of respiratory disease, 1977, Volume: 116, Issue:5

    Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart

1977
[Treatment of bronchospastic attack and the asthmatic state].
    Sovetskaia meditsina, 1977, Issue:9

    Topics: Albuterol; Asthma; Bronchial Spasm; Drug Combinations; Drug Evaluation; Ephedrine; Humans; Prednisol

1977
[Bronchopulmonary ememgencies in childhood (author's transl)].
    Praxis der Pneumologie, 1976, Volume: 30, Issue:2

    Topics: Albuterol; Asthma; Child; Emergencies; Humans; Intubation; Laryngitis; Pneumonia; Prednisolone; Trac

1976
Asthma due to 'glycyl compound' powder--an intermediate in production of salbutamol.
    Clinical allergy, 1976, Volume: 6, Issue:4

    Topics: Acetophenones; Albuterol; Asthma; Chemical Phenomena; Chemistry; Drug Industry; Humans; Male; Middle

1976
Effect of intravenous injection of salbutamol in asthma.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:3

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous

1976
Intramuscular salbutamol in acute asthma.
    British journal of clinical pharmacology, 1976, Volume: 3, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Humans; Injections, Intramuscular; Middle Aged

1976
Comparison of intravenous and aerosol salbutamol.
    British medical journal, 1976, Oct-16, Volume: 2, Issue:6041

    Topics: Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous

1976
[Salbutamol therapy of chronic bronchopathic patients with cardiac arrhythmias].
    Il Torace, 1976, Volume: 18, Issue:1-2

    Topics: Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Chronic Disease; Female; Heart Rate; Humans; Lung Dis

1976
Important new drugs in asthma.
    American family physician, 1976, Volume: 14, Issue:6

    Topics: Albuterol; Asthma; Beclomethasone; Humans

1976
Nocturnal asthma and sudden death.
    American family physician, 1976, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; D

1976
[Evaluations of the effects of salbutamol retard on the functional indices of asthmatic children].
    Minerva pediatrica, 1976, Mar-17, Volume: 28, Issue:9

    Topics: Albuterol; Asthma; Child; Delayed-Action Preparations; Humans; Respiration

1976
Salbutamol by various routes.
    British medical journal, 1976, Dec-11, Volume: 2, Issue:6049

    Topics: Albuterol; Asthma; Humans; Injections, Intramuscular

1976
[Orciprenaline: an "old" bronchodilator still valid. Comparative study of the bronchodilator effect of orciprenaline and salbutamol in patients with obstructive type respiratory dysfunctional syndrome].
    La Clinica terapeutica, 1976, Dec-31, Volume: 79, Issue:6

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Metaproterenol; M

1976
[Salbutamol in the early diagnosis of infantile asthma].
    Minerva pediatrica, 1976, Sep-15, Volume: 28, Issue:28

    Topics: Age Factors; Albuterol; Asthma; Child, Preschool; Humans; Infant; Infant, Newborn; Time Factors

1976
[Salbutamol. Clinical and functional evaluation in the pediatric field].
    Minerva pediatrica, 1976, Sep-15, Volume: 28, Issue:28

    Topics: Age Factors; Albuterol; Asthma; Cardiovascular System; Child; Humans

1976
Intravenous salbutamol in management of status asthmaticus.
    British medical journal, 1975, Jan-11, Volume: 1, Issue:5949

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Carbon Dioxide; Female; Humans;

1975
[Use in anesthesiology of a new beta-2-stimulator, Salbutamol. Original technic and considerations].
    Minerva anestesiologica, 1975, Volume: 41, Issue:1

    Topics: Adjuvants, Anesthesia; Administration, Oral; Administration, Topical; Adult; Aerosols; Aged; Albuter

1975
Ventilatory response to carbon dioxide in Nigerian asthmatics before and after aerosol salbutamol inhalation.
    The South African journal of medical sciences, 1975, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Carbon Dioxide; Female; Forced Expiratory Volu

1975
New bronchodilator aerosol, salmefamol, in asthma.
    Acta allergologica, 1975, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Anisoles; Asthma; Bronchodilator Agents; Cresols; Epin

1975
[Data on the use in pediatrics of oral administration of salbutamol in soluble tablets in the therapy of asthmatic attacks].
    La Pediatria, 1975, Jun-30, Volume: 83, Issue:2

    Topics: Administration, Oral; Age Factors; Albuterol; Asthma; Child; Female; Heart; Humans; Male; Respiratio

1975
Editorial: Management of acute asthma.
    British medical journal, 1975, Oct-11, Volume: 4, Issue:5988

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Humans; Oxygen Inhalation

1975
[Comparison of the bronchodilator action of fenoterol and salbutamol by aerosol administration in patients with bronchial asthma].
    Minerva medica, 1975, Dec-08, Volume: 66, Issue:84

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Evaluation;

1975
Patterns of response to isoprenaline in asthmatic patients.
    British journal of diseases of the chest, 1975, Volume: 69, Issue:0

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Isoproterenol

1975
Letter: Deaths in asthma.
    British medical journal, 1975, Dec-13, Volume: 4, Issue:5997

    Topics: Albuterol; Asthma; Bronchodilator Agents; Death, Sudden; Heart; Humans

1975
[Prospects of inhalation therapy in infantile bronchial asthma].
    La Pediatria, 1975, Mar-31, Volume: 83, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Child; Drug Evaluation; Humans; Metaproterenol; Methylp

1975
Intravenous infusion of salbutamol in the treatment of asthma.
    British journal of clinical pharmacology, 1975, Volume: 2, Issue:6

    Topics: Adult; Albuterol; Asthma; Blood Pressure; Female; Forced Expiratory Volume; Heart Rate; Humans; Infu

1975
Proceedings: Treatment of severe acute attacks of bronchial asthma and wheezy bronchitis with salbutamol administered by nebulizer.
    Israel journal of medical sciences, 1976, Volume: 12, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Bronchitis; Humans

1976
Wheezing children.
    British medical journal, 1976, Mar-27, Volume: 1, Issue:6012

    Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; D

1976
[Salbutamol in the treatment of bronchial asthma].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Middle Aged

1976
[The broncholytic effect of salbutamol in relation to method of administration and dosage].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Albuterol; Asthma; Bronchitis; Humans; Metaproterenol; Respiratory Function Tests

1976
[Some effects of salbutamol in severe obstructive chronic emphysema].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Albuterol; Asthma; Blood Glucose; Child; Child, Preschool; Drug Evaluation; Fatty Acids, Nonesterifi

1976
[Study of the ventilatory and cardiocirculatory effects of a beta-2-stimulating drug (salbutamol) in patients with the respiratory dysfunctional syndrome of the obstructive type].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cardiovascular System; Drug Evaluation; Hemodynamics; Hu

1976
[Clinical study of the use of salbutamol in patients with bronchial asthma].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Adult; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Middle Aged

1976
[Data on the use of the aerosol salbutamol in infantile bronchial asthma].
    Minerva medica, 1976, Mar-13, Volume: 67, Issue:15

    Topics: Aerosols; Age Factors; Albuterol; Asthma; Child; Drug Evaluation; Female; Humans; Male

1976
[Comparative study of the effect of some bronchodilator substances].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Aged; Albuterol; Aminophylline; Asthma; Bronchial Diseases; Bronchodilator Agents; Doxylamine; Drug

1976
[Clinical experience with delayed-action salbutamol].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Albuterol; Asthma; Chronic Disease; Delayed-Action Preparations; Drug Evaluation; Hemodynamics; Huma

1976
[Our experience with salbutamol in the treatment of bronchial asthma and chronic asthmatiform bronchitis].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Albuterol; Asthma; Bronchitis; Chronic Disease; Delayed-Action Preparations; Humans; Respiratory Fun

1976
[Study of the effects of salbutamol in chronic obstructive bronchopneumopathies].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Albuterol; Asthma; Drug Evaluation; Hemodynamics; Humans; Lung Diseases, Obstructive; Respiration; S

1976
[Possibilities of the use of salbutamol in anesthesia and resuscitation].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adjuvants, Anesthesia; Albuterol; Anesthesia; Asthma; Bronchitis; Humans; Preanesthetic Medication;

1976
[Action of salbutamol by aerosol administration on ventilatory mechanics in asthmatic subjects].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchial Spasm; Drug Evaluation; Female; Humans; Ma

1976
[Clinical and functional considerations on the use of salbutamol].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adult; Albuterol; Asthma; Bronchitis; Drug Evaluation; Female; Hemodynamics; Humans; Lung Volume Mea

1976
[Comparison of the bronchodilator action of salbutamol and orciprenaline by aerosol administration in patients with chronic bronchopneumopathy].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchial Spasm; Bronchitis; Drug Evaluation; Female; Huma

1976
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol].
    Minerva medica, 1976, Mar-31, Volume: 67, Issue:16

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Child; Drug Evaluation; Female; Humans; Isop

1976
[The salbutamol test in the early diagnosis of infantile asthma].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Age Factors; Albuterol; Asthma; Child; Humans

1976
[Effects of salbutamol in bronchial asthma and in chronic obstructive bronchopathy].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Adult; Albuterol; Asthma; Bronchitis; Cardiovascular System; Chronic Disease; Drug Evaluation; Femal

1976
[Beta 2 specificity of salbutamol: clinical and functional evaluation in children].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Albuterol; Asthma; Cardiovascular System; Child; Child, Preschool; Drug Evaluation; Humans; Infant;

1976
[Ventilatory and cardiocirculatory effects of salbutamol].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Adult; Aged; Albuterol; Asthma; Bronchial Spasm; Cardiovascular System; Drug Evaluation; Female; Hum

1976
[Changes in static and dynamic volumes in bronchial asthmatics treated with salbutamol by oral administration].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Drug Evaluation; Female; Humans; Lung Vo

1976
[Bronchodilator action and side effects of salbutamol in patients with bronchospasm of the respiratory tract].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Drug Evaluation; Dyspnea; Female;

1976
[Clinical study of the use of salbutamol (ventolin Glaxo)].
    Minerva medica, 1976, Apr-07, Volume: 67, Issue:17

    Topics: Adult; Albuterol; Asthma; Bronchitis; Drug Evaluation; Humans; Isoproterenol; Middle Aged; Respirati

1976
Effects of salbutamol and propranolol on closing volume in extrinsic bronchial asthma.
    The Indian journal of chest diseases & allied sciences, 1976, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Female; Humans; Male; Propranolol; Respiratory Function Tests;

1976
[Effect of compounds selectively stimulating beta adrenergic receptors on pulmonary circulation, ventilation and gas exchange in patients with asthma].
    Pneumonologia polska, 1976, Volume: 44, Issue:5

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Ethanolamines; Female; Fenoterol; Humans; Male; Middle A

1976
RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo.
    Pulmonary pharmacology, 1992, Volume: 5, Issue:3

    Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Anesthesia; A

1992
[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma].
    Pneumonologia i alergologia polska, 1992, Volume: 60, Issue:11-12

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Female; Humans; Male; Middle Aged; Procaterol

1992
Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma.
    Clinical science (London, England : 1979), 1992, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchi; Carbachol; Dyspnea; Female;

1992
Recovery of leukotriene E4 from the urine of patients with airway obstruction.
    The American review of respiratory disease, 1992, Volume: 146, Issue:1

    Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Leukotriene E4; Male; Middle Aged; Pe

1992
Evolution of therapy for childhood asthma.
    The American review of respiratory disease, 1992, Volume: 146, Issue:3

    Topics: Aerosols; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator Agents; Budeson

1992
Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy.
    European journal of clinical investigation, 1992, Volume: 22, Issue:11

    Topics: Adult; Albuterol; Asthma; Calcimycin; Female; Humans; In Vitro Techniques; Leukotriene B4; Macrophag

1992
Mood and peak flow in asthma.
    Lancet (London, England), 1992, Feb-01, Volume: 339, Issue:8788

    Topics: Affect; Albuterol; Asthma; Humans; Peak Expiratory Flow Rate; Time Factors

1992
The use of beta-agonists and the risk of death and near death from asthma.
    The New England journal of medicine, 1992, Feb-20, Volume: 326, Issue:8

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies

1992
Bronchodilator treatment in asthma: continuous or on demand?
    BMJ (Clinical research ed.), 1992, Jan-11, Volume: 304, Issue:6819

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedule; Forced Expiratory Volume;

1992
Continuous subcutaneous infusion of beta 2-agonists in infantile asthma.
    Pediatric pulmonology, 1992, Volume: 12, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Feasibility Studies; Humans; Infant; Infusion Pumps; In

1992
[Can the management of patients with asthma be improved at present?].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Health Education; Humans; Physical Therapy Modalities;

1992
[Salmeterol: towards new perspectives in the treatment of asthma].
    Revue des maladies respiratoires, 1992, Volume: 9 Suppl 1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents, Non-S

1992
Beta-agonists and death from asthma.
    The New England journal of medicine, 1992, Jul-30, Volume: 327, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Dose-Response Relationship, Drug;

1992
Media mishandle medical news.
    Minnesota medicine, 1992, Volume: 75, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Mass Media; Public Opinion; Substance Withdrawa

1992
Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and beta-sympathicomimetics.
    European journal of pharmacology, 1992, May-01, Volume: 228, Issue:1

    Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Dinoproston

1992
Asthma mortality and inhaled beta agonist therapy.
    Australian and New Zealand journal of medicine, 1992, Volume: 22, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Guinea Pigs; Humans

1992
Muscling in on salbutamol.
    Lancet (London, England), 1992, Dec-05, Volume: 340, Issue:8832

    Topics: Albuterol; Animals; Asthma; Clenbuterol; Delayed-Action Preparations; Doping in Sports; Humans; Musc

1992
Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells.
    Allergy, 1992, Volume: 47, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Platelet

1992
Myopathy in severe asthma.
    The American review of respiratory disease, 1992, Volume: 146, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Aminophylline; Asthma; Blood

1992
Asthma drug therapy debate.
    North Carolina medical journal, 1992, Volume: 53, Issue:5

    Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Ther

1992
Pulse oximetry and peak flow as indicators of wheezing severity in children and improvement following bronchodilator treatments.
    The American journal of emergency medicine, 1992, Volume: 10, Issue:6

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hos

1992
Salmeterol, a long acting bronchodilator, in the treatment of asthma.
    Irish medical journal, 1992, Volume: 85, Issue:3

    Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate

1992
High-dose systemic glucocorticoid therapy in the treatment of severe asthma: a case of resistance and patterns of response.
    The Journal of allergy and clinical immunology, 1992, Volume: 90, Issue:4 Pt 1

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Dose-Response Relationship, Drug;

1992
[Study of circadian rhythm of bronchial patency for timely correction and evaluation of the effectiveness of inhalation powder forms of salbutamol in children with bronchial asthma].
    Pediatriia, 1992, Issue:4-6

    Topics: Administration, Inhalation; Adolescent; Airway Obstruction; Albuterol; Asthma; Bronchi; Child; Circa

1992
Development of an animal model of late asthmatic response in guinea pigs and effects of anti-asthmatic drugs.
    Prostaglandins, 1992, Volume: 43, Issue:6

    Topics: Albuterol; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cromolyn Sodium; Cytodiagnosis;

1992
Frequently nebulized beta-agonists for asthma: effects on serum electrolytes.
    Annals of emergency medicine, 1992, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Electrolytes; Female; Humans; Magn

1992
Chest radiography and high resolution computed tomography of the lungs in asthma.
    The American review of respiratory disease, 1992, Volume: 146, Issue:4

    Topics: Adult; Albuterol; Asthma; Female; Humans; Lung; Male; Methylprednisolone; Time Factors; Tomography,

1992
Albuterol dosage and acute asthma.
    Clinical pediatrics, 1992, Volume: 31, Issue:11

    Topics: Acute Disease; Albuterol; Asthma; Humans

1992
An evaluation of severity-modulated compliance with q.i.d. dosing of inhaled beclomethasone.
    Chest, 1992, Volume: 102, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule;

1992
A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.
    The European respiratory journal, 1992, Volume: 5, Issue:8

    Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Sectional Studies; Female; For

1992
A protocol for aerosol therapy in acute hospitalized asthmatics.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1992, Volume: 29, Issue:6

    Topics: Acute Disease; Aerosols; Albuterol; Algorithms; Asthma; Child; Clinical Protocols; Hospitalization;

1992
Transcutaneous blood gas monitoring during salbutamol inhalations in young children with acute asthmatic symptoms.
    Pediatric pulmonology, 1992, Volume: 14, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous;

1992
Transcutaneous and arterial blood gas monitoring during acute asthmatic symptoms in older children.
    Pediatric pulmonology, 1992, Volume: 14, Issue:2

    Topics: Acute Disease; Adolescent; Albuterol; Arteries; Asthma; Blood Gas Monitoring, Transcutaneous; Carbon

1992
Creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) activity in serum before and after intravenous salbutamol administration of patients with bronchial asthma.
    International journal of clinical pharmacology, therapy, and toxicology, 1992, Volume: 30, Issue:10

    Topics: Adult; Albuterol; Asthma; Creatine Kinase; Female; Heart; Humans; Injections, Intravenous; Isoenzyme

1992
The prehospital use of nebulized albuterol on patients with wheezing whose chief complaint is shortness of breath.
    Delaware medical journal, 1992, Volume: 64, Issue:11

    Topics: Adult; Aged; Albuterol; Asthma; Child; Child, Preschool; Emergency Medical Services; Female; Humans;

1992
[The experience of using Ditec in bronchial asthma].
    Voenno-meditsinskii zhurnal, 1992, Issue:7

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Cromolyn Sodium; Drug Combinations; Drug Evaluation; Femal

1992
Acute childhood asthma and plasma salbutamol levels.
    The Medical journal of Australia, 1992, Oct-19, Volume: 157, Issue:8

    Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers

1992
Early diagnosis of proximal femoral deficiency.
    Gynecologic and obstetric investigation, 1992, Volume: 34, Issue:4

    Topics: Adult; Albuterol; Asthma; Female; Femur; Fetal Diseases; Gestational Age; Humans; Maternal Age; Olig

1992
Lung volumes measured by the forced rebreathing technique in children with airways obstruction.
    The European respiratory journal, 1992, Volume: 5, Issue:7

    Topics: Adolescent; Albuterol; Asthma; Child; Cystic Fibrosis; Female; Humans; Lung Volume Measurements; Mal

1992
Maximum voluntary cough ratios reflect antitussive activity of inhaled albuterol.
    New Jersey medicine : the journal of the Medical Society of New Jersey, 1992, Volume: 89, Issue:8

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Cough; Female; Humans; Male; Maximal Exp

1992
Perception of bronchoconstriction in chronic asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1992, Volume: 29, Issue:5

    Topics: Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Female;

1992
[Lung function of adult patients with bronchial asthma or chronic obstructive lung disease prior to and following a 3-month-stay in the Dutch Asthma Center in Davos].
    Nederlands tijdschrift voor geneeskunde, 1992, Mar-07, Volume: 136, Issue:10

    Topics: Albuterol; Asthma; Female; Hospitals, Special; Humans; Lung Diseases, Obstructive; Lung Volume Measu

1992
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma.
    The American review of respiratory disease, 1992, Volume: 145, Issue:3

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Biopsy; Bronchi; Bronchitis; Bronchoscopy; Dru

1992
Reversible volume changes of trapped gas in nonspecific bronchoprovocation tests.
    Chest, 1992, Volume: 101, Issue:4

    Topics: Acetylcholine; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Forced Exp

1992
Methotrexate treatment of severe asthma in children.
    Pediatrics, 1992, Volume: 89, Issue:4 Pt 1

    Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Body Height; Body Weight; Child; Child, Preschool; Cr

1992
[Sudden unexpected death and near death among children with asthma].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1992, Feb-20, Volume: 112, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Child; Death, Sudden; Female; Humans; Infant; Male; Norway

1992
Profound, reversible, myocardial depression in acute asthma treated with high-dose catecholamines.
    Critical care medicine, 1992, Volume: 20, Issue:5

    Topics: Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Barotrauma; Cardiomyopathies; C

1992
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study.
    Clinical pharmacology and therapeutics, 1992, Volume: 51, Issue:5

    Topics: Adolescent; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child, Preschool; Fenoterol; Huma

1992
Effects of NZ-107 on bronchoconstriction in guinea pigs.
    International archives of allergy and immunology, 1992, Volume: 97, Issue:3

    Topics: Albuterol; Animals; Asthma; Bronchoconstriction; Cromolyn Sodium; Disease Models, Animal; Guinea Pig

1992
Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children.
    Thorax, 1992, Volume: 47, Issue:5

    Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Child; Female; Forc

1992
Management of asthma.
    Pediatric emergency care, 1992, Volume: 8, Issue:3

    Topics: Albuterol; Asthma; Child; Child, Preschool; Emergencies; Female; Hospitalization; Humans; Male; Oxyg

1992
Asthma knowledge and management in primary schools in south Auckland.
    The New Zealand medical journal, 1992, Jul-08, Volume: 105, Issue:937

    Topics: Albuterol; Asthma; Beclomethasone; Child; Cromolyn Sodium; Evaluation Studies as Topic; Faculty; Hea

1992
Influence of short- and long-term inhalation of salbutamol on lung function and beta 2-adrenoceptors of mononuclear blood cells in asthmatic children.
    European journal of pediatrics, 1991, Volume: 150, Issue:3

    Topics: Administration, Inhalation; Adolescent; Airway Resistance; Albuterol; Asthma; Child; Forced Expirato

1991
Beta 2-agonists in asthma.
    Lancet (London, England), 1991, Feb-02, Volume: 337, Issue:8736

    Topics: Albuterol; Asthma; Drug Information Services; Fenoterol; Humans; Product Surveillance, Postmarketing

1991
The severity of asthma in relation to beta agonist prescribing.
    The New Zealand medical journal, 1991, Feb-13, Volume: 104, Issue:905

    Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Chronic Dise

1991
Salmeterol in nocturnal asthma.
    BMJ (Clinical research ed.), 1991, Feb-09, Volume: 302, Issue:6772

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate; Sleep

1991
Salmeterol.
    Lancet (London, England), 1991, May-04, Volume: 337, Issue:8749

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate; Time Factors

1991
Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol.
    The American review of respiratory disease, 1991, Volume: 143, Issue:5 Pt 1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio

1991
Beta 2 agonists and asthma.
    BMJ (Clinical research ed.), 1991, May-18, Volume: 302, Issue:6786

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; E

1991
[Pharmacological action of SN-408, a novel long-acting selective beta 2-adrenoceptor agonist].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1991, Volume: 98, Issue:1

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchodilator Agents; Capillary Permeability;

1991
[Treatment of asthma with salmeterol--a new prolonged-action inhalatory beta 2 agonist].
    Ugeskrift for laeger, 1991, Oct-28, Volume: 153, Issue:44

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Delayed-Action Preparations

1991
Salmeterol in children.
    British journal of hospital medicine, 1991, Volume: 46, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Humans; Salmeterol Xinafoate

1991
Salmeterol therapy in mild asthma.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1991, Volume: 41, Issue:349

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate

1991
Salmeterol therapy in mild asthma.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1991, Volume: 41, Issue:350

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Quality of Life; Salmeterol Xinafoate

1991
A European respiratory review on salmeterol.
    The European respiratory journal, 1991, Volume: 4, Issue:10

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Humans; Inflammation; Salmeterol Xinafoate

1991
Appropriate prescribing of beta-2 agonists.
    The Practitioner, 1991, Volume: 235, Issue:1509

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Nebulizers and Vaporizers; Salmeterol Xinafoate

1991
Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist.
    Archives of oral biology, 1990, Volume: 35, Issue:12

    Topics: Adolescent; Adult; Albuterol; Amylases; Asthma; Buffers; Female; Hexosamines; Humans; Hydrogen-Ion C

1990
In vitro and in vivo effect of salbutamol on histamine release from human basophils.
    International journal of clinical pharmacology, therapy, and toxicology, 1991, Volume: 29, Issue:1

    Topics: Adult; Albuterol; Asthma; Basophils; Female; Histamine Release; Humans; Hypersensitivity; Injections

1991
Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma.
    The Journal of allergy and clinical immunology, 1991, Volume: 88, Issue:3 Pt 1

    Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Cel

1991
Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.
    Thorax, 1991, Volume: 46, Issue:10

    Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Female; Forced Exp

1991
Acute asthma in children.
    The Medical journal of Australia, 1991, Aug-19, Volume: 155, Issue:4

    Topics: Acute Disease; Albuterol; Asthma; Emergencies; Humans; Patient Education as Topic; Theophylline

1991
Management of acute asthma attacks in general practice.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1991, Volume: 41, Issue:351

    Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Attitude of Health Personnel; Attitude to

1991
The effect of salbutamol on breath alcohol testing in asthmatics.
    Medicine, science, and the law, 1991, Volume: 31, Issue:3

    Topics: Adult; Aged; Albuterol; Asthma; Breath Tests; Ethanol; Female; Humans; Male; Middle Aged

1991
Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs.
    Drugs under experimental and clinical research, 1991, Volume: 17, Issue:8

    Topics: Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Guinea Pigs; Male; Pla

1991
T cell receptor gamma delta bearing cells are decreased in the peripheral blood of patients with atopic diseases.
    Clinical and experimental immunology, 1991, Volume: 86, Issue:3

    Topics: Adolescent; Adult; Albuterol; Antibodies, Monoclonal; Asthma; Beclomethasone; CD8 Antigens; Child; C

1991
Outcome of assessments for occupational asthma.
    Chest, 1991, Volume: 100, Issue:2

    Topics: Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Diagnosis, Differential; Female; F

1991
Assessment of bronchodilator response to a beta-adrenergic delivered from an ultrasonic nebulizer.
    Chest, 1991, Volume: 100, Issue:2

    Topics: Adult; Aerosols; Albuterol; Analysis of Variance; Asthma; Blood Pressure; Bronchi; Equipment Design;

1991
Saliva composition and caries development in asthmatic patients treated with beta 2-adrenoceptor agonists: a 4-year follow-up study.
    Scandinavian journal of dental research, 1991, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Dental Caries; DMF Index; Female; Follow-Up Studies; Humans; H

1991
[New aspects of using adrenomimetics in the diagnosis and treatment of bronchial asthma].
    Klinicheskaia meditsina, 1991, Volume: 69, Issue:2

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc

1991
[Effects of inhaled prostaglandin E1, salbutamol and verapamil on the bronchial reactivity in asthmatics].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1991, Volume: 14, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Alprostadil; Asthma; Bronchi; Female; Forced Expirator

1991
Hypokalaemic effect of salbutamol and terbutaline in bronchial asthma.
    The Journal of the Association of Physicians of India, 1991, Volume: 39, Issue:3

    Topics: Adult; Aged; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Hypokalemia; Male; Middle

1991
The use of inhaled formoterol in asthma.
    Respiratory medicine, 1991, Volume: 85, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule;

1991
Relationship between response to inhaled salbutamol and methacholine bronchial provocation in children with suspected asthma.
    Pediatric pulmonology, 1991, Volume: 10, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Chi

1991
Cyclosporin for steroid-dependent asthma.
    Allergy, 1991, Volume: 46, Issue:4

    Topics: Adult; Albuterol; Aminophylline; Asthma; Beclomethasone; Cyclosporins; Female; Humans; Male; Middle

1991
Occupational rhinitis and asthma caused by inhalation of Balfourodendron riedelianum (Pau Marfim) wood dust.
    Allergy, 1991, Volume: 46, Issue:4

    Topics: Adult; Air Pollutants, Occupational; Albuterol; Asthma; Dust; Electrophoresis, Polyacrylamide Gel; H

1991
The ventilatory and oxygen costs in the anesthetized rhesus monkey of inhaling drugs used in the therapy and diagnosis of asthma.
    The American review of respiratory disease, 1991, Volume: 143, Issue:4 Pt 1

    Topics: Administration, Inhalation; Albuterol; Anesthesia; Animals; Asthma; Cromolyn Sodium; Epinephrine; Fu

1991
Pharmacological modulation of a model of bronchial inflammation after aerosol-induced active anaphylactic shock in conscious guinea pigs.
    International journal of immunopharmacology, 1991, Volume: 13, Issue:4

    Topics: Albuterol; Anaphylaxis; Animals; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Cromolyn Sodium;

1991
Audit of the effect of a nurse run asthma clinic on workload and patient morbidity in a general practice.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1991, Volume: 41, Issue:347

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Child; Emergenci

1991
Recently introduced products.
    Drug and therapeutics bulletin, 1991, Mar-04, Volume: 29, Issue:5

    Topics: Albuterol; Asthma; Bacterial Infections; Breast Diseases; Carboprost; Cefixime; Cefotaxime; Fatty Ac

1991
Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma.
    The European respiratory journal, 1991, Volume: 4, Issue:5

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Female; Heart Rate; Humans; Infusions, I

1991
Sensitivity of FEV1 response following one and two inhalations of albuterol: a pilot study.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1991, Volume: 28, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Dose-Response Relationship,

1991
Asthma.
    Australian family physician, 1991, Volume: 20, Issue:8

    Topics: Administration, Inhalation; Albuterol; Asthma; Australia; Humans; Patient Education as Topic

1991
Special comment.
    Australian family physician, 1991, Volume: 20, Issue:8

    Topics: Albuterol; Asthma; Drug Hypersensitivity; Female; Humans; Nebulizers and Vaporizers; Oleic Acids

1991
Are you taking the medicine?
    Lancet (London, England), 1990, Feb-03, Volume: 335, Issue:8684

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Mal

1990
[Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1990, Volume: 95, Issue:1

    Topics: Acetylcholine; Administration, Inhalation; Albuterol; Aminophylline; Animals; Asthma; Atropine Deriv

1990
Effect of salbutamol on potassium influx in erythrocytes of allergic subjects and investigation of beta 2 receptor autoantibodies.
    Annals of allergy, 1990, Volume: 65, Issue:1

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Antibodies, Monoclonal; Ast

1990
Response of acute asthma to a beta 2 agonist in children less than two years of age.
    Annals of allergy, 1990, Volume: 65, Issue:2

    Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Female; Humans; Infant

1990
Approaches to a long-acting, selective beta 2-adrenoceptor stimulant.
    Lung, 1990, Volume: 168 Suppl

    Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Asthma; Delayed-Action Preparations

1990
Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.
    The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:5

    Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchi; Bronchial Provo

1990
[The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma].
    Nihon Kyobu Shikkan Gakkai zasshi, 1990, Volume: 28, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br

1990
Salbutamol nebuliser and precipitation of critical cardiac ischaemia.
    Lancet (London, England), 1990, Nov-17, Volume: 336, Issue:8725

    Topics: Acute Disease; Albuterol; Asthma; Coronary Disease; Humans; Male; Middle Aged; Myocardial Infarction

1990
Use of antiasthmatic drugs in Australia.
    The Medical journal of Australia, 1990, Sep-17, Volume: 153, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be

1990
Salmeterol.
    British journal of hospital medicine, 1990, Volume: 44, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Chemical Ph

1990
The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma.
    The American review of respiratory disease, 1991, Volume: 143, Issue:4 Pt 1

    Topics: Adult; Aged; Albuterol; Asthma; Biopsy, Needle; Bronchial Provocation Tests; Bronchoalveolar Lavage

1991
The allergic patient who is noncompliant and abusive: dealing with the adverse experience.
    Annals of allergy, 1991, Volume: 66, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Female; Humans; Middle Aged; Pa

1991
Peak flow rates in young children.
    Annals of allergy, 1991, Volume: 66, Issue:4

    Topics: Albuterol; Asthma; Child, Preschool; Humans; Peak Expiratory Flow Rate

1991
Home nebulisers in childhood asthma: survey of hospital supervised use.
    BMJ (Clinical research ed.), 1991, May-18, Volume: 302, Issue:6786

    Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Home Nursing;

1991
Salbutamol injections.
    The Medical journal of Australia, 1991, Jun-03, Volume: 154, Issue:11

    Topics: Albuterol; Asthma; Humans; Injections, Intramuscular

1991
Pulse oximetry in acute asthma.
    Archives of disease in childhood, 1991, Volume: 66, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospitalization; Humans; Infa

1991
Ventilation-perfusion mismatch after methacholine challenge in patients with mild bronchial asthma.
    The American review of respiratory disease, 1991, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory Volume;

1991
Occupational asthma due to styrene.
    Thorax, 1991, Volume: 46, Issue:5

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Forced Expiratory Volume; Humans; Male; Military Personnel

1991
Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children.
    Pediatric pulmonology, 1990, Volume: 8, Issue:4

    Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Cromolyn Sodium; Energy Metabolism

1990
Gas exchange abnormalities in asthma.
    Lung, 1990, Volume: 168 Suppl

    Topics: Airway Resistance; Albuterol; Asthma; Follow-Up Studies; Forced Expiratory Volume; Humans; Infusions

1990
A request for an inhaler.
    The Practitioner, 1990, May-22, Volume: 234, Issue:1489

    Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Cromolyn Sodium; Diagnosis, Differe

1990
Bronchoconstriction induced by spirometric maneuvers in patients with bronchial asthma.
    Annals of allergy, 1990, Volume: 65, Issue:4

    Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Female; Humans; Ipratropium; Male; Middle Aged; Spiro

1990
Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction.
    Respiratory medicine, 1990, Volume: 84, Issue:5

    Topics: Administration, Inhalation; Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchod

1990
Osmolality and pH of anti-asthmatic drug solutions.
    Agents and actions, 1990, Volume: 31, Issue:3-4

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cromolyn Sodium; Fenoterol; Humans; Hydrogen-Ion

1990
Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.
    European journal of clinical pharmacology, 1990, Volume: 38, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Dose-Response Relationship, Dru

1990
Metabolic and hormonal responses to salbutamol in asthma. Evidence of beta-adrenergic overactivity?
    Respiration; international review of thoracic diseases, 1990, Volume: 57, Issue:1

    Topics: Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Hemodynamics; Humans; Insulin;

1990
Evaluation of beta-adrenergic function in normal and asthmatic children.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1990, Volume: 27, Issue:4

    Topics: Albuterol; Asthma; Blood Glucose; Child; Epinephrine; Female; Humans; Male; Receptors, Adrenergic, b

1990
The effect of benzalkonium chloride on the bronchodilator response to salbutamol nebuliser solution.
    The New Zealand medical journal, 1990, Sep-26, Volume: 103, Issue:898

    Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchi; Forced Expiratory Volume; Humans; Nebulizers and

1990
Treatment of the asthmatic child.
    Bulletin of the Pan American Health Organization, 1990, Volume: 24, Issue:3

    Topics: Adrenal Cortex Hormones; Albuterol; Algorithms; Asthma; Child; Costa Rica; Drug Therapy, Combination

1990
[Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol].
    Zhonghua nei ke za zhi, 1990, Volume: 29, Issue:4

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchial Spasm;

1990
Asthma and its management at a student health service.
    The New Zealand medical journal, 1990, Oct-24, Volume: 103, Issue:900

    Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Albuterol; Asthma; Attitude to Health;

1990
The asthmatic child.
    The Practitioner, 1990, Volume: 234, Issue:1494

    Topics: Albuterol; Asthma; Child, Preschool; Humans; Nebulizers and Vaporizers

1990
Treatment for acute asthma in the ambulance.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1990, Volume: 40, Issue:338

    Topics: Adult; Aerosols; Albuterol; Ambulances; Asthma; Humans

1990
Aerosol addiction.
    The British journal of psychiatry : the journal of mental science, 1990, Volume: 157

    Topics: Adult; Aerosols; Albuterol; Asthma; Humans; Intellectual Disability; Male; Nebulizers and Vaporizers

1990
Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma.
    Chest, 1990, Volume: 97, Issue:2

    Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Infusions, Int

1990
Description of a delivery method for continuously aerosolized albuterol in status asthmaticus.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1990, Volume: 27, Issue:1

    Topics: Adult; Aerosols; Albuterol; Asthma; Critical Care; Equipment Design; Humans; Male; Status Asthmaticu

1990
Spacer-induced atrial fibrillation.
    New Jersey medicine : the journal of the Medical Society of New Jersey, 1990, Volume: 87, Issue:2

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Fibrillation; Humans; Male; Time Factor

1990
Pulmonary gas exchange in severe chronic asthma. Response to 100% oxygen and salbutamol.
    The American review of respiratory disease, 1990, Volume: 141, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Gas Analysis; Chronic Disease; Hem

1990
Effects of increasing doses of beta-agonists on airway and parenchymal hysteresis.
    Journal of applied physiology (Bethesda, Md. : 1985), 1990, Volume: 68, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchi; Female; Humans; Lung Volume Measureme

1990
Late asthmatic reactions to occupational sensitizing agents: frequency of changes in nonspecific bronchial responsiveness and of response to inhaled beta 2-adrenergic agent.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:5

    Topics: Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Forced Expiratory Volume; Humans; Hypersens

1990
Late-onset asthma in a demented elderly patient. The value of methacholine challenge in diagnosis.
    Journal of the American Geriatrics Society, 1990, Volume: 38, Issue:5

    Topics: Aged; Albuterol; Alzheimer Disease; Asthma; Bronchial Provocation Tests; Diagnosis, Differential; Fe

1990
Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects.
    Journal of applied physiology (Bethesda, Md. : 1985), 1990, Volume: 68, Issue:5

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Child; Cystic Fibrosis; Female; Fo

1990
[High-dose inhaled beta-2 sympathomimetics in severe bronchial asthma].
    Pneumologie (Stuttgart, Germany), 1990, Volume: 44 Suppl 1

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Dose-Response Relationship, Dru

1990
Compliance with inhaled therapy and morbidity from asthma.
    Respiratory medicine, 1990, Volume: 84, Issue:1

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volu

1990
Plasma concentrations of salbutamol in acute severe asthmatics.
    Australian and New Zealand journal of medicine, 1990, Volume: 20, Issue:3

    Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Peak Expiratory Fl

1990
Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects.
    International journal of tissue reactions, 1990, Volume: 12, Issue:1

    Topics: Adenosine; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Bronchi; Bronchitis; Bronchodi

1990
Time course of change in oxygen saturation and peak expiratory flow in children admitted to hospital with acute asthma.
    Thorax, 1990, Volume: 45, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; F

1990
Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.
    Thorax, 1990, Volume: 45, Issue:6

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Lung; Male; Mid

1990
Albuterol and spacer-induced atrial fibrillation.
    Chest, 1990, Volume: 98, Issue:3

    Topics: Adult; Albuterol; Asthma; Atrial Fibrillation; Electrocardiography; Humans; Male; Nebulizers and Vap

1990
Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children.
    Annals of allergy, 1990, Volume: 65, Issue:3

    Topics: Albuterol; Asthma; Child; Child, Preschool; Electrocardiography, Ambulatory; Exercise Test; Heart; H

1990
[Comparative study of the bronchodilator effect of inhaled fenoterol and aerosol salbutamol in patients with chronic bronchial asthma].
    Anales de medicina interna (Madrid, Spain : 1984), 1989, Volume: 6, Issue:2

    Topics: Administration, Inhalation; Adult; Aerosols; Aged; Albuterol; Asthma; Chronic Disease; Female; Fenot

1989
Late asthmatic response to allergen challenge (LAR), its clinical feature and pharmacological modulation.
    Agents and actions, 1989, Volume: 26, Issue:1-2

    Topics: Albuterol; Allergens; Asthma; Beclomethasone; Bronchial Provocation Tests; Cromolyn Sodium; Humans;

1989
Therapeutic use of bronchoalveolar lavage in a very difficult asthmatic: a case report.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1989, Volume: 26, Issue:3

    Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; Hu

1989
[Treatment of asthma in the emergency clinic of a pediatric hospital].
    Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau, 1989, Volume: 107, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Costa Rica; Emergencies; Humans

1989
Maximum achievable bronchodilatation in asthma.
    Respiratory medicine, 1989, Volume: 83, Issue:6

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory

1989
Prostaglandin E2 and salbutamol are less effective in raising cAMP levels of alveolar macrophages from ovalbumin-sensitized guinea-pigs as compared to controls.
    Agents and actions, 1989, Volume: 26, Issue:1-2

    Topics: Albuterol; Animals; Asthma; Cyclic AMP; Dinoprostone; Guinea Pigs; Immunization; Macrophages; Ovalbu

1989
Responses of neutrophilic granulocytes in vitro of asthmatic and healthy subjects and the degree of inhibition by several drugs.
    Agents and actions, 1989, Volume: 26, Issue:1-2

    Topics: Adolescent; Albuterol; Asthma; Calcimycin; Child; Child, Preschool; Cromolyn Sodium; Enzyme Inhibito

1989
Preferences for salbutamol delivery systems among young asthmatics.
    The Journal of the Royal College of General Practitioners, 1989, Volume: 39, Issue:323

    Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers

1989
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.
    Lancet (London, England), 1989, Apr-29, Volume: 1, Issue:8644

    Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors;

1989
Preservatives in bronchodilator nebuliser solutions.
    Lancet (London, England), 1989, Sep-23, Volume: 2, Issue:8665

    Topics: Acute Disease; Albuterol; Asthma; Atropine Derivatives; Drug Therapy, Combination; Humans; Ipratropi

1989
[Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients].
    Annales de pediatrie, 1989, Volume: 36, Issue:7

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Death, Sudden; Drug Interactions; Female; Humans

1989
Does urinary salbutamol reflect compliance with the aerosol regimen in patients with asthma?
    Respiratory medicine, 1989, Volume: 83, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Chromatography, Thin Layer; Female; Humans; Male; Middle Aged; Patient

1989
Exercise-induced allergic syndromes on the increase.
    Cleveland Clinic journal of medicine, 1989, Volume: 56, Issue:7

    Topics: Adolescent; Adult; Albuterol; Anaphylaxis; Asthma; Asthma, Exercise-Induced; Beclomethasone; Exercis

1989
Cardiac arrhythmias during acute exacerbations of chronic airflow limitation: effect of fall in plasma potassium concentration induced by nebulised beta 2-agonist therapy.
    Postgraduate medical journal, 1989, Volume: 65, Issue:765

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Albuterol; Arrhythmias, Cardiac; Asthma; Humans; Male

1989
Plasma potassium in acute severe asthma before and after treatment.
    The British journal of clinical practice, 1989, Volume: 43, Issue:10

    Topics: Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Female; Humans

1989
Assessing the cost of albuterol inhalers in the Michigan and California Medicaid Programs: a total cost-of-care approach.
    Clinical therapeutics, 1989, Volume: 11, Issue:1

    Topics: Adult; Albuterol; Asthma; California; Costs and Cost Analysis; Female; Humans; Male; Medicaid; Michi

1989
Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1989, Volume: 26, Issue:3

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory

1989
Serum potassium responses to nebulized salbutamol administered during an acute asthmatic attack.
    Archives of emergency medicine, 1989, Volume: 6, Issue:1

    Topics: Adult; Aerosols; Albuterol; Asthma; Female; Humans; Hypokalemia; Male; Potassium; Prospective Studie

1989
The use of non-prescription salbutamol inhalers by asthmatic patients in the Hunter Valley, New South Wales. Newcastle Retail Pharmacy Research Group.
    The Medical journal of Australia, 1989, Apr-17, Volume: 150, Issue:8

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Drug Pres

1989
Experience with a metered-dose inhaler with a spacer in the pediatric emergency department.
    American journal of diseases of children (1960), 1989, Volume: 143, Issue:6

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergency Service, Hospital;

1989
2 year old asthmatics can learn to operate a tube spacer by copying their mothers.
    Archives of disease in childhood, 1989, Volume: 64, Issue:5

    Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Female; Humans; Infant; Learning; M

1989
The biochemical effects of high-dose inhaled salbutamol in patients with asthma.
    European journal of clinical pharmacology, 1989, Volume: 36, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Dose-Response

1989
Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach.
    The European respiratory journal, 1989, Volume: 2, Issue:6

    Topics: Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Diagnosis, Differential; Female; Forced Exp

1989
Acute asthma attack due to ophthalmic indomethacin.
    Annals of internal medicine, 1989, Aug-15, Volume: 111, Issue:4

    Topics: Aged; Albuterol; Asthma; Combined Modality Therapy; Female; Glucocorticoids; Humans; Indomethacin; O

1989
Benzalkonium chloride and bronchoconstriction.
    The Journal of allergy and clinical immunology, 1989, Volume: 84, Issue:2

    Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchi; Constriction, Pathologic; Drug Therapy, Combinat

1989
Ventilation-perfusion mismatching in acute severe asthma: effects of salbutamol and 100% oxygen.
    Thorax, 1989, Volume: 44, Issue:4

    Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Female; Humans; Infusions

1989
The effects of deep inhalation on maximal expiratory flow during intensive treatment of spontaneous asthmatic episodes.
    The American review of respiratory disease, 1989, Volume: 140, Issue:2

    Topics: Adult; Albuterol; Asthma; Constriction, Pathologic; Dilatation, Pathologic; Female; Glucocorticoids;

1989
Breath-actuated inhalers: comparison of terbutaline Turbohaler with salbutamol Rotahaler.
    The European respiratory journal, 1989, Volume: 2, Issue:7

    Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Chronic Disease; Evaluation

1989
Nebulisers in acute childhood asthma.
    The Practitioner, 1989, Feb-08, Volume: 233, Issue:1462

    Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Humans; Nebulizers and Vaporizers

1989
Asthma in the very young baby.
    The Practitioner, 1989, Feb-08, Volume: 233, Issue:1462

    Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Infant; Nebulizers and Vaporizer

1989
Beta-adrenoceptor density and resolution of high and low affinity state on B- and T-cells in asthmatic and non-asthmatic children.
    European journal of pediatrics, 1988, Volume: 147, Issue:2

    Topics: Adolescent; Albuterol; Asthma; B-Lymphocytes; Child; Child, Preschool; Humans; Infant; Iodocyanopind

1988
Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.
    British journal of clinical pharmacology, 1988, Volume: 26, Issue:5

    Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Pressure; Cyclic AMP; Dose-Respons

1988
Home nebulisers.
    Lancet (London, England), 1985, Feb-16, Volume: 1, Issue:8425

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Oxygen

1985
Beta 2 agonists for acute asthma.
    American family physician, 1985, Volume: 31, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Isoetharine; Metaproterenol; Terbutaline

1985
Clinical use of beta-adrenergic agonists.
    The Journal of allergy and clinical immunology, 1985, Volume: 76, Issue:2 Pt 2

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Catecholamines; Drug Resistance; Heart Rate;

1985
A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma.
    British journal of clinical pharmacology, 1985, Volume: 19, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Ethanolamines; Force

1985
[Evaluation of procaterol aerosol as an aerosolized beta 2-adrenergic bronchodilator in conscious guinea pigs].
    Arerugi = [Allergy], 1985, Volume: 34, Issue:11

    Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Drug Resistan

1985
Treatment of asthma.
    Lancet (London, England), 1986, Mar-08, Volume: 1, Issue:8480

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Terbutaline

1986
Asthma death due to ibuprofen.
    Lancet (London, England), 1987, May-09, Volume: 1, Issue:8541

    Topics: Acute Disease; Aged; Albuterol; Asthma; Beclomethasone; Drug Interactions; Female; Humans; Ibuprofen

1987
[A new aerosol adrenergic bronchodilator, procaterol. Comparative study of salbutamol and procaterol].
    L'union medicale du Canada, 1987, Volume: 116, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Me

1987
Bronchodilator action of the anti-histaminic terfenadine.
    British journal of clinical pharmacology, 1987, Volume: 24, Issue:1

    Topics: Adult; Albuterol; Asthma; Benzhydryl Compounds; Bronchodilator Agents; Female; Forced Expiratory Vol

1987
Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs.
    Acta physiologica Hungarica, 1987, Volume: 70, Issue:2-3

    Topics: Adrenergic beta-Agonists; Adult; Aerosols; Airway Resistance; Albuterol; Asthma; Female; Forced Expi

1987
Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cyclic AMP; Female; Hu

1988
Effects of theophylline, beta-adrenergic stimulants and prednisolone on platelet and urine cyclic guanosine monophosphate (cGMP).
    The Tohoku journal of experimental medicine, 1988, Volume: 156, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminophylline; Asthma; Blood Platelets; Cyclic GMP

1988
[Severe asthma in children. Value of home nebulization of salbutamol].
    Presse medicale (Paris, France : 1983), 1986, May-31, Volume: 15, Issue:22

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Home Care Services; Humans

1986
[An uncommon adverse effect of salbutamol].
    Presse medicale (Paris, France : 1983), 1987, Sep-26, Volume: 16, Issue:31

    Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Humans; Male

1987
Emergency use of nebulised bronchodilator drugs in British hospitals.
    Thorax, 1987, Volume: 42, Issue:7

    Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Utilization; Emergencies; Hospitals, Distri

1987
Fixed dose combination therapy in the treatment of asthma--the case against it.
    Progress in clinical and biological research, 1988, Volume: 263

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Combinations; Fenoterol; Hu

1988
Home nebulizers in childhood asthma. Parental perceptions and practices.
    Clinical pediatrics, 1988, Volume: 27, Issue:9

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Cromolyn Sodium; Female; Hospitalization; Hu

1988
The duration of action of the combination of fenoterol hydrobromide and ipratropium bromide in protecting against asthma provoked by hyperpnea.
    Chest, 1988, Volume: 94, Issue:4

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Drug Therapy

1988
Emergency endotracheal drug administration using aerosol.
    Resuscitation, 1987, Volume: 15, Issue:2

    Topics: Adult; Aerosols; Albuterol; Asthma; Emergencies; Female; Humans; Intermittent Positive-Pressure Vent

1987
Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects.
    The European respiratory journal, 1988, Volume: 1, Issue:10

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Lung; Male; Methacho

1988
The assessment of a computer administered questionnaire in the differential diagnosis of asthma and chronic airflow limitation.
    British journal of diseases of the chest, 1988, Volume: 82, Issue:3

    Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Diagnosis, Computer-Assisted;

1988
Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis.
    Annals of allergy, 1986, Volume: 56, Issue:4

    Topics: Albuterol; Asthma; Cromolyn Sodium; Humans; Hypersensitivity; Injections, Intravenous; Ketotifen; Lu

1986
The U.S. Olympic Committee experience with exercise-induced bronchospasm, 1984.
    Medicine and science in sports and exercise, 1986, Volume: 18, Issue:3

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cromolyn Sodium; Female; Humans; Male; Sex Facto

1986
Exercise-induced asthma.
    European journal of respiratory diseases. Supplement, 1986, Volume: 143

    Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Humans; Peak Expirato

1986
Effect of drugs used in the treatment of asthma on the production of eosinophil-activating factor by monocytes.
    International archives of allergy and applied immunology, 1988, Volume: 85, Issue:2

    Topics: Albuterol; Asthma; Beclomethasone; Cromolyn Sodium; Eosinophils; Humans; Lymphokines; Methylpredniso

1988
Intravenous beta agonist in severe acute asthma.
    BMJ (Clinical research ed.), 1988, Oct-22, Volume: 297, Issue:6655

    Topics: Acute Disease; Albuterol; Asthma; Humans

1988
The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs.
    The American review of respiratory disease, 1988, Volume: 138, Issue:5

    Topics: Airway Obstruction; Airway Resistance; Albuterol; Allergens; Animals; Asthma; Bronchi; Bronchoalveol

1988
[Effect of the diagnosis and prevention of exercise-induced bronchial obstruction on sports participation by asthmatic school children].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1988, Volume: 136, Issue:12

    Topics: Airway Resistance; Albuterol; Asthma; Asthma, Exercise-Induced; Beclomethasone; Child; Cromolyn Sodi

1988
A study of acute asthma in the accident and emergency department.
    British journal of diseases of the chest, 1988, Volume: 82, Issue:2

    Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aerosols; Aged; Albuterol; Asthma; Bronch

1988
Ability of asthmatics with and without respiratory arrest to detect added resistive loads.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1988, Volume: 25, Issue:3

    Topics: Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Regression An

1988
[The effect of hyperosmolar mixed solution of sodium chloride and beta 2 sympathomimetics on lung function in asthmatic children and adolescents].
    Schweizerische medizinische Wochenschrift, 1988, Sep-24, Volume: 118, Issue:38

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Humans; Lung; Osmolar Concentration; Respirat

1988
Comparison of beta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients.
    Chest, 1988, Volume: 94, Issue:6

    Topics: Adult; Albuterol; Asthma; Female; Hospitalization; Humans; Male; Metaproterenol; Nebulizers and Vapo

1988
[Effects of salbutamol spray administered with metered dose inhaler on oral cavities in asthma patients].
    Arerugi = [Allergy], 1988, Volume: 37, Issue:7

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Blood

1988
Pharmacodynamics of salbutamol in humans.
    International journal of clinical pharmacology, therapy, and toxicology, 1988, Volume: 26, Issue:8

    Topics: Aged; Albuterol; Asthma; Blood Pressure; Electrocardiography; Fatty Acids, Nonesterified; Female; He

1988
[Asymptomatic electrical myocardial necrosis during the infusion of betamimetics in status asthmaticus].
    Annales francaises d'anesthesie et de reanimation, 1988, Volume: 7, Issue:6

    Topics: Albuterol; Asthma; Cardiomyopathy, Dilated; Electrocardiography; Female; Humans; Middle Aged; Myocar

1988
Trachea-noise biofeedback in asthma: a comparison of the effect of trachea-noise biofeedback, a bronchodilator, and no treatment on the rate of recovery from exercise- and eucapnic hyperventilation-induced asthma.
    Biofeedback and self-regulation, 1988, Volume: 13, Issue:3

    Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Biofeedback, Psychology; Bronchial Spasm; Double

1988
Influence of breathing pattern on lung deposition and bronchodilator response to nebulised salbutamol in patients with stable asthma.
    Thorax, 1988, Volume: 43, Issue:12

    Topics: Airway Resistance; Albuterol; Asthma; Female; Humans; Lung; Male; Middle Aged; Nebulizers and Vapori

1988
Intermittent and continuous salbutamol rotacaps inhalation in asthmatic patients.
    Respiration; international review of thoracic diseases, 1988, Volume: 54, Issue:3

    Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Female; Humans; Male; Middl

1988
[Effect of salbutamol on post-exertion bronchial spasm and post-exertion refraction time].
    Pneumonologia polska, 1988, Volume: 56, Issue:11

    Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Depression, Chemical; Exercise Test; Female; Forced Expir

1988
[Nonspecific bronchial hyperreactivity after long-term use of a beta 2 agonist].
    Pneumonologia polska, 1988, Volume: 56, Issue:11

    Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchi; Bronchial Spasm; Female; Forced Expir

1988
An assessment of methacholine inhalation tests in elderly asthmatics.
    Age and ageing, 1988, Volume: 17, Issue:2

    Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Dizziness;

1988
Aerosol treatment abuse.
    Archives of disease in childhood, 1988, Volume: 63, Issue:1

    Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Child, Preschool; Chlorofluorocarbons, Methane; Humans;

1988
Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study.
    Thorax, 1988, Volume: 43, Issue:2

    Topics: Adult; Aged; Albuterol; Aspirin; Asthma; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Drug Comb

1988
Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol).
    Annals of emergency medicine, 1988, Volume: 17, Issue:4

    Topics: Acute Disease; Aged; Albuterol; Asthma; Female; Humans; Intubation, Intratracheal; Respiratory Insuf

1988
Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection.
    Pediatrics, 1988, Volume: 81, Issue:5

    Topics: Albuterol; Asthma; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Metaproterenol

1988
Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma.
    Clinical allergy, 1988, Volume: 18, Issue:2

    Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Female; Forced Expiratory Volume; Humans; Male; M

1988
Effects of salbutamol.
    The Medical journal of Australia, 1988, Jul-04, Volume: 149, Issue:1

    Topics: Albuterol; Asthma; Child Behavior Disorders; Child, Preschool; Female; Humans

1988
[The possibilities and prospects in using the calcium antagonist korinfar in patients with bronchial asthma].
    Terapevticheskii arkhiv, 1988, Volume: 60, Issue:3

    Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Bronchial Provocation Tests; Calcium Channel Bl

1988
[Treatment of asthma crises in children with nebulized salbutamol].
    Pediatrie, 1988, Volume: 43, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Female; Humans; Male; Nebul

1988
Enhancement of theophylline clearance by intravenous albuterol.
    Chest, 1988, Volume: 94, Issue:2

    Topics: Albuterol; Asthma; Drug Interactions; Humans; Infant; Infusions, Intravenous; Male; Metabolic Cleara

1988
Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma.
    The Journal of allergy and clinical immunology, 1988, Volume: 82, Issue:2

    Topics: Acute Disease; Administration, Inhalation; Albuterol; Aminophylline; Asthma; Child; Drug Therapy, Co

1988
Predictive value of oxygen saturation in emergency evaluation of asthmatic children.
    BMJ (Clinical research ed.), 1988, Aug-06, Volume: 297, Issue:6645

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergencies; Female; Humans;

1988
Rising asthma admissions and self referral.
    Archives of disease in childhood, 1988, Volume: 63, Issue:7

    Topics: Adolescent; Age Factors; Albuterol; Asthma; Child; Child, Preschool; England; Hospitals, Pediatric;

1988
Muscle atrophy in severe exacerbation of asthma requiring mechanical ventilation.
    Respiration; international review of thoracic diseases, 1988, Volume: 53, Issue:3

    Topics: Albuterol; Asthma; Beclomethasone; Humans; Male; Methylprednisolone; Middle Aged; Muscular Atrophy;

1988
A dosage schedule for salbutamol nebulisation in childhood asthma.
    The Ceylon medical journal, 1987, Volume: 32, Issue:2

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Administration Schedule; Female; Humans

1987
[Effects of a spacer on beta-stimulant inhalation].
    Nihon Kyobu Shikkan Gakkai zasshi, 1987, Volume: 25, Issue:11

    Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Evaluation Studies as Topic; Femal

1987
Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients.
    Thorax, 1986, Volume: 41, Issue:7

    Topics: Adult; Albuterol; Asthma; Female; Humans; Krypton; Lung; Male; Middle Aged; Posture; Radioisotopes;

1986
Bronchoalveolar lavage does not alter airway responsiveness in asthmatic subjects.
    The American review of respiratory disease, 1987, Volume: 135, Issue:3

    Topics: Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Humans; Methacholine Chloride; Methacholine

1987
Salbutamol versus atropine. Site of bronchodilatation in asthmatic patients.
    Respiration; international review of thoracic diseases, 1987, Volume: 51, Issue:1

    Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Atropine; Humans; Respiratory Function Test

1987
"Aerosol-in-bag" administration of inhaled bronchodilators.
    European journal of respiratory diseases, 1987, Volume: 70, Issue:4

    Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebul

1987
Nebulized salbutamol in acute childhood asthma.
    The Ceylon medical journal, 1986, Volume: 31, Issue:4

    Topics: Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Infant; Male; Nebulizers and Vaporizers

1986
Failure of long-acting, recently introduced beta-agonist in asthma.
    Journal of the Indian Medical Association, 1987, Volume: 85, Issue:2

    Topics: Albuterol; Asthma; Delayed-Action Preparations; Humans; Tablets, Enteric-Coated; Terbutaline

1987
[Acute effect of intravenous salbutamol in status asthmaticus].
    Medicina, 1987, Volume: 47, Issue:1

    Topics: Adult; Albuterol; Asthma; Female; Hemodynamics; Humans; Infusions, Intravenous; Injections, Intraven

1987
[Ventolin--measured aerosol].
    Soins; la revue de reference infirmiere, 1986, Issue:477-478

    Topics: Aerosols; Albuterol; Asthma; Humans

1986
Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients.
    European journal of respiratory diseases, 1987, Volume: 71, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Animals; Asthma; Female; Human

1987
Postcoital severe exacerbation of asthma requiring mechanical ventilation.
    European journal of respiratory diseases, 1987, Volume: 71, Issue:1

    Topics: Acute Disease; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Coitus; Emotions; Female; Humans;

1987
Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma.
    Thorax, 1987, Volume: 42, Issue:6

    Topics: Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Humans; Lung; Male; Middle Aged; Nebuli

1987
[Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis].
    Anales espanoles de pediatria, 1987, Volume: 27, Issue:1

    Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Huma

1987
Underdiagnosis of asthma in the elderly.
    British journal of diseases of the chest, 1987, Volume: 81, Issue:1

    Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Cough; Humans; Respiratory Function Tests

1987
Asthma management.
    The Practitioner, 1987, Volume: 231, Issue:1423

    Topics: Albuterol; Asthma; Child; Humans

1987
Aerosol deposition in automatic dosimeter nebulization.
    European journal of respiratory diseases, 1987, Volume: 71, Issue:3

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Evaluation Studies as Topic; Female; Humans; Lung; Male; M

1987
Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1987, Volume: 28, Issue:12

    Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents

1987
Use of anti-asthma drugs in New Zealand.
    Thorax, 1987, Volume: 42, Issue:9

    Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Child; Drug Therapy, Combination; Drug Utili

1987
Paradoxical response to nebulised salbutamol in wheezy infants.
    Thorax, 1987, Volume: 42, Issue:9

    Topics: Airway Resistance; Albuterol; Asthma; Humans; Infant

1987
A near fatal asthma attack in a patient unaware of deteriorating lung function.
    European journal of respiratory diseases, 1987, Volume: 71, Issue:4

    Topics: Albuterol; Aminophylline; Asthma; Emergencies; Forced Expiratory Volume; Humans; Male; Middle Aged;

1987
Dynamic lung volumes in children with bronchial asthma.
    Indian pediatrics, 1987, Volume: 24, Issue:7

    Topics: Albuterol; Asthma; Child; Humans; Lung; Lung Volume Measurements

1987
The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment.
    The Journal of allergy and clinical immunology, 1987, Volume: 80, Issue:6

    Topics: Albuterol; Asthma; Drug Administration Schedule; Humans; Theophylline

1987
[Hyperkalemia precipitated by beta 2 receptor agonists].
    Ugeskrift for laeger, 1986, Apr-07, Volume: 148, Issue:15

    Topics: Aged; Albuterol; Asthma; Female; Humans; Hyperkalemia; Terbutaline

1986
The perception of asthma.
    Australian paediatric journal, 1986, Volume: 22, Issue:1

    Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Child; Female; Forced Expiratory Volume; Humans;

1986
[The effects of inhalation combined with high-frequency vibration on asthmatic children].
    Arerugi = [Allergy], 1986, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Evaluation Studies as Topic; Female; Humans;

1986
Cardiac effects of salbutamol given by air driven nebuliser at home.
    Thorax, 1986, Volume: 41, Issue:4

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Electrocardiography; Female; Heart; Heart Rate; Home Care

1986
Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis.
    Annals of allergy, 1986, Volume: 57, Issue:2

    Topics: Albuterol; Arthritis, Rheumatoid; Asthma; Bronchial Spasm; Choline; Drug Combinations; Drug Hypersen

1986
Albuterol nebulizer solution for the treatment of asthma.
    Annals of allergy, 1986, Volume: 57, Issue:3

    Topics: Albuterol; Asthma; Humans

1986
Ventide--a useful combination?
    Drug and therapeutics bulletin, 1986, Feb-24, Volume: 24, Issue:4

    Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Combinations; Humans

1986
[Treatment of acute crises of bronchial asthma in children using subcutaneous salbutamol as an alternative to adrenaline: comparative study].
    Anales espanoles de pediatria, 1986, Volume: 25, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Female; Heart

1986
Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol. Influence of mouth rinsing and gargling.
    Chest, 1987, Volume: 91, Issue:3

    Topics: Adult; Aerosols; Albuterol; Asthma; Blood Glucose; Female; Heart Rate; Humans; Lung Volume Measureme

1987
[The nurse in front of an asthma crisis].
    Soins. Chirurgie (Paris, France : 1982), 1985, Issue:58

    Topics: Aerosols; Albuterol; Asthma; Blood Gas Analysis; Emergencies; Humans; Theophylline

1985
Children with asthma: will nebulised salbutamol reduce hospital admissions?
    British medical journal (Clinical research ed.), 1985, Feb-23, Volume: 290, Issue:6468

    Topics: Acute Disease; Adolescent; Aerosols; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Drug A

1985
Histamine-induced asthma in children: effects on the ventilation-perfusion relationship.
    Clinical physiology (Oxford, England), 1985, Volume: 5, Issue:1

    Topics: Adolescent; Albuterol; Arteries; Asthma; Bronchial Provocation Tests; Carbon Dioxide; Cardiac Output

1985
Children with asthma: will nebulised salbutamol reduce hospital admissions?
    British medical journal (Clinical research ed.), 1985, Apr-06, Volume: 290, Issue:6474

    Topics: Aerosols; Albuterol; Asthma; Child; Hospitalization; Humans

1985
Asthma in a country hospital.
    The New Zealand medical journal, 1985, Apr-10, Volume: 98, Issue:776

    Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cromolyn Sodium; Female

1985
Domiciliary nebulisers in asthma.
    British medical journal (Clinical research ed.), 1985, Jul-20, Volume: 291, Issue:6489

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Self Admini

1985
[Bronchial hyperreactivity to pneumo-allergens].
    Anales espanoles de pediatria, 1985, Nov-30, Volume: 23, Issue:7

    Topics: Adolescent; Albuterol; Allergens; Asthma; Beclomethasone; Bronchi; Bronchial Provocation Tests; Bron

1985
Effects of treatment on mortality from asthma.
    Annals of allergy, 1986, Volume: 56, Issue:3

    Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Inject

1986
[Relation between blood theophylline levels and bronchodilator effect in asthmatics: comparison with salbutamol].
    La Tunisie medicale, 1985, Volume: 63

    Topics: Adult; Albuterol; Asthma; Humans; Middle Aged; Theophylline

1985
Relapse after single dose nebulised salbutamol in children with acute asthma.
    Irish medical journal, 1985, Volume: 78, Issue:4

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Peak Expiratory Flow R

1985
The effect of intravenously administered salbutamol on serum potassium in asthmatic and nonasthmatic atopic subjects.
    Journal of clinical immunology, 1985, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Albuterol; Asthma; Blood Glucose; Blood Pressure; Female; Heart Rate; Humans; Hyp

1985
Intravenous vs. nebulized salbutamol for treatment of severe status asthmaticus.
    Critical care medicine, 1985, Volume: 13, Issue:8

    Topics: Aerosols; Albuterol; Asthma; Humans; Infusions, Parenteral; Status Asthmaticus

1985
Intravenous salbutamol for status asthmaticus.
    Critical care medicine, 1985, Volume: 13, Issue:10

    Topics: Albuterol; Asthma; Child; Humans; Infusions, Parenteral; Status Asthmaticus

1985
Effects of histamine on lung permeability in normal and asthmatic subjects.
    Thorax, 1985, Volume: 40, Issue:8

    Topics: Adult; Albuterol; Asthma; Histamine; Humans; Lung; Middle Aged; Mucous Membrane; Peak Expiratory Flo

1985
[Relation between number of attacks per year and respiratory function tests in the asthmatic child: importance of spirometry in the child with episodic asthma].
    Minerva pediatrica, 1985, Jul-31, Volume: 37, Issue:13-14

    Topics: Albuterol; Asthma; Child; Female; Forced Expiratory Flow Rates; Forced Expiratory Volume; Humans; Ma

1985
Acute asthma in childhood and the role of nebulisers.
    The Practitioner, 1985, Volume: 229, Issue:1408

    Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant

1985
Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma.
    British journal of clinical pharmacology, 1985, Volume: 20, Issue:6

    Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Hemodynamics; Humans; Mid

1985
Salbutamol by intermittent positive pressure ventilation in status asthmaticus.
    Scottish medical journal, 1974, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Carbon Dioxide; Cardiac Complexes, Premature;

1974
[Bronchoconstrictor effects of beta-adrenergic blockade in asthma: influence of baseline value (author's transl)].
    Respiration; international review of thoracic diseases, 1974, Volume: 31, Issue:1

    Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchi

1974
Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma.
    Drugs, 1973, Volume: 6, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Airway Resistance; Albuterol; Asthma; Bloo

1973
Problems of interpreting exercise-induced asthma.
    The Journal of allergy and clinical immunology, 1973, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Heart Rate; Humans; Isoproterenol; Phy

1973
Maximal expiratory flow and lung volume changes associated with exercise-induced asthma in children and the effect of breathing a low-density gas mixture.
    Clinical science and molecular medicine, 1974, Volume: 46, Issue:3

    Topics: Adolescent; Albuterol; Asthma; Atmospheric Pressure; Child; Helium; Humans; Lung; Oxygen; Physical E

1974
Bronchial asthma.
    The Practitioner, 1974, Volume: 212, Issue:1269

    Topics: Adrenocorticotropic Hormone; Aerosols; Airway Obstruction; Albuterol; Aminophylline; Antigens; Asthm

1974
Oral salbutamol in bronchial asthma.
    The Indian journal of chest diseases, 1974, Volume: 16, Issue:2

    Topics: Administration, Oral; Albuterol; Asthma; Drug Combinations; Ephedrine; Humans; Phenobarbital; Theoph

1974
Changes in specific airways conductance and forced expiratory volume in one second after a bronchodilator in normal subjects and patients with airways obstruction.
    Thorax, 1974, Volume: 29, Issue:5

    Topics: Administration, Oral; Adult; Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bro

1974
The effects of pressurized isoproterenol and salbutamol in asthmatic children.
    Pediatrics, 1974, Volume: 54, Issue:6

    Topics: Administration, Intranasal; Adolescent; Aerosols; Albuterol; Asthma; Child; Dose-Response Relationsh

1974
[Inhalation of salbutamol 0,5% water solution in the treatment of acute asthma in children].
    Lakartidningen, 1974, Dec-18, Volume: 71, Issue:51

    Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Therapy

1974
[Treatment of bronchiolar obstruction].
    Minerva medica, 1974, Dec-19, Volume: 65, Issue:91

    Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Bronchial Diseases; Bronchial Spasm; Diagnosis, Dif

1974
[Beta 2 specificity of salbutamol: metabolic evaluations].
    Bollettino della Societa italiana di biologia sperimentale, 1974, May-30, Volume: 50, Issue:10

    Topics: Albuterol; Asthma; Blood Glucose; Carbohydrate Metabolism; Child, Preschool; Fatty Acids, Nonesterif

1974
Effect of beta receptor-stimulating drugs on the cardiovascular and respiratory function of critically ill patients with serious heart disorders.
    Resuscitation, 1974, Volume: 3, Issue:3

    Topics: Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Cardiovascular System; Female; Heart; Heart

1974
Closing volume, spirometry and nitrogen wash-out in provoked asthma treated with salbutamol.
    Scandinavian journal of respiratory diseases. Supplementum, 1974, Volume: 85

    Topics: Adolescent; Adult; Airway Obstruction; Airway Resistance; Albuterol; Allergens; Asthma; Female; Huma

1974
[Effect of B2 adrenergic drugs in asthma].
    AMB : revista da Associacao Medica Brasileira, 1973, Volume: 19, Issue:8

    Topics: Albuterol; Asthma; Humans; Pulmonary Ventilation; Respiration; Respiratory Function Tests

1973
The fate of nebulized salbutamol (albuterol) administered by intermittent positive pressure respiration to asthmatic patients.
    The American review of respiratory disease, 1973, Volume: 108, Issue:3

    Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Feces; Female; Humans; Male; Positive-Pressure Respi

1973
A comparison of three different techniques for giving nebulized albuterol to asthmatic patients.
    The American review of respiratory disease, 1974, Volume: 109, Issue:2

    Topics: Aerosols; Albuterol; Asthma; Humans; Methods; Positive-Pressure Respiration; Spirometry

1974
Salbutamol therapy in status asthmaticus.
    Journal of the Indian Medical Association, 1974, Mar-01, Volume: 62, Issue:5

    Topics: Acetylcysteine; Albuterol; Asthma; Epinephrine; Humans; Positive-Pressure Respiration

1974
[Basic broncholytic therapy with Salbutamol. Literature review and our experience].
    Fortschritte der Medizin, 1972, Apr-13, Volume: 90, Issue:11

    Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchitis; Child; Female; Humans; Male; Middle Aged

1972
[Effects of salbutamol on pulmonary circulation, ventilation, and gas exchanges in bronchial asthma patients].
    Le Poumon et le coeur, 1973, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Blood Pressure; Carbon Dioxide; Cardi

1973
Arterial blood levels of fluorocarbons in asthmatic patients following use of pressurized aerosols.
    Clinical pharmacology and therapeutics, 1974, Volume: 15, Issue:1

    Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Chlorofluorocarbons, Methane; Chromatography, Gas; Compute

1974
Management of severe viral bronchiolitis and severe acute asthma.
    Archives of disease in childhood, 1974, Volume: 49, Issue:2

    Topics: Acute Disease; Airway Obstruction; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Bronchio

1974
[Over-8-hour salbutamol effect in obstructive respiratory tract diseases].
    Fortschritte der Medizin, 1974, Apr-18, Volume: 92, Issue:11

    Topics: Adult; Albuterol; Asthma; Bronchitis; Child; Chronic Disease; Humans; Lung Diseases, Obstructive; Ti

1974